<?xml version='1.0' encoding='utf-8'?>
<graphml xmlns="http://graphml.graphdrawing.org/xmlns" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://graphml.graphdrawing.org/xmlns http://graphml.graphdrawing.org/xmlns/1.0/graphml.xsd"><key id="d32" for="edge" attr.name="assertedBy" attr.type="string"/>
<key id="d31" for="edge" attr.name="score" attr.type="string"/>
<key id="d30" for="edge" attr.name="type" attr.type="string"/>
<key id="d29" for="edge" attr.name="targetDomainId" attr.type="string"/>
<key id="d28" for="edge" attr.name="sourceDomainId" attr.type="string"/>
<key id="d27" for="edge" attr.name="node2" attr.type="string"/>
<key id="d26" for="edge" attr.name="node1" attr.type="string"/>
<key id="d25" for="edge" attr.name="targetId" attr.type="string"/>
<key id="d24" for="edge" attr.name="sourceId" attr.type="string"/>
<key id="d23" for="node" attr.name="sequences" attr.type="string"/>
<key id="d22" for="node" attr.name="_cls" attr.type="string"/>
<key id="d21" for="node" attr.name="indication" attr.type="string"/>
<key id="d20" for="node" attr.name="smiles" attr.type="string"/>
<key id="d19" for="node" attr.name="inchi" attr.type="string"/>
<key id="d18" for="node" attr.name="allDatasets" attr.type="string"/>
<key id="d17" for="node" attr.name="primaryDataset" attr.type="string"/>
<key id="d16" for="node" attr.name="casNumber" attr.type="string"/>
<key id="d15" for="node" attr.name="molecularFormula" attr.type="string"/>
<key id="d14" for="node" attr.name="iupacName" attr.type="string"/>
<key id="d13" for="node" attr.name="drugCategories" attr.type="string"/>
<key id="d12" for="node" attr.name="drugGroups" attr.type="string"/>
<key id="d11" for="node" attr.name="icd10" attr.type="string"/>
<key id="d10" for="node" attr.name="type" attr.type="string"/>
<key id="d9" for="node" attr.name="description" attr.type="string"/>
<key id="d8" for="node" attr.name="synonyms" attr.type="string"/>
<key id="d7" for="node" attr.name="mapLocation" attr.type="string"/>
<key id="d6" for="node" attr.name="chromosome" attr.type="string"/>
<key id="d5" for="node" attr.name="geneType" attr.type="string"/>
<key id="d4" for="node" attr.name="symbols" attr.type="string"/>
<key id="d3" for="node" attr.name="approvedSymbol" attr.type="string"/>
<key id="d2" for="node" attr.name="domainIds" attr.type="string"/>
<key id="d1" for="node" attr.name="primaryDomainId" attr.type="string"/>
<key id="d0" for="node" attr.name="displayName" attr.type="string"/>
<graph edgedefault="undirected"><node id="entrez.2">
  <data key="d0">A2M</data>
  <data key="d1">entrez.2</data>
  <data key="d2">[entrez.2]</data>
  <data key="d3">A2M</data>
  <data key="d4">[A2MD, CPAMD5, FWP007, S863-7]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">12</data>
  <data key="d7">12p13.31</data>
  <data key="d8">[alpha-2-macroglobulin, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 5, alpha-2-M]</data>
  <data key="d9">alpha-2-macroglobulin</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.498">
  <data key="d0">ATP5F1A</data>
  <data key="d1">entrez.498</data>
  <data key="d2">[entrez.498]</data>
  <data key="d3">ATP5F1A</data>
  <data key="d4">[ATP5A, ATP5A1, ATP5AL2, ATPM, COXPD22, HEL-S-123m, MC5DN4, MOM2, OMR, ORM, hATP1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">18</data>
  <data key="d7">18q21.1</data>
  <data key="d8">[ATP synthase subunit alpha, mitochondrial, ATP synthase alpha chain, mitochondrial, ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle, ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 1, cardiac muscle, ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 2, non-cardiac muscle-like 2, ATP sythase (F1-ATPase) alpha subunit, epididymis secretory sperm binding protein Li 123m, mitochondrial ATP synthetase, oligomycin-resistant]</data>
  <data key="d9">ATP synthase F1 subunit alpha</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.627">
  <data key="d0">BDNF</data>
  <data key="d1">entrez.627</data>
  <data key="d2">[entrez.627]</data>
  <data key="d3">BDNF</data>
  <data key="d4">[ANON2, BULN2]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">11</data>
  <data key="d7">11p14.1</data>
  <data key="d8">[brain-derived neurotrophic factor, abrineurin, neurotrophin]</data>
  <data key="d9">brain derived neurotrophic factor</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.581">
  <data key="d0">BAX</data>
  <data key="d1">entrez.581</data>
  <data key="d2">[entrez.581]</data>
  <data key="d3">BAX</data>
  <data key="d4">[BCL2L4]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">19</data>
  <data key="d7">19q13.33</data>
  <data key="d8">[apoptosis regulator BAX, BCL2 associated X protein, BCL2-associated X protein omega, Baxdelta2G9, Baxdelta2G9omega, Baxdelta2omega, bcl-2-like protein 4, bcl2-L-4]</data>
  <data key="d9">BCL2 associated X, apoptosis regulator</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.590">
  <data key="d0">BCHE</data>
  <data key="d1">entrez.590</data>
  <data key="d2">[entrez.590]</data>
  <data key="d3">BCHE</data>
  <data key="d4">[BCHED, CHE1, CHE2, E1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">3</data>
  <data key="d7">3q26.1</data>
  <data key="d8">[cholinesterase, acylcholine acylhydrolase, butyrylcholine esterase, choline esterase II, cholinesterase (serum) 2, cholinesterase 1, pseudocholinesterase]</data>
  <data key="d9">butyrylcholinesterase</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.596">
  <data key="d0">BCL2</data>
  <data key="d1">entrez.596</data>
  <data key="d2">[entrez.596]</data>
  <data key="d3">BCL2</data>
  <data key="d4">[Bcl-2, PPP1R50]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">18</data>
  <data key="d7">18q21.33</data>
  <data key="d8">[apoptosis regulator Bcl-2, B-cell CLL/lymphoma 2, protein phosphatase 1, regulatory subunit 50]</data>
  <data key="d9">BCL2 apoptosis regulator</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.274">
  <data key="d0">BIN1</data>
  <data key="d1">entrez.274</data>
  <data key="d2">[entrez.274]</data>
  <data key="d3">BIN1</data>
  <data key="d4">[AMPH2, AMPHL, CNM2, SH3P9]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">2</data>
  <data key="d7">2q14.3</data>
  <data key="d8">[myc box-dependent-interacting protein 1, amphiphysin II, amphiphysin-like protein, box dependant MYC interacting protein 1, box-dependent myc-interacting protein 1]</data>
  <data key="d9">bridging integrator 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.267">
  <data key="d0">AMFR</data>
  <data key="d1">entrez.267</data>
  <data key="d2">[entrez.267]</data>
  <data key="d3">AMFR</data>
  <data key="d4">[GP78, RNF45]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">16</data>
  <data key="d7">16q13</data>
  <data key="d8">[E3 ubiquitin-protein ligase AMFR, RING finger protein 45, RING-type E3 ubiquitin transferase AMFR]</data>
  <data key="d9">autocrine motility factor receptor</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.23607">
  <data key="d0">CD2AP</data>
  <data key="d1">entrez.23607</data>
  <data key="d2">[entrez.23607]</data>
  <data key="d3">CD2AP</data>
  <data key="d4">[CMS]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">6</data>
  <data key="d7">6p12.3</data>
  <data key="d8">[CD2-associated protein, Cas ligand with multiple Src homology 3 (SH3) domains, adapter protein CMS, cas ligand with multiple SH3 domains]</data>
  <data key="d9">CD2 associated protein</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.23621">
  <data key="d0">BACE1</data>
  <data key="d1">entrez.23621</data>
  <data key="d2">[entrez.23621]</data>
  <data key="d3">BACE1</data>
  <data key="d4">[ASP2, BACE, HSPC104]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">11</data>
  <data key="d7">11q23.3</data>
  <data key="d8">[beta-secretase 1, APP beta-secretase, asp 2, aspartyl protease 2, beta-secretase 1 precursor variant 1, beta-site APP cleaving enzyme 1, beta-site APP-cleaving enzyme, beta-site amyloid beta A4 precursor protein-cleaving enzyme, memapsin-2, membrane-associated aspartic protease 2, transmembrane aspartic proteinase Asp2]</data>
  <data key="d9">beta-secretase 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.23646">
  <data key="d0">PLD3</data>
  <data key="d1">entrez.23646</data>
  <data key="d2">[entrez.23646]</data>
  <data key="d3">PLD3</data>
  <data key="d4">[AD19, HU-K4, HUK4, SCA46]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">19</data>
  <data key="d7">19q13.2</data>
  <data key="d8">[phospholipase D3, choline phosphatase 3, hindIII K4L homolog, phosphatidylcholine-hydrolyzing phospholipase D3]</data>
  <data key="d9">phospholipase D family member 3</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.323">
  <data key="d0">APBB2</data>
  <data key="d1">entrez.323</data>
  <data key="d2">[entrez.323]</data>
  <data key="d3">APBB2</data>
  <data key="d4">[FE65L, FE65L1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">4</data>
  <data key="d7">4p14-p13</data>
  <data key="d8">[amyloid-beta A4 precursor protein-binding family B member 2, Fe65-like 1, protein Fe65-like 1]</data>
  <data key="d9">amyloid beta precursor protein binding family B member 2</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.351">
  <data key="d0">APP</data>
  <data key="d1">entrez.351</data>
  <data key="d2">[entrez.351]</data>
  <data key="d3">APP</data>
  <data key="d4">[AAA, ABETA, ABPP, AD1, APPI, CTFgamma, CVAP, PN-II, PN2, preA4]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">21</data>
  <data key="d7">21q21.3</data>
  <data key="d8">[amyloid-beta precursor protein, alzheimer disease amyloid protein, amyloid beta (A4) precursor protein, amyloid beta A4 protein, amyloid precursor protein, beta-amyloid peptide, beta-amyloid peptide(1-40), beta-amyloid peptide(1-42), beta-amyloid precursor protein, cerebral vascular amyloid peptide, peptidase nexin-II, protease nexin-II, testicular tissue protein Li 2]</data>
  <data key="d9">amyloid beta precursor protein</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.348">
  <data key="d0">APOE</data>
  <data key="d1">entrez.348</data>
  <data key="d2">[entrez.348]</data>
  <data key="d3">APOE</data>
  <data key="d4">[AD2, APO-E, ApoE4, LDLCQ5, LPG]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">19</data>
  <data key="d7">19q13.32</data>
  <data key="d8">[apolipoprotein E, apolipoprotein E3]</data>
  <data key="d9">apolipoprotein E</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.945">
  <data key="d0">CD33</data>
  <data key="d1">entrez.945</data>
  <data key="d2">[entrez.945]</data>
  <data key="d3">CD33</data>
  <data key="d4">[SIGLEC-3, SIGLEC3, p67]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">19</data>
  <data key="d7">19q13.41</data>
  <data key="d8">[myeloid cell surface antigen CD33, CD33 antigen (gp67), CD33 molecule transcript, gp67, sialic acid-binding Ig-like lectin 3]</data>
  <data key="d9">CD33 molecule</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.23385">
  <data key="d0">NCSTN</data>
  <data key="d1">entrez.23385</data>
  <data key="d2">[entrez.23385]</data>
  <data key="d3">NCSTN</data>
  <data key="d4">[ATAG1874]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">1</data>
  <data key="d7">1q23.2</data>
  <data key="d8">[nicastrin, anterior pharynx-defective 2]</data>
  <data key="d9">nicastrin</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.642">
  <data key="d0">BLMH</data>
  <data key="d1">entrez.642</data>
  <data key="d2">[entrez.642]</data>
  <data key="d3">BLMH</data>
  <data key="d4">[BH, BMH]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">17</data>
  <data key="d7">17q11.2</data>
  <data key="d8">[bleomycin hydrolase, BLM hydrolase]</data>
  <data key="d9">bleomycin hydrolase</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.801">
  <data key="d0">CALM1</data>
  <data key="d1">entrez.801</data>
  <data key="d2">[entrez.801]</data>
  <data key="d3">CALM1</data>
  <data key="d4">[CALML2, CAM2, CAM3, CAMB, CAMC, CAMI, CAMIII, CPVT4, DD132, LQT14, PHKD, caM]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">14</data>
  <data key="d7">14q32.11</data>
  <data key="d8">[calmodulin-1, Calmodulin-2, Calmodulin-3, calmodulin 1 (phosphorylase kinase, delta), phosphorylase kinase subunit delta, phosphorylase kinase, delta subunit, prepro-calmodulin 1]</data>
  <data key="d9">calmodulin 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.836">
  <data key="d0">CASP3</data>
  <data key="d1">entrez.836</data>
  <data key="d2">[entrez.836]</data>
  <data key="d3">CASP3</data>
  <data key="d4">[CPP32, CPP32B, SCA-1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">4</data>
  <data key="d7">4q35.1</data>
  <data key="d8">[caspase-3, CASP-3, CPP-32, PARP cleavage protease, SREBP cleavage activity 1, apopain, caspase 3, apoptosis-related cysteine peptidase, caspase 3, apoptosis-related cysteine protease, cysteine protease CPP32, procaspase3, protein Yama]</data>
  <data key="d9">caspase 3</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.23237">
  <data key="d0">ARC</data>
  <data key="d1">entrez.23237</data>
  <data key="d2">[entrez.23237]</data>
  <data key="d3">ARC</data>
  <data key="d4">[Arg3.1, hArc]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">8</data>
  <data key="d7">8q24.3</data>
  <data key="d8">[activity-regulated cytoskeleton-associated protein, ARC/ARG3.1, activity-regulated gene 3.1 protein homolog]</data>
  <data key="d9">activity regulated cytoskeleton associated protein</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.102">
  <data key="d0">ADAM10</data>
  <data key="d1">entrez.102</data>
  <data key="d2">[entrez.102]</data>
  <data key="d3">ADAM10</data>
  <data key="d4">[AD10, AD18, CD156c, CDw156, HsT18717, MADM, RAK, kuz]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">15</data>
  <data key="d7">15q21.3</data>
  <data key="d8">[disintegrin and metalloproteinase domain-containing protein 10, a disintegrin and metalloprotease domain 10, kuzbanian protein homolog, mammalian disintegrin-metalloprotease]</data>
  <data key="d9">ADAM metallopeptidase domain 10</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.4852">
  <data key="d0">NPY</data>
  <data key="d1">entrez.4852</data>
  <data key="d2">[entrez.4852]</data>
  <data key="d3">NPY</data>
  <data key="d4">[PYY4]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">7</data>
  <data key="d7">7p15.3</data>
  <data key="d8">[pro-neuropeptide Y, prepro-neuropeptide Y]</data>
  <data key="d9">neuropeptide Y</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.4846">
  <data key="d0">NOS3</data>
  <data key="d1">entrez.4846</data>
  <data key="d2">[entrez.4846]</data>
  <data key="d3">NOS3</data>
  <data key="d4">[ECNOS, eNOS]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">7</data>
  <data key="d7">7q36.1</data>
  <data key="d8">[nitric oxide synthase, endothelial, EC-NOS, NOS type III, NOSIII, cNOS, constitutive NOS, endothelial NOS, nitric oxide synthase 3 (endothelial cell), nitric oxide synthase 3 transcript variant eNOS-delta20, nitric oxide synthase 3 transcript variant eNOS-delta20-21, nitric oxide synthase 3 transcript variant eNOS-delta21]</data>
  <data key="d9">nitric oxide synthase 3</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.4353">
  <data key="d0">MPO</data>
  <data key="d1">entrez.4353</data>
  <data key="d2">[entrez.4353]</data>
  <data key="d3">MPO</data>
  <data key="d4">[-]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">17</data>
  <data key="d7">17q22</data>
  <data key="d8">[myeloperoxidase]</data>
  <data key="d9">myeloperoxidase</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.4524">
  <data key="d0">MTHFR</data>
  <data key="d1">entrez.4524</data>
  <data key="d2">[entrez.4524]</data>
  <data key="d3">MTHFR</data>
  <data key="d4">[-]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">1</data>
  <data key="d7">1p36.22</data>
  <data key="d8">[methylenetetrahydrofolate reductase, 5, 10-methylenetetrahydrofolate reductase (NADPH), methylenetetrahydrofolate reductase (NAD(P)H)]</data>
  <data key="d9">methylenetetrahydrofolate reductase</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.4137">
  <data key="d0">MAPT</data>
  <data key="d1">entrez.4137</data>
  <data key="d2">[entrez.4137]</data>
  <data key="d3">MAPT</data>
  <data key="d4">[DDPAC, FTDP-17, MAPTL, MSTD, MTBT1, MTBT2, PPND, PPP1R103, TAU]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">17</data>
  <data key="d7">17q21.31</data>
  <data key="d8">[microtubule-associated protein tau, G protein beta1/gamma2 subunit-interacting factor 1, PHF-tau, neurofibrillary tangle protein, paired helical filament-tau, protein phosphatase 1, regulatory subunit 103]</data>
  <data key="d9">microtubule associated protein tau</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.4129">
  <data key="d0">MAOB</data>
  <data key="d1">entrez.4129</data>
  <data key="d2">[entrez.4129]</data>
  <data key="d3">MAOB</data>
  <data key="d4">[-]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">X</data>
  <data key="d7">Xp11.3</data>
  <data key="d8">[amine oxidase [flavin-containing] B, MAO, brain, MAO, platelet, MAO-B, adrenalin oxidase, monoamine oxidase type B, tyramine oxidase]</data>
  <data key="d9">monoamine oxidase B</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.10347">
  <data key="d0">ABCA7</data>
  <data key="d1">entrez.10347</data>
  <data key="d2">[entrez.10347]</data>
  <data key="d3">ABCA7</data>
  <data key="d4">[ABCA-SSN, ABCX, AD9]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">19</data>
  <data key="d7">19p13.3</data>
  <data key="d8">[phospholipid-transporting ATPase ABCA7, ATP-binding cassette sub-family A member 7, ATP-binding cassette, sub-family A (ABC1), member 7, autoantigen SS-N, macrophage ABC transporter]</data>
  <data key="d9">ATP binding cassette subfamily A member 7</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3952">
  <data key="d0">LEP</data>
  <data key="d1">entrez.3952</data>
  <data key="d2">[entrez.3952]</data>
  <data key="d3">LEP</data>
  <data key="d4">[LEPD, OB, OBS]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">7</data>
  <data key="d7">7q32.1</data>
  <data key="d8">[leptin, leptin (murine obesity homolog), leptin (obesity homolog, mouse), obese protein, obese, mouse, homolog of, obesity factor]</data>
  <data key="d9">leptin</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.8301">
  <data key="d0">PICALM</data>
  <data key="d1">entrez.8301</data>
  <data key="d2">[entrez.8301]</data>
  <data key="d3">PICALM</data>
  <data key="d4">[CALM, CLTH, LAP]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">11</data>
  <data key="d7">11q14.2</data>
  <data key="d8">[phosphatidylinositol-binding clathrin assembly protein, clathrin assembly lymphoid myeloid leukemia protein]</data>
  <data key="d9">phosphatidylinositol binding clathrin assembly protein</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.780912">
  <data key="d0">entrez.780912</data>
  <data key="d1">entrez.780912</data>
  <data key="d2">[entrez.780912]</data>
  <data key="d3">NA</data>
  <data key="d4">[-]</data>
  <data key="d5">unknown</data>
  <data key="d6">7</data>
  <data key="d7">7q36</data>
  <data key="d8">[-]</data>
  <data key="d9">Alzheimer disease-10</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.114475">
  <data key="d0">entrez.114475</data>
  <data key="d1">entrez.114475</data>
  <data key="d2">[entrez.114475]</data>
  <data key="d3">NA</data>
  <data key="d4">[-]</data>
  <data key="d5">unknown</data>
  <data key="d6">10</data>
  <data key="d7">10p13</data>
  <data key="d8">[-]</data>
  <data key="d9">Alzheimer disease 7</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.8081">
  <data key="d0">entrez.8081</data>
  <data key="d1">entrez.8081</data>
  <data key="d2">[entrez.8081]</data>
  <data key="d3">NA</data>
  <data key="d4">[-]</data>
  <data key="d5">unknown</data>
  <data key="d6">12</data>
  <data key="d7">12p11.23-q13.12</data>
  <data key="d8">[Alzheimer disease, familial, type 5]</data>
  <data key="d9">Alzheimer disease 5</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.7782">
  <data key="d0">SLC30A4</data>
  <data key="d1">entrez.7782</data>
  <data key="d2">[entrez.7782]</data>
  <data key="d3">SLC30A4</data>
  <data key="d4">[ZNT4, znT-4]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">15</data>
  <data key="d7">15q21.1|15q21.1</data>
  <data key="d8">[zinc transporter 4, solute carrier family 30 (zinc transporter), member 4]</data>
  <data key="d9">solute carrier family 30 member 4</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.7422">
  <data key="d0">VEGFA</data>
  <data key="d1">entrez.7422</data>
  <data key="d2">[entrez.7422]</data>
  <data key="d3">VEGFA</data>
  <data key="d4">[MVCD1, VEGF, VPF]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">6</data>
  <data key="d7">6p21.1</data>
  <data key="d8">[vascular endothelial growth factor A, vascular endothelial growth factor A121, vascular endothelial growth factor A165, vascular permeability factor]</data>
  <data key="d9">vascular endothelial growth factor A</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.7447">
  <data key="d0">VSNL1</data>
  <data key="d1">entrez.7447</data>
  <data key="d2">[entrez.7447]</data>
  <data key="d3">VSNL1</data>
  <data key="d4">[HLP3, HPCAL3, HUVISL1, VILIP, VILIP-1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">2</data>
  <data key="d7">2p24.2</data>
  <data key="d8">[visinin-like protein 1, VLP-1, hippocalcin-like protein 3]</data>
  <data key="d9">visinin like 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.54209">
  <data key="d0">TREM2</data>
  <data key="d1">entrez.54209</data>
  <data key="d2">[entrez.54209]</data>
  <data key="d3">TREM2</data>
  <data key="d4">[PLOSL2, TREM-2, Trem2a, Trem2b, Trem2c]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">6</data>
  <data key="d7">6p21.1</data>
  <data key="d8">[triggering receptor expressed on myeloid cells 2, triggering receptor expressed on monocytes 2, triggering receptor expressed on myeloid cells 2a]</data>
  <data key="d9">triggering receptor expressed on myeloid cells 2</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3553">
  <data key="d0">IL1B</data>
  <data key="d1">entrez.3553</data>
  <data key="d2">[entrez.3553]</data>
  <data key="d3">IL1B</data>
  <data key="d4">[IL-1, IL1-BETA, IL1F2, IL1beta]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">2</data>
  <data key="d7">2q14.1</data>
  <data key="d8">[interleukin-1 beta, IL-1 beta, catabolin, interleukin 1beta, preinterleukin 1 beta, pro-interleukin-1-beta]</data>
  <data key="d9">interleukin 1 beta</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3643">
  <data key="d0">INSR</data>
  <data key="d1">entrez.3643</data>
  <data key="d2">[entrez.3643]</data>
  <data key="d3">INSR</data>
  <data key="d4">[CD220, HHF5]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">19</data>
  <data key="d7">19p13.2</data>
  <data key="d8">[insulin receptor, IR]</data>
  <data key="d9">insulin receptor</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3630">
  <data key="d0">INS</data>
  <data key="d1">entrez.3630</data>
  <data key="d2">[entrez.3630]</data>
  <data key="d3">INS</data>
  <data key="d4">[IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">11</data>
  <data key="d7">11p15.5</data>
  <data key="d8">[insulin, preproinsulin, proinsulin]</data>
  <data key="d9">insulin</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3481">
  <data key="d0">IGF2</data>
  <data key="d1">entrez.3481</data>
  <data key="d2">[entrez.3481]</data>
  <data key="d3">IGF2</data>
  <data key="d4">[C11orf43, GRDF, IGF-II, PP9974]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">11</data>
  <data key="d7">11p15.5</data>
  <data key="d8">[insulin-like growth factor II, T3M-11-derived growth factor, insulin-like growth factor 2 (somatomedin A), insulin-like growth factor type 2, preptin]</data>
  <data key="d9">insulin like growth factor 2</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3482">
  <data key="d0">IGF2R</data>
  <data key="d1">entrez.3482</data>
  <data key="d2">[entrez.3482]</data>
  <data key="d3">IGF2R</data>
  <data key="d4">[CD222, CI-M6PR, CIMPR, M6P-R, M6P/IGF2R, MPR 300, MPR1, MPR300, MPRI]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">6</data>
  <data key="d7">6q25.3</data>
  <data key="d8">[cation-independent mannose-6-phosphate receptor, 300 kDa mannose 6-phosphate receptor, CI Man-6-P receptor, IGF-II receptor, M6P/IGF2 receptor, insulin-like growth factor II receptor]</data>
  <data key="d9">insulin like growth factor 2 receptor</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3480">
  <data key="d0">IGF1R</data>
  <data key="d1">entrez.3480</data>
  <data key="d2">[entrez.3480]</data>
  <data key="d3">IGF1R</data>
  <data key="d4">[CD221, IGFIR, IGFR, JTK13]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">15</data>
  <data key="d7">15q26.3</data>
  <data key="d8">[insulin-like growth factor 1 receptor, IGF-I receptor, soluble IGF1R variant 1, soluble IGF1R variant 2]</data>
  <data key="d9">insulin like growth factor 1 receptor</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3479">
  <data key="d0">IGF1</data>
  <data key="d1">entrez.3479</data>
  <data key="d2">[entrez.3479]</data>
  <data key="d3">IGF1</data>
  <data key="d4">[IGF, IGF-I, IGFI, MGF]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">12</data>
  <data key="d7">12q23.2</data>
  <data key="d8">[insulin-like growth factor I, insulin-like growth factor 1 (somatomedin C), insulin-like growth factor IB, mechano growth factor, somatomedin-C]</data>
  <data key="d9">insulin like growth factor 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3416">
  <data key="d0">IDE</data>
  <data key="d1">entrez.3416</data>
  <data key="d2">[entrez.3416]</data>
  <data key="d3">IDE</data>
  <data key="d4">[INSULYSIN]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">10</data>
  <data key="d7">10q23.33</data>
  <data key="d8">[insulin-degrading enzyme, Abeta-degrading protease, insulin protease, insulinase]</data>
  <data key="d9">insulin degrading enzyme</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3077">
  <data key="d0">HFE</data>
  <data key="d1">entrez.3077</data>
  <data key="d2">[entrez.3077]</data>
  <data key="d3">HFE</data>
  <data key="d4">[HFE1, HH, HLA-H, MVCD7, TFQTL2]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">6</data>
  <data key="d7">6p22.2</data>
  <data key="d8">[hereditary hemochromatosis protein, MHC class I-like protein HFE, hereditary hemochromatosis protein HLA-H, high Fe]</data>
  <data key="d9">homeostatic iron regulator</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3127">
  <data key="d0">HLA-DRB5</data>
  <data key="d1">entrez.3127</data>
  <data key="d2">[entrez.3127]</data>
  <data key="d3">HLA-DRB5</data>
  <data key="d4">[-]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">6</data>
  <data key="d7">6p21.32</data>
  <data key="d8">[major histocompatibility complex, class II, DR beta 5, DR beta-5, HLA class II histocompatibility antigen, DR-5 beta chain, MHC class II antigen DRB5]</data>
  <data key="d9">major histocompatibility complex, class II, DR beta 5</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.3162">
  <data key="d0">HMOX1</data>
  <data key="d1">entrez.3162</data>
  <data key="d2">[entrez.3162]</data>
  <data key="d3">HMOX1</data>
  <data key="d4">[HMOX1D, HO-1, HSP32, bK286B10]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">22</data>
  <data key="d7">22q12.3</data>
  <data key="d8">[heme oxygenase 1, heat shock protein, 32-kD, heme oxygenase (decycling) 1]</data>
  <data key="d9">heme oxygenase 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.10858">
  <data key="d0">CYP46A1</data>
  <data key="d1">entrez.10858</data>
  <data key="d2">[entrez.10858]</data>
  <data key="d3">CYP46A1</data>
  <data key="d4">[CP46, CYP46]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">14</data>
  <data key="d7">14q32.2</data>
  <data key="d8">[cholesterol 24-hydroxylase, CH24H, cholesterol 24-monooxygenase, cholesterol 24S-hydroxylase, cytochrome P450 46A1, cytochrome P450, family 46, subfamily A, polypeptide 1, cytochrome P450, subfamily 46 (cholesterol 24-hydroxylase)]</data>
  <data key="d9">cytochrome P450 family 46 subfamily A member 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.2932">
  <data key="d0">GSK3B</data>
  <data key="d1">entrez.2932</data>
  <data key="d2">[entrez.2932]</data>
  <data key="d3">GSK3B</data>
  <data key="d4">[-]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">3</data>
  <data key="d7">3q13.33</data>
  <data key="d8">[glycogen synthase kinase-3 beta, GSK-3 beta, GSK3beta isoform, serine/threonine-protein kinase GSK3B]</data>
  <data key="d9">glycogen synthase kinase 3 beta</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.7019">
  <data key="d0">TFAM</data>
  <data key="d1">entrez.7019</data>
  <data key="d2">[entrez.7019]</data>
  <data key="d3">TFAM</data>
  <data key="d4">[MTDPS15, MTTF1, MTTFA, TCF6, TCF6L1, TCF6L2, TCF6L3]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">10</data>
  <data key="d7">10q21.1</data>
  <data key="d8">[transcription factor A, mitochondrial, mitochondrial transcription factor 1, mitochondrial transcription factor A, transcription factor 6, transcription factor 6-like 1, transcription factor 6-like 2 (mitochondrial transcription factor), transcription factor 6-like 3]</data>
  <data key="d9">transcription factor A, mitochondrial</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.7018">
  <data key="d0">TF</data>
  <data key="d1">entrez.7018</data>
  <data key="d2">[entrez.7018]</data>
  <data key="d3">TF</data>
  <data key="d4">[HEL-S-71p, PRO1557, PRO2086, TFQTL1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">3</data>
  <data key="d7">3q22.1</data>
  <data key="d8">[serotransferrin, beta-1 metal-binding globulin, epididymis secretory sperm binding protein Li 71p, siderophilin]</data>
  <data key="d9">transferrin</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.7167">
  <data key="d0">TPI1</data>
  <data key="d1">entrez.7167</data>
  <data key="d2">[entrez.7167]</data>
  <data key="d3">TPI1</data>
  <data key="d4">[HEL-S-49, TIM, TPI, TPID]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">12</data>
  <data key="d7">12p13.31</data>
  <data key="d8">[triosephosphate isomerase, epididymis secretory protein Li 49, methylglyoxal synthase, triose-phosphate isomerase]</data>
  <data key="d9">triosephosphate isomerase 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.7124">
  <data key="d0">TNF</data>
  <data key="d1">entrez.7124</data>
  <data key="d2">[entrez.7124]</data>
  <data key="d3">TNF</data>
  <data key="d4">[DIF, TNF-alpha, TNFA, TNFSF2, TNLG1F]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">6</data>
  <data key="d7">6p21.33</data>
  <data key="d8">[tumor necrosis factor, APC1 protein, TNF, macrophage-derived, TNF, monocyte-derived, TNF-a, cachectin, tumor necrosis factor ligand 1F, tumor necrosis factor ligand superfamily member 2, tumor necrosis factor-alpha]</data>
  <data key="d9">tumor necrosis factor</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.406938">
  <data key="d0">MIR146A</data>
  <data key="d1">entrez.406938</data>
  <data key="d2">[entrez.406938]</data>
  <data key="d3">MIR146A</data>
  <data key="d4">[MIRN146, MIRN146A, miR-146a, miRNA146A]</data>
  <data key="d5">ncRNA</data>
  <data key="d6">5</data>
  <data key="d7">5q33.3</data>
  <data key="d8">[hsa-mir-146, hsa-mir-146a]</data>
  <data key="d9">microRNA 146a</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.64851">
  <data key="d0">entrez.64851</data>
  <data key="d1">entrez.64851</data>
  <data key="d2">[entrez.64851]</data>
  <data key="d3">NA</data>
  <data key="d4">[-]</data>
  <data key="d5">unknown</data>
  <data key="d6">10</data>
  <data key="d7">10q</data>
  <data key="d8">[-]</data>
  <data key="d9">Alzheimer disease 6</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.43">
  <data key="d0">ACHE</data>
  <data key="d1">entrez.43</data>
  <data key="d2">[entrez.43]</data>
  <data key="d3">ACHE</data>
  <data key="d4">[ACEE, ARACHE, N-ACHE, YT]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">7</data>
  <data key="d7">7q22.1</data>
  <data key="d8">[acetylcholinesterase, Yt blood group, acetylcholinesterase (Yt blood group), apoptosis-related acetylcholinesterase]</data>
  <data key="d9">acetylcholinesterase (Cartwright blood group)</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.101290498">
  <data key="d0">entrez.101290498</data>
  <data key="d1">entrez.101290498</data>
  <data key="d2">[entrez.101290498]</data>
  <data key="d3">NA</data>
  <data key="d4">[-]</data>
  <data key="d5">unknown</data>
  <data key="d6">6</data>
  <data key="d7">6p21.2</data>
  <data key="d8">[-]</data>
  <data key="d9">Alzheimer disease 17</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.353128">
  <data key="d0">entrez.353128</data>
  <data key="d1">entrez.353128</data>
  <data key="d2">[entrez.353128]</data>
  <data key="d3">NA</data>
  <data key="d4">[-]</data>
  <data key="d5">unknown</data>
  <data key="d6">20</data>
  <data key="d7">20p</data>
  <data key="d8">[-]</data>
  <data key="d9">Alzheimer disease 8</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.6653">
  <data key="d0">SORL1</data>
  <data key="d1">entrez.6653</data>
  <data key="d2">[entrez.6653]</data>
  <data key="d3">SORL1</data>
  <data key="d4">[C11orf32, LR11, LRP9, SORLA, SorLA-1, gp250]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">11</data>
  <data key="d7">11q24.1</data>
  <data key="d8">[sortilin-related receptor, LDLR relative with 11 ligand-binding repeats, low-density lipoprotein receptor relative with 11 ligand-binding repeats, mosaic protein LR11, sortilin-related receptor, L(DLR class) A repeats containing, sorting protein-related receptor containing LDLR class A repeats]</data>
  <data key="d9">sortilin related receptor 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.6648">
  <data key="d0">SOD2</data>
  <data key="d1">entrez.6648</data>
  <data key="d2">[entrez.6648]</data>
  <data key="d3">SOD2</data>
  <data key="d4">[GClnc1, IPO-B, IPOB, MNSOD, MVCD6, Mn-SOD]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">6</data>
  <data key="d7">6q25.3</data>
  <data key="d8">[superoxide dismutase [Mn], mitochondrial, Mn superoxide dismutase, epididymis secretory sperm binding protein, gastric cancer-associated lncRNA 1, indophenoloxidase B, manganese-containing superoxide dismutase, mangano-superoxide dismutase, superoxide dismutase 2, mitochondrial]</data>
  <data key="d9">superoxide dismutase 2</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.6517">
  <data key="d0">SLC2A4</data>
  <data key="d1">entrez.6517</data>
  <data key="d2">[entrez.6517]</data>
  <data key="d3">SLC2A4</data>
  <data key="d4">[GLUT4]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">17</data>
  <data key="d7">17p13.1</data>
  <data key="d8">[solute carrier family 2, facilitated glucose transporter member 4, GLUT-4, glucose transporter type 4, insulin-responsive, insulin-responsive glucose transporter type 4, solute carrier family 2 (facilitated glucose transporter), member 4]</data>
  <data key="d9">solute carrier family 2 member 4</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.100271718">
  <data key="d0">entrez.100271718</data>
  <data key="d1">entrez.100271718</data>
  <data key="d2">[entrez.100271718]</data>
  <data key="d3">NA</data>
  <data key="d4">[-]</data>
  <data key="d5">unknown</data>
  <data key="d6">X</data>
  <data key="d7">Xq21.3</data>
  <data key="d8">[-]</data>
  <data key="d9">Alzheimer disease 16</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.55676">
  <data key="d0">SLC30A6</data>
  <data key="d1">entrez.55676</data>
  <data key="d2">[entrez.55676]</data>
  <data key="d3">SLC30A6</data>
  <data key="d4">[MST103, MSTP103, ZNT6]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">2</data>
  <data key="d7">2p22.3</data>
  <data key="d8">[zinc transporter 6, solute carrier family 30 (zinc transporter), member 6]</data>
  <data key="d9">solute carrier family 30 member 6</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.2023">
  <data key="d0">ENO1</data>
  <data key="d1">entrez.2023</data>
  <data key="d2">[entrez.2023]</data>
  <data key="d3">ENO1</data>
  <data key="d4">[ENO1L1, HEL-S-17, MPB1, NNE, PPH]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">1</data>
  <data key="d7">1p36.23</data>
  <data key="d8">[alpha-enolase, c-myc promoter-binding protein-1, 2-phospho-D-glycerate hydro-lyase, MYC promoter-binding protein 1, alpha enolase like 1, enolase 1, (alpha), enolase-alpha, epididymis secretory protein Li 17, non-neural enolase, phosphopyruvate hydratase, plasminogen-binding protein, tau-crystallin]</data>
  <data key="d9">enolase 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.2099">
  <data key="d0">ESR1</data>
  <data key="d1">entrez.2099</data>
  <data key="d2">[entrez.2099]</data>
  <data key="d3">ESR1</data>
  <data key="d4">[ER, ESR, ESRA, ESTRR, Era, NR3A1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">6</data>
  <data key="d7">6q25.1-q25.2</data>
  <data key="d8">[estrogen receptor, E2 receptor alpha, ER-alpha, estradiol receptor, estrogen nuclear receptor alpha, estrogen receptor alpha E1-E2-1-2, estrogen receptor alpha E1-N2-E2-1-2, nuclear receptor subfamily 3 group A member 1, oestrogen receptor alpha]</data>
  <data key="d9">estrogen receptor 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.2041">
  <data key="d0">EPHA1</data>
  <data key="d1">entrez.2041</data>
  <data key="d2">[entrez.2041]</data>
  <data key="d3">EPHA1</data>
  <data key="d4">[EPH, EPHT, EPHT1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">7</data>
  <data key="d7">7q34-q35</data>
  <data key="d8">[ephrin type-A receptor 1, eph tyrosine kinase 1, erythropoietin-producing hepatoma amplified sequence, erythropoietin-producing hepatoma receptor, hEpha1, oncogene EPH, soluble EPHA1 variant 1, soluble EPHA1 variant 2, tyrosine-protein kinase receptor EPH]</data>
  <data key="d9">EPH receptor A1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.2147">
  <data key="d0">F2</data>
  <data key="d1">entrez.2147</data>
  <data key="d2">[entrez.2147]</data>
  <data key="d3">F2</data>
  <data key="d4">[PT, RPRGL2, THPH1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">11</data>
  <data key="d7">11p11.2</data>
  <data key="d8">[prothrombin, prepro-coagulation factor II, prothrombin B-chain, serine protease, thrombin factor II]</data>
  <data key="d9">coagulation factor II, thrombin</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.1718">
  <data key="d0">DHCR24</data>
  <data key="d1">entrez.1718</data>
  <data key="d2">[entrez.1718]</data>
  <data key="d3">DHCR24</data>
  <data key="d4">[DCE, Nbla03646, SELADIN1, seladin-1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">1</data>
  <data key="d7">1p32.3</data>
  <data key="d8">[delta(24)-sterol reductase, 3 beta-hydroxysterol delta 24-reductase, desmosterol-to-cholesterol enzyme, diminuto/dwarf1 homolog, seladin 1, selective AD indicator 1]</data>
  <data key="d9">24-dehydrocholesterol reductase</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.1808">
  <data key="d0">DPYSL2</data>
  <data key="d1">entrez.1808</data>
  <data key="d2">[entrez.1808]</data>
  <data key="d3">DPYSL2</data>
  <data key="d4">[CRMP-2, CRMP2, DHPRP2, DRP-2, DRP2, N2A3, ULIP-2, ULIP2]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">8</data>
  <data key="d7">8p21.2</data>
  <data key="d8">[dihydropyrimidinase-related protein 2, collapsin response mediator protein hCRMP-2, unc-33-like phosphoprotein 2]</data>
  <data key="d9">dihydropyrimidinase like 2</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.1565">
  <data key="d0">CYP2D6</data>
  <data key="d1">entrez.1565</data>
  <data key="d2">[entrez.1565]</data>
  <data key="d3">CYP2D6</data>
  <data key="d4">[CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">22</data>
  <data key="d7">22q13.2</data>
  <data key="d8">[cytochrome P450 2D6, cholesterol 25-hydroxylase, cytochrome P450, family 2, subfamily D, polypeptide 6, cytochrome P450, family 2, subfamily D, polypeptide 7 pseudogene 2, cytochrome P450, family 2, subfamily D, polypeptide 8 pseudogene 2, cytochrome P450, subfamily II (debrisoquine, sparteine, etc., -metabolising), polypeptide 7 pseudogene 2, cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolising), polypeptide 8 pseudogene 2, cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolizing), polypeptide 6, cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolizing)-like 1, cytochrome P450-DB1, debrisoquine 4-hydroxylase, flavoprotein-linked monooxygenase, microsomal monooxygenase, nonfunctional cytochrome P450 2D6, xenobiotic monooxygenase]</data>
  <data key="d9">cytochrome P450 family 2 subfamily D member 6</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.1636">
  <data key="d0">ACE</data>
  <data key="d1">entrez.1636</data>
  <data key="d2">[entrez.1636]</data>
  <data key="d3">ACE</data>
  <data key="d4">[ACE1, CD143, DCP, DCP1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">17</data>
  <data key="d7">17q23.3</data>
  <data key="d8">[angiotensin-converting enzyme, CD143 antigen, angiotensin I converting enzyme (peptidyl-dipeptidase A) 1, angiotensin converting enzyme, somatic isoform, carboxycathepsin, dipeptidyl carboxypeptidase 1, dipeptidyl carboxypeptidase I, kininase II, peptidase P]</data>
  <data key="d9">angiotensin I converting enzyme</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.1392">
  <data key="d0">CRH</data>
  <data key="d1">entrez.1392</data>
  <data key="d2">[entrez.1392]</data>
  <data key="d3">CRH</data>
  <data key="d4">[CRF, CRH1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">8</data>
  <data key="d7">8q13.1</data>
  <data key="d8">[corticoliberin, corticotropin-releasing factor]</data>
  <data key="d9">corticotropin releasing hormone</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.1378">
  <data key="d0">CR1</data>
  <data key="d1">entrez.1378</data>
  <data key="d2">[entrez.1378]</data>
  <data key="d3">CR1</data>
  <data key="d4">[C3BR, C4BR, CD35, KN]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">1</data>
  <data key="d7">1q32.2</data>
  <data key="d8">[complement receptor type 1, C3-binding protein, C3b/C4b receptor, CD35 antigen, Knops blood group antigen, complement component (3b/4b) receptor 1 (Knops blood group), complement receptor 1]</data>
  <data key="d9">complement C3b/C4b receptor 1 (Knops blood group)</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.1471">
  <data key="d0">CST3</data>
  <data key="d1">entrez.1471</data>
  <data key="d2">[entrez.1471]</data>
  <data key="d3">CST3</data>
  <data key="d4">[ARMD11, HEL-S-2]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">20</data>
  <data key="d7">20p11.21</data>
  <data key="d8">[cystatin-C, bA218C14.4 (cystatin C), cystatin 3, epididymis secretory protein Li 2, gamma-trace, neuroendocrine basic polypeptide, post-gamma-globulin]</data>
  <data key="d9">cystatin C</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.1141">
  <data key="d0">CHRNB2</data>
  <data key="d1">entrez.1141</data>
  <data key="d2">[entrez.1141]</data>
  <data key="d3">CHRNB2</data>
  <data key="d4">[EFNL3, nAChRB2]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">1</data>
  <data key="d7">1q21.3</data>
  <data key="d8">[neuronal acetylcholine receptor subunit beta-2, acetylcholine receptor, nicotinic, beta 2 (neuronal), beta2 human neuronal nicotinic acetylcholine receptor, cholinergic receptor, nicotinic beta 2, cholinergic receptor, nicotinic, beta 2 (neuronal), cholinergic receptor, nicotinic, beta polypeptide 2 (neuronal), neuronal nicotinic acetylcholine receptor beta 2]</data>
  <data key="d9">cholinergic receptor nicotinic beta 2 subunit</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.1139">
  <data key="d0">CHRNA7</data>
  <data key="d1">entrez.1139</data>
  <data key="d2">[entrez.1139]</data>
  <data key="d3">CHRNA7</data>
  <data key="d4">[CHRNA7-2, NACHRA7]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">15</data>
  <data key="d7">15q13.3</data>
  <data key="d8">[neuronal acetylcholine receptor subunit alpha-7, a7 nicotinic acetylcholine receptor, alpha 7 neuronal nicotinic acetylcholine receptor, alpha-7 nicotinic cholinergic receptor subunit, cholinergic receptor, nicotinic alpha 7, cholinergic receptor, nicotinic, alpha 7 (neuronal), cholinergic receptor, nicotinic, alpha polypeptide 7, neuronal acetylcholine receptor protein, alpha-7 chain]</data>
  <data key="d9">cholinergic receptor nicotinic alpha 7 subunit</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.1191">
  <data key="d0">CLU</data>
  <data key="d1">entrez.1191</data>
  <data key="d2">[entrez.1191]</data>
  <data key="d3">CLU</data>
  <data key="d4">[AAG4, APO-J, APOJ, CLI, CLU1, CLU2, KUB1, NA1/NA2, SGP-2, SGP2, SP-40, TRPM-2, TRPM2]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">8</data>
  <data key="d7">8p21.1</data>
  <data key="d8">[clusterin, aging-associated protein 4, apolipoprotein J, complement cytolysis inhibitor, complement lysis inhibitor, complement-associated protein SP-40, 40, epididymis secretory sperm binding protein, ku70-binding protein 1, sulfated glycoprotein 2, testosterone-repressed prostate message 2]</data>
  <data key="d9">clusterin</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.1200">
  <data key="d0">TPP1</data>
  <data key="d1">entrez.1200</data>
  <data key="d2">[entrez.1200]</data>
  <data key="d3">TPP1</data>
  <data key="d4">[CLN2, GIG1, LPIC, SCAR7, TPP-1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">11</data>
  <data key="d7">11p15.4</data>
  <data key="d8">[tripeptidyl-peptidase 1, cell growth-inhibiting gene 1 protein, growth-inhibiting protein 1, lysosomal pepstatin insensitive protease, tripeptidyl aminopeptidase, tripeptidyl peptidase I]</data>
  <data key="d9">tripeptidyl peptidase 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.1965">
  <data key="d0">EIF2S1</data>
  <data key="d1">entrez.1965</data>
  <data key="d2">[entrez.1965]</data>
  <data key="d3">EIF2S1</data>
  <data key="d4">[EIF-2, EIF-2A, EIF-2alpha, EIF2, EIF2A]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">14</data>
  <data key="d7">14q23.3</data>
  <data key="d8">[eukaryotic translation initiation factor 2 subunit 1, eIF-2-alpha, eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa]</data>
  <data key="d9">eukaryotic translation initiation factor 2 subunit alpha</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.26330">
  <data key="d0">GAPDHS</data>
  <data key="d1">entrez.26330</data>
  <data key="d2">[entrez.26330]</data>
  <data key="d3">GAPDHS</data>
  <data key="d4">[GAPD2, GAPDH-2, GAPDS, HEL-S-278, HSD-35]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">19</data>
  <data key="d7">19q13.12</data>
  <data key="d8">[glyceraldehyde-3-phosphate dehydrogenase, testis-specific, epididymis secretory protein Li 278, spermatogenic cell-specific glyceraldehyde 3-phosphate dehydrogenase 2, spermatogenic glyceraldehyde-3-phosphate dehydrogenase]</data>
  <data key="d9">glyceraldehyde-3-phosphate dehydrogenase, spermatogenic</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.51338">
  <data key="d0">MS4A4A</data>
  <data key="d1">entrez.51338</data>
  <data key="d2">[entrez.51338]</data>
  <data key="d3">MS4A4A</data>
  <data key="d4">[4SPAN1, CD20-L1, CD20L1, HDCME31P, MS4A4, MS4A7]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">11</data>
  <data key="d7">11q12.2</data>
  <data key="d8">[membrane-spanning 4-domains subfamily A member 4A, CD20 antigen-like 1, Fc epsilon receptor beta subunit homolog, epididymis secretory sperm binding protein, four-span transmembrane protein 1, membrane-spanning 4-domains, subfamily A, member 4]</data>
  <data key="d9">membrane spanning 4-domains A4A</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.51225">
  <data key="d0">ABI3</data>
  <data key="d1">entrez.51225</data>
  <data key="d2">[entrez.51225]</data>
  <data key="d3">ABI3</data>
  <data key="d4">[NESH, SSH3BP3]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">17</data>
  <data key="d7">17q21.32</data>
  <data key="d8">[ABI gene family member 3, new molecule including SH3]</data>
  <data key="d9">ABI family member 3</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.5328">
  <data key="d0">PLAU</data>
  <data key="d1">entrez.5328</data>
  <data key="d2">[entrez.5328]</data>
  <data key="d3">PLAU</data>
  <data key="d4">[ATF, BDPLT5, QPD, UPA, URK, u-PA]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">10</data>
  <data key="d7">10q22.2</data>
  <data key="d8">[urokinase-type plasminogen activator, U-plasminogen activator, plasminogen activator, urinary]</data>
  <data key="d9">plasminogen activator, urokinase</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.5336">
  <data key="d0">PLCG2</data>
  <data key="d1">entrez.5336</data>
  <data key="d2">[entrez.5336]</data>
  <data key="d3">PLCG2</data>
  <data key="d4">[APLAID, FCAS3, PLC-IV, PLC-gamma-2]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">16</data>
  <data key="d7">16q23.3</data>
  <data key="d8">[1-phosphatidylinositol 4, 5-bisphosphate phosphodiesterase gamma-2, phosphoinositide phospholipase C-gamma-2, phospholipase C, gamma 2 (phosphatidylinositol-specific), phospholipase C-IV]</data>
  <data key="d9">phospholipase C gamma 2</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.27328">
  <data key="d0">PCDH11X</data>
  <data key="d1">entrez.27328</data>
  <data key="d2">[entrez.27328]</data>
  <data key="d3">PCDH11X</data>
  <data key="d4">[PCDH-X, PCDH-Y, PCDH11, PCDH11Y, PCDH22, PCDHX, PPP1R119]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">X</data>
  <data key="d7">Xq21.31</data>
  <data key="d8">[protocadherin-11 X-linked, Protocadherin on the Y chromosome, Protocadherin prostate cancer, Protocadherin-11 Y-linked, Protocadherin-22, Protocadherin-PC, protein phosphatase 1, regulatory subunit 119, protocadherin 11X, protocadherin on the X chromosome, protocadherin-S]</data>
  <data key="d9">protocadherin 11 X-linked</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.100188837">
  <data key="d0">entrez.100188837</data>
  <data key="d1">entrez.100188837</data>
  <data key="d2">[entrez.100188837]</data>
  <data key="d3">NA</data>
  <data key="d4">[-]</data>
  <data key="d5">unknown</data>
  <data key="d6">1</data>
  <data key="d7">1q21</data>
  <data key="d8">[-]</data>
  <data key="d9">Alzheimer disease-13</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.100188830">
  <data key="d0">entrez.100188830</data>
  <data key="d1">entrez.100188830</data>
  <data key="d2">[entrez.100188830]</data>
  <data key="d3">NA</data>
  <data key="d4">[-]</data>
  <data key="d5">unknown</data>
  <data key="d6">8</data>
  <data key="d7">8p12-q22</data>
  <data key="d8">[-]</data>
  <data key="d9">Alzheimer disease 12</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.5697">
  <data key="d0">PYY</data>
  <data key="d1">entrez.5697</data>
  <data key="d2">[entrez.5697]</data>
  <data key="d3">PYY</data>
  <data key="d4">[PYY-I, PYY1]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">17</data>
  <data key="d7">17q21.31</data>
  <data key="d8">[peptide YY, peptide tyrosine tyrosine, prepro-PYY]</data>
  <data key="d9">peptide YY</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.22976">
  <data key="d0">PAXIP1</data>
  <data key="d1">entrez.22976</data>
  <data key="d2">[entrez.22976]</data>
  <data key="d3">PAXIP1</data>
  <data key="d4">[CAGF28, CAGF29, PACIP1, PAXIP1L, PTIP, TNRC2]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">7</data>
  <data key="d7">7q36.2</data>
  <data key="d8">[PAX-interacting protein 1, PAX interacting (with transcription-activation domain) protein 1, PAX transcription activation domain interacting protein 1 like, protein encoded by CAG trinucleotide repeats]</data>
  <data key="d9">PAX interacting protein 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.100188754">
  <data key="d0">entrez.100188754</data>
  <data key="d1">entrez.100188754</data>
  <data key="d2">[entrez.100188754]</data>
  <data key="d3">NA</data>
  <data key="d4">[-]</data>
  <data key="d5">unknown</data>
  <data key="d6">1</data>
  <data key="d7">1q25</data>
  <data key="d8">[-]</data>
  <data key="d9">Alzheimer disease 14</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.100188795">
  <data key="d0">entrez.100188795</data>
  <data key="d1">entrez.100188795</data>
  <data key="d2">[entrez.100188795]</data>
  <data key="d3">NA</data>
  <data key="d4">[-]</data>
  <data key="d5">unknown</data>
  <data key="d6">9</data>
  <data key="d7">9p22.1</data>
  <data key="d8">[-]</data>
  <data key="d9">Alzheimer disease-11</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.5468">
  <data key="d0">PPARG</data>
  <data key="d1">entrez.5468</data>
  <data key="d2">[entrez.5468]</data>
  <data key="d3">PPARG</data>
  <data key="d4">[CIMT1, GLM1, NR1C3, PPARG1, PPARG2, PPARgamma]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">3</data>
  <data key="d7">3p25.2</data>
  <data key="d8">[peroxisome proliferator-activated receptor gamma, PPAR-gamma, nuclear receptor subfamily 1 group C member 3, peroxisome proliferator-activated nuclear receptor gamma variant 1]</data>
  <data key="d9">peroxisome proliferator activated receptor gamma</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.5649">
  <data key="d0">RELN</data>
  <data key="d1">entrez.5649</data>
  <data key="d2">[entrez.5649]</data>
  <data key="d3">RELN</data>
  <data key="d4">[ETL7, LIS2, PRO1598, RL]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">7</data>
  <data key="d7">7q22.1</data>
  <data key="d8">[reelin]</data>
  <data key="d9">reelin</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.5664">
  <data key="d0">PSEN2</data>
  <data key="d1">entrez.5664</data>
  <data key="d2">[entrez.5664]</data>
  <data key="d3">PSEN2</data>
  <data key="d4">[AD3L, AD4, CMD1V, PS2, STM2]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">1</data>
  <data key="d7">1q42.13</data>
  <data key="d8">[presenilin-2, AD3LP, AD5, Alzheimer disease 4, E5-1, PS-2, STM-2]</data>
  <data key="d9">presenilin 2</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.5663">
  <data key="d0">PSEN1</data>
  <data key="d1">entrez.5663</data>
  <data key="d2">[entrez.5663]</data>
  <data key="d3">PSEN1</data>
  <data key="d4">[ACNINV3, AD3, FAD, PS-1, PS1, S182]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">14</data>
  <data key="d7">14q24.2</data>
  <data key="d8">[presenilin-1, presenilin-1 isoform I-467]</data>
  <data key="d9">presenilin 1</data>
  <data key="d10">gene</data>
</node>
<node id="entrez.5621">
  <data key="d0">PRNP</data>
  <data key="d1">entrez.5621</data>
  <data key="d2">[entrez.5621]</data>
  <data key="d3">PRNP</data>
  <data key="d4">[ASCR, AltPrP, CD230, CJD, GSS, KURU, PRIP, PrP, PrP27-30, PrP33-35C, PrPc, p27-30]</data>
  <data key="d5">protein-coding</data>
  <data key="d6">20</data>
  <data key="d7">20p13</data>
  <data key="d8">[major prion protein, alternative prion protein, CD230 antigen, prion-related protein]</data>
  <data key="d9">prion protein</data>
  <data key="d10">gene</data>
</node>
<node id="mondo.0011777">
  <data key="d0">Alzheimer disease 8</data>
  <data key="d1">mondo.0011777</data>
  <data key="d2">[mondo.0011777, umls.C1846735, omim.607116, doid.0110041, mesh.C564622]</data>
  <data key="d11">[G30]</data>
  <data key="d8">[Alzheimer disease 8, AD8, Alzheimer's disease 8, Alzheimer disease, familial 8, Alzheimer disease type 8, Alzheimer's disease type 8]</data>
  <data key="d9">An Alzheimer's disease that is characterized by an associated with variation in the region 20p12.2-q11.21.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0010422">
  <data key="d0">Alzheimer disease 16</data>
  <data key="d1">mondo.0010422</data>
  <data key="d2">[mondo.0010422, omim.300756, umls.C2677888, mesh.C567463, doid.0110036]</data>
  <data key="d11">[]</data>
  <data key="d8">[AD16, Alzheimer's disease 16, Alzheimer's disease type 16, Alzheimer disease 16]</data>
  <data key="d9">An Alzheimer's disease that is characterized by an associated with a risk allele in in the PCDH11X gene on chromosome Xq21.3.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0011743">
  <data key="d0">Alzheimer disease 4</data>
  <data key="d1">mondo.0011743</data>
  <data key="d2">[mondo.0011743, umls.C1847200, ncit.C123413, mesh.C536596, doid.0110040, omim.606889]</data>
  <data key="d11">[]</data>
  <data key="d8">[Alzheimer's disease 4, Alzheimer disease type 4, Alzheimer disease, familial4, Alzheimer's disease type 4, familial Alzheimer disease, type 4, Alzheimer disease 4, AD4, familial Alzheimer's disease, type 4]</data>
  <data key="d9">Alzheimer's disease with an early onset (starts before the age of 65). It is caused by mutations in the PSEN2 gene.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0011647">
  <data key="d0">Alzheimer disease 7</data>
  <data key="d1">mondo.0011647</data>
  <data key="d2">[mondo.0011647, omim.606187, mesh.C565251, doid.0110039, umls.C1853555]</data>
  <data key="d11">[G30]</data>
  <data key="d8">[AD7, Alzheimer disease, familial 7, Alzheimer disease 7, Alzheimer disease type 7, Alzheimer's disease type 7, Alzheimer's disease 7]</data>
  <data key="d9">An Alzheimer's disease that is characterized by an associated with variation in the region 10p13.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0011513">
  <data key="d0">Alzheimer disease, familial early-onset, with Coexisting amyloid and prion pathology</data>
  <data key="d1">mondo.0011513</data>
  <data key="d2">[mondo.0011513, umls.C1857933, omim.605055, mesh.C565728]</data>
  <data key="d11">[]</data>
  <data key="d8">[Alzheimer disease, familial early-onset, with Coexisting amyloid and prion pathology]</data>
  <data key="d9"></data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0011561">
  <data key="d0">Alzheimer disease 6</data>
  <data key="d1">mondo.0011561</data>
  <data key="d2">[mondo.0011561, mesh.C565325, doid.0110038, omim.605526]</data>
  <data key="d11">[G30]</data>
  <data key="d8">[Alzheimer disease type 6, Alzheimer disease 6, AD6, Alzheimer's disease type 6, Alzheimer disease 6, late onset, Alzheimer's disease 6]</data>
  <data key="d9">An Alzheimer's disease that is characterized by an associated with variation in the region 10q24.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0011401">
  <data key="d0">Alzheimer disease without neurofibrillary tangles</data>
  <data key="d1">mondo.0011401</data>
  <data key="d2">[mondo.0011401, mesh.C536599, omim.604154, umls.C1858751]</data>
  <data key="d11">[]</data>
  <data key="d8">[Alzheimer disease without neurofibrillary tangles]</data>
  <data key="d9"></data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0012632">
  <data key="d0">Alzheimer disease 15</data>
  <data key="d1">mondo.0012632</data>
  <data key="d2">[mondo.0012632, umls.C1970143, omim.611155, mesh.C566998, doid.0110048]</data>
  <data key="d11">[G30]</data>
  <data key="d8">[Alzheimer disease 15, Alzheimer's disease type 15, Alzheimer's disease 15, AD15]</data>
  <data key="d9">An Alzheimer's disease that is characterized by an associated with variations in the region 3q22-q24.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0012631">
  <data key="d0">Alzheimer disease 14</data>
  <data key="d1">mondo.0012631</data>
  <data key="d2">[mondo.0012631, umls.C1970144, omim.611154, doid.0110047, mesh.C566999]</data>
  <data key="d11">[G30]</data>
  <data key="d8">[Alzheimer disease 14, AD14, Alzheimer's disease 14, Alzheimer's disease type 14]</data>
  <data key="d9">An Alzheimer's disease that is characterized by an associated with variation in the region 1q25.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0012630">
  <data key="d0">Alzheimer disease 13</data>
  <data key="d1">mondo.0012630</data>
  <data key="d2">[mondo.0012630, umls.C1970147, mesh.C567000, omim.611152, doid.0110046]</data>
  <data key="d11">[G30]</data>
  <data key="d8">[Alzheimer's disease type 13, Alzheimer disease 13, AD13, Alzheimer's disease 13]</data>
  <data key="d9">An Alzheimer's disease that is characterized by an associated with variation in the region 1q21.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0012609">
  <data key="d0">Alzheimer disease 12</data>
  <data key="d1">mondo.0012609</data>
  <data key="d2">[mondo.0012609, mesh.C567022, omim.611073, doid.0110045, umls.C1970209]</data>
  <data key="d11">[G30]</data>
  <data key="d8">[Alzheimer disease 12, Alzheimer disease familial 12, Alzheimer's disease 12, Alzheimer's disease type 12, Alzheimer disease type 12, AD12]</data>
  <data key="d9">An Alzheimer's disease that is characterized by an associated with variation in the region 8p12-q22.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0011194">
  <data key="d0">Alzheimer disease 5</data>
  <data key="d1">mondo.0011194</data>
  <data key="d2">[mondo.0011194, mesh.C566578, doid.0110037, omim.602096, umls.C1865868]</data>
  <data key="d11">[G30]</data>
  <data key="d8">[Alzheimer disease, familial 5, Alzheimer disease type 5, Alzheimer disease 5, Alzheimer's disease type 5, AD5]</data>
  <data key="d9"></data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0012344">
  <data key="d0">Alzheimer disease 11</data>
  <data key="d1">mondo.0012344</data>
  <data key="d2">[mondo.0012344, umls.C1853360, omim.609790, mesh.C565228, doid.0110044]</data>
  <data key="d11">[G30]</data>
  <data key="d8">[Alzheimer's disease 11, AD11, Alzheimer's disease type 11, Alzheimer disease 11, Alzheimer disease type 11]</data>
  <data key="d9">An Alzheimer's disease that is characterized by an associated with variation in the region 9p22.1.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0012321">
  <data key="d0">Alzheimer disease 10</data>
  <data key="d1">mondo.0012321</data>
  <data key="d2">[mondo.0012321, doid.0110043, umls.C1864828, omim.609636, mesh.C566465]</data>
  <data key="d11">[G30]</data>
  <data key="d8">[Alzheimer disease 10, Alzheimer's disease 10, AD10, Alzheimer's disease type 10, Alzheimer disease type 10, Alzheimer disease familial 10]</data>
  <data key="d9">An Alzheimer's disease that is characterized by an associated with variation in the region 7q36.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0100088">
  <data key="d0">late-onset familial alzheimer disease</data>
  <data key="d1">mondo.0100088</data>
  <data key="d2">[mondo.0100088]</data>
  <data key="d11">[]</data>
  <data key="d8">[Alzheimer disease type 2]</data>
  <data key="d9">A form of familial Alzheimer disease, that begins after age 65.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0100087">
  <data key="d0">familial Alzheimer disease</data>
  <data key="d1">mondo.0100087</data>
  <data key="d2">[mondo.0100087]</data>
  <data key="d11">[]</data>
  <data key="d8">[Alzheimer disease, familial, FAD, GARD:0000632]</data>
  <data key="d9">A degenerative disease of the brain that causes gradual loss of memory, judgment, and the ability to function socially. About 25% of all Alzheimer disease is familial (more than 2 people in a family have AD). When Alzheimer disease begins before 60 or 65 years of age (early-onset AD) about 60% of the cases are familial (also known as Early-onset familial AD). These cases appear to be inherited in an autosomal dominant manner.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0014316">
  <data key="d0">Alzheimer disease 19</data>
  <data key="d1">mondo.0014316</data>
  <data key="d2">[mondo.0014316, doid.0110051, omim.615711, umls.C3810349]</data>
  <data key="d11">[]</data>
  <data key="d8">[Alzheimer disease 19, Alzheimer's disease type 19, Alzheimer disease caused by mutation in PLD3, AD19, Alzheimer disease type 19, Alzheimer disease 19 late onset, Alzheimer's disease 19, PLD3 Alzheimer disease]</data>
  <data key="d9">Any Alzheimer disease in which the cause of the disease is a mutation in the PLD3 gene.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0004975">
  <data key="d0">Alzheimer disease</data>
  <data key="d1">mondo.0004975</data>
  <data key="d2">[mondo.0004975, doid.10652, ncit.C38778, snomedct.142811000119104, umls.C0002395, ncit.C2866, mesh.D000544]</data>
  <data key="d11">[G30, G30.9]</data>
  <data key="d8">[Alzheimer dementia, Alzheimers dementia, Alzheimer's disease, AD, Alzheimer disease, Alzheimers disease, Alzheimer's dementia]</data>
  <data key="d9">A progressive, neurodegenerative disease characterized by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0014265">
  <data key="d0">Alzheimer disease 18</data>
  <data key="d1">mondo.0014265</data>
  <data key="d2">[mondo.0014265, doid.0110050, umls.C3810041, omim.615590]</data>
  <data key="d11">[]</data>
  <data key="d8">[Alzheimer disease caused by mutation in ADAM10, Alzheimer's disease type 18, Alzheimer disease 18, ADAM10 Alzheimer disease, Alzheimer disease type 18, Alzheimer's disease 18, AD18]</data>
  <data key="d9">Any Alzheimer disease in which the cause of the disease is a mutation in the ADAM10 gene.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0014036">
  <data key="d0">Alzheimer disease 17</data>
  <data key="d1">mondo.0014036</data>
  <data key="d2">[mondo.0014036, umls.C3554452, omim.615080, doid.0110049]</data>
  <data key="d11">[]</data>
  <data key="d8">[AD17, Alzheimer disease 17, late onset, Alzheimer's disease type 17, Alzheimer's disease 17, Alzheimer disease 17]</data>
  <data key="d9">An Alzheimer's disease that is characterized by an associated with mutations in the gene TREM2.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0015140">
  <data key="d0">early-onset autosomal dominant Alzheimer disease</data>
  <data key="d1">mondo.0015140</data>
  <data key="d2">[mondo.0015140, orpha.1020, umls.CN043596]</data>
  <data key="d11">[G30.0]</data>
  <data key="d8">[early-onset familial autosomal dominant Alzheimer disease, EOFAD]</data>
  <data key="d9">Early-onset autosomal dominant Alzheimer disease (EOAD) is a progressive dementia with reduction of cognitive functions. EOAD presents the same phenotype as sporadic Alzheimer disease (AD) but has an early age of onset, usually before 60 years old.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0010783">
  <data key="d0">Alzheimer disease, susceptibility to, mitochondrial</data>
  <data key="d1">mondo.0010783</data>
  <data key="d2">[mondo.0010783, omim.502500]</data>
  <data key="d11">[]</data>
  <data key="d8">[Alzheimer disease, susceptibility to, mitochondrial]</data>
  <data key="d9"></data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0007089">
  <data key="d0">Alzheimer disease 2</data>
  <data key="d1">mondo.0007089</data>
  <data key="d2">[mondo.0007089, mesh.C536595, doid.0110035, omim.104310, umls.C1863051]</data>
  <data key="d11">[G30]</data>
  <data key="d8">[Alzheimer's disease type 2, Alzheimer disease type 2, AD2, Alzheimer disease-2, Alzheimer disease 2, late onset, Alzheimer disease associated with APOE4, Alzheimer disease 2, Alzheimer's disease 2]</data>
  <data key="d9">An Alzheimer's disease that is characterized by an association of the apolipoprotein E E4 allele.</data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0007088">
  <data key="d0">Alzheimer disease type 1</data>
  <data key="d1">mondo.0007088</data>
  <data key="d2">[mondo.0007088, doid.0080348, omim.104300, umls.C2931257]</data>
  <data key="d11">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">disorder</data>
</node>
<node id="mondo.0011913">
  <data key="d0">Alzheimer disease 3</data>
  <data key="d1">mondo.0011913</data>
  <data key="d2">[mondo.0011913, ncit.C123412, doid.0110042, omim.607822]</data>
  <data key="d11">[]</data>
  <data key="d8">[Alzheimer's disease 3, Alzheimer disease type 3, Alzheimer's disease type 3, AD3, Alzheimer disease familial 3, early-onset autosomal dominant Alzheimer disease caused by mutation in PSEN1, familial Alzheimer disease, type 3, Alzheimer disease 3, Alzheimer disease 3, early onset, familial Alzheimer's disease, type 3, PSEN1 early-onset autosomal dominant Alzheimer disease]</data>
  <data key="d9">Alzheimer's disease with an early onset (starts before the age of 65). It is caused by mutations in the PSEN1 gene.</data>
  <data key="d10">disorder</data>
</node>
<node id="drugbank.DB04591">
  <data key="d0">N-{2,2-DIFLUORO-2-[(2R)-PIPERIDIN-2-YL]ETHYL}-2-[2-(1H-1,2,4-TRIAZOL-1-YL)BENZYL][1,3]OXAZOLO[4,5-C]PYRIDIN-4-AMINE</data>
  <data key="d1">drugbank.DB04591</data>
  <data key="d2">[drugbank.DB04591]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-{2,2-difluoro-2-[(2R)-piperidin-2-yl]ethyl}-2-{[2-(1H-1,2,4-triazol-1-yl)phenyl]methyl}-[1,3]oxazolo[4,5-c]pyridin-4-amine</data>
  <data key="d15">C22H23F2N7O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H23F2N7O/c23-22(24,18-7-3-4-9-26-18)12-28-21-20-17(8-10-27-21)32-19(30-20)11-15-5-1-2-6-16(15)31-14-25-13-29-31/h1-2,5-6,8,10,13-14,18,26H,3-4,7,9,11-12H2,(H,27,28)/t18-/m1/s1</data>
  <data key="d20">[H][C@@]1(CCCCN1)C(F)(F)CNC1=NC=CC2=C1N=C(CC1=CC=CC=C1N1C=NC=N1)O2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03283">
  <data key="d0">beta-L-fucose</data>
  <data key="d1">drugbank.DB03283</data>
  <data key="d2">[drugbank.DB03283, drugbank.EXPT01510]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S,3S,4R,5S,6S)-6-methyloxane-2,3,4,5-tetrol</data>
  <data key="d15">C6H12O5</data>
  <data key="d16">13224-93-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3+,4+,5-,6-/m0/s1</data>
  <data key="d20">C[C@@H]1O[C@H](O)[C@@H](O)[C@H](O)[C@@H]1O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[6-deoxy-beta-L-galactopyranose, beta-L-fucopyranose]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04534">
  <data key="d0">5-Nitroindazole</data>
  <data key="d1">drugbank.DB04534</data>
  <data key="d2">[drugbank.DB04534, drugbank.EXPT00255]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Pyrazoles]</data>
  <data key="d14">5-nitro-1H-indazole</data>
  <data key="d15">C7H5N3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H5N3O2/c11-10(12)6-1-2-7-5(3-6)4-8-9-7/h1-4H,(H,8,9)</data>
  <data key="d20">O=N(=O)C1=CC=C2NN=CC2=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05869">
  <data key="d0">Ethyl pyruvate</data>
  <data key="d1">drugbank.DB05869</data>
  <data key="d2">[drugbank.DB05869]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Keto Acids]</data>
  <data key="d14">ethyl 2-oxopropanoate</data>
  <data key="d15">C5H8O3</data>
  <data key="d16">617-35-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C5H8O3/c1-3-8-5(7)4(2)6/h3H2,1-2H3</data>
  <data key="d20">CCOC(=O)C(C)=O</data>
  <data key="d21">Investigated for use/treatment in burns and burn infections, cardiac surgery, inflammatory disorders (unspecified), ischemic reperfusion injury, and sepsis and septicemia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-oxopropanoic acid ethyl ester, 2-oxopropionic acid ethyl ester, Ethyl 2-oxopropanoate, Ethyl 2-oxopropionate, Ethyl methylglyoxylate, Pyruvic acid ethyl ester, Pyruvic acid, ethyl ester]</data>
  <data key="d9">CTI-01 (ethyl pyruvate) is a novel anti-inflammatory agent for the treatment of critical inflammatory conditions. CTI-01 shows a  potent anti-inflammatory and tissue protection activity in multiple animal models of disease including pancreatitis, ischemia-reperfusion injury, sepsis, renal injury and endotoxemia.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05882">
  <data key="d0">CHF 4227</data>
  <data key="d1">drugbank.DB05882</data>
  <data key="d2">[drugbank.DB05882]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Pyrans]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in osteoporosis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">CHF 4227 is a new selective estrogen receptor modulator (SERM). The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used in postmenopausal therapy.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05879">
  <data key="d0">AME-527</data>
  <data key="d1">drugbank.DB05879</data>
  <data key="d2">[drugbank.DB05879]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in rheumatoid arthritis.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">AME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05890">
  <data key="d0">Veglin</data>
  <data key="d1">drugbank.DB05890</data>
  <data key="d2">[drugbank.DB05890]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">1220118-27-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[VEGF-AS]</data>
  <data key="d9">VEGF-AS (Veglin) is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by VasGene Therapeutics, Inc. for the treatment of a variety of malignancies including mesothelioma. Veglin is one of several newly developed non-chemotherapy drugs being tested for possible utilization in the ongoing struggle to combat malignant mesothelioma.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04556">
  <data key="d0">3-[(1s)-1-(Dimethylamino)Ethyl]Phenol</data>
  <data key="d1">drugbank.DB04556</data>
  <data key="d2">[drugbank.DB04556, drugbank.EXPT02841]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-[(1S)-1-(dimethylamino)ethyl]phenol</data>
  <data key="d15">C10H15NO</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H15NO/c1-8(11(2)3)9-5-4-6-10(12)7-9/h4-8,12H,1-3H3/t8-/m0/s1</data>
  <data key="d20">[H][C@@](C)(N(C)C)C1=CC(O)=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04559">
  <data key="d0">N-(Chlorophenyl)-N'-Hydroxyguanidine</data>
  <data key="d1">drugbank.DB04559</data>
  <data key="d2">[drugbank.DB04559, drugbank.EXPT02578]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-(4-chlorophenyl)-1-hydroxyguanidine</data>
  <data key="d15">C7H8ClN3O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H8ClN3O/c8-5-1-3-6(4-2-5)10-7(9)11-12/h1-4,12H,(H3,9,10,11)</data>
  <data key="d20">ONC(=N)NC1=CC=C(Cl)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04573">
  <data key="d0">Estriol</data>
  <data key="d1">drugbank.DB04573</data>
  <data key="d2">[drugbank.DB04573, drugbank.EXPT01361, drugbank.DB05375]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Estradiol Congeners, Estranes, Estrenes, Estrogens, Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Natural and Semisynthetic Estrogens, Plain, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Substrates, Sex Hormones and Modulators of the Genital System, Steroids]</data>
  <data key="d14">(1S,10R,11S,13R,14R,15S)-15-methyltetracyclo[8.7.0.0,.0,]heptadeca-2(7),3,5-triene-5,13,14-triol</data>
  <data key="d15">C18H24O3</data>
  <data key="d16">50-27-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H24O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3/t13-,14-,15+,16-,17+,18+/m1/s1</data>
  <data key="d20">[H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3</data>
  <data key="d21">Used as a test to determine the general health of an unborn fetus.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(16, 17)-estra-1, 3, 5(10)-triene-3, 16, 17-triol, 1, 3, 5(10)-Estratriene-3, 16-alpha, 17beta-triol, 16-alpha-Hydroxyestradiol, 16alpha-hydroxyestradiol, 16-hydroxyestradiol, 16, 17-estriol, 3, 16alpha, 17beta-Trihydroxy-delta(1, 3, 5)-estratriene, Estriol, Oestriol, striol, Trihydroxyestrin]</data>
  <data key="d9">A hydroxylated metabolite of estradiol or estrone that has a hydroxyl group at C3-beta, 16-alpha, and 17-beta position. Estriol is a major urinary estrogen. During pregnancy, large amount of estriol is produced by the placenta. Isomers with inversion of the hydroxyl group or groups are called epiestriol. Though estriol is used as part of the primarily North American phenomenon of bioidentical hormone replacement therapy, it is not approved for use by the FDA or Health Canada. It is however available in the United States by prescription filled only by compounding pharmacies. It has also been approved and marketed throughout Europe and Asia for approximately 40 years for the treatment of post-menopausal hot flashes.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04575">
  <data key="d0">Quinestrol</data>
  <data key="d1">drugbank.DB04575</data>
  <data key="d2">[drugbank.DB04575]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Estradiol Congeners, Estrogenic Steroids, Alkylated, Estrogens, Ethinyl Estradiol, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Norpregnanes, Norpregnatrienes, Norsteroids, Steroids]</data>
  <data key="d14">(1S,10R,11S,14R,15S)-5-(cyclopentyloxy)-14-ethynyl-15-methyltetracyclo[8.7.0.0,.0,]heptadeca-2(7),3,5-trien-14-ol</data>
  <data key="d15">C25H32O2</data>
  <data key="d16">152-43-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C25H32O2/c1-3-25(26)15-13-23-22-10-8-17-16-19(27-18-6-4-5-7-18)9-11-20(17)21(22)12-14-24(23,25)2/h1,9,11,16,18,21-23,26H,4-8,10,12-15H2,2H3/t21-,22-,23+,24+,25+/m1/s1</data>
  <data key="d20">[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC1CCCC1)C=C3</data>
  <data key="d21">Used in hormone replacement therapy, treating symptoms of menopause such as hot flashes. Also used to treat breast and prostate cancer.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[17-alpha-Ethinylestradiol 3-cyclopentyl ether, 17alpha-Ethynylestradiol 3-cyclopentyl ether, Estradiol-17-beta 3-cyclopentyl ether, Quinestrol, Quinestrolo, Quinestrolum]</data>
  <data key="d9">The 3-cyclopentyl ether of ethinyl estradiol.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04574">
  <data key="d0">Estrone sulfate</data>
  <data key="d1">drugbank.DB04574</data>
  <data key="d2">[drugbank.DB04574]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[17-Ketosteroids, Adrenal Cortex Hormones, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Estradiol Congeners, Estranes, Estrenes, Estrogens, Estrogens, Conjugated (USP), Gonadal Hormones, Gonadal Steroid Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Ketosteroids, MATE 1 Substrates, MATE 2 Substrates, MATE substrates, Reproductive Control Agents, Steroids]</data>
  <data key="d14">[(1S,10R,11S,15S)-15-methyl-14-oxotetracyclo[8.7.0.0,.0,]heptadeca-2(7),3,5-trien-5-yl]oxidanesulfonic acid</data>
  <data key="d15">C18H22O5S</data>
  <data key="d16">481-97-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H22O5S/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22)/t14-,15-,16+,18+/m1/s1</data>
  <data key="d20">C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O</data>
  <data key="d21">Estropipate is used for the treatment of moderate to severe vasomotor symptoms associated with the monopause, and moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. It is also used to treat hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and prevent postmenopausal osteoporosis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Estra-1, 3, 5 (10)-triene-17-one-3-yl-sulfate, Estrone 3-sulfate, Estrone bisulfate, Estrone hemisulfate, Estrone hydrogen sulfate, estrone sulphate, Estrone-3-sulphate, Estrone, hydrogen sulfate]</data>
  <data key="d9">Estrone sulfate (as estropipate) is a form of estrogen. It has several uses such as: alleviate symptoms of menopause as hormone replacement therapy, treatment some types of infertility, treatment of some conditions leading to underdevelopment of female sexual characteristics, treatment of vaginal atrophy, treatment of some types of breast cancer (particularly in men and postmenopausal women), treatment of prostate cancer and prevention of osteoporosis.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05897">
  <data key="d0">rhIGFBP-3</data>
  <data key="d1">drugbank.DB05897</data>
  <data key="d2">[drugbank.DB05897]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in cancer/tumors (unspecified).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmeds proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of human. It is developed by Insmed  and is currently under phase I of the clinical trail.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04510">
  <data key="d0">3-phospho-D-glyceric acid</data>
  <data key="d1">drugbank.DB04510</data>
  <data key="d2">[drugbank.DB04510, drugbank.EXPT00187]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Acids, Acyclic, Carbohydrates, Hydroxy Acids, Sugar Acids]</data>
  <data key="d14">(2R)-2-hydroxy-3-(phosphonooxy)propanoic acid</data>
  <data key="d15">C3H7O7P</data>
  <data key="d16">820-11-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C3H7O7P/c4-2(3(5)6)1-10-11(7,8)9/h2,4H,1H2,(H,5,6)(H2,7,8,9)/t2-/m1/s1</data>
  <data key="d20">O[C@H](COP(O)(O)=O)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3-Phospho-(R)-glycerate, 3-phospho-D-glycerate, 3-Phosphoglycerate, D-glycerate 3-phosphate]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04513">
  <data key="d0">N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide</data>
  <data key="d1">drugbank.DB04513</data>
  <data key="d2">[drugbank.DB04513, drugbank.EXPT03246]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Amides, Calcium-Calmodulin-Dependent Protein Kinases, antagonists &amp; inhibitors, Cardiovascular Agents, Enzyme Inhibitors, Sulfones, Sulfur Compounds, Vasodilating Agents]</data>
  <data key="d14">N-(6-aminohexyl)-5-chloronaphthalene-1-sulfonamide</data>
  <data key="d15">C16H21ClN2O2S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H21ClN2O2S/c17-15-9-5-8-14-13(15)7-6-10-16(14)22(20,21)19-12-4-2-1-3-11-18/h5-10,19H,1-4,11-12,18H2</data>
  <data key="d20">NCCCCCCNS(=O)(=O)C1=CC=CC2=C1C=CC=C2Cl</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05846">
  <data key="d0">Mito-4509</data>
  <data key="d1">drugbank.DB05846</data>
  <data key="d2">[drugbank.DB05846]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in alzheimer's disease, neurologic disorders, parkinson's disease, and retinal disorders (unspecified).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Mito-4509 is a non-feminizing estrogen analog that could affect mitochondrial metabolic pathways.  It is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05855">
  <data key="d0">Rivanicline</data>
  <data key="d1">drugbank.DB05855</data>
  <data key="d2">[drugbank.DB05855]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Alkaloids, Pyridines, Solanaceous Alkaloids]</data>
  <data key="d14">methyl[(3E)-4-(pyridin-3-yl)but-3-en-1-yl]amine</data>
  <data key="d15">C10H14N2</data>
  <data key="d16">15585-43-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H14N2/c1-11-7-3-2-5-10-6-4-8-12-9-10/h2,4-6,8-9,11H,3,7H2,1H3/b5-2+</data>
  <data key="d20">CNCC\C=C\C1=CN=CC=C1</data>
  <data key="d21">Investigated for use/treatment in ulcerative colitis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(3E)-N-methyl-4-(pyridin-3-yl)but-3-en-1-amine, (E)-metanicotine, (E)-N-Methyl-4-(3-pyridinyl)-3-butene-1-amine, N-methyl-4-(3-pyridinyl)-(3E)-3-buten-1-amine, trans-metanicotine]</data>
  <data key="d9">Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a partial agonist at neuronal nicotinic acetylcholine receptors, binding primarily to the 42 subtype. It was originally developed as a potential treatment for Alzheimer's disease for its nootropic effects but has also been found to inhibit the production of Interleukin-8. It has subsequently been developed as a potential anti-inflammatory treatment for ulcerative colitis. Rivanicline also has stimulant and analgesic actions which are thought due to increased noradrenaline release.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05854">
  <data key="d0">CLX-0921</data>
  <data key="d1">drugbank.DB05854</data>
  <data key="d2">[drugbank.DB05854]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Sulfur Compounds]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in diabetes mellitus type 2.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">CLX-0921 is investigated for use/treatment in diabetes mellitus type 2. CLX-0921 is a solid. CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. This substance targets the protein peroxisome proliferator-activated receptor gamma. It is a pharmacologically active antihyperglycemic agent that acts by increasing peripheral tissue sensitivity to insulin.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03297">
  <data key="d0">Benzylsulfinic Acid</data>
  <data key="d1">drugbank.DB03297</data>
  <data key="d2">[drugbank.DB03297, drugbank.EXPT02622]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">phenylmethanesulfonic acid</data>
  <data key="d15">C7H8O3S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H8O3S/c8-11(9,10)6-7-4-2-1-3-5-7/h1-5H,6H2,(H,8,9,10)</data>
  <data key="d20">OS(=O)(=O)CC1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02044">
  <data key="d0">N-(3-(Aminomethyl)Benzyl)Acetamidine</data>
  <data key="d1">drugbank.DB02044</data>
  <data key="d2">[drugbank.DB02044, drugbank.EXPT00036]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Amines, Benzene Derivatives, Benzyl Compounds, Enzyme Inhibitors, Nitric Oxide Synthase, antagonists &amp; inhibitors]</data>
  <data key="d14">N-{[3-(aminomethyl)phenyl]methyl}ethanimidamide</data>
  <data key="d15">C10H15N3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H15N3/c1-8(12)13-7-10-4-2-3-9(5-10)6-11/h2-5H,6-7,11H2,1H3,(H2,12,13)</data>
  <data key="d20">CC(=N)NCC1=CC=CC(CN)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04697">
  <data key="d0">TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE</data>
  <data key="d1">drugbank.DB04697</data>
  <data key="d2">[drugbank.DB04697]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(1s,4s)-N-[(2R)-1-[(2S)-2-{[(1R)-1-{[(1S)-1-carbamoyl-5-[(diaminomethylidene)amino]pentyl]carbamoyl}-2-(4-hydroxyphenyl)ethyl]carbamoyl}azetidin-1-yl]-3-cyclohexyl-1-oxopropan-2-yl]-4-{[(diaminomethylidene)amino]methyl}cyclohexane-1-carboxamide</data>
  <data key="d15">C38H61N11O6</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C38H61N11O6/c39-32(51)28(8-4-5-18-44-37(40)41)46-34(53)29(20-24-11-15-27(50)16-12-24)47-35(54)31-17-19-49(31)36(55)30(21-23-6-2-1-3-7-23)48-33(52)26-13-9-25(10-14-26)22-45-38(42)43/h11-12,15-16,23,25-26,28-31,50H,1-10,13-14,17-22H2,(H2,39,51)(H,46,53)(H,47,54)(H,48,52)(H4,40,41,44)(H4,42,43,45)/t25-,26+,28-,29+,30+,31-/m0/s1</data>
  <data key="d20">NC(N)=NCCCC[C@H](NC(=O)[C@@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H]1CCN1C(=O)[C@@H](CC1CCCCC1)NC(=O)[C@@H]1CC[C@H](CN=C(N)N)CC1)C(N)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14034">
  <data key="d0">Darglitazone</data>
  <data key="d1">drugbank.DB14034</data>
  <data key="d2">[drugbank.DB14034]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Sulfur Compounds, Thiazoles]</data>
  <data key="d14">5-({4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl}methyl)-1,3-thiazolidine-2,4-dione</data>
  <data key="d15">C23H20N2O4S</data>
  <data key="d16">141200-24-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H20N2O4S/c1-14-18(24-22(29-14)17-5-3-2-4-6-17)11-12-19(26)16-9-7-15(8-10-16)13-20-21(27)25-23(28)30-20/h2-10,20H,11-13H2,1H3,(H,25,27,28)</data>
  <data key="d20">CC1=C(CCC(=O)C2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C(O1)C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03380">
  <data key="d0">L-tyrosinamide</data>
  <data key="d1">drugbank.DB03380</data>
  <data key="d2">[drugbank.DB03380, drugbank.EXPT03135]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Amino Acids, Amino Acids, Aromatic, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins]</data>
  <data key="d14">(2S)-2-amino-3-(4-hydroxyphenyl)propanamide</data>
  <data key="d15">C9H12N2O2</data>
  <data key="d16">4985-46-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H12N2O2/c10-8(9(11)13)5-6-1-3-7(12)4-2-6/h1-4,8,12H,5,10H2,(H2,11,13)/t8-/m0/s1</data>
  <data key="d20">[H][C@](N)(CC1=CC=C(O)C=C1)C(N)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(2S)-2-amino-3-(4-hydroxyphenyl)propanamide, L-Tyrosine amide, Tyrosinamide, Tyrosine amide]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02052">
  <data key="d0">Indirubin-3'-Monoxime</data>
  <data key="d1">drugbank.DB02052</data>
  <data key="d2">[drugbank.DB02052, drugbank.EXPT01949]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Amines, Hydroxylamines]</data>
  <data key="d14">3-[(2Z,3E)-3-(hydroxyimino)-2,3-dihydro-1H-indol-2-ylidene]-2,3-dihydro-1H-indol-2-one</data>
  <data key="d15">C16H11N3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H11N3O2/c20-16-13(9-5-1-3-7-11(9)18-16)15-14(19-21)10-6-2-4-8-12(10)17-15/h1-8,17,21H,(H,18,20)/b15-13-,19-14+</data>
  <data key="d20">O\N=C1\C(\NC2=C\1C=CC=C2)=C1\C(=O)NC2=C1C=CC=C2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02048">
  <data key="d0">1,2,4-Triazole-Carboxamidine</data>
  <data key="d1">drugbank.DB02048</data>
  <data key="d2">[drugbank.DB02048, drugbank.EXPT03150]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">[amino(1H-1,2,4-triazol-1-yl)methylidene]azanium</data>
  <data key="d15">C3H6N5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C3H5N5/c4-3(5)8-2-6-1-7-8/h1-2H,(H3,4,5)/p+1</data>
  <data key="d20">NC(=[NH2+])N1C=NC=N1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03379">
  <data key="d0">2-Carboxyethylphosphonic Acid</data>
  <data key="d1">drugbank.DB03379</data>
  <data key="d2">[drugbank.DB03379, drugbank.EXPT00189]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-phosphonopropanoic acid</data>
  <data key="d15">C3H7O5P</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C3H7O5P/c4-3(5)1-2-9(6,7)8/h1-2H2,(H,4,5)(H2,6,7,8)</data>
  <data key="d20">OC(=O)CCP(O)(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02073">
  <data key="d0">Biliverdine IX Alpha</data>
  <data key="d1">drugbank.DB02073</data>
  <data key="d2">[drugbank.DB02073, drugbank.EXPT00714]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-(2-{[(2Z)-3-(2-carboxyethyl)-5-{[(2Z)-4-ethenyl-3-methyl-5-oxo-2,5-dihydro-1H-pyrrol-2-ylidene]methyl}-4-methyl-2H-pyrrol-2-ylidene]methyl}-5-{[(2Z)-3-ethenyl-4-methyl-5-oxo-2,5-dihydro-1H-pyrrol-2-ylidene]methyl}-4-methyl-1H-pyrrol-3-yl)propanoic acid</data>
  <data key="d15">C33H34N4O6</data>
  <data key="d16">114-25-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C33H34N4O6/c1-7-20-19(6)32(42)37-27(20)14-25-18(5)23(10-12-31(40)41)29(35-25)15-28-22(9-11-30(38)39)17(4)24(34-28)13-26-16(3)21(8-2)33(43)36-26/h7-8,13-15,35H,1-2,9-12H2,3-6H3,(H,36,43)(H,37,42)(H,38,39)(H,40,41)/b26-13-,27-14-,28-15-</data>
  <data key="d20">CC1=C(C=C)\C(NC1=O)=C\C1=C(C)C(CCC(O)=O)=C(N1)\C=C1/N=C(/C=C2\NC(=O)C(C=C)=C2C)C(C)=C1CCC(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02077">
  <data key="d0">L-N(omega)-Nitroarginine-(4R)-Amino-L-Proline Amide</data>
  <data key="d1">drugbank.DB02077</data>
  <data key="d2">[drugbank.DB02077, drugbank.EXPT01254]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S,4R)-4-[(2S)-2-amino-5-(1-nitrocarbamimidamido)pentanamido]pyrrolidine-2-carboxamide</data>
  <data key="d15">C11H22N8O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H22N8O4/c12-7(2-1-3-15-11(14)18-19(22)23)10(21)17-6-4-8(9(13)20)16-5-6/h6-8,16H,1-5,12H2,(H2,13,20)(H,17,21)(H3,14,15,18)/t6-,7+,8+/m1/s1</data>
  <data key="d20">N[C@@H](CCCNC(=N)N[N+]([O-])=O)C(=O)N[C@H]1CN[C@@H](C1)C(N)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05992">
  <data key="d0">Plinabulin</data>
  <data key="d1">drugbank.DB05992</data>
  <data key="d2">[drugbank.DB05992]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Piperazines]</data>
  <data key="d14">(3Z,6Z)-3-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]-6-(phenylmethylidene)piperazine-2,5-dione</data>
  <data key="d15">C19H20N4O2</data>
  <data key="d16">714272-27-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H20N4O2/c1-19(2,3)16-13(20-11-21-16)10-15-18(25)22-14(17(24)23-15)9-12-7-5-4-6-8-12/h4-11H,1-3H3,(H,20,21)(H,22,25)(H,23,24)/b14-9-,15-10-</data>
  <data key="d20">CC(C)(C)C1=C(\C=C2/NC(=O)\C(NC2=O)=C\C2=CC=CC=C2)N=CN1</data>
  <data key="d21">Investigated for use/treatment in cancer/tumors (unspecified).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03331">
  <data key="d0">N-Naphthalen-1-Ylmethyl-2'-[3,5-Dimethoxybenzamido]-2'-Deoxy-Adenosine</data>
  <data key="d1">drugbank.DB03331</data>
  <data key="d2">[drugbank.DB03331, drugbank.EXPT02362]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-[(2R,3R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-2-{6-[(naphthalen-1-ylmethyl)amino]-9H-purin-9-yl}oxolan-3-yl]-3,5-dimethoxybenzene-1-carboximidic acid</data>
  <data key="d15">C30H30N6O6</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C30H30N6O6/c1-40-20-10-19(11-21(12-20)41-2)29(39)35-24-26(38)23(14-37)42-30(24)36-16-34-25-27(32-15-33-28(25)36)31-13-18-8-5-7-17-6-3-4-9-22(17)18/h3-12,15-16,23-24,26,30,37-38H,13-14H2,1-2H3,(H,35,39)(H,31,32,33)/t23-,24-,26-,30-/m1/s1</data>
  <data key="d20">[H][C@]1(CO)O[C@@]([H])(N2C=NC3=C(NCC4=CC=CC5=CC=CC=C45)N=CN=C23)[C@]([H])(N=C(O)C2=CC(OC)=CC(OC)=C2)[C@]1([H])O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03332">
  <data key="d0">5,6-Cyclic-Tetrahydropteridine</data>
  <data key="d1">drugbank.DB03332</data>
  <data key="d2">[drugbank.DB03332, drugbank.EXPT00534]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(6aR)-3-amino-1H,2H,5H,6H,6aH,7H,9H-[1,3]oxazolo[3,4-f]pteridine-1,9-dione</data>
  <data key="d15">C8H9N5O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C8H9N5O3/c9-7-11-5-4(6(14)12-7)13-3(1-10-5)2-16-8(13)15/h3H,1-2H2,(H4,9,10,11,12,14)/t3-/m1/s1</data>
  <data key="d20">NC1=NC2=C(N3[C@@H](COC3=O)CN2)C(=O)N1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02010">
  <data key="d0">Staurosporine</data>
  <data key="d1">drugbank.DB02010</data>
  <data key="d2">[drugbank.DB02010, drugbank.EXPT02970, drugbank.EXPT02972]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Alkaloids, Carbazoles, Enzyme Inhibitors, Indole Alkaloids, Indoles, P-glycoprotein/ABCB1 Inhibitors]</data>
  <data key="d14">(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1,.0,.0,.0,.0,.0,]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one</data>
  <data key="d15">C28H26N4O3</data>
  <data key="d16">62996-74-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1</data>
  <data key="d20">[H][C@]1(C[C@@]2([H])O[C@](C)(N3C4=CC=CC=C4C4=C5CNC(=O)C5=C5C6=CC=CC=C6N2C5=C34)[C@]1([H])OC)NC</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">An indolocarbazole that is a potent protein kinase C inhibitor which enhances cAMP-mediated responses in human neuroblastoma cells. (Biochem Biophys Res Commun 1995;214(3):1114-20)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04677">
  <data key="d0">N-METHYL-N-[(1R)-1-METHYL-2-PHENYLETHYL]PROP-2-EN-1-AMINE</data>
  <data key="d1">drugbank.DB04677</data>
  <data key="d2">[drugbank.DB04677]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">methyl[(2R)-1-phenylpropan-2-yl](prop-2-en-1-yl)amine</data>
  <data key="d15">C13H19N</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H19N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h4-9,12H,1,10-11H2,2-3H3/t12-/m1/s1</data>
  <data key="d20">[H][C@@](C)(CC1=CC=CC=C1)N(C)CC=C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03348">
  <data key="d0">Huperzine B</data>
  <data key="d1">drugbank.DB03348</data>
  <data key="d2">[drugbank.DB03348, drugbank.EXPT01794]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Drugs, Chinese Herbal]</data>
  <data key="d14">(1R,9R,10R)-16-methyl-6,14-diazatetracyclo[7.5.3.0,.0,]heptadeca-2(7),3,5,16-tetraen-5-ol</data>
  <data key="d15">C16H20N2O</data>
  <data key="d16">103548-82-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H20N2O/c1-10-7-11-8-14-13(4-5-15(19)18-14)16(9-10)12(11)3-2-6-17-16/h4-5,7,11-12,17H,2-3,6,8-9H2,1H3,(H,18,19)/t11-,12+,16+/m0/s1</data>
  <data key="d20">[H][C@@]12CC3=C(C=CC(O)=N3)[C@]3(CC(C)=C1)NCCC[C@]23[H]</data>
  <data key="d21">Under investigation for the treatment of Alzheimer's disease.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[HupB]</data>
  <data key="d9">Huperzine B is a novel acetylcholinesterase inhibitor.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14011">
  <data key="d0">Nabiximols</data>
  <data key="d1">drugbank.DB14011</data>
  <data key="d2">[drugbank.DB14011]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Agents producing tachycardia, Analgesics, BCRP/ABCG2 Inhibitors, Biological Products, Cannabinoid Receptor Agonists, Cannabinoids and similars, Complex Mixtures, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Pharmaceutical Preparations, Plant Preparations, Terpenes]</data>
  <data key="d14">(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6H,6aH,7H,8H,10aH-benzo[c]isochromen-1-ol; 2-[(1R,6R)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol</data>
  <data key="d15">C42H60O4</data>
  <data key="d16">56575-23-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/2C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15;1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,16-17,22H,5-10H2,1-4H3;11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t16-,17-;17-,18+/m10/s1</data>
  <data key="d20">[H][C@]1(CCC(C)=C[C@@]1([H])C1=C(O)C=C(CCCCC)C=C1O)C(C)=C.[H][C@@]12CCC(C)=C[C@@]1([H])C1=C(O)C=C(CCCCC)C=C1OC2(C)C</data>
  <data key="d21">In Canada, Sativex has received a Notice of Compliance (NOC) for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis (MS) who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy. \n\nSativex has also received a Notice of Compliance with Conditions (NOC/c) for use as an adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis (MS) and as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain. \n\nMarketing authorisations with conditions reflect the promising nature of the clinical evidence and the need for confirmatory studies to verify the clinical benefit. Patients should be advised of the conditional nature of the authorizations with conditions.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Nabiximols (tradename Sativex) is a whole plant extract from the Cannabis species _Cannabis sativa L._ that has been purified into the active components CBD (cannabidiol) and THC (delta-9-tetrahydrocannabinol). For trademark purposes, purified CBD is branded as Nabidiolex, while THC is purified as the product Tetrabinex. Sativex is available in a 1:1 formulation of THC:CBD as an oro-mucosal pump spray used for treatment of neuropathic pain from Multiple Sclerosis (MS) and for intractable cancer pain. Although still largely debated, Cannabis has been shown to have analgesic, anticonvulsant, muscle relaxant, anxiolytic, neuroprotective, anti-oxidant, and anti-psychotic activity [A32477, A32469]. \n\nFrom a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon cannabinoid receptors of the body [A32584]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are two types of cannabinoids found naturally in the resin of the marijuana plant, both of which interact with the cannabinoid receptors found in the human body. While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. While cannabis in its natural plant form is currently used "off-label" for the management of many medical conditions, THC is currently commercially available in synthetic form as [DB00486], as purified isomer as [DB00470], or in a 1:1 formulation with CBD from purified plant extract as [DB14011].\n\nThe primary psychoactive component of Cannabis, delta 9-tetrahydrocannabinol (9-THC), demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors. This activity results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. In contrast to THC's weak agonist activity, CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body [A32469]. Allosteric regulation is achieved through the modulation of receptor activity on a functionally distinct site from the agonist or antagonist binding site. The negative allosteric modulatory effects of CBD are therapeutically important as direct agonists are limited by their psychomimetic effects while direct antagonists are limited by their depressant effects [A32469]. \n\nIn Canada, Sativex has received a Notice of Compliance (NOC) for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis (MS) who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy. \n\nSativex has also received a Notice of Compliance with Conditions (NOC/c) for use as an adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis (MS) and as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02032">
  <data key="d0">1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid</data>
  <data key="d1">drugbank.DB02032</data>
  <data key="d2">[drugbank.DB02032, drugbank.EXPT02137]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Acids, Acyclic, Agents Acting on the Renin-Angiotensin System, Agents that produce hypertension, Amino Acids, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Agents, Enzyme Inhibitors, Imines, Imino Acids, Proline, Protease Inhibitors]</data>
  <data key="d14">(2S)-1-[(2R)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid</data>
  <data key="d15">C9H15NO3S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7-/m0/s1</data>
  <data key="d20">[H][C@](C)(CS)C(=O)N1CCC[C@@]1([H])C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04689">
  <data key="d0">2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID</data>
  <data key="d1">drugbank.DB04689</data>
  <data key="d2">[drugbank.DB04689]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-(5-{3-[(6-benzoyl-1-propylnaphthalen-2-yl)oxy]propoxy}-1H-indol-1-yl)acetic acid</data>
  <data key="d15">C33H31NO5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C33H31NO5/c1-2-7-29-28-13-10-26(33(37)23-8-4-3-5-9-23)20-24(28)11-15-31(29)39-19-6-18-38-27-12-14-30-25(21-27)16-17-34(30)22-32(35)36/h3-5,8-17,20-21H,2,6-7,18-19,22H2,1H3,(H,35,36)</data>
  <data key="d20">CCCC1=C(OCCCOC2=CC3=C(C=C2)N(CC(O)=O)C=C3)C=CC2=C1C=CC(=C2)C(=O)C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02027">
  <data key="d0">N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N'-Nitroguanidine</data>
  <data key="d1">drugbank.DB02027</data>
  <data key="d2">[drugbank.DB02027, drugbank.EXPT01253]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-[(4S)-4-amino-5-[(2-aminoethyl)amino]pentyl]-1-nitroguanidine</data>
  <data key="d15">C8H21N7O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C8H21N7O2/c9-3-5-12-6-7(10)2-1-4-13-8(11)14-15(16)17/h7,12H,1-6,9-10H2,(H3,11,13,14)/t7-/m0/s1</data>
  <data key="d20">NCCNC[C@@H](N)CCCNC(=N)N[N+]([O-])=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03359">
  <data key="d0">M-(N,N,N-Trimethylammonio)-2,2,2-Trifluoro-1,1-Dihydroxyethylbenzene</data>
  <data key="d1">drugbank.DB03359</data>
  <data key="d2">[drugbank.DB03359, drugbank.EXPT02285]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N,N,N-trimethyl-3-(2,2,2-trifluoro-1,1-dihydroxyethyl)anilinium</data>
  <data key="d15">C11H15F3NO2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H15F3NO2/c1-15(2,3)9-6-4-5-8(7-9)10(16,17)11(12,13)14/h4-7,16-17H,1-3H3/q+1</data>
  <data key="d20">C[N+](C)(C)C1=CC=CC(=C1)C(O)(O)C(F)(F)F</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14009">
  <data key="d0">Medical Cannabis</data>
  <data key="d1">drugbank.DB14009</data>
  <data key="d2">[drugbank.DB14009]</data>
  <data key="d12">[experimental, investigational]</data>
  <data key="d13">[Agents producing tachycardia, BCRP/ABCG2 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Pharmaceutical Preparations]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21"></data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Cannabis, Cannabis indica, Cannabis indica top, Cannabis sativa subsp. indica top, Cannabis sativa subsp. indica top extract, Hashish top, Marihuana, Marijuana, Marijuana top]</data>
  <data key="d9">The use of the plant species _Cannabis sativa_ and _Cannabis indica_, popularly known as marijuana, has gained popularity in recent years for the management of a wide variety of medical conditions as a wave of legalization in North America has changed public and medical opinion on its use. Consequently, an expanding body of evidence has begun to emerge that has demonstrated its potential usefulness in the management of conditions such as chronic pain, spasticity, inflammation, epilepsy, and chemotherapy-induced nausea and vomiting among many others[A32585]. This area of research is controversial and has been heavily debated, however, due to concerns over risks of addiction, long-term health effects, and Cannabis' association with schizophrenia.\n\nFrom a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon cannabinoid receptors of the body [A32584]. Tetrahydrocannabinol (THC) and [DB09061] (CBD) are two types of cannabinoids found naturally in the resin of the marijuana plant, both of which interact with the cannabinoid receptors that are found throughout the body. Although THC and CBD have been the most studied cannabinoids, there are many others identified to date including cannabinol (CBN), cannabigerol (CBG), [DB14050] (CBDV), and [DB11755] (THCV) that have been shown to modify the physiological effects of cannabis [A32830]. \n\nWhile both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. THC and CBD are converted from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation when unfertilized female cannabis flowers are activated either through heating, smoking, vaporization, or baking. While cannabis in its natural plant form is currently used "off-label" for the management of many medical conditions, THC is currently commercially available in synthetic form as [DB00486], as purified isomer as [DB00470], or in a 1:1 formulation with CBD from purified plant extract as [DB14011].\n\nCannabinoid receptors are utilized endogenously by the body through the endocannabinoid system, which includes a group of lipid proteins, enzymes, and receptors that are involved in many physiological processes. Through its modulation of neurotransmitter release, the endocannabinoid system regulates cognition, pain sensation, appetite, memory, sleep, immune function, and mood among many others. These effects are largely mediated through two members of the G-protein coupled receptor family, cannabinoid receptors 1 and 2 (CB1 and CB2)[A32585]. CB1 receptors are found in both the central and peripheral nervous systems, with the majority of receptors localized to the hippocampus and amygdala of the brain. Physiological effects of using cannabis make sense in the context of its receptor activity as the hippocampus and amygdala are primarily involved with regulation of memory, fear, and emotion. In contrast, CB2 receptors are mainly found peripherally in immune cells, lymphoid tissue, and peripheral nerve terminals [A32676].\n\nThe primary psychoactive component of Cannabis, delta 9-tetrahydrocannabinol (9-THC), demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors. This activity results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. In contrast to THC's weak agonist activity, CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body [A32469]. Allosteric regulation is achieved through the modulation of receptor activity on a functionally distinct site from the agonist or antagonist binding site, which is therapeutically important as direct agonists are limited by their psychomimetic effects while direct antagonists are limited by their depressant effects [A32469]. \n\nThere is further evidence that CBD also activates 5-HT1A serotonergic and TRPV12 vanilloid receptors, antagonizes alpha-1 adrenergic and -opioid receptors, inhibits synaptosomal uptake of noradrenaline, dopamine, serotonin and gaminobutyric acid and cellular uptake of anandamide, acts on mitochondria Ca2 stores, blocks low-voltage-activated (T-type) Ca2 channels, stimulates activity of the inhibitory glycine-receptor, and inhibits activity of fatty amide hydrolase (FAAH) [A31555, A31574].\n\nDue to the differences in receptor profile between CBD and THC, these cannabinoids are understandably used to treat different conditions. Furthermore, when combined with THC, CBD has been shown to modulate THC's activity, resulting in differences in pharmacological effect between "strains", or chemovars, of the Cannabis plant which are bred to contain different concentrations of CBD and THC. For example, strains containing a high proportion of CBD have been shown to reduce the psychosis- and anxiety-inducing effects of THC [A32833]. Reliably studying the effects of Cannabis is complicated by the large variety of available strains and by the numerous other compounds that Cannabis contains such as terpenes, flavonoids, phenols, amino acids, and fatty acids among many others that have shown potential to modulate the plant's pharmacological effect [A32832,A32824].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14006">
  <data key="d0">Choline salicylate</data>
  <data key="d1">drugbank.DB14006</data>
  <data key="d2">[drugbank.DB14006, drugbank.DBSALT001576]</data>
  <data key="d12">[approved, nutraceutical]</data>
  <data key="d13">[Acids, Carbocyclic, Alcohols, Amines, Amino Alcohols, Ammonium Compounds, Analgesics, Benzene Derivatives, Benzoates, Drugs that are Mainly Renally Excreted, Ethanolamines, Hydroxy Acids, Hydroxybenzoates, Nervous System, Nitrogen Compounds, OCT1 inhibitors, OCT1 substrates, OCT2 Inhibitors, OCT2 Substrates, OCT2 substrates with narrow therapeutic index, Onium Compounds, Pharmaceutical Preparations, Phenols, Quaternary Ammonium Compounds, Salicylates, Salicylic Acid and Derivatives, Trimethyl Ammonium Compounds]</data>
  <data key="d14">(2-hydroxyethyl)trimethylazanium 2-hydroxybenzoate</data>
  <data key="d15">C12H19NO4</data>
  <data key="d16">2016-36-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H6O3.C5H14NO/c8-6-4-2-1-3-5(6)7(9)10;1-6(2,3)4-5-7/h1-4,8H,(H,9,10);7H,4-5H2,1-3H3/q;+1/p-1</data>
  <data key="d20">C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O</data>
  <data key="d21">The oral gel is indicated for the relief of pain and discomfort of common mouth ulcers, cold sores, denture sore spots, infant teething and mouth ulcers, and sore spots due to orthodontic devices in children [L2135].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Choline salicylate]</data>
  <data key="d9">Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever [L2129].\n\nCholine Salicylate is the choline salt of salicylic acid, used as an analgesic, antipyretic and antirheumatic. It relieves mild to moderate pain and reduce fever and inflammation or swelling. Choline salicylate is effective in the treatment of gout, rheumatic fever, rheumatoid arthritis and muscle injuries [L2136].\n\nThis drug is also a main ingredient in teething gels to relieve pains associated with tooth growth in the infant population [L2134].  The UK government has regulated its use, due to toxicity in those under 16 years of age.  Topical oral salicylate gels are no longer indicated for people younger than 16 years for pain associated with infant teething, orthodontic devices, cold sores, or mouth ulcers [L2134].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04614">
  <data key="d0">(R)-tacrine(10)-hupyridone</data>
  <data key="d1">drugbank.DB04614</data>
  <data key="d2">[drugbank.DB04614]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(5R)-5-({10-[(1,2,3,4-tetrahydroacridin-9-yl)amino]decyl}amino)-1,2,5,6,7,8-hexahydroquinolin-2-one</data>
  <data key="d15">C32H44N4O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C32H44N4O/c37-31-21-20-24-27(18-13-19-28(24)36-31)33-22-11-5-3-1-2-4-6-12-23-34-32-25-14-7-9-16-29(25)35-30-17-10-8-15-26(30)32/h7,9,14,16,20-21,27,33H,1-6,8,10-13,15,17-19,22-23H2,(H,34,35)(H,36,37)/t27-/m1/s1</data>
  <data key="d20">O=C1NC2=C(C=C1)[C@@H](CCC2)NCCCCCCCCCCNC1=C2CCCCC2=NC2=CC=CC=C12</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04616">
  <data key="d0">TACRINE(8)-4-AMINOQUINOLINE</data>
  <data key="d1">drugbank.DB04616</data>
  <data key="d2">[drugbank.DB04616]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N1-(quinolin-4-yl)-N8-(1,2,3,4-tetrahydroacridin-9-yl)octane-1,8-diamine</data>
  <data key="d15">C30H36N4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C30H36N4/c1(3-11-20-31-27-19-22-32-26-16-8-5-13-23(26)27)2-4-12-21-33-30-24-14-6-9-17-28(24)34-29-18-10-7-15-25(29)30/h5-6,8-9,13-14,16-17,19,22H,1-4,7,10-12,15,18,20-21H2,(H,31,32)(H,33,34)</data>
  <data key="d20">C(CCCCNC1=C2CCCCC2=NC2=CC=CC=C12)CCCNC1=CC=NC2=CC=CC=C12</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04615">
  <data key="d0">(S)-tacrine(10)-hupyridone</data>
  <data key="d1">drugbank.DB04615</data>
  <data key="d2">[drugbank.DB04615]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(5S)-5-({10-[(1,2,3,4-tetrahydroacridin-9-yl)amino]decyl}amino)-1,2,5,6,7,8-hexahydroquinolin-2-one</data>
  <data key="d15">C32H44N4O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C32H44N4O/c37-31-21-20-24-27(18-13-19-28(24)36-31)33-22-11-5-3-1-2-4-6-12-23-34-32-25-14-7-9-16-29(25)35-30-17-10-8-15-26(30)32/h7,9,14,16,20-21,27,33H,1-6,8,10-13,15,17-19,22-23H2,(H,34,35)(H,36,37)/t27-/m0/s1</data>
  <data key="d20">O=C1NC2=C(C=C1)[C@H](CCC2)NCCCCCCCCCCNC1=C2CCCCC2=NC2=CC=CC=C12</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04617">
  <data key="d0">(9S)-9-[(8-AMMONIOOCTYL)AMINO]-1,2,3,4,9,10-HEXAHYDROACRIDINIUM</data>
  <data key="d1">drugbank.DB04617</data>
  <data key="d2">[drugbank.DB04617]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">9-[(8-azaniumyloctyl)amino]-1,2,3,4-tetrahydroacridin-10-ium</data>
  <data key="d15">C21H33N3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H31N3/c22-15-9-3-1-2-4-10-16-23-21-17-11-5-7-13-19(17)24-20-14-8-6-12-18(20)21/h5,7,11,13H,1-4,6,8-10,12,14-16,22H2,(H,23,24)/p+2</data>
  <data key="d20">[NH3+]CCCCCCCCNC1=C2CCCCC2=[NH+]C2=CC=CC=C12</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03305">
  <data key="d0">N5-Iminoethyl-L-Ornithine</data>
  <data key="d1">drugbank.DB03305</data>
  <data key="d2">[drugbank.DB03305, drugbank.EXPT01862]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-2-amino-5-ethanimidamidopentanoic acid</data>
  <data key="d15">C7H15N3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H15N3O2/c1-5(8)10-4-2-3-6(9)7(11)12/h6H,2-4,9H2,1H3,(H2,8,10)(H,11,12)/t6-/m0/s1</data>
  <data key="d20">[H][C@](N)(CCCNC(C)=N)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05966">
  <data key="d0">TAS-108</data>
  <data key="d1">drugbank.DB05966</data>
  <data key="d2">[drugbank.DB05966]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">(1S,9R,10S,11S,14R,15R)-14-(2-{4-[(diethylamino)methyl]-2-methoxyphenoxy}ethyl)-9,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-trien-5-ol; 2-hydroxypropane-1,2,3-tricarboxylic acid</data>
  <data key="d15">C39H55NO10</data>
  <data key="d16">229634-97-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C33H47NO3.C6H8O7/c1-6-34(7-2)21-23-8-13-30(31(19-23)36-5)37-17-15-25-9-12-29-32-22(3)18-24-20-26(35)10-11-27(24)28(32)14-16-33(25,29)4;7-3(8)1-6(13,5(11)12)2-4(9)10/h8,10-11,13,19-20,22,25,28-29,32,35H,6-7,9,12,14-18,21H2,1-5H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t22-,25-,28-,29+,32-,33-;/m1./s1</data>
  <data key="d20">OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CC1=CC=C(OCC[C@H]2CC[C@H]3[C@@H]4[C@H](C)CC5=C(C=CC(O)=C5)[C@H]4CC[C@]23C)C(OC)=C1</data>
  <data key="d21">Investigated for use/treatment in breast cancer.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05969">
  <data key="d0">SNS-032</data>
  <data key="d1">drugbank.DB05969</data>
  <data key="d2">[drugbank.DB05969]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Sulfur Compounds]</data>
  <data key="d14">N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide</data>
  <data key="d15">C17H24N4O2S2</data>
  <data key="d16">345627-80-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H24N4O2S2/c1-17(2,3)12-8-19-13(23-12)10-24-14-9-20-16(25-14)21-15(22)11-4-6-18-7-5-11/h8-9,11,18H,4-7,10H2,1-3H3,(H,20,21,22)</data>
  <data key="d20">CC(C)(C)C1=CN=C(CSC2=CN=C(NC(=O)C3CCNCC3)S2)O1</data>
  <data key="d21">Investigated for use/treatment in cancer/tumors (unspecified), leukemia (unspecified), lymphoma (unspecified), multiple myeloma, and solid tumors.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05968">
  <data key="d0">PR-104</data>
  <data key="d1">drugbank.DB05968</data>
  <data key="d2">[drugbank.DB05968]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Hydrocarbons, Halogenated, Mustard Compounds]</data>
  <data key="d14">[2-({2-[(2-bromoethyl)[2-(methanesulfonyloxy)ethyl]amino]-3,5-dinitrophenyl}formamido)ethoxy]phosphonic acid</data>
  <data key="d15">C14H20BrN4O12PS</data>
  <data key="d16">851627-62-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H20BrN4O12PS/c1-33(28,29)31-7-5-17(4-2-15)13-11(14(20)16-3-6-30-32(25,26)27)8-10(18(21)22)9-12(13)19(23)24/h8-9H,2-7H2,1H3,(H,16,20)(H2,25,26,27)</data>
  <data key="d20">CS(=O)(=O)OCCN(CCBr)C1=C(C=C(C=C1[N+]([O-])=O)[N+]([O-])=O)C(=O)NCCOP(O)(O)=O</data>
  <data key="d21">Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03314">
  <data key="d0">5-fluorotryptophan</data>
  <data key="d1">drugbank.DB03314</data>
  <data key="d2">[drugbank.DB03314, drugbank.EXPT01505]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Amino Acids, Amino Acids, Aromatic, Amino Acids, Cyclic, Amino Acids, Essential, Amino Acids, Peptides, and Proteins, Carbon Radioisotopes]</data>
  <data key="d14">(2S)-2-amino-3-(5-fluoro-1H-indol-3-yl)propanoic acid</data>
  <data key="d15">C11H11FN2O2</data>
  <data key="d16">16626-02-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H11FN2O2/c12-7-1-2-10-8(4-7)6(5-14-10)3-9(13)11(15)16/h1-2,4-5,9,14H,3,13H2,(H,15,16)/t9-/m0/s1</data>
  <data key="d20">N[C@@H](CC1=CNC2=C1C=C(F)C=C2)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[5-fluoro-L-tryptophan, Fluorotryptophane, L-5-fluorotryptophan]</data>
  <data key="d9">5-fluorotryptophan can be used as substrate analogue to study enzyme mechanisms by NMR spectroscopy.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05932">
  <data key="d0">Denibulin</data>
  <data key="d1">drugbank.DB05932</data>
  <data key="d2">[drugbank.DB05932]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">N-[6-({4-[(2S)-2-aminopropanamido]phenyl}sulfanyl)-1H-1,3-benzodiazol-2-yl]methoxycarboximidic acid</data>
  <data key="d15">C18H19N5O3S</data>
  <data key="d16">284019-34-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H19N5O3S/c1-10(19)16(24)20-11-3-5-12(6-4-11)27-13-7-8-14-15(9-13)22-17(21-14)23-18(25)26-2/h3-10H,19H2,1-2H3,(H,20,24)(H2,21,22,23,25)/t10-/m0/s1</data>
  <data key="d20">[H][C@@](C)(N)C(=O)NC1=CC=C(SC2=CC3=C(C=C2)N=C(N3)N=C(O)OC)C=C1</data>
  <data key="d21">Investigated for use/treatment in solid tumors.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05938">
  <data key="d0">Edonerpic</data>
  <data key="d1">drugbank.DB05938</data>
  <data key="d2">[drugbank.DB05938]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Acyclic, Dicarboxylic Acids, Sulfur Compounds]</data>
  <data key="d14">1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}azetidin-3-ol</data>
  <data key="d15">C16H21NO2S</data>
  <data key="d16">519187-23-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H21NO2S/c18-15-11-17(12-15)6-1-7-19-8-4-13-2-3-16-14(10-13)5-9-20-16/h2-3,5,9-10,15,18H,1,4,6-8,11-12H2</data>
  <data key="d20">OC1CN(CCCOCCC2=CC3=C(SC=C3)C=C2)C1</data>
  <data key="d21">Investigated for use/treatment in alzheimer's disease.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Edonerpic is a neurotrophic agent intended for the treatment of Alzheimer's disease which is under phase I clinical trial.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02095">
  <data key="d0">Isatin</data>
  <data key="d1">drugbank.DB02095</data>
  <data key="d2">[drugbank.DB02095, drugbank.EXPT01935]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Indoles]</data>
  <data key="d14">2,3-dihydro-1H-indole-2,3-dione</data>
  <data key="d15">C8H5NO2</data>
  <data key="d16">91-56-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C8H5NO2/c10-7-5-3-1-2-4-6(5)9-8(7)11/h1-4H,(H,9,10,11)</data>
  <data key="d20">O=C1NC2=CC=CC=C2C1=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1H-indole-2, 3-dione]</data>
  <data key="d9">Isatin is an indole derivative first obtained by Erdman and Laurent in 1841 as an oxidation product of Indigo dye with nitric acid and chromic acids. The compound is found in many plants and Schiff bases of Isatin are have been investigated for pharmaceutical applications.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03005">
  <data key="d0">3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-5-Yl]Hexyl]-Phenanthridinium</data>
  <data key="d1">drugbank.DB03005</data>
  <data key="d2">[drugbank.DB03005, drugbank.EXPT03147]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3,8-diamino-6-phenyl-5-[6-(1-{2-[(1,2,3,4-tetrahydroacridin-9-yl)amino]ethyl}-1H-1,2,3-triazol-5-yl)hexyl]phenanthridin-5-ium</data>
  <data key="d15">C42H45N8</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C42H44N8/c43-30-19-21-33-34-22-20-31(44)27-40(34)49(42(37(33)26-30)29-12-4-3-5-13-29)24-11-2-1-6-14-32-28-46-48-50(32)25-23-45-41-35-15-7-9-17-38(35)47-39-18-10-8-16-36(39)41/h3-5,7,9,12-13,15,17,19-22,26-28,44H,1-2,6,8,10-11,14,16,18,23-25,43H2,(H,45,47)/p+1</data>
  <data key="d20">NC1=CC2=C(C=C1)C1=CC=C(N)C=C1C(C1=CC=CC=C1)=[N+]2CCCCCCC1=CN=NN1CCNC1=C2CCCCC2=NC2=C1C=CC=C2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06996">
  <data key="d0">D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide</data>
  <data key="d1">drugbank.DB06996</data>
  <data key="d2">[drugbank.DB06996]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-1-[(2R)-2-amino-4-methylpentanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide</data>
  <data key="d15">C19H29N5O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H29N5O2/c1-12(2)10-15(20)19(26)24-9-3-4-16(24)18(25)23-11-13-5-7-14(8-6-13)17(21)22/h5-8,12,15-16H,3-4,9-11,20H2,1-2H3,(H3,21,22)(H,23,25)/t15-,16+/m1/s1</data>
  <data key="d20">[H][C@@](N)(CC(C)C)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=C(C=C1)C(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05676">
  <data key="d0">Apremilast</data>
  <data key="d1">drugbank.DB05676</data>
  <data key="d2">[drugbank.DB05676]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Carbocyclic, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Antineoplastic and Immunomodulating Agents, Antirheumatic Agents, Central Nervous System Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Disease-modifying Antirheumatic Agents, Drugs that are Mainly Renally Excreted, Imides, Immunosuppressive Agents, Isoindoles, Peripheral Nervous System Agents, Phosphodiesterase 4 Inhibitors, Phosphodiesterase Inhibitors, Phthalic Acids, Phthalimides, Piperidines, Piperidones, Selective Immunosuppressants, Sensory System Agents]</data>
  <data key="d14">N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}ethanimidic acid</data>
  <data key="d15">C22H24N2O7S</data>
  <data key="d16">608141-41-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1</data>
  <data key="d20">[H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1</data>
  <data key="d21">Investigated for use/treatment in psoriasis and psoriatic disorders.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Apremilast, Aprmilast, Apremilastum, N-{2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1, 3-dioxo-2, 3-dihydro-1H-isoindol-4-yl}acetamide]</data>
  <data key="d9">Apremilast is a novel, orally available small molecule inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4). It is indicated in the treatment of active psoriatic arthritis in adults (approved by the FDA in March 2014) and moderate to severe plaque psoriasis (approved by the FDA in September 2014). PDE-4 is a cyclic adenosine monophosphate (cAMP)-specific phosphodiesterase that is predominantly located in inflammatory cells. By inhibiting PDE-4, apremilast increases intracellular levels of cAMP and thereby inhibits the production of multiple proinflammatory mediators including PDE-4, TNF-alpha, interleukin-2 (IL-2), interferon-gamma, leukotrienes, and nitric oxide synthase. By targeting a central component of the inflammatory signaling cascade rather than a single inflammatory marker, PDE-4 inhibition may restore the homeostatic balance between pro- and anti-inflammatory signalling.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03017">
  <data key="d0">Lauric acid</data>
  <data key="d1">drugbank.DB03017</data>
  <data key="d2">[drugbank.DB03017, drugbank.EXPT01112, drugbank.EXPT02006]</data>
  <data key="d12">[approved, experimental]</data>
  <data key="d13">[Fatty Acids, Lipids]</data>
  <data key="d14">dodecanoic acid</data>
  <data key="d15">C12H24O2</data>
  <data key="d16">143-07-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H24O2/c1-2-3-4-5-6-7-8-9-10-11-12(13)14/h2-11H2,1H3,(H,13,14)</data>
  <data key="d20">CCCCCCCCCCCC(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-undecanecarboxylic acid, ABL, C12 fatty acid, C12:0, Coconut oil fatty acids, DAO, Dodecanoic acid, Dodecoic acid, Dodecylcarboxylate, Dodecylic acid, Duodecyclic acid, Duodecylic acid, Laurinsure, Laurostearic acid, n-dodecanoic acid, Undecane-1-carboxylic acid, Vulvic acid]</data>
  <data key="d9">Lauric acid is an inexpensive, non-toxic and safe to handle compound often used in laboratory investigations of melting-point depression. Lauric acid is a solid at room temperature but melts easily in boiling water, so liquid lauric acid can be treated with various solutes and used to determine their molecular masses.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03026">
  <data key="d0">Phosphoglycolohydroxamic Acid</data>
  <data key="d1">drugbank.DB03026</data>
  <data key="d2">[drugbank.DB03026, drugbank.EXPT02570]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">[(hydroxycarbamoyl)methoxy]phosphonic acid</data>
  <data key="d15">C2H6NO6P</data>
  <data key="d16">51528-59-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C2H6NO6P/c4-2(3-5)1-9-10(6,7)8/h5H,1H2,(H,3,4)(H2,6,7,8)</data>
  <data key="d20">ONC(=O)COP(O)(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03046">
  <data key="d0">7-Methoxy-8-[1-(Methylsulfonyl)-1h-Pyrazol-4-Yl]Naphthalene-2-Carboximidamide</data>
  <data key="d1">drugbank.DB03046</data>
  <data key="d2">[drugbank.DB03046, drugbank.EXPT03180]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">8-(1-methanesulfonyl-1H-pyrazol-4-yl)-7-methoxynaphthalene-2-carboximidamide</data>
  <data key="d15">C16H16N4O3S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H16N4O3S/c1-23-14-6-5-10-3-4-11(16(17)18)7-13(10)15(14)12-8-19-20(9-12)24(2,21)22/h3-9H,1-2H3,(H3,17,18)</data>
  <data key="d20">COC1=CC=C2C=CC(=CC2=C1C1=CN(N=C1)S(C)(=O)=O)C(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04307">
  <data key="d0">5-Hydroxy-N-Propargyl-1(R)-Aminoindan</data>
  <data key="d1">drugbank.DB04307</data>
  <data key="d2">[drugbank.DB04307, drugbank.EXPT02781]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(3R)-3-[(prop-2-yn-1-yl)amino]-2,3-dihydro-1H-inden-5-ol</data>
  <data key="d15">C12H13NO</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H13NO/c1-2-7-13-12-6-4-9-3-5-10(14)8-11(9)12/h1,3,5,8,12-14H,4,6-7H2/t12-/m1/s1</data>
  <data key="d20">[H][C@]1(CCC2=CC=C(O)C=C12)NCC#C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05662">
  <data key="d0">NP-50301</data>
  <data key="d1">drugbank.DB05662</data>
  <data key="d2">[drugbank.DB05662]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in eye disorders/infections.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this population.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04326">
  <data key="d0">Dihydroxyacetone phosphate</data>
  <data key="d1">drugbank.DB04326</data>
  <data key="d2">[drugbank.DB04326, drugbank.EXPT00026, drugbank.DB12496]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Carbohydrates, Sugar Phosphates]</data>
  <data key="d14">(3-hydroxy-2-oxopropoxy)phosphonic acid</data>
  <data key="d15">C3H7O6P</data>
  <data key="d16">57-04-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C3H7O6P/c4-1-3(5)2-9-10(6,7)8/h4H,1-2H2,(H2,6,7,8)</data>
  <data key="d20">OCC(=O)COP(O)(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-hydroxy-3-(phosphonooxy)-2-Propanone, 1-Hydroxy-3-(phosphonooxy)acetone, 1, 3-Dihydroxy-2-propanone monodihydrogen phosphate, 1, 3-Dihydroxy-2-propanone phosphate, 1, 3-Dihydroxyacetone 1-phosphate, 3-hydroxy-2-oxopropyl phosphate, DHAP, Dihydroxyacetone monophosphate, Glycerone monophosphate, Glycerone phosphate]</data>
  <data key="d9">Dihydroxyacetone phosphate is an important intermediate in lipid biosynthesis and in glycolysis. Dihydroxyacetone phosphate has been investigated for the treatment of Lymphoma, Large-Cell, Diffuse.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06911">
  <data key="d0">D-leucyl-N-(3-chlorobenzyl)-L-prolinamide</data>
  <data key="d1">drugbank.DB06911</data>
  <data key="d2">[drugbank.DB06911]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-1-[(2R)-2-amino-4-methylpentanoyl]-N-[(3-chlorophenyl)methyl]pyrrolidine-2-carboxamide</data>
  <data key="d15">C18H26ClN3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H26ClN3O2/c1-12(2)9-15(20)18(24)22-8-4-7-16(22)17(23)21-11-13-5-3-6-14(19)10-13/h3,5-6,10,12,15-16H,4,7-9,11,20H2,1-2H3,(H,21,23)/t15-,16+/m1/s1</data>
  <data key="d20">[H][C@@](N)(CC(C)C)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC(Cl)=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06914">
  <data key="d0">1-({2-[2-(4-CHLOROPHENYL)ETHYL]-1,3-DIOXOLAN-2-YL}METHYL)-1H-IMIDAZOLE</data>
  <data key="d1">drugbank.DB06914</data>
  <data key="d2">[drugbank.DB06914]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">1-({2-[2-(4-chlorophenyl)ethyl]-1,3-dioxolan-2-yl}methyl)-1H-imidazole</data>
  <data key="d15">C15H17ClN2O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H17ClN2O2/c16-14-3-1-13(2-4-14)5-6-15(19-9-10-20-15)11-18-8-7-17-12-18/h1-4,7-8,12H,5-6,9-11H2</data>
  <data key="d20">ClC1=CC=C(CCC2(CN3C=CN=C3)OCCO2)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06919">
  <data key="d0">D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide</data>
  <data key="d1">drugbank.DB06919</data>
  <data key="d2">[drugbank.DB06919]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-[(3-chlorophenyl)methyl]pyrrolidine-2-carboxamide</data>
  <data key="d15">C21H24ClN3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H24ClN3O2/c22-17-9-4-8-16(12-17)14-24-20(26)19-10-5-11-25(19)21(27)18(23)13-15-6-2-1-3-7-15/h1-4,6-9,12,18-19H,5,10-11,13-14,23H2,(H,24,26)/t18-,19+/m1/s1</data>
  <data key="d20">[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC(Cl)=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06926">
  <data key="d0">(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid</data>
  <data key="d1">drugbank.DB06926</data>
  <data key="d2">[drugbank.DB06926]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid</data>
  <data key="d15">C18H32O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H32O3/c1-2-3-11-14-17(19)15-12-9-7-5-4-6-8-10-13-16-18(20)21/h7,9,12,15,17,19H,2-6,8,10-11,13-14,16H2,1H3,(H,20,21)/b9-7-,15-12+/t17-/m0/s1</data>
  <data key="d20">[H][C@](O)(CCCCC)\C=C\C=C/CCCCCCCC(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06929">
  <data key="d0">1-butanoyl-N-(4-carbamimidoylbenzyl)-L-prolinamide</data>
  <data key="d1">drugbank.DB06929</data>
  <data key="d2">[drugbank.DB06929]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-1-butanoyl-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide</data>
  <data key="d15">C17H24N4O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H24N4O2/c1-2-4-15(22)21-10-3-5-14(21)17(23)20-11-12-6-8-13(9-7-12)16(18)19/h6-9,14H,2-5,10-11H2,1H3,(H3,18,19)(H,20,23)/t14-/m0/s1</data>
  <data key="d20">[H][C@]1(CCCN1C(=O)CCC)C(=O)NCC1=CC=C(C=C1)C(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06927">
  <data key="d0">[5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE</data>
  <data key="d1">drugbank.DB06927</data>
  <data key="d2">[drugbank.DB06927]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-[5-hydroxy-2-(4-hydroxyphenyl)-1-benzofuran-7-yl]acetonitrile</data>
  <data key="d15">C16H11NO3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H11NO3/c17-6-5-11-7-14(19)8-12-9-15(20-16(11)12)10-1-3-13(18)4-2-10/h1-4,7-9,18-19H,5H2</data>
  <data key="d20">OC1=CC=C(C=C1)C1=CC2=C(O1)C(CC#N)=CC(O)=C2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06930">
  <data key="d0">N-[amino(imino)methyl]-2-(2,5-diphenyl-1H-pyrrol-1-yl)acetamide</data>
  <data key="d1">drugbank.DB06930</data>
  <data key="d2">[drugbank.DB06930]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-carbamimidoyl-2-(2,5-diphenyl-1H-pyrrol-1-yl)acetamide</data>
  <data key="d15">C19H18N4O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H18N4O/c20-19(21)22-18(24)13-23-16(14-7-3-1-4-8-14)11-12-17(23)15-9-5-2-6-10-15/h1-12H,13H2,(H4,20,21,22,24)</data>
  <data key="d20">NC(=N)NC(=O)CN1C(=CC=C1C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06936">
  <data key="d0">N-(4-carbamimidoylbenzyl)-1-(4-methylpentanoyl)-L-prolinamide</data>
  <data key="d1">drugbank.DB06936</data>
  <data key="d2">[drugbank.DB06936]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-N-[(4-carbamimidoylphenyl)methyl]-1-(4-methylpentanoyl)pyrrolidine-2-carboxamide</data>
  <data key="d15">C19H28N4O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H28N4O2/c1-13(2)5-10-17(24)23-11-3-4-16(23)19(25)22-12-14-6-8-15(9-7-14)18(20)21/h6-9,13,16H,3-5,10-12H2,1-2H3,(H3,20,21)(H,22,25)/t16-/m0/s1</data>
  <data key="d20">[H][C@]1(CCCN1C(=O)CCC(C)C)C(=O)NCC1=CC=C(C=C1)C(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06942">
  <data key="d0">N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-L-prolinamide</data>
  <data key="d1">drugbank.DB06942</data>
  <data key="d2">[drugbank.DB06942]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-N-[(4-carbamimidoylphenyl)methyl]-1-(3-phenylpropanoyl)pyrrolidine-2-carboxamide</data>
  <data key="d15">C22H26N4O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H26N4O2/c23-21(24)18-11-8-17(9-12-18)15-25-22(28)19-7-4-14-26(19)20(27)13-10-16-5-2-1-3-6-16/h1-3,5-6,8-9,11-12,19H,4,7,10,13-15H2,(H3,23,24)(H,25,28)/t19-/m0/s1</data>
  <data key="d20">[H][C@]1(CCCN1C(=O)CCC1=CC=CC=C1)C(=O)NCC1=CC=C(C=C1)C(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-l-prolinamide is a solid. This compound belongs to the alpha amino acid amides. These are amide derivatives of alpha amino acids. This medication targets the protein prothrombin.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06947">
  <data key="d0">1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide</data>
  <data key="d1">drugbank.DB06947</data>
  <data key="d2">[drugbank.DB06947]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-1-[(2R)-2-aminobutanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide</data>
  <data key="d15">C17H25N5O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H25N5O2/c1-2-13(18)17(24)22-9-3-4-14(22)16(23)21-10-11-5-7-12(8-6-11)15(19)20/h5-8,13-14H,2-4,9-10,18H2,1H3,(H3,19,20)(H,21,23)/t13-,14+/m1/s1</data>
  <data key="d20">[H][C@@](N)(CC)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=C(C=C1)C(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06908">
  <data key="d0">(2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID</data>
  <data key="d1">drugbank.DB06908</data>
  <data key="d2">[drugbank.DB06908]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-3-(1-{[2-(2-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-1H-indol-5-yl)-2-ethoxypropanoic acid</data>
  <data key="d15">C24H23ClN2O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H23ClN2O4/c1-3-30-22(24(28)29)13-16-8-9-21-17(12-16)10-11-27(21)14-20-15(2)31-23(26-20)18-6-4-5-7-19(18)25/h4-12,22H,3,13-14H2,1-2H3,(H,28,29)/t22-/m0/s1</data>
  <data key="d20">[H][C@@](CC1=CC2=C(C=C1)N(CC1=C(C)OC(=N1)C1=C(Cl)C=CC=C1)C=C2)(OCC)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04395">
  <data key="d0">Phosphoaminophosphonic Acid-Adenylate Ester</data>
  <data key="d1">drugbank.DB04395</data>
  <data key="d2">[drugbank.DB04395, drugbank.EXPT00524]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">({[({[(2S,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}amino)phosphonic acid</data>
  <data key="d15">C10H17N6O12P3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H17N6O12P3/c11-8-5-9(13-2-12-8)16(3-14-5)10-7(18)6(17)4(27-10)1-26-31(24,25)28-30(22,23)15-29(19,20)21/h2-4,6-7,10,17-18H,1H2,(H,24,25)(H2,11,12,13)(H4,15,19,20,21,22,23)/t4-,6-,7+,10+/m0/s1</data>
  <data key="d20">NC1=NC=NC2=C1N=CN2[C@@H]1O[C@@H](CO[P@](O)(=O)O[P@@](O)(=O)NP(O)(O)=O)[C@H](O)[C@H]1O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">5&amp;#39;-Adenylic acid, monoanhydride with imidodiphosphoric acid. An analog of ATP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It is a potent competitive inhibitor of soluble and membrane-bound mitochondrial ATPase and also inhibits ATP-dependent reactions of oxidative phosphorylation. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03065">
  <data key="d0">7-Nitroindazole-2-Carboxamidine</data>
  <data key="d1">drugbank.DB03065</data>
  <data key="d2">[drugbank.DB03065, drugbank.EXPT00312]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">7-nitro-2H-indazole-2-carboximidamide</data>
  <data key="d15">C8H7N5O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C8H7N5O2/c9-8(10)12-4-5-2-1-3-6(13(14)15)7(5)11-12/h1-4H,(H3,9,10)</data>
  <data key="d20">NC(=N)N1C=C2C=CC=C(C2=N1)[N+]([O-])=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03082">
  <data key="d0">6-[(Z)-Amino(Imino)Methyl]-N-[4-(Aminomethyl)Phenyl]-4-(Pyrimidin-2-Ylamino)-2-Naphthamide</data>
  <data key="d1">drugbank.DB03082</data>
  <data key="d2">[drugbank.DB03082, drugbank.EXPT03178]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-[4-(aminomethyl)phenyl]-6-carbamimidoyl-4-[(pyrimidin-2-yl)amino]naphthalene-2-carboxamide</data>
  <data key="d15">C23H21N7O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H21N7O/c24-13-14-2-6-18(7-3-14)29-22(31)17-10-15-4-5-16(21(25)26)11-19(15)20(12-17)30-23-27-8-1-9-28-23/h1-12H,13,24H2,(H3,25,26)(H,29,31)(H,27,28,30)</data>
  <data key="d20">NCC1=CC=C(NC(=O)C2=CC(NC3=NC=CC=N3)=C3C=C(C=CC3=C2)C(N)=N)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03088">
  <data key="d0">Pidolic Acid</data>
  <data key="d1">drugbank.DB03088</data>
  <data key="d2">[drugbank.DB03088, drugbank.EXPT00247]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Acyclic, Alimentary Tract and Metabolism, Amino Acids, Amino Acids, Acidic, Amino Acids, Cyclic, Amino Acids, Dicarboxylic, Amino Acids, Peptides, and Proteins, Glutamates, Imines, Imino Acids, Mineral Supplements, Pyrrolidines, Pyrrolidinones]</data>
  <data key="d14">(2S)-5-oxopyrrolidine-2-carboxylic acid</data>
  <data key="d15">C5H7NO3</data>
  <data key="d16">98-79-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C5H7NO3/c7-4-2-1-3(6-4)5(8)9/h3H,1-2H2,(H,6,7)(H,8,9)/t3-/m0/s1</data>
  <data key="d20">OC(=O)[C@@H]1CCC(=O)N1</data>
  <data key="d21">There is currently no clinically approved and/or marketed medicine that relies upon pidolic acid as an active ingredient for any formal therapeutic indication.\n\nAlthough pidolic acid may be sold in a variety of non-prescription, over-the-counter dietary supplement products for cognitive or memory enhancement, there are many studies that suggest that such products or such supplementation do not elicit any kind of cognitive benefit to users [A32981, A32982]. In fact, the general suggestion for any such pidolic acid product is to exercise caution in their recommendation as much more research is necessary [A32981].\n\nPidolic acid and sodium pidolic acid are, however, used to some extent in skin and hair conditioning agents owing to their humectant characteristics [F53].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-2-pyrrolidone-5-carboxylic acid, (S)-()-2-pyrrolidone-5-carboxylic acid, (S)-pyroglutamic acid, 5-L-oxoproline, 5-oxo-2-pyrrolidinecarboxylic acid, 5-oxo-L-proline, 5-Pyrrolidone-2-carboxylic acid, Glutimic acid, L-5-Pyrrolidone-2-carboxylic acid, L-pyroglutamic acid, L-pyrrolidone carboxylic acid, PCA, Pidolic Acid, Pyroglutamic Acid]</data>
  <data key="d9">Pidolic acid is a naturally occurring but little-studied amino acid derivative that can be formed enzymatically or non-enzymatically and participates as a biological intermediate with unique pharmacodynamics in various chemical pathways [A32991, L2729]. Elevations of the acid in blood levels may be associated with problems of glutamine or glutathione metabolism [L2729]. Pidolic acid, in general, is found in large quantities in brain tissue and other tissues in bound form, like skin [L2729].\n\nThere are currently little to no medicines available that are clinically approved or marketed for employing pidolic acid as an active ingredient for any particular formal indication. Although pidolic acid is included in some over-the-counter, non-prescription dietary supplements for the proposed purpose of facilitating cognitive or memory enhancement, most available research suggest exercising caution in their recommendation as much more research is necessary [A32981, A32982].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03132">
  <data key="d0">3-(2-Benzothiazolylthio)-1-Propanesulfonic Acid</data>
  <data key="d1">drugbank.DB03132</data>
  <data key="d2">[drugbank.DB03132, drugbank.EXPT00770]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Acids, Acids, Noncarboxylic, Alkanes, Hydrocarbons, Acyclic, Sulfonic Acids, Sulfur Acids, Sulfur Compounds, Thiazoles, Triose-Phosphate Isomerase, antagonists &amp; inhibitors]</data>
  <data key="d14">3-(1,3-benzothiazol-2-ylsulfanyl)propane-1-sulfonic acid</data>
  <data key="d15">C10H11NO3S3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H11NO3S3/c12-17(13,14)7-3-6-15-10-11-8-4-1-2-5-9(8)16-10/h1-2,4-5H,3,6-7H2,(H,12,13,14)</data>
  <data key="d20">OS(=O)(=O)CCCSC1=NC2=C(S1)C=CC=C2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03124">
  <data key="d0">5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid</data>
  <data key="d1">drugbank.DB03124</data>
  <data key="d2">[drugbank.DB03124, drugbank.EXPT00045]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">5-{[(4-{[(2S)-1-carboxy-3-oxobutan-2-yl]carbamoyl}phenyl)methyl]sulfamoyl}-2-hydroxybenzoic acid</data>
  <data key="d15">C20H20N2O9S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H20N2O9S/c1-11(23)16(9-18(25)26)22-19(27)13-4-2-12(3-5-13)10-21-32(30,31)14-6-7-17(24)15(8-14)20(28)29/h2-8,16,21,24H,9-10H2,1H3,(H,22,27)(H,25,26)(H,28,29)/t16-/m0/s1</data>
  <data key="d20">[H][C@@](CC(O)=O)(NC(=O)C1=CC=C(CNS(=O)(=O)C2=CC(C(O)=O)=C(O)C=C2)C=C1)C(C)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03127">
  <data key="d0">Benzamidine</data>
  <data key="d1">drugbank.DB03127</data>
  <data key="d2">[drugbank.DB03127, drugbank.EXPT00669]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Amidines, Enzyme Inhibitors, Serine Proteinase Inhibitors]</data>
  <data key="d14">[amino(phenyl)methylidene]azanium</data>
  <data key="d15">C7H9N2</data>
  <data key="d16">618-39-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H8N2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H3,8,9)/p+1</data>
  <data key="d20">NC(=[NH2+])C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03128">
  <data key="d0">Acetylcholine</data>
  <data key="d1">drugbank.DB03128</data>
  <data key="d2">[drugbank.DB03128, drugbank.EXPT00412]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Amines, Antiglaucoma Preparations and Miotics, Biogenic Amines, Cardiovascular Agents, Cholinergic Agents, Cholinergic Agonists, Cholinergic Receptor Agonist, Miotics, Neurotransmitter Agents, OCT1 substrates, Ophthalmologicals, Parasympathomimetics, Sensory Organs, Vasodilating Agents]</data>
  <data key="d14">[2-(acetyloxy)ethyl]trimethylazanium</data>
  <data key="d15">C7H16NO2</data>
  <data key="d16">51-84-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H16NO2/c1-7(9)10-6-5-8(2,3)4/h5-6H2,1-4H3/q+1</data>
  <data key="d20">CC(=O)OCC[N+](C)(C)C</data>
  <data key="d21">Used to obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy and other anterior segment surgery where rapid miosis may be required.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[ACh, Choline acetate, O-Acetylcholine]</data>
  <data key="d9">A neurotransmitter. Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. It is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04471">
  <data key="d0">2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol</data>
  <data key="d1">drugbank.DB04471</data>
  <data key="d2">[drugbank.DB04471, drugbank.EXPT02683]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(1R)-2-phenyl-1-{4-[2-(piperidin-1-yl)ethoxy]phenyl}-1,2,3,4-tetrahydroisoquinolin-6-ol</data>
  <data key="d15">C28H32N2O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C28H32N2O2/c31-25-11-14-27-23(21-25)15-18-30(24-7-3-1-4-8-24)28(27)22-9-12-26(13-10-22)32-20-19-29-16-5-2-6-17-29/h1,3-4,7-14,21,28,31H,2,5-6,15-20H2/t28-/m1/s1</data>
  <data key="d20">OC1=CC=C2[C@H](N(CCC2=C1)C1=CC=CC=C1)C1=CC=C(OCCN2CCCCC2)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03144">
  <data key="d0">N-Omega-Hydroxy-L-Arginine</data>
  <data key="d1">drugbank.DB03144</data>
  <data key="d2">[drugbank.DB03144, drugbank.EXPT01692]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Amino Acids, Amino Acids, Basic, Amino Acids, Diamino, Amino Acids, Essential, Amino Acids, Peptides, and Proteins]</data>
  <data key="d14">(2S)-2-amino-5-(1-hydroxycarbamimidamido)pentanoic acid</data>
  <data key="d15">C6H14N4O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C6H14N4O3/c7-4(5(11)12)2-1-3-9-6(8)10-13/h4,13H,1-3,7H2,(H,11,12)(H3,8,9,10)/t4-/m0/s1</data>
  <data key="d20">N[C@@H](CCCNC(=N)NO)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03135">
  <data key="d0">[2(Formyl-Hydroxy-Amino)-Ethyl]-Phosphonic Acid</data>
  <data key="d1">drugbank.DB03135</data>
  <data key="d2">[drugbank.DB03135, drugbank.EXPT00020]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">[2-(N-hydroxyformamido)ethyl]phosphonic acid</data>
  <data key="d15">C3H8NO5P</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C3H8NO5P/c5-3-4(6)1-2-10(7,8)9/h3,6H,1-2H2,(H2,7,8,9)</data>
  <data key="d20">ON(CCP(O)(O)=O)C=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03136">
  <data key="d0">4-Iodobenzo[B]Thiophene-2-Carboxamidine</data>
  <data key="d1">drugbank.DB03136</data>
  <data key="d2">[drugbank.DB03136, drugbank.EXPT01360]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">[amino(4-iodo-1-benzothiophen-2-yl)methylidene]azanium</data>
  <data key="d15">C9H8IN2S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H7IN2S/c10-6-2-1-3-7-5(6)4-8(13-7)9(11)12/h1-4H,(H3,11,12)/p+1</data>
  <data key="d20">NC(=[NH2+])C1=CC2=C(S1)C=CC=C2I</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04468">
  <data key="d0">Afimoxifene</data>
  <data key="d1">drugbank.DB04468</data>
  <data key="d2">[drugbank.DB04468, drugbank.EXPT02425]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Androstanes, Androstenes, Androstenols, Antineoplastic Agents, Benzene Derivatives, Benzylidene Compounds, Estrogen Antagonists, Estrogen Receptor Modulators, Gonadal Hormones, Gonadal Steroid Hormones, Hormone Antagonists, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Receptors, Estrogen, agonists, Selective Estrogen Receptor Modulators, Steroids, Stilbenes]</data>
  <data key="d14">4-[(1Z)-1-{4-[2-(dimethylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl]phenol</data>
  <data key="d15">C26H29NO2</data>
  <data key="d16">68392-35-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-</data>
  <data key="d20">CC\C(=C(/C1=CC=C(O)C=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1</data>
  <data key="d21">For the potential treatment of menstrual-cycle related mastalgia, fibrocystic breast disease, breast disease, gynecomastia and Keloid scarring.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[4-hydroxytamoxifen, 4-monohydroxytamoxifen, 4-OHT, Afimoxifene]</data>
  <data key="d9">Afimoxifene (4-Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of estrogen-dependent conditions, including cyclic breast pain and gynecomastia. TamoGel is formulated using Enhanced Hydroalcoholic Gel (EHG) Technology. This technology enables percutaneous delivery of drugs that cannot be delivered orally. It is being developed by Ascent Therapeutics.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03147">
  <data key="d0">Flavin adenine dinucleotide</data>
  <data key="d1">drugbank.DB03147</data>
  <data key="d2">[drugbank.DB03147, drugbank.EXPT01391]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adenine Nucleotides, Biological Factors, Carbohydrates, Coenzymes, Enzymes and Coenzymes, Flavins, Glycosides, Nucleic Acids, Nucleotides, and Nucleosides, Nucleotides, Pigments, Biological, Pteridines, Purine Nucleotides, Purines, Ribonucleotides, Vitamin B Complex, Vitamins]</data>
  <data key="d14">[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]({[(2R,3S,4S)-5-{7,8-dimethyl-2,4-dioxo-2H,3H,4H,10H-benzo[g]pteridin-10-yl}-2,3,4-trihydroxypentyl]oxy})phosphinic acid</data>
  <data key="d15">C27H33N9O15P2</data>
  <data key="d16">146-14-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C27H33N9O15P2/c1-10-3-12-13(4-11(10)2)35(24-18(32-12)25(42)34-27(43)33-24)5-14(37)19(39)15(38)6-48-52(44,45)51-53(46,47)49-7-16-20(40)21(41)26(50-16)36-9-31-17-22(28)29-8-30-23(17)36/h3-4,8-9,14-16,19-21,26,37-41H,5-7H2,1-2H3,(H,44,45)(H,46,47)(H2,28,29,30)(H,34,42,43)/t14-,15+,16+,19-,20+,21+,26+/m0/s1</data>
  <data key="d20">CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)CO[P@](O)(=O)O[P@@](O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC3=C1N=CN=C3N)C1=NC(=O)NC(=O)C1=N2</data>
  <data key="d21">Used to treat eye diseases caused by vitamin B2 deficiency, such as keratitis and blepharitis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Adenosine 5'-(trihydrogen pyrophosphate), 5'-5'-ester with riboflavine, adenosine 5'-[3-(riboflavin-5'-yl) dihydrogen diphosphate], FAD, Flavin adenine dinucleotide, Flavin-Adenine Dinucleotide, Flavine adenine dinucleotide, Riboflavin 5'-(trihydrogen diphosphate), 5'-5'-ester with adenosine, Riboflavin 5'-adenosine diphosphate]</data>
  <data key="d9">A condensation product of riboflavin and adenosine diphosphate. The coenzyme of various aerobic dehydrogenases, e.g., D-amino acid oxidase and L-amino acid oxidase. (Lehninger, Principles of Biochemistry, 1982, p972)\nFlavin adenine dinucleotide is approved for use in Japan under the trade name Adeflavin as an ophthalmic treatment for vitamin B2 deficiency.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04477">
  <data key="d0">N-1,2,3,4-Tetrahydronaphth-1-Yl-2'-[3,5-Dimethoxybenzamido]-2'-Deoxy-Adenosine</data>
  <data key="d1">drugbank.DB04477</data>
  <data key="d2">[drugbank.DB04477, drugbank.EXPT03076]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-[(2R,3R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-2-(6-{[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]amino}-9H-purin-9-yl)oxolan-3-yl]-3,5-dimethoxybenzene-1-carboximidic acid</data>
  <data key="d15">C29H32N6O6</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C29H32N6O6/c1-39-18-10-17(11-19(12-18)40-2)28(38)34-23-25(37)22(13-36)41-29(23)35-15-32-24-26(30-14-31-27(24)35)33-21-9-5-7-16-6-3-4-8-20(16)21/h3-4,6,8,10-12,14-15,21-23,25,29,36-37H,5,7,9,13H2,1-2H3,(H,34,38)(H,30,31,33)/t21-,22-,23-,25-,29-/m1/s1</data>
  <data key="d20">[H][C@]1(CO)O[C@@]([H])(N2C=NC3=C(N[C@]4([H])CCCC5=CC=CC=C45)N=CN=C23)[C@]([H])(N=C(O)C2=CC(OC)=CC(OC)=C2)[C@]1([H])O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03159">
  <data key="d0">CRA_8696</data>
  <data key="d1">drugbank.DB03159</data>
  <data key="d2">[drugbank.DB03159, drugbank.EXPT00282]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-{5-[amino(iminiumyl)methyl]-1H-indol-2-yl}-6-phenylbenzen-1-olate</data>
  <data key="d15">C21H17N3O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H17N3O/c22-21(23)14-9-10-18-15(11-14)12-19(24-18)17-8-4-7-16(20(17)25)13-5-2-1-3-6-13/h1-12,24-25H,(H3,22,23)</data>
  <data key="d20">NC(=[NH2+])C1=CC=C2NC(=CC2=C1)C1=CC=CC(=C1[O-])C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05744">
  <data key="d0">CRx-139</data>
  <data key="d1">drugbank.DB05744</data>
  <data key="d2">[drugbank.DB05744]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in rheumatoid arthritis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. The synergistic combination containing low doses of the glucocorticoid steroid prednisolone and the antidepressant paroxetine. This novel synergistic combination is developed for the treatment of immuno-inflammatory diseases.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03100">
  <data key="d0">6-Nitroindazole</data>
  <data key="d1">drugbank.DB03100</data>
  <data key="d2">[drugbank.DB03100, drugbank.EXPT00288]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Nitric Oxide Synthase, antagonists &amp; inhibitors, Pyrazoles]</data>
  <data key="d14">6-nitro-2H-indazole</data>
  <data key="d15">C7H5N3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H5N3O2/c11-10(12)6-2-1-5-4-8-9-7(5)3-6/h1-4H,(H,8,9)</data>
  <data key="d20">O=N(=O)C1=CC2=NNC=C2C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05758">
  <data key="d0">CYT007-TNFQb</data>
  <data key="d1">drugbank.DB05758</data>
  <data key="d2">[drugbank.DB05758]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in psoriasis and psoriatic disorders.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">CYT007-TNFQb is an active immunization therapy that aims at\nproviding a novel treatment to people suffering from RA or psoriasis. The vaccine should allow for administration of low\namounts of drug to individual patients (in the microgram range) and for convenient dosing schedules.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04436">
  <data key="d0">3-Fluoro-L-tyrosine</data>
  <data key="d1">drugbank.DB04436</data>
  <data key="d2">[drugbank.DB04436, drugbank.EXPT03275]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-2-amino-3-(3-fluoro-4-hydroxyphenyl)propanoic acid</data>
  <data key="d15">C9H10FNO3</data>
  <data key="d16">7423-96-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H10FNO3/c10-6-3-5(1-2-8(6)12)4-7(11)9(13)14/h1-3,7,12H,4,11H2,(H,13,14)/t7-/m0/s1</data>
  <data key="d20">N[C@@H](CC1=CC(F)=C(O)C=C1)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3-fluoro-L-tyrosine, L-m-Fluorotyrosine]</data>
  <data key="d9">3-Fluoro-L-tyrosine is a solid. This compound belongs to the phenylpropanoic acids. These are compounds whose structure contain a benzene ring conjugated to a propanoic acid. 3-Fluoro-L-tyrosine targets the protein superoxide dismutase [mn], mitochondrial.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05767">
  <data key="d0">Andrographolide</data>
  <data key="d1">drugbank.DB05767</data>
  <data key="d2">[drugbank.DB05767]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Analgesics, Analgesics, Non-Narcotic, Anti-Infective Agents, Anti-Inflammatory Agents, Antiparasitic Agents, Antiplatelet agents, Antiprotozoals, Antirheumatic Agents, Biological Products, Central Nervous System Agents, Colitis, Ulcerative, drug therapy, Complex Mixtures, Hematologic Agents, Peripheral Nervous System Agents, Pharmaceutical Preparations, Plant Preparations, Sensory System Agents, Stereoisomerism, Terpenes]</data>
  <data key="d14">(3E,4S)-3-{2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-decahydronaphthalen-1-yl]ethylidene}-4-hydroxyoxolan-2-one</data>
  <data key="d15">C20H30O5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H30O5/c1-12-4-7-16-19(2,9-8-17(23)20(16,3)11-21)14(12)6-5-13-15(22)10-25-18(13)24/h5,14-17,21-23H,1,4,6-11H2,2-3H3/b13-5+/t14-,15-,16+,17-,19+,20+/m1/s1</data>
  <data key="d20">[H]\C(C[C@]1([H])C(=C)CC[C@]2([H])[C@](C)(CO)[C@]([H])(O)CC[C@@]12C)=C1/C(=O)OC[C@@]1([H])O</data>
  <data key="d21">Investigated for use/treatment in ulcerative colitis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">HMPL-004 is a botanical product extracted from a herb that occurs naturally in China. The herb has an extensive history of use in TCM for the treatment of upper respiratory tract infections and other inflammatory and infectious diseases.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04447">
  <data key="d0">1,4-Dithiothreitol</data>
  <data key="d1">drugbank.DB04447</data>
  <data key="d2">[drugbank.DB04447, drugbank.EXPT01291]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2R,3R)-1,4-disulfanylbutane-2,3-diol</data>
  <data key="d15">C4H10O2S2</data>
  <data key="d16">3483-12-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C4H10O2S2/c5-3(1-7)4(6)2-8/h3-8H,1-2H2/t3-,4-/m0/s1</data>
  <data key="d20">O[C@@H](CS)[C@@H](O)CS</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2, 3-dihydroxy-1, 4-dithiobutane]</data>
  <data key="d9">A reagent commonly used in biochemical studies as a protective agent to prevent the oxidation of SH (thiol) groups and for reducing disulphides to dithiols. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05777">
  <data key="d0">Thrombomodulin Alfa</data>
  <data key="d1">drugbank.DB05777</data>
  <data key="d2">[drugbank.DB05777]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Carbohydrates, Glycoconjugates, Glycoproteins, Membrane Glycoproteins, Membrane Proteins, Platelet Membrane Glycoproteins, Proteins, Receptors, Cell Surface, Receptors, G-Protein-Coupled, Receptors, Immunologic, Receptors, Peptide, Receptors, Proteinase-Activated, Receptors, Thrombin]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">120313-91-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Thrombomodulin (human 498-amino acid fragment)]</data>
  <data key="d9">Thrombomodulin Alfa is a novel, recombinant and soluble thrombomodulin (ART-123). It is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular thromboembolism. [A18701]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05708">
  <data key="d0">GTS-21</data>
  <data key="d1">drugbank.DB05708</data>
  <data key="d2">[drugbank.DB05708]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Benzene Derivatives, Cholinergic Agents, Cholinergic Agonists, Neurotransmitter Agents, Nicotinic Agonists]</data>
  <data key="d14">3-[(3E)-3-[(2,4-dimethoxyphenyl)methylidene]-3,4,5,6-tetrahydropyridin-2-yl]pyridine</data>
  <data key="d15">C19H20N2O2</data>
  <data key="d16">148372-04-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H20N2O2/c1-22-17-8-7-14(18(12-17)23-2)11-15-5-4-10-21-19(15)16-6-3-9-20-13-16/h3,6-9,11-13H,4-5,10H2,1-2H3/b15-11+</data>
  <data key="d20">[H]\C(=C1\CCCN=C1C1=CN=CC=C1)C1=C(OC)C=C(OC)C=C1</data>
  <data key="d21">Investigated for use/treatment in alzheimer's disease and schizophrenia and schizoaffective disorders.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3-(2, 4-dimethoxybenzylidene)anabaseine, Dimethoxybenzylidene anabaseine, DMXB-A, DMXB-Anabaseine]</data>
  <data key="d9">GTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials. Athenagen licensed the exclusive rights to the compound and a related library of analogs as part of the acquisition of Osprey Pharmaceutical Company in April 2006. GTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in schizophrenic patients. In all studies, the compound was well tolerated. In a Phase I multi-dose, double-blind, placebo controlled study in healthy adults, GTS-21 also demonstrated cognitive enhancement across all doses, with a statistically significant improvement in attention related and memory related tasks (Kitagawa, et al. Neuropsychopharmacology (2003), 28, 542-551).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05714">
  <data key="d0">Flovagatran</data>
  <data key="d1">drugbank.DB05714</data>
  <data key="d2">[drugbank.DB05714]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Acids, Noncarboxylic, Amino Acids, Peptides, and Proteins, Boron Compounds, Oligopeptides, Peptides]</data>
  <data key="d14">[(1R)-1-{[(2S)-1-[(2R)-2-{[(benzyloxy)carbonyl]amino}-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-4-methoxybutyl]boronic acid</data>
  <data key="d15">C27H36BN3O7</data>
  <data key="d16">871576-03-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C27H36BN3O7/c1-37-17-9-15-24(28(35)36)30-25(32)23-14-8-16-31(23)26(33)22(18-20-10-4-2-5-11-20)29-27(34)38-19-21-12-6-3-7-13-21/h2-7,10-13,22-24,35-36H,8-9,14-19H2,1H3,(H,29,34)(H,30,32)/t22-,23+,24+/m1/s1</data>
  <data key="d20">COCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CC1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1)B(O)O</data>
  <data key="d21">Investigated for use/treatment in thrombosis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Flovagatran]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05740">
  <data key="d0">RPI-78M</data>
  <data key="d1">drugbank.DB05740</data>
  <data key="d2">[drugbank.DB05740]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in multiple sclerosis, neurologic disorders, and pain (acute or chronic).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03193">
  <data key="d0">Stearic acid</data>
  <data key="d1">drugbank.DB03193</data>
  <data key="d2">[drugbank.DB03193, drugbank.EXPT02965]</data>
  <data key="d12">[approved, experimental]</data>
  <data key="d13">[Fatty Acids, Lipids]</data>
  <data key="d14">octadecanoic acid</data>
  <data key="d15">C18H36O2</data>
  <data key="d16">57-11-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H36O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h2-17H2,1H3,(H,19,20)</data>
  <data key="d20">CCCCCCCCCCCCCCCCCC(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Acide octadcanoque, Acide starique, C18:0, n-octadecanoic acid, Octadecanoic acid, Octadecansure, Octadecoic acid, Oktadekansure, Stearic acid, Stearinsure]</data>
  <data key="d9">Stearic acid (IUPAC systematic name: octadecanoic acid) is one of the useful types of saturated fatty acids that comes from many animal and vegetable fats and oils. It is a waxy solid.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01069">
  <data key="d0">Promethazine</data>
  <data key="d1">drugbank.DB01069</data>
  <data key="d2">[drugbank.DB01069, drugbank.APRD00601]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acid Reducers, Agents producing tachycardia, Agents that reduce seizure threshold, Amines, Anti-Allergic Agents, Anticholinergic Agents, Antidepressive Agents, Antidotes, Antihistamines for Systemic Use, Antihistamines for Topical Use, Antipruritics, Antipruritics, Incl. Antihistamines, Anesthetics, Etc., Antipsychotic Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs that are Mainly Renally Excreted, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine H2 Antagonists, Miscellaneous Anxiolytics Sedatives and Hypnotics, Muscarinic Antagonists, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein/ABCB1 Inhibitors, Phenothiazine Derivatives, Phenothiazines, Potential QTc-Prolonging Agents, Propylamines, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators, Sulfur Compounds]</data>
  <data key="d14">dimethyl[1-(10H-phenothiazin-10-yl)propan-2-yl]amine</data>
  <data key="d15">C17H20N2S</data>
  <data key="d16">60-87-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3</data>
  <data key="d20">CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C</data>
  <data key="d21">For the treatment of allergic disorders, and nausea/vomiting.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(2-dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine, 10-(2-Dimethylaminopropyl)phenothiazine, 10-[2-(dimethylamino)propyl]phenothiazine, N-(2'-dimethylamino-2'-methyl)ethylphenothiazine, N, N, alpha-trimethyl-10H-phenothiazine-10-ethanamine, N, N, -trimethyl-10H-phenothiazine-10-ethanamine, Proazamine, Prometazina, Promethazine, Promethazinum]</data>
  <data key="d9">A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01067">
  <data key="d0">Glipizide</data>
  <data key="d1">drugbank.DB01067</data>
  <data key="d2">[drugbank.DB01067, drugbank.APRD00436]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Blood Glucose Lowering Agents, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Drugs that are Mainly Renally Excreted, Drugs Used in Diabetes, Hypoglycemia-Associated Agents, Oral Hypoglycemics, Sulfones, Sulfonylurea Compounds, Sulfonylureas, Sulfur Compounds, UGT1A1 Substrates, Urea]</data>
  <data key="d14">N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide</data>
  <data key="d15">C21H27N5O4S</data>
  <data key="d16">29094-61-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)</data>
  <data key="d20">CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1</data>
  <data key="d21">Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.[label]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-cyclohexyl-3-({p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl}sulfonyl)urea, Glipizida, Glipizide, Glipizidum, N-{4-[-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-N'-cyclohexylurea]</data>
  <data key="d9">Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 [A179491] and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin.[L6712] Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure.[T28] Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency.[A179488] Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents.[A179485] Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol, as well as in combination with metformin under the brand name Metaglip.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02398">
  <data key="d0">6-[N-(4-(Aminomethyl)Phenyl)Carbamyl]-2-Naphthalenecarboxamidine</data>
  <data key="d1">drugbank.DB02398</data>
  <data key="d2">[drugbank.DB02398, drugbank.EXPT00091]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-[4-(aminomethyl)phenyl]-6-carbamimidoylnaphthalene-2-carboxamide</data>
  <data key="d15">C19H18N4O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H18N4O/c20-11-12-1-7-17(8-2-12)23-19(24)16-6-4-13-9-15(18(21)22)5-3-14(13)10-16/h1-10H,11,20H2,(H3,21,22)(H,23,24)</data>
  <data key="d20">NCC1=CC=C(NC(=O)C2=CC=C3C=C(C=CC3=C2)C(N)=N)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01075">
  <data key="d0">Diphenhydramine</data>
  <data key="d1">drugbank.DB01075</data>
  <data key="d2">[drugbank.DB01075, drugbank.APRD00587, drugbank.DB06975]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents producing tachycardia, Amines, Aminoalkyl Ethers, Anesthetics, Anesthetics, Local, Anti-Allergic Agents, Anticholinergic Agents, Antiemetics, Antihistamines for Systemic Use, Antihistamines for Topical Use, Antipruritics, Incl. Antihistamines, Anesthetics, Etc., Benzene Derivatives, Benzhydryl Compounds, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Ethanolamine Derivatives, Ethylamines, First Generation Antihistamines, Gastrointestinal Agents, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Hypnotics and Sedatives, Muscarinic Antagonists, OCT2 Inhibitors, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Sleep Aids, Pharmaceutical]</data>
  <data key="d14">[2-(diphenylmethoxy)ethyl]dimethylamine</data>
  <data key="d15">C17H21NO</data>
  <data key="d16">58-73-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3</data>
  <data key="d20">CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d21">Diphenhydramine is a first-generation histamine H1 receptor antagonist (H1 antihistamine) that is widely available as a non-prescription, over-the-counter (OTC) medication. As an OTC medication, diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing, runny nose, itchy/watery eyes, itching of nose or throat, insomnia, pruritis, urticaria, insect bites/stings, allergic rashes, and nausea [L5263, L5266, L5269, F3379, A174541].\n\nAdditionally, when the use of oral diphenhydramine is impractical, there are also prescription-only formulations such as diphenhydramine injection products that are effective in adults and pediatric patients (other than premature infants and neonates) for:\ni) the amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after acute allergic reaction symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated [F3352];\nii) the active treatment of motion sickness [F3352]; and\niii) use in parkinsonism when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents [F3352].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-(benzhydryloxy)-N, N-dimethylethylamine, 2-diphenylmethoxy-N, N-demthylethanamine, Difenhidramina, Diphenhydramine, Diphenhydraminum, N-(2-(diphenylmethoxy)ethyl)-N, N-dimethylamine, O-benzhydryldimethylaminoethanol, -(2-dimethylaminoethoxy)diphenylmethane, -dimethylaminoethanol diphenylmethyl ether, -dimethylaminoethyl benzhydryl ether]</data>
  <data key="d9">Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for "night time" use [L5263, L5281, L5287]. \n\nDiphenhydramine is also used in combination with [DB14132] as the anti-nausea drug [DB00985] where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system [A1540].\n\nDiphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid [A1539]. As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01074">
  <data key="d0">Perhexiline</data>
  <data key="d1">drugbank.DB01074</data>
  <data key="d2">[drugbank.DB01074, drugbank.APRD00107]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents causing hyperkalemia, Antiarrhythmic agents, Bradycardia-Causing Agents, Calcium Channel Blockers, Cardiovascular Agents, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Membrane Transport Modulators, Non-Selective Calcium Channel Blockers, Piperidines, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Vasodilating Agents]</data>
  <data key="d14">2-(2,2-dicyclohexylethyl)piperidine</data>
  <data key="d15">C19H35N</data>
  <data key="d16">6621-47-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2</data>
  <data key="d20">C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1</data>
  <data key="d21">For the management of severe angina pectoris.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Perhexilene, Perhexilina, Perhexiline, Perhexilinum]</data>
  <data key="d9">Perhexiline is a coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01087">
  <data key="d0">Primaquine</data>
  <data key="d1">drugbank.DB01087</data>
  <data key="d2">[drugbank.DB01087, drugbank.APRD00604]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Aminoquinolines, Anti-Infective Agents, Antimalarials, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (unknown strength), Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Methemoglobinemia Associated Agents, Moderate Risk QTc-Prolonging Agents, P-glycoprotein/ABCB1 Inhibitors, QTc Prolonging Agents, Quinolines]</data>
  <data key="d14">N4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine</data>
  <data key="d15">C15H21N3O</data>
  <data key="d16">90-34-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3</data>
  <data key="d20">COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1</data>
  <data key="d21">For the treatment of malaria.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline, 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline, 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline, Primachin, Primachina, Primachinum, Primaquin, Primaquina, Primaquine, Primaquinum]</data>
  <data key="d9">An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01094">
  <data key="d0">Hesperetin</data>
  <data key="d1">drugbank.DB01094</data>
  <data key="d2">[drugbank.DB01094, drugbank.APRD00117]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[BCRP/ABCG2 Inhibitors, Benzopyrans, Chromones, Cytochrome P-450 CYP1A2 Substrates, Flavanones, Flavonoids, Pyrans]</data>
  <data key="d14">(2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,4-dihydro-2H-1-benzopyran-4-one</data>
  <data key="d15">C16H14O6</data>
  <data key="d16">520-33-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H14O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-6,14,17-19H,7H2,1H3/t14-/m0/s1</data>
  <data key="d20">COC1=C(O)C=C(C=C1)[C@@H]1CC(=O)C2=C(O)C=C(O)C=C2O1</data>
  <data key="d21">For lowering cholesterol and, possibly, otherwise favorably affecting lipids. &lt;i&gt;In vitro&lt;/i&gt; research also suggests the possibility that hesperetin might have some anticancer effects and that it might have some anti-aromatase activity, as well as activity again.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-(S)-hesperetin, ()-hesperetin, (S)-2, 3-dihydro-5, 7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one, 3', 5, 7-Trihydroxy-4'-methoxyflavanone, Hesperitin]</data>
  <data key="d9">Hesperetin belongs to the flavanone class of flavonoids. Hesperetin, in the form of its glycoside [hesperidin], is the predominant flavonoid in lemons and oranges.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01091">
  <data key="d0">Butenafine</data>
  <data key="d1">drugbank.DB01091</data>
  <data key="d2">[drugbank.DB01091, drugbank.APRD00833]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amines, Anti-Infective Agents, Antifungal Agents, Antifungals for Dermatological Use, Antifungals for Topical Use, Benzene Derivatives, Benzyl Compounds, Benzylamine Antifungal, Benzylamines, Dermatologicals]</data>
  <data key="d14">[(4-tert-butylphenyl)methyl](methyl)(naphthalen-1-ylmethyl)amine</data>
  <data key="d15">C23H27N</data>
  <data key="d16">101828-21-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H27N/c1-23(2,3)21-14-12-18(13-15-21)16-24(4)17-20-10-7-9-19-8-5-6-11-22(19)20/h5-15H,16-17H2,1-4H3</data>
  <data key="d20">CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12</data>
  <data key="d21">For the topical treatment of the following dermatologic infections: tinea (pityriasis) versicolor due to &lt;i&gt;M. furfur&lt;/i&gt;, interdigital tinea pedis (athlete&amp;rsquo;s foot), tinea corporis (ringworm) and tinea cruris (jock itch) due to &lt;i&gt;E. floccosum&lt;/i&gt;, &lt;i&gt;T. mentagrophytes&lt;/i&gt;, &lt;i&gt;T. rubrum&lt;/i&gt;, and &lt;i&gt;T. tonsurans&lt;/i&gt;.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(4-tert-Butyl-benzyl)-methyl-naphthalen-1-ylmethyl-amine, (4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine, 4-tert-butylbenzyl(methyl)(1-naphthalenemethyl)amine, Butenafina, Butenafine, Butenafinum, N-(p-tert-butylbenzyl)-N-methyl-1-naphthalenemethylamine]</data>
  <data key="d9">Butenafine hydrochloride is a synthetic benzylamine antifungal agent. Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols. In particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01023">
  <data key="d0">Felodipine</data>
  <data key="d1">drugbank.DB01023</data>
  <data key="d2">[drugbank.DB01023, drugbank.APRD00374]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[ACE Inhibitors and Calcium Channel Blockers, Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Antiarrhythmic agents, Antihypertensive Agents, Beta blocking agents and calcium channel blockers, Bradycardia-Causing Agents, BSEP/ABCB11 Substrates, Calcium Channel Blockers, Calcium Channel Blockers (Dihydropyridine), Cardiovascular Agents, CYP3A Substrates (Sensitive), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Dihydropyridine Derivatives, Dihydropyridines, Hypotensive Agents, Membrane Transport Modulators, P-glycoprotein/ABCB1 Inhibitors, Potential QTc-Prolonging Agents, Pyridines, QTc Prolonging Agents, Selective Calcium Channel Blockers With Mainly Vascular Effects, Vasodilating Agents]</data>
  <data key="d14">3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate</data>
  <data key="d15">C18H19Cl2NO4</data>
  <data key="d16">72509-76-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3</data>
  <data key="d20">CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC</data>
  <data key="d21">For the treatment of mild to moderate essential hypertension.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-ethyl methyl 4-(2, 3-dichlorophenyl)-1, 4-dihydro-2, 6-dimethyl-3, 5-pyridinedicarboxylate, 3-ethyl 5-methyl 4-(2, 3-dichlorophenyl)-2, 6-dimethyl-1, 4-dihydro-3, 5-pyridinedicarboxylate, 4-(2, 3-dichlorophenyl)-1, 4-dihydro-2, 6-dimethyl-3, 5-pyridinedicarboxylic acid ethyl methyl ester, Felodipina, Felodipine, Felodipino, Felodipinum]</data>
  <data key="d9">Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction. Felodipine is the most potent CCB in use and is unique in that it exhibits fluorescent activity. In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase, and blocks calcium influx through voltage-gated T-type calcium channels. Felodipine is used to treat mild to moderate essential hypertension.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01039">
  <data key="d0">Fenofibrate</data>
  <data key="d1">drugbank.DB01039</data>
  <data key="d2">[drugbank.DB01039, drugbank.APRD00405, drugbank.DB09545]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acids, Acyclic, Agents Causing Muscle Toxicity, Benzene Derivatives, Benzhydryl Compounds, Benzophenones, BSEP/ABCB11 Substrates, Butyrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Ethers, Fatty Acids, Fatty Acids, Volatile, Fibric Acids, Fribic Acid Derivatives, Hypolipidemic Agents, Isobutyrates, Ketones, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, Lipids, Noxae, P-glycoprotein/ABCB1 Inhibitors, Peroxisome Proliferator Receptor alpha Agonist, Peroxisome Proliferator-activated Receptor alpha Agonists, Phenols, Phenyl Ethers, Toxic Actions, UGT1A1 Substrates]</data>
  <data key="d14">propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate</data>
  <data key="d15">C20H21ClO4</data>
  <data key="d16">49562-28-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3</data>
  <data key="d20">CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1</data>
  <data key="d21">For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester, Fenofibrate, Fenofibrato, Fenofibratum, Finofibrate, FNF, Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate, Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate, Procetofen]</data>
  <data key="d9">Fenofibrate is a prodrug of fenofibric acid, an antilipemic agent which reduces both cholesterol and triglycerides in the blood.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01037">
  <data key="d0">Selegiline</data>
  <data key="d1">drugbank.DB01037</data>
  <data key="d2">[drugbank.DB01037, drugbank.APRD00525]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Agents that produce hypertension, Agents that reduce seizure threshold, Amines, Anti-Dyskinesia Agents, Anti-Parkinson Drugs, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dopamine Agents, Enzyme Inhibitors, Ethylamines, Hypotensive Agents, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase B Inhibitors, Monoamine Oxidase Inhibitors, Monoamine Oxidase-B Inhibitors, Nervous System, Neuroprotective Agents, P-glycoprotein/ABCB1 Inhibitors, Phenethylamines, Protective Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators]</data>
  <data key="d14">methyl[(2R)-1-phenylpropan-2-yl](prop-2-yn-1-yl)amine</data>
  <data key="d15">C13H17N</data>
  <data key="d16">14611-51-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1</data>
  <data key="d20">C[C@H](CC1=CC=CC=C1)N(C)CC#C</data>
  <data key="d21">Monotherapy for initial treatment of Parkinson's disease, as well as an adjunct therapy in patients with a decreased response to levodopa/carbadopa. Also used for the palliative treatment of mild to moderate Alzheimer's disease and at higher doses, for the treatment of depression.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-selegiline, L-Deprenalin, Selegilina, Selegiline, Selegilinum]</data>
  <data key="d9">A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01035">
  <data key="d0">Procainamide</data>
  <data key="d1">drugbank.DB01035</data>
  <data key="d2">[drugbank.DB01035, drugbank.APRD00509]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acids, Carbocyclic, Agents Causing Muscle Toxicity, Agents that produce neuromuscular block (indirect), Amides, Aminobenzoates, Antiarrhythmic agents, Antiarrhythmics, Class I, Antiarrhythmics, Class Ia, Benzamides and benzamide derivatives, Benzene Derivatives, Benzoates, Cardiac Therapy, Cardiovascular Agents, Cholinesterase Inhibitors, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index, Highest Risk QTc-Prolonging Agents, MATE 1 Substrates, MATE 1 Substrates with a Narrow Therapeutic Index, MATE 2 Substrates, MATE 2 Substrates with a Narrow Therapeutic Index, MATE substrates, Membrane Transport Modulators, Narrow Therapeutic Index Drugs, OCT1 inhibitors, OCT2 Inhibitors, OCT2 substrates with narrow therapeutic index, para-Aminobenzoates, QTc Prolonging Agents, Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers]</data>
  <data key="d14">4-amino-N-[2-(diethylamino)ethyl]benzamide</data>
  <data key="d15">C13H21N3O</data>
  <data key="d16">51-06-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17)</data>
  <data key="d20">CCN(CC)CCNC(=O)C1=CC=C(N)C=C1</data>
  <data key="d21">For the treatment of life-threatening ventricular arrhythmias.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[p-Amino-N-(2-diethylaminoethyl)benzamide, p-Aminobenzoic diethylaminoethylamide, Procainamida, Procainamide, Procanamide, Procainamidum]</data>
  <data key="d9">A derivative of procaine with less CNS action.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01041">
  <data key="d0">Thalidomide</data>
  <data key="d1">drugbank.DB01041</data>
  <data key="d2">[drugbank.DB01041, drugbank.APRD01251]</data>
  <data key="d12">[approved, investigational, withdrawn]</data>
  <data key="d13">[Acids, Carbocyclic, Angiogenesis Inhibitors, Angiogenesis Modulating Agents, Anti-Bacterial Agents, Anti-Infective Agents, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cardiotoxic antineoplastic agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Decreased Immunologically Active Molecule Activity, Growth Inhibitors, Growth Substances, Hypotensive Agents, Imides, Immunologic Factors, Immunomodulatory Agents, Immunosuppressive Agents, Isoindoles, Leprostatic Agents, Myelosuppressive Agents, Noxae, Phthalic Acids, Phthalimides, Piperidines, Piperidones, Teratogens, Toxic Actions]</data>
  <data key="d14">2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione</data>
  <data key="d15">C13H10N2O4</data>
  <data key="d16">50-35-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)</data>
  <data key="d20">O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12</data>
  <data key="d21">For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+-)-N-(2, 6-dioxo-3-Piperidyl)phthalimide, (+-)-Thalidomide, ()-N-(2, 6-dioxo-3-piperidyl)phthalimide, ()-thalidomide, 1, 3-dioxo-2-(2, 6-dioxopiperidin-3-yl)isoindoline, 2, 6-dioxo-3-phthalimidopiperidine, 3-Phthalimidoglutarimide, alpha-(N-Phthalimido)glutarimide, alpha-N-Phthalylglutaramide, N-(2, 6-dioxo-3-piperidyl)phthalimide, N-Phthaloylglutamimide, N-Phthalyl-glutaminsaeure-imid, N-Phthalylglutamic acid imide, Talidomida, Thalidomide, Thalidomidum, -(N-phthalimido)glutarimide, -N-phthalylglutaramide, -phthalimidoglutarimide]</data>
  <data key="d9">A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02378">
  <data key="d0">MMI-175</data>
  <data key="d1">drugbank.DB02378</data>
  <data key="d2">[drugbank.DB02378, drugbank.EXPT02196]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2R,4S,5S)-N-[(1S)-1-(benzyl-C-hydroxycarbonimidoyl)-2-methylpropyl]-4-hydroxy-5-({hydroxy[(4S,7S)-2,5,9-trihydroxy-4-(propan-2-yl)-1-oxa-3,6,10-triazacyclohexadeca-2,5,9-trien-7-yl]methylidene}amino)-2,7-dimethyloctanimidic acid</data>
  <data key="d15">C38H62N6O8</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C38H62N6O8/c1-23(2)19-28(30(45)20-26(7)34(47)43-32(24(3)4)36(49)40-22-27-15-11-10-12-16-27)41-35(48)29-21-31(46)39-17-13-8-9-14-18-52-38(51)44-33(25(5)6)37(50)42-29/h10-12,15-16,23-26,28-30,32-33,45H,8-9,13-14,17-22H2,1-7H3,(H,39,46)(H,40,49)(H,41,48)(H,42,50)(H,43,47)(H,44,51)/t26-,28+,29+,30+,32+,33+/m1/s1</data>
  <data key="d20">[H][C@@](C)(C[C@]([H])(O)[C@]([H])(CC(C)C)N=C(O)[C@]1([H])CC(O)=NCCCCCCOC(O)=N[C@@]([H])(C(C)C)C(O)=N1)C(O)=N[C@@]([H])(C(C)C)C(O)=NCC1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01050">
  <data key="d0">Ibuprofen</data>
  <data key="d1">drugbank.DB01050</data>
  <data key="d2">[drugbank.DB01050, drugbank.APRD00372]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acids, Carbocyclic, Agents causing angioedema, Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antiinflammatory Preparations, Non-Steroids for Topical Use, Antiinflammatory Products for Vaginal Administration, Antirheumatic Agents, Central Nervous System Agents, COX-1 Inhibitors, COX-2 Inhibitors, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Nephrotoxic agents, Nervous System, Non COX-2 selective NSAIDS, Nonsteroidal Anti-inflammatory Compounds, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, Opioids, Other Nonsteroidal Antiimflammatory Agents, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Peripheral Nervous System Agents, Phenylpropionates, Propionates, Sensory System Agents, Throat Preparations, Topical Products for Joint and Muscular Pain, UGT1A1 Substrates, UGT1A3 substrates, UGT1A9 Substrates, UGT2B7 substrates]</data>
  <data key="d14">2-[4-(2-methylpropyl)phenyl]propanoic acid</data>
  <data key="d15">C13H18O2</data>
  <data key="d16">15687-27-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)</data>
  <data key="d20">CC(C)CC1=CC=C(C=C1)C(C)C(O)=O</data>
  <data key="d21">Ibuprofen is the most commonly used and prescribed NSAID. It is very common over the counter medication widely used as an analgesic, anti-inflammatory and antipyretic.[A39096]\n\nThe use of ibuprofen and its enantiomer [DB09213] in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea, headache, migraine, postoperative dental pain, spondylitis, osteoarthritis, rheumatoid arthritis, and soft tissue disorder.[A39097]\n\nDue to its activity against prostaglandin and thromboxane synthesis, ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labor.[A39092]\n\nAs ibuprofen is a widely used medication, the main therapeutic indications are:\n\n* Patent Ductus Arteriosus - it is a neonatal condition wherein the ductus arteriosus (blood vessel that connects the main pulmonary artery to the proximal descending aorta) fails to close after birth causing severe risk of heart failure. The prostaglandin inhibition of ibuprofen has been studied for the treatment of this condition as it is known that prostaglandin E2 is responsible for keeping the ductus arteriosus open.[A39100]\n\n* Rheumatoid- and osteo-arthritis - ibuprofen is very commonly used in the symptomatic treatment of inflammatory, musculoskeletal and rheumatic disorders.[A39176]\n\n* Cystic fibrosis - the use of high dosages of ibuprofen has been proven to decrease inflammation and decreasing polymorphonuclear cell influx in the lungs.[A39177]\n\n* Orthostatic hypotension - ibuprofen can induce sodium retention and antagonize the effect of diuretics which has been reported to be beneficial for patients with severe orthostatic hypotension.[A1651]\n\n* Dental pain - ibuprofen is used to manage acute and chronic orofacial pain.[A10901]\n\n* Minor pain - ibuprofen is widely used to reduce minor aches and pains as well as to reduce fever and manage dysmenorrhea. It is very commonly used for the relief of acute indications such as fever and tension headaches.[A39092]\n\n* Investigational uses - efforts have been put into developing ibuprofen for the prophylaxis of Alzheimer's disease, Parkinson disease, and breast cancer.[A39092]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-2-(p-isobutylphenyl)propionic acid, ()-ibuprofen, ()-p-isobutylhydratropic acid, ()--methyl-4-(2-methylpropyl)benzeneacetic acid, (4-isobutylphenyl)--methylacetic acid, (RS)-ibuprofen, 2-(4-isobutylphenyl)propanoic acid, 4-isobutylhydratropic acid, Ibuprofen, Ibuprofene, Ibuprofeno, Ibuprofenum, Ibuprophen, -(4-isobutylphenyl)propionic acid, -(p-isobutylphenyl)propionic acid]</data>
  <data key="d9">Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[A39076]\n\nOn the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer.[A39194]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13044">
  <data key="d0">Gossypol</data>
  <data key="d1">drugbank.DB13044</data>
  <data key="d2">[drugbank.DB13044]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Adrenal Cortex Hormones, Contraceptive Agents, Male, Hormonal Contraceptives for Systemic Use, Reproductive Control Agents, Sesquiterpenes, Terpenes]</data>
  <data key="d14">7-[8-formyl-1,6,7-trihydroxy-3-methyl-5-(propan-2-yl)naphthalen-2-yl]-2,3,8-trihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carbaldehyde</data>
  <data key="d15">C30H30O8</data>
  <data key="d16">303-45-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C30H30O8/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36/h7-12,33-38H,1-6H3</data>
  <data key="d20">CC(C)C1=C2C=C(C)C(=C(O)C2=C(C=O)C(O)=C1O)C1=C(O)C2=C(C=O)C(O)=C(O)C(C(C)C)=C2C=C1C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Gossypol has been used in trials studying the treatment of Non-small Cell Lung Cancer.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01057">
  <data key="d0">Echothiophate</data>
  <data key="d1">drugbank.DB01057</data>
  <data key="d2">[drugbank.DB01057, drugbank.APRD00942]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Antiglaucoma Preparations and Miotics, Autonomic Agents, Cholinergic Agents, Cholinesterase Inhibitors, Enzyme Inhibitors, Miotics, Neurotransmitter Agents, Ophthalmologicals, Organophosphates, Organophosphorus Compounds, Organothiophosphates, Organothiophosphorus Compounds, Parasympathomimetics, Peripheral Nervous System Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sensory Organs, Sulfur Compounds]</data>
  <data key="d14">diethyl {[2-(trimethylazaniumyl)ethyl]sulfanyl}phosphonate</data>
  <data key="d15">C9H23NO3PS</data>
  <data key="d16">6736-03-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H23NO3PS/c1-6-12-14(11,13-7-2)15-9-8-10(3,4)5/h6-9H2,1-5H3/q+1</data>
  <data key="d20">CCOP(=O)(OCC)SCC[N+](C)(C)C</data>
  <data key="d21">For use in the treatment of subacute or chronic angle-closure glaucoma after iridectomy or where surgery is refused or contraindicated.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-(Diethoxyphosphorylsulfanyl)ethyl-N, N, N-trimethylazanium iodide, Echothiophate, Ecothiopate, Ecothiopatum, Phospholine]</data>
  <data key="d9">A potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01065">
  <data key="d0">Melatonin</data>
  <data key="d1">drugbank.DB01065</data>
  <data key="d2">[drugbank.DB01065, drugbank.APRD00742, drugbank.DB08189]</data>
  <data key="d12">[approved, nutraceutical, vet_approved]</data>
  <data key="d13">[Amines, Antioxidants, Biogenic Amines, Biogenic Monoamines, Central Nervous System Agents, Central Nervous System Depressants, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C9 Substrates, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypnotics and Sedatives, Indoles, Melatonin Receptor Agonists, Nervous System, OAT3/SLC22A8 Inhibitors, Protective Agents, Psycholeptics, Tryptamines]</data>
  <data key="d14">N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide</data>
  <data key="d15">C13H16N2O2</data>
  <data key="d16">73-31-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)</data>
  <data key="d20">COC1=CC2=C(NC=C2CCNC(C)=O)C=C1</data>
  <data key="d21">Used orally for jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind (evidence for efficacy), and benzodiazepine and nicotine withdrawal. Evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults. It has received FDA orphan drug status as an oral medication for this use. A number of studies have shown that melatonin may be effective for treating sleep-wake cycle disturbances in children and adolescents with mental retardation, autism, and other central nervous system disorders. It appears to decrease the time to fall asleep in children with developmental disabilities, such as cerebral palsy, autism, and mental retardation. It may also improve secondary insomnia associated with various sleep-wake cycle disturbances. Other possible uses for which there is some evidence for include: benzodiazepine withdrawal, cluster headache, delayed sleep phase syndrome (DSPS), primary insomnia, jet lag, nicotine withdrawal, preoperative anxiety and sedation, prostate cancer, solid tumors (when combined with IL-2 therapy in certain cancers), sunburn prevention (topical use), tardive dyskinesia, thrombocytopenia associated with cancer, chemotherapy and other disorders.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[5-methoxy-N-acetyltryptamine, Melatonin, Melatonina, Mlatonine, N-[2-(5-methoxyindol-3-yl)ethyl]acetamide, N-Acetyl-5-methoxytryptamine]</data>
  <data key="d9">Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958.  In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature.  Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant.  Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04991">
  <data key="d0">XL784</data>
  <data key="d1">drugbank.DB04991</data>
  <data key="d2">[drugbank.DB04991]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">For treatment in patients with diabetes who have clinically significant proteinuria.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation. XL784 was specifically optimized to be MMP-1 sparing, thus potentially enhancing its safety profile and enabling higher dosing compared with other previously studied metalloprotease inhibitors. Results of single dose Phase I clinical trials of XL784 administered orally to 96 healthy volunteers have demonstrated that XL784 has attractive safety and pharmacokinetic profiles. It is being developed by Exelixis, Inc.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02325">
  <data key="d0">Isopropyl alcohol</data>
  <data key="d1">drugbank.DB02325</data>
  <data key="d2">[drugbank.DB02325, drugbank.EXPT01912, drugbank.DB04402]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alcohols, Antiseptics and Disinfectants, Compounds used in a research, industrial, or household setting, Dermatologicals, Miscellaneous Local Anti-infectives, Propanols, Solvents]</data>
  <data key="d14">propan-2-ol</data>
  <data key="d15">C3H8O</data>
  <data key="d16">67-63-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C3H8O/c1-3(2)4/h3-4H,1-2H3</data>
  <data key="d20">CC(C)O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-Propanol, Alcohol isoproplico, Isopropanol, Isopropyl alcohol]</data>
  <data key="d9">An isomer of 1-propanol. It is a colorless liquid having disinfectant properties. It is used in the manufacture of acetone and its derivatives and as a solvent. Topically, it is used as an antiseptic.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01002">
  <data key="d0">Levobupivacaine</data>
  <data key="d1">drugbank.DB01002</data>
  <data key="d2">[drugbank.DB01002, drugbank.APRD00110]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Amides, Anesthetics, Anesthetics, Local, Anilides, Central Nervous System Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Drugs that are Mainly Renally Excreted, Hypotensive Agents, Nervous System, Neuraxial Anesthetics, Peripheral Nervous System Agents, Pipecolic Acids, Piperidines, Sensory System Agents]</data>
  <data key="d14">(2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide</data>
  <data key="d15">C18H28N2O</data>
  <data key="d16">27262-47-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)/t16-/m0/s1</data>
  <data key="d20">CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C</data>
  <data key="d21">For the production of local or regional anesthesia for surgery and obstetrics, and for post-operative pain management</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(-)-bupivacaine, (S)-1-butyl-2', 6'-pipecoloxylidide, (S)-bupivacaine, L-(-)-1-Butyl-2', 6'-pipecoloxylidide, L-()-bupivacaine, Levobupivacana, Levobupivacaine]</data>
  <data key="d9">Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted\npipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine. In particular, the specific levobupivacaine enantiomer is a worthwhile pursuit because it demonstrates less vasodilation and possesses a greater length of action in comparison to bupivacaine. It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children. When administered appropriately, the occurrence of adverse effects is not anticipated much if at all. In general, the majority of potential adverse effects are predominantly associated with inappropriate administration methods that may cause systemic exposure and/or toxicity associated with overexposure to an anesthetic. Regardless, allergic reactions may also occur - although only rarely.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03672">
  <data key="d0">9-N-Phenylmethylamino-Tacrine</data>
  <data key="d1">drugbank.DB03672</data>
  <data key="d2">[drugbank.DB03672, drugbank.EXPT00297]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-benzyl-1,2,3,4-tetrahydroacridin-9-amine</data>
  <data key="d15">C20H20N2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H20N2/c1-2-8-15(9-3-1)14-21-20-16-10-4-6-12-18(16)22-19-13-7-5-11-17(19)20/h1-4,6,8-10,12H,5,7,11,13-14H2,(H,21,22)</data>
  <data key="d20">C(NC1=C2C=CC=CC2=NC2=C1CCCC2)C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01010">
  <data key="d0">Edrophonium</data>
  <data key="d1">drugbank.DB01010</data>
  <data key="d2">[drugbank.DB01010, drugbank.APRD00944]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amines, Ammonium Compounds, Antidotes, Cholinergic Agents, Cholinesterase Inhibitors, Compounds used in a research, industrial, or household setting, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Neurotransmitter Agents, Nitrogen Compounds, Onium Compounds, Phenylammonium Compounds, Protective Agents, Quaternary Ammonium Compounds]</data>
  <data key="d14">N-ethyl-3-hydroxy-N,N-dimethylanilinium</data>
  <data key="d15">C10H16NO</data>
  <data key="d16">312-48-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H15NO/c1-4-11(2,3)9-6-5-7-10(12)8-9/h5-8H,4H2,1-3H3/p+1</data>
  <data key="d20">CC[N+](C)(C)C1=CC(O)=CC=C1</data>
  <data key="d21">For the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(3-hydroxyphenyl)dimethylethylammonium, 3-hydroxy-N, N-dimethyl-N-ethylanilinium, Edrophonium cation, Edrophonium ion, Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium, N-ethyl-3-hydroxy-N, N-dimethylanilinium, N-ethyl-3-hydroxy-N, N-dimethylbenzenaminium]</data>
  <data key="d9">A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02335">
  <data key="d0">2-Aminothiazoline</data>
  <data key="d1">drugbank.DB02335</data>
  <data key="d2">[drugbank.DB02335, drugbank.EXPT00587]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Sulfur Compounds]</data>
  <data key="d14">4,5-dihydro-1,3-thiazol-2-amine</data>
  <data key="d15">C3H6N2S</data>
  <data key="d16">1779-81-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C3H6N2S/c4-3-5-1-2-6-3/h1-2H2,(H2,4,5)</data>
  <data key="d20">NC1=NCCS1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01017">
  <data key="d0">Minocycline</data>
  <data key="d1">drugbank.DB01017</data>
  <data key="d2">[drugbank.DB01017, drugbank.APRD00547]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents Causing Muscle Toxicity, Agents that produce neuromuscular block (indirect), Alimentary Tract and Metabolism, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives and Antiseptics for Local Oral Treatment, Antiinfectives for Systemic Use, Naphthacenes, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, Stomatological Preparations, Tetracyclines]</data>
  <data key="d14">(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide</data>
  <data key="d15">C23H27N3O7</data>
  <data key="d16">10118-90-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27,29-30,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1</data>
  <data key="d20">[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2</data>
  <data key="d21">For the treatment of infections caused by susceptible strains of microorganisms, such as Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox and tick fevers caused by Rickettsiae, upper respiratory tract infections caused by &lt;i&gt;Streptococcus pneumoniae&lt;/i&gt; and for the treatment of asymptomatic carriers of &lt;i&gt;Neisseria meningitidis&lt;/i&gt;.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(4S, 4aS, 5aR, 12aS)-4, 7-bis(dimethylamino)-3, 10, 12, 12a-tetrahydroxy-1, 11-dioxo-1, 4, 4a, 5, 5a, 6, 11, 12a-octahydrotetracene-2-carboxamide, 7-Dimethylamino-6-demethyl-6-deoxytetracycline, Minociclina, Minociclinum, Minocyclin, Minocycline, Minocyclinum, Minomycin]</data>
  <data key="d9">A tetracycline analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant staphylococcus infections.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01014">
  <data key="d0">Balsalazide</data>
  <data key="d1">drugbank.DB01014</data>
  <data key="d2">[drugbank.DB01014, drugbank.APRD00141]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Carbocyclic, Agents causing hyperkalemia, Agents that produce hypertension, Alimentary Tract and Metabolism, Aminobenzoates, Aminosalicylate, Aminosalicylic Acids, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Benzene Derivatives, Benzoates, Central Nervous System Agents, Colitis, Ulcerative, Gastrointestinal Agents, Hydrazines, Hydroxy Acids, Hydroxybenzoates, Inflammatory Bowel Diseases, Intestinal Antiinflammatory Agents, meta-Aminobenzoates, Nephrotoxic agents, Non COX-2 selective NSAIDS, Peripheral Nervous System Agents, Phenols, Prodrugs, Salicylates, Sensory System Agents]</data>
  <data key="d14">5-[(E)-2-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazen-1-yl]-2-hydroxybenzoic acid</data>
  <data key="d15">C17H15N3O6</data>
  <data key="d16">80573-04-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)/b20-19+</data>
  <data key="d20">OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O</data>
  <data key="d21">For the treatment of mildly to moderately active ulcerative colitis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(E)-5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid, (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid, 3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1, 4-diene-1-carboxylic acid, 5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid, Balsalazida, Balsalazide, Balsalazidum]</data>
  <data key="d9">Balsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK.\n\nThe chemical name is (E)-5-[[-4-(2-carboxyethyl) aminocarbonyl] phenyl]azo] -2-hydroxybenzoic acid. It is usually administered as the disodium salt.\n\nBalsalazide works by deliverying mesalazine to the large intestine to act directly on ulcerative colitis. Mesalazine is also known as 5-aminosalicylic acid, or 5-ASA.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02343">
  <data key="d0">3,6,9,12,15-Pentaoxaheptadecane</data>
  <data key="d1">drugbank.DB02343</data>
  <data key="d2">[drugbank.DB02343, drugbank.EXPT02478]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3,6,9,12,15-pentaoxaheptadecane</data>
  <data key="d15">C12H26O5</data>
  <data key="d16">4353-28-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H26O5/c1-3-13-5-7-15-9-11-17-12-10-16-8-6-14-4-2/h3-12H2,1-2H3</data>
  <data key="d20">CCOCCOCCOCCOCCOCC</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03600">
  <data key="d0">Capric acid</data>
  <data key="d1">drugbank.DB03600</data>
  <data key="d2">[drugbank.DB03600, drugbank.EXPT01213, drugbank.DB03838]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Anti-Infective Agents, Antifungal Agents, Fatty Acids, Lipids]</data>
  <data key="d14">decanoic acid</data>
  <data key="d15">C10H20O2</data>
  <data key="d16">334-48-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H20O2/c1-2-3-4-5-6-7-8-9-10(11)12/h2-9H2,1H3,(H,11,12)</data>
  <data key="d20">CCCCCCCCCC(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-nonanecarboxylic acid, Capric acid, Decanoic acid, n-capric acid, n-decanoic acid, n-decylic acid]</data>
  <data key="d9">Decanoic acid is a solid. This compound belongs to the straight chain fatty acids. These are fatty acids with a straight aliphatic chain. The proteins that decanoic acid targets include furin, octanoyltransferase, 3-oxoacyl-[acyl-carrier-protein] synthase 1, peptostreptococcal albumin-binding protein, and putative uncharacterized protein tcp14.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04930">
  <data key="d0">Permethrin</data>
  <data key="d1">drugbank.DB04930</data>
  <data key="d2">[drugbank.DB04930]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agrochemicals, Antiparasitic Products, Insecticides and Repellents, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Drugs that are Mainly Renally Excreted, Ectoparasiticides, Incl. Scabicides, Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents, Enzyme Inhibitors, Insecticides, Monoterpenes, Pesticides, Pyrethrines, Incl. Synthetic Compounds, Pyrethrins, Scabicides and Pediculicides, Terpenes, Toxic Actions]</data>
  <data key="d14">(3-phenoxyphenyl)methyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate</data>
  <data key="d15">C21H20Cl2O3</data>
  <data key="d16">52645-53-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H20Cl2O3/c1-21(2)17(12-18(22)23)19(21)20(24)25-13-14-7-6-10-16(11-14)26-15-8-4-3-5-9-15/h3-12,17,19H,13H2,1-2H3</data>
  <data key="d20">CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC(OC2=CC=CC=C2)=CC=C1</data>
  <data key="d21">For the treatment of infestation with &lt;i&gt;Sarcoptes scabiei&lt;/i&gt; (scabies).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(3-Phenoxyphenyl)methyl ()-cis, trans-3-(2, 2-dichloroethenyl)-2, 2-dimethylcyclopropanecarboxylate, 3-(2, 2-Dichloroethenyl)-2, 2-dimethylcyclopropane carboxylic acid, (3-phenoxyphenyl) methyl ester, Permethrin]</data>
  <data key="d9">A pyrethroid insecticide commonly used in the treatment of lice infestations and scabies. It is a yellow to light orange-brown, low melt-ing solid or viscous liquid.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04938">
  <data key="d0">Ospemifene</data>
  <data key="d1">drugbank.DB04938</data>
  <data key="d2">[drugbank.DB04938]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Benzene Derivatives, Benzylidene Compounds, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Estrogen Agonist/Antagonist, Genito Urinary System and Sex Hormones, Selective Estrogen Receptor Modulators, Sex Hormones and Modulators of the Genital System, Stilbenes]</data>
  <data key="d14">2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}ethan-1-ol</data>
  <data key="d15">C24H23ClO2</data>
  <data key="d16">128607-22-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23-</data>
  <data key="d20">OCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1</data>
  <data key="d21">Ospemifene is used for the treatment of moderate to dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-(4-(4-Chloro-1, 2-diphenyl-but-1-enyl)phenoxy)ethanol, 2-(p-((Z)-4-Chloro-1, 2-diphenyl-1-butenyl)phenoxy)ethanol, Deamino-hydroxytoremifene, Ospemifene, Ospemifeno]</data>
  <data key="d9">Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04956">
  <data key="d0">Afelimomab</data>
  <data key="d1">drugbank.DB04956</data>
  <data key="d2">[drugbank.DB04956]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Agents reducing cytokine levels, Amino Acids, Peptides, and Proteins, Antibodies, Antineoplastic and Immunomodulating Agents, Blood Proteins, Globulins, Immunoglobulins, Immunologic Factors, Immunoproteins, Immunosuppressive Agents, Proteins, Serum Globulins, Tumor Necrosis Factor Alpha (TNF-) Inhibitors]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">156227-98-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in sepsis and septicemia.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF- monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04971">
  <data key="d0">Reglitazar</data>
  <data key="d1">drugbank.DB04971</data>
  <data key="d2">[drugbank.DB04971]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">4-({4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}methyl)-1,2-oxazolidine-3,5-dione</data>
  <data key="d15">C22H20N2O5</data>
  <data key="d16">170861-63-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H20N2O5/c1-14-19(23-21(28-14)16-5-3-2-4-6-16)11-12-27-17-9-7-15(8-10-17)13-18-20(25)24-29-22(18)26/h2-10,18H,11-13H2,1H3,(H,24,25)</data>
  <data key="d20">CC1=C(CCOC2=CC=C(CC3C(=O)NOC3=O)C=C2)N=C(O1)C1=CC=CC=C1</data>
  <data key="d21">For the treatment of diabetes mellitus type 1 and 2.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Reglitazar, Reglixane]</data>
  <data key="d9">Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03707">
  <data key="d0">S-Ethyl-N-Phenyl-Isothiourea</data>
  <data key="d1">drugbank.DB03707</data>
  <data key="d2">[drugbank.DB03707, drugbank.EXPT02689]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(E)-N'-phenyl(ethylsulfanyl)methanimidamide</data>
  <data key="d15">C9H12N2S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H12N2S/c1-2-12-9(10)11-8-6-4-3-5-7-8/h3-7H,2H2,1H3,(H2,10,11)</data>
  <data key="d20">CCS\C(N)=N\C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13173">
  <data key="d0">Cerliponase alfa</data>
  <data key="d1">drugbank.DB13173</data>
  <data key="d2">[drugbank.DB13173]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Enzymes, Hydrolytic Lysosomal N-terminal Tripeptidyl Peptidase, P-glycoprotein/ABCB1 Substrates]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">151662-36-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Cerliponase alfa is a treatment for late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease to decelerate the progressive motor function decline in patients 3 years of age and older. CLN2 disease is a form of Batten disease, a rare inherited neurodegenerative disorder and is associated with seizures, ataxia, rapid loss of language and motor functions, blindness, and early death [L755]. It is caused by the lack the lysosomal enzyme tripeptidyl peptidase-1 (TPP1) and subsequent accumulation of lysosomal storage materials normally metabolized by this enzyme in the central nervous system.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;3e77b0a3-2851-448d-a55a-200ed7c8be8b Cerliponase alfa Sequence\nSYSPEPDQRRTLPPGWVSLGRADPEEELSLTFALRQQNVERLSELVQAVSDPSSPQYGKYLTLENVADLVRPSPLTLHTVQKWLLAAGAQKCHSVITQDFLTCWLSIRQAELLLPGAEFHHYVGGPTETHVVRSPHPYQLPQALAPHVDFVGGLHRFPPTSSLRQRPEPQVTGTVGLHLGVTPSVIRKRYNLTSQDVGSGTSNNSQACAQFLEQYFHDSDLAQFMRLFGGNFAHQASVARVVGQQGRGRAGIEASLDVQYLMSAGANISTWVYSSPGRHEGQEPFLQWLMLLSNESALPHVHTVSYGDDEDSLSSAYIQRVNTELMKAAARGLTLLFASGDSGAGCWSVSGRHQFRPTFPASSPYVTTVGGTSFQEPFLITNEIVDYISGGGFSNVFPRPSYQEEAVTKFLSSSPHLPPSSYFNASGRAYPDVAALSDGYWVVSNRVPIPWVSGTSASTPVFGGILSLINEHRILSGRPPLGFLNPRLYQQHGAGLFDVTRGCHESCLDEEVEGQGFCSGPGWDPVTGWGTPNFPALLKTLLNP]</data>
  <data key="d8">[Immature cell growth-inhibiting gene 1 protein, Immature human tripeptidyl-peptidase 1, Immature lysosomal pepstatin-insensitive protease, Immature tripeptidyl-peptidase I]</data>
  <data key="d9">Cerliponase alfa is an enzyme replacement treatment for a specific form of Batten disease. It was the first FDA-approved treatment to slow loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase-1 (TPP1) deficiency. Intraventricular administration of the drug allows significant uptake into the brain. Cerliponase alfa was approved in April, 2017 (as Brineura).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13170">
  <data key="d0">Plecanatide</data>
  <data key="d1">drugbank.DB13170</data>
  <data key="d2">[drugbank.DB13170, drugbank.DB06377]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Amino Acids, Peptides, and Proteins, Drugs for Constipation, Enzyme Activators, Guanylate Cyclase Activators, Guanylate Cyclase-C Agonist, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Laxatives, Peptide Hormones, Peptides]</data>
  <data key="d14">(4S)-4-{[(2S)-2-{[(2S)-2-amino-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene]amino}-3-carboxy-1-hydroxypropylidene]amino}-4-{[(1R,4S,7S,10S,13S,16R,19S,22S,25R,32S,38R)-38-{[(1S)-1-carboxy-3-methylbutyl]-C-hydroxycarbonimidoyl}-22-(2-carboxyethyl)-3,6,9,12,15,18,21,24,30,33,36-undecahydroxy-10-[(C-hydroxycarbonimidoyl)methyl]-32-[(1R)-1-hydroxyethyl]-4-methyl-19-(2-methylpropyl)-7,13-bis(propan-2-yl)-27,28,40,41-tetrathia-2,5,8,11,14,17,20,23,31,34,37-undecaazabicyclo[14.13.13]dotetraconta-2,5,8,11,14,17,20,23,30,33,36-undecaen-25-yl]-C-hydroxycarbonimidoyl}butanoic acid</data>
  <data key="d15">C65H104N18O26S4</data>
  <data key="d16">467426-54-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C65H104N18O26S4/c1-25(2)15-34-55(98)80-41-24-113-110-21-38(58(101)77-37(65(108)109)16-26(3)4)71-44(87)20-69-62(105)50(30(10)84)83-61(104)40(78-51(94)29(9)70-63(106)48(27(5)6)81-57(100)35(18-43(68)86)76-64(107)49(28(7)8)82-60(41)103)23-112-111-22-39(59(102)73-32(53(96)75-34)11-13-45(88)89)79-54(97)33(12-14-46(90)91)72-56(99)36(19-47(92)93)74-52(95)31(66)17-42(67)85/h25-41,48-50,84H,11-24,66H2,1-10H3,(H2,67,85)(H2,68,86)(H,69,105)(H,70,106)(H,71,87)(H,72,99)(H,73,102)(H,74,95)(H,75,96)(H,76,107)(H,77,101)(H,78,94)(H,79,97)(H,80,98)(H,81,100)(H,82,103)(H,83,104)(H,88,89)(H,90,91)(H,92,93)(H,108,109)/t29-,30+,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,48-,49-,50-/m0/s1</data>
  <data key="d20">[H][C@](C)(O)[C@]1([H])N=C(O)[C@]2([H])CSSC[C@]([H])(N=C(O)[C@]([H])(CCC(O)=O)N=C(O)[C@]([H])(CC(O)=O)N=C(O)[C@@]([H])(N)CC(O)=N)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CSSC[C@]([H])(N=C(O)CN=C1O)C(O)=N[C@@]([H])(CC(C)C)C(O)=O)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(C)C(O)=N2</data>
  <data key="d21">Plecanatide stimulates intestinal fluid secretions in the gastrointestinal tract to support regular bowel function. Plecanatide, taken orally once daily, works locally in the upper GI tract to stimulate secretion of intestinal fluid and support regular bowel function.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Guanilib, Plecanatide]</data>
  <data key="d9">Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC). It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01197">
  <data key="d0">Captopril</data>
  <data key="d1">drugbank.DB01197</data>
  <data key="d2">[drugbank.DB01197, drugbank.APRD00164]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[ACE Inhibitors and Diuretics, Acids, Acyclic, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Agents Causing Muscle Toxicity, Amino Acids, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Substrates, Enzyme Inhibitors, Hypotensive Agents, Imines, Imino Acids, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Substrates, P-glycoprotein/ABCB1 Inhibitors, Proline]</data>
  <data key="d14">(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid</data>
  <data key="d15">C9H15NO3S</data>
  <data key="d16">62571-86-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1</data>
  <data key="d20">C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O</data>
  <data key="d21">For the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, &amp;beta;-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid, Captopril, Captoprilum, Captopryl, CP, D-2-methyl-3-mercaptopropanoyl-L-proline, D-3-mercapto-2-methylpropanoyl-L-proline, L-Captopril]</data>
  <data key="d9">Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01196">
  <data key="d0">Estramustine</data>
  <data key="d1">drugbank.DB01196</data>
  <data key="d2">[drugbank.DB01196, drugbank.APRD00625]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alkylating Activity, Alkylating Drugs, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Estradiol, Estradiol Congeners, Estranes, Estrenes, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hydrocarbons, Halogenated, Immunosuppressive Agents, Mustard Compounds, Nitrogen Mustard Compounds, Noxae, P-glycoprotein/ABCB1 Inhibitors, Steroids, Toxic Actions]</data>
  <data key="d14">(1S,10R,11S,14S,15S)-14-hydroxy-15-methyltetracyclo[8.7.0.0,.0,]heptadeca-2,4,6-trien-5-yl N,N-bis(2-chloroethyl)carbamate</data>
  <data key="d15">C23H31Cl2NO3</data>
  <data key="d16">2998-57-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H31Cl2NO3/c1-23-9-8-18-17-5-3-16(29-22(28)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)27/h3,5,14,18-21,27H,2,4,6-13H2,1H3/t18-,19-,20+,21+,23+/m1/s1</data>
  <data key="d20">[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H]</data>
  <data key="d21">For the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[17-Estradiol 3-(bis(2-chloroethyl)carbamate), Estradiol 3-(N, N-bis(2-chloroethyl)carbamate), Estramustina, Estramustine, Estramustinum]</data>
  <data key="d9">A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13169">
  <data key="d0">Nandrolone</data>
  <data key="d1">drugbank.DB13169</data>
  <data key="d2">[drugbank.DB13169]</data>
  <data key="d12">[experimental, investigational]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Anabolic Agents, Anabolic Agents for Systemic Use, Anabolic Steroids, Androgens, Estranes, Estren Derivatives, Estrenes, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Nandrolone, Ophthalmologicals, Sensory Organs, Steroids, Testosterone Congeners]</data>
  <data key="d14">(1S,2R,10R,11S,14S,15S)-14-hydroxy-15-methyltetracyclo[8.7.0.0,.0,]heptadec-6-en-5-one</data>
  <data key="d15">C18H26O2</data>
  <data key="d16">434-22-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-17,20H,2-9H2,1H3/t13-,14+,15+,16-,17-,18-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(17)-17-hydroxyestr-4-en-3-one, 19-norandrostenolone, 19-nortestosterone, Nandrolona, Nandrolone, Nandrolonum]</data>
  <data key="d9">Nandrolone, also known as 19-nortestosterone or 19-norandrostenolone, is a synthetic anabolic-androgenic steroid (AAS) derived from testosterone.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01199">
  <data key="d0">Tubocurarine</data>
  <data key="d1">drugbank.DB01199</data>
  <data key="d2">[drugbank.DB01199, drugbank.APRD00176]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Alkaloids, Amines, Ammonium Compounds, Anticholinergic Agents, Benzylisoquinolines, Central Nervous System Depressants, Cholinergic Agents, Cholinesterase Inhibitors, Cholinesterase substrates, Curare Alkaloids, Ganglion Blockers, Isoquinolines, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular-Blocking Agents (Nondepolarizing), Neurotoxic agents, Neurotransmitter Agents, Nicotinic Antagonists, Nitrogen Compounds, OCT1 substrates, Onium Compounds, Peripheral Nervous System Agents, Quaternary Ammonium Compounds, Tetrahydroisoquinolines]</data>
  <data key="d14">(1S,16R)-9,21-dihydroxy-10,25-dimethoxy-15,15,30-trimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.2,.1,.1,.0,.0,]hexatriaconta-3,5,8(34),9,11,18(33),19,21,24,26,31,35-dodecaen-15-ium</data>
  <data key="d15">C37H41N2O6</data>
  <data key="d16">57-95-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C37H40N2O6/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41)/p+1/t28-,29+/m0/s1</data>
  <data key="d20">[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CCN1C)C2=C6)=C(O)C=C5)=CC(OC)=C4O)C=C3</data>
  <data key="d21">Used as a diagnosis agent for myasthenia gravis, and also to facilitate the intubation after induction of anesthesia in surgical procedure</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+)-tubocurarine, 7', 12'-dihydroxy-6, 6'-dimethoxy-2, 2', 2'-trimethyltubocuraranium, d-tubocurarine, Tubocurarin, Tubocurarine, Tubocurarinum]</data>
  <data key="d9">A neuromuscular blocker and active ingredient in curare; plant based alkaloid of Menispermaceae.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01146">
  <data key="d0">Diphenylpyraline</data>
  <data key="d1">drugbank.DB01146</data>
  <data key="d2">[drugbank.DB01146, drugbank.APRD00719]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Aminoalkyl Ethers, Antihistamines for Systemic Use, Histamine Antagonists, Histamine H1 Antagonists]</data>
  <data key="d14">4-(diphenylmethoxy)-1-methylpiperidine</data>
  <data key="d15">C19H23NO</data>
  <data key="d16">147-20-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3</data>
  <data key="d20">CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d21">For use in the treatment of allergic rhinitis, hay fever, and allergic skin disorders.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-methyl-4-hydroxypiperidine benzhydryl ether, 1-methyl-4-piperidyl benzhydryl ether, 4-(benzhydryloxy)-1-methylpiperidine, 4-(benzhydryloxy)-N-methylpiperidine, Difenilpiralina, Diphenylpyralamine, Diphenylpyraline, Diphenylpyralinum]</data>
  <data key="d9">Diphenylpyraline is an antihistamine. Antihistamines used in the treatment of allergy act by competing with histamine for H 1-receptor sites on effector cells. Antihistamines prevent, but do not reverse, responses mediated by histamine alone. Antihistamines antagonize, in varying degrees, most of the pharmacological effects of histamine, including urticaria and pruritus.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01156">
  <data key="d0">Bupropion</data>
  <data key="d1">drugbank.DB01156</data>
  <data key="d2">[drugbank.DB01156, drugbank.APRD00621]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents that reduce seizure threshold, Alimentary Tract and Metabolism, Aminoketone, Antidepressive Agents, Antidepressive Agents, Second-Generation, Antiobesity Preparations, Excl. Diet Products, Central Nervous System Agents, Central Nervous System Depressants, Centrally Acting Antiobesity Products, Chemically-Induced Disorders, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dopamine Agents, Dopamine Uptake Inhibitors, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Increased Dopamine Activity, Increased Norepinephrine Activity, Ketones, Membrane Transport Modulators, Miscellaneous Antidepressants, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Norepinephrine Uptake Inhibitors, OCT2 Inhibitors, Propiophenones, Psychoanaleptics, Psychotropic Drugs]</data>
  <data key="d14">2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one</data>
  <data key="d15">C13H18ClNO</data>
  <data key="d16">34911-55-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3</data>
  <data key="d20">CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1</data>
  <data key="d21">Bupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation. \n\nWhen used in combination with [naltrexone] as the marketed product Contrave, bupropion is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:\n30 kg/m^2 or greater (obese) or\n27 kg/m^2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).\n\nBupropion is also used off-label as a first-line treatment in patients with ADHD and comorbid bipolar disorder when used as an adjunct to mood stabilizers.[F4624]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Amfebutamone, Bupropion]</data>
  <data key="d9">Bupropion (also known as the brand name product Wellbutrin) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810]\n\nBupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), or Selective Serotonin Reuptake Inhibitors (SSRIs). While it has comparable effectiveness to typical first-line options for the treatment of depression such as SSRIs,[A178798,A178804] bupropion is a unique option for the treatment of MDD as it lacks any clinically relevant serotonergic effects, typical of other mood medications, or any effects on histamine or adrenaline receptors.[A6399,A198804] Lack of activity at these receptors results in a more tolerable side effect profile; bupropion is less likely to cause sexual side effects, sedation, or weight gain as compared to SSRIs or TCAs, for example.[A178804,A178807]\n\nWhen used as an aid to smoking cessation, bupropion is thought to confer its anti-craving and anti-withdrawal effects by inhibiting dopamine reuptake, which is thought to be involved in the reward pathways associated with nicotine, and through the antagonism of the nicotinic acetylcholinergic receptor.[A178825,A1966,A16508] A Cochrane Review of meta-analyses of available treatment modalities for smoking cessation found that abstinence rates approximately doubled when bupropion was used as compared to placebo, and was found to have similar rates of smoking cessation as [nicotine] replacement therapy (NRT).[A178816]\n\nBupropion is sometimes used as an add-on agent to first-line treatments of depression such as selective serotonin reuptake inhibitor (SSRI) medications when there is a treatment-failure or only partial response.[A178789] Bupropion is also used off-label for the management of Attention/Deficit-Hyperactivity Disorder (ADHD) in adults with comorbid bipolar depression to avoid mood destabilization caused by typical stimulant medications used for the treatment of ADHD.[F4624]\n\nWhen used in combination with [naltrexone] in the marketed product Contrave for chronic weight management, the two components are thought to have effects on areas of the brain involved in the regulation of food intake. This includes the hypothalamus, which is involved in appetite regulation, and the mesolimbic dopamine circuit, which is involved in reward pathways.[L6562] Studies have shown that the combined activity of bupropion and [naltrexone] increase the firing rate of hypothalamic pro-opiomelanocortin (POMC) neurons and blockade of opioid receptor-mediated POMC auto-inhibition, which are associated with a reduction in food intake and increased energy expenditure.[L6562,A179038,A179050] The combination of naltrexone and bupropion was shown to result in a statistically significant weight loss, with a mean change in body weight of -6.3% compared to -1.3% for placebo.[A179047]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13152">
  <data key="d0">Coagulation Factor IX Human</data>
  <data key="d1">drugbank.DB13152</data>
  <data key="d2">[drugbank.DB13152]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Blood Coagulation Factors, Hemostatics, Increased Coagulation Activity]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">9001-28-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Factor IX is used to treat Christmas disease. Factor IX deficiency is treated by injection factor IX produced from human plasma. Tranexamic acid may be of value in patients undergoing surgery who have inherited factor IX deficiency in order to reduce the perioperative risk of bleeding.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;5424ed33-5125-48e5-8823-9a12fea8043d DB00100 sequence\nYNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAEAVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT]</data>
  <data key="d8">[Antihemophilic factor B, Coagulation factor IX (human), Factor IX (Human), Factor IX purificado, Human coagulation factor IX]</data>
  <data key="d9">Factor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes hemophilia B.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13151">
  <data key="d0">Anti-inhibitor coagulant complex</data>
  <data key="d1">drugbank.DB13151</data>
  <data key="d2">[drugbank.DB13151]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Blood and Blood Forming Organs, Blood Coagulation Factors, Hemostatics, Reversed Anticoagulation Activity]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">For use in the control of bleeding episodes, perioperative management, and routine prophylaxis against bleeding episodes in hemophilia A and B patients with inhibitors [FDA Label]. It is not indicated in the absence of factor VIII or IX inhibitors.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Activated prothrombin complex concentrate, Antiinhibitor coagulant complex, Factor VIII bypassing fraction, Factor VIII inhibitor bypassing activity, Factor VIII inhibitor bypassing fraction]</data>
  <data key="d9">Anti-inhibitor coagulant complex, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex. It is used to control bleeding in hemophilia A and B patients with inhibitors.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14481">
  <data key="d0">Calcium phosphate dihydrate</data>
  <data key="d1">drugbank.DB14481</data>
  <data key="d2">[drugbank.DB14481, drugbank.DBSALT001593]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acids, Acids, Noncarboxylic, Anions, Calcium Compounds, Electrolytes, Ions, Phosphate salts, Phosphoric Acids, Phosphorus Acids, Phosphorus Compounds]</data>
  <data key="d14">calcium dihydrate hydrogen phosphate</data>
  <data key="d15">CaH5O6P</data>
  <data key="d16">7789-77-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/Ca.H3O4P.2H2O/c;1-5(2,3)4;;/h;(H3,1,2,3,4);2*1H2/q+2;;;/p-2</data>
  <data key="d20">O.O.[Ca++].OP([O-])([O-])=O</data>
  <data key="d21">For use as an over the counter calcium and phosphate supplement, antacid, or a source of calcium and phosphate in toothpaste [FDA Label] [L851].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Calcium monohydrogen phosphate dihydrate, Calcium phosphate dibasic, hydrous, Calcium phosphate dihydrate, dibasic, Calcium phosphate, dibasic, dihydrate, Calcium phosphate, dibasic, hydrous, D.C.P., Dibasic calcium phosphate dihydrate, Dibasic calcium phosphate hydrate, Dicalcium phosphate dihydrate]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01168">
  <data key="d0">Procarbazine</data>
  <data key="d1">drugbank.DB01168</data>
  <data key="d2">[drugbank.DB01168, drugbank.APRD00695]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Carbocyclic, Agents Causing Muscle Toxicity, Alkylating Activity, Alkylating Drugs, Amides, Antidepressive Agents, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Benzamides and benzamide derivatives, Benzene Derivatives, Benzoates, Central Nervous System Depressants, Immunosuppressive Agents, Methylhydrazines, Monoamine Oxidase Inhibitors, Myelosuppressive Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators]</data>
  <data key="d14">4-[(2-methylhydrazin-1-yl)methyl]-N-(propan-2-yl)benzamide</data>
  <data key="d15">C12H19N3O</data>
  <data key="d16">671-16-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16)</data>
  <data key="d20">CNNCC1=CC=C(C=C1)C(=O)NC(C)C</data>
  <data key="d21">For use with other anticancer drugs for the treatment of stage III and stage IV Hodgkin's disease.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine, 2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine, 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide, N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide, N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine, N-isopropyl-4-[(2-methylhydrazino)methyl]benzamide, N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide, N-Isopropyl--(2-methylhydrazino)-p-toluamide, p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide, Procarbazin, Procarbazina, Procarbazine, Procarbazinum]</data>
  <data key="d9">An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01176">
  <data key="d0">Cyclizine</data>
  <data key="d1">drugbank.DB01176</data>
  <data key="d2">[drugbank.DB01176, drugbank.APRD00061]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Antiemetics, Antihistamines for Systemic Use, Autonomic Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Gastrointestinal Agents, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Neurotransmitter Agents, Peripheral Nervous System Agents, Piperazine Derivatives, Piperazines, Potential QTc-Prolonging Agents, QTc Prolonging Agents]</data>
  <data key="d14">1-(diphenylmethyl)-4-methylpiperazine</data>
  <data key="d15">C18H22N2</data>
  <data key="d16">82-92-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H22N2/c1-19-12-14-20(15-13-19)18(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18H,12-15H2,1H3</data>
  <data key="d20">CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d21">For prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness, and vertigo (dizziness caused by other medical problems).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-1-diphenylmethyl-4-methylpiperazine, (N-Benzhydryl)(N'-methyl)diethylenediamine, 1-(Diphenylmethyl)-4-methylpiperazine, 1-Benzhydryl-4-methylpiperazin, Ciclizina, Cyclizine, Cyclizinum, N-Benzhydryl-N'-methylpiperazine, N-methyl-N'-benzhydrylpiperazine]</data>
  <data key="d9">A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01174">
  <data key="d0">Phenobarbital</data>
  <data key="d1">drugbank.DB01174</data>
  <data key="d2">[drugbank.DB01174, drugbank.APRD00184]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Anticholinergic Agents, Anticonvulsants, Barbiturates, Barbiturates and Derivatives, BSEP/ABCB11 inducers, Central Nervous System Agents, Central Nervous System Depressants, Chemically-Induced Disorders, Cytochrome P-450 2C18 Inducers, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strong), Cytochrome P-450 CYP2A6 Inducers, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strong), Cytochrome P-450 CYP2C18 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (unknown strength), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inducers (strong), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2E1 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strong), Cytochrome P-450 CYP3A7 Inducers, Cytochrome P-450 CYP3A7 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Enzyme Inducing Antiepileptic Drugs, Excitatory Amino Acid Agents, Excitatory Amino Acid Antagonists, GABA Agents, GABA Modulators, Hypnotics and Sedatives, Methemoglobinemia Associated Agents, Narrow Therapeutic Index Drugs, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Substrates, P-glycoprotein/ABCB1 Substrates with narrow therapeutic index, Phenobarbital and similars, Psycholeptics, Pyrimidines, Pyrimidinones, UGT1A1 Inducers, UGT2B7 inducers]</data>
  <data key="d14">5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione</data>
  <data key="d15">C12H12N2O3</data>
  <data key="d16">50-06-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)</data>
  <data key="d20">CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1</data>
  <data key="d21">For the treatment of all types of seizures except absence seizures.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[5-ethyl-5-phenyl-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione, 5-Ethyl-5-phenyl-pyrimidine-2, 4, 6-trione, 5-Ethyl-5-phenylbarbituric acid, 5-ethyl-5-phenylpyrimidine-2, 4, 6(1H, 3H, 5H)-trione, 5-Phenyl-5-ethylbarbituric acid, Fenobarbital, Phenobarbital, Phenobarbitol, Phenobarbitone, Phenobarbituric Acid, Phenylthylbarbitursure, Phenylethylbarbiturate, Phenylethylbarbituric Acid, Phenylethylbarbitursure, Phenylethylmalonylurea]</data>
  <data key="d9">A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01173">
  <data key="d0">Orphenadrine</data>
  <data key="d1">drugbank.DB01173</data>
  <data key="d2">[drugbank.DB01173, drugbank.APRD00097]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents producing tachycardia, Amines, Anti-Dyskinesia Agents, Anti-Parkinson Drugs, Anticholinergic Agents, Autonomic Agents, Benzene Derivatives, Benzhydryl Compounds, Central Nervous System Agents, Central Nervous System Depressants, Centrally-mediated Muscle Relaxation, Chemically-Induced Disorders, Cholinergic Agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strong), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Ethers, Chemically Close to Antihistamines, Ethylamines, Histamine Antagonists, Histamine H1 Antagonists, Miscellaneous Skeletal Muscle Relaxants, Muscarinic Antagonists, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Musculo-Skeletal System, Nervous System, Neurotransmitter Agents, NMDA Receptor Antagonists, Parasympatholytics, Peripheral Nervous System Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents]</data>
  <data key="d14">dimethyl({2-[(2-methylphenyl)(phenyl)methoxy]ethyl})amine</data>
  <data key="d15">C18H23NO</data>
  <data key="d16">83-98-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H23NO/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16/h4-12,18H,13-14H2,1-3H3</data>
  <data key="d20">CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C</data>
  <data key="d21">Indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculo skeletal conditions.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-(phenyl-o-tolylmethoxy)ethyldimethylamine, 2-methyldiphenhydramine, beta-Dimethylaminoethyl 2-methylbenzhydryl ether, Dimethyl-[2-(phenyl-o-tolyl-methoxy)-ethyl]-amine, N, N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine, N, N-dimethyl-2-(phenyl(o-tolyl)methoxy)ethanamine, N, N-dimethyl-2-[(o-methyl--phenylbenzyl)oxy]ethylamine, o-methyldiphenhydramine, o-monomethyldiphenhydramine, Orfenadrina, Orphenadrine, Orphenadrinum, phenyl-o-tolylmethyl dimethyaminoethyl ether, -dimethylaminoethyl 2-methylbenzhydryl ether]</data>
  <data key="d9">A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01171">
  <data key="d0">Moclobemide</data>
  <data key="d1">drugbank.DB01171</data>
  <data key="d2">[drugbank.DB01171, drugbank.APRD00603]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Carbocyclic, Agents that produce hypertension, Agents that reduce seizure threshold, Amides, Antidepressive Agents, Benzamides and benzamide derivatives, Benzene Derivatives, Benzoates, Central Nervous System Agents, Central Nervous System Depressants, Chlorobenzoates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Monoamine Oxidase A Inhibitors, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase Inhibitors, Nervous System, Psychoanaleptics, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators]</data>
  <data key="d14">4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide</data>
  <data key="d15">C13H17ClN2O2</data>
  <data key="d16">71320-77-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)</data>
  <data key="d20">ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1</data>
  <data key="d21">For the treatment of major depressive disorder and bipolar disorder [A31901].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[4-Chlor-N-(2-morpholinoethyl)benzamid, Moclobemid, Moclobemida, Moclobemide, Moclobemidum, p-Chloro-N-(2-morpholinoethyl)benzamide]</data>
  <data key="d9">A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder. Most meta-analyses and most studies indicate that in the acute management of depression, moclobemide is more efficacious than placebo medication and similarly efficacious as tricyclic antidepressants (TCA) or selective serotonin reuptake inhibitors (SSRIs).  Due to negligible anticholinergic and antihistaminic actions, moclobemide has been better tolerated than tri- or heterocyclic antidepressants [A3901].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13166">
  <data key="d0">Zofenopril</data>
  <data key="d1">drugbank.DB13166</data>
  <data key="d2">[drugbank.DB13166]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[ACE Inhibitors and Diuretics, Acids, Acyclic, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Amino Acids, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Agents, Enzyme Inhibitors, Imines, Imino Acids, Proline, Protease Inhibitors]</data>
  <data key="d14">(2S,4S)-1-[(2S)-3-(benzoylsulfanyl)-2-methylpropanoyl]-4-(phenylsulfanyl)pyrrolidine-2-carboxylic acid</data>
  <data key="d15">C22H23NO4S2</data>
  <data key="d16">81872-10-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H23NO4S2/c1-15(14-28-22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17/h2-11,15,18-19H,12-14H2,1H3,(H,25,26)/t15-,18+,19+/m1/s1</data>
  <data key="d20">C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Zofenil, Zofnopril, Zofenopril, Zofenoprilum]</data>
  <data key="d9">Zofenopril is employed as both a cardioprotective and anti-hypertensive agent. It is an angiotensin-converting enzyme (ACE) inhibitor.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14491">
  <data key="d0">Ferrous fumarate</data>
  <data key="d1">drugbank.DB14491</data>
  <data key="d2">[drugbank.DB14491, drugbank.DBSALT000079]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Antianemic Preparations, Blood and Blood Forming Organs, Diet, Food, and Nutrition, Food, Food and Beverages, Growth Substances, Iron Bivalent, Oral Preparations, Iron Compounds, Iron Preparations, Micronutrients, Minerals, Organometallic Compounds, Physiological Phenomena, Trace Elements]</data>
  <data key="d14">lambda2-iron(2+) (2E)-but-2-enedioate</data>
  <data key="d15">C4H2FeO4</data>
  <data key="d16">141-01-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C4H4O4.Fe/c5-3(6)1-2-4(7)8;/h1-2H,(H,5,6)(H,7,8);/q;+2/p-2/b2-1+;</data>
  <data key="d20">[Fe++].[H]\C(=C(\[H])C([O-])=O)C([O-])=O</data>
  <data key="d21">Used in preventing and treating iron-deficiency anemia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Iron(2+) fumarate]</data>
  <data key="d9">Used in treatment of iron deficiency anemia.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14490">
  <data key="d0">Ferrous ascorbate</data>
  <data key="d1">drugbank.DB14490</data>
  <data key="d2">[drugbank.DB14490, drugbank.DBSALT000075]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acids, Acyclic, Antianemic Preparations, Antioxidants, Blood and Blood Forming Organs, Carbohydrates, Compounds used in a research, industrial, or household setting, Diet, Food, and Nutrition, Food, Food and Beverages, Growth Substances, Hydroxy Acids, Iron Bivalent, Oral Preparations, Iron Preparations, Micronutrients, Physiological Phenomena, Polyvalent cation containing laxatives, antacids, oral supplements, Protective Agents, Sugar Acids, Urinary Acidifying Agents]</data>
  <data key="d14">lambda2-iron(2+) (2R)-2-[(1S)-1,2-dihydroxyethyl]-5-oxo-2,5-dihydrofuran-3,4-bis(olate) (5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2,5-dihydrofuran-2-one</data>
  <data key="d15">C12H14FeO12</data>
  <data key="d16">24808-52-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/2C6H8O6.Fe/c2*7-1-2(8)5-3(9)4(10)6(11)12-5;/h2*2,5,7-10H,1H2;/q;;+2/p-2/t2*2-,5+;/m00./s1</data>
  <data key="d20">[Fe++].[H][C@](O)(CO)[C@@]1([H])OC(=O)C(O)=C1O.[H][C@](O)(CO)[C@@]1([H])OC(=O)C([O-])=C1[O-]</data>
  <data key="d21">Used in preventing and treating iron-deficiency anemia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Ferrous cevitamate, Iron(2+) L-ascorbate, L-Ascorbic acid, iron complex]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01186">
  <data key="d0">Pergolide</data>
  <data key="d1">drugbank.DB01186</data>
  <data key="d2">[drugbank.DB01186, drugbank.APRD00663]</data>
  <data key="d12">[approved, investigational, vet_approved, withdrawn]</data>
  <data key="d13">[Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Agents producing tachycardia, Agents that produce hypertension, Alkaloids, Anti-Parkinson Drugs, Antidepressive Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dopamine Agents, Dopamine Agonists, Ergolines, Ergot Alkaloids and Derivatives, Ergot-derivative Dopamine Receptor Agonists, Ergot-derived Dopamine Receptor Agonist, Nervous System, Neurotransmitter Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Agonists, Serotonin Agents, Serotonin Receptor Agonists]</data>
  <data key="d14">(2R,4R,7R)-4-[(methylsulfanyl)methyl]-6-propyl-6,11-diazatetracyclo[7.6.1.0,.0,]hexadeca-1(16),9,12,14-tetraene</data>
  <data key="d15">C19H26N2S</data>
  <data key="d16">66104-22-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s1</data>
  <data key="d20">[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC</data>
  <data key="d21">Indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson's disease. It was withdrawn from the US and Canadian markets in 2007 due to an increased risk of cardiac valvulopathy.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Pergolida, Pergolide, Pergolidum]</data>
  <data key="d9">Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinsons Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. While the use of pergolide in humans is still approved in only some countries, pergolide is mainly used for veterinary purposes.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01185">
  <data key="d0">Fluoxymesterone</data>
  <data key="d1">drugbank.DB01185</data>
  <data key="d2">[drugbank.DB01185, drugbank.APRD00981]</data>
  <data key="d12">[approved, illicit]</data>
  <data key="d13">[3-Oxoandrosten (4) Derivatives, Anabolic Agents, Androgens, Androstanes, Androstenediols, Androstenes, Androstenols, Genito Urinary System and Sex Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Sex Hormones and Modulators of the Genital System, Steroids, Steroids, Fluorinated]</data>
  <data key="d14">(1R,2S,10S,11S,14S,15S,17S)-1-fluoro-14,17-dihydroxy-2,14,15-trimethyltetracyclo[8.7.0.0,.0,]heptadec-6-en-5-one</data>
  <data key="d15">C20H29FO3</data>
  <data key="d16">76-43-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C</data>
  <data key="d21">In males, used as replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. In females, for palliation of androgenresponsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[11, 17-Dihydroxy-9-fluoro-17-methyl-4-androster-3-one, 17-Methyl-9-fluoro-11-hydroxytesterone, 9-Fluoro-11, 17-dihydroxy-17-methylandrost-4-en-3-one, 9-Fluoro-11-hydroxy-17-methyltestosterone, Fluoximesterona, Fluoxymesterone, Fluoxymestrone, Fluoxymesteronum]</data>
  <data key="d9">An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01184">
  <data key="d0">Domperidone</data>
  <data key="d1">drugbank.DB01184</data>
  <data key="d2">[drugbank.DB01184, drugbank.APRD00418]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Antiemetics, Autonomic Agents, Benzimidazoles, Central Nervous System Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs for Functional Gastrointestinal Disorders, Gastrointestinal Agents, Highest Risk QTc-Prolonging Agents, Neurotransmitter Agents, P-glycoprotein/ABCB1 Substrates, Peripheral Nervous System Agents, Piperidines, Prokinetic Agents, Propulsives, QTc Prolonging Agents]</data>
  <data key="d14">5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-1-yl)propyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one</data>
  <data key="d15">C22H24ClN5O2</data>
  <data key="d16">57808-66-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)</data>
  <data key="d20">ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2</data>
  <data key="d21">For management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-(3-(4-(5-chloro-2-oxo-2, 3-dihydrobenzo[d]imidazol-1-yl)piperidin-1-yl)propyl)-1H-benzo[d]imidazol-2(3H)-one, 5-chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone, 5-chloro-1-(1-(3-(2-oxo-2, 3-dihydrobenzo[d]imidazol-1-yl)propyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one, 5-chloro-1-{1-[3-(2-oxo-2, 3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1, 3-dihydro-benzoimidazol-2-one, Domperidona, Domperidone, Domperidonum]</data>
  <data key="d9">A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01183">
  <data key="d0">Naloxone</data>
  <data key="d1">drugbank.DB01183</data>
  <data key="d2">[drugbank.DB01183, drugbank.APRD00025]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Alkaloids, Analgesics, Antidotes, Central Nervous System Agents, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inhibitors (strong), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 Enzyme Inhibitors, Drugs for Constipation, Drugs that are Mainly Renally Excreted, Morphinans, Natural Opium Alkaloids, Nervous System, Opiate Alkaloids, Opiate Antagonists, Opioid Antagonists, Opioids, P-glycoprotein/ABCB1 Substrates, Peripheral Nervous System Agents, Peripheral Opioid Receptor Antagonists, Phenanthrenes, Sensory System Agents, UGT1A1 Substrates]</data>
  <data key="d14">(1S,5R,13R,17S)-10,17-dihydroxy-4-(prop-2-en-1-yl)-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one</data>
  <data key="d15">C19H21NO4</data>
  <data key="d16">465-65-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1</data>
  <data key="d20">OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O</data>
  <data key="d21">For the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids including natural and synthetic narcotics, propoxyphene, methadone and the narcotic-antagonist analgesics: nalbuphine, pentazocine and butorphanol. It is also indicated for the diagnosis of suspected acute opioid overdose. It may also be used as an adjunctive agent to increase blood pressure in the management of septic shock.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-naloxone, 1-N-Allyl-14-hydroxynordihydromorphinone, 17-allyl-3, 14-dihydroxy-4, 5-epoxymorphinan-6-one, Nalossone, Naloxona, Naloxone, Naloxonum]</data>
  <data key="d9">Naloxone is an opioid antagonist medication used to block or reverse the effects of opioid drugs, particularly within the setting of drug overdoses which are rapidly becoming a leading cause of death worldwide. More specifically, naloxone has a high affinity for -opioid receptors, where it acts as an inverse agonist, causing the rapid removal of any other drugs bound to these receptors. When taken in large quantities, opioid medications such as morphine, hydromorphone, methadone, heroin, or fentanyl are capable of causing life-threatening symptoms such as respiratory depression, reduced heart rate, slurred speech, drowsiness, and constricted pupils. If untreated, this can progress to vomiting, absent pulse and breathing, loss of consciousness, and even death. Naloxone is indicated for the rapid reversal of these symptoms of central nervous system depression in opioid overdose. It's important to note that naloxone only works on opioid receptors within the body, and is therefore not capable of reversing the effects of non-opioid medications such as stimulants like methamphetamine or cocaine, or benzodiazepines like lorazepam or diazepam. \n\nAlso known as the brand name product Narcan, naloxone is currently available by intramuscular (IM) or subcutaneous (SubQ) injection, nasal spray, or intravenous (IV) infusion. Naloxone IM injections are commonly available in the form of "kits", which is ideal for making overdose treatment accessible and readily available for administration by minimally trained individuals within the community. Kits commonly include the supplies necessary to treat an overdose in a non-medical setting such as alcohol swabs, syringes, a rescue breathing mask, and instructions for use. Frequently also carried by medical and emergency personnel and at events known to be associated with heavy drug use like music festivals, naloxone kits are considered a key component of harm reduction strategies.\n\nWhen injected intramuscularly (IM), naloxone acts within 3-5 minutes and can last from 30-60 minutes before its effects wear off. Administration of naloxone is associated with very few side effects. Notably, if injected into a person not currently using opioid medications, there would be no noticeable effects at all. However, for individuals using opioid medications or experiencing an overdose, IM injection of naloxone rapidly reverses opioid effects and can cause the injected individual to immediately experience withdrawal symptoms. Common symptoms of opioid withdrawal include nausea, vomiting, sweating, runny nose, aches, and diarrhea. Although certainly physically uncomfortable, opioid withdrawal symptoms are not life-threatening like they are for alcohol withdrawals. Administration of naloxone is therefore appropriate for any person appearing to have any symptoms of an opioid overdose. Due to its short duration of action, person's injected with naloxone should be monitored for responsiveness and potentially injected a second time or taken to the hospital.\n\nNaloxone is also available within the combination product Suboxone with the opioid medication buprenorphine. Suboxone is used for the maintentance treatment of opioid dependence and addiction. When taken orally, naloxone has no pharmacological effect and does not reduce the effectiveness of the opioid effect of buprenorphine. The primary purpose of including naloxone within Suboxone is to act as a deterrent to injection, as injected naloxone would rapidly reverse the effects of buprenorphine.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01182">
  <data key="d0">Propafenone</data>
  <data key="d1">drugbank.DB01182</data>
  <data key="d2">[drugbank.DB01182, drugbank.APRD00261]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Agents that produce hypertension, Antiarrhythmic agents, Antiarrhythmics, Class I, Antiarrhythmics, Class Ic, Bradycardia-Causing Agents, Cardiac Therapy, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Ketones, Membrane Transport Modulators, Moderate Risk QTc-Prolonging Agents, P-glycoprotein/ABCB1 Inhibitors, Propiophenones, QTc Prolonging Agents, Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers]</data>
  <data key="d14">1-{2-[2-hydroxy-3-(propylamino)propoxy]phenyl}-3-phenylpropan-1-one</data>
  <data key="d15">C21H27NO3</data>
  <data key="d16">54063-53-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3</data>
  <data key="d20">CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1</data>
  <data key="d21">Used to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone, 2-(2'-hydroxy-3'-propylaminopropoxy)--phenylpropiophenone, Propafenona, Propafenone, Propafenonum]</data>
  <data key="d9">An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01180">
  <data key="d0">Rescinnamine</data>
  <data key="d1">drugbank.DB01180</data>
  <data key="d2">[drugbank.DB01180, drugbank.APRD00112]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Agents that produce hypertension, Alkaloids, Angiotensin-Converting Enzyme Inhibitors, Antiadrenergic Agents, Centrally Acting, Antihypertensive Agents, Indole Alkaloids, Indoles, Secologanin Tryptamine Alkaloids, Yohimbine]</data>
  <data key="d14">methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-{[3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]oxy}-3,13-diazapentacyclo[11.8.0.0,.0,.0,]henicosa-2(10),4(9),5,7-tetraene-19-carboxylate</data>
  <data key="d15">C35H42N2O9</data>
  <data key="d16">24815-24-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C35H42N2O9/c1-40-21-8-9-22-23-11-12-37-18-20-15-29(46-30(38)10-7-19-13-27(41-2)33(43-4)28(14-19)42-3)34(44-5)31(35(39)45-6)24(20)17-26(37)32(23)36-25(22)16-21/h7-10,13-14,16,20,24,26,29,31,34,36H,11-12,15,17-18H2,1-6H3/b10-7+/t20-,24+,26-,29-,31+,34+/m1/s1</data>
  <data key="d20">[H][C@]12C[C@@H](OC(=O)C=CC3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2</data>
  <data key="d21">For the treatment of hypertension.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3, 4, 5-Trimethoxycinnamoyl methyl reserpate, Rescinnamine, Trimethoxy cinnamoyl reserpate de methyl]</data>
  <data key="d9">Rescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from _Rauwolfia serpentina_ and other species of _Rauwolfia_.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14489">
  <data key="d0">Ferrous succinate</data>
  <data key="d1">drugbank.DB14489</data>
  <data key="d2">[drugbank.DB14489, drugbank.DBSALT000083]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Antianemic Preparations, Blood and Blood Forming Organs, Iron Bivalent, Oral Preparations, Iron Compounds, Iron Preparations, Organometallic Compounds]</data>
  <data key="d14">lambda2-iron(2+) butanedioate</data>
  <data key="d15">C4H4FeO4</data>
  <data key="d16">10030-90-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C4H6O4.Fe/c5-3(6)1-2-4(7)8;/h1-2H2,(H,5,6)(H,7,8);/q;+2/p-2</data>
  <data key="d20">[Fe++].[O-]C(=O)CCC([O-])=O</data>
  <data key="d21">Used in preventing and treating iron-deficiency anemia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Iron succinate]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14488">
  <data key="d0">Ferrous gluconate</data>
  <data key="d1">drugbank.DB14488</data>
  <data key="d2">[drugbank.DB14488, drugbank.DBSALT000080]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Anemia, Iron-Deficiency, Antianemia Drugs, Antianemic Preparations, Blood and Blood Forming Organs, Hematinics, Hematologic Agents, Iron Bivalent, Oral Preparations, Iron Compounds, Iron Preparations, Minerals, Organometallic Compounds, Polyvalent cation containing laxatives, antacids, oral supplements]</data>
  <data key="d14">lambda2-iron(2+) bis((2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate)</data>
  <data key="d15">C12H22FeO14</data>
  <data key="d16">299-29-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/2C6H12O7.Fe/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;/h2*2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t2*2-,3-,4+,5-;/m11./s1</data>
  <data key="d20">[Fe++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O</data>
  <data key="d21">Used in preventing and treating iron-deficiency anemia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[D-gluconic acid, iron(2+) salt (2:1), Ferric Gluconate, Ferrous gluconate anhydrous, Iron(2+) gluconate (1:2), Iron(II) gluconate, anhydrous]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14487">
  <data key="d0">Zinc acetate</data>
  <data key="d1">drugbank.DB14487</data>
  <data key="d2">[drugbank.DB14487, drugbank.DBSALT001308]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acetates, Acetic Acid, Acids, Acyclic, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Alimentary Tract and Metabolism, Copper Absorption Inhibitor, Fatty Acids, Fatty Acids, Volatile, Lipids, Metal cations, Metal divalent cations, Various Alimentary Tract and Metabolism Products, Vasoprotectives, Zinc Compounds]</data>
  <data key="d14">zinc(2+) diacetate</data>
  <data key="d15">C4H6O4Zn</data>
  <data key="d16">557-34-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/2C2H4O2.Zn/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2</data>
  <data key="d20">[Zn++].CC([O-])=O.CC([O-])=O</data>
  <data key="d21">Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Acetic acid, zinc salt, Dicarbomethoxyzinc, Zinc acetate anhydrous, Zinc acetato, Zinc diacetate, Zinc(II) acetate]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01108">
  <data key="d0">Trilostane</data>
  <data key="d1">drugbank.DB01108</data>
  <data key="d2">[drugbank.DB01108, drugbank.APRD01276]</data>
  <data key="d12">[approved, investigational, vet_approved, withdrawn]</data>
  <data key="d13">[3-Hydroxysteroid Dehydrogenases, antagonists &amp; inhibitors, Abortifacient Agents, Abortifacient Agents, Steroidal, Adrenal Cortex Hormones, Androstanes, Androstanols, Antiadrenal Preparations, Anticorticosteroids, Antineoplastic Agents, Corticosteroids, Corticosteroids for Systemic Use, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Enzyme Inhibitors, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Immunosuppressive Agents, Oxidative Phosphorylation Coupling Factors, Reproductive Control Agents, Steroids, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Testosterone Congeners]</data>
  <data key="d14">(1S,2R,6R,8S,11S,12S,15S,16S)-5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.0^{2,8}.0^{6,8}.0^{12,16}]octadec-4-ene-4-carbonitrile</data>
  <data key="d15">C20H27NO3</data>
  <data key="d16">13647-35-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h12-15,17,22-23H,3-9H2,1-2H3/t12-,13-,14-,15-,17+,18-,19+,20+/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N</data>
  <data key="d21">Used in the treatment of Cushing's syndrome. It is normally used in short-term treatment until permanent therapy is possible.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Trilostane, Trilostano, Trilostanum]</data>
  <data key="d9">Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01103">
  <data key="d0">Quinacrine</data>
  <data key="d1">drugbank.DB01103</data>
  <data key="d2">[drugbank.DB01103, drugbank.APRD00317]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acridines, Aminoacridines, Anti-Infective Agents, Anticestodal Agents, Antimalarials, Antinematodal Agents, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiplatyhelmintic Agents, Antiprotozoals, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Enzyme Inhibitors, OCT2 Inhibitors, P-glycoprotein/ABCB1 Inhibitors]</data>
  <data key="d14">6-chloro-N-[5-(diethylamino)pentan-2-yl]-2-methoxyacridin-9-amine</data>
  <data key="d15">C23H30ClN3O</data>
  <data key="d16">83-89-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H30ClN3O/c1-5-27(6-2)13-7-8-16(3)25-23-19-11-9-17(24)14-22(19)26-21-12-10-18(28-4)15-20(21)23/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26)</data>
  <data key="d20">CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=C1C=CC(Cl)=C2</data>
  <data key="d21">For the treatment of giardiasis and cutaneous leishmaniasis and the management of malignant effusions.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-methoxy-6-chloro-9-diethylaminopentylaminoacridine, 3-chloro-7-methoxy-9-(1-methyl-4-diethylaminobutylamino)acridine, 6-chloro-9-((4-(diethylamino)-1-methylbutyl)amino)-2-methoxyacridine, Mepacrine, N4-(6-chloro-2-methoxy-9-acridinyl)-N1, N1-diethyl-1, 4-pentanediamine]</data>
  <data key="d9">An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01100">
  <data key="d0">Pimozide</data>
  <data key="d1">drugbank.DB01100</data>
  <data key="d2">[drugbank.DB01100, drugbank.APRD00218]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents that reduce seizure threshold, Anti-Dyskinesia Agents, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Benzimidazoles, Central Nervous System Agents, Central Nervous System Depressants, CYP3A Substrates (Sensitive), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Diphenylbutylpiperidine Derivatives, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Highest Risk QTc-Prolonging Agents, Miscellaneous Antipsychotics, Narrow Therapeutic Index Drugs, Nervous System, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein/ABCB1 Inhibitors, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Tranquilizing Agents]</data>
  <data key="d14">1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one</data>
  <data key="d15">C28H29F2N3O</data>
  <data key="d16">2062-78-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)</data>
  <data key="d20">FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1</data>
  <data key="d21">Used for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Pimozida, Pimozide, Pimozidum]</data>
  <data key="d9">A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01110">
  <data key="d0">Miconazole</data>
  <data key="d1">drugbank.DB01110</data>
  <data key="d2">[drugbank.DB01110, drugbank.APRD01115]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[14-alpha Demethylase Inhibitors, Alimentary Tract and Metabolism, Anti-Infective Agents, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antifungal Agents, Antifungal Agents (Vaginal), Antifungals for Dermatological Use, Antifungals for Topical Use, Antiinfectives and Antiseptics for Local Oral Treatment, Antiinfectives for Systemic Use, Antimycotics for Systemic Use, Azole Antifungals, Chemically-Induced Disorders, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strong), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors (strong), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strong), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Imidazole and Triazole Derivatives, Imidazole Derivatives, Imidazoles, Intestinal Antiinfectives, Otologicals, P-glycoprotein/ABCB1 Inhibitors, Sensory Organs, Steroid Synthesis Inhibitors, Stomatological Preparations, Vaginal Creams, Foams, and Jellies]</data>
  <data key="d14">1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole</data>
  <data key="d15">C18H14Cl4N2O</data>
  <data key="d16">22916-47-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2</data>
  <data key="d20">ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1</data>
  <data key="d21">For topical application in the treatment of tinea pedis (athlete&amp;rsquo;s foot), tinea cruris, and tinea corporis caused by &lt;i&gt;Trichophyton rubrum&lt;/i&gt;, &lt;i&gt;Trichophyton mentagrophytes&lt;/i&gt;, and &lt;i&gt;Epidermophyton floccosum&lt;/i&gt;, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-(2, 4-Dichloro-beta-((2, 4-dichlorobenzyl)oxy)phenethyl)imidazole, 1-[2-(2, 4-Dichloro-benzyloxy)-2-(2, 4-dichloro-phenyl)-ethyl]-1H-imidazole, Miconazol, Miconazole]</data>
  <data key="d9">An imidazole antifungal agent that is used topically and by intravenous infusion.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01118">
  <data key="d0">Amiodarone</data>
  <data key="d1">drugbank.DB01118</data>
  <data key="d2">[drugbank.DB01118, drugbank.APRD00288]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents causing hyperkalemia, Agents Causing Muscle Toxicity, Agents that reduce seizure threshold, alpha-Galactosidase, antagonists &amp; inhibitors, Antiarrhythmic agents, Antiarrhythmics, Class III, Benzofurans, Bradycardia-Causing Agents, BSEP/ABCB11 Substrates, BSEP/ABCB11 Substrates with Narrow Therapeutic Index, Calcium Channel Blockers, Cardiac Therapy, Cardiovascular Agents, Chemically-Induced Disorders, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (moderate), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P450 1A2 Inhibitors, Cytochrome P450 2C9 Inhibitors, Cytochrome P450 2D6 Inhibitors, Cytochrome P450 3A4 Inhibitors, Enzyme Inhibitors, Highest Risk QTc-Prolonging Agents, Hypotensive Agents, Membrane Transport Modulators, Narrow Therapeutic Index Drugs, OCT2 Inhibitors, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Inhibitors, Potassium Channel Blockers, QTc Prolonging Agents, Sodium Channel Blockers, Vasodilating Agents]</data>
  <data key="d14">{2-[4-(2-butyl-1-benzofuran-3-carbonyl)-2,6-diiodophenoxy]ethyl}diethylamine</data>
  <data key="d15">C25H29I2NO3</data>
  <data key="d16">1951-25-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3</data>
  <data key="d20">CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2</data>
  <data key="d21">Intravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-Butyl-3-(3, 5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran, 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3, 5-diiodophenyl ketone, 2-n-Butyl-3', 5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran, Amiodarona, Amiodarone, Amiodaronum]</data>
  <data key="d9">An antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01116">
  <data key="d0">Trimethaphan</data>
  <data key="d1">drugbank.DB01116</data>
  <data key="d2">[drugbank.DB01116, drugbank.APRD00044]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Adjuvants, Anesthesia, Antiadrenergic Agents, Ganglion-Blocking, Anticholinergic Agents, Antihypertensive Agents, Autonomic Agents, Cardiovascular Agents, Central Nervous System Agents, Cholinergic Agents, Cholinesterase substrates, Ganglion Blockers, Imidazoles, Neurotransmitter Agents, Nicotinic Antagonists, Peripheral Nervous System Agents, Sulfonium Derivatives, Vasodilating Agents]</data>
  <data key="d14">3,5-dibenzyl-4-oxo-8-thia-3,5-diazatricyclo[6.3.0.0,]undecan-8-ylium</data>
  <data key="d15">C22H25N2OS</data>
  <data key="d16">7187-66-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H25N2OS/c25-22-23(14-17-8-3-1-4-9-17)19-16-26-13-7-12-20(26)21(19)24(22)15-18-10-5-2-6-11-18/h1-6,8-11,19-21H,7,12-16H2/q+1</data>
  <data key="d20">O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1</data>
  <data key="d21">For the controlled reduction of blood pressure during surgery and in the treatment of hypertensive emergencies.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Thimethaphan, Trimetaphan, Trimetaphanum]</data>
  <data key="d9">A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01115">
  <data key="d0">Nifedipine</data>
  <data key="d1">drugbank.DB01115</data>
  <data key="d2">[drugbank.DB01115, drugbank.APRD00590]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenal Cortex Hormones, Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Antiarrhythmic agents, Beta blocking agents and calcium channel blockers, Bradycardia-Causing Agents, BSEP/ABCB11 Substrates, Calcium Channel Blockers, Calcium Channel Blockers (Dihydropyridine), Calcium Channel Blockers and Diuretics, Cardiovascular Agents, Contraceptive Agents, Male, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Dihydropyridine Derivatives, Dihydropyridines, Drugs that are Mainly Renally Excreted, Hormonal Contraceptives for Systemic Use, Hypotensive Agents, Membrane Transport Modulators, Moderate Risk QTc-Prolonging Agents, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Pyridines, QTc Prolonging Agents, Reproductive Control Agents, Selective Calcium Channel Blockers With Mainly Vascular Effects, Tocolytic Agents, Vasodilating Agents]</data>
  <data key="d14">3,5-dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate</data>
  <data key="d15">C17H18N2O6</data>
  <data key="d16">21829-25-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3</data>
  <data key="d20">COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC</data>
  <data key="d21">For the management of vasospastic angina, chronic stable angina, hypertension, and Raynaud's phenomenon. May be used as a first line agent for left ventricular hypertrophy and isolated systolic hypertension (long-acting agents).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[4-(2'-Nitrophenyl)-2, 6-dimethyl-1, 4-dihydropyridin-3, 5-dicarbonsuredimethylester, Nifedipine, Nifedipino, Nifedipinum]</data>
  <data key="d9">Nifedipine has been formulated as both a long- and short-acting 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nifedipine prevents calcium-dependent myocyte contraction and vasoconstriction. A second proposed mechanism for the drugs vasodilatory effects involves pH-dependent inhibition of calcium influx via inhibition of smooth muscle carbonic anhydrase. Nifedipine is used to treat hypertension and chronic stable angina.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01114">
  <data key="d0">Chlorphenamine</data>
  <data key="d1">drugbank.DB01114</data>
  <data key="d2">[drugbank.DB01114, drugbank.APRD00001, drugbank.DB09440]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Anti-Allergic Agents, Antidepressive Agents, Antihistamines for Systemic Use, Antipruritics, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Moderate Risk QTc-Prolonging Agents, Neurotransmitter Agents, OCT1 inhibitors, OCT2 Inhibitors, Pheniramine, Propylamine Derivatives, Pyridines, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators, Substituted Alkylamines]</data>
  <data key="d14">[3-(4-chlorophenyl)-3-(pyridin-2-yl)propyl]dimethylamine</data>
  <data key="d15">C16H19ClN2</data>
  <data key="d16">132-22-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3</data>
  <data key="d20">CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1</data>
  <data key="d21">For the treatment of rhinitis, urticaria, allergy, common cold, asthma and hay fever.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-(p-chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane, 1-(p-chlorophenyl)-1-(2-pyridyl)-3-N, N-dimethylpropylamine, 2-[p-chloro--[2-(dimethylamino)ethyl]benzyl]pyridine, 3-(p-chlorophenyl)-3-(2-pyridyl)-N, N-dimethylpropylamine, Chlorophenylpyridamine, Chlorphenamin, Chlorphenamine, Chlorphenaminum, Chlorpheniramine, Chlorpheniramine polistirex, Chlorpheniraminum, Clorfenamina, Clorfeniramina, -(4-chlorophenyl)-N, N-dimethyl-2-pyridinepropanamine, -(4-chlorophenyl)--(2-pyridyl)propyldimethylamine]</data>
  <data key="d9">A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01113">
  <data key="d0">Papaverine</data>
  <data key="d1">drugbank.DB01113</data>
  <data key="d2">[drugbank.DB01113, drugbank.APRD00628, drugbank.DB07725]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Alkaloids, Benzylisoquinolines, Cardiovascular Agents, Drugs for Functional Gastrointestinal Disorders, Drugs Used in Erectile Dysfunction, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Hypotensive Agents, Isoquinolines, Miscellaneous Vasodilatating Agents, Moderate Risk QTc-Prolonging Agents, Opiate Alkaloids, Papaverine and Derivatives, Phosphodiesterase Inhibitors, QTc Prolonging Agents, Urological Agents, Urologicals, Vasodilating Agents]</data>
  <data key="d14">1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline</data>
  <data key="d15">C20H21NO4</data>
  <data key="d16">58-74-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3</data>
  <data key="d20">COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1</data>
  <data key="d21">For the treatment of impotence and vasospasms.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Papaverina, Papaverine]</data>
  <data key="d9">An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03782">
  <data key="d0">N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea</data>
  <data key="d1">drugbank.DB03782</data>
  <data key="d2">[drugbank.DB03782, drugbank.EXPT00454]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-(adamantan-1-yl)-1-[(4-carbamimidamidophenyl)methyl]urea</data>
  <data key="d15">C19H27N5O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H27N5O/c20-17(21)23-16-3-1-12(2-4-16)11-22-18(25)24-19-8-13-5-14(9-19)7-15(6-13)10-19/h1-4,13-15H,5-11H2,(H4,20,21,23)(H2,22,24,25)/t13-,14+,15-,19-</data>
  <data key="d20">[H]C12CC3([H])CC([H])(C1)CC(C2)(C3)NC(=O)NCC1=CC=C(NC(N)=N)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01120">
  <data key="d0">Gliclazide</data>
  <data key="d1">drugbank.DB01120</data>
  <data key="d2">[drugbank.DB01120, drugbank.APRD00460]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Blood Glucose Lowering Agents, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inhibitors, Drugs Used in Diabetes, Hypoglycemia-Associated Agents, Oral Hypoglycemics, Sulfones, Sulfonylurea Compounds, Sulfonylureas, Sulfur Compounds, Urea]</data>
  <data key="d14">1-(4-methylbenzenesulfonyl)-3-{octahydrocyclopenta[c]pyrrol-2-yl}urea</data>
  <data key="d15">C15H21N3O3S</data>
  <data key="d16">21187-98-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)</data>
  <data key="d20">CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1</data>
  <data key="d21">For the treatment of NIDDM in conjunction with diet and exercise.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-(3-azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea, 1-(hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea, Gliclazida, Gliclazide, Gliclazidum]</data>
  <data key="d9">Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It has been classified differently according to its drug properties in which based on its chemical structure, gliclazide is considered a first-generation sulfonylurea due to the structural presence of a sulfonamide group able to release a proton and the presence of one aromatic group.[A39546] On the other hand, based on the pharmacological efficacy, gliclazide is considered a second-generation sulfonylurea which presents a higher potency and a shorter half-life.[T238, T360] Gliclazide belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating &amp;beta; cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic &amp;beta; cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Gliclazide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Gliclazide is extensively metabolized by the liver; its metabolites are excreted in both urine (60-70%) and feces (10-20%).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01127">
  <data key="d0">Econazole</data>
  <data key="d1">drugbank.DB01127</data>
  <data key="d2">[drugbank.DB01127, drugbank.APRD00943]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[14-alpha Demethylase Inhibitors, Anti-Infective Agents, Antifungal Agents, Antifungal Agents (Vaginal), Antifungals for Dermatological Use, Antifungals for Topical Use, Azole Antifungals, Chemically-Induced Disorders, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inhibitors (strong), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Imidazole and Triazole Derivatives, Imidazole Derivatives, Imidazoles, P-glycoprotein/ABCB1 Inhibitors, Steroid Synthesis Inhibitors]</data>
  <data key="d14">1-{2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole</data>
  <data key="d15">C18H15Cl3N2O</data>
  <data key="d16">27220-47-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H15Cl3N2O/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21/h1-9,12,18H,10-11H2</data>
  <data key="d20">ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1</data>
  <data key="d21">For topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by &lt;i&gt;Trichophyton rubrum&lt;/i&gt;, &lt;i&gt;Trichophyton mentagrophytes&lt;/i&gt;, &lt;i&gt;Trichophyton tonsurans&lt;/i&gt;, &lt;i&gt;Microsporum canis&lt;/i&gt;, &lt;i&gt;Microsporum audouini&lt;/i&gt;, &lt;i&gt;Microsporum gypseum&lt;/i&gt;, and &lt;i&gt;Epidermophyton floccosum&lt;/i&gt;, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+-)-Econazole, Econazol, Econazole]</data>
  <data key="d9">A broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01123">
  <data key="d0">Proflavine</data>
  <data key="d1">drugbank.DB01123</data>
  <data key="d2">[drugbank.DB01123, drugbank.APRD00535]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acridines, Aminoacridines, Anti-Infective Agents, Anti-Infective Agents, Local]</data>
  <data key="d14">acridine-3,6-diamine</data>
  <data key="d15">C13H11N3</data>
  <data key="d16">92-62-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H11N3/c14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10/h1-7H,14-15H2</data>
  <data key="d20">NC1=CC2=NC3=C(C=CC(N)=C3)C=C2C=C1</data>
  <data key="d21">Topical antiseptic used mainly in wound dressings.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2, 8-Diaminoacridine, 3, 6-acridinediamine, 3, 6-diaminoacridine, Diaminoacridine, Proflavin, Proflavina, Proflavine, Proflavinum]</data>
  <data key="d9">3,6-Diaminoacridine. Topical antiseptic used mainly in wound dressings.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01122">
  <data key="d0">Ambenonium</data>
  <data key="d1">drugbank.DB01122</data>
  <data key="d2">[drugbank.DB01122, drugbank.APRD00771]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amines, Ammonium Compounds, Autonomic Agents, Benzylammonium Compounds, Cholinergic Agents, Cholinesterase Inhibitors, Enzyme Inhibitors, Nervous System, Neurotransmitter Agents, Nitrogen Compounds, Onium Compounds, Parasympathomimetics, Peripheral Nervous System Agents, Quaternary Ammonium Compounds]</data>
  <data key="d14">[(2-chlorophenyl)methyl](2-{[(2-{[(2-chlorophenyl)methyl]diethylazaniumyl}ethyl)carbamoyl]formamido}ethyl)diethylazanium</data>
  <data key="d15">C28H42Cl2N4O2</data>
  <data key="d16">7648-98-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C28H40Cl2N4O2/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30/h9-16H,5-8,17-22H2,1-4H3/p+2</data>
  <data key="d20">CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC1=CC=CC=C1Cl</data>
  <data key="d21">Ambenonium is used to treat muscle weakness due to muscle disease (myasthenia gravis).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Ambenonium, Ambenonium base, Ambenonum]</data>
  <data key="d9">Ambenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01132">
  <data key="d0">Pioglitazone</data>
  <data key="d1">drugbank.DB01132</data>
  <data key="d2">[drugbank.DB01132, drugbank.APRD00653]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Blood Glucose Lowering Agents, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Drugs Used in Diabetes, Hypoglycemia-Associated Agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, Oral Hypoglycemics, Peroxisome Proliferator Receptor alpha Agonist, Peroxisome Proliferator Receptor gamma Agonist, Peroxisome Proliferator-activated Receptor Activity, Sulfur Compounds, Thiazoles, Thiazolidinediones]</data>
  <data key="d14">5-({4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione</data>
  <data key="d15">C19H20N2O3S</data>
  <data key="d16">111025-46-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)</data>
  <data key="d20">CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1</data>
  <data key="d21">Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [FDA Label].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2, 4-thiazolidinedione, 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1, 3-thiazolidine-2, 4-dione, Pioglitazona, Pioglitazone, Pioglitazonum]</data>
  <data key="d9">Pioglitazone is a medication belonging to the thiazolidinedione class of drugs that are used as adjuncts to diet, exercise, and other diabetes medications to manage type 2 diabetes mellitus. The thiazolidinedione class of medications exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose. Following entry into fat cell nuclei, pioglitazone selectively binds to the Peroxisome Proliferator-Activated Receptor Gamma (PPAR)[A19757]. PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes, and affect numerous metabolic processes, notably lipid and glucose homeostasis [A19759]. PPAR in particular is abundantly expressed in lipid cells (adipocytes), where it plays a central role in lipid production and regulation of lipid metabolism.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01139">
  <data key="d0">Cefapirin</data>
  <data key="d1">drugbank.DB01139</data>
  <data key="d2">[drugbank.DB01139, drugbank.APRD00860]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Aza Compounds, Azabicyclo Compounds, beta-Lactams, Cephacetrile, Cephalosporins, First-Generation Cephalosporins, Lactams, Nephrotoxic agents, Sulfur Compounds, Thiazines]</data>
  <data key="d14">(6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-[2-(pyridin-4-ylsulfanyl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid</data>
  <data key="d15">C17H17N3O6S2</data>
  <data key="d16">21593-23-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H17N3O6S2/c1-9(21)26-6-10-7-28-16-13(15(23)20(16)14(10)17(24)25)19-12(22)8-27-11-2-4-18-5-3-11/h2-5,13,16H,6-8H2,1H3,(H,19,22)(H,24,25)/t13-,16-/m1/s1</data>
  <data key="d20">[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CSC1=CC=NC=C1)C(O)=O</data>
  <data key="d21">For treatment of infections caused by susceptible bacteria.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(6R, 7R)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, Cefapirin, Cefapirina, Cefapirine, Cefapirinum, Cefaprin, Cephapirin, Cephapirine, CEPR]</data>
  <data key="d9">Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations. Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01136">
  <data key="d0">Carvedilol</data>
  <data key="d1">drugbank.DB01136</data>
  <data key="d2">[drugbank.DB01136, drugbank.APRD00091]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Adrenergic beta-1 Receptor Antagonists, Adrenergic beta-Antagonists, Adrenergic beta2-Antagonists, Agents causing hyperkalemia, Alcohols, Alpha and Beta Blocking Agents, Amines, Amino Alcohols, Antihypertensive Agents, Bradycardia-Causing Agents, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Hypotensive Agents, Indoles, Neurotransmitter Agents, P-glycoprotein/ABCB1 Inhibitors, Propanols, UGT1A1 Substrates, Vasodilating Agents]</data>
  <data key="d14">1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol</data>
  <data key="d15">C24H26N2O4</data>
  <data key="d16">72956-09-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3</data>
  <data key="d20">COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2</data>
  <data key="d21">For the treatment of mild or moderate (NYHA class II or III) heart failure of ischemic or cardiomyopathic origin.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol, Carvdilol, Carvedilol, Carvedilolum]</data>
  <data key="d9">Carvedilol is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). It blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-1 adrenergic receptors.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02473">
  <data key="d0">6-[N-(1-Isopropyl-3,4-Dihydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine</data>
  <data key="d1">drugbank.DB02473</data>
  <data key="d2">[drugbank.DB02473, drugbank.EXPT00041]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">6-carbamimidoyl-N-[1-(propan-2-yl)-3,4-dihydroisoquinolin-7-yl]naphthalene-2-carboxamide</data>
  <data key="d15">C24H24N4O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H24N4O/c1-14(2)22-21-13-20(8-7-15(21)9-10-27-22)28-24(29)19-6-4-16-11-18(23(25)26)5-3-17(16)12-19/h3-8,11-14H,9-10H2,1-2H3,(H3,25,26)(H,28,29)</data>
  <data key="d20">CC(C)C1=NCCC2=C1C=C(NC(=O)C1=CC=C3C=C(C=CC3=C1)C(N)=N)C=C2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02468">
  <data key="d0">12-Phenylheme</data>
  <data key="d1">drugbank.DB02468</data>
  <data key="d2">[drugbank.DB02468, drugbank.EXPT00073]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">5,9-bis(2-carboxyethyl)-15,20-diethenyl-4,10,14,19-tetramethyl-17-phenyl-2,22,23,25-tetraaza-1-ferraoctacyclo[11.9.1.1,.1,.0,.0,.0,.0,]pentacosa-3,5,7,9,11,13,15,17,21(24)-nonaene-1,1-bis(ylium)</data>
  <data key="d15">C40H38FeN4O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C40H38N4O4.Fe/c1-7-26-24(6)39-38(25-12-10-9-11-13-25)40-27(8-2)21(3)32(43-40)18-30-22(4)28(14-16-36(45)46)34(41-30)20-35-29(15-17-37(47)48)23(5)31(42-35)19-33(26)44-39;/h7-13,18-20,24,26H,1-2,14-17H2,3-6H3,(H,45,46)(H,47,48);/q-4;+6/b30-18-,33-19-,34-20-,39-38-;</data>
  <data key="d20">CC1C(C=C)C2=CC3=C(C)C(CCC(O)=O)=C4C=C5N6C(=CC7=C(C)C(C=C)=C8N7[Fe++]6(N34)N2C1=C8C1=CC=CC=C1)C(C)=C5CCC(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13115">
  <data key="d0">Saroglitazar</data>
  <data key="d1">drugbank.DB13115</data>
  <data key="d2">[drugbank.DB13115]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Carbocyclic]</data>
  <data key="d14">(2S)-2-ethoxy-3-[4-(2-{2-methyl-5-[4-(methylsulfanyl)phenyl]-1H-pyrrol-1-yl}ethoxy)phenyl]propanoic acid</data>
  <data key="d15">C25H29NO4S</data>
  <data key="d16">495399-09-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C25H29NO4S/c1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20/h5-14,24H,4,15-17H2,1-3H3,(H,27,28)/t24-/m0/s1</data>
  <data key="d20">CCO[C@@H](CC1=CC=C(OCCN2C(C)=CC=C2C2=CC=C(SC)C=C2)C=C1)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Saroglitazar, Saroglitazarum]</data>
  <data key="d9">Saroglitazar has been investigated for the treatment of Fatty Liver.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03729">
  <data key="d0">2-Amino-5-Hydroxy-Benzimidazole</data>
  <data key="d1">drugbank.DB03729</data>
  <data key="d2">[drugbank.DB03729, drugbank.EXPT00052]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-imino-2,3-dihydro-1H-1,3-benzodiazol-5-ol</data>
  <data key="d15">C7H7N3O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H7N3O/c8-7-9-5-2-1-4(11)3-6(5)10-7/h1-3,11H,(H3,8,9,10)</data>
  <data key="d20">OC1=CC2=C(NC(=N)N2)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02404">
  <data key="d0">1-Deoxy-1-Thio-Heptaethylene Glycol</data>
  <data key="d1">drugbank.DB02404</data>
  <data key="d2">[drugbank.DB02404, drugbank.EXPT02540]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">20-sulfanyl-3,6,9,12,15,18-hexaoxaicosan-1-ol</data>
  <data key="d15">C14H30O7S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H30O7S/c15-1-2-16-3-4-17-5-6-18-7-8-19-9-10-20-11-12-21-13-14-22/h15,22H,1-14H2</data>
  <data key="d20">OCCOCCOCCOCCOCCOCCOCCS</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03740">
  <data key="d0">N-acetyl-alpha-D-glucosamine</data>
  <data key="d1">drugbank.DB03740</data>
  <data key="d2">[drugbank.DB03740, drugbank.EXPT02319]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]ethanimidic acid</data>
  <data key="d15">C8H15NO6</data>
  <data key="d16">10036-64-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6-,7-,8+/m1/s1</data>
  <data key="d20">[H][C@]1(O)O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])N=C(C)O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-(acetylamino)-2-deoxy-A-D-glucopyranose, 2-(acetylamino)-2-deoxy--D-glucopyranose, N-acetyl--D-glucosamine, -D-GlcNAc, -GlcNAc]</data>
  <data key="d9">The N-acetyl derivative of glucosamine.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03742">
  <data key="d0">Compound 4-D</data>
  <data key="d1">drugbank.DB03742</data>
  <data key="d2">[drugbank.DB03742, drugbank.EXPT01315]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S,3R)-3-(4-hydroxyphenyl)-2-{4-[2-(piperidin-1-yl)ethoxy]phenyl}-2,3-dihydro-1,4-benzoxathiin-6-ol</data>
  <data key="d15">C27H29NO4S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C27H29NO4S/c29-21-8-4-20(5-9-21)27-26(32-24-13-10-22(30)18-25(24)33-27)19-6-11-23(12-7-19)31-17-16-28-14-2-1-3-15-28/h4-13,18,26-27,29-30H,1-3,14-17H2/t26-,27+/m0/s1</data>
  <data key="d20">[H][C@]1(OC2=C(S[C@]1([H])C1=CC=C(O)C=C1)C=C(O)C=C2)C1=CC=C(OCCN2CCCCC2)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03754">
  <data key="d0">Tromethamine</data>
  <data key="d1">drugbank.DB03754</data>
  <data key="d2">[drugbank.DB03754, drugbank.EXPT03072]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Alcohols, Blood and Blood Forming Organs, Blood Substitutes and Perfusion Solutions, Buffers, Compounds used in a research, industrial, or household setting, Drug Delivery Systems, Excipients, Glycols, I.V. Solution Additives, i.v. Solutions, Laboratory Chemicals, Pharmaceutic Aids, Pharmaceutical Preparations, Pharmaceutical Vehicles, Propylene Glycols, Solutions Affecting the Electrolyte Balance, Tromethamine]</data>
  <data key="d14">2-amino-2-(hydroxymethyl)propane-1,3-diol</data>
  <data key="d15">C4H11NO3</data>
  <data key="d16">77-86-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2</data>
  <data key="d20">NC(CO)(CO)CO</data>
  <data key="d21">For the prevention and correction of metabolic acidosis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1, 1, 1-tris(hydroxymethyl)methanamine, 2-Amino-2-(hydroxymethyl)-1, 3-propanediol, aminotris(hydroxymethyl)methane, THAM, Tris, Tris(hydroxymethyl)aminomethane, Trometamol, Tromethamine]</data>
  <data key="d9">An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03756">
  <data key="d0">Doconexent</data>
  <data key="d1">drugbank.DB03756</data>
  <data key="d2">[drugbank.DB03756, drugbank.EXPT01798, drugbank.DB11070]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inhibitors, Diet, Food, and Nutrition, Dietary Fats, Dietary Fats, Unsaturated, Fats, Fatty Acids, Fatty Acids, Omega-3, Fatty Acids, Unsaturated, Fish Oils, Food, Food and Beverages, Lipids, Oils, Physiological Phenomena]</data>
  <data key="d14">(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid</data>
  <data key="d15">C22H32O2</data>
  <data key="d16">6217-54-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-</data>
  <data key="d20">CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O</data>
  <data key="d21">Used as a high-docosahexaenoic acid (DHA) oral supplement.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(4Z, 7Z, 10Z, 13Z, 16Z, 19Z)-Docosahexaenoic acid, 22:6-4, 7, 10, 13, 16, 19, 22:6(n-3), 4, 7, 10, 13, 16, 19-docosahexaenoic acid, all-cis-4, 7, 10, 13, 16, 19-docosahexaenoic acid, all-cis-DHA, cervonic acid, DHA, Doconexent, docosa-4, 7, 10, 13, 16, 19-hexaenoic acid, Docosahexaenoic acid]</data>
  <data key="d9">A mixture of fish oil and primrose oil, doconexent is used as a high-docosahexaenoic acid (DHA) supplement. DHA is a 22 carbon chain with 6 cis double bonds with anti-inflammatory effects. It can be biosythesized from alpha-linolenic acid or commercially manufactured from microalgae. It is an omega-3 fatty acid and primary structural component of the human brain, cerebral cortex, skin, and retina thus plays an important role in their development and function. The amino-phospholipid DHA is found at a high concentration across several brain subcellular fractions, including nerve terminals, microsomes, synaptic vesicles, and synaptosomal plasma membranes [A19436].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03802">
  <data key="d0">1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol</data>
  <data key="d1">drugbank.DB03802</data>
  <data key="d2">[drugbank.DB03802, drugbank.EXPT00446]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(1R)-1-{4-[(9aS)-octahydro-1H-pyrido[1,2-a]piperazin-2-yl]phenyl}-2-phenyl-1,2,3,4-tetrahydroisoquinolin-6-ol</data>
  <data key="d15">C29H33N3O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C29H33N3O/c33-27-13-14-28-23(20-27)15-17-32(25-6-2-1-3-7-25)29(28)22-9-11-24(12-10-22)31-19-18-30-16-5-4-8-26(30)21-31/h1-3,6-7,9-14,20,26,29,33H,4-5,8,15-19,21H2/t26-,29+/m0/s1</data>
  <data key="d20">[H][C@@]12CCCCN1CCN(C2)C1=CC=C(C=C1)[C@@]1([H])N(CCC2=CC(O)=CC=C12)C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03808">
  <data key="d0">Hexamidine</data>
  <data key="d1">drugbank.DB03808</data>
  <data key="d2">[drugbank.DB03808, drugbank.EXPT01203]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Amidines, Anti-Infective Agents, Anti-Infective Agents, Local, Antiseptics and Disinfectants, Biguanides and Amidines, Dermatologicals, Nasal Preparations, Ophthalmological and Otological Preparations, Ophthalmologicals, Sensory Organs, Throat Preparations]</data>
  <data key="d14">4-{[6-(4-carbamimidoylphenoxy)hexyl]oxy}benzene-1-carboximidamide</data>
  <data key="d15">C20H26N4O2</data>
  <data key="d16">3811-75-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H26N4O2/c21-19(22)15-5-9-17(10-6-15)25-13-3-1-2-4-14-26-18-11-7-16(8-12-18)20(23)24/h5-12H,1-4,13-14H2,(H3,21,22)(H3,23,24)</data>
  <data key="d20">NC(=N)C1=CC=C(OCCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[hexamidina, Hexamidine]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03814">
  <data key="d0">2-(N-Morpholino)-Ethanesulfonic Acid</data>
  <data key="d1">drugbank.DB03814</data>
  <data key="d2">[drugbank.DB03814, drugbank.EXPT02154]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-(2-sulfonatoethyl)morpholin-4-ium</data>
  <data key="d15">C6H13NO4S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C6H13NO4S/c8-12(9,10)6-3-7-1-4-11-5-2-7/h1-6H2,(H,8,9,10)</data>
  <data key="d20">[O-]S(=O)(=O)CC[NH+]1CCOCC1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03822">
  <data key="d0">Ethyl Dihydrogen Phosphate</data>
  <data key="d1">drugbank.DB03822</data>
  <data key="d2">[drugbank.DB03822, drugbank.EXPT01327]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Acids, Acids, Noncarboxylic, Anions, Electrolytes, Ions, Phosphoric Acids, Phosphorus Acids, Phosphorus Compounds]</data>
  <data key="d14">ethoxyphosphonic acid</data>
  <data key="d15">C2H7O4P</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C2H7O4P/c1-2-6-7(3,4)5/h2H2,1H3,(H2,3,4,5)</data>
  <data key="d20">CCOP(O)(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02509">
  <data key="d0">Farnesol</data>
  <data key="d1">drugbank.DB02509</data>
  <data key="d2">[drugbank.DB02509, drugbank.EXPT01466]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Alcohols, Fatty Alcohols, Lipids, Sesquiterpenes, Terpenes]</data>
  <data key="d14">(2Z,6Z)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol</data>
  <data key="d15">C15H26O</data>
  <data key="d16">4602-84-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H26O/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-16/h7,9,11,16H,5-6,8,10,12H2,1-4H3/b14-9-,15-11-</data>
  <data key="d20">CC(C)=CCC\C(C)=C/CC\C(C)=C/CO</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">A colorless liquid extracted from oils of plants such as citronella, neroli, cyclamen, and tuberose. It is an intermediate step in the biological synthesis of cholesterol from mevalonic acid in vertebrates. It has a delicate odor and is used in perfumery. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02166">
  <data key="d0">Propidium</data>
  <data key="d1">drugbank.DB02166</data>
  <data key="d2">[drugbank.DB02166, drugbank.EXPT02661]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Coloring Agents, Compounds used in a research, industrial, or household setting, Indicators and Reagents, Intercalating Agents, Laboratory Chemicals, Phenanthridines]</data>
  <data key="d14">3,8-diamino-5-{3-[diethyl(methyl)azaniumyl]propyl}-6-phenylphenanthridin-5-ium</data>
  <data key="d15">C27H34N4</data>
  <data key="d16">36015-30-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C27H33N4/c1-4-31(3,5-2)17-9-16-30-26-19-22(29)13-15-24(26)23-14-12-21(28)18-25(23)27(30)20-10-7-6-8-11-20/h6-8,10-15,18-19,29H,4-5,9,16-17,28H2,1-3H3/q+1/p+1</data>
  <data key="d20">CC[N+](C)(CC)CCC[N+]1=C(C2=CC=CC=C2)C2=C(C=CC(N)=C2)C2=C1C=C(N)C=C2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Quaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes with cholinesterase which it inhibits. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02187">
  <data key="d0">Equilin</data>
  <data key="d1">drugbank.DB02187</data>
  <data key="d2">[drugbank.DB02187, drugbank.EXPT01355]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[17-Ketosteroids, Adrenal Cortex Hormones, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Estradiol Congeners, Estranes, Estrenes, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Ketosteroids, Steroids]</data>
  <data key="d14">(1S,11S,15S)-5-hydroxy-15-methyltetracyclo[8.7.0.0,.0,]heptadeca-2(7),3,5,9-tetraen-14-one</data>
  <data key="d15">C18H20O2</data>
  <data key="d16">474-86-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H20O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3-5,10,14,16,19H,2,6-9H2,1H3/t14-,16+,18+/m1/s1</data>
  <data key="d20">[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC=C21)C=C(O)C=C3</data>
  <data key="d21">For the treatment of moderate to severe vasomotor symptoms associated with the menopause, atrophic vaginitis, osteoporosis, hypoestrogenism due to hypogonadism, castration, primary ovarian failure, breast cancer (for palliation only), and Advanced androgen-dependent carcinoma of the prostate (for palliation only)</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1, 3, 5, 7-Estratetraen-3-ol-17-one, 7-Dehydroestrone, Dihydroequilenin, Equilin]</data>
  <data key="d9">An estrogenic steroid produced by horses. It has a total of four double bonds in the A- and B-ring. High concentration of equilin is found in the urine of pregnant mares.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03444">
  <data key="d0">(3e)-6'-Bromo-2,3'-Biindole-2',3(1h,1'h)-Dione 3-Oxime</data>
  <data key="d1">drugbank.DB03444</data>
  <data key="d2">[drugbank.DB03444, drugbank.EXPT00759]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">6-bromo-3-[(2Z,3E)-3-(hydroxyimino)-2,3-dihydro-1H-indol-2-ylidene]-2,3-dihydro-1H-indol-2-one</data>
  <data key="d15">C16H10BrN3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H10BrN3O2/c17-8-5-6-9-12(7-8)19-16(21)13(9)15-14(20-22)10-3-1-2-4-11(10)18-15/h1-7,18,22H,(H,19,21)/b15-13-,20-14+</data>
  <data key="d20">O\N=C1\C(\NC2=C\1C=CC=C2)=C1\C(=O)NC2=C1C=CC(Br)=C2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04786">
  <data key="d0">Suramin</data>
  <data key="d1">drugbank.DB04786</data>
  <data key="d2">[drugbank.DB04786]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Acids, Noncarboxylic, Agents Against Leishmaniasis and Trypanosomiasis, Anti-Infective Agents, Antinematodal Agents, Antineoplastic Agents, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Arylsulfonates, Arylsulfonic Acids, Naphthalenes, Naphthalenesulfonates, Sulfonic Acids, Sulfur Acids, Sulfur Compounds, Trypanocidal Agents]</data>
  <data key="d14">8-{4-methyl-3-[3-({[3-({2-methyl-5-[(4,6,8-trisulfonaphthalen-1-yl)carbamoyl]phenyl}carbamoyl)phenyl]carbamoyl}amino)benzamido]benzamido}naphthalene-1,3,5-trisulfonic acid</data>
  <data key="d15">C51H40N6O23S6</data>
  <data key="d16">145-63-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C51H40N6O23S6/c1-25-9-11-29(49(60)54-37-13-15-41(83(69,70)71)35-21-33(81(63,64)65)23-43(45(35)37)85(75,76)77)19-39(25)56-47(58)27-5-3-7-31(17-27)52-51(62)53-32-8-4-6-28(18-32)48(59)57-40-20-30(12-10-26(40)2)50(61)55-38-14-16-42(84(72,73)74)36-22-34(82(66,67)68)24-44(46(36)38)86(78,79)80/h3-24H,1-2H3,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80)</data>
  <data key="d20">CC1=C(NC(=O)C2=CC(NC(=O)NC3=CC=CC(=C3)C(=O)NC3=C(C)C=CC(=C3)C(=O)NC3=C4C(C=C(C=C4S(O)(=O)=O)S(O)(=O)=O)=C(C=C3)S(O)(=O)=O)=CC=C2)C=C(C=C1)C(=O)NC1=C2C(C=C(C=C2S(O)(=O)=O)S(O)(=O)=O)=C(C=C1)S(O)(=O)=O</data>
  <data key="d21">For treatment of human sleeping sickness, onchocerciasis and other diseases caused by trypanosomes and worms.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Suramin, Suramine]</data>
  <data key="d9">A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties. Suramin is manufactured by Bayer in Germany as Germanin.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02141">
  <data key="d0">S,S'-(1,4-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea</data>
  <data key="d1">drugbank.DB02141</data>
  <data key="d2">[drugbank.DB02141, drugbank.EXPT00205]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">[(2-{4-[2-(carbamimidoylsulfanyl)ethyl]phenyl}ethyl)sulfanyl]methanimidamide</data>
  <data key="d15">C12H18N4S2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H18N4S2/c13-11(14)17-7-5-9-1-2-10(4-3-9)6-8-18-12(15)16/h1-4H,5-8H2,(H3,13,14)(H3,15,16)</data>
  <data key="d20">NC(=N)SCCC1=CC=C(CCSC(N)=N)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03467">
  <data key="d0">Naringenin</data>
  <data key="d1">drugbank.DB03467</data>
  <data key="d2">[drugbank.DB03467, drugbank.EXPT02295]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Anti-Ulcer Agents, BCRP/ABCG2 Inhibitors, Benzopyrans, Chromones, Estrogen Antagonists, Flavonoids, Gastrointestinal Agents, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Pyrans]</data>
  <data key="d14">(2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-4-one</data>
  <data key="d15">C15H12O5</data>
  <data key="d16">480-41-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H12O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-6,13,16-18H,7H2/t13-/m0/s1</data>
  <data key="d20">[H][C@]1(CC(=O)C2=C(O1)C=C(O)C=C2O)C1=CC=C(O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03476">
  <data key="d0">Trans-6-(2-Phenylcyclopropyl)-Naphthalene-2-Carboxamidine</data>
  <data key="d1">drugbank.DB03476</data>
  <data key="d2">[drugbank.DB03476, drugbank.EXPT00296]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">6-[(1R,2R)-2-phenylcyclopropyl]naphthalene-2-carboximidamide</data>
  <data key="d15">C20H18N2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H18N2/c21-20(22)17-9-7-14-10-16(8-6-15(14)11-17)19-12-18(19)13-4-2-1-3-5-13/h1-11,18-19H,12H2,(H3,21,22)/t18-,19-/m0/s1</data>
  <data key="d20">[H][C@]1(C[C@@]1([H])C1=CC2=CC=C(C=C2C=C1)C(N)=N)C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04743">
  <data key="d0">Nimesulide</data>
  <data key="d1">drugbank.DB04743</data>
  <data key="d2">[drugbank.DB04743]</data>
  <data key="d12">[approved, investigational, withdrawn]</data>
  <data key="d13">[Agents causing hyperkalemia, Agents that produce hypertension, Amides, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Antiarrhythmic agents, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antiinflammatory Preparations, Non-Steroids for Topical Use, Antiplatelet agents, Antirheumatic Agents, Bradycardia-Causing Agents, Calcium Channel Blockers, Central Nervous System Agents, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Enzyme Inhibitors, Musculo-Skeletal System, Nephrotoxic agents, Peripheral Nervous System Agents, Selective Cyclooxygenase 2 Inhibitors (NSAIDs), Sensory System Agents, Sulfones, Sulfur Compounds, Topical Products for Joint and Muscular Pain]</data>
  <data key="d14">N-(4-nitro-2-phenoxyphenyl)methanesulfonamide</data>
  <data key="d15">C13H12N2O5S</data>
  <data key="d16">51803-78-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H12N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h2-9,14H,1H3</data>
  <data key="d20">CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O</data>
  <data key="d21">For the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04771">
  <data key="d0">1-GUANIDINO-4-(N-NITRO-BENZOYLAMINO-L-LEUCYL-L-PROLYLAMINO)BUTANE</data>
  <data key="d1">drugbank.DB04771</data>
  <data key="d2">[drugbank.DB04771]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-N-{4-[(diaminomethylidene)amino]butyl}-1-[(2S)-4-methyl-2-[(4-nitrophenyl)formamido]pentanoyl]pyrrolidine-2-carboxamide</data>
  <data key="d15">C23H35N7O5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H35N7O5/c1-15(2)14-18(28-20(31)16-7-9-17(10-8-16)30(34)35)22(33)29-13-5-6-19(29)21(32)26-11-3-4-12-27-23(24)25/h7-10,15,18-19H,3-6,11-14H2,1-2H3,(H,26,32)(H,28,31)(H4,24,25,27)/t18-,19-/m0/s1</data>
  <data key="d20">CC(C)C[C@H](NC(=O)C1=CC=C(C=C1)[N+]([O-])=O)C(=O)N1CCC[C@H]1C(=O)NCCCCN=C(N)N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04772">
  <data key="d0">1-GUANIDINO-4-(N-PHENYLMETHANESULFONYL-L-LEUCYL-L-PROLYLAMINO)BUTANE</data>
  <data key="d1">drugbank.DB04772</data>
  <data key="d2">[drugbank.DB04772]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-N-{4-[(diaminomethylidene)amino]butyl}-1-[(2S)-4-methyl-2-phenylmethanesulfonamidopentanoyl]pyrrolidine-2-carboxamide</data>
  <data key="d15">C23H38N6O4S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H38N6O4S/c1-17(2)15-19(28-34(32,33)16-18-9-4-3-5-10-18)22(31)29-14-8-11-20(29)21(30)26-12-6-7-13-27-23(24)25/h3-5,9-10,17,19-20,28H,6-8,11-16H2,1-2H3,(H,26,30)(H4,24,25,27)/t19-,20-/m0/s1</data>
  <data key="d20">CC(C)C[C@H](NS(=O)(=O)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)NCCCCN=C(N)N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04722">
  <data key="d0">2-(3-CHLORO-6-{[2,2-DIFLUORO-2-(1-OXIDOPYRIDIN-2-YL)ETHYL]AMINO}-1-OXIDOPYRIDIN-2-YL)-N-[1-(3-CHLOROPHENYL)ETHYL]ACETAMIDE</data>
  <data key="d1">drugbank.DB04722</data>
  <data key="d2">[drugbank.DB04722]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-chloro-2-({[(1R)-1-(3-chlorophenyl)ethyl]carbamoyl}methyl)-6-{[2,2-difluoro-2-(1-oxidopyridin-1-ium-2-yl)ethyl]amino}pyridin-1-ium-1-olate</data>
  <data key="d15">C22H20Cl2F2N4O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H20Cl2F2N4O3/c1-14(15-5-4-6-16(23)11-15)28-21(31)12-18-17(24)8-9-20(30(18)33)27-13-22(25,26)19-7-2-3-10-29(19)32/h2-11,14,27H,12-13H2,1H3,(H,28,31)/t14-/m1/s1</data>
  <data key="d20">[H][C@](C)(NC(=O)CC1=[N+]([O-])C(NCC(F)(F)C2=[N+]([O-])C=CC=C2)=CC=C1Cl)C1=CC=CC(Cl)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04803">
  <data key="d0">Verdoheme</data>
  <data key="d1">drugbank.DB04803</data>
  <data key="d2">[drugbank.DB04803]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Biological Factors, Metalloporphyrins, Pigments, Biological, Porphyrins]</data>
  <data key="d14">19-(2-carboxyethyl)-4,9-diethenyl-5,10,14,20-tetramethyl-7-oxa-2,22,23,25-tetraaza-1-ferraoctacyclo[11.9.1.1,.1,.0,.0,.0,.0,]pentacosa-3,5,8,10,12,14,16,18(22),19,21(24)-decaen-22-ylium</data>
  <data key="d15">C30H27FeN4O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C30H28N4O3.Fe/c1-7-20-18(6)29-34-27(20)14-24-17(5)22(9-10-28(35)36)26(32-24)12-19-11-15(3)23(31-19)13-25-16(4)21(8-2)30(33-25)37-29;/h7-8,11-14H,1-2,9-10H2,3-6H3,(H2-2,31,32,33,34,35,36);/q-2;+4/p-1</data>
  <data key="d20">CC1=CC2=CC3=[N+]4C(=CC5=C(C=C)C(C)=C6OC7=C(C=C)C(C)=C8C=C1N2[Fe]4(N56)N78)C(C)=C3CCC(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02287">
  <data key="d0">2-(2-Hydroxy-Phenyl)-3h-Benzoimidazole-5-Carboxamidine</data>
  <data key="d1">drugbank.DB02287</data>
  <data key="d2">[drugbank.DB02287, drugbank.EXPT00728, drugbank.EXPT00016, drugbank.DB02193]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">{amino[2-(2-hydroxyphenyl)-1H-1,3-benzodiazol-6-yl]methylidene}azanium</data>
  <data key="d15">C14H13N4O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H12N4O/c15-13(16)8-5-6-10-11(7-8)18-14(17-10)9-3-1-2-4-12(9)19/h1-7,19H,(H3,15,16)(H,17,18)/p+1</data>
  <data key="d20">NC(=[NH2+])C1=CC2=C(C=C1)N=C(N2)C1=CC=CC=C1O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02234">
  <data key="d0">S-Ethylisothiourea</data>
  <data key="d1">drugbank.DB02234</data>
  <data key="d2">[drugbank.DB02234, drugbank.EXPT01944, drugbank.EXPT02886, drugbank.DB02539]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Cardiovascular Agents, Central Nervous System Agents, Central Nervous System Depressants, Enzyme Inhibitors, Hypnotics and Sedatives, Nitric Oxide Synthase, antagonists &amp; inhibitors, Sulfur Compounds, Thiourea, Urea, Vasoconstrictor Agents]</data>
  <data key="d14">(ethylsulfanyl)methanimidamide</data>
  <data key="d15">C3H8N2S</data>
  <data key="d16">2986-20-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C3H8N2S/c1-2-6-3(4)5/h2H2,1H3,(H3,4,5)</data>
  <data key="d20">CCSC(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-Ethyl-2-thiopseudourea, Ethyron, Etiron]</data>
  <data key="d9">S-Ethylisothiourea is a nitric oxide synthase inhibitor.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04895">
  <data key="d0">Pegaptanib</data>
  <data key="d1">drugbank.DB04895</data>
  <data key="d2">[drugbank.DB04895]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Antineovascularisation Agents, Carbohydrates, Drugs that are Mainly Renally Excreted, Glycosides, Nucleic Acids, Nucleotides, and Nucleosides, Nucleotides, Ocular Vascular Disorder Agents, Oligonucleotides, Ophthalmologicals, Pegylated agents, Polynucleotides, Sensory Organs, Vascular Endothelial Growth Factor A]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">222716-86-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">For the treatment of neovascular (wet) age-related macular degeneration.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[EYE 001, NX 1838, NX1838, Pegaptanib Octasodium, Pegaptanib sodium]</data>
  <data key="d9">Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02235">
  <data key="d0">L-methionine (R)-S-oxide</data>
  <data key="d1">drugbank.DB02235</data>
  <data key="d2">[drugbank.DB02235, drugbank.EXPT02921]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Amino Acids, Amino Acids, Essential, Amino Acids, Neutral, Amino Acids, Peptides, and Proteins, Amino Acids, Sulfur, Sulfur Compounds]</data>
  <data key="d14">(2S)-2-amino-4-[(R)-methanesulfinyl]butanoic acid</data>
  <data key="d15">C5H11NO3S</data>
  <data key="d16">62697-73-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C5H11NO3S/c1-10(9)3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-,10+/m0/s1</data>
  <data key="d20">C[S@@](=O)CC[C@H](N)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Methionine Sulfoxide]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04898">
  <data key="d0">Ximelagatran</data>
  <data key="d1">drugbank.DB04898</data>
  <data key="d2">[drugbank.DB04898]</data>
  <data key="d12">[approved, investigational, withdrawn]</data>
  <data key="d13">[Amines, Anticoagulants, Antithrombins, Azetines, Benzene Derivatives, Benzyl Compounds, Blood and Blood Forming Organs, Cytochrome P-450 CYP2C9 Substrates, Enzyme Inhibitors, Hematologic Agents, Protease Inhibitors, Serine Proteinase Inhibitors]</data>
  <data key="d14">ethyl 2-{[(1R)-1-cyclohexyl-2-[(2S)-2-[({4-[(Z)-N'-hydroxycarbamimidoyl]phenyl}methyl)carbamoyl]azetidin-1-yl]-2-oxoethyl]amino}acetate</data>
  <data key="d15">C24H35N5O5</data>
  <data key="d16">192939-46-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H35N5O5/c1-2-34-20(30)15-26-21(17-6-4-3-5-7-17)24(32)29-13-12-19(29)23(31)27-14-16-8-10-18(11-9-16)22(25)28-33/h8-11,17,19,21,26,33H,2-7,12-15H2,1H3,(H2,25,28)(H,27,31)/t19-,21+/m0/s1</data>
  <data key="d20">CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(\N)=N\O)C1CCCCC1</data>
  <data key="d21">For the treatment of acute deep vein thrombosis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[ethyl 2-[[(1R)-1-cyclohexyl-2- [(2S)-2-[[4-(N'-hydroxycarbamimidoyl) phenyl]methylcarbamoyl]azetidin-1-yl]- 2-oxo-ethyl]amino]acetate, Ximelagatran, Ximlagatran, Ximelagatrn, Ximelagatranum]</data>
  <data key="d9">Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former. In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries where the drug had been approved.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03568">
  <data key="d0">Butyric Acid</data>
  <data key="d1">drugbank.DB03568</data>
  <data key="d2">[drugbank.DB03568, drugbank.EXPT00774]</data>
  <data key="d12">[experimental, investigational]</data>
  <data key="d13">[Acids, Acyclic, Butyrates, Fatty Acids, Fatty Acids, Volatile, Histamine Agents, Lipids, Neurotransmitter Agents]</data>
  <data key="d14">butanoic acid</data>
  <data key="d15">C4H8O2</data>
  <data key="d16">107-92-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C4H8O2/c1-2-3-4(5)6/h2-3H2,1H3,(H,5,6)</data>
  <data key="d20">CCCC(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-propanecarboxylic acid, Butanoic acid, Butyrate, Butyricum acidum, Ethylacetic acid, N-butanoic acid, N-butyric acid, Propylformic acid]</data>
  <data key="d9">A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02266">
  <data key="d0">Flufenamic Acid</data>
  <data key="d1">drugbank.DB02266</data>
  <data key="d2">[drugbank.DB02266, drugbank.EXPT01442]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acids, Carbocyclic, Amines, Aminobenzoates, Aniline Compounds, Anti-Inflammatory Agents, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Benzene Derivatives, Benzoates, Fenamates, Musculo-Skeletal System, OAT1/SLC22A6 inhibitors, ortho-Aminobenzoates]</data>
  <data key="d14">2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid</data>
  <data key="d15">C14H10F3NO2</data>
  <data key="d16">530-78-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H10F3NO2/c15-14(16,17)9-4-3-5-10(8-9)18-12-7-2-1-6-11(12)13(19)20/h1-8,18H,(H,19,20)</data>
  <data key="d20">OC(=O)C1=CC=CC=C1NC1=CC(=CC=C1)C(F)(F)F</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[acide flufnamique, cido flufenmico, acidum flufenamicum, Flufenamic Acid]</data>
  <data key="d9">An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04859">
  <data key="d0">Zanapezil</data>
  <data key="d1">drugbank.DB04859</data>
  <data key="d2">[drugbank.DB04859]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">3-(1-benzylpiperidin-4-yl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)propan-1-one</data>
  <data key="d15">C25H32N2O</data>
  <data key="d16">142852-50-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C25H32N2O/c28-25(23-11-10-22-8-4-5-15-26-24(22)18-23)12-9-20-13-16-27(17-14-20)19-21-6-2-1-3-7-21/h1-3,6-7,10-11,18,20,26H,4-5,8-9,12-17,19H2</data>
  <data key="d20">O=C(CCC1CCN(CC2=CC=CC=C2)CC1)C1=CC2=C(CCCCN2)C=C1</data>
  <data key="d21">For the treatment of dementia in subjects with Alzheimers disease.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Zanepezil]</data>
  <data key="d9">Zanapezil (TAK-147) is a selective acetylcholine (ACh) esterase inhibitor under investigation as a drug for Alzheimer's disease (AD) treatment.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04864">
  <data key="d0">Huperzine A</data>
  <data key="d1">drugbank.DB04864</data>
  <data key="d2">[drugbank.DB04864, drugbank.EXPT01795, drugbank.DB01928, drugbank.DB05510]</data>
  <data key="d12">[approved, experimental]</data>
  <data key="d13">[Central Nervous System Agents, Cholinergic Agents, Cholinesterase Inhibitors, Compounds used in a research, industrial, or household setting, Enzyme Inhibitors, Neuroprotective Agents, Neurotransmitter Agents, Protective Agents, Terpenes]</data>
  <data key="d14">(1R,9R,13E)-1-amino-13-ethylidene-11-methyl-6-azatricyclo[7.3.1.0^{2,7}]trideca-2(7),3,10-trien-5-one</data>
  <data key="d15">C15H18N2O</data>
  <data key="d16">102518-79-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H18N2O/c1-3-11-10-6-9(2)8-15(11,16)12-4-5-14(18)17-13(12)7-10/h3-6,10H,7-8,16H2,1-2H3,(H,17,18)/b11-3+/t10-,15+/m0/s1</data>
  <data key="d20">[H][C@@]12CC3=C(C=CC(=O)N3)[C@@](N)(CC(C)=C1)\C2=C\C</data>
  <data key="d21">Investigated for use/treatment in alzheimer's disease.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-huperazine A, ()-selagine, Huperzine-A, L-huperzine A, Selagine]</data>
  <data key="d9">Huperzine A, is a naturally occurring sesquiterpene alkaloid found in the extracts of the firmoss &lt;i&gt;Huperzia serrata&lt;/i&gt;. The botanical has been used in China for centuries for the treatment of swelling, fever and blood disorders. Recently in clinical trials in China, it has demonstrated neuroprotective effects. It is currently being investigated as a possible treatment for diseases characterized by neurodegeneration  particularly Alzheimers disease.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02205">
  <data key="d0">6-(1,1-Dimethylallyl)-2-(1-Hydroxy-1-Methylethyl)-2,3-Dihydro-7h-Furo[3,2-G]Chromen-7-One</data>
  <data key="d1">drugbank.DB02205</data>
  <data key="d2">[drugbank.DB02205, drugbank.EXPT00760]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-2-(2-hydroxypropan-2-yl)-6-(2-methylbut-3-en-2-yl)-2H,3H,7H-furo[3,2-g]chromen-7-one</data>
  <data key="d15">C19H22O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H22O4/c1-6-18(2,3)13-8-11-7-12-9-16(19(4,5)21)22-14(12)10-15(11)23-17(13)20/h6-8,10,16,21H,1,9H2,2-5H3/t16-/m0/s1</data>
  <data key="d20">[H][C@]1(CC2=C(O1)C=C1OC(=O)C(=CC1=C2)C(C)(C)C=C)C(C)(C)O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02207">
  <data key="d0">7-Nitroindazole</data>
  <data key="d1">drugbank.DB02207</data>
  <data key="d2">[drugbank.DB02207, drugbank.EXPT00314]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Analgesics, Anti-Anxiety Agents, Anticonvulsants, Central Nervous System Agents, Central Nervous System Depressants, Compounds used in a research, industrial, or household setting, Enzyme Inhibitors, Neuroprotective Agents, Nitric Oxide Synthase, antagonists &amp; inhibitors, Peripheral Nervous System Agents, Protective Agents, Psychotropic Drugs, Pyrazoles, Sensory System Agents, Tranquilizing Agents]</data>
  <data key="d14">7-nitro-2H-indazole</data>
  <data key="d15">C7H5N3O2</data>
  <data key="d16">2942-42-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H5N3O2/c11-10(12)6-3-1-2-5-4-8-9-7(5)6/h1-4H,(H,8,9)</data>
  <data key="d20">O=N(=O)C1=CC=CC2=CNN=C12</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04868">
  <data key="d0">Nilotinib</data>
  <data key="d1">drugbank.DB04868</data>
  <data key="d2">[drugbank.DB04868]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inhibitors (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Highest Risk QTc-Prolonging Agents, Hyperglycemia-Associated Agents, Immunosuppressive Agents, Kinase Inhibitor, Myelosuppressive Agents, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, QTc Prolonging Agents, Tyrosine Kinase Inhibitors, UGT1A1 Inhibitors]</data>
  <data key="d14">4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide</data>
  <data key="d15">C28H22F3N7O</data>
  <data key="d16">641571-10-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)</data>
  <data key="d20">CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F</data>
  <data key="d21">For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Nilotinib, Nilotinibum]</data>
  <data key="d9">Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02211">
  <data key="d0">N-Methyl-N-Propargyl-1(R)-Aminoindan</data>
  <data key="d1">drugbank.DB02211</data>
  <data key="d2">[drugbank.DB02211, drugbank.EXPT02792]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(1R)-N-methyl-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine</data>
  <data key="d15">C13H15N</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H15N/c1-3-10-14(2)13-9-8-11-6-4-5-7-12(11)13/h1,4-7,13H,8-10H2,2H3/t13-/m1/s1</data>
  <data key="d20">[H][C@]1(CCC2=C1C=CC=C2)N(C)CC#C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04892">
  <data key="d0">Phenserine</data>
  <data key="d1">drugbank.DB04892</data>
  <data key="d2">[drugbank.DB04892]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Acyclic, Alkaloids, Carbamates, Cholinesterase Inhibitors, Indole Alkaloids, Indoles, Phenylcarbamates, Stereoisomerism]</data>
  <data key="d14">(3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-phenylcarbamate</data>
  <data key="d15">C20H23N3O2</data>
  <data key="d16">101246-66-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H23N3O2/c1-20-11-12-22(2)18(20)23(3)17-10-9-15(13-16(17)20)25-19(24)21-14-7-5-4-6-8-14/h4-10,13,18H,11-12H2,1-3H3,(H,21,24)/t18-,20+/m1/s1</data>
  <data key="d20">[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC3=CC=CC=C3)=C1)N2C</data>
  <data key="d21">For the treatment of Alzheimer's disease (AD).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(-)-eseroline phenylcarbamate, (-)-phenserine]</data>
  <data key="d9">Phenserine is under development by Axonyx, a US biopharmaceutical company that focuses on treatments for dementia. Phenserine is a next generation acetylcholinesterase (AChE) inhibitor indicated for the treatment of AD. Unlike currently marketed AChE inhibitors, it has a dual mechanism of action that also includes anti-amyloid activity, which may confer disease-modifying effects in patients with AD. If this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD. Axonyx announced on 20 September 2005 that phenserine was ineffective in two curtailed phase 3 trials.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02226">
  <data key="d0">3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-4-Yl]Hexyl]-Phenanthridinium</data>
  <data key="d1">drugbank.DB02226</data>
  <data key="d2">[drugbank.DB02226, drugbank.EXPT03146]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3,8-diamino-6-phenyl-5-[6-(1-{2-[(1,2,3,4-tetrahydroacridin-9-yl)amino]ethyl}-1H-1,2,3-triazol-4-yl)hexyl]phenanthridin-5-ium</data>
  <data key="d15">C42H45N8</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C42H44N8/c43-30-19-21-33-34-22-20-31(44)27-40(34)50(42(37(33)26-30)29-12-4-3-5-13-29)24-11-2-1-6-14-32-28-49(48-47-32)25-23-45-41-35-15-7-9-17-38(35)46-39-18-10-8-16-36(39)41/h3-5,7,9,12-13,15,17,19-22,26-28,44H,1-2,6,8,10-11,14,16,18,23-25,43H2,(H,45,46)/p+1</data>
  <data key="d20">NC1=CC2=C(C=C1)C1=CC=C(N)C=C1C(C1=CC=CC=C1)=[N+]2CCCCCCC1=CN(CCNC2=C3CCCCC3=NC3=C2C=CC=C3)N=N1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04813">
  <data key="d0">Bithionol</data>
  <data key="d1">drugbank.DB04813</data>
  <data key="d2">[drugbank.DB04813]</data>
  <data key="d12">[approved, withdrawn]</data>
  <data key="d13">[Anthelmintics, Anti-Acne Preparations, Anti-Acne Preparations for Topical Use, Anti-Infective Agents, Anti-Infective Agents, Local, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiplatyhelmintic Agents, Antitrematodals, Benzene Derivatives, Dermatologicals, Phenols, Preparations Containing Sulfur]</data>
  <data key="d14">2,4-dichloro-6-[(3,5-dichloro-2-hydroxyphenyl)sulfanyl]phenol</data>
  <data key="d15">C12H6Cl4O2S</data>
  <data key="d16">97-18-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H6Cl4O2S/c13-5-1-7(15)11(17)9(3-5)19-10-4-6(14)2-8(16)12(10)18/h1-4,17-18H</data>
  <data key="d20">OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-Hydroxy-3, 5-dichlorophenyl sulfide, 2-Hydroxy-3, 5-dichlorophenyl sulphide, 2, 2'-Dihydroxy-3, 3', 5, 5'-tetrachlorodiphenyl sulfide, 2, 2'-Dihydroxy-3, 3', 5, 5'-tetrachlorodiphenylsulfide, 2, 2'-sulfanediylbis(4, 6-dichlorophenol), 2, 2'-Thiobis(4, 6-dichlorophenol), Bis(3, 5-dichloro-2-hydroxyphenyl) sulfide, Bithionol, Bithionol sulfide, Bithionolate, Bithionolum, Bitionol]</data>
  <data key="d9">Bithionol, formerly marketed as an active ingredient in various topical drug products, was shown to be a potent photosensitizer with the potential to cause serious skin disorders. Approvals of the NDA's for bithionol drug products were withdrawn on October 24, 1967 (see the Federal Register of October 31, 1967 (32 FR 15046)).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04815">
  <data key="d0">Clioquinol</data>
  <data key="d1">drugbank.DB04815</data>
  <data key="d2">[drugbank.DB04815]</data>
  <data key="d12">[approved, vet_approved, withdrawn]</data>
  <data key="d13">[Anti-Infective Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Antiseptics and Disinfectants, Cell-mediated Immunity, Dermatologicals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hydroxyquinoline Derivatives, Hydroxyquinolines, Increased Histamine Release, Medicated Dressings, Medicated Dressings With Antiinfectives, Miscellaneous Antifungals, Otologicals, Oxyquinoline, Quinoline Derivatives, Quinolines, Sensory Organs, Standardized Chemical Allergen]</data>
  <data key="d14">5-chloro-7-iodoquinolin-8-ol</data>
  <data key="d15">C9H5ClINO</data>
  <data key="d16">130-26-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H</data>
  <data key="d20">OC1=C(I)C=C(Cl)C2=C1N=CC=C2</data>
  <data key="d21">Used as a topical antifungal treatment.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[5-Chlor-7-jod-8-hydroxy-chinolin, 5-Chloro-7-iodo-8-hydroxyquinoline, 5-Chloro-7-iodo-8-quinolinol, 5-chloro-7-iodoquinolin-8-ol, 5-Chloro-8-hydroxy-7-iodoquinoline, 7-Iodo-5-chloro-8-hydroxyquinoline, 7-Iodo-5-chloroxine, Chloroiodoquin, Clioquinol, Clioquinolum, Iodochlorhydroxyquin, Iodochlorhydroxyquinoline, Iodochlorohydroxyquin, Iodochloroxyquinoline]</data>
  <data key="d9">Clioquinol was withdrawn in 1983 due to neurotoxicity.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04818">
  <data key="d0">Iproniazid</data>
  <data key="d1">drugbank.DB04818</data>
  <data key="d2">[drugbank.DB04818]</data>
  <data key="d12">[withdrawn]</data>
  <data key="d13">[Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Hydrazines, Isonicotinic Acids, Monoamine Oxidase Inhibitors, Monoamine Oxidase Inhibitors, Non-Selective, Psychotropic Drugs, Pyridines, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome]</data>
  <data key="d14">N'-(propan-2-yl)pyridine-4-carbohydrazide</data>
  <data key="d15">C9H13N3O</data>
  <data key="d16">54-92-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H13N3O/c1-7(2)11-12-9(13)8-3-5-10-6-4-8/h3-7,11H,1-2H3,(H,12,13)</data>
  <data key="d20">CC(C)NNC(=O)C1=CC=NC=C1</data>
  <data key="d21">For the treatment of depression (originally intended to treat tuberculosis).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Withdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04819">
  <data key="d0">Methapyrilene</data>
  <data key="d1">drugbank.DB04819</data>
  <data key="d2">[drugbank.DB04819]</data>
  <data key="d12">[withdrawn]</data>
  <data key="d13">[Amines, Aminopyridines, Anti-Allergic Agents, Antihistamines for Systemic Use, Central Nervous System Agents, Central Nervous System Depressants, Diamines, Ethylenediamines, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Hypnotics and Sedatives, Neurotransmitter Agents, Polyamines, Pyridines, Substituted Ethylene Diamines]</data>
  <data key="d14">N-[2-(dimethylamino)ethyl]-N-[(thiophen-2-yl)methyl]pyridin-2-amine</data>
  <data key="d15">C14H19N3S</data>
  <data key="d16">91-80-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H19N3S/c1-16(2)9-10-17(12-13-6-5-11-18-13)14-7-3-4-8-15-14/h3-8,11H,9-10,12H2,1-2H3</data>
  <data key="d20">CN(C)CCN(CC1=CC=CS1)C1=NC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-[[2-(Dimethylamino)ethyl]-2-thenylamino]pyridine, Methypyrilene, N-(-pyridyl)-N-(-thenyl)-N', N'-dimethylethylenediamine, N, N-dimethyl-N'-pyrid-2-yl-N'-2-thenylethylenediamine, N, N-dimethyl-N'-pyridin-2-yl-N'-(2-thienylmethyl)ethane-1, 2-diamine, Thenylpyramine]</data>
  <data key="d9">Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04821">
  <data key="d0">Nomifensine</data>
  <data key="d1">drugbank.DB04821</data>
  <data key="d2">[drugbank.DB04821]</data>
  <data key="d12">[approved, withdrawn]</data>
  <data key="d13">[Antidepressive Agents, Central Nervous System Depressants, Dopamine Agents, Dopamine Uptake Inhibitors, Isoquinolines, Membrane Transport Modulators, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Psychoanaleptics]</data>
  <data key="d14">2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-amine</data>
  <data key="d15">C16H18N2</data>
  <data key="d16">24526-64-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H18N2/c1-18-10-14(12-6-3-2-4-7-12)13-8-5-9-16(17)15(13)11-18/h2-9,14H,10-11,17H2,1H3</data>
  <data key="d20">CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+-)-nomifensin, (+-)-nomifensine, 2-Methyl-4-phenyl-1, 2, 3, 4-tetrahydro-isoquinolin-8-ylamine, 8-Amino-2-methyl-4-phenyl-1, 2, 3, 4-tetrahydroisoquinoline, D, L-nomifensine, Nomifensin, Nomifensina, Nomifensine, Nomifensinum]</data>
  <data key="d9">Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia. The approved application holder removed Merital capsules from the market on January 23, 1986. FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal Register of June 17, 1986 (51 FR 21981)). Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04820">
  <data key="d0">Nialamide</data>
  <data key="d1">drugbank.DB04820</data>
  <data key="d2">[drugbank.DB04820]</data>
  <data key="d12">[approved, withdrawn]</data>
  <data key="d13">[Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Enzyme Inhibitors, Isonicotinic Acids, Monoamine Oxidase Inhibitors, Monoamine Oxidase Inhibitors, Non-Selective, Nervous System, Psychoanaleptics, Psychotropic Drugs, Pyridines, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome]</data>
  <data key="d14">N-benzyl-3-(pyridin-4-ylformohydrazido)propanamide</data>
  <data key="d15">C16H18N4O2</data>
  <data key="d16">51-12-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H18N4O2/c21-15(18-12-13-4-2-1-3-5-13)8-11-19-20-16(22)14-6-9-17-10-7-14/h1-7,9-10,19H,8,11-12H2,(H,18,21)(H,20,22)</data>
  <data key="d20">O=C(CCNNC(=O)C1=CC=NC=C1)NCC1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-(2-(Benzylcarbamoyl)ethyl)-2-isonicotinoylhydrazine, 2-(2-(Benzylcarbamoyl)ethyl)hydrazide isonicotinic acid, 2-(2-(Benzylcarbamyl)ethyl)hydrazide isonicotinic acid, BEIH, Isonicotinic acid 2-((2-benzylcarbamoyl)ethyl)hydrazide, Isonicotinic acid, 2-(2-(benzylcarbamoyl)ethyl)hydrazide, N-(2-(Benzylcarbamyl)ethylamino)isonicotinamide, N-benzyl-beta-(isonicotinoylhydrazine)propionamide, N-benzyl-beta-(isonicotinylhydrazino)propionamide, N-Isonicotinoyl-N'(beta-N-benzylcarboxamidoethyl)hydrazine, Nialamida, Nialamide, Nialamidum]</data>
  <data key="d9">Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04825">
  <data key="d0">Prenylamine</data>
  <data key="d1">drugbank.DB04825</data>
  <data key="d2">[drugbank.DB04825]</data>
  <data key="d12">[approved, withdrawn]</data>
  <data key="d13">[Adrenergic Agents, Agents causing hyperkalemia, Amines, Antiarrhythmic agents, Bradycardia-Causing Agents, Calcium Channel Blockers, Calmodulin, antagonists &amp; inhibitors, Cardiac Therapy, Cardiovascular Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Ethylamines, Hydroxy Acids, Membrane Transport Modulators, Moderate Risk QTc-Prolonging Agents, Neurotransmitter Agents, Phenethylamines, QTc Prolonging Agents, Vasodilating Agents, Vasodilators Used in Cardiac Diseases]</data>
  <data key="d14">(3,3-diphenylpropyl)(1-phenylpropan-2-yl)amine</data>
  <data key="d15">C24H27N</data>
  <data key="d16">390-64-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H27N/c1-20(19-21-11-5-2-6-12-21)25-18-17-24(22-13-7-3-8-14-22)23-15-9-4-10-16-23/h2-16,20,24-25H,17-19H2,1H3</data>
  <data key="d20">CC(CC1=CC=CC=C1)NCCC(C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-Phenyl-2-(1', 1'-diphenylpropyl-3'-amino)propane, DL-prenylamine, N-(1-Methyl-2-phenylethyl)-gamma-phenylbenzenepropanamine, N-(3, 3-Diphenylpropyl)-alpha-methylphenaethylamin, N-(3, 3-Diphenylpropyl)-alpha-methylphenethylamine, Prenilamina, Prenylamine, Prenylaminum]</data>
  <data key="d9">Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04824">
  <data key="d0">Phenolphthalein</data>
  <data key="d1">drugbank.DB04824</data>
  <data key="d2">[drugbank.DB04824]</data>
  <data key="d12">[approved, withdrawn]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Benzene Derivatives, Compounds used in a research, industrial, or household setting, Contact Laxatives, Drugs for Constipation, Indicators and Reagents, Laboratory Chemicals, Laxatives, Phenolphthaleins, Phenols]</data>
  <data key="d14">3,3-bis(4-hydroxyphenyl)-1,3-dihydro-2-benzofuran-1-one</data>
  <data key="d15">C20H14O4</data>
  <data key="d16">77-09-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H14O4/c21-15-9-5-13(6-10-15)20(14-7-11-16(22)12-8-14)18-4-2-1-3-17(18)19(23)24-20/h1-12,21-22H</data>
  <data key="d20">OC1=CC=C(C=C1)C1(OC(=O)C2=CC=CC=C12)C1=CC=C(O)C=C1</data>
  <data key="d21">Used for over a century as a laxative.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3, 3-Bis(4-hydroxyphenyl)phthalide, Fenolftalein, Fenolftaleina, Phenolphtaleine, Phenolphthaleinum, Phthalimetten, phthalin, Yellow phenolphthalein]</data>
  <data key="d9">Phenolphthalein was withdrawn in Canada due to concerns with carcinogenicity in 1997.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04832">
  <data key="d0">Zimelidine</data>
  <data key="d1">drugbank.DB04832</data>
  <data key="d2">[drugbank.DB04832]</data>
  <data key="d12">[approved, withdrawn]</data>
  <data key="d13">[Antidepressive Agents, Brompheniramine, Central Nervous System Depressants, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 Enzyme Inhibitors, Hypoglycemia-Associated Agents, Membrane Transport Modulators, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, P-glycoprotein/ABCB1 Inhibitors, Pheniramine, Psychoanaleptics, Pyridines, Selective Serotonin Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators]</data>
  <data key="d14">[(2Z)-3-(4-bromophenyl)-3-(pyridin-3-yl)prop-2-en-1-yl]dimethylamine</data>
  <data key="d15">C16H17BrN2</data>
  <data key="d16">56775-88-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H17BrN2/c1-19(2)11-9-16(14-4-3-10-18-12-14)13-5-7-15(17)8-6-13/h3-10,12H,11H2,1-2H3/b16-9-</data>
  <data key="d20">CN(C)C\C=C(\C1=CC=C(Br)C=C1)C1=CC=CN=C1</data>
  <data key="d21">For the treatment of depression.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(Z)-3-(4'-Bromophenyl)-3-(3''-pyridyl)dimethylallylamine, (Z)-zimelidine, cis-zimelidine, Zimeldina, Zimeldine, Zimeldinum]</data>
  <data key="d9">Zimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barr syndrome and due to a peculiar hypersensitivity reaction involving many organs including skin exanthema, flu-like symptoms, arthralgias, and sometimes eosinophilia. Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04841">
  <data key="d0">Flunarizine</data>
  <data key="d1">drugbank.DB04841</data>
  <data key="d2">[drugbank.DB04841]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents causing hyperkalemia, Antiarrhythmic agents, Anticonvulsants, Antimigraine Agents, Miscellaneous, Antivertigo Preparations, Bradycardia-Causing Agents, Calcium Channel Blockers, Cardiovascular Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Membrane Transport Modulators, Nervous System, Neurotransmitter Agents, Piperazine Derivatives, Piperazines, Vasodilating Agents]</data>
  <data key="d14">1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine</data>
  <data key="d15">C26H26F2N2</data>
  <data key="d16">52468-60-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+</data>
  <data key="d20">FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1</data>
  <data key="d21">Used in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine, Flunarizina, Flunarizine, Flunarizinum]</data>
  <data key="d9">Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04840">
  <data key="d0">Debrisoquine</data>
  <data key="d1">drugbank.DB04840</data>
  <data key="d2">[drugbank.DB04840]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Adrenergic Agents, Antiadrenergic Agents, Peripherally Acting, Antihypertensive Agents, Autonomic Agents, Cardiovascular Agents, Catecholamines, Cytochrome P-450 CYP2D6 Substrates, Guanidine Derivatives, Isoquinolines, Neurotransmitter Agents, P-glycoprotein/ABCB1 Substrates, Peripheral Nervous System Agents, Sympatholytics]</data>
  <data key="d14">1,2,3,4-tetrahydroisoquinoline-2-carboximidamide</data>
  <data key="d15">C10H13N3</data>
  <data key="d16">1131-64-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)</data>
  <data key="d20">NC(=N)N1CCC2=CC=CC=C2C1</data>
  <data key="d21">For the treatment of moderate and severe hypertension, either alone or as an adjunct, and for the treatment of renal hypertension.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Debrisochinum, Debrisoquin, Debrisoquina, Dbrisoquine, Debrisoquine, Debrisoquinum]</data>
  <data key="d9">An adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04912">
  <data key="d0">Stannsoporfin</data>
  <data key="d1">drugbank.DB04912</data>
  <data key="d2">[drugbank.DB04912]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Biological Factors, Enzyme Inhibitors, Heme Oxygenase (Decyclizing), antagonists &amp; inhibitors, Pigments, Biological, Porphyrins]</data>
  <data key="d14">tin(4+) ion 5,9-bis(2-carboxyethyl)-14,19-diethyl-4,10,15,20-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1(20),2,4,6(24),7,9,11,13(22),14,16,18-undecaene-21,23-diide dichloride</data>
  <data key="d15">C34H36Cl2N4O4Sn</data>
  <data key="d16">106344-20-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C34H38N4O4.2ClH.Sn/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;;;/h13-16H,7-12H2,1-6H3,(H4,35,36,37,38,39,40,41,42);2*1H;/q;;;+4/p-4/b25-13-,26-13-,27-14-,28-15-,29-14-,30-15-,31-16-,32-16-;;;</data>
  <data key="d20">[Cl-].[Cl-].[Sn+4].CCC1=C2[N-]C(\C=C3/N=C(/C=C4\[N-]\C(=C/C5=N/C(=C\2)/C(C)=C5CC)C(C)=C4CCC(O)=O)C(CCC(O)=O)=C3C)=C1C</data>
  <data key="d21">Investigated for use/treatment in liver disease, metabolic disease, and pediatric indications.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Sn Mesoporphyrin, SnMP, Stannsoporfin, Tin mesoporphyrin]</data>
  <data key="d9">Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing jaundice.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04924">
  <data key="d0">Itopride</data>
  <data key="d1">drugbank.DB04924</data>
  <data key="d2">[drugbank.DB04924]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Carbocyclic, Alimentary Tract and Metabolism, Amides, Benzene Derivatives, Benzoates, Drugs for Functional Gastrointestinal Disorders, Propulsives]</data>
  <data key="d14">N-({4-[2-(dimethylamino)ethoxy]phenyl}methyl)-3,4-dimethoxybenzamide</data>
  <data key="d15">C20H26N2O4</data>
  <data key="d16">122898-67-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H26N2O4/c1-22(2)11-12-26-17-8-5-15(6-9-17)14-21-20(23)16-7-10-18(24-3)19(13-16)25-4/h5-10,13H,11-12,14H2,1-4H3,(H,21,23)</data>
  <data key="d20">COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1</data>
  <data key="d21">Investigated for use/treatment in gastrointestinal diseases and disorders (miscellaneous).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Itopride, N-(p-(2-(Dimethylamino)ethoxy)benzyl)veratramide]</data>
  <data key="d9">Itopride is a dopamine D2 antagonist with acetylcholinesterase inhibitory actions.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00179">
  <data key="d0">Masoprocol</data>
  <data key="d1">drugbank.DB00179</data>
  <data key="d2">[drugbank.DB00179, drugbank.APRD01084, drugbank.DB05900]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Antioxidants, Benzene Derivatives, Benzyl Compounds, Catechols, Central Nervous System Agents, Compounds used in a research, industrial, or household setting, Cyclooxygenase Inhibitors, Enzyme Inhibitors, Lignans, Lipoxygenase Inhibitors, Peripheral Nervous System Agents, Phenols, Protective Agents, Sensory System Agents]</data>
  <data key="d14">4-[(2S,3R)-3-[(3,4-dihydroxyphenyl)methyl]-2-methylbutyl]benzene-1,2-diol</data>
  <data key="d15">C18H22O4</data>
  <data key="d16">27686-84-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+</data>
  <data key="d20">C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1</data>
  <data key="d21">Used for the treatment of actinic keratoses (precancerous skin growths that can become malignant if left untreated).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[erythro-nordihydroguaiaretic acid, masoprocol, Masoprocolum, meso-1, 4-bis(3, 4-dihydroxyphenyl)-2, 3-dimethylbutane, meso-2, 3-bis(3, 4-dihydroxyphenylmethyl)butane, meso-4-[4-(3, 4-dihydroxyphenyl)-2, 3-dimethylbutyl]benzene-1, 2-diol, meso-4, 4'-(2, 3-dimethyl-1, 4-butanediyl)bis(pyrocatechol), meso-4, 4'-(2, 3-dimethyltetramethylene)dipyrocatechol, meso-NDGA, meso-nordihydroguaiaretic acid, meso-, -dimethyl-, -bis(3, 4-dihydroxyphenyl)butan, Nordihydroguaiaretic acid]</data>
  <data key="d9">A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00178">
  <data key="d0">Ramipril</data>
  <data key="d1">drugbank.DB00178</data>
  <data key="d2">[drugbank.DB00178, drugbank.APRD00009]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[ACE Inhibitors and Calcium Channel Blockers, ACE Inhibitors and Diuretics, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Agents, Cholinesterase Inhibitors, Enzyme Inhibitors, Hypotensive Agents, Lipid Modifying Agents, Protease Inhibitors]</data>
  <data key="d14">(2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydrocyclopenta[b]pyrrole-2-carboxylic acid</data>
  <data key="d15">C23H32N2O5</data>
  <data key="d16">87333-19-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1</data>
  <data key="d20">[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC</data>
  <data key="d21">For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. [FDA Label] To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy. [T116]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(2S-(1(R*(R*)), 2alpha, 3abeta, 6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, Ramipril, Ramiprilum]</data>
  <data key="d9">Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00184">
  <data key="d0">Nicotine</data>
  <data key="d1">drugbank.DB00184</data>
  <data key="d2">[drugbank.DB00184, drugbank.APRD00200, drugbank.EXPT02315, drugbank.DB09463, drugbank.DB11303]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents producing tachycardia, Alkaloids, Autonomic Agents, Cholinergic Agents, Cholinergic Agonists, Cholinergic Nicotinic Agonist, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strength unknown), Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2E1 Inducers (strength unknown), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Drugs Used in Addictive Disorders, Drugs Used in Nicotine Dependence, Ganglion Blockers, Ganglionic Stimulants, Miscellaneous Autonomic Drugs, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Nervous System, Neurotransmitter Agents, Nicotinic Agonists, OCT1 inhibitors, OCT2 Inhibitors, Peripheral Nervous System Agents, Pyridines, Solanaceous Alkaloids]</data>
  <data key="d14">3-[(2S)-1-methylpyrrolidin-2-yl]pyridine</data>
  <data key="d15">C10H14N2</data>
  <data key="d16">54-11-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3/t10-/m0/s1</data>
  <data key="d20">CN1CCC[C@H]1C1=CN=CC=C1</data>
  <data key="d21">For the relief of nicotine withdrawal symptoms and as an aid to smoking cessation.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-nicotine, (S)-()-nicotine, (S)-3-(1-methylpyrrolidin-2-yl)pyridine, (S)-3-(N-methylpyrrolidin-2-yl)pyridine, (S)-Nicotine, 3-(2-(N-methylpyrrolidinyl))pyridine, 3-(N-methylpyrollidino)pyridine, L()-nicotine, Nicotina, Nicotine betadex, Nicotine polacrilex, Nikotin, Nikotyna]</data>
  <data key="d9">Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00182">
  <data key="d0">Amphetamine</data>
  <data key="d1">drugbank.DB00182</data>
  <data key="d2">[drugbank.DB00182, drugbank.APRD00480]</data>
  <data key="d12">[approved, illicit, investigational]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic Uptake Inhibitors, Agents producing tachycardia, Agents that produce hypertension, Agents that reduce seizure threshold, Amines, Amphetamines, Antidepressive Agents, Autonomic Agents, Central Nervous System Agents, Central Nervous System Depressants, Central Nervous System Stimulants, Central Nervous System Stimulation, Centrally Acting Sympathomimetics, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Enzyme Inhibitors, Dopamine Agents, Dopamine Uptake Inhibitors, Drugs that are Mainly Renally Excreted, Membrane Transport Modulators, Monoamine Oxidase Inhibitors, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Peripheral Nervous System Agents, Phenethylamines, Psychoanaleptics, Psychostimulants, Agents Used for Adhd and Nootropics, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Sympathomimetics]</data>
  <data key="d14">1-phenylpropan-2-amine</data>
  <data key="d15">C9H13N</data>
  <data key="d16">300-62-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3</data>
  <data key="d20">CC(N)CC1=CC=CC=C1</data>
  <data key="d21">Amphetamine is indicated for the treatment of attention-deficit/hyperactivity disorders (ADHD) as well as for the treatment of central nervous system disorders such as narcolepsy.[A18540] \n\nADHD is a complex disorder associated with the substantial heterogeneity in etiology, clinical presentation, and treatment outcome. ADHD comes from a complex interplay between interdependent genetic and non-genetic factors which cause complex mental disorders in children and teenagers.[A174271]\n\nOn the other hand, narcolepsy is a chronic sleep disorder typically resenting during adolescence and characterized by excessive daytime sleepiness.[A174274]\n\nAmphetamine is also being used nowadays off-label for the treatment of obesity, depression and chronic pain.[A174268, A174283]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+-)-alpha-Methylphenylethylamine, 1-phenyl-2-aminopropane, alpha-Methylbenzeneethaneamine, Amfetamina, Amfetamine, Amfetaminum, Amphetamine, beta-Aminopropylbenzene, beta-Phenylisopropylamin, Desoxynorephedrine, rac-(2R)-1-phenylpropan-2-amine, rac-amphetamine, -methylbenzeneethaneamine, -methylphenethylamine, -aminopropylbenzene, -phenylisopropylamine]</data>
  <data key="d9">Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 and first synthesized by 1927. After being proven to reduce drug-induced anesthesia and produce arousal and insomnia, amphetamine racemic mix was registered by Smith, Kline and French in 1935. Amphetamine structure presents one chiral center and it exists in the form of dextro- and levo-isomers.[A18540] The first product of Smith, Kline and French was approved by the FDA on 1976.[L5194]\n\nDuring World War II, amphetamine was used to promote wakefulness in the soldiers. This use derived into a large overproduction of amphetamine and all the surplus after the war finalized ended up in the black market, producing the initiation of the illicit abuse.[A18540]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00188">
  <data key="d0">Bortezomib</data>
  <data key="d1">drugbank.DB00188</data>
  <data key="d2">[drugbank.DB00188, drugbank.APRD00828, drugbank.DB07475]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Acids, Noncarboxylic, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Boron Compounds, Boronic Acids, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (moderate), Cytochrome P-450 CYP1A2 Inhibitors (weak), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Hypotensive Agents, Immunosuppressive Agents, Myelosuppressive Agents, Potential QTc-Prolonging Agents, Proteasome Inhibitors, Pyrazines, QTc Prolonging Agents]</data>
  <data key="d14">[(1R)-3-methyl-1-[(2S)-3-phenyl-2-(pyrazin-2-ylformamido)propanamido]butyl]boronic acid</data>
  <data key="d15">C19H25BN4O4</data>
  <data key="d16">179324-69-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1</data>
  <data key="d20">CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O</data>
  <data key="d21">For treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid, Bortezomib, N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide]</data>
  <data key="d9">Bortezomib (originally PS-341 and marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. The boron atom within bortezomib catalytically binds the active site of the 26S proteasome with high affinity and specificity, thereby resulting in cell cycle arrest and apoptosis. In normal cells, the proteasome is involved in degradation of ubiquitylated proteins that have been tagged for destruction because they are damaged or unneeded by the cell. However, in cancerous cells, proteasome activity degrades pro-apoptotic proteins such as p53 that would normally result in programmed cell death of the dysfunctional cells. Proteasome inhibitors such as bortezomib interrupt this process, resulting in destruction of cancerous cells. Bortezomib is currently approved in the United States for the treatment of relapsed multiple myeloma and mantle cell lymphoma.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00197">
  <data key="d0">Troglitazone</data>
  <data key="d1">drugbank.DB00197</data>
  <data key="d2">[drugbank.DB00197, drugbank.APRD00488]</data>
  <data key="d12">[investigational, withdrawn]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Benzopyrans, Blood Glucose Lowering Agents, BSEP/ABCB11 Inhibitors, Chemically-Induced Disorders, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Drugs Used in Diabetes, OATP1B1/SLCO1B1 Inhibitors, Oral Hypoglycemics, Peroxisome Proliferator-Activated Receptors, agonists, Pyrans, Sulfur Compounds, Thiazoles, Thiazolidinediones, UGT1A1 Substrates, UGT1A3 substrates, UGT1A4 substrates, UGT1A6 Inhibitors, UGT1A6 substrate, UGT1A9 Substrates, UGT2B7 substrates]</data>
  <data key="d14">5-({4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-2-yl)methoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione</data>
  <data key="d15">C24H27NO5S</data>
  <data key="d16">97322-87-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28)</data>
  <data key="d20">CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O</data>
  <data key="d21">For the treatment of Type II diabetes mellitus. It is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[troglitazona]</data>
  <data key="d9">Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00191">
  <data key="d0">Phentermine</data>
  <data key="d1">drugbank.DB00191</data>
  <data key="d2">[drugbank.DB00191, drugbank.APRD00093]</data>
  <data key="d12">[approved, illicit]</data>
  <data key="d13">[Adrenergic Agents, Agents producing tachycardia, Agents that produce hypertension, Alimentary Tract and Metabolism, Amines, Amphetamines, Anti-Obesity Agents, Antiobesity Preparations, Excl. Diet Products, Appetite Depressants, Appetite Suppression, Autonomic Agents, Central Nervous System Agents, Centrally Acting Antiobesity Products, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Increased Sympathetic Activity, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Neurotransmitter Agents, Peripheral Nervous System Agents, Phenethylamines, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Sympathomimetic Amine Anorectic, Sympathomimetics]</data>
  <data key="d14">2-methyl-1-phenylpropan-2-amine</data>
  <data key="d15">C10H15N</data>
  <data key="d16">122-09-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3</data>
  <data key="d20">CC(C)(N)CC1=CC=CC=C1</data>
  <data key="d21">Phentermine is indicated, alone or in combination with topiramate, as a short-term adjunct, not pass a few weeks, in a regimen of weight reduction based on exercise, behavioral modifications and caloric restriction in the management of exogenous obesity for patients with an initial body mass index (BMI) greater than 30 kg/m2 or greater than 27 kg/m2 in presence of other risk factors such as controller hypertension, diabetes or hyperlipidemia.[FDA label]\n\nExogenous obesity is considered when the overweight is caused by consuming more food than the person activity level warrants. This condition commonly causes an increase in fat storage. It is an epidemic condition in the United States where over two-thirds of adults are overweight or obese and one in three Americans is obese. In the world, the incidence of obesity has nearly doubled.[A174391]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[alpha, alpha-Dimethylphenethylamine, Fentermina, Phentermine, Phentermine resin, Phenterminum]</data>
  <data key="d9">Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine.[A174370] Phentermine has not been reported an addictive potential which allows this agent to be classified under the Schedule IV drugs (low abuse potential).[A174367]\n\nPhentermine was FDA approved for short-term weight management in 1959 and it became widely used in 1960. This initial product, formed by the combination of phentermine with [fenfluramine] and [dexfenfluramine] was discontinued after finding several reports of abnormal valves in nearly 30% of the consumers.[A174376, T403] Later on, phentermine was approved alone and in combination with topiramate in 2012 as a new alternative that required lower doses of phentermine to obtain the desired effect.[A174373]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12191">
  <data key="d0">Obatoclax</data>
  <data key="d1">drugbank.DB12191</data>
  <data key="d2">[drugbank.DB12191, drugbank.DB05567]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">2-[(2Z)-2-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-3-methoxy-2H-pyrrol-5-yl]-1H-indole</data>
  <data key="d15">C20H19N3O</data>
  <data key="d16">803712-67-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H19N3O/c1-12-8-13(2)21-16(12)10-19-20(24-3)11-18(23-19)17-9-14-6-4-5-7-15(14)22-17/h4-11,21-22H,1-3H3/b19-10-</data>
  <data key="d20">COC1=CC(=N\C1=C/C1=C(C)C=C(C)N1)C1=CC2=CC=CC=C2N1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Obatoclax has been used in trials studying the treatment of AML, Leukemia, Myelofibrosis, Hodgkin's Lymphoma, and Mantle-Cell Lymphoma, among others.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00132">
  <data key="d0">Alpha-Linolenic Acid</data>
  <data key="d1">drugbank.DB00132</data>
  <data key="d2">[drugbank.DB00132, drugbank.NUTR00034]</data>
  <data key="d12">[approved, investigational, nutraceutical]</data>
  <data key="d13">[Diet, Food, and Nutrition, Dietary Fats, Dietary Fats, Unsaturated, Dietary Supplements, Fats, Fatty Acids, Fatty Acids, Essential, Fatty Acids, Omega-3, Fatty Acids, Unsaturated, Fish Oils, Food, Food and Beverages, Linolenic Acids, Lipids, Oils, Physiological Phenomena, Supplements]</data>
  <data key="d14">(9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid</data>
  <data key="d15">C18H30O2</data>
  <data key="d16">463-40-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h3-4,6-7,9-10H,2,5,8,11-17H2,1H3,(H,19,20)/b4-3-,7-6-,10-9-</data>
  <data key="d20">CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O</data>
  <data key="d21">For nutritional supplementation and for treating dietary shortage or imbalance.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(9, 12, 15)-linolenic acid, (9Z, 12Z, 15Z)-Octadecatrienoic acid, (Z, Z, Z)-9, 12, 15-octadecatrienoic acid, 9-cis, 12-cis, 15-cis-octadecatrienoic acid, 9, 12, 15-Octadecatrienoic acid, ALA, all-cis-9, 12, 15-Octadecatrienoic acid, alpha-Linolenic acid, cis-delta(9, 12, 15)-Octadecatrienoic acid, cis, cis, cis-9, 12, 15-Octadecatrienoic acid, Linolenic acid, -linolenic acid]</data>
  <data key="d9">Alpha-linolenic acid (ALA) is a polyunsaturated omega-3 fatty acid. It is a component of many common vegetable oils and is important to human nutrition.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01472">
  <data key="d0">4-Methoxyamphetamine</data>
  <data key="d1">drugbank.DB01472</data>
  <data key="d2">[drugbank.DB01472, drugbank.EXPT03303]</data>
  <data key="d12">[experimental, illicit]</data>
  <data key="d13">[Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-Agonists, Agents producing tachycardia, Agents that produce hypertension, Amines, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Substrates, Ethylamines, Hallucinogens, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Phenethylamines, Psychotropic Drugs]</data>
  <data key="d14">1-(4-methoxyphenyl)propan-2-amine</data>
  <data key="d15">C10H15NO</data>
  <data key="d16">64-13-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H15NO/c1-8(11)7-9-3-5-10(12-2)6-4-9/h3-6,8H,7,11H2,1-2H3</data>
  <data key="d20">COC1=CC=C(CC(C)N)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(2RS)-1-(4-methoxyphenyl)propan-2-amine, 4-methoxyamfetamine, D, L-p-methoxyamphetamine, Formoterol fumarate related compound G, P-methoxyamfetamine, P-methoxyamphetamine, Paramethoxyamphetamine]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12119">
  <data key="d0">Gevokizumab</data>
  <data key="d1">drugbank.DB12119</data>
  <data key="d2">[drugbank.DB12119, drugbank.DB06062]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Antibodies, Antibodies, Monoclonal, Blood Proteins, Globulins, Immunoglobulins, Immunoproteins, Proteins, Serum Globulins]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">1129435-60-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21"></data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Gevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine imbalance in IL-1 mediated disease states. It has a very high binding affinity of 300fM and blocks the activation of IL-1 receptors.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01483">
  <data key="d0">Barbital</data>
  <data key="d1">drugbank.DB01483</data>
  <data key="d2">[drugbank.DB01483]</data>
  <data key="d12">[illicit]</data>
  <data key="d13">[Anticholinergic Agents, Anticonvulsants, Barbiturates, Barbiturates, Plain, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (unknown strength), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, GABA Agents, GABA Modulators, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones]</data>
  <data key="d14">5,5-diethyl-1,3-diazinane-2,4,6-trione</data>
  <data key="d15">C8H12N2O3</data>
  <data key="d16">57-44-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C8H12N2O3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4H2,1-2H3,(H2,9,10,11,12,13)</data>
  <data key="d20">CCC1(CC)C(=O)NC(=O)NC1=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">A long-acting barbiturate that depresses most metabolic processes at high doses. It is used as a hypnotic and sedative and may induce dependence. Barbital is also used in veterinary practice for central nervous system depression. Barbital is a schedule IV controlled drug.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12129">
  <data key="d0">Tideglusib</data>
  <data key="d1">drugbank.DB12129</data>
  <data key="d2">[drugbank.DB12129]</data>
  <data key="d12">[investigational, withdrawn]</data>
  <data key="d13">[Glycogen Synthase Kinase 3, antagonists &amp; inhibitors, Sulfur Compounds, Thiazoles]</data>
  <data key="d14">4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione</data>
  <data key="d15">C19H14N2O2S</data>
  <data key="d16">865854-05-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H14N2O2S/c22-18-20(13-14-7-2-1-3-8-14)19(23)24-21(18)17-12-6-10-15-9-4-5-11-16(15)17/h1-12H,13H2</data>
  <data key="d20">O=C1SN(C(=O)N1CC1=CC=CC=C1)C1=C2C=CC=CC2=CC=C1</data>
  <data key="d21">Tideglusib was initially formulated for the treatment of Alzheimer and progressive supranuclear palsy.[A31601] The raising interest for the use of tideglusib comes from the significant upregulation of GSK-3 in the brain in patients with Alzheimer disease. Its function as a degradant of -catenin, was also important, as it prevents the transcription of cell survival genes. All these factors have directed current research towards this kinase as a potential target.[A31603] Alzheimer disease is the most prevalent form of dementia. The most accepted hypothesis to explain this disease is related to the presence of amyloid , which triggers a cascade that will alter the Tau protein and provoke synaptic dysfunction and neuronal death.[A31605] \n\nGSK-3 importance in the tissue repair pathway has also pointed out a novel application for tideglusib. Thus, it is also under the research for the natural repair treatment of deep caries lesions.[A31602]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy. It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3).[A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12140">
  <data key="d0">Dilmapimod</data>
  <data key="d1">drugbank.DB12140</data>
  <data key="d2">[drugbank.DB12140, drugbank.DB05250]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[p38 Mitogen-Activated Protein Kinases, antagonists &amp; inhibitors, Pyridines]</data>
  <data key="d14">8-(2,6-difluorophenyl)-2-[(1,3-dihydroxypropan-2-yl)amino]-4-(4-fluoro-2-methylphenyl)-7H,8H-pyrido[2,3-d]pyrimidin-7-one</data>
  <data key="d15">C23H19F3N4O3</data>
  <data key="d16">444606-18-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H19F3N4O3/c1-12-9-13(24)5-6-15(12)20-16-7-8-19(33)30(21-17(25)3-2-4-18(21)26)22(16)29-23(28-20)27-14(10-31)11-32/h2-9,14,31-32H,10-11H2,1H3,(H,27,28,29)</data>
  <data key="d20">CC1=CC(F)=CC=C1C1=C2C=CC(=O)N(C2=NC(NC(CO)CO)=N1)C1=C(F)C=CC=C1F</data>
  <data key="d21">Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others. Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis). Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00159">
  <data key="d0">Icosapent</data>
  <data key="d1">drugbank.DB00159</data>
  <data key="d2">[drugbank.DB00159, drugbank.NUTR00024]</data>
  <data key="d12">[approved, nutraceutical]</data>
  <data key="d13">[Agents causing hyperkalemia, Agents that produce hypertension, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Autacoids, Biological Factors, Diet, Food, and Nutrition, Dietary Fats, Dietary Fats, Unsaturated, Dietary Supplements, Eicosanoids, Fats, Fatty Acids, Fatty Acids, Omega-3, Fatty Acids, Unsaturated, Fish Oils, Food, Food and Beverages, Hypolipidemic Agents, Inflammation Mediators, Lipids, Nephrotoxic agents, Non COX-2 selective NSAIDS, Oils, Physiological Phenomena, Supplements]</data>
  <data key="d14">(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid</data>
  <data key="d15">C20H30O2</data>
  <data key="d16">10417-94-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,13-12-,16-15-</data>
  <data key="d20">CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O</data>
  <data key="d21">EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(5Z, 8Z, 11Z, 14Z, 17Z)-5, 8, 11, 14, 17-eicosapentaenoic acid, (5Z, 8Z, 11Z, 14Z, 17Z)-Eicosapentaenoate, (5Z, 8Z, 11Z, 14Z, 17Z)-Eicosapentaenoic acid, (5Z, 8Z, 11Z, 14Z, 17Z)-Icosapentaenoic acid, (all-Z)-5, 8, 11, 14, 17-eicosapentaenoic acid, 5, 8, 11, 14, 17-eicosapentaenoic acid, 5, 8, 11, 14, 17-Icosapentaenoic acid, all-cis-5, 8, 11, 14, 17-eicosapentaenoic acid, all-cis-5, 8, 11, 14, 17-icosapentaenoic acid, all-cis-icosa-5, 8, 11, 14, 17-pentaenoic acid, cis-5, 8, 11, 14, 17-eicosapentaenoic acid, cis-5, 8, 11, 14, 17-EPA, cis-delta(5, 8, 11, 14, 17)-Eicosapentaenoic acid, Eicosapentaenoic acid, EPA, Icosapent, Icosapentaenoic acid, Icosapento, Icosapentum, Timnodonic acid]</data>
  <data key="d9">Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00157">
  <data key="d0">NADH</data>
  <data key="d1">drugbank.DB00157</data>
  <data key="d2">[drugbank.DB00157, drugbank.NUTR00041, drugbank.DB01907, drugbank.EXPT02287, drugbank.DB03527]</data>
  <data key="d12">[approved, nutraceutical]</data>
  <data key="d13">[Adenine Nucleotides, Carbohydrates, Coenzymes, Dietary Supplements, Enzymes and Coenzymes, Glycosides, Nucleic Acids, Nucleotides, and Nucleosides, Nucleotides, Purine Nucleotides, Purines, Ribonucleotides, Supplements]</data>
  <data key="d14">[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]({[(2R,3S,4R,5R)-5-(3-carbamoyl-1,4-dihydropyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy})phosphinic acid</data>
  <data key="d15">C21H29N7O14P2</data>
  <data key="d16">58-68-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H29N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1,3-4,7-8,10-11,13-16,20-21,29-32H,2,5-6H2,(H2,23,33)(H,34,35)(H,36,37)(H2,22,24,25)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1</data>
  <data key="d20">NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C(N)N=CN=C23)[C@@H](O)[C@H]1O</data>
  <data key="d21">Some evidence suggests that NADH might be useful in treating Parkinson's disease, chronic fatigue syndrome, Alzheimer's disease and cardiovascular disease.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1, 4-dihydronicotinamide adenine dinucleotide, DPNH, NAD reduced form, Nicotinamide adenine dinucleotide (reduced), Nicotinamide-adenine dinucleotide, reduced, Reduced nicotinamide adenine diphosphate, Reduced nicotinamide-adenine dinucleotide]</data>
  <data key="d9">NADH is the reduced form of NAD+, and NAD+ is the oxidized form of NADH, a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). It forms NADP with the addition of a phosphate group to the 2' position of the adenosyl nucleotide through an ester linkage. (Dorland, 27th ed)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00155">
  <data key="d0">L-Citrulline</data>
  <data key="d1">drugbank.DB00155</data>
  <data key="d2">[drugbank.DB00155, drugbank.NUTR00021]</data>
  <data key="d12">[approved, investigational, nutraceutical]</data>
  <data key="d13">[Amino Acids, Amino Acids, Diamino, Amino Acids, Peptides, and Proteins, Dietary Supplements, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Substrates, Proteins, Supplements]</data>
  <data key="d14">(2S)-2-amino-5-(carbamoylamino)pentanoic acid</data>
  <data key="d15">C6H13N3O3</data>
  <data key="d16">372-75-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C6H13N3O3/c7-4(5(10)11)2-1-3-9-6(8)12/h4H,1-3,7H2,(H,10,11)(H3,8,9,12)/t4-/m0/s1</data>
  <data key="d20">N[C@@H](CCCNC(N)=O)C(O)=O</data>
  <data key="d21">Used for nutritional supplementation, also for treating dietary shortage or imbalance.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(S)-2-Amino-5-ureidopentanoic acid, 2-Amino-5-ureidovaleric acid, alpha-amino-delta-Ureidovaleric acid, Cit, Citrulina, Citrulline, delta-Ureidonorvaline, L-2-Amino-5-ureidovaleric acid, N(5)-(Aminocarbonyl)-L-ornithine, N(delta)-Carbamylornithine, N5-(Aminocarbonyl)ornithine, N5-Carbamoyl-L-ornithine, N5-carbamoylornithine, -amino--ureidovaleric acid, -ureidonorvaline]</data>
  <data key="d9">Citrulline is an amino acid.  It is made from ornithine and carbamoyl phosphate in one of the central reactions in the urea cycle. It is also produced from arginine as a by-product of the reaction catalyzed by NOS family.  Its name is derived from citrullus, the Latin word for watermelon, from which it was first isolated.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01493">
  <data key="d0">Ethylestrenol</data>
  <data key="d1">drugbank.DB01493</data>
  <data key="d2">[drugbank.DB01493]</data>
  <data key="d12">[withdrawn]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Anabolic Agents, Anabolic Agents for Systemic Use, Anabolic Steroids, Estren Derivatives, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Norpregnanes, Norpregnenes, Norsteroids, Steroids]</data>
  <data key="d14">(1S,2R,10R,11S,14S,15S)-14-ethyl-15-methyltetracyclo[8.7.0.0,.0,]heptadec-6-en-14-ol</data>
  <data key="d15">C20H32O</data>
  <data key="d16">965-90-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H32O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h6,15-18,21H,3-5,7-13H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@@](O)(CC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Ethylestrenol, etilestrenol]</data>
  <data key="d9">An anabolic steroid with some progestational activity and little androgenic effect. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00166">
  <data key="d0">Lipoic Acid</data>
  <data key="d1">drugbank.DB00166</data>
  <data key="d2">[drugbank.DB00166, drugbank.NUTR00035]</data>
  <data key="d12">[approved, investigational, nutraceutical]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Antioxidants, Coenzymes, Compounds used in a research, industrial, or household setting, Diet, Food, and Nutrition, Dietary Supplements, Enzymes and Coenzymes, Fatty Acids, Food, Food and Beverages, Growth Substances, Hypoglycemia-Associated Agents, Lipids, Micronutrients, Physiological Phenomena, Protective Agents, Sulfur Compounds, Supplements, Thiophenes, Various Alimentary Tract and Metabolism Products, Vitamin B Complex, Vitamins]</data>
  <data key="d14">5-[(3R)-1,2-dithiolan-3-yl]pentanoic acid</data>
  <data key="d15">C8H14O2S2</data>
  <data key="d16">1200-22-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C8H14O2S2/c9-8(10)4-2-1-3-7-5-6-11-12-7/h7H,1-6H2,(H,9,10)/t7-/m1/s1</data>
  <data key="d20">OC(=O)CCCC[C@@H]1CCSS1</data>
  <data key="d21">For nutritional supplementation, also for treating dietary shortage or imbalance.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+)-alpha-Lipoic acid, (R)-(+)-Lipoate, (R)-(+)-lipoic acid, (R)-1, 2-Dithiolane-3-pentanoic acid, (R)-1, 2-dithiolane-3-valeric acid, (R)-6, 8-thioctic acid, (R)-lipoic acid, Alpha lipoic acid, alpha-Lipoic acid, alpha-Liponsure, D-thioctic acid, R-(+)-thioctic acid, R-alpha-lipoic acid, Thioctic acid, Thioctic acid D-form, -lipoic acid]</data>
  <data key="d9">A vitamin-like antioxidant.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01496">
  <data key="d0">Barbituric acid derivative</data>
  <data key="d1">drugbank.DB01496</data>
  <data key="d2">[drugbank.DB01496]</data>
  <data key="d12">[experimental, illicit]</data>
  <data key="d13">[Anticholinergic Agents, Nicotinic Antagonists]</data>
  <data key="d14">2-sulfanylidene-5-({5-[2-(trifluoromethyl)phenyl]furan-2-yl}methyl)-1,3-diazinane-4,6-dione</data>
  <data key="d15">C16H11F3N2O3S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H11F3N2O3S/c17-16(18,19)11-4-2-1-3-9(11)12-6-5-8(24-12)7-10-13(22)20-15(25)21-14(10)23/h1-6,10H,7H2,(H2,20,21,22,23,25)</data>
  <data key="d20">FC(F)(F)C1=CC=CC=C1C1=CC=C(CC2C(=O)NC(=S)NC2=O)O1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00172">
  <data key="d0">Proline</data>
  <data key="d1">drugbank.DB00172</data>
  <data key="d2">[drugbank.DB00172, drugbank.NUTR00047]</data>
  <data key="d12">[approved, nutraceutical]</data>
  <data key="d13">[Acids, Acyclic, Amino Acids, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Dietary Supplements, Imines, Imino Acids, Supplements]</data>
  <data key="d14">(2S)-pyrrolidine-2-carboxylic acid</data>
  <data key="d15">C5H9NO2</data>
  <data key="d16">147-85-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)/t4-/m0/s1</data>
  <data key="d20">OC(=O)[C@@H]1CCCN1</data>
  <data key="d21">L-Proline is extremely important for the proper functioning of joints and tendons and also helps maintain and strengthen heart muscles.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(-)-2-Pyrrolidinecarboxylic acid, ()-(S)-proline, ()-2-pyrrolidinecarboxylic acid, ()-proline, (2S)-pyrrolidine-2-carboxylic acid, (S)-2-Carboxypyrrolidine, (S)-2-Pyrrolidinecarboxylic acid, (S)-pyrrolidine-2-carboxylic acid, 2-Pyrrolidinecarboxylic acid, L-()-proline, L-alpha-pyrrolidinecarboxylic acid, L-Prolin, L-Proline, L-pyrrolidine-2-carboxylic acid, L--pyrrolidinecarboxylic acid, P, Prolina, Proline, Prolinum]</data>
  <data key="d9">L-Proline is one of the twenty amino acids used in living organisms as the building blocks of proteins. Proline is sometimes called an imino acid, although the IUPAC definition of an imine requires a carbon-nitrogen double bond. Proline is a non-essential amino acid that is synthesized from glutamic acid. It is an essential component of collagen and is important for proper functioning of joints and tendons.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00170">
  <data key="d0">Menadione</data>
  <data key="d1">drugbank.DB00170</data>
  <data key="d2">[drugbank.DB00170, drugbank.NUTR00062]</data>
  <data key="d12">[approved, nutraceutical]</data>
  <data key="d13">[Antifibrinolytic Agents, Blood and Blood Forming Organs, Coagulants, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (unknown strength), Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Diet, Food, and Nutrition, Dietary Supplements, Diterpenes, Fibrin Modulating Agents, Food, Food and Beverages, Growth Substances, Hematologic Agents, Hemostatics, Micronutrients, Naphthalenes, Naphthoquinones, Physiological Phenomena, Phytol, Quinones, Supplements, Terpenes, Vitamin K, Vitamins, Vitamins (Fat Soluble)]</data>
  <data key="d14">2-methyl-1,4-dihydronaphthalene-1,4-dione</data>
  <data key="d15">C11H8O2</data>
  <data key="d16">58-27-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H3</data>
  <data key="d20">CC1=CC(=O)C2=CC=CC=C2C1=O</data>
  <data key="d21">The primary known function of vitamin K is to assist in the normal clotting of blood, but it may also play a role in normal bone calcification.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-Methyl-1, 4-Naphthalenedione, 2-Methyl-1, 4-naphthochinon, 2-Methyl-1, 4-naphthoquinone, Vitamin K 3, Vitamin K3]</data>
  <data key="d9">A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01429">
  <data key="d0">Aprindine</data>
  <data key="d1">drugbank.DB01429</data>
  <data key="d2">[drugbank.DB01429]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Antiarrhythmic agents, Antiarrhythmics, Class I, Antiarrhythmics, Class Ib, Cardiac Therapy, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Substrates, Indans, Indenes, Membrane Transport Modulators, Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers]</data>
  <data key="d14">N-[3-(diethylamino)propyl]-N-phenyl-2,3-dihydro-1H-inden-2-amine</data>
  <data key="d15">C22H30N2</data>
  <data key="d16">37640-71-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H30N2/c1-3-23(4-2)15-10-16-24(21-13-6-5-7-14-21)22-17-19-11-8-9-12-20(19)18-22/h5-9,11-14,22H,3-4,10,15-18H2,1-2H3</data>
  <data key="d20">CCN(CC)CCCN(C1CC2=CC=CC=C2C1)C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Aprindina, Aprindine, Aprindinum]</data>
  <data key="d9">Aprindine is a cardiac depressant used in arrhythmias.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01428">
  <data key="d0">Oxybenzone</data>
  <data key="d1">drugbank.DB01428</data>
  <data key="d2">[drugbank.DB01428]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Benzene Derivatives, Benzhydryl Compounds, Compounds used in a research, industrial, or household setting, Cosmetics, Dermatologicals, Drugs that are Mainly Renally Excreted, Household Products, Ketones, Protective Agents, Radiation-Protective Agents, Sunscreening Agents]</data>
  <data key="d14">2-benzoyl-5-methoxyphenol</data>
  <data key="d15">C14H12O3</data>
  <data key="d16">131-57-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H12O3/c1-17-11-7-8-12(13(15)9-11)14(16)10-5-3-2-4-6-10/h2-9,15H,1H3</data>
  <data key="d20">COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1</data>
  <data key="d21">Used as an ingredient in sunscreen and other cosmetics.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-Benzoyl-5-methoxyphenol, 2-Hydroxy-4-methoxybenzophenone, 4-Methoxy-2-hydroxybenzophenone, Benzophenone-3, Oxibenzona, Oxybenzone, Oxybenzonum]</data>
  <data key="d9">Oxybenzone is an organic compound used in sunscreens. It is a derivative of benzophenone. It forms colorless crystals that are readily soluble in most organic solvents. It is used as an ingredient in sunscreen and other cosmetics because it absorbs UV-A ultraviolet rays.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01427">
  <data key="d0">Amrinone</data>
  <data key="d1">drugbank.DB01427</data>
  <data key="d2">[drugbank.DB01427]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amines, Aminopyridines, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Membrane Transport Modulators, Phosphodiesterase 3 Inhibitors, Phosphodiesterase Inhibitors, Protective Agents, Pyridines, Vasodilating Agents]</data>
  <data key="d14">3-amino-5-(pyridin-4-yl)-1,2-dihydropyridin-2-one</data>
  <data key="d15">C10H9N3O</data>
  <data key="d16">60719-84-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H9N3O/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7/h1-6H,11H2,(H,13,14)</data>
  <data key="d20">NC1=CC(=CNC1=O)C1=CC=NC=C1</data>
  <data key="d21">Used in the treatment of congestive heart failure.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Amrinona, Amrinone, Amrinonum, Inamrinone]</data>
  <data key="d9">Amrinone (or inamrinone) is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01426">
  <data key="d0">Ajmaline</data>
  <data key="d1">drugbank.DB01426</data>
  <data key="d2">[drugbank.DB01426]</data>
  <data key="d12">[approved, experimental]</data>
  <data key="d13">[Alkaloids, Antiarrhythmic agents, Antiarrhythmics, Class I, Antiarrhythmics, Class Ia, Antiarrhythmics, Class Ic, Cardiac Therapy, Cardiovascular Agents, Indole Alkaloids, Indoles, Membrane Transport Modulators, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Secologanin Tryptamine Alkaloids, Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers]</data>
  <data key="d14">(1R,9R,10S,12R,13S,14R,16S,18R)-13-ethyl-8-methyl-8,15-diazahexacyclo[14.2.1.0,.0,.0,.0,]nonadeca-2,4,6-triene-14,18-diol</data>
  <data key="d15">C20H26N2O2</data>
  <data key="d16">4360-12-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H26N2O2/c1-3-10-11-8-14-17-20(12-6-4-5-7-13(12)21(17)2)9-15(16(11)18(20)23)22(14)19(10)24/h4-7,10-11,14-19,23-24H,3,8-9H2,1-2H3/t10-,11-,14-,15-,16?,17-,18+,19+,20+/m0/s1</data>
  <data key="d20">CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)C5=CC=CC=C5[C@]44C[C@@H](C2[C@H]4O)N3[C@@H]1O</data>
  <data key="d21">For use as an antiarrhythmic agent.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+)-Ajmaline, (5aR, 6S, 8S, 10S, 11S, 11aS, 12aR, 13R)-5-methyl-5a, 6, 8, 9, 10, 11, 11a, 12-octahydro-5H-6, 10:11, 12a-dimethanoindolo[3, 2-b]quinolizine-8, 13-diol, Ajmalin, Ajmaline]</data>
  <data key="d9">An alkaloid found in the root of Rauwolfia serpentina, among other plant sources. It is a class Ia antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac action potentials. Ajmaline produces potent sodium channel blocking effects and a very short half-life which makes it a very useful drug for acute intravenous treatments. The drug has been very popular in some countries for the treatment of atrial fibrillation in patients with the WolffParkinsonWhite syndrome and in well tolerated monomorphic ventricular tachycardias. It has also been used for many years as a drug to challenge the conduction system of the heart in cases of bundle branch block and syncope. In these cases, abnormal prolongation of the HV interval has been taken as a proof for infrahisian conduction defects tributary for permanent pacemaker implantation.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14738">
  <data key="d0">Turoctocog alfa pegol</data>
  <data key="d1">drugbank.DB14738</data>
  <data key="d2">[drugbank.DB14738]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Biological Factors, Blood Coagulation Factors, Blood Proteins, Factor VIII, Hemostatics, Proteins, Recombinant Proteins]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">1309086-46-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Turoctocog alfa pegol (N8-GP) is indicated for use in adults and children of all ages with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis in reducing the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes, and the perioperative management of bleeding [F3649].</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[N8-GP, Turoctocog alfa pegol, Turoctocog alfa pegol, N8-GP]</data>
  <data key="d9">Turoctocog alfa pegol is a pegylated version of [turoctocog alfa]. Novo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February 19, 2019.\n\nFundamentally, the N8-GP moiety is identical to [turoctocog alfa], a recombinant human clotting factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of the naturally occurring B-domain [F3685]. Turoctocog alfa is produced in Chinese hamster ovary (CHO) cells without addition of any human or animal-derived materials [F3685]. During secretion, some rFVIII molecules are cleaved at the C-terminal of the heavy chain (HC) at amino acid 720, and a monoclonal antibody binding C-terminal to this position is used in the purification process allowing isolation of the intact rFVIII [A31504]. It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104].\n\nThe essential difference between turoctocog alfa and N8-GP, however, is the specific attachment of a 40-kDa polyethylene glycol (PEG) group to a specific _O_-glycan in the truncated B-domain of the general turoctocog alfa rFVIII structure [A31506, A32069]. This modification to the general turoctocog alfa rFVIII structure makes N8-GP an extended half-life factor VIII molecule for factor VIII replacement therapy in patients with factor VIII deficiency, or hemophilia A [F3649]. As such, turoctocog alfa pegol is a valuable expansion to the drug therapies available for treating hemophilia A as it ultimately provides a less burdensome and more convenient dosing regimen for patients that is less frequent than that for turoctocog alfa.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02757">
  <data key="d0">Pyrazole</data>
  <data key="d1">drugbank.DB02757</data>
  <data key="d2">[drugbank.DB02757, drugbank.EXPT02727]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Alcohol Dehydrogenase, antagonists &amp; inhibitors, Enzyme Inhibitors]</data>
  <data key="d14">1H-pyrazole</data>
  <data key="d15">C3H4N2</data>
  <data key="d16">288-13-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C3H4N2/c1-2-4-5-3-1/h1-3H,(H,4,5)</data>
  <data key="d20">N1C=CC=N1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1, 2-Diazole, 1H-Pyrazol, 1H-pyrazole]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00102">
  <data key="d0">Becaplermin</data>
  <data key="d1">drugbank.DB00102</data>
  <data key="d2">[drugbank.DB00102, drugbank.BTD00053, drugbank.BIOD00053]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Amino Acids, Peptides, and Proteins, Angiogenesis Inducing Agents, Angiogenesis Modulating Agents, Biological Factors, Blood Proteins, Cicatrizants, Dermatologicals, DNA-Binding Proteins, Growth Substances, Human Platelet-derived Growth Factor, Intercellular Signaling Peptides and Proteins, Neoplasm Proteins, Oncogene Proteins, Peptides, Platelet-Derived Growth Factor, Preparations for Treatment of Wounds and Ulcers, Proteins, Proto-Oncogene Proteins, Recombinant Proteins, Stomatological Preparations]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">165101-51-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">For topical treatment of skin ulcers (from diabetes)</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;6d66f976-9d2b-4c6a-addb-621d0a04b7ce DB00102 sequence\nSLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSGCCNNRNVQCRPTQVQLRPVQVRKIEIVRKKPIFKKATVTLEDHLACKCETVAAARPVT]</data>
  <data key="d8">[Becaplermin, PDGF-2, PDGF-BB, PDGFB, Platelet-derived growth factor BB, recombinant, Platelet-derived growth factor beta polypeptide, Recombinant platelet-derived growth factor BB, rhPDGF-BB, rPDGF-BB, SH-POLYPEPTIDE-59]</data>
  <data key="d9">Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00100">
  <data key="d0">Coagulation Factor IX (Recombinant)</data>
  <data key="d1">drugbank.DB00100</data>
  <data key="d2">[drugbank.DB00100, drugbank.BTD00038, drugbank.BIOD00038]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Blood Coagulation Factors, Hemostatics, Increased Coagulation Activity]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">181054-95-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">For treatment of hemophilia (Christmas disease).</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;75074f6d-5d69-40f3-b8f6-71bd9fba9a5f DB00100 sequence\nYNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAEAVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT]</data>
  <data key="d8">[Coagulation factor IX (recombinant), Coagulation factor IX recombinant human, Factor IX (Recombinant), nonacog alfa, nonacog gamma, Recombinant factor IX]</data>
  <data key="d9">Recombinant Coagulation Factor IX is a purified Factor IX glycoprotein produced by recombinant DNA technology. It has a primary amino acid sequence that is identical to the Ala148 allelic form of human factor IX, and has structural and functional characteristics similar to those of endogenous factor IX. It is not derived from human blood (unlike human Factor IX complex), and is instead produced by a genetically engineered Chinese hamster ovary (CHO) cell line that secretes recombinant Factor IX into cell medium that is then processed and purified for use as a pharmaceutical agent. \n\nRecombinant Factor IX is indicated for the control and prevention of bleeding episodes in adult and pediatric patients with congenital factor IX deficiency (Hemophilia B).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01431">
  <data key="d0">Allylestrenol</data>
  <data key="d1">drugbank.DB01431</data>
  <data key="d2">[drugbank.DB01431]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Adrenal Cortex Hormones, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Drugs that are Mainly Renally Excreted, Estranes, Estren Derivatives, Estrenes, Genito Urinary System and Sex Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Progestins, Sex Hormones and Modulators of the Genital System, Steroids]</data>
  <data key="d14">(1S,2R,10R,11S,14R,15S)-15-methyl-14-(prop-2-en-1-yl)tetracyclo[8.7.0.0,.0,]heptadec-6-en-14-ol</data>
  <data key="d15">C21H32O</data>
  <data key="d16">432-60-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]</data>
  <data key="d21">Allylestrenol was designed to be used for miscarriage prevention, prevention of premature labour and has been investigated for possible use in men for treatment for benign prostatic hyperplasia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[17-allylestr-4-en-17-ol, 3-deketo-17-allyl-19-nortestosterone, Alilestrenol, Allilestrenolo, Allyl estrenol, Allylestrenol, Allylestrenolum, Allyloestrenol]</data>
  <data key="d9">A synthetic steroid with progestational activity. It is widely marketed throughout Europe, including Russia and many other European countries, and is also available in Japan, Hong Kong, India, Bangladesh, Indonesia, and much of Southeast Asia, though notably not in the United States or Canada.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00116">
  <data key="d0">Tetrahydrofolic acid</data>
  <data key="d1">drugbank.DB00116</data>
  <data key="d2">[drugbank.DB00116, drugbank.NUTR00056]</data>
  <data key="d12">[nutraceutical]</data>
  <data key="d13">[Biological Factors, Coenzymes, Dietary Supplements, Enzymes and Coenzymes, Folic Acid, Folic Acid and Derivatives, Pigments, Biological, Pteridines, Pterins, Supplements, Vitamin B Complex, Vitamins]</data>
  <data key="d14">(2S)-2-[(4-{[(2-amino-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid</data>
  <data key="d15">C19H23N7O6</data>
  <data key="d16">135-16-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H23N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,11-12,21,23H,5-8H2,(H,24,29)(H,27,28)(H,31,32)(H4,20,22,25,26,30)/t11?,12-/m0/s1</data>
  <data key="d20">NC1=NC(=O)C2=C(NCC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2)N1</data>
  <data key="d21">For nutritional supplementation, also for treating dietary shortage or imbalance.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[5, 6, 7, 8-tetrahydrofolate, 5, 6, 7, 8-tetrahydrofolic acid, Tetrahydrofolate]</data>
  <data key="d9">Tetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase. It is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00115">
  <data key="d0">Cyanocobalamin</data>
  <data key="d1">drugbank.DB00115</data>
  <data key="d2">[drugbank.DB00115, drugbank.NUTR00004, drugbank.APRD00326, drugbank.EXPT00965]</data>
  <data key="d12">[approved, nutraceutical]</data>
  <data key="d13">[Antianemic Preparations, Blood and Blood Forming Organs, Corrinoids, Diet, Food, and Nutrition, Drugs that are Mainly Renally Excreted, Food, Food and Beverages, Growth Substances, Iron Preparations, Micronutrients, Vitamin B Complex, VITAMIN B12 AND FOLIC ACID, Vitamins]</data>
  <data key="d14">(10S,12R,13S,17R,23R,24R,25R,30S,35S,36S,40S,41S,42R,46R)-30,35,40-tris(2-carbamoylethyl)-24,36,41-tris(carbamoylmethyl)-1-cyano-46-hydroxy-12-(hydroxymethyl)-5,6,17,23,28,31,31,36,38,41,42-undecamethyl-15,20-dioxo-11,14,16-trioxa-2,9,19,26,43,44,45-heptaaza-15-phospha-1-cobaltadodecacyclo[27.14.1.1,.1,.1,.0,.0,.0,.0,.0,.0,.0,]heptatetraconta-2(47),3,5,7,27,29(44),32,34(45),37,39(43)-decaene-2,43,44,45-tetrakis(ylium)-1,1,1-triuid-15-olate</data>
  <data key="d15">C63H88CoN14O14P</data>
  <data key="d16">68-19-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C62H90N13O14P.CN.Co/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;1-2;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;/q;;+2/p-2/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;;/m1../s1</data>
  <data key="d20">[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO</data>
  <data key="d21">**Nasal spray**\n\nThe cyanocobalamin nasal spray is indicated for the maintenance of vitamin B12 concentrations after normalization with intramuscular vitamin B12 therapy in patients with deficiency of this vitamin who have no nervous system involvement [FDA label].\n\nNote:  CaloMist [FDA label], the nasal spray form, has not been evaluated for the treatment of newly diagnosed vitamin B12 deficiency.\n\n**Injection forms (subcutaneous, intramuscular)**\n\nThese forms are indicated for vitamin B12 deficiencies due to various causes, with or without neurologic manifestations [F3736].  Vitamin B12 deficiency is frequently caused by malabsorption, which is often associated with the following conditions [L5545]:\n\nAddisonian (pernicious) anemia\n\nGastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacterial overgrowth, total or partial gastrectomy\n\nFish tapeworm infestation\n\nMalignancy of the pancreas or bowel\n\nFolic acid deficiency\n\n\n**Oral forms**\n\nVitamin B12 supplements are widely available and indicated in patients who require supplementation for various reasons.  Dose requirements for vitamin B12 which are higher than normal (caused by pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be achieved with oral supplementation [L5545].   Oral products of vitamin B12 are not recommended in patients with malabsorption, as these forms are primarily absorbed in the gastrointestinal tract [F3739].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Cianocobalamina, Cyanocob(III)alamin, Cyanocobalamin, Vitamin B12, Vitamin B12 complex, Vitamin B12 NOS]</data>
  <data key="d9">Cyanocobalamin (commonly known as Vitamin B12) is a highly complex, essential vitamin, owing its name to the fact that it contains the mineral, cobalt. This vitamin is produced naturally by bacteria [A175276], and is necessary for DNA synthesis and cellular energy production. Vitamin B12 has many forms, including the cyano-, methyl-, deoxyadenosyl- and hydroxy-cobalamin forms. The _cyano_ form, is the most widely used form in supplements and prescription drugs [A175255], [FDA label].  Several pharmaceutical forms of cyanocobalamin have been developed, including the tablet, injection, and nasal spray forms [FDA label], [L5542], [L5545].  This drug was initially approved by the FDA in 1942 [FDA label].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00112">
  <data key="d0">Bevacizumab</data>
  <data key="d1">drugbank.DB00112</data>
  <data key="d2">[drugbank.DB00112, drugbank.BTD00087, drugbank.BIOD00087]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Angiogenesis Inhibitors, Angiogenesis Modulating Agents, Antibodies, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Blood Proteins, Cardiotoxic antineoplastic agents, Globulins, Growth Inhibitors, Growth Substances, Immunoglobulins, Immunoproteins, Immunosuppressive Agents, Myelosuppressive Agents, Proteins, Serum Globulins, Vascular Endothelial Growth Factor Inhibitor, Vascular Endothelial Growth Factor Inhibitors, Vascular Endothelial Growth Factor-directed Antibody Interactions]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">216974-75-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">As part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;278ad4ef-75d7-4c4c-b10d-c34c97226f94 "Bevacizumab light chain"\nDIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC, &gt;f01fbe05-f6ad-4e15-a0ba-3d7c3c22f0bc "Bevacizumab heavy chain"\nEVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK]</data>
  <data key="d8">[Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF monoclonal antibody, Bevacizumab, bevacizumab-awwb, rhuMAb-VEGF]</data>
  <data key="d9">A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01442">
  <data key="d0">MMDA</data>
  <data key="d1">drugbank.DB01442</data>
  <data key="d2">[drugbank.DB01442]</data>
  <data key="d12">[experimental, illicit]</data>
  <data key="d13">[Agents producing tachycardia, Agents that produce hypertension, Amines, Amphetamines, Antidepressive Agents, Central Nervous System Depressants, Ethylamines, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Phenethylamines, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Agonists, Serotonin Agents, Serotonin Receptor Agonists, Sympathomimetics]</data>
  <data key="d14">1-(7-methoxy-2H-1,3-benzodioxol-5-yl)propan-2-amine</data>
  <data key="d15">C11H15NO3</data>
  <data key="d16">13674-05-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H15NO3/c1-7(12)3-8-4-9(13-2)11-10(5-8)14-6-15-11/h4-5,7H,3,6,12H2,1-2H3</data>
  <data key="d20">COC1=CC(CC(C)N)=CC2=C1OCO2</data>
  <data key="d21">MMDA is a recreational drug. It has no current medical uses and is a Schedule I controlled substance in the USA at present.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+-)-MMDA, 3-Methoxy-4, 5-methylenedioxyphenylisopropylamine, 3-Methoxy-alpha-methyl-4, 5-methylenedioxyphenethylamine, 3-methoxy-methylenedioxyamphetamine, 5-Methoxy-3, 4-methylenedioxyamphetamine]</data>
  <data key="d9">MMDA, or 3-methoxy-4,5-methylenedioxyamphetamine, is a member of the amphetamine drug class with stimulant and psychedelic properties. It also acts as an entheogen and an entactogen. MMDA bears resemblance to the psychopharmacologically active essential oils elemicin and myristicin found in nutmeg. The effects of MMDA includes feelings of euphoria and warmth, as well as realistic closed-eye visuals.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14751">
  <data key="d0">Mecasermin rinfabate</data>
  <data key="d1">drugbank.DB14751</data>
  <data key="d2">[drugbank.DB14751]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Anterior Pituitary Lobe Hormones and Analogues, Pituitary and Hypothalamic Hormones and Analogues, Somatropin and Somatropin Agonists, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">478166-15-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Mecasermin rinfabate was approved for treatment of severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH)[A176020].\nSevere primary IGF-1 deficiency is defined by:[FDA Label]\n\nA) height standard deviation (SD) score less than or equal to 3 SD below normal\n\nB) basal IGF-1 SD score less than or equal to 3 SD below normal\n\nC) normal or above normal levels of growth hormone\n\nIn 2007, Insmed (Mecasermin rinfabate's manufacturer) made an agreement with Tercica (Mecasermin's manufacturer) that Mecasermin would no longer be available for this indication but could be developed for non short stature conditions such as severe insulin resistance, myotonic muscular dystrophy, and HIV associated adipose redistribution syndrome[A176125].</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Mecasermin rinfabate, Mecasermin rinfabate recombinant, rhIGF-I/rhIGFBP-3]</data>
  <data key="d9">Mecasermin rinfabate is approved for severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH)[A176020]. Mecasermin rinfabate is similar to [DB01277] in that both drugs contain recombinant DNA origin insulin-like growth factor 1 (IGF-1). Mecasermin rinfabate however, is already bound to recombinant DNA origin insulin-like growth factor binding protein 3 (IGFBP-3)[A12605]. The binding of IGF-1 to IGFBP-3 is said to extend the half life and reduce the clearance of IGF-1 in patients with growth hormone resistant syndromes and low levels of IGFBP-3 though this may represent &lt;500 patients worldwide[A176065].\n\nMecasermin rinfabate manufactured by Insmed Incorporated under the brand name Iplex was approved by the FDA in 2005[L5722]. In 2007 Insmed withdrew their application for a marketing authorization with The European Medicines Agency[F4075].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00125">
  <data key="d0">L-Arginine</data>
  <data key="d1">drugbank.DB00125</data>
  <data key="d2">[drugbank.DB00125, drugbank.NUTR00014]</data>
  <data key="d12">[approved, nutraceutical]</data>
  <data key="d13">[Amino Acids, Amino Acids, Basic, Amino Acids, Diamino, Amino Acids, Essential, Amino Acids, Peptides, and Proteins, Blood and Blood Forming Organs, Blood Substitutes and Perfusion Solutions, Dietary Supplements, I.V. Solution Additives, Pituitary Function, Supplements]</data>
  <data key="d14">(2S)-2-amino-5-carbamimidamidopentanoic acid</data>
  <data key="d15">C6H14N4O2</data>
  <data key="d16">74-79-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1</data>
  <data key="d20">N[C@@H](CCCNC(N)=N)C(O)=O</data>
  <data key="d21">Used for nutritional supplementation, also for treating dietary shortage or imbalance.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(2S)-2-amino-5-(carbamimidamido)pentanoic acid, (2S)-2-amino-5-guanidinopentanoic acid, (S)-2-amino-5-guanidinopentanoic acid, (S)-2-Amino-5-guanidinovaleric acid, Arg, Arginina, Arginine, L-(+)-Arginine, L-Arg, L-Arginin, R]</data>
  <data key="d9">An essential amino acid that is physiologically active in the L-form.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00122">
  <data key="d0">Choline</data>
  <data key="d1">drugbank.DB00122</data>
  <data key="d2">[drugbank.DB00122, drugbank.NUTR00020]</data>
  <data key="d12">[approved, nutraceutical]</data>
  <data key="d13">[Alcohols, Amines, Amino Alcohols, Ammonium Compounds, Analgesics, Antimetabolites, Central Nervous System Agents, Dietary Supplements, Ethanolamines, Gastrointestinal Agents, Hypolipidemic Agents, Lipid Regulating Agents, Lipotropic Agents, Nervous System, Nitrogen Compounds, Nootropic Agents, Noxae, OCT1 inhibitors, OCT1 substrates, OCT2 Inhibitors, OCT2 Substrates, OCT2 substrates with narrow therapeutic index, Onium Compounds, Other Nutritional Agents, Quaternary Ammonium Compounds, Salicylic Acid and Derivatives, Supplements, Toxic Actions, Trimethyl Ammonium Compounds, Vitamin B Complex, Vitamins]</data>
  <data key="d14">(2-hydroxyethyl)trimethylazanium</data>
  <data key="d15">C5H14NO</data>
  <data key="d16">62-49-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C5H14NO/c1-6(2,3)4-5-7/h7H,4-5H2,1-3H3/q+1</data>
  <data key="d20">C[N+](C)(C)CCO</data>
  <data key="d21">For nutritional supplementation, also for treating dietary shortage or imbalance</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Bilineurine, Choline ion, N-trimethylethanolamine, N, N, N-trimethylethanol-ammonium, trimethylethanolamine, Vitamin J]</data>
  <data key="d9">A basic constituent of lecithin that is found in many plants and animal organs. It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00121">
  <data key="d0">Biotin</data>
  <data key="d1">drugbank.DB00121</data>
  <data key="d2">[drugbank.DB00121, drugbank.NUTR00019]</data>
  <data key="d12">[approved, investigational, nutraceutical]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Coenzymes, Diet, Food, and Nutrition, Dietary Supplements, Enzymes and Coenzymes, Food, Food and Beverages, Growth Substances, Imidazoles, Micronutrients, Physiological Phenomena, Supplements, Vitamin B Complex, Vitamins]</data>
  <data key="d14">5-[(3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4-d]imidazolidin-4-yl]pentanoic acid</data>
  <data key="d15">C10H16N2O3S</data>
  <data key="d16">58-85-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H16N2O3S/c13-8(14)4-2-1-3-7-9-6(5-16-7)11-10(15)12-9/h6-7,9H,1-5H2,(H,13,14)(H2,11,12,15)/t6-,7-,9-/m0/s1</data>
  <data key="d20">[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2</data>
  <data key="d21">For nutritional supplementation, also for treating dietary shortage or imbalance.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+)-cis-Hexahydro-2-oxo-1H-thieno[3, 4]imidazole-4-valeric acid, (3aS, 4S, 6aR)-Hexahydro-2-oxo-1H-thieno[3, 4-d]imidazole-4-valeric acid, 5-(2-oxohexahydro-1H-thieno[3, 4-d]imidazol-4-yl)pentanoic acid, Biotin, Biotina, Biotine, Biotinum, cis-(+)-Tetrahydro-2-oxothieno[3, 4]imidazoline-4-valeric acid, cis-Hexahydro-2-oxo-1H-thieno(3, 4)imidazole-4-valeric acid, cis-Tetrahydro-2-oxothieno(3, 4-d)imidazoline-4-valeric acid, Coenzyme R, D-(+)-biotin, D-Biotin, Vitamin B7, Vitamin H]</data>
  <data key="d9">A water-soluble, enzyme co-factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02845">
  <data key="d0">Methylphosphinic Acid</data>
  <data key="d1">drugbank.DB02845</data>
  <data key="d2">[drugbank.DB02845, drugbank.EXPT02226, drugbank.DB04390]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Acids, Acids, Noncarboxylic, Organophosphorus Compounds, Phosphorus Acids, Phosphorus Compounds]</data>
  <data key="d14">methylphosphinic acid</data>
  <data key="d15">CH5O2P</data>
  <data key="d16">4206-94-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/CH5O2P/c1-4(2)3/h4H,1H3,(H,2,3)</data>
  <data key="d20">CP(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01524">
  <data key="d0">Androstenediol</data>
  <data key="d1">drugbank.DB01524</data>
  <data key="d2">[drugbank.DB01524]</data>
  <data key="d12">[experimental, illicit]</data>
  <data key="d13">[Anabolic Agents, Androstanes, Androstenediols, Androstenes, Androstenols, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Steroids, Testosterone Congeners]</data>
  <data key="d14">(1S,2R,5S,10R,11S,14S,15S)-2,15-dimethyltetracyclo[8.7.0.0,.0,]heptadec-7-ene-5,14-diol</data>
  <data key="d15">C19H30O2</data>
  <data key="d16">521-17-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-17,20-21H,4-11H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[5-andendiol, 5-androstenediol, androst-5-ene-3beta, 17beta-diol, androst-5-enediol, Androstenediol, hermaphrodiol]</data>
  <data key="d9">Androstenediol is an intermediate in [testosterone] biosynthesis, found in the testis or the adrenal glands. Androstenediol, derived from dehydroepiandrosterone by the reduction of the 17-keto group (17-hydroxysteroid dehydrogenases), is converted to testosterone by the oxidation of the 3-beta hydroxyl group to a 3-keto group (3-hydroxysteroid dehydrogenases).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13503">
  <data key="d0">Tyrothricin</data>
  <data key="d1">drugbank.DB13503</data>
  <data key="d2">[drugbank.DB13503]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Anti-Bacterial Agents, Anti-Infective Agents, Anti-Infective Agents, Local, Antibiotics for Topical Use, Cholinesterase Inhibitors, Dermatologicals, Ophthalmologicals, Peptides, Peptides, Cyclic, Sensory Organs, Throat Preparations]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">1404-88-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Tyrothricin is used as an over the counter topical antibiotic.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Bactratycin, Hydrotricine, Tirotricina, Tyrothricin, Tyrothricine, Tyrothricinum]</data>
  <data key="d9">Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus brevis and Bacillus aneurinolyticus [A36353]. This complex is a mixture comprised of 60% tyrocidine cationic cyclic decapeptides (consisting largely of the six predominant tyrocidines, TrcA/A1, TrcB/B1, TrcC/C1, and other more minor contributors) and 40% neutral linear gramicidins (where valine-gramicidin A is often the major gramicidin present, although the mixture composition can vary) [L4019, L4021, L4022]. Moreover, tyrothricin possesses broad spectrum Gram-positive antibacterial and antifungal activity that has not seen many - if any - significant reportings of microbial resistance during the over 60 years of therapeutic use the complex has provided [A36360]. Nevertheless, as tyrothricin is both cytolytic and hemolytic, it does demonstrate systemic toxicity [L4019, L4021, L4022], although certain formulations that are safe for human use like throat lozenges do exist [L4028].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00208">
  <data key="d0">Ticlopidine</data>
  <data key="d1">drugbank.DB00208</data>
  <data key="d2">[drugbank.DB00208, drugbank.APRD01257]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Antiplatelet agents, Blood and Blood Forming Organs, Cardiovascular Agents, Chemically-Induced Disorders, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strong), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (weak), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (weak), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Decreased Platelet Aggregation, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Fibrin Modulating Agents, Hematologic Agents, Neurotransmitter Agents, Platelet Aggregation Inhibitors Excl. Heparin, Purinergic Agents, Purinergic Antagonists, Purinergic P2 Receptor Antagonists, Purinergic P2Y Receptor Antagonists, Pyridines, Sulfur Compounds, Thienopyridines, Thiophenes]</data>
  <data key="d14">5-[(2-chlorophenyl)methyl]-4H,5H,6H,7H-thieno[3,2-c]pyridine</data>
  <data key="d15">C14H14ClNS</data>
  <data key="d16">55142-85-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2</data>
  <data key="d20">ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2</data>
  <data key="d21">Used in patients, who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked, to try to prevent another thrombotic stroke.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Ticlopidina, Ticlopidine, Ticlopidinum]</data>
  <data key="d9">Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00201">
  <data key="d0">Caffeine</data>
  <data key="d1">drugbank.DB00201</data>
  <data key="d2">[drugbank.DB00201, drugbank.APRD00673]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acids, Acyclic, Alkaloids, Anorexigenic Agents &amp; Respiratory and CNS Stimulants, Apnea, Caffeine and Caffeine Containing Products, Central Nervous System Agents, Central Nervous System Stimulants, Central Nervous System Stimulation, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (moderate), Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Diagnostic Agents, Drugs for Obstructive Airway Diseases, Enzyme Inhibitors, Nervous System, Neurotransmitter Agents, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Phosphodiesterase Inhibitors, Psychoanaleptics, Psychostimulants, Agents Used for Adhd and Nootropics, Purinergic Agents, Purinergic Antagonists, Purinergic P1 Receptor Antagonists, Purines, Purinones, Respiratory and CNS Stimulants, Tests for Gastric Secretion, Tricarboxylic Acids, Xanthine derivatives]</data>
  <data key="d14">1,3,7-trimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione</data>
  <data key="d15">C8H10N4O2</data>
  <data key="d16">58-08-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3</data>
  <data key="d20">CN1C=NC2=C1C(=O)N(C)C(=O)N2C</data>
  <data key="d21">For management of fatigue, orthostatic hypotension, and for the short term treatment of apnea of prematurity in infants.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-methyltheobromine, 1, 3, 7-trimethyl-2, 6-dioxopurine, 1, 3, 7-trimethylpurine-2, 6-dione, 1, 3, 7-trimethylxanthine, 3, 7-Dihydro-1, 3, 7-trimethyl-1H-purin-2, 6-dion, 7-methyltheophylline, Anhydrous caffeine, Cafena, Cafine, Caffeinum, Coffein, Coffeinum, Guaranine, Koffein, Matena, Methyltheobromine, Tena, Thein, Theine]</data>
  <data key="d9">A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes smooth muscle, stimulates cardiac muscle, stimulates diuresis, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide phosphodiesterases, antagonism of adenosine receptors, and modulation of intracellular calcium handling.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02868">
  <data key="d0">3''-(Beta-Chloroethyl)-2'',4''-Dioxo-3, 5''-Spiro-Oxazolidino-4-Deacetoxy-Vinblastine</data>
  <data key="d1">drugbank.DB02868</data>
  <data key="d2">[drugbank.DB02868, drugbank.EXPT01963]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">methyl (13S,15R,17S)-13-[(1'R,2R,9'R,12'R,19'S)-4-(2-chloroethyl)-12'-ethyl-5'-methoxy-8'-methyl-3,5-dioxo-8',16'-diazaspiro[1,4-oxazolidine-2,10'-pentacyclo[10.6.1.0,.0,.0,]nonadecane]-2',4',6',13'-tetraen-4'-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.0,.0,]nonadeca-4(12),5,7,9-tetraene-13-carboxylate</data>
  <data key="d15">C46H56ClN5O7</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C46H56ClN5O7/c1-6-42-14-10-17-51-19-15-44(37(42)51)31-21-32(35(57-4)22-34(31)49(3)38(44)46(26-42)39(53)52(20-16-47)41(55)59-46)45(40(54)58-5)24-28-23-43(56,7-2)27-50(25-28)18-13-30-29-11-8-9-12-33(29)48-36(30)45/h8-12,14,21-22,28,37-38,48,56H,6-7,13,15-20,23-27H2,1-5H3/t28-,37-,38+,42-,43-,44+,45-,46+/m0/s1</data>
  <data key="d20">[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)(C[C@@]22OC(=O)N(CCCl)C2=O)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02811">
  <data key="d0">Diethylphosphono Group</data>
  <data key="d1">drugbank.DB02811</data>
  <data key="d2">[drugbank.DB02811, drugbank.EXPT01161]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">diethyl phosphonate</data>
  <data key="d15">C4H11O3P</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C4H11O3P/c1-3-6-8(5)7-4-2/h8H,3-4H2,1-2H3</data>
  <data key="d20">CCOP(=O)OCC</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02825">
  <data key="d0">Methylphosphonic Acid Ester Group</data>
  <data key="d1">drugbank.DB02825</data>
  <data key="d2">[drugbank.DB02825, drugbank.EXPT03237]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">methylphosphinate</data>
  <data key="d15">CH4O2P</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/CH5O2P/c1-4(2)3/h4H,1H3,(H,2,3)/p-1</data>
  <data key="d20">CP([O-])=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12285">
  <data key="d0">Verubecestat</data>
  <data key="d1">drugbank.DB12285</data>
  <data key="d2">[drugbank.DB12285, drugbank.DB08929]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">N-{3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-5,6-dihydro-2H-1lambda6,2,4-thiadiazin-5-yl]-4-fluorophenyl}-5-fluoropyridine-2-carboxamide</data>
  <data key="d15">C17H17F2N5O3S</data>
  <data key="d16">1286770-55-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H17F2N5O3S/c1-17(9-28(26,27)24(2)16(20)23-17)12-7-11(4-5-13(12)19)22-15(25)14-6-3-10(18)8-21-14/h3-8H,9H2,1-2H3,(H2,20,23)(H,22,25)/t17-/m0/s1</data>
  <data key="d20">CN1C(N)=N[C@@](C)(CS1(=O)=O)C1=CC(NC(=O)C2=CC=C(F)C=N2)=CC=C1F</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Verubecestat is under investigation for the treatment of Alzheimer's Disease, Prodromal Alzheimer's disease, and Amnestic Mild Cognitive Impairment. \n\nVerubecestat is Mercks investigational oral -site amyloid precursor protein cleaving enzyme (BACE1 or  secretase) inhibitor. In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat. In the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of 57, 79 and 84 percent, respectively.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00297">
  <data key="d0">Bupivacaine</data>
  <data key="d1">drugbank.DB00297</data>
  <data key="d2">[drugbank.DB00297, drugbank.APRD00247]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents that reduce seizure threshold, Amide Local Anesthetic, Amides, Anesthetics, Anesthetics, Local, Anilides, Central Nervous System Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Hypotensive Agents, Local Anesthesia, Nervous System, Neuraxial Anesthetics, Peripheral Nervous System Agents, Pipecolic Acids, Piperidines, Sensory System Agents]</data>
  <data key="d14">1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide</data>
  <data key="d15">C18H28N2O</data>
  <data key="d16">38396-39-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)</data>
  <data key="d20">CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C</data>
  <data key="d21">For the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-bupivacaine, (RS)-bupivacaine, 1-Butyl-2', 6'-pipecoloxylidide, 1-Butyl-N-(2, 6-dimethylphenyl)-2-piperidinecarboxamide, Bupivacaina, Bupivacaine, Bupivacainum, dl-1-Butyl-2', 6'-pipecoloxylidide, DL-Bupivacaine, racemic bupivacaine]</data>
  <data key="d9">A widely used local anesthetic agent. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00257">
  <data key="d0">Clotrimazole</data>
  <data key="d1">drugbank.DB00257</data>
  <data key="d2">[drugbank.DB00257, drugbank.APRD00244]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Anti-Infective Agents, Anti-Infective Agents, Local, Antifungal Agents, Antifungal Agents (Vaginal), Antifungals for Dermatological Use, Antifungals for Topical Use, Antiinfectives and Antiseptics for Local Oral Treatment, Azole Antifungals, BSEP/ABCB11 Inhibitors, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strong), Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strong), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors (strong), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (moderate), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inhibitors (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A7 Inducers, Cytochrome P-450 CYP3A7 Inducers (strong), Cytochrome P-450 CYP3A7 Inducers (weak), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Enzyme Inhibitors, Gynecological Antiinfectives and Antiseptics, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Imidazole and Triazole Derivatives, Imidazole Derivatives, Imidazoles, OATP1B1/SLCO1B1 Inhibitors, OATP1B1/SLCO1B1 Substrates, OATP1B3 inducers, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Steroid Synthesis Inhibitors, Stomatological Preparations]</data>
  <data key="d14">1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole</data>
  <data key="d15">C22H17ClN2</data>
  <data key="d16">23593-75-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H</data>
  <data key="d20">ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d21">**Topical preparations**\n\nClotrimazole topical cream is indicated for the topical treatment of the following dermal infections [F3088], [F3121]:\n\nTinea pedis, tinea cruris, and tinea corporis due to _Trichophyton rubrum_, _Trichophyton mentagrophytes_, _Epidermophyton floccosum_\n\nCandidiasis due to _Candida albicans_\n\nTinea versicolor due to _Malassezia furfur_\n\nDiaper rash infected by _Candida albicans_\n\n\nIn some preparations, clotrimazole may be combined with betamethasone dipropionate, a corticosteroid [F3121]. \n\n**Oral preparations**\n\nThe oral troche preparation is indicated for the local treatment of oropharyngeal candidiasis [FDA label].  It is also indicated as a prophylactic drug to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions such as chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation [FDA label]. Troche preparations are not indicated for the treatment of any systemic mycoses [FDA label].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole, 1-(o-Chloro-, -diphenylbenzyl)imidazole, 1-(o-Chlorotrityl)imidazole, 1-(-(2-Chlorophenyl)benzhydryl)imidazole, Clotrimazol, Clotrimazole, Clotrimazolum]</data>
  <data key="d9">This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s [A174094]. Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity [A174094].  It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets).  As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers [A174094].  The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot [A174097].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00255">
  <data key="d0">Diethylstilbestrol</data>
  <data key="d1">drugbank.DB00255</data>
  <data key="d2">[drugbank.DB00255, drugbank.APRD00920, drugbank.EXPT01164]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Adrenal Cortex Hormones, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, Benzene Derivatives, Benzylidene Compounds, BSEP/ABCB11 Substrates, Carcinogens, COMT Substrates, Contraceptive Agents, Female, Contraceptive Agents, Male, Contraceptives, Postcoital, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strong), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Endocrine Therapy, Estrogen Contraceptives, Estrogens, Estrogens, Non-Steroidal, Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, Noxae, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Sex Hormones and Modulators of the Genital System, Stilbenes, Synthetic Estrogens, Plain, Toxic Actions]</data>
  <data key="d14">4-[(3E)-4-(4-hydroxyphenyl)hex-3-en-3-yl]phenol</data>
  <data key="d15">C18H20O2</data>
  <data key="d16">56-53-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,19-20H,3-4H2,1-2H3/b18-17+</data>
  <data key="d20">CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1</data>
  <data key="d21">Used in the treatment of prostate cancer. Previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(E)-3, 4-bis(4-hydroxyphenyl)-3-hexene, (E)-4, 4'-(1, 2-diethyl-1, 2-ethenediyl)bisphenol, 4, 4'-dihydroxy-, -diethylstilbene, DES, Diethylstilbestrol, Dithylstilbestrol, Diethylstilbestrolum, Dietilestilbestrol, Stilboestrol, trans-4, 4'-(1, 2-diethyl-1, 2-ethenediyl)bisphenol, trans-Diethylstilbesterol, trans-Diethylstilbestrol, trans-Diethylstilboesterol, , '-diethyl-(E)-4, 4'-stilbenediol]</data>
  <data key="d9">A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01593">
  <data key="d0">Zinc</data>
  <data key="d1">drugbank.DB01593</data>
  <data key="d2">[drugbank.DB01593]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Copper Absorption Inhibitor, Diet, Food, and Nutrition, Elements, Food, Food and Beverages, Growth Substances, Laxatives, Metal cations, Metal divalent cations, Metals, Metals, Heavy, Micronutrients, Minerals, Osmotic Laxative, Physiological Phenomena, Replacement Preparations, Trace Elements, Transition Elements, Vasoprotectives, Zinc Compounds]</data>
  <data key="d14">zinc</data>
  <data key="d15">Zn</data>
  <data key="d16">7440-66-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/Zn</data>
  <data key="d20">[Zn]</data>
  <data key="d21">Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Zinc, chelated, Zinc, elemental, Zincum metallicum, Zn]</data>
  <data key="d9">A metallic element of atomic number 30 and atomic weight 65.38. It is a necessary trace element in the diet, forming an essential part of many enzymes, and playing an important role in protein synthesis and in cell division. Zinc deficiency is associated with anemia, short stature, hypogonadism, impaired wound healing, and geophagia. It is identified by the symbol _Zn_ [L2098].\n\nA newer study suggests implies that an imbalance of zinc is associated with the neuronal damage associated with traumatic brain injury, stroke, and seizures [A32465].\n\n Understanding the mechanisms that control brain zinc homeostasis is, therefore, imperative to the development of preventive and treatment regimens for these and other neurological disorders [A32465].\n\nIn addition to the above, recent review articles have already demonstrated the important role of zinc in the pathophysiology and treatment of affective disorders, plus discussed the potential value of zinc as a marker of these diseases [L2097].  Most recently, research has shown that polymorphism of the common polymorphism in zinc transporter _SLC30A8/ZnT8_ may increase susceptibility to type 2 diabetes provided novel insights into the role of zinc in diabetes [A32416].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01592">
  <data key="d0">Iron</data>
  <data key="d1">drugbank.DB01592</data>
  <data key="d2">[drugbank.DB01592]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Antianemic Preparations, Blood and Blood Forming Organs, Diet, Food, and Nutrition, Elements, Food, Food and Beverages, Growth Substances, Iron Compounds, Iron Preparations, Metals, Metals, Heavy, Micronutrients, Minerals, Organometallic Compounds, Physiological Phenomena, Supplements, Trace Elements, Transition Elements]</data>
  <data key="d14">iron</data>
  <data key="d15">Fe</data>
  <data key="d16">7439-89-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/Fe</data>
  <data key="d20">[Fe]</data>
  <data key="d21">Used in preventing and treating iron-deficiency anemia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Carbonyl iron, Eisen, Electrolytic iron, Fe, fer, Ferrum, Ferrum metallicum, Hierro, Iron powder, Iron, carbonyl, Iron, electrolytic, Iron, elemental, Iron, reduced, Reduced iron]</data>
  <data key="d9">A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12250">
  <data key="d0">Cixutumumab</data>
  <data key="d1">drugbank.DB12250</data>
  <data key="d2">[drugbank.DB12250, drugbank.DB05759]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Antibodies, Blood Proteins, Globulins, Immunoglobulins, Immunoproteins, Proteins, Radiation-Sensitizing Agents, Receptor, IGF Type 1, Serum Globulins]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">947687-12-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21"></data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate.\n\nCixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00269">
  <data key="d0">Chlorotrianisene</data>
  <data key="d1">drugbank.DB00269</data>
  <data key="d2">[drugbank.DB00269, drugbank.APRD00715]</data>
  <data key="d12">[investigational, withdrawn]</data>
  <data key="d13">[Antineoplastic Agents, Antineoplastic Agents, Hormonal, Benzene Derivatives, Benzylidene Compounds, Estrogens, Estrogens, Non-Steroidal, Genito Urinary System and Sex Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Natural and Semisynthetic Estrogens, Plain, Sex Hormones and Modulators of the Genital System, Stilbenes]</data>
  <data key="d14">1-[1-chloro-2,2-bis(4-methoxyphenyl)ethenyl]-4-methoxybenzene</data>
  <data key="d15">C23H21ClO3</data>
  <data key="d16">569-57-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H21ClO3/c1-25-19-10-4-16(5-11-19)22(17-6-12-20(26-2)13-7-17)23(24)18-8-14-21(27-3)15-9-18/h4-15H,1-3H3</data>
  <data key="d20">COC1=CC=C(C=C1)C(Cl)=C(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1</data>
  <data key="d21">Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Chloortrianisestrol, Chlorestrolo, Chlorotrianisene, Chlorotrianisenum, Chlorotrianisine, Chlorotrianizen, Chlortrianisen, Chlortrianisestrol, Chlortrianisoestrolum, Chlortrianizen, Clorotrianiseno]</data>
  <data key="d9">A powerful synthetic, non-steroidal estrogen. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00278">
  <data key="d0">Argatroban</data>
  <data key="d1">drugbank.DB00278</data>
  <data key="d2">[drugbank.DB00278, drugbank.APRD00105]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Anticoagulants, Antithrombins, Blood and Blood Forming Organs, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Enzyme Inhibitors, Fibrinolytic Agents, Hematologic Agents, Narrow Therapeutic Index Drugs, Piperidines, Serine Proteinase Inhibitors, Thrombin Inhibitors]</data>
  <data key="d14">(2R,4R)-1-[(2S)-5-carbamimidamido-2-(3-methyl-1,2,3,4-tetrahydroquinoline-8-sulfonamido)pentanoyl]-4-methylpiperidine-2-carboxylic acid</data>
  <data key="d15">C23H36N6O5S</data>
  <data key="d16">74863-84-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15?,17+,18-/m1/s1</data>
  <data key="d20">C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2</data>
  <data key="d21">Argatroban is indicated for prevention and treatment of thrombosis caused by heparin induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Argatroban, Argatroban anhydrous]</data>
  <data key="d9">Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00276">
  <data key="d0">Amsacrine</data>
  <data key="d1">drugbank.DB00276</data>
  <data key="d2">[drugbank.DB00276, drugbank.APRD00064]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acridines, Aminoacridines, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cardiotoxic antineoplastic agents, Compounds used in a research, industrial, or household setting, Immunosuppressive Agents, Indicators and Reagents, Intercalating Agents, Laboratory Chemicals, Myelosuppressive Agents, P-glycoprotein/ABCB1 Inhibitors]</data>
  <data key="d14">N-{4-[(acridin-9-yl)amino]-3-methoxyphenyl}methanesulfonamide</data>
  <data key="d15">C21H19N3O3S</data>
  <data key="d16">51264-14-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H19N3O3S/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21/h3-13,24H,1-2H3,(H,22,23)</data>
  <data key="d20">COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1</data>
  <data key="d21">For treatment of acute myeloid leukaemia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide, 4'-(9-Acridinylamino)methanesulfon-m-anisidide, 4'-(9-Acridinylamino)methanesulfon-meta-anisidide, 4'-(9-Acridinylamino)methanesulphon-m-anisidide, Acridinyl anisidide, Amsacrina, Amsacrine, Amsacrinum, m-AMSA, mAMSA]</data>
  <data key="d9">Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00283">
  <data key="d0">Clemastine</data>
  <data key="d1">drugbank.DB00283</data>
  <data key="d2">[drugbank.DB00283, drugbank.APRD00875]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Aminoalkyl Ethers, Anti-Allergic Agents, Antihistamines for Systemic Use, Antihistamines for Topical Use, Antipruritics, Antipruritics, Incl. Antihistamines, Anesthetics, Etc., Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Highest Risk QTc-Prolonging Agents, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Neurotransmitter Agents, Pyrrolidines, QTc Prolonging Agents]</data>
  <data key="d14">(2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine</data>
  <data key="d15">C21H26ClNO</data>
  <data key="d16">15686-51-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1</data>
  <data key="d20">CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1</data>
  <data key="d21">For the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and acrimation. Also for the management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Used as self-medication for temporary relief of symptoms associated with the common cold.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+)-(2R)-2-(2-(((R)-p-chloro--methyl--phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine, (+)-(2R)-2-[2-[[(R)-p-chloro--methyl--phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine, Clemastina, Clemastine, Clemastinum]</data>
  <data key="d9">An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00289">
  <data key="d0">Atomoxetine</data>
  <data key="d1">drugbank.DB00289</data>
  <data key="d2">[drugbank.DB00289, drugbank.APRD00614]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenergic Agents, Agents producing tachycardia, Agents that produce hypertension, Amines, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Membrane Transport Modulators, Miscellaneous Central Nervous System Agents, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Norepinephrine Reuptake Inhibitor, Norepinephrine Uptake Inhibitors, Potential QTc-Prolonging Agents, Propylamines, Psychostimulants, Agents Used for Adhd and Nootropics, QTc Prolonging Agents]</data>
  <data key="d14">methyl[(3R)-3-(2-methylphenoxy)-3-phenylpropyl]amine</data>
  <data key="d15">C17H21NO</data>
  <data key="d16">83015-26-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1</data>
  <data key="d20">CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1</data>
  <data key="d21">Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(-)-Tomoxetine, Atomoxetina, Atomoxetine, Tomoxetina, Tomoxetine, Tomoxetinum]</data>
  <data key="d9">Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Although the underlying pathophysiology that causes ADHD remains unclear, evidence suggests that dysregulation in noradrenergic and dopaminergic pathways plays a critical role in suboptimal executive functioning within prefrontal regions of the brain, which are involved in attention and memory [A178090]. Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum [A18262]. This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and striatum is associated with many stimulant-associated side effects and an increase in abuse potential, which is a limiting factor associated with the use of stimulant medications such as [DB00422], [DB01576], and [DB01255] [A18262]. Use of non-stimulant medications such as atomoxetine is therefore thought to offer a clinical advantage over the use of traditional medications for the management of ADHD. More recently, positron emission tomography (PET) imaging studies in rhesus monkeys have shown that atomoxetine also binds to the serotonin transporter (SERT)[A178111], and blocks the N-methyl-d-aspartate (NMDA) receptor [A18263], indicating a role for the glutamatergic system in the pathophysiology of ADHD. \n\nLong-acting formulations of psychostimulants (such as [DB00422], [DB01576], and [DB01255]) are typically considered the most effective and first-line treatment for ADHD in adults and children as recommended by CADDRA (Canadian ADHD Resource Alliance) [L6037]. However, these stimulant medications are limited by dose-related side effects and concerns of abuse. Many contain a blackbox warning stating that CNS stimulants, including methylphenidate-containing products and amphetamines, have a high potential for abuse and dependence. In particular, increased dopamine in key areas caused by these stimulant medications is associated with their reinforcing and addictive properties, and even amplifies the potency and reinforcing effects of other drugs of abuse such as amphetamines, making ADHD sufferers more susceptible to their addictive effects[A177556]. Concerns about abuse potential have spurred research into medications with fewer effects on DA and the use of non-stimulant ADHD medications including atomoxetine, [DB00745] and [DB01018]. The non-stimulant norepinephrine/dopamine reuptake inhibitor [DB01156] (commonly used for the treatment of depression and for smoking cessation) has also been shown to be effective in the treatment of ADHD [A178099].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00286">
  <data key="d0">Conjugated estrogens</data>
  <data key="d1">drugbank.DB00286</data>
  <data key="d2">[drugbank.DB00286, drugbank.APRD00396]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents causing angioedema, BCRP/ABCG2 Substrates, COMT Substrates, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (weak), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Estradiol Congeners, Estrogens, Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Natural and Semisynthetic Estrogens, Plain, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, OATP1B1/SLCO1B1 Inhibitors, OATP1B1/SLCO1B1 Substrates, OATP1B3 substrates, P-glycoprotein/ABCB1 Substrates, Sex Hormones and Modulators of the Genital System, Thyroxine-binding globulin inducers]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">12126-59-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">The conjugated estrogens are indicated for several different conditions including:\n\n- Treatment of moderate to severe vasomotor symptoms due to menopause.\n- Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.\n- Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure.\n- Palliative treatment of breast cancer in appropriately selected patients with metastatic disease.\n- Palliative treatment of androgen-dependent carcinoma of the prostate.\n- Preventive therapy of postmenopausal osteoporosis.[A38238]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Conjugated equine estrogens, conjugated estrogens, Estrogens, Conjugated, Estrogens, conjugated]</data>
  <data key="d9">The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.[L5605, T475] \n\nThe conjugated estrogen product contains a mix of estrogen from which about 50% is represented by estrone sulfate followed by 25% of equilin sulfate, 15% of 17-alpha-dehydroequilenin sulfate, 3% of equilenin sulfate, 5% of 17-alpha and 17-beta-dihydroequilenin sulfate, 2% of 17-alpha-estradiolsulfate and 3% of 17-beta-estradiolsulfate. It also presents a large number of unidentified molecules with weak estrogenic activity as well as non-human molecules when it is obtained from pregnant mares urine.[T475] \n\nThe conjugated estrogen mixture was approved for marketing in US in 1942 based on the efficacy against certain conditions. However, until 1986 official clinical trials were performed and this product was determined to be effective for the treatment of osteoporosis.[T484] The currently approved product of conjugated estrogens was developed by Wyeth Ayerst and FDA approved in 2003.[L5608]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00294">
  <data key="d0">Etonogestrel</data>
  <data key="d1">drugbank.DB00294</data>
  <data key="d2">[drugbank.DB00294, drugbank.APRD00766]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Adrenal Cortex Hormones, Combination Contraceptives (with Estrogen and derivatives), Contraceptive Agents, Female, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Drugs that are Mainly Renally Excreted, Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Hyperglycemia-Associated Agents, Intravaginal Contraceptives, Norpregnanes, Norpregnenes, Norsteroids, Progesterone Congeners, Progestins, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids]</data>
  <data key="d14">(1S,2R,10S,11S,14R,15S)-15-ethyl-14-ethynyl-14-hydroxy-17-methylidenetetracyclo[8.7.0.0,.0,]heptadec-6-en-5-one</data>
  <data key="d15">C22H28O2</data>
  <data key="d16">54048-10-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]</data>
  <data key="d21">Etonogestrel is administered in subdermal implants as long-acting reversible contraception. It is known to be effective in postpartum insertion including breastfeeding women.[A175990]\n\nEtonogestrel is part of the long-acting contraceptive implants that prevent pregnancy. The implant's effect can remain for 5 years.[L5698]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3-Ketodesogestrel, 3-Oxodesogestrel, Etonogestrel, tonogestrel, Etonogestrelum]</data>
  <data key="d9">Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel.[A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12267">
  <data key="d0">Brigatinib</data>
  <data key="d1">drugbank.DB12267</data>
  <data key="d2">[drugbank.DB12267]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P450 3A Inducers, Kinase Inhibitor, MATE 1 Inhibitors, MATE 2 Inhibitors, MATE inhibitors, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d14">5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine</data>
  <data key="d15">C29H39ClN7O2P</data>
  <data key="d16">1197953-54-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)</data>
  <data key="d20">COC1=CC(=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)N1CCC(CC1)N1CCN(C)CC1</data>
  <data key="d21">The anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target.[A31311] The ALK-related cases of NSCLC are associated with the presence of the fusion gene EML4-ALK which fused the ALK protein with the echinoderm microtubule-associated protein like-4 whose original function is the correct formation of microtubules.[A31313] The presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth, proliferation and survival.[A31316] Crizotinib is indicated for the treatment of such cases but the presence of ALK kinase domain mutations confer resistance to the treatment. Thus, brigatinib is indicated for the treatment of patients with ALK+ NSCLC with intolerance to Crizotinib.[A31314]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Brigatinib]</data>
  <data key="d9">Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type.[A31311] It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma.[A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13520">
  <data key="d0">Metergoline</data>
  <data key="d1">drugbank.DB13520</data>
  <data key="d2">[drugbank.DB13520]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Agents that produce hypertension, Alkaloids, Antidepressive Agents, Central Nervous System Depressants, Dopamine Agents, Dopamine Agonists, Ergolines, Ergot Alkaloids and Derivatives, Ergot-derivative Dopamine Receptor Agonists, Genito Urinary System and Sex Hormones, Neurotransmitter Agents, Prolactine Inhibitors, Serotonin Agents, Serotonin Receptor Agonists]</data>
  <data key="d14">N-{[(2R,4R,7R)-6,11-dimethyl-6,11-diazatetracyclo[7.6.1.0,.0,]hexadeca-1(16),9,12,14-tetraen-4-yl]methyl}(benzyloxy)carboximidic acid</data>
  <data key="d15">C25H29N3O2</data>
  <data key="d16">17692-51-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C25H29N3O2/c1-27-14-18(13-26-25(29)30-16-17-7-4-3-5-8-17)11-21-20-9-6-10-22-24(20)19(12-23(21)27)15-28(22)2/h3-10,15,18,21,23H,11-14,16H2,1-2H3,(H,26,29)/t18-,21+,23+/m0/s1</data>
  <data key="d20">[H][C@]1(CN=C(O)OCC2=CC=CC=C2)CN(C)[C@]2([H])CC3=CN(C)C4=CC=CC(=C34)[C@@]2([H])C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[metergolina, Metergoline]</data>
  <data key="d9">Metergoline is an ergot-derived psychoactive drug that acts as a ligand for serotonin and dopamine receptors. Metergoline is an antagonist at various 5-HT receptor subtypes at a relatively low concentration and agonist at dopamine receptors [A27181]. Its use has been studied in various clinical settings such as a treatment for seasonal affective disorder, prolactin hormone regulation due to its inhibitory effect on prolactin release [A27182], premenstrual dysphoric disorder in women and antianxiety treatment [A27183].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00239">
  <data key="d0">Oxiconazole</data>
  <data key="d1">drugbank.DB00239</data>
  <data key="d2">[drugbank.DB00239, drugbank.APRD01154]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Anti-Infective Agents, Antifungal Agents, Antifungals for Dermatological Use, Antifungals for Topical Use, Azole Antifungals, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Dermatologicals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Imidazole and Triazole Derivatives, Imidazole Derivatives]</data>
  <data key="d14">(Z)-[1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethylidene][(2,4-dichlorophenyl)methoxy]amine</data>
  <data key="d15">C18H13Cl4N3O</data>
  <data key="d16">64211-45-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H13Cl4N3O/c19-13-2-1-12(16(21)7-13)10-26-24-18(9-25-6-5-23-11-25)15-4-3-14(20)8-17(15)22/h1-8,11H,9-10H2/b24-18+</data>
  <data key="d20">ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1</data>
  <data key="d21">For treatment of dermal fungal infection.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2', 4'-Dichloro-2-imidazol-1-ylacetophenone (Z)-[O-(2, 4-dichlorobenzyl)oxime], Oxiconazol, Oxiconazole, Oxiconazolum]</data>
  <data key="d9">Oxiconazole is an antifungal agent that is commonly found in topical formulations. It is marketed under the brand names Oxistat and Oxistat, and is used in the treatment of various skin infections such as athlete's foot, jock itch and ringworm.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00237">
  <data key="d0">Butabarbital</data>
  <data key="d1">drugbank.DB00237</data>
  <data key="d2">[drugbank.DB00237, drugbank.APRD00752]</data>
  <data key="d12">[approved, illicit]</data>
  <data key="d13">[Anticholinergic Agents, Central Nervous System Agents, Central Nervous System Depressants, Drugs that are Mainly Renally Excreted, Hypnotics and Sedatives, Nicotinic Antagonists, Pyrimidines, Pyrimidinones]</data>
  <data key="d14">5-(butan-2-yl)-5-ethyl-1,3-diazinane-2,4,6-trione</data>
  <data key="d15">C10H16N2O3</data>
  <data key="d16">125-40-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)</data>
  <data key="d20">CCC(C)C1(CC)C(=O)NC(=O)NC1=O</data>
  <data key="d21">For short-term treatment of insomnia and anxiety disorders</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[5-ethyl-5-(1-methylpropyl)-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione, 5-ethyl-5-(1-methylpropyl)barbituric acid, 5-sec-butyl-5-ethyl-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione, 5-sec-butyl-5-ethylbarbituric acid, 5-sec-butyl-5-ethylpyrimidine-2, 4, 6(1H, 3H, 5H)-trione, Butabarbital, Secbutabarbital, Secbutabarbitale, Secbutabarbitalum]</data>
  <data key="d9">Butabarbital (trade name Butisol) is a barbiturate with a particularly fast onset of effects and short duration of action compared to other barbiturates. This makes butabarbital a useful drug for certain applications such as treating severe insomnia and relieving anxiety before surgical procedures. However, like other barbiturate drugs, butabarbital is associated with profound CNS depressant effects, especially when combined with alcohol, as well as the risk of drug misuse and dependence. While its clinical use is typically limited, it is still prescribed in some Eastern European and South American countries. Its short duration of action gives butabarbital a high abuse potential, comparable to [secobarbital].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00241">
  <data key="d0">Butalbital</data>
  <data key="d1">drugbank.DB00241</data>
  <data key="d2">[drugbank.DB00241, drugbank.APRD00266]</data>
  <data key="d12">[approved, illicit]</data>
  <data key="d13">[Anticholinergic Agents, Anticonvulsants, Barbiturates, Central Nervous System Depressants, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Hypnotics and Sedatives, Methemoglobinemia Associated Agents, Nervous System, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones]</data>
  <data key="d14">5-(2-methylpropyl)-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione</data>
  <data key="d15">C11H16N2O3</data>
  <data key="d16">77-26-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)</data>
  <data key="d20">CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O</data>
  <data key="d21">Indicated for the management of the symptom complex of tension (or muscle contraction) headache, when other non-opioid analgesics and alternative treatments are inadequate, in various combinations with acetaminophen, aspirin, caffeine, and codeine [FDA Label].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[5-(2-methylpropyl)-5-prop-2-enyl-1, 3-diazinane-2, 4, 6-trione, 5-allyl-5-(2-methylpropyl)barbituric acid, 5-allyl-5-(2'-methyl-n-propyl) barbituric acid, 5-allyl-5-isobutyl-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione, 5-Allyl-5-isobutyl-pyrimidine-2, 4, 6-trione, 5-allyl-5-isobutylbarbituric acid, 5-isobutyl-5-allylbarbituric acid, Allylbarbital, Allylbarbitone, Allylbarbituric acid, Butalbarbital, Butalbital, Butalbitalum, iso-butylallylbarbituric acid, Itobarbital, Tetrallobarbital]</data>
  <data key="d9">Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervous system (CNS) depression that ranges from mild sedation to general anesthesia [A177754]. Butalbital has a low degree of selectivity and a narrow therapeutic index [A177754]. Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin, and caffeine. There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines [A177754] thus it is not indicated for such condition. As with other barbiturates, butalbital carries a risk of abuse or misuse potential, intoxication, hangover, tolerance, dependence, and overdosage possibly leading to death [FDA Label]. Butalbitalcontaining analgesics can also produce a druginduced headache in addition to tolerance and dependence. Due to these risks, the use of butalbital-containing combination products is typically limited for use only in cases where other medications are deemed ineffective and such usage is advised to be carefully monitored [A177754].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01577">
  <data key="d0">Metamfetamine</data>
  <data key="d1">drugbank.DB01577</data>
  <data key="d2">[drugbank.DB01577]</data>
  <data key="d12">[approved, illicit]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic Uptake Inhibitors, Agents producing tachycardia, Agents that produce hypertension, Amines, Amphetamine Anorectic, Amphetamines, Antidepressive Agents, Appetite Suppression, Autonomic Agents, Central Nervous System Agents, Central Nervous System Depressants, Central Nervous System Stimulants, Central Nervous System Stimulation, Centrally Acting Sympathomimetics, Cytochrome P-450 CYP2D6 Substrates, Dopamine Agents, Dopamine Uptake Inhibitors, Drugs that are Mainly Renally Excreted, Ethylamines, Increased Sympathetic Activity, Membrane Transport Modulators, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Peripheral Nervous System Agents, Phenethylamines, Psychoanaleptics, Psychostimulants, Agents Used for Adhd and Nootropics, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Sympathomimetics]</data>
  <data key="d14">methyl[(2S)-1-phenylpropan-2-yl]amine</data>
  <data key="d15">C10H15N</data>
  <data key="d16">537-46-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m0/s1</data>
  <data key="d20">CN[C@@H](C)CC1=CC=CC=C1</data>
  <data key="d21">For the treatment of Attention Deficit Disorder with Hyperactivity (ADHD) and exogenous obesity.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+)-(S)-N--dimethylphenethylamine, (S)-N, -dimethylbenzeneethanamine, (S)-N, -dimethylbenzeneethanamine, d-1-phenyl-2-methylaminopropane, d-deoxyephedrine, d-desoxyephedrine, d-N-methylamphetamine, d-phenylisopropylmethylamine, Dextromethamphetamine, Mtamftamine, Metamfetamine, Metamfetaminum, Metanfetamina, Methamphetamine, Methamphetaminum, methyl--phenylisopropylamine]</data>
  <data key="d9">Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug. It is a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00244">
  <data key="d0">Mesalazine</data>
  <data key="d1">drugbank.DB00244</data>
  <data key="d2">[drugbank.DB00244, drugbank.APRD01098, drugbank.DB05376, drugbank.DB06396]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents causing hyperkalemia, Agents that produce hypertension, Aminosalicylate, Aminosalicylic Acids, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Benzene Derivatives, Hydroxybenzoates, Intestinal Antiinflammatory Agents, Nephrotoxic agents, Non COX-2 selective NSAIDS, Phenols, Salicylates]</data>
  <data key="d14">5-amino-2-hydroxybenzoic acid</data>
  <data key="d15">C7H7NO3</data>
  <data key="d16">89-57-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)</data>
  <data key="d20">NC1=CC(C(O)=O)=C(O)C=C1</data>
  <data key="d21">Mesalazine is indicated for the induction of remission in patients with active or mild to moderate acute exacerbations of ulcerative colitis and for the maintenance of remission of ulcerative colitis [FDA Label], [L5101]. Prescribing information for mesalazine in the UK also indicates the medication for the maintenance of remission of Crohn's ileo-colitis [L5101].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3-carboxy-4-hydroxyaniline, 5-aminosalicylic acid, 5-ASA, m-Aminosalicylic acid, Mesalamine, Mesalazina, Msalazine, Mesalazine, Mesalazinum, p-Aminosalicylsaeure]</data>
  <data key="d9">An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease [A174022]. It is considered to be the active moiety of sulphasalazine. (From Martindale, The Extra Pharmacopoeia, 30th ed) Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent [A174019]. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules [A174019]. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained [A174019, A174022].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00251">
  <data key="d0">Terconazole</data>
  <data key="d1">drugbank.DB00251</data>
  <data key="d2">[drugbank.DB00251, drugbank.APRD00659]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Anti-Infective Agents, Antifungal Agents, Antifungal Agents (Vaginal), Azole Antifungals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Triazole Derivatives]</data>
  <data key="d14">1-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-(propan-2-yl)piperazine</data>
  <data key="d15">C26H31Cl2N5O3</data>
  <data key="d16">67915-31-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3/t23-,26-/m0/s1</data>
  <data key="d20">CC(C)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1</data>
  <data key="d21">For the treatment of candidiasis (a yeast-like fungal infection) of the vulva and vagina.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Terconazole]</data>
  <data key="d9">Terconazole is an anti-fungal drug that is mainly used to treat vaginal yeast infections (or vaginal candidiasis). It is classified as a _triazole ketal derivative_.[A178096] Terconazole was initially approved by the FDA in 1987.[FDA label] This drug is available in cream and suppository forms and both have demonstrated high levels of safety, efficacy, and tolerability in clinical trials. [A178093]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01626">
  <data key="d0">Pargyline</data>
  <data key="d1">drugbank.DB01626</data>
  <data key="d2">[drugbank.DB01626]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents that produce hypertension, Agents that reduce seizure threshold, Amines, Antidepressive Agents, Antihypertensive Agents, Benzene Derivatives, Benzyl Compounds, Benzylamines, Cardiovascular Agents, Central Nervous System Depressants, Enzyme Inhibitors, MAO Inhibitors and Diuretics, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome]</data>
  <data key="d14">benzyl(methyl)(prop-2-yn-1-yl)amine</data>
  <data key="d15">C11H13N</data>
  <data key="d16">555-57-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3</data>
  <data key="d20">CN(CC#C)CC1=CC=CC=C1</data>
  <data key="d21">For the treatment of moderate to severe hypertension.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Pargilina, Pargyline, Pargylinum]</data>
  <data key="d9">Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02952">
  <data key="d0">Alpha-Aminoisobutyric Acid</data>
  <data key="d1">drugbank.DB02952</data>
  <data key="d2">[drugbank.DB02952, drugbank.EXPT00471]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Acids, Acyclic, Amino Acids, Amino Acids, Branched-Chain, Amino Acids, Peptides, and Proteins, Aminobutyrates, Butyrates, Fatty Acids, Fatty Acids, Volatile, Isobutyrates, Lipids]</data>
  <data key="d14">2-amino-2-methylpropanoic acid</data>
  <data key="d15">C4H9NO2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C4H9NO2/c1-4(2,5)3(6)7/h5H2,1-2H3,(H,6,7)</data>
  <data key="d20">CC(C)(N)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00307">
  <data key="d0">Bexarotene</data>
  <data key="d1">drugbank.DB00307</data>
  <data key="d2">[drugbank.DB00307, drugbank.APRD00114]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Anticarcinogenic Agents, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Immunosuppressive Agents, Myelosuppressive Agents, Naphthalenes, Protective Agents, Retinoids]</data>
  <data key="d14">4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid</data>
  <data key="d15">C24H28O2</data>
  <data key="d16">153559-49-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)</data>
  <data key="d20">CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C</data>
  <data key="d21">Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[4-[1-(3, 5, 5, 8, 8-pentamethyltetralin-2-yl)ethenyl]benzoic acid, 4-[1-(5, 6, 7, 8, -Tetrahydro-3, 5, 5, 8, 8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid, Bexaroten, Bexarotne, Bexarotene, Bexaroteno, Bexarotenum, p-(1-(5, 6, 7, 8-Tetrahydro-3, 5, 5, 8, 8-pentamethyl-2-naphthyl)vinyl)benzoic acid]</data>
  <data key="d9">Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00306">
  <data key="d0">Talbutal</data>
  <data key="d1">drugbank.DB00306</data>
  <data key="d2">[drugbank.DB00306, drugbank.APRD01333]</data>
  <data key="d12">[approved, illicit]</data>
  <data key="d13">[Anticholinergic Agents, Barbiturates, Plain, Central Nervous System Depressants, Hypnotics and Sedatives, Nervous System, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones]</data>
  <data key="d14">5-(butan-2-yl)-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione</data>
  <data key="d15">C11H16N2O3</data>
  <data key="d16">115-44-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H16N2O3/c1-4-6-11(7(3)5-2)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)</data>
  <data key="d20">CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O</data>
  <data key="d21">For use as a sedative and hypnotic.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(RS)-5-allyl-5-sec-butylpyrimidine-2, 4, 6(1H, 3H, 5H)-trione, 5-allyl-5-sec-butylbarbituric acid, sec-Butyl allyl barbituric acid, Talbutal, Talbutale, Talbutalum]</data>
  <data key="d9">Talbutal, also called 5-allyl-5-sec-butylbarbituric acid, is a barbiturate with a short to intermediate duration of action. Talbutal is a schedule III drug in the U.S.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00304">
  <data key="d0">Desogestrel</data>
  <data key="d1">drugbank.DB00304</data>
  <data key="d2">[drugbank.DB00304, drugbank.APRD00762]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenal Cortex Hormones, Combination Contraceptives (with Estrogen and derivatives), Contraceptive Agents, Female, Contraceptives, Oral, Contraceptives, Oral, Synthetic, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Norpregnanes, Norpregnenes, Norsteroids, Progestin Contraceptives, Progestins, Progestogens and Estrogens, Sequential Preparations, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids, UGT1A1 Inducers]</data>
  <data key="d14">(1S,2R,10S,11S,14R,15S)-15-ethyl-14-ethynyl-17-methylidenetetracyclo[8.7.0.0,.0,]heptadec-6-en-14-ol</data>
  <data key="d15">C22H30O</data>
  <data key="d16">54024-22-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]</data>
  <data key="d21">Oral desogestrel is used in combination with [ethinylestradiol] as a contraceptive agent for the prevention of pregnancy.[FDA label]\n\nDesogestrel is part of the combined oral contraceptives that contain a mix of estrogen and progestin which inhibit ovulation.[L5698]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[13-Ethyl-11-methylene-18, 19-dinor-17-pregn-4-en-20-yn-17-ol, Desogestrel, Dsogestrel, Desogestrelum]</data>
  <data key="d9">Desogestrel, a prodrug, is a third generation progestogen[A176315] and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada.[A176339] It was firstly generated from a study that showed that 11-beta and 11-alkylidene substituent in nortestosterone can enhance the biological activity.[T521] Desogestrel is now produced semi-synthetically from naturally occurred plant steroids.[F4127] In the US, desogestrel is found only in combination with [ethinyl estradiol].[A176342] The first approved drug containing desogestrel was developed by Organon USA Inc in 1972 and FDA approved in 1992.[L5762]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00317">
  <data key="d0">Gefitinib</data>
  <data key="d1">drugbank.DB00317</data>
  <data key="d2">[drugbank.DB00317, drugbank.APRD00997, drugbank.DB07998]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Kinase Inhibitor, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, Receptor, Epidermal Growth Factor, antagonists &amp; inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d14">N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine</data>
  <data key="d15">C22H24ClFN4O3</data>
  <data key="d16">184475-35-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)</data>
  <data key="d20">COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1</data>
  <data key="d21">For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline, Gefitinib, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine]</data>
  <data key="d9">Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01645">
  <data key="d0">Genistein</data>
  <data key="d1">drugbank.DB01645</data>
  <data key="d2">[drugbank.DB01645, drugbank.EXPT01582]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Anticarcinogenic Agents, Antineoplastic Agents, BCRP/ABCG2 Inhibitors, Benzopyrans, Chromones, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (weak), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (weak), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Estrogens, Non-Steroidal, Flavonoids, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Isoflavones, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, Phytoestrogens, Protective Agents, Protein Kinase Inhibitors, Pyrans, Tyrosine Kinase Inhibitors]</data>
  <data key="d14">5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one</data>
  <data key="d15">C15H10O5</data>
  <data key="d16">446-72-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H</data>
  <data key="d20">OC1=CC=C(C=C1)C1=COC2=C(C(O)=CC(O)=C2)C1=O</data>
  <data key="d21">Currently Genistein is being studied in clinical trials as a treatment for prostate cancer.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[4', 5, 7-trihydroxyisoflavone, 5, 7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one, 5, 7, 4'-trihydroxyisoflavone, Genistein, Genisteol, Genisterin]</data>
  <data key="d9">An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines.\n\nAdditionally, genistein has antihelmintic activity. It has been determined to be the active ingredient in &lt;I&gt;Felmingia vestita&lt;/I&gt;, which is a plant traditionally used against worms. It has shown to be effective in the treatment of common liver fluke, pork trematode and poultry cestode.\n\nFurther, genistein is a phytoestrogen which has selective estrogen receptor modulator properties. It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women [A14417].  \n\nNatural sources of genistein include tofu, fava beans, soybeans, kudzu, and lupin.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00313">
  <data key="d0">Valproic Acid</data>
  <data key="d1">drugbank.DB00313</data>
  <data key="d2">[drugbank.DB00313, drugbank.APRD00256, drugbank.DB00510, drugbank.APRD00066]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Acyclic, Anti-epileptic Agent, Anticonvulsants, Antimanic Agents, Antineoplastic Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP2A6 Inducers, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C18 Inhibitors, Cytochrome P-450 CYP2C18 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Decreased Central Nervous System Disorganized Electrical Activity, Enzyme Inhibitors, Fatty Acid Derivatives, Fatty Acids, Fatty Acids, Volatile, GABA Agents, Highest Risk QTc-Prolonging Agents, Histone Deacetylase Inhibitors, Lipids, Methemoglobinemia Associated Agents, Miscellaneous Anticonvulsants, Mood Stabilizer, Narrow Therapeutic Index Drugs, Nervous System, Neurotransmitter Agents, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, OAT3/SLC22A8 Substrates with Narrow Therapeutic Index, Pentanoic Acids, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Tranquilizing Agents, UGT1A1 Inhibitors, UGT1A1 Substrates, UGT1A1 substrates with narrow therapeutic index, UGT1A3 substrates, UGT1A3 substrates with narrow therapeutic index, UGT1A4 substrates, UGT1A6 substrate, UGT1A6 substrate with narrow therapeutic index, UGT1A9 Substrates, UGT1A9 substrates with narrow therapeutic index, UGT2B7 substrates, UGT2B7 substrates with narrow therapeutic index, Valerates]</data>
  <data key="d14">2-propylpentanoic acid</data>
  <data key="d15">C8H16O2</data>
  <data key="d16">99-66-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)</data>
  <data key="d20">CCCC(CCC)C(O)=O</data>
  <data key="d21">**Indicated** for:[Label] \n\n1) Use as monotherapy or adjunctive therapy in the management of complex partial seizures and simple or complex absence seizures. \n\n2) Adjunctive therapy in the management of multiple seizure types that include absence seizures. \n\n3) Prophylaxis of migraine headaches.\n\n4) Acute management of mania associated with bipolar disorder.\n\n\n**Off-label** uses include:\n \n1) Maintenance therapy for bipolar disorder.[A177919]\n\n2) Treatment for acute bipolar depression.[A177928,A177931,A177934]\n\n3) Emergency treatment of status epilepticus.[A177955]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-n-propyl-n-valeric acid, 2-propyl-pentanoic acid, 2-Propylpentanoic Acid, 2-Propylvaleric Acid, 4-heptanecarboxylic acid, acide valproque, cido valproico, acidum valproicum, di-n-propylacetic acid, Di-n-propylessigsure, Dipropylacetic acid, DPA, n-DPA, Valproate, Valproic Acid, Valproinsure, VPA]</data>
  <data key="d9">Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton.[A178051] It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects of khelline when he found that all of his samples, dissolved in valproic acid, exerted a similar degree of anticonvulsive activity. It first received approval on February 28, 1978 from the FDA under the trade name Depakene.[L6190]\n\nSince then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects. It is currently a compound of interest in the field of oncology for its anti-proliferative effects and is the subject of many clinical trials in a variety of cancer types.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00312">
  <data key="d0">Pentobarbital</data>
  <data key="d1">drugbank.DB00312</data>
  <data key="d2">[drugbank.DB00312, drugbank.APRD01174]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Adjuvants, Anesthesia, Anticholinergic Agents, Anticonvulsants, Barbiturates, Barbiturates, Plain, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2A6 Inducers, Cytochrome P-450 CYP2A6 Inducers (strong), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 Enzyme Inducers, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Modulators, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones]</data>
  <data key="d14">5-ethyl-5-(pentan-2-yl)-1,3-diazinane-2,4,6-trione</data>
  <data key="d15">C11H18N2O3</data>
  <data key="d16">76-74-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H18N2O3/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)</data>
  <data key="d20">CCCC(C)C1(CC)C(=O)NC(=O)NC1=O</data>
  <data key="d21">For the short-term treatment of insomnia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[5-Ethyl-5-(1-methyl-butyl)-pyrimidine-2, 4, 6-trione, 5-Ethyl-5-(1-methylbutyl)-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)barbituric acid, 5-ethyl-5-(sec-pentyl)barbituric acid, Pentobarbital, Pentobarbitone]</data>
  <data key="d9">A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02979">
  <data key="d0">N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane</data>
  <data key="d1">drugbank.DB02979</data>
  <data key="d2">[drugbank.DB02979, drugbank.EXPT02394]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(E)-N'-{14-[(E)-N'-[amino(methylsulfanyl)methylidene]amino]tetradecyl}(methylsulfanyl)methanimidamide</data>
  <data key="d15">C18H38N4S2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H38N4S2/c1-23-17(19)21-15-13-11-9-7-5-3-4-6-8-10-12-14-16-22-18(20)24-2/h3-16H2,1-2H3,(H2,19,21)(H2,20,22)</data>
  <data key="d20">CS\C(N)=N\CCCCCCCCCCCCCC\N=C(/N)SC</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00328">
  <data key="d0">Indometacin</data>
  <data key="d1">drugbank.DB00328</data>
  <data key="d2">[drugbank.DB00328, drugbank.APRD00109]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acetic Acid Derivatives and Related Substances, Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antigout Preparations, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antiinflammatory Preparations, Non-Steroids for Topical Use, Antirheumatic Agents, BSEP/ABCB11 Substrates, Cardiac Therapy, Cardiovascular Agents, Central Nervous System Agents, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Hypoglycemia-Associated Agents, Immunosuppressive Agents, Indoles, Musculo-Skeletal System, Myelosuppressive Agents, Nephrotoxic agents, Non COX-2 selective NSAIDS, Nonsteroidal Anti-inflammatory Compounds, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, OATP1B1/SLCO1B1 Inhibitors, Ophthalmologicals, Other Nonsteroidal Antiimflammatory Agents, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Peripheral Nervous System Agents, Sensory Organs, Sensory System Agents, Tocolytic Agents, Topical Products for Joint and Muscular Pain, UGT1A1 Inhibitors, UGT1A1 Substrates, UGT1A9 Substrates, UGT2B7 Inhibitors, UGT2B7 substrates]</data>
  <data key="d14">2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid</data>
  <data key="d15">C19H16ClNO4</data>
  <data key="d16">53-86-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)</data>
  <data key="d20">COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O</data>
  <data key="d21">Oral indometacin is indicated for symptomatic management of moderate to severe rheumatoid arthritis including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.[A177871,L6778]\n \nIntravenous indometacin is indicated to induce closure of a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective.[F4600]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid, Indometacin, Indometacina, Indometacine, Indometacinum, Indomethacin]</data>
  <data key="d9">Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlorobenzoyl)25-methoxy-2-methylindole-3-acetic acid.[A177871] The pharmacological effect of indometacin is not fully understood, however, it is thought to be mediated through potent and nonselective inhibition of the enzyme cyclooxygenase (COX), which is the main enzyme responsible for catalyzes the rate-limiting step in prostaglandin and thromboxane biosynthesis via the arachidonic acid (AA) pathway. Indometacin was first discovered in 1963 and it was first approved for use in the U.S. by the Food and Drug Administration in 1965, [A486] along with other acetic acid derivatives such as [diclofenac] and [sulindac] that were also developed during the 1960s.[A177871] Since then, indometacin has been extensively studied in clinical trials as one of the most potent NSAIDs in blocking prostaglandin synthesis and was among the first NSAIDs to be used in the symptomatic treatment of migraine and for headaches that eventually became known as indomethacin-responsive headache disorders.[A177871] \n\nMost commonly used in rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute shoulder pains, and acute gouty arthritis, indometacin is currently available as oral capsules as well as other methods of administration, including rectal and intravenous formulations. Intravenous indometacin is administered to close a hemodynamically significant patent ductus arteriosus, as indicated by clinical evidence, in premature infants.[F4600] Ophthalmic indometacin has been studied and used in the symptomatic treatment of postoperative ocular inflammation and pain and/or complications after cataract surgery. Although deemed effective in reducing ocular inflammation in clinical studies, topical NSAIDs were also associated with a potential reduction in corneal sensitivity accompanied by an increased risk of superficial punctate keratitis and subjective symptoms of discomfort, including pain, burning or pricking, or a tingling sensation after instillation into the culdesac.[A177949]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02911">
  <data key="d0">2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine</data>
  <data key="d1">drugbank.DB02911</data>
  <data key="d2">[drugbank.DB02911, drugbank.EXPT00536]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(6R)-6-phenyl-5,6,7,8-tetrahydropteridine-2,4-diamine</data>
  <data key="d15">C12H14N6</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H14N6/c13-10-9-11(18-12(14)17-10)15-6-8(16-9)7-4-2-1-3-5-7/h1-5,8,16H,6H2,(H5,13,14,15,17,18)/t8-/m0/s1</data>
  <data key="d20">[H][C@]1(CNC2=C(N1)C(N)=NC(N)=N2)C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01614">
  <data key="d0">Acepromazine</data>
  <data key="d1">drugbank.DB01614</data>
  <data key="d2">[drugbank.DB01614]</data>
  <data key="d12">[experimental, vet_approved]</data>
  <data key="d13">[Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Antidepressive Agents, Antipsychotic Agents, Central Nervous System Agents, Central Nervous System Depressants, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Phenothiazines, Phenothiazines With Aliphatic Side-Chain, Psycholeptics, Psychotropic Drugs, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Sulfur Compounds, Tranquilizing Agents]</data>
  <data key="d14">1-{10-[3-(dimethylamino)propyl]-10H-phenothiazin-2-yl}ethan-1-one</data>
  <data key="d15">C19H22N2OS</data>
  <data key="d16">61-00-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H22N2OS/c1-14(22)15-9-10-19-17(13-15)21(12-6-11-20(2)3)16-7-4-5-8-18(16)23-19/h4-5,7-10,13H,6,11-12H2,1-3H3</data>
  <data key="d20">CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O</data>
  <data key="d21">Acepromazine was first used in humans in the 1950s as an antipsychotic agent. It is now rarely used in humans. Acepromazine is frequently used in animals as a sedative and antiemetic. Its principal value is in quietening and calming anxious animals.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-[10-(3-dimethylamino-propyl)-10H-phenothiazin-2-yl]-ethanone, 10-(3-dimethylaminopropyl)phenothiazin-3-yl methyl ketone, 10-(3-dimethylaminopropyl)phenothiazine-3-ethylone, Acepromazina, Acepromazine, Acepromazinum, Acetazine, Acetopromazine, Acetylpromazine]</data>
  <data key="d9">Acepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02900">
  <data key="d0">alpha-D-mannose 6-phosphate</data>
  <data key="d1">drugbank.DB02900</data>
  <data key="d2">[drugbank.DB02900, drugbank.EXPT02088]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">{[(2R,3S,4S,5S,6S)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy}phosphonic acid</data>
  <data key="d15">C6H13O9P</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C6H13O9P/c7-3-2(1-14-16(11,12)13)15-6(10)5(9)4(3)8/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5+,6+/m1/s1</data>
  <data key="d20">[H][C@]1(O)O[C@]([H])(COP(O)(O)=O)[C@@]([H])(O)[C@]([H])(O)[C@]1([H])O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(6P)Mana, (6P)Man, 6-H2PO3Man, 6-O-phosphono--D-mannopyranose, Man6P]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02901">
  <data key="d0">Stanolone</data>
  <data key="d1">drugbank.DB02901</data>
  <data key="d2">[drugbank.DB02901, drugbank.EXPT01199]</data>
  <data key="d12">[illicit, investigational]</data>
  <data key="d13">[5-Androstanon (3) Derivatives, Alimentary Tract and Metabolism, Anabolic Agents for Systemic Use, Anabolic Steroids, Androgens, Androstan Derivatives, Androstanes, Androstanols, Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, P-glycoprotein/ABCB1 Substrates, Sex Hormones and Modulators of the Genital System, Steroids, Testosterone and derivatives, Testosterone Congeners]</data>
  <data key="d14">(1S,2S,7S,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0,.0,]heptadecan-5-one</data>
  <data key="d15">C19H30O2</data>
  <data key="d16">521-18-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[17beta-Hydroxy-5alpha-androstan-3-one, 17beta-Hydroxy-5alpha-androstane-3-one, 17beta-Hydroxyandrostan-3-one, 17-hydroxy-3-oxo-5-androstanone, 17-hydroxy-5-androstan-3-one, 4-Dihydrotestosterone, 5alpha-Dihydrotestosterone, 5-DHT, Androstanolona, Androstanolone, Androstanolonum, DHT, Dihydrotestosteron, Dihydrotestostrone, Dihydrotestosterone]</data>
  <data key="d9">A potent androgenic metabolite of testosterone. Dihydrotestosterone (DHT) is generated by a 5-alpha reduction of testosterone. Unlike testosterone, DHT cannot be aromatized to estradiol therefore DHT is considered a pure androgenic steroid.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01268">
  <data key="d0">Sunitinib</data>
  <data key="d1">drugbank.DB01268</data>
  <data key="d2">[drugbank.DB01268, drugbank.DB07417]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Angiogenesis Inhibitors, Angiogenesis Modulating Agents, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, Blood Glucose Lowering Agents, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Growth Inhibitors, Growth Substances, Hypoglycemia-Associated Agents, Immunosuppressive Agents, Kinase Inhibitor, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Potential QTc-Prolonging Agents, Protein Kinase Inhibitors, QTc Prolonging Agents, Tyrosine Kinase Inhibitors]</data>
  <data key="d14">N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide</data>
  <data key="d15">C22H27FN4O2</data>
  <data key="d16">557795-19-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-</data>
  <data key="d20">CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C</data>
  <data key="d21">For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Sunitinib, Sunitinibum]</data>
  <data key="d9">Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01273">
  <data key="d0">Varenicline</data>
  <data key="d1">drugbank.DB01273</data>
  <data key="d2">[drugbank.DB01273]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Benzazepines, Cholinergic Agents, Cholinergic Agonists, Drugs that are Mainly Renally Excreted, Drugs Used in Addictive Disorders, Drugs Used in Nicotine Dependence, Miscellaneous Autonomic Drugs, Nervous System, Neurotransmitter Agents, Nicotinic Agonists, OCT2 Inhibitors, OCT2 Substrates, OCT2 substrates with narrow therapeutic index, Partial Cholinergic Nicotinic Agonist, Partial Cholinergic Nicotinic Agonists, Quinoxalines]</data>
  <data key="d14">(1R,12S)-5,8,14-triazatetracyclo[10.3.1.0,.0,]hexadeca-2,4,6,8,10-pentaene</data>
  <data key="d15">C13H13N3</data>
  <data key="d16">249296-44-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2/t8-,9+</data>
  <data key="d20">[H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21</data>
  <data key="d21">For use as an aid in smoking cessation.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[vareniclina, Varenicline]</data>
  <data key="d9">Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors.\n\nOn March 9, 2015, the U.S. Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out. Pfizer is conducting an additional safety study of the drug, results of which are  expected in late 2015. The FDA said it is keeping the black box in place at least until the results of the trial are announced.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01270">
  <data key="d0">Ranibizumab</data>
  <data key="d1">drugbank.DB01270</data>
  <data key="d2">[drugbank.DB01270]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Angiogenesis Inhibitors, Angiogenesis Modulating Agents, Antibodies, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineovascularisation Agents, Blood Proteins, EENT Drugs, Miscellaneous, Globulins, Growth Inhibitors, Growth Substances, Immunoglobulins, Immunologic Factors, Immunoproteins, Ocular Vascular Disorder Agents, Ophthalmics, Ophthalmologicals, Proteins, Sensory Organs, Serum Globulins, Vascular Endothelial Growth Factor Inhibitor, Vascular Endothelial Growth Factor Inhibitors]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">347396-82-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">For the treatment of patients with macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;5718d5d4-8c2b-4b7a-88cf-297af9714caf Ranibizumab Light Chain\nDIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC, &gt;ab05ae9f-2ade-4f80-bcbf-441164807cb7 Ranibizumab Heavy Chain\nEVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHL]</data>
  <data key="d8">[rhuFab V2]</data>
  <data key="d9">Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline (tetracycline is not detectable in the final product). Ranibizumab is marketed under the name Lucentis. It is indicated for the treatment of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01277">
  <data key="d0">Mecasermin</data>
  <data key="d1">drugbank.DB01277</data>
  <data key="d2">[drugbank.DB01277]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Anterior Pituitary Lobe Hormones and Analogues, Biological Factors, Blood Glucose Lowering Agents, Blood Proteins, Hypoglycemia-Associated Agents, Intercellular Signaling Peptides and Proteins, Peptides, Pituitary and Hypothalamic Hormones and Analogues, Proteins, Somatomedins, Somatropin and Somatropin Agonists, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">68562-41-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">For the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH [A2322]. It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or other causes; it is not a substitute for GH therapy.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;d97e12dc-1845-4f2b-a998-c20eef54dd46 Mecasermin\nGPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA]</data>
  <data key="d8">[Human somatomedin C, Mecasermin recombinant, Mecasermina, Mechano growth factor]</data>
  <data key="d9">Mecasermin contains recombinant-DNA-engineered human insulin-like growth factor-1 (rhIGF-1)[FDA Label]. IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges and a molecular weight of 7649 daltons. The amino acid sequence of the product is identical to that of endogenous human IGF-1. The rhIGF-1 protein is synthesized in bacteria (E. coli) that have been modified by the addition of the gene for human IGF-1.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01285">
  <data key="d0">Corticotropin</data>
  <data key="d1">drugbank.DB01285</data>
  <data key="d2">[drugbank.DB01285, drugbank.DB09547]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Adrenal Cortex Hormones, Adrenocorticotropic Hormone, Amino Acids, Peptides, and Proteins, Anterior Pituitary Lobe Hormones and Analogues, Corticosteroids, Corticosteroids for Systemic Use, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Immunosuppressive Agents, Melanocortins, Nerve Tissue Proteins, Neuropeptides, Peptide Hormones, Peptides, Pituitary and Hypothalamic Hormones and Analogues, Pituitary Hormones, Pituitary Hormones, Anterior, Pro-Opiomelanocortin, Protein Precursors, Proteins, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">12427-33-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;d746930f-e7ae-445b-83a2-8039b9fb866d ACTH(1-39)\nSYSMEHFRWGKPVGKKRRPVKVYPDGAEDQLAEAFPLEF]</data>
  <data key="d8">[ACTH, Adrenocorticotrophin, Adrenocorticotropic hormone, Corticotrophin, Corticotropin, Cortigel, H.P. acthar gel]</data>
  <data key="d9">Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01296">
  <data key="d0">Glucosamine</data>
  <data key="d1">drugbank.DB01296</data>
  <data key="d2">[drugbank.DB01296, drugbank.EXPT01563]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Amino Sugars, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Carbohydrates, Hexosamines, Musculo-Skeletal System]</data>
  <data key="d14">(3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol</data>
  <data key="d15">C6H13NO5</data>
  <data key="d16">3416-24-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5-,6?/m1/s1</data>
  <data key="d20">N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O</data>
  <data key="d21">Glucosamine is usually used in the treatment of osteoarthritis, although its efficacy is still in question.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-amino-2-deoxy-D-glucose, Chitosamine, D-Glucosamine, Glucosamina, Glucosamine]</data>
  <data key="d9">Glucosamine is commonly used as a treatment for osteoarthritis, although its acceptance as a medical therapy varies. It is an amino sugar and precursor of glycosylated proteins and lipids. Since glucosamine is a precursor for glycosaminoglycans, and glycosaminoglycans are a major component of joint cartilage, supplemental glucosamine may help to rebuild cartilage and treat arthritis.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01229">
  <data key="d0">Paclitaxel</data>
  <data key="d1">drugbank.DB01229</data>
  <data key="d2">[drugbank.DB01229, drugbank.APRD00259, drugbank.DB05261, drugbank.DB05927, drugbank.DB05526, drugbank.DB05281]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Agents Causing Muscle Toxicity, Albumins, Amino Acids, Peptides, and Proteins, Antimitotic Agents, Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, BSEP/ABCB11 Inhibitors, BSEP/ABCB11 Substrates, BSEP/ABCB11 Substrates with Narrow Therapeutic Index, Cardiotoxic antineoplastic agents, Cyclodecanes, Cycloparaffins, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inducers, Diterpenes, Hypotensive Agents, Immunosuppressive Agents, Microtubule Inhibition, Microtubule Inhibitors, Mitosis Modulators, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Neurotoxic agents, OATP1B3 substrates, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, P-glycoprotein/ABCB1 Substrates with narrow therapeutic index, Proteins, Taxane Derivatives, Taxoids, Terpenes, Tubulin Modulators]</data>
  <data key="d14">(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0,.0,]heptadec-13-en-2-yl benzoate</data>
  <data key="d15">C47H51NO14</data>
  <data key="d16">33069-62-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1</data>
  <data key="d20">[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C</data>
  <data key="d21">Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(2aR-(2aalpha, 4beta, 4abeta, 6beta, 9alpha(alpha R*, betaS*), 11alpha, 12alpha, 12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6, 12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-methano-1H-cyclodeca(3, 4)benz(1, 2-b)oxet-9-yl ester, 5beta, 20-Epoxy-1, 2-alpha, 4, 7beta, 10beta, 13alpha-hexahydroxytax-11-en-9-one 4, 10-diacetate 2-benzoate 13-ester with (2R, 3S)-N-benzoyl-3-phenylisoserine, Paclitaxel, Taxol A]</data>
  <data key="d9">Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01226">
  <data key="d0">Mivacurium</data>
  <data key="d1">drugbank.DB01226</data>
  <data key="d2">[drugbank.DB01226, drugbank.APRD01119]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents producing tachycardia, Anticholinergic Agents, Central Nervous System Depressants, Cholinergic Agents, Muscarinic Antagonists, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular-Blocking Agents (Nondepolarizing), Nicotinic Antagonists, Peripheral Nervous System Agents]</data>
  <data key="d14">(1R)-2-(3-{[(4E)-8-{3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl]propoxy}-8-oxooct-4-enoyl]oxy}propyl)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium</data>
  <data key="d15">C58H80N2O14</data>
  <data key="d16">133814-19-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C58H80N2O14/c1-59(25-21-41-35-47(63-3)49(65-5)37-43(41)45(59)29-39-31-51(67-7)57(71-11)52(32-39)68-8)23-17-27-73-55(61)19-15-13-14-16-20-56(62)74-28-18-24-60(2)26-22-42-36-48(64-4)50(66-6)38-44(42)46(60)30-40-33-53(69-9)58(72-12)54(34-40)70-10/h13-14,31-38,45-46H,15-30H2,1-12H3/q+2/b14-13+/t45-,46-,59?,60?/m1/s1</data>
  <data key="d20">COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC</data>
  <data key="d21">For inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Mivacurium]</data>
  <data key="d9">Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01221">
  <data key="d0">Ketamine</data>
  <data key="d1">drugbank.DB01221</data>
  <data key="d2">[drugbank.DB01221, drugbank.APRD00493]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Agents producing tachycardia, Amino Acids, Amino Acids, Acidic, Amino Acids, Dicarboxylic, Amino Acids, Peptides, and Proteins, Analgesics, Anesthetics, Anesthetics, Dissociative, Anesthetics, General, Anesthetics, Intravenous, Aspartic Acid, Central Nervous System Agents, Central Nervous System Depressants, Cholinesterase Inhibitors, Cyclohexanes, Cycloparaffins, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Drugs that are Mainly Renally Excreted, Excitatory Amino Acid Agents, Excitatory Amino Acid Agonists, Excitatory Amino Acid Antagonists, Excitatory Amino Acids, Miscellaneous General Anesthetics, Nervous System, Neurotransmitter Agents, NMDA Receptor Antagonists, Peripheral Nervous System Agents, Sensory System Agents, Vasodilating Agents]</data>
  <data key="d14">2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one</data>
  <data key="d15">C13H16ClNO</data>
  <data key="d16">6740-88-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3</data>
  <data key="d20">CNC1(CCCCC1=O)C1=CC=CC=C1Cl</data>
  <data key="d21">Ketamine is indicated as an anesthetic agent for recommended diagnostic and surgical procedures. If skeletal muscle relaxation is needed, it should be combined with a muscle relaxant. If the surgical procedure involves visceral pain, it should be supplemented with an agent that obtunds visceral pain. Ketamine can be used for induction of anesthesia prior other general anesthetic agents and as a supplement of low potency agents.[L1336, FDA label]\n\nReports have indicated a potential use of ketamine as a therapeutic tool for the management of depression when administered in lower doses.[A31873] These reports have increased the interest for ketamine in this area and several clinical trials are launched for this indication.[L1337, A31874]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+-)-Ketamine, ()-ketamine, 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone, 2-(methylamino)-2-(2-chlorophenyl)cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone, DL-ketamine, Ketamina, Ketamine, Ktamine, Ketaminum, NMDA, Special K]</data>
  <data key="d9">Ketamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects. It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.[L1332]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01231">
  <data key="d0">Diphenidol</data>
  <data key="d1">drugbank.DB01231</data>
  <data key="d2">[drugbank.DB01231, drugbank.APRD00929]</data>
  <data key="d12">[approved, investigational, withdrawn]</data>
  <data key="d13">[Agents producing tachycardia, Anticholinergic Agents, Antiemetics, Autonomic Agents, Central Nervous System Agents, Emesis Suppression, Gastrointestinal Agents, Muscarinic Antagonists, Peripheral Nervous System Agents]</data>
  <data key="d14">1,1-diphenyl-4-(piperidin-1-yl)butan-1-ol</data>
  <data key="d15">C21H27NO</data>
  <data key="d16">972-02-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H27NO/c23-21(19-11-4-1-5-12-19,20-13-6-2-7-14-20)15-10-18-22-16-8-3-9-17-22/h1-2,4-7,11-14,23H,3,8-10,15-18H2</data>
  <data key="d20">OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d21">For use in the prevention and symptomatic treatment of peripheral (labyrinthine) vertigo and associated nausea and vomiting that occur in such conditions as Meniere's disease and surgery of the middle and inner ear. Also for the control of nausea and vomiting associated with postoperative states, malignant neoplasms, labyrinthine disturbances, antineoplastic agent therapy, radiation sickness, and infectious diseases.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[alpha, alpha-Diphenyl-1-piperidinebutanol, Difenidol, Difnidol, Difenidolo, Difenidolum, Diphenidol, Diphenyl(3-(1-piperidyl)propyl)carbinol]</data>
  <data key="d9">Diphenidol is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02556">
  <data key="d0">D-Phenylalanine</data>
  <data key="d1">drugbank.DB02556</data>
  <data key="d2">[drugbank.DB02556, drugbank.EXPT01257]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2R)-2-amino-3-phenylpropanoic acid</data>
  <data key="d15">C9H11NO2</data>
  <data key="d16">673-06-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m1/s1</data>
  <data key="d20">N[C@H](CC1=CC=CC=C1)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">An essential aromatic amino acid that is a precursor of melanin; dopamine; noradrenalin (norepinephrine), and thyroxine. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14533">
  <data key="d0">Zinc chloride</data>
  <data key="d1">drugbank.DB14533</data>
  <data key="d2">[drugbank.DB14533, drugbank.DBSALT001307]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Acids, Noncarboxylic, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Anions, Basic Ointments and Protectants, Biomedical and Dental Materials, Blood and Blood Forming Organs, Blood Substitutes and Perfusion Solutions, Chlorine Compounds, Compounds used in a research, industrial, or household setting, Copper Absorption Inhibitor, Cosmetics, Dental Agents, EENT Drugs, Miscellaneous, Electrolyte Solutions, Electrolytes, Household Products, Hydrochloric Acid, I.V. Solution Additives, Ions, Metal cations, Metal divalent cations, Mouthwashes, Skin Ulcer, drug therapy, Vasoprotectives, Zinc Compounds]</data>
  <data key="d14">zinc(2+) dichloride</data>
  <data key="d15">Cl2Zn</data>
  <data key="d16">7646-85-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/2ClH.Zn/h2*1H;/q;;+2/p-2</data>
  <data key="d20">[Cl-].[Cl-].[Zn++]</data>
  <data key="d21">Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01233">
  <data key="d0">Metoclopramide</data>
  <data key="d1">drugbank.DB01233</data>
  <data key="d2">[drugbank.DB01233, drugbank.APRD00665]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Carbocyclic, Agents Causing Muscle Toxicity, Alimentary Tract and Metabolism, Amides, Aminobenzoates, Antiemetics, Autonomic Agents, Benzamides and benzamide derivatives, Benzene Derivatives, Benzoates, Central Nervous System Agents, Chlorobenzoates, Cholinesterase Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 Enzyme Inhibitors, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs for Functional Gastrointestinal Disorders, Drugs that are Mainly Renally Excreted, Ethers, Gastrointestinal Agents, Hydroxy Acids, Hydroxybenzoate Ethers, Hydroxybenzoates, Methemoglobinemia Associated Agents, Neurotransmitter Agents, para-Aminobenzoates, Peripheral Nervous System Agents, Phenols, Phenyl Ethers, Potential QTc-Prolonging Agents, Prokinetic Agents, Propulsives, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome]</data>
  <data key="d14">4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide</data>
  <data key="d15">C14H22ClN3O2</data>
  <data key="d16">364-62-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)</data>
  <data key="d20">CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC</data>
  <data key="d21">For the treatment of gastroesophageal reflux disease (GERD). It is also used in treating nausea and vomiting, and to increase gastric emptying.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-methoxy-4-amino-5-chloro-N, N-(dimethylaminoethyl)benzamide, 2-methoxy-5-chloroprocainamide, 4-amino-5-chloro-2-methoxy-N-(-diethylaminoethyl)benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide, Metoclopramida, Metoclopramide, Metoclopramidum]</data>
  <data key="d9">A dopamine D2 antagonist that is used as an antiemetic.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01242">
  <data key="d0">Clomipramine</data>
  <data key="d1">drugbank.DB01242</data>
  <data key="d2">[drugbank.DB01242, drugbank.APRD00253, drugbank.DB07600]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Antidepressive Agents, Tricyclic, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Dibenzazepines, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index, Hypotensive Agents, Membrane Transport Modulators, Moderate Risk QTc-Prolonging Agents, Narrow Therapeutic Index Drugs, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Non-Selective Monoamine Reuptake Inhibitors, P-glycoprotein/ABCB1 Inhibitors, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Antagonists, Tertiary amine tricyclic antidepressants, Tricyclics and Other Norepinephrine-reuptake Inhibitors]</data>
  <data key="d14">(3-{14-chloro-2-azatricyclo[9.4.0.0,]pentadeca-1(11),3,5,7,12,14-hexaen-2-yl}propyl)dimethylamine</data>
  <data key="d15">C19H23ClN2</data>
  <data key="d16">303-49-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3</data>
  <data key="d20">CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2</data>
  <data key="d21">May be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourettes disorder).\nUnlabeled indications include: depression, panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy (limited evidence), autistic disorder (limited evidence), trichotillomania (limited evidence), onchophagia (limited evidence), stuttering (limited evidence), premature ejaculation, and premenstrual syndrome.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3-(3-chloro-10, 11-dihydro-5H-dibenzo[b, f]azepin-5-yl)-N, N-dimethyl-1-propanamine, 3-(3-chloro-5H-dibenzo[b, F]azepin-5-yl)-N, N-dimethylpropan-1-amine, 3-Chloroimipramine, Chlorimipramine, Clomipramina, Clomipramine, Clomipraminum, Monochlorimipramine]</data>
  <data key="d9">Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical &amp;beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H&lt;sub&gt;1&lt;/sub&gt; receptors, &amp;alpha;&lt;sub&gt;1&lt;/sub&gt;-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourettes disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03894">
  <data key="d0">N-Propargyl-1(S)-Aminoindan</data>
  <data key="d1">drugbank.DB03894</data>
  <data key="d2">[drugbank.DB03894, drugbank.EXPT02818]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(1S)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine</data>
  <data key="d15">C12H13N</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m0/s1</data>
  <data key="d20">[H][C@@]1(CCC2=C1C=CC=C2)NCC#C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01248">
  <data key="d0">Docetaxel</data>
  <data key="d1">drugbank.DB01248</data>
  <data key="d2">[drugbank.DB01248, drugbank.APRD00932]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents Causing Muscle Toxicity, Antimitotic Agents, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Cardiotoxic antineoplastic agents, Cyclodecanes, Cycloparaffins, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Diterpenes, Immunosuppressive Agents, Microtubule Inhibition, Microtubule Inhibitors, Mitosis Modulators, Myelosuppressive Agents, OATP1B3 substrates, P-glycoprotein/ABCB1 Substrates, Taxane Derivatives, Taxoids, Terpenes, Tubulin Modulators]</data>
  <data key="d14">(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0,.0,]heptadec-13-en-2-yl benzoate</data>
  <data key="d15">C43H53NO14</data>
  <data key="d16">114977-28-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1</data>
  <data key="d20">[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1</data>
  <data key="d21">For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Docetaxel, Docetaxel anhydrous, N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel, N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol, TXL]</data>
  <data key="d9">Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel reversibly binds to tubulin with high affinity in a 1:1 stoichiometric ratio</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01247">
  <data key="d0">Isocarboxazid</data>
  <data key="d1">drugbank.DB01247</data>
  <data key="d2">[drugbank.DB01247, drugbank.APRD00701]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Enzyme Inhibitors, Hypotensive Agents, Isoxazoles, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase Inhibitors, Monoamine Oxidase Inhibitors, Non-Selective, Nervous System, Psychoanaleptics, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators]</data>
  <data key="d14">N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide</data>
  <data key="d15">C12H13N3O2</data>
  <data key="d16">59-63-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16)</data>
  <data key="d20">CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1</data>
  <data key="d21">Isocarboxazid is indicated for the treatment of the enduring and debilitating symptoms of depression that have not responded to other antidepressant drugs.[L1372] Depression is a common but serious mood disorder. The patient will present changes in its feelings, thoughts, and ability to handle everyday activities. For a mood disorder to be considered as depression, the symptoms should be present for at least two weeks.[L1375]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Isocarboxazid, Isocarboxazida, Isocarboxazide, Isocarboxazidum]</data>
  <data key="d9">Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor.[A31930] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders.[T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01245">
  <data key="d0">Decamethonium</data>
  <data key="d1">drugbank.DB01245</data>
  <data key="d2">[drugbank.DB01245, drugbank.APRD00696]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amines, Ammonium Compounds, Bis-Trimethylammonium Compounds, Central Nervous System Depressants, Cholinesterase Inhibitors, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular Depolarizing Agents, Neurotoxic agents, Nitrogen Compounds, Onium Compounds, Peripheral Nervous System Agents, Quaternary Ammonium Compounds]</data>
  <data key="d14">trimethyl[10-(trimethylazaniumyl)decyl]azanium</data>
  <data key="d15">C16H38N2</data>
  <data key="d16">156-74-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H38N2/c1-17(2,3)15-13-11-9-7-8-10-12-14-16-18(4,5)6/h7-16H2,1-6H3/q+2</data>
  <data key="d20">C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C</data>
  <data key="d21">For use as a skeletal muscle relaxant</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Decamethonium, Decamethonium cation, Decamethonium ion, Decamethonum, Decamethylenebis(trimethylammonium), N, N, N, N', N', N'-hexamethyl-1, 10-decanediaminium]</data>
  <data key="d9">Decamethonium is used in anesthesia to cause paralysis. It is a short acting depolarizing muscle relaxant. It is similar to acetylcholine and acts as a partial agonist of the nicotinic acetylcholine receptor.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01244">
  <data key="d0">Bepridil</data>
  <data key="d1">drugbank.DB01244</data>
  <data key="d2">[drugbank.DB01244, drugbank.APRD00727]</data>
  <data key="d12">[approved, withdrawn]</data>
  <data key="d13">[Agents causing hyperkalemia, Antiarrhythmic agents, Antihypertensive Agents, Bradycardia-Causing Agents, Calcium Channel Blockers, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Highest Risk QTc-Prolonging Agents, Hypotensive Agents, Membrane Transport Modulators, Non-Selective Calcium Channel Blockers, P-glycoprotein/ABCB1 Inhibitors, Phenylalkylamine Derivatives, Pyrrolidines, QTc Prolonging Agents, Vasodilating Agents]</data>
  <data key="d14">N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline</data>
  <data key="d15">C24H34N2O</data>
  <data key="d16">64706-54-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3</data>
  <data key="d20">CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1</data>
  <data key="d21">For the treatment of hypertension, and chronic stable angina (classic effort-associated angina).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Bepadin, Bepridil]</data>
  <data key="d9">A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01252">
  <data key="d0">Mitiglinide</data>
  <data key="d1">drugbank.DB01252</data>
  <data key="d2">[drugbank.DB01252]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Blood Glucose Lowering Agents, Drugs Used in Diabetes, Oral Hypoglycemics, UGT1A3 substrates, UGT2B7 substrates]</data>
  <data key="d14">(2S)-4-[(3aR,7aS)-octahydro-1H-isoindol-2-yl]-2-benzyl-4-oxobutanoic acid</data>
  <data key="d15">C19H25NO3</data>
  <data key="d16">145375-43-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1</data>
  <data key="d20">[H][C@@](CC(=O)N1C[C@@]2([H])CCCC[C@@]2([H])C1)(CC1=CC=CC=C1)C(O)=O</data>
  <data key="d21">For the treatment of type 2 diabetes.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Mitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01259">
  <data key="d0">Lapatinib</data>
  <data key="d1">drugbank.DB01259</data>
  <data key="d2">[drugbank.DB01259, drugbank.DB02584]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Kinase Inhibitor, P-glycoprotein/ABCB1 Inhibitors, Potential QTc-Prolonging Agents, Protein Kinase Inhibitors, QTc Prolonging Agents, Tyrosine Kinase Inhibitors]</data>
  <data key="d14">N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine</data>
  <data key="d15">C29H26ClFN4O4S</data>
  <data key="d16">231277-92-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)</data>
  <data key="d20">CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1</data>
  <data key="d21">Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Lapatinib, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine]</data>
  <data key="d9">Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug Capecitabine. Lapatinib is human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01254">
  <data key="d0">Dasatinib</data>
  <data key="d1">drugbank.DB01254</data>
  <data key="d2">[drugbank.DB01254]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, CYP3A Substrates (Sensitive), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P450 3A4 Inhibitors, Enzyme Inhibitors, Immunosuppressive Agents, Kinase Inhibitor, Myelosuppressive Agents, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Potential QTc-Prolonging Agents, Protein Kinase Inhibitors, Pyrimidines, QTc Prolonging Agents, Sulfur Compounds, Thiazoles, Tyrosine Kinase Inhibitors]</data>
  <data key="d14">N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide</data>
  <data key="d15">C22H26ClN7O2S</data>
  <data key="d16">302962-49-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)</data>
  <data key="d20">CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1</data>
  <data key="d21">For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[anh. dasatinib, Anhydrous dasatinib, BMS dasatinib, Dasatinib, Dasatinib (anh.), dasatinib (anhydrous), Dasatinib anhydrous, Dasatinibum, N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1, 3-thiazole-5-carboxamide]</data>
  <data key="d9">Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02589">
  <data key="d0">Se-Ethyl-Isoselenourea</data>
  <data key="d1">drugbank.DB02589</data>
  <data key="d2">[drugbank.DB02589, drugbank.EXPT01939]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(ethylselanyl)methanimidamide</data>
  <data key="d15">C3H8N2Se</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C3H8N2Se/c1-2-6-3(4)5/h2H2,1H3,(H3,4,5)</data>
  <data key="d20">CC[Se]C(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03847">
  <data key="d0">Gamma-Carboxy-Glutamic Acid</data>
  <data key="d1">drugbank.DB03847</data>
  <data key="d2">[drugbank.DB03847, drugbank.EXPT00902]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(1S)-1-aminopropane-1,3,3-tricarboxylic acid</data>
  <data key="d15">C6H9NO6</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C6H9NO6/c7-3(6(12)13)1-2(4(8)9)5(10)11/h2-3H,1,7H2,(H,8,9)(H,10,11)(H,12,13)/t3-/m0/s1</data>
  <data key="d20">N[C@@H](CC(C(O)=O)C(O)=O)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14509">
  <data key="d0">Lithium carbonate</data>
  <data key="d1">drugbank.DB14509</data>
  <data key="d2">[drugbank.DB14509, drugbank.DBSALT001075]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acids, Acids, Noncarboxylic, Alkalies, Anions, Antidepressive Agents, Antimanic Agents, Carbon Compounds, Inorganic, Carbonates, Carbonic Acid, Central Nervous System Agents, Central Nervous System Depressants, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index, Electrolytes, Enzyme Inhibitors, Ions, Lithium Compounds, Mood Stabilizer, Narrow Therapeutic Index Drugs, Psychotropic Drugs, Tranquilizing Agents]</data>
  <data key="d14">dilithium(1+) carbonate</data>
  <data key="d15">CLi2O3</data>
  <data key="d16">554-13-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/CH2O3.2Li/c2-1(3)4;;/h(H2,2,3,4);;/q;2*+1/p-2</data>
  <data key="d20">[Li+].[Li+].[O-]C([O-])=O</data>
  <data key="d21">Lithium is used as a mood stabilizer, and is indicated for the treatment of manic episodes and maintenance of bipolar disorder[FDA Label].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Carbonic acid, dilithium salt, Dilithium carbonate, Lithii carbonas, Lithium carbonate, Lithonate]</data>
  <data key="d9">Lithium has been used to treat manic episodes since the 19th century[A176642]. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14508">
  <data key="d0">Lithium succinate</data>
  <data key="d1">drugbank.DB14508</data>
  <data key="d2">[drugbank.DB14508, drugbank.DBSALT002479]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Acids, Acyclic, Dermatologicals, Dicarboxylic Acids, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index, Lithium Compounds, Narrow Therapeutic Index Drugs, Ointments]</data>
  <data key="d14">dilithium(1+) butanedioate</data>
  <data key="d15">C4H4Li2O4</data>
  <data key="d16">29126-50-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C4H6O4.2Li/c5-3(6)1-2-4(7)8;;/h1-2H2,(H,5,6)(H,7,8);;/q;2*+1/p-2</data>
  <data key="d20">[Li+].[Li+].[O-]C(=O)CCC([O-])=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Butanedioic acid, dilithium salt, Dilithium succinate, Lithium succinate dibasic, Lithium succinate, dibasic, Succinic acid dilithium salt, Succinic acid, dilithium salt]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14507">
  <data key="d0">Lithium citrate</data>
  <data key="d1">drugbank.DB14507</data>
  <data key="d2">[drugbank.DB14507, drugbank.DBSALT001430]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acids, Acyclic, Antimanic Agents, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index, Lithium Compounds, Mood Stabilizer, Narrow Therapeutic Index Drugs, Tricarboxylic Acids]</data>
  <data key="d14">trilithium(1+) 2-hydroxypropane-1,2,3-tricarboxylate</data>
  <data key="d15">C6H5Li3O7</data>
  <data key="d16">919-16-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C6H8O7.3Li/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3</data>
  <data key="d20">[Li+].[Li+].[Li+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O</data>
  <data key="d21">Lithium is used as a mood stabilizer, and is used for treatment of depression and mania. It is often used in bipolar disorder treatment.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Anhydrous lithium citrate, Citric acid, trilithium salt, Lithium citrate (anhydrous), Trilithium citrate]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02526">
  <data key="d0">CRA_10655</data>
  <data key="d1">drugbank.DB02526</data>
  <data key="d2">[drugbank.DB02526, drugbank.EXPT00270]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-{5-[amino(iminiumyl)methyl]-1H-1,3-benzodiazol-2-yl}-6-(cyclopentyloxy)benzen-1-olate</data>
  <data key="d15">C19H20N4O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H20N4O2/c20-18(21)11-8-9-14-15(10-11)23-19(22-14)13-6-3-7-16(17(13)24)25-12-4-1-2-5-12/h3,6-10,12,24H,1-2,4-5H2,(H3,20,21)(H,22,23)</data>
  <data key="d20">NC(=[NH2+])C1=CC=C2NC(=NC2=C1)C1=CC=CC(OC2CCCC2)=C1[O-]</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14501">
  <data key="d0">Ferrous glycine sulfate</data>
  <data key="d1">drugbank.DB14501</data>
  <data key="d2">[drugbank.DB14501, drugbank.DBSALT000081]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Antianemic Preparations, Blood and Blood Forming Organs, Iron Bivalent, Oral Preparations, Iron Preparations]</data>
  <data key="d14">lambda2-iron(2+) sulfuric acid bis(2-aminoacetate)</data>
  <data key="d15">C4H10FeN2O8S</data>
  <data key="d16">14729-84-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/2C2H5NO2.Fe.H2O4S/c2*3-1-2(4)5;;1-5(2,3)4/h2*1,3H2,(H,4,5);;(H2,1,2,3,4)/q;;+2;/p-2</data>
  <data key="d20">[Fe++].NCC([O-])=O.NCC([O-])=O.OS(O)(=O)=O</data>
  <data key="d21">Used in preventing and treating iron-deficiency anemia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Ferrous (II) Glycine Sulphate Complex, Ferrous glycine sulphate, Iron(II) glycine sulfate]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03865">
  <data key="d0">6-Chloro-2-(2-Hydroxy-Biphenyl-3-Yl)-1h-Indole-5-Carboxamidine</data>
  <data key="d1">drugbank.DB03865</data>
  <data key="d2">[drugbank.DB03865, drugbank.EXPT00023]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">{amino[6-chloro-2-(2-hydroxy-3-phenylphenyl)-1H-indol-5-yl]methylidene}azanium</data>
  <data key="d15">C21H17ClN3O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H16ClN3O/c22-17-11-18-13(9-16(17)21(23)24)10-19(25-18)15-8-4-7-14(20(15)26)12-5-2-1-3-6-12/h1-11,25-26H,(H3,23,24)/p+1</data>
  <data key="d20">NC(=[NH2+])C1=CC2=C(NC(=C2)C2=CC=CC(=C2O)C2=CC=CC=C2)C=C1Cl</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14518">
  <data key="d0">Aluminum acetate</data>
  <data key="d1">drugbank.DB14518</data>
  <data key="d2">[drugbank.DB14518, drugbank.DBSALT001466]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Acyclic, Fatty Acids, Fatty Acids, Volatile, Lipids]</data>
  <data key="d14">aluminium(3+) triacetate</data>
  <data key="d15">C6H9AlO6</data>
  <data key="d16">139-12-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/3C2H4O2.Al/c3*1-2(3)4;/h3*1H3,(H,3,4);/q;;;+3/p-3</data>
  <data key="d20">[Al+3].CC([O-])=O.CC([O-])=O.CC([O-])=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14517">
  <data key="d0">Aluminium phosphate</data>
  <data key="d1">drugbank.DB14517</data>
  <data key="d2">[drugbank.DB14517, drugbank.DBSALT002422]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Acids, Noncarboxylic, Adjuvants, Immunologic, Alimentary Tract and Metabolism, Aluminium Compounds, Anions, Antacids, Drugs for Acid Related Disorders, Electrolytes, Gastric Acid Lowering Agents, Gastrointestinal Agents, Immunologic Factors, Ions, Metal cations, Metal divalent cations, Phosphoric Acids, Phosphorus Acids, Phosphorus Compounds]</data>
  <data key="d14">aluminium(3+) phosphate</data>
  <data key="d15">AlO4P</data>
  <data key="d16">7784-30-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/Al.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+3;/p-3</data>
  <data key="d20">[Al+3].[O-]P([O-])([O-])=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Aluminum phosphate]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02551">
  <data key="d0">6-[N-(4-Ethyl-1,2,3,4-Tetrahydro-6-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine</data>
  <data key="d1">drugbank.DB02551</data>
  <data key="d2">[drugbank.DB02551, drugbank.EXPT00201]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">6-carbamimidoyl-N-[(4R)-4-ethyl-1,2,3,4-tetrahydroisoquinolin-6-yl]naphthalene-2-carboxamide</data>
  <data key="d15">C23H24N4O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H24N4O/c1-2-14-12-26-13-19-7-8-20(11-21(14)19)27-23(28)18-6-4-15-9-17(22(24)25)5-3-16(15)10-18/h3-11,14,26H,2,12-13H2,1H3,(H3,24,25)(H,27,28)/t14-/m0/s1</data>
  <data key="d20">[H][C@]1(CC)CNCC2=C1C=C(NC(=O)C1=CC=C3C=C(C=CC3=C1)C(N)=N)C=C2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03876">
  <data key="d0">Thieno[2,3-B]Pyridine-2-Carboxamidine</data>
  <data key="d1">drugbank.DB03876</data>
  <data key="d2">[drugbank.DB03876, drugbank.EXPT01363]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">[amino(thieno[2,3-b]pyridin-2-yl)methylidene]azanium</data>
  <data key="d15">C8H8N3S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C8H7N3S/c9-7(10)6-4-5-2-1-3-11-8(5)12-6/h1-4H,(H3,9,10)/p+1</data>
  <data key="d20">NC(=[NH2+])C1=CC2=C(S1)N=CC=C2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02615">
  <data key="d0">Compound 19</data>
  <data key="d1">drugbank.DB02615</data>
  <data key="d2">[drugbank.DB02615, drugbank.EXPT00478, drugbank.EXPT00338]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S,3R)-3-(4-hydroxyphenyl)-2-{4-[(2R)-2-(pyrrolidin-1-yl)propoxy]phenyl}-2,3-dihydro-1,4-benzoxathiin-6-ol</data>
  <data key="d15">C27H29NO4S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C27H29NO4S/c1-18(28-14-2-3-15-28)17-31-23-11-6-19(7-12-23)26-27(20-4-8-21(29)9-5-20)33-25-16-22(30)10-13-24(25)32-26/h4-13,16,18,26-27,29-30H,2-3,14-15,17H2,1H3/t18-,26+,27-/m1/s1</data>
  <data key="d20">[H][C@@](C)(COC1=CC=C(C=C1)[C@]1([H])OC2=C(S[C@]1([H])C1=CC=C(O)C=C1)C=C(O)C=C2)N1CCCC1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03900">
  <data key="d0">2-Methyl-2-Propanol</data>
  <data key="d1">drugbank.DB03900</data>
  <data key="d2">[drugbank.DB03900, drugbank.EXPT03021]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-methylpropan-2-ol</data>
  <data key="d15">C4H10O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C4H10O/c1-4(2,3)5/h5H,1-3H3</data>
  <data key="d20">CC(C)(C)O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03906">
  <data key="d0">2-Phenylheme</data>
  <data key="d1">drugbank.DB03906</data>
  <data key="d2">[drugbank.DB03906, drugbank.EXPT00117]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">5,9-bis(2-carboxyethyl)-14,19-diethenyl-4,10,15,20-tetramethyl-7-phenyl-2,22,23,25-tetraaza-1-ferraoctacyclo[11.9.1.1,.1,.0,.0,.0,.0,]pentacosa-2,4,6,8,10,12,14,16(23),17,19,21(24)-undecaene-2,23-bis(ylium)</data>
  <data key="d15">C40H36FeN4O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C40H38N4O4.Fe/c1-7-26-21(3)30-18-32-23(5)28(14-16-36(45)46)39(43-32)38(25-12-10-9-11-13-25)40-29(15-17-37(47)48)24(6)33(44-40)20-35-27(8-2)22(4)31(42-35)19-34(26)41-30;/h7-13,18-20H,1-2,14-17H2,3-6H3,(H4,41,42,43,44,45,46,47,48);/q;+4/p-2/b30-18-,31-19-,32-18-,33-20-,34-19-,35-20-,39-38-,40-38-;</data>
  <data key="d20">CC1=C(C=C)C2=CC3=[N+]4C(=CC5=C(C)C(CCC(O)=O)=C6N5[Fe]44N2C1=CC1=[N+]4C(C(CCC(O)=O)=C1C)=C6C1=CC=CC=C1)C(C=C)=C3C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03909">
  <data key="d0">Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate</data>
  <data key="d1">drugbank.DB03909</data>
  <data key="d2">[drugbank.DB03909, drugbank.EXPT00416]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">({[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}methyl)phosphonic acid</data>
  <data key="d15">C11H18N5O12P3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H18N5O12P3/c12-9-6-10(14-2-13-9)16(3-15-6)11-8(18)7(17)5(27-11)1-26-31(24,25)28-30(22,23)4-29(19,20)21/h2-3,5,7-8,11,17-18H,1,4H2,(H,22,23)(H,24,25)(H2,12,13,14)(H2,19,20,21)/t5-,7-,8-,11-/m1/s1</data>
  <data key="d20">[H][C@]1(COP(O)(=O)OP(O)(=O)CP(O)(O)=O)O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03910">
  <data key="d0">S,S'-(1,3-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea</data>
  <data key="d1">drugbank.DB03910</data>
  <data key="d2">[drugbank.DB03910, drugbank.EXPT00164]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">[(2-{3-[2-(carbamimidoylsulfanyl)ethyl]phenyl}ethyl)sulfanyl]methanimidamide</data>
  <data key="d15">C12H18N4S2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H18N4S2/c13-11(14)17-6-4-9-2-1-3-10(8-9)5-7-18-12(15)16/h1-3,8H,4-7H2,(H3,13,14)(H3,15,16)</data>
  <data key="d20">NC(=N)SCCC1=CC(CCSC(N)=N)=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03918">
  <data key="d0">6S-5,6,7,8-Tetrahydrobiopterin</data>
  <data key="d1">drugbank.DB03918</data>
  <data key="d2">[drugbank.DB03918, drugbank.EXPT00702]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(1S,2R)-1-[(6R)-4-hydroxy-2-imino-1,2,5,6,7,8-hexahydropteridin-6-yl]propane-1,2-diol</data>
  <data key="d15">C9H15N5O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,4-,6-/m1/s1</data>
  <data key="d20">[H][C@](C)(O)[C@@]([H])(O)[C@@]1([H])CNC2=C(N1)C(O)=NC(=N)N2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00056">
  <data key="d0">Gemtuzumab ozogamicin</data>
  <data key="d1">drugbank.DB00056</data>
  <data key="d2">[drugbank.DB00056, drugbank.BTD00077, drugbank.BIOD00077]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Antibodies, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Blood Proteins, Carbohydrates, CD33-directed Antibody Interactions, CD33-directed Cytotoxin, Globulins, Glycosides, Immunoconjugates, Immunoglobulins, Immunoproteins, Immunosuppressive Agents, Immunotoxins, Myelosuppressive Agents, Noxae, Proteins, Serum Globulins, Toxic Actions]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">220578-59-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Indicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory).</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;dbbb0660-51d3-479b-925f-a63d1615fa1e  Light Chain No. 1\nQIVLTQSPAIMSASPGEKVTITCSASSSISYMHWFQQKPGTSPKLWIYTTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCHQRSTYPLTFGSGTKLELK, &gt;6f657172-e862-485f-98fd-70b568b0ea2c  Light Chain No. 2\nDIQMTQSPSTLSASVGDRVTITCRASQSINTWLAWYQQKPGKAPKLLMYKASSLESGVPSRFIGSGSGTEFTLTISSLQPDDFATYYCQQYNSDSKMFGQGTKVEVK, &gt;6d68b5b8-d7f6-4200-9b03-7c24452031ee  Heavy Chain No. 1\nQVQLQQSGAELAKPGASVKMSCKASGYTFTSYRMHWVKQRPGQGLEWIGYINPSTGYTEYNQKFKDKATLTADKSSSTAYMQLSSLTFEDSAVYYCARGGGVFDYWGQGTTLTVSS, &gt;7b9e34ff-4d8b-43c8-9ad2-92e8a67a5752  Heavy Chain No. 2\nQVQLVQSGAEVKKPGSSVKVSCKASGGTFSRSAIIWVRQAPGQGLEWMGGIVPMFGPPNYAQKFQGRVTITADESTNTAYMELSSLRSEDTAFYFCAGGYGIYSPEEYNGGLVTVSS]</data>
  <data key="d8">[]</data>
  <data key="d9">Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody [FDA Label]. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death. \n\nMarketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy [A98]. However, it was voluntarily withdrawn from the market in 2010 due to safety concerns, increased patient deaths and insufficient evidence of clinical benefit during confirmatory trials [L941]. On September 1 2017, gemtuzumab ozogamicin was again approved for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia but with a lower dosing regimen and a different schedule in combination with chemotherapy or on its own [L941]. It is also indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory) [L941].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00055">
  <data key="d0">Drotrecogin alfa</data>
  <data key="d1">drugbank.DB00055</data>
  <data key="d2">[drugbank.DB00055, drugbank.BTD00068, drugbank.BIOD00068]</data>
  <data key="d12">[approved, investigational, withdrawn]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Anti-Infective Agents, Anticoagulants, Biological Factors, Blood and Blood Forming Organs, Blood Coagulation Factor Inhibitors, Blood Proteins, Carbohydrates, Enzyme Precursors, Enzymes, Enzymes and Coenzymes, Fibrinolytic Agents, Glycoconjugates, Glycoproteins, Proteins, Recombinant Activated Protein C]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">98530-76-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">For reduction of mortality in patients with severe sepsis.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;c9f29266-ecaa-4f04-8487-d681c1e45a99 Heavy chain\nLIDGKMTRRGDSPWQVVLLDSKKKLACGAVLIHPSWVLTAAHCMDESKKLLVRLGEYDLRRWEKWELDLDIKEVFVHPNYSKSTTDNDIALLHLAQPATLSQTIVPICLPDSGLAERELNQAGQETLVTGWGYHSSREKEAKRNRTFVLNFIKIPVVPHNECSEVMSNMVSENMLCAGILGDRQDACEGDSGGPMVASFHGTWFLVGLVSWGEGCGLLHNYGVYTKVSRYLDWIHGHIRDKEAPQKSWAP, &gt;473c696b-1ea5-4d98-b5ea-d66b3d2e5d64 Light chain\nSKHVDGDQCLVLPLEHPCASLCCGHGTCIXGIGSFSCDCRSGWEGRFCQREVSFLNCSLDNGGCTHYCLEEVGWRRCSCAPGYKLGDDLLQCHPAVKFPCGRPWKRMEKKRSHL]</data>
  <data key="d8">[Activated protein C, Blood coagulation factor XIV (human), Drotrecogin alfa (activated), Drotrecogin alfa (activated), lyophilized, Drotrecogin alfa activated, Drotrecogin alfa, activated, Drotrecogin-alfa, Recombinant human activated protein C (rH-APC)]</data>
  <data key="d9">Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00065">
  <data key="d0">Infliximab</data>
  <data key="d1">drugbank.DB00065</data>
  <data key="d2">[drugbank.DB00065, drugbank.BTD00004, drugbank.BIOD00004]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents Causing Muscle Toxicity, Agents reducing cytokine levels, Amino Acids, Peptides, and Proteins, Antibodies, Antibodies, Monoclonal, Antineoplastic and Immunomodulating Agents, Antirheumatic Agents, Biologics for Rheumatoid Arthritis Treatment, Blood Proteins, Dermatologicals, Disease-modifying Antirheumatic Agents, Gastrointestinal Agents, Globulins, Immunoglobulins, Immunoproteins, Immunosuppressive Agents, Proteins, Serum Globulins, Tumor Necrosis Factor Alpha (TNF-) Inhibitors, Tumor Necrosis Factor Blocker, Tumor Necrosis Factor Receptor Blocking Activity]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">170277-31-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">* Indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult or pediatric ( 6 years of age) patients with moderately to severely active **Crohns disease** who have had an inadequate response to conventional therapy\n* Indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing **Crohns disease**. \n* Indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric ( 6 years of age) patients with moderately to severely active **ulcerative colitis** who have had an inadequate response to conventional therapy. \n* Indicated for, in combination with methotrexate, reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active **rheumatoid arthritis**. \n* Indicated for reducing signs and symptoms in patients with active **ankylosing spondylitis**. \n* Indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with **psoriatic arthritis**. \n* Indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) **plaque psoriasis** who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Infliximab (genetical recombination), Infliximab-abda, Infliximab-dyyb, Infliximab-qbtx]</data>
  <data key="d9">Infliximab is a tumor necrosis factor (TNF-alpha or TNF-) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions [A31469]. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-) is a key proinflammatory cytokine involved in chronic inflammatory diseases [A31469]. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF- [A106], infliximab disrupts the interaction of TNF- with its receptors and may also cause lysis of cells that produce TNF- [A106].\n\nInfliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment of various inflammatory disorders such as adult or pediatric Chron's disease, adult or pediatric ulcerative colitis, rheumatoid arthritis in combination with methotrexate, ankylosing spondyliti, psoriatic arthritis, and plaque psoriasis [FDA Label]. In clinical trials, multiple infusions of infliximab displayed in a reduction of signs and symptoms of inflammatory diseases and induction of remission in patients who have had an inadequate response to alternative first-line therapies for that disorder [FDA Label]. \n\nThere are currently two biosilimars of infliximab available in the US market that demonstrate a high degree of similarity to the reference product, Remicade. They are approved for all eligible indications of the reference product. Inflectra, a first biosimilar drug product, was approved in 2016. In December 2017, Ixifi, a second biosimilar that was developed by Pfizer, was granted approval by the FDA.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01393">
  <data key="d0">Bezafibrate</data>
  <data key="d1">drugbank.DB01393</data>
  <data key="d2">[drugbank.DB01393, drugbank.DB08380]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Acyclic, Acids, Carbocyclic, Agents Causing Muscle Toxicity, Amides, Benzamides and benzamide derivatives, Benzene Derivatives, Benzoates, Butyrates, Chlorobenzoates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Ethers, Fatty Acids, Fatty Acids, Volatile, Fibric Acids, Fribic Acid Derivatives, Hypolipidemic Agents, Isobutyrates, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, Lipids, Noxae, OATP1B1/SLCO1B1 Inhibitors, Phenols, Phenyl Ethers, Toxic Actions]</data>
  <data key="d14">2-(4-{2-[(4-chlorophenyl)formamido]ethyl}phenoxy)-2-methylpropanoic acid</data>
  <data key="d15">C19H20ClNO4</data>
  <data key="d16">41859-67-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)</data>
  <data key="d20">CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O</data>
  <data key="d21">For the treatment of primary hyperlipidaemia types IIa, IIb, III, IV and V (Fredrickson classification) corresponding to groups I, II and III of the European Atherosclerosis Society guidelines - when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. Also for the treatment of secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid, Bezafibrate, Bezafibrato, Bezafibratum]</data>
  <data key="d9">Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01392">
  <data key="d0">Yohimbine</data>
  <data key="d1">drugbank.DB01392</data>
  <data key="d2">[drugbank.DB01392]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic alpha-2 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Alkaloids, Antidepressive Agents, Autonomic Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs Used in Erectile Dysfunction, Genito Urinary System and Sex Hormones, Indole Alkaloids, Indoles, Mydriatics, Neurotransmitter Agents, Other Miscellaneous Therapeutic Agents, P-glycoprotein/ABCB1 Inhibitors, Peripheral Nervous System Agents, Secologanin Tryptamine Alkaloids, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Urological Agents, Urologicals]</data>
  <data key="d14">methyl (1S,15R,18S,19R,20S)-18-hydroxy-3,13-diazapentacyclo[11.8.0.0,.0,.0,]henicosa-2(10),4,6,8-tetraene-19-carboxylate</data>
  <data key="d15">C21H26N2O3</data>
  <data key="d16">146-48-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2</data>
  <data key="d21">Indicated as a sympatholytic and mydriatic. Impotence has been successfully treated with yohimbine in male patients with vascular or diabetic origins and psychogenic origins.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+)-yohimbine, (16, 17)-17-hydroxyyohimban-16-carboxylic acid methyl ester, 17-hydroxyyohimban-16-carboxylic acid methyl ester, Johimbin, Quebrachin, Yohimbic acid methyl ester, Yohimbin, Yohimbine, Yohimbinum]</data>
  <data key="d9">A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00071">
  <data key="d0">Insulin Pork</data>
  <data key="d1">drugbank.DB00071</data>
  <data key="d2">[drugbank.DB00071, drugbank.BTD00031, drugbank.BIOD00031]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Amino Acids, Peptides, and Proteins, Blood Glucose Lowering Agents, Drugs Used in Diabetes, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Insulin, Insulins and Analogues, Insulins and Analogues for Injection, Fast-Acting, Insulins and Analogues for Injection, Intermediate- or Long-Acting Combined With Fast-Acting, Insulins and Analogues for Injection, Intermediate-Acting, Insulins and Analogues for Injection, Long-Acting, Pancreatic Hormones, Peptide Hormones, Peptides, Proinsulin, Protein Precursors, Proteins]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">12584-58-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">For the treatment of type I and II diabetes mellitus.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;f8baf406-ae6b-49ac-8f57-1f2b59cf7b41 A chain\nGIVEQCCTSICSLYQLENYCN, &gt;6a82e6dc-cf1e-4d23-b8cf-df5a6c0412f0 B chain\nFVNQHLCGSHLVEALYLVCGERGFFYTPKT]</data>
  <data key="d8">[Insulin (pork), Insulin porcine, Insulin purified porcine, Insulin purified pork, Insulin, porcine, Insulin, regular, pork, Porcine insulin]</data>
  <data key="d9">Insulin isolated from pig pancreas. Composed of alpha and beta chains, processed from pro-insulin. Forms a hexameric structure.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01348">
  <data key="d0">Spirapril</data>
  <data key="d1">drugbank.DB01348</data>
  <data key="d2">[drugbank.DB01348]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Amino Acids, Peptides, and Proteins, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Agents, Dipeptides, Enzyme Inhibitors, Oligopeptides, Peptides, Protease Inhibitors]</data>
  <data key="d14">(8S)-7-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid</data>
  <data key="d15">C22H30N2O5S2</data>
  <data key="d16">83647-97-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1</data>
  <data key="d20">CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(O)=O)SCCS2</data>
  <data key="d21">Spirapril is an ACE inhibitor class drug used to treat hypertension.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Espirapril, Spirapril, Spiraprilum]</data>
  <data key="d9">Spirapril is an ACE inhibitor antihypertensive drug used to treat hypertension. Spirapril is converted to the active spiraprilat after administration. ACE inhibitors are used primarily in treatment of hypertension and congestive heart failure.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00013">
  <data key="d0">Urokinase</data>
  <data key="d1">drugbank.DB00013</data>
  <data key="d2">[drugbank.DB00013, drugbank.BTD00030, drugbank.BIOD00030]</data>
  <data key="d12">[approved, investigational, withdrawn]</data>
  <data key="d13">[Agents causing angioedema, Amino Acids, Peptides, and Proteins, Anticoagulants, Biological Factors, Blood and Blood Forming Organs, Blood Proteins, Endopeptidases, Enzymes, Enzymes and Coenzymes, Fibrinolytic Agents, Hydrolases, Increased Thrombolysis, Peptide Hydrolases, Plasminogen Activators, Proteins, Serine Endopeptidases, Serine Proteases]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">9039-53-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Urokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;785d6dbf-e4d2-49a5-823b-329fbdc4e720 DB00013 sequence\nKPSSPPEELKFQCGQKTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLMSPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLAL]</data>
  <data key="d8">[Kinase (enzyme-activating), uro-urokinase, TCUK, Tissue culture urokinase, Two-chain urokinase, Urochinasi, Urokinase, Urokinasum, Uroquinasa]</data>
  <data key="d9">Low molecular weight form of human urokinase, that consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a B chain of 30,400 daltons. Recombinant urokinase plasminogen activator.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01352">
  <data key="d0">Aprobarbital</data>
  <data key="d1">drugbank.DB01352</data>
  <data key="d2">[drugbank.DB01352]</data>
  <data key="d12">[experimental, illicit]</data>
  <data key="d13">[Anticholinergic Agents, Barbiturates, Plain, Central Nervous System Depressants, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Hypnotics and Sedatives, Nervous System, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones]</data>
  <data key="d14">5-(prop-2-en-1-yl)-5-(propan-2-yl)-1,3-diazinane-2,4,6-trione</data>
  <data key="d15">C10H14N2O3</data>
  <data key="d16">77-02-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H14N2O3/c1-4-5-10(6(2)3)7(13)11-9(15)12-8(10)14/h4,6H,1,5H2,2-3H3,(H2,11,12,13,14,15)</data>
  <data key="d20">CC(C)C1(CC=C)C(=O)NC(=O)NC1=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[5-(1-methylethyl)-5-(2-propenyl)-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione, 5-allyl-5-isopropylbarbituric acid, 5-allyl-5-isopropylpyrimidine-2, 4, 6(1H, 3H, 5H)-trione, 5-isopropyl-5-allylbarbituric acid, Allypropymal, Aprobarbital, Aprobarbitale, Aprobarbitalum]</data>
  <data key="d9">Aprobarbital is a barbiturate derivative synthesized in the 1920s by Ernst Preiswerk. It was determined that the substance was capable of demonstrating sedative, hypnotic, and anticonvulsant effects. A primary treatment indicated for the use of aprobarbital was subsequently insomnia. Aprobarbital was never as widely used as more common barbiturate derivatives such as phenobarbital and is now rarely prescribed.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02673">
  <data key="d0">(4ar,6s,8ar)-11-[8-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Octyl]-6-Hydroxy-3-Methoxy-5,6,9,10-Tetrahydro-4ah-[1]Benzofuro[3a,3,2-Ef][2]Benzazepin-11-Ium</data>
  <data key="d1">drugbank.DB02673</data>
  <data key="d2">[drugbank.DB02673, drugbank.EXPT01601]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">[(1S,12S,14R)-4-[8-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)octyl]-14-hydroxy-11-oxa-4-azatetracyclo[8.6.1.0,.0,]heptadeca-5,7,10(17),15-tetraen-9-ylidene](methyl)oxidanium</data>
  <data key="d15">C32H37N2O5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C32H37N2O5/c1-38-26-13-12-22-21-33(19-16-32-15-14-23(35)20-27(32)39-29(26)28(22)32)17-8-4-2-3-5-9-18-34-30(36)24-10-6-7-11-25(24)31(34)37/h6-7,10-15,21,23,27,35H,2-5,8-9,16-20H2,1H3/q+1/t23-,27-,32-/m0/s1</data>
  <data key="d20">[H][C@]12C[C@@]([H])(O)C=C[C@]11CCN(CCCCCCCCN3C(=O)C4=CC=CC=C4C3=O)C=C3C=CC(=[O+]C)C(O2)=C13</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01351">
  <data key="d0">Amobarbital</data>
  <data key="d1">drugbank.DB01351</data>
  <data key="d2">[drugbank.DB01351]</data>
  <data key="d12">[approved, illicit]</data>
  <data key="d13">[Anticholinergic Agents, Anticonvulsants, Barbiturates, Barbiturates, Plain, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2A6 Inducers, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, GABA Agents, GABA Modulators, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones]</data>
  <data key="d14">5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione</data>
  <data key="d15">C11H18N2O3</data>
  <data key="d16">57-43-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)</data>
  <data key="d20">CCC1(CCC(C)C)C(=O)NC(=O)NC1=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[5-ethyl-5-(3-methylbutyl)-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione, 5-ethyl-5-(3-methylbutyl)barbituric acid, 5-ethyl-5-isoamylbarbituric acid, 5-ethyl-5-isopentylbarbituric acid, Amobarbital, Amobarbitale, Amylobarbitone, Barbamil, Barbamyl]</data>
  <data key="d9">A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12010">
  <data key="d0">Fostamatinib</data>
  <data key="d1">drugbank.DB12010</data>
  <data key="d2">[drugbank.DB12010]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[BCRP/ABCG2 Inhibitors, Blood and Blood Forming Organs, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Hemostatics, Phosphodiesterase 5 Inhibitors, Tyrosine Kinase Inhibitors, UGT1A1 Inhibitors, UGT1A9 Substrates, Vasodilating Agents]</data>
  <data key="d14">{[6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-3-oxo-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-4-yl]methoxy}phosphonic acid</data>
  <data key="d15">C23H26FN6O9P</data>
  <data key="d16">901119-35-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)</data>
  <data key="d20">COC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC</data>
  <data key="d21">Fostamatinib is indicated for use in the treatment of chronic immune thrombocytopenia (ITP) in patients who have had insufficient response to previous therapy [FDA Label].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Fostamatinib]</data>
  <data key="d9">Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018 under the trade name Tavalisse for use in ITP [L2644,FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA [L2644].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01357">
  <data key="d0">Mestranol</data>
  <data key="d1">drugbank.DB01357</data>
  <data key="d2">[drugbank.DB01357]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenal Cortex Hormones, Contraceptive Agents, Female, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Estradiol Congeners, Estrogen Contraceptives, Estrogenic Steroids, Alkylated, Estrogens, Ethinyl Estradiol, Gonadal Hormones, Gonadal Steroid Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Norpregnanes, Norpregnatrienes, Norsteroids, Steroids]</data>
  <data key="d14">(1S,10R,11S,14R,15S)-14-ethynyl-5-methoxy-15-methyltetracyclo[8.7.0.0,.0,]heptadeca-2(7),3,5-trien-14-ol</data>
  <data key="d15">C21H26O2</data>
  <data key="d16">72-33-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H26O2/c1-4-21(22)12-10-19-18-7-5-14-13-15(23-3)6-8-16(14)17(18)9-11-20(19,21)2/h1,6,8,13,17-19,22H,5,7,9-12H2,2-3H3/t17-,18-,19+,20+,21+/m1/s1</data>
  <data key="d20">[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC)C=C3</data>
  <data key="d21">Mestranol was used as one of the first oral contraceptives.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Mestranol]</data>
  <data key="d9">The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01356">
  <data key="d0">Lithium cation</data>
  <data key="d1">drugbank.DB01356</data>
  <data key="d2">[drugbank.DB01356]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Antidepressive Agents, Antimanic Agents, Antipsychotic Agents, Central Nervous System Depressants, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index, Highest Risk QTc-Prolonging Agents, Lithium Compounds, Mood Stabilizer, Nephrotoxic agents, Neurotoxic agents, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators]</data>
  <data key="d14">lithium(1+) ion</data>
  <data key="d15">Li</data>
  <data key="d16">7439-93-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/Li/q+1</data>
  <data key="d20">[Li+]</data>
  <data key="d21">Lithium is used as a mood stabilizer, and is used for treatment of depression and mania. It is often used in bipolar disorder treatment.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Li(+), Lithium ion, Lithium, ion, Lithium, ion (li1+)]</data>
  <data key="d9">Lithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches. The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several critical neuronal enzymes and neurotransmitter receptors.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01355">
  <data key="d0">Hexobarbital</data>
  <data key="d1">drugbank.DB01355</data>
  <data key="d2">[drugbank.DB01355, drugbank.EXPT03301]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Adjuvants, Anesthetics, Anesthetics, General, Anticholinergic Agents, Anticonvulsants, Barbiturates, Barbiturates, Plain, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), GABA Agents, GABA Modulators, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones]</data>
  <data key="d14">5-(cyclohex-1-en-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione</data>
  <data key="d15">C12H16N2O3</data>
  <data key="d16">56-29-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H16N2O3/c1-12(8-6-4-3-5-7-8)9(15)13-11(17)14(2)10(12)16/h6H,3-5,7H2,1-2H3,(H,13,15,17)</data>
  <data key="d20">CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1</data>
  <data key="d21">For the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[5-(1-cyclohexen-1-yl)-1, 5-dimethyl-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1, 5-dimethylbarbituric acid, 5-Cyclohex-1-enyl-1, 5-dimethyl-pyrimidine-2, 4, 6-trione, Hexobarbitone, Methexenyl, Methylhexabital]</data>
  <data key="d9">A barbiturate that is effective as a hypnotic and sedative.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01354">
  <data key="d0">Heptabarbital</data>
  <data key="d1">drugbank.DB01354</data>
  <data key="d2">[drugbank.DB01354]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Anticholinergic Agents, Barbiturates, Plain, Central Nervous System Depressants, Hypnotics and Sedatives, Nervous System, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones]</data>
  <data key="d14">5-(cyclohept-1-en-1-yl)-5-ethyl-1,3-diazinane-2,4,6-trione</data>
  <data key="d15">C13H18N2O3</data>
  <data key="d16">509-86-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H18N2O3/c1-2-13(9-7-5-3-4-6-8-9)10(16)14-12(18)15-11(13)17/h7H,2-6,8H2,1H3,(H2,14,15,16,17,18)</data>
  <data key="d20">CCC1(C(=O)NC(=O)NC1=O)C1=CCCCCC1</data>
  <data key="d21">Used mainly for sedation and hypnosis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Heptabarb, Heptabarbe, Heptabarbital, Heptabarbitone, Heptabarbo, Heptabarbum]</data>
  <data key="d9">Heptabarbital is an intermediate or short term barbiturate used mainly for sedation and hypnosis.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01353">
  <data key="d0">Butobarbital</data>
  <data key="d1">drugbank.DB01353</data>
  <data key="d2">[drugbank.DB01353]</data>
  <data key="d12">[approved, illicit]</data>
  <data key="d13">[Anticholinergic Agents, Barbiturates, Plain, Central Nervous System Agents, Central Nervous System Depressants, Hypnotics and Sedatives, Nervous System, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones]</data>
  <data key="d14">5-butyl-5-ethyl-1,3-diazinane-2,4,6-trione</data>
  <data key="d15">C10H16N2O3</data>
  <data key="d16">77-28-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H16N2O3/c1-3-5-6-10(4-2)7(13)11-9(15)12-8(10)14/h3-6H2,1-2H3,(H2,11,12,13,14,15)</data>
  <data key="d20">CCCCC1(CC)C(=O)NC(=O)NC1=O</data>
  <data key="d21">For the treatment of insomnia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Butethal, Butobarbital, Butobarbitone]</data>
  <data key="d9">Butobarbital is a sedative and a hypnotic drug.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01363">
  <data key="d0">Ephedra sinica root</data>
  <data key="d1">drugbank.DB01363</data>
  <data key="d2">[drugbank.DB01363]</data>
  <data key="d12">[nutraceutical]</data>
  <data key="d13">[Adrenergic Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Agents producing tachycardia, Agents that produce hypertension, Alpha-and Beta-adrenergic Agonists, Herbs and Natural Products, Hyperglycemia-Associated Agents, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Sympathomimetic (Adrenergic) Agents]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Ephedra is indicated for the temporary relief of shortness of breath, tightness of chest, and wheezing due to bronchial asthma.  For the temporary relief of bronchial asthma in over-the-counter formulations.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Cao ma huang root, Chinese ephedra root (ephedra sinica), Chinese jointfir, Ephedra, Ephedra ma-huang root, Ephedra root (ephedra sinica), Ephedra sinica root, Ephedrae radix, Hemp yellow root, Ma huang gen (ephedra sinica), Mahuanggen (ephedra sinica)]</data>
  <data key="d9">Ephedra is an alkaloid chemical compound traditionally obtained from the plant _Ephedra sinica_. The sale of ephedra-containing supplements intended to increase muscle weight or promote weight loss was banned in the United States in 2004 due to the risk for adverse effects and a lack of evidence for clinical effectiveness. The drug is still sold in Canada in OTC formulations for respiratory conditions associated with bronchial asthma.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00030">
  <data key="d0">Insulin Human</data>
  <data key="d1">drugbank.DB00030</data>
  <data key="d2">[drugbank.DB00030, drugbank.BTD00105, drugbank.BIOD00105, drugbank.DB01383, drugbank.DB05278, drugbank.DB05215, drugbank.DB05283, drugbank.DB08914]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Amino Acids, Peptides, and Proteins, Blood Glucose Lowering Agents, Drugs Used in Diabetes, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypoglycemia-Associated Agents, Insulin, Insulin, Long-Acting, Insulins and Analogues, Insulins and Analogues for Inhalation, Insulins and Analogues for Injection, Fast-Acting, Insulins and Analogues for Injection, Intermediate- or Long-Acting Combined With Fast-Acting, Insulins and Analogues for Injection, Intermediate-Acting, Pancreatic Hormones, Peptide Hormones, Peptides]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">11061-68-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;52037387-cbc6-4ec5-bcde-8a67bcd1c863 A chain\nGIVEQCCTSICSLYQLENYCN, &gt;af6ac1b6-1378-4147-b4d5-eb9761dee316 B chain\nFVNQHLCGSHLVEALYLVCGERGFFYTPKT]</data>
  <data key="d8">[High molecular weight insulin human, Human insulin, human insulin (rDNA), Insulin (human), Insulin human [rDNA origin], Insulin Human Regular, Insulin human regular (rDNA), Insulin human, rDNA origin, Insulin recombinant human, Insulin recombinant purified human, Insulin regular, Insulin, human, Insulina regular, Regular Insulin, human]</data>
  <data key="d9">Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.\n\nInsulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after trying several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. \n\nMarketed as the brand name product Humulin R or Novolin R, human insulin begins to exert its effects within 30 minutes of subcutaneous administration, while peak levels occur 3-4 hours after administration. Due to its quick onset of action, human insulin is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as [DB01307], [DB09564], and [DB00047] to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia.\n\nHuman insulin is also available in an inhalable form, intended to be used as a bolus meal-time insulin. Exubera was the first inhaled insulin available on the market and was developed by Inhale Therapeutics (later named Nektar Therapeutics). Unfortunately, limited uptake by physicians and patients, poor sales, bulky packaging, and concerns over the possible impact on lung cancer development resulted in Exubera products being withdrawn from the US markets [A176005]. Exubera was followed by Afrezza, a monomeric inhaled insulin developed by Mannkind Corporation, which received FDA approval in 2016. While still available in the US, Afrezza has had similar concerns associated with its use, and had an FDA "black box" warning added to it to warn about use in patients with chronic lung disease. Afrezza does not currently have Health Canada or European Medicines Agency approval for marketing in Canada or the EU. \n\nHuman Insulin is a 51 residue peptide hormone produced by recombinant DNA technology by inserting the human insulin gene into Escherichia coli bacteria or Saccharomyces cerevisiae. The structure is identical to native human insulin, with two amino acid chains covalently linked by disulfide bonds. \n\nHuman insulin is also available in an intermediate-acting form as NPH (Neutral Protamine Hagedorn) as the marketed products Novolin N and Humulin N. NPH insulin is provided as a crystalline suspension of insulin with protamine and zinc, resulting in an onset of action in 1 to 3 hours, duration of action up to 24 hours, and peak action from 6 to 8 hours. Due to the added crystals, NPH insulin is typically cloudy when compared to other forms of insulin and has a neutral pH.\n\nWithout an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12007">
  <data key="d0">Isoflavone</data>
  <data key="d1">drugbank.DB12007</data>
  <data key="d2">[drugbank.DB12007]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Drugs that are Mainly Renally Excreted]</data>
  <data key="d14">3-phenyl-4H-chromen-4-one</data>
  <data key="d15">C15H10O2</data>
  <data key="d16">574-12-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H10O2/c16-15-12-8-4-5-9-14(12)17-10-13(15)11-6-2-1-3-7-11/h1-10H</data>
  <data key="d20">O=C1C(=COC2=CC=CC=C12)C1=CC=CC=C1</data>
  <data key="d21">Indicated for over-the-counter use as a dietary supplement for increasing bone density and regulating blood fat.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3-phenyl-4H-1-benzopyran-4-one, 3-Phenylchromone, Isoflavon]</data>
  <data key="d9">Isoflavone is a soy phytoestrogen and a biologically active component of several agriculturally important legumes such as soy, peanut, green peas, chick peas and alfalfa [A33103]. Soybean is an exceptionally rich source of dietary isoflavones, where the average isoflavone content is 1-2 mg/gram [A33103]. The main soy isoflavones are mostly present in glycosylated forms and include [DB01645], [DB13182], and glycitein, which accounts for approximately 50%, 40%, and 10%, respectively, of the total soybean isoflavone content [A33098]. The clinical benefits of soy proteins have been studied and demonstrated for many years, with some evidence of soy products associated with a reduced incidences of coronary heart disease, atherosclerosis, type II diabetes mellitus, and breast and prostate cancer [A33099]. While existing data are consistent or inadequate in supporting most of the suggested health benefits of consuming soy proteins and isoflavones [A33099], the trials investigating isoflavone as a potential treatment for atrophy, menopause, and postmenopausal symptoms are ongoing. Isoflavone is found as one of constituents in oral over-the-counter dietary supplements indicated for improved bone mass density and body fat regulation.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01367">
  <data key="d0">Rasagiline</data>
  <data key="d1">drugbank.DB01367</data>
  <data key="d2">[drugbank.DB01367, drugbank.EXPT02758]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents that produce hypertension, Agents that reduce seizure threshold, Anti-Parkinson Drugs, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates, Dopamine Agents, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hypotensive Agents, Indenes, Monoamine Oxidase B Inhibitors, Monoamine Oxidase Inhibitors, Nervous System, Neuroprotective Agents, Protective Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators]</data>
  <data key="d14">(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine</data>
  <data key="d15">C12H13N</data>
  <data key="d16">136236-51-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1</data>
  <data key="d20">C#CCN[C@@H]1CCC2=CC=CC=C12</data>
  <data key="d21">For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(1R)-N-propargylindan-1-amine, (R)-indan-1-yl-prop-2-ynyl-amine, (R)-N-2-Propynyl-1-indanamine, RAS, Rasagilina, Rasagiline]</data>
  <data key="d9">Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01364">
  <data key="d0">Ephedrine</data>
  <data key="d1">drugbank.DB01364</data>
  <data key="d2">[drugbank.DB01364]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-Agonists, Adrenergic and Dopaminergic Agents, Adrenergic beta-Agonists, Adrenergics for Systemic Use, Agents producing tachycardia, Agents that produce hypertension, Alcohols, Alimentary Tract and Metabolism, Alpha-and Beta-adrenergic Agonists, Amines, Amino Alcohols, Antiobesity Preparations, Excl. Diet Products, Autonomic Agents, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiovascular Agents, Central Nervous System Agents, Central Nervous System Stimulants, Centrally Acting Antiobesity Products, Cholinesterase substrates, Drugs for Obstructive Airway Diseases, Ethylamines, Herbs and Natural Products, Increased Norepinephrine Activity, Mydriatics and Cycloplegics, Nasal Preparations, Neurotransmitter Agents, Norepinephrine Releasing Agent, Ophthalmologicals, Peripheral Nervous System Agents, Phenethylamines, Propanolamines, Propanols, Sensory Organs, Sympathomimetic (Adrenergic) Agents, Sympathomimetics, Sympathomimetics Excl. Antiglaucoma Preparations, Sympathomimetics, Plain, Vasoconstrictor Agents]</data>
  <data key="d14">(1R,2S)-2-(methylamino)-1-phenylpropan-1-ol</data>
  <data key="d15">C10H15NO</data>
  <data key="d16">299-42-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m0/s1</data>
  <data key="d20">CN[C@@H](C)[C@H](O)C1=CC=CC=C1</data>
  <data key="d21">Ephedrine commonly used as a stimulant, appetite suppressant, concentration aid, decongestant, and to treat hypotension associated with anaesthesia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(-)-Ephedrine, (1R, 2S)-1-Phenyl-1-hydroxy-2-methylaminopropane, Efedrina, L-Ephedrine, L-erythro-2-(Methylamino)-1-phenylpropan-1-ol, L()-ephedrine]</data>
  <data key="d9">An alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used in the treatment of several disorders including asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01373">
  <data key="d0">Calcium</data>
  <data key="d1">drugbank.DB01373</data>
  <data key="d2">[drugbank.DB01373]</data>
  <data key="d12">[approved, nutraceutical]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Amino Acids, Peptides, and Proteins, Antacids and Adsorbents, Biological Factors, Blood Coagulation Factors, Blood Proteins, Calcium Salts, Drugs Affecting Bone Structure and Mineralization, Drugs for Treatment of Bone Diseases, Elements, Metals, Metals, Alkaline Earth, Minerals, Musculo-Skeletal System, Phosphate Binder, Phosphate Chelating Activity, Proteins, Replacement Preparations]</data>
  <data key="d14">calcium</data>
  <data key="d15">Ca</data>
  <data key="d16">7440-70-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/Ca</data>
  <data key="d20">[Ca]</data>
  <data key="d21">Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. It is vital in cell signaling, muscular contractions, bone health, and signalling cascades.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Calcio, Calcium, elemental, Elemental calcium, Kalzium]</data>
  <data key="d9">Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions into the bloodstream under controlled conditions. Circulating calcium is either in the free, ionized form or bound to blood proteins such as serum albumin. Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day. Bone serves as an important storage point for calcium, as it contains 99% of the total body calcium. Low calcium intake may also be a risk factor in the development of osteoporosis. The best-absorbed form of calcium from a pill is a calcium salt like carbonate or phosphate. Calcium gluconate and calcium lactate are absorbed well by pregnant women. Seniors absorb calcium lactate, gluconate and citrate better unless they take their calcium supplement with a full breakfast.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01370">
  <data key="d0">Aluminium</data>
  <data key="d1">drugbank.DB01370</data>
  <data key="d2">[drugbank.DB01370, drugbank.DB11314]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Aluminium Compounds, Antacids, Elements, Gastric Acid Lowering Agents, Metal cations, Metal divalent cations, Metals, Metals, Light]</data>
  <data key="d14">alumane</data>
  <data key="d15">Al</data>
  <data key="d16">7429-90-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/Al</data>
  <data key="d20">[Al]</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Al, Aluminio, Aluminium, Aluminium atom, Aluminium metallicum, Aluminum, Aluminum metal, Aluminum powder, Metallic aluminum]</data>
  <data key="d9">A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00047">
  <data key="d0">Insulin glargine</data>
  <data key="d1">drugbank.DB00047</data>
  <data key="d2">[drugbank.DB00047, drugbank.BTD00045, drugbank.BIOD00045, drugbank.DB01308]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Amino Acids, Peptides, and Proteins, Blood Glucose Lowering Agents, Drugs Used in Diabetes, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypoglycemia-Associated Agents, Insulin, Insulin Analog, Insulin, Long-Acting, Insulins and Analogues, Insulins and Analogues for Injection, Long-Acting, Pancreatic Hormones, Peptide Hormones, Peptides]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">160337-95-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Insulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;9ae0f90e-24c3-42ff-9401-7eaa126f674e A chain\nGIVEQCCTSICSLYQLENYCG, &gt;b0ae3c8b-09fd-4845-bdd8-06681ae7e751 B chain\nFVNQHLCGSHLVEALYLVCGERGFFYTPKTRR]</data>
  <data key="d8">[Insulin glargine, Insulin Glargine (rDNA origin), Insulin glargine recombinant, Insulina glargina]</data>
  <data key="d9">Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis.\n\nInsulin is an important treatment in the management of Type 1 Diabetes (T1D), which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glargine, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. \n\nAvailable as the brand name product Lantus, insulin glargine has a duration of action up to 24 hours allowing for once-daily dosing, typically at bedtime. Due to its duration of action, Lantus is considered "basal insulin" as it provides low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Basal insulin is often combined with short-acting "bolus insulin" such as [DB00046], [DB01309], and [DB01306] to provide higher doses of insulin that are required following meals. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia. \n\nInsulin glargine is also available as the biosimilar, or "follow-on" product, Basaglar in the US and as Abasaglar in the EU. As of 2015, insulin glargine was reformulated by Sanofi as the product Toujeo in an extra-concentrated form containing 300IU/mL (compared to 100IU/mL contained in Lantus). Use of the higher concentrated Toujeo as compared to Lantus results in slightly different pharmacokinetics, with a later onset (up to 6 hours) and duration of action (up to 30 hours). \n\nInsulin glargine is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from endogenous human insulin by the replacement of an asparagine residue at position A21 of the A-chain with glycine and addition of two arginines to the C-terminus (positions B31 and 32) of the B-chain. The resulting protein is soluble at pH 4 and forms microprecipitates at physiological pH 7.4 allowing for the slow release of small amounts of insulin glargine, giving the drug a long duration of action and no pronounced peak concentration.\n\nWithout an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00046">
  <data key="d0">Insulin Lispro</data>
  <data key="d1">drugbank.DB00046</data>
  <data key="d2">[drugbank.DB00046, drugbank.BTD00065, drugbank.BIOD00065, drugbank.DB01310]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Amino Acids, Peptides, and Proteins, Blood Glucose Lowering Agents, Drugs Used in Diabetes, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypoglycemia-Associated Agents, Insulin, Insulin Analog, Insulin, Short-Acting, Insulins and Analogues, Insulins and Analogues for Injection, Fast-Acting, Insulins and Analogues for Injection, Intermediate- or Long-Acting Combined With Fast-Acting, Pancreatic Hormones, Peptide Hormones, Peptides]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">133107-64-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Insulin lispro is indicated to improve glycemic control in adults and children with diabetes mellitus.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;5c6ddcb2-8b5f-4636-a89f-ea3dda872275 A chain\nGIVEQCCTSICSLYQLENYCN, &gt;bc218e5b-f4dd-4115-adf9-099c2e053f66 B chain\nFVNQHLCGSHLVEALYLVCGERGFFYTKPT]</data>
  <data key="d8">[Insulin lispro (genetical recombination), Insulin lispro (rDNA origin), Insulin lispro protamine, Insulin lispro protamine recombinant, Insulin lispro recombinant, Insulin, lispro, human/rDNA, Insulin, lispro, protamine/rDNA, Insulina lispro]</data>
  <data key="d9">Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.\n\nInsulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin lispro, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, and when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. \n\nMarketed as the brand name product Humalog, insulin lispro begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, Humalog is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as [DB01307], [DB09564], or [DB00047] to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia.\n\nInsulin lispro is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli and was the first commercially available insulin analog. Formerly called LYSPRO from the chemical nomenclature [LYS(B28), PRO(B29)], insulin lispro differs from human insulin in that the amino acid proline at position B28 is replaced by lysine and the lysine in position B29 is replaced by proline. These biochemical changes result in a reduced tendency for self-association resulting in dissolution to a dimer and then to a monomer that is absorbed more rapidly after subcutaneous injection compared to endogenous human insulin. \n\nWithout an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00051">
  <data key="d0">Adalimumab</data>
  <data key="d1">drugbank.DB00051</data>
  <data key="d2">[drugbank.DB00051, drugbank.BTD00049, drugbank.BIOD00049]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents reducing cytokine levels, Amino Acids, Peptides, and Proteins, Anti-Inflammatory Agents, Antibodies, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic and Immunomodulating Agents, Antirheumatic Agents, Biologics for Rheumatoid Arthritis Treatment, Blood Proteins, Disease-modifying Antirheumatic Agents, Globulins, Immunoglobulins, Immunoproteins, Immunosuppressive Agents, Proteins, Serum Globulins, Tumor Necrosis Factor Alpha (TNF-) Inhibitors, Tumor Necrosis Factor Blocker, Tumor Necrosis Factor Receptor Blocking Activity]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">331731-18-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">The following are conditions for which adalimumab has been indicated [F2118], [FDA label], [L4805], [A40001], [A40002], [L4806]. \n\nRheumatoid Arthritis (Moderate to Severe)\n\nJuvenile Idiopathic Arthritis (Moderately to Severely Active)\n\nPsoriatic Arthritis (Active)\n\nAnkylosing Spondylitis (Active)\n\nCrohns Disease (Moderately to Severely Active)\n\nUlcerative Colitis (Moderately to Severely Active)\n\nPlaque Psoriasis (Moderate to Severe Chronic)\n\nNon-infectious Intermediate, Posterior and Panuveitis\n\nHidradenitis Suppurativa (Moderate to Severe)\n\nPyoderma Gangrenosum (off-label)</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;f0b36d04-80ea-4006-ba1e-bcbf74bc2f67  Adalimumab Light chain:\nDIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC, &gt;24d641c4-3871-4660-aabd-cbbcdbb11c83  Adalimumab Heavy chain:\nEVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK]</data>
  <data key="d8">[Adalimumab (genetical recombination), adalimumab-adaz, adalimumab-adbm, adalimumab-atto]</data>
  <data key="d9">Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor [A39984], [A39999]. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA [A39983]. This drug is frequently known as _Humira_.   It is produced by recombinant DNA technology using a mammalian cell expression system. This drug is available in a prefilled syringe form and convenient pen form for subcutaneous self-administered doses [A39983]. A new biosimilar to adalimumab, named _adalimumab-adaz_, was approved by the FDA on October 31, 2018.  This biosimilar is known as _Hyrimoz_, and is a trademark of Novartis AG [L4799].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01309">
  <data key="d0">Insulin Glulisine</data>
  <data key="d1">drugbank.DB01309</data>
  <data key="d2">[drugbank.DB01309]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Amino Acids, Peptides, and Proteins, Blood Glucose Lowering Agents, Drugs Used in Diabetes, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypoglycemia-Associated Agents, Insulin, Insulin Analog, Insulins and Analogues, Insulins and Analogues for Injection, Fast-Acting, Pancreatic Hormones, Peptide Hormones, Peptides, Proteins]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">207748-29-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;295a1c3c-1452-43d0-9ff3-caa361db2373 A chain\nGIVEQCCTSICSLYQLENYCN, &gt;7a5ccd3f-e6b5-458b-a5e4-eaed95055d4e B chain\nFVKQHLCGSHLVEALYLVCGERGFFYTPET]</data>
  <data key="d8">[Insulin Glulisine (recombinant DNA origin), Insulin glulisine recombinant, Insulina glulisina]</data>
  <data key="d9">Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.\n\nInsulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glulisine, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after trying several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. \n\nMarketed as the brand name product Apidra, insulin glulisine begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, Apidra is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as [DB01307], [DB09564], and [DB00047] to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia.\n\nInsulin glulisine is a biosynthetic, rapid-acting human insulin analogue produced in a non-pathogenic laboratory strain of _Escherichia coli_ (K12). This recombinant hormone differs from native human insulin in that the amino acid arginine at position B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid. These structural modifications decrease hexamer formation, stabilize insulin glulisine monomers and increase the rate of absorption and onset of action compared to human insulin.\n\nWithout an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01307">
  <data key="d0">Insulin Detemir</data>
  <data key="d1">drugbank.DB01307</data>
  <data key="d2">[drugbank.DB01307]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Amino Acids, Peptides, and Proteins, Blood Glucose Lowering Agents, Drugs Used in Diabetes, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypoglycemia-Associated Agents, Insulin, Insulin Analog, Insulin, Long-Acting, Insulins and Analogues, Insulins and Analogues for Injection, Long-Acting, Pancreatic Hormones, Peptide Hormones, Peptides]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">169148-63-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;f822290f-33b4-4d8f-bb7e-7a641b81d651 Protein sequence for A chain\nGIVEQCCTSICSLYQLENYCN, &gt;acb67975-8234-43ec-b51d-706e5b4151fc Protein sequence for B chain \nFVNQHLCGSHLVEALYLVCGERGFFYTPK]</data>
  <data key="d8">[Detemir, Insulin detemir recombinant, Insulin, detemir, human, Insulina detemir]</data>
  <data key="d9">Insulin detemir is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.\n\nInsulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin detemir, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. \n\nMarketed as the brand name product Levemir, insulin detemir has a duration of action of 16-24 hours allowing for once-daily dosing, typically at bedtime. Due to its duration of action, Levemir is considered "basal insulin" as it provides low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Basal insulin is often combined with short-acting "bolus insulin" such as [DB00046], [DB01309], and [DB01306] to provide higher doses of insulin required following meals. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia.\n\nInsulin detemir is produced using recombinant DNA technology in yeast cells. This insulin analogue has a 14-C fatty acid, myristic acid, bound to the lysine amino acid at position B29. The myristoyl side chain increases self-association and albumin binding. This along with slow systemic absorption from the injection site prolongs distribution of the hormone into tissues and results in a long duration of action. \n\nWithout an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01306">
  <data key="d0">Insulin Aspart</data>
  <data key="d1">drugbank.DB01306</data>
  <data key="d2">[drugbank.DB01306]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Amino Acids, Peptides, and Proteins, Blood Glucose Lowering Agents, Drugs Used in Diabetes, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypoglycemia-Associated Agents, Insulin, Insulin Analog, Insulin, Short-Acting, Insulins and Analogues, Insulins and Analogues for Injection, Fast-Acting, Insulins and Analogues for Injection, Intermediate- or Long-Acting Combined With Fast-Acting, Pancreatic Hormones, Peptide Hormones, Peptides]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">116094-23-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;449b5008-c9b2-4f64-b3c0-759d444f6370 A chain\nGIVEQCCTSICSLYQLENYCN, &gt;61b61946-5d94-496f-af2f-0fce75e6ac4b B chain\nFVNQHLCGSHLVEALYLVCGERGFFYTDKT]</data>
  <data key="d8">[Aspart, Aspart Insulin, B28-Aspart-Insulin, Insulin aspart protamine, Insulin aspart protamine recombinant, Insulin aspart recombinant, Insulin X14, Insulin, aspart protamine, human, Insulin, aspart, human, Insulin, aspart protamine, Insulina asparta]</data>
  <data key="d9">Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.\n\nInsulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin aspart, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after trying several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. \n\nMarketed as the brand name product NovoRapid, insulin aspart begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, NovoRapid is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as [DB01307], [DB09564], and [DB00047] to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia.\n\nInsulin aspart is a recombinant, biosynthetic, fast-acting insulin analogue. Compared to human insulin, it has a single amino acid substitution at position B28 where proline is replaced with aspartic acid. This substitution decreases its propensity to form hexamers and gives it a higher rate of absorption following subcutaneous administration compared to native insulin. Insulin aspart is produced in a genetically modified strain of _Saccharomyces cerevisiae_ (baker's yeast)\n\nWithout an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03963">
  <data key="d0">S-(Dimethylarsenic)Cysteine</data>
  <data key="d1">drugbank.DB03963</data>
  <data key="d2">[drugbank.DB03963, drugbank.EXPT00832]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2R)-2-amino-3-[(dimethylarsanyl)sulfanyl]propanoic acid</data>
  <data key="d15">C5H12AsNO2S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C5H12AsNO2S/c1-6(2)10-3-4(7)5(8)9/h4H,3,7H2,1-2H3,(H,8,9)/t4-/m0/s1</data>
  <data key="d20">[H][C@](N)(CS[As](C)C)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02643">
  <data key="d0">N-Dodecyl-N,N-Dimethyl-3-Ammonio-1-Propanesulfonate</data>
  <data key="d1">drugbank.DB02643</data>
  <data key="d2">[drugbank.DB02643, drugbank.EXPT00799]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Amines, Ammonium Compounds, Compounds used in a research, industrial, or household setting, Detergents, Household Products, Nitrogen Compounds, Onium Compounds, Surface-Active Agents]</data>
  <data key="d14">dodecyldimethyl(3-sulfopropyl)azanium</data>
  <data key="d15">C17H38NO3S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H37NO3S/c1-4-5-6-7-8-9-10-11-12-13-15-18(2,3)16-14-17-22(19,20)21/h4-17H2,1-3H3/p+1</data>
  <data key="d20">CCCCCCCCCCCC[N+](C)(C)CCCS(O)(=O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03974">
  <data key="d0">L-Homoarginine</data>
  <data key="d1">drugbank.DB03974</data>
  <data key="d2">[drugbank.DB03974, drugbank.EXPT01779]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-2-amino-6-carbamimidamidohexanoic acid</data>
  <data key="d15">C7H16N4O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H16N4O2/c8-5(6(12)13)3-1-2-4-11-7(9)10/h5H,1-4,8H2,(H,12,13)(H4,9,10,11)/t5-/m0/s1</data>
  <data key="d20">N[C@@H](CCCCNC(N)=N)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB03977">
  <data key="d0">N-Trimethyllysine</data>
  <data key="d1">drugbank.DB03977</data>
  <data key="d2">[drugbank.DB03977, drugbank.EXPT02087]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">[(5S)-5-amino-5-carboxypentyl]trimethylazanium</data>
  <data key="d15">C9H21N2O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H20N2O2/c1-11(2,3)7-5-4-6-8(10)9(12)13/h8H,4-7,10H2,1-3H3/p+1/t8-/m0/s1</data>
  <data key="d20">[H][C@](N)(CCCC[N+](C)(C)C)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14635">
  <data key="d0">Curcumin sulfate</data>
  <data key="d1">drugbank.DB14635</data>
  <data key="d2">[drugbank.DB14635, drugbank.DBSALT002044]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">{4-[(1E,6E)-7-(4-hydroxy-3-methoxyphenyl)-3,5-dioxohepta-1,6-dien-1-yl]-2-methoxyphenyl}oxidanesulfonic acid</data>
  <data key="d15">C21H20O9S</data>
  <data key="d16">339286-19-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H20O9S/c1-28-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(21(12-15)29-2)30-31(25,26)27/h3-12,24H,13H2,1-2H3,(H,25,26,27)/b7-3+,8-4+</data>
  <data key="d20">COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC=C(OS(O)(=O)=O)C(OC)=C2)=CC=C1O</data>
  <data key="d21">No approved therapeutic indications.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Curcumin monosulfate, Curcumin sulphate]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01339">
  <data key="d0">Vecuronium</data>
  <data key="d1">drugbank.DB01339</data>
  <data key="d2">[drugbank.DB01339]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Androstanes, Androstanols, Anticholinergic Agents, Central Nervous System Depressants, Cholinergic Agents, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular Nondepolarizing Blockade, Neuromuscular-Blocking Agents (Nondepolarizing), Neurotransmitter Agents, Nicotinic Antagonists, P-glycoprotein/ABCB1 Substrates, Peripheral Nervous System Agents, Steroids]</data>
  <data key="d14">1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-2,15-dimethyl-4-(piperidin-1-yl)tetracyclo[8.7.0.0,.0,]heptadecan-13-yl]-1-methylpiperidin-1-ium</data>
  <data key="d15">C34H57N2O4</data>
  <data key="d16">86029-43-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C34H57N2O4/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36/h25-32H,6-22H2,1-5H3/q+1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1</data>
  <data key="d20">[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1</data>
  <data key="d21">Vecuronium is a muscle relaxing agent and is used as an adjunct in general anesthesia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Vecuronio, Vecuronium cation]</data>
  <data key="d9">Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01338">
  <data key="d0">Pipecuronium</data>
  <data key="d1">drugbank.DB01338</data>
  <data key="d2">[drugbank.DB01338]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents producing tachycardia, Anticholinergic Agents, Central Nervous System Depressants, Cholinergic Agents, Cholinesterase Inhibitors, Muscarinic Antagonists, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular-Blocking Agents (Nondepolarizing), Neurotransmitter Agents, Nicotinic Antagonists, Peripheral Nervous System Agents, Piperazines]</data>
  <data key="d14">4-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-13-(4,4-dimethylpiperazin-4-ium-1-yl)-2,15-dimethyltetracyclo[8.7.0.0,.0,]heptadecan-4-yl]-1,1-dimethylpiperazin-1-ium</data>
  <data key="d15">C35H62N4O4</data>
  <data key="d16">68399-58-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C35H62N4O4/c1-24(40)42-32-21-26-9-10-27-28(35(26,4)23-31(32)37-15-19-39(7,8)20-16-37)11-12-34(3)29(27)22-30(33(34)43-25(2)41)36-13-17-38(5,6)18-14-36/h26-33H,9-23H2,1-8H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1</data>
  <data key="d20">[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1</data>
  <data key="d21">Used as a muscle relaxant during anesthesia and surgical procedures.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Pipecurium, Pipecuronium]</data>
  <data key="d9">Pipecuronium is a piperazinyl androstane derivative which is a non-depolarizing neuromuscular blocking agent.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00006">
  <data key="d0">Bivalirudin</data>
  <data key="d1">drugbank.DB00006</data>
  <data key="d2">[drugbank.DB00006, drugbank.BTD00076, drugbank.EXPT03302, drugbank.BIOD00076, drugbank.DB02351]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Anticoagulants, Antithrombin Proteins, Antithrombins, Blood and Blood Forming Organs, Enzyme Inhibitors, Hematologic Agents, Peptides, Proteins, Serine Proteinase Inhibitors, Serpins, Thrombin Inhibitors]</data>
  <data key="d14">(4S)-4-[(2S)-2-[(2S)-2-[(2S)-2-{2-[(2S)-2-(2-{2-[2-(2-{[(2S)-1-[(2S)-2-{[(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]formamido}acetamido)acetamido]acetamido}acetamido)-3-carbamoylpropanamido]acetamido}-3-carboxypropanamido]-3-phenylpropanamido]-4-carboxybutanamido]-4-{[(2S,3S)-1-[(2S)-2-{[(1S)-3-carboxy-1-{[(1S)-3-carboxy-1-{[(1S)-1-{[(1S)-1-carboxy-3-methylbutyl]carbamoyl}-2-(4-hydroxyphenyl)ethyl]carbamoyl}propyl]carbamoyl}propyl]carbamoyl}pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]carbamoyl}butanoic acid</data>
  <data key="d15">C98H138N24O33</data>
  <data key="d16">128270-60-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1</data>
  <data key="d20">CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O</data>
  <data key="d21">For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Bivalirudin, Bivalirudina, Bivalirudinum]</data>
  <data key="d9">Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01337">
  <data key="d0">Pancuronium</data>
  <data key="d1">drugbank.DB01337</data>
  <data key="d2">[drugbank.DB01337]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents producing tachycardia, Androstanes, Androstanols, Anticholinergic Agents, Central Nervous System Depressants, Cholinergic Agents, Cholinesterase Inhibitors, Muscarinic Antagonists, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular Nondepolarizing Blockade, Neuromuscular-Blocking Agents (Nondepolarizing), Neurotransmitter Agents, Nicotinic Antagonists, OCT1 inhibitors, OCT1 substrates, Peripheral Nervous System Agents, Steroids]</data>
  <data key="d14">1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-2,15-dimethyl-13-(1-methylpiperidin-1-ium-1-yl)tetracyclo[8.7.0.0,.0,]heptadecan-4-yl]-1-methylpiperidin-1-ium</data>
  <data key="d15">C35H60N2O4</data>
  <data key="d16">16974-53-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C35H60N2O4/c1-24(38)40-32-21-26-13-14-27-28(35(26,4)23-31(32)37(6)19-11-8-12-20-37)15-16-34(3)29(27)22-30(33(34)41-25(2)39)36(5)17-9-7-10-18-36/h26-33H,7-23H2,1-6H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1</data>
  <data key="d20">[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1</data>
  <data key="d21">Used as a muscle relaxant during anesthesia and surgical procedures.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Pancuronium]</data>
  <data key="d9">A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00005">
  <data key="d0">Etanercept</data>
  <data key="d1">drugbank.DB00005</data>
  <data key="d2">[drugbank.DB00005, drugbank.BTD00052, drugbank.BIOD00052]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents reducing cytokine levels, Amino Acids, Peptides, and Proteins, Anti-Inflammatory Agents, Antibodies, Antirheumatic Agents, Biologics for Rheumatoid Arthritis Treatment, Disease-modifying Antirheumatic Agents, Immunoglobulin Isotypes, Immunologic Factors, Immunoproteins, Immunosuppressive Agents, Membrane Proteins, Proteins, Receptors, Cell Surface, Receptors, Cytokine, Receptors, Immunologic, Receptors, Tumor Necrosis Factor, Serum Globulins, Tumor Necrosis Factor Alpha (TNF-) Inhibitors, Tumor Necrosis Factor Blocker, Tumor Necrosis Factor Receptor Blocking Activity]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">185243-69-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more disease-modifying anti-rheumatic drugs. Etanercept is also used to improve psoriatic arthritis and ankylosing spondylitis.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;67fd2067-11fe-4199-9975-2380cae44f85  Etanercept Sequence\nLPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK]</data>
  <data key="d8">[Etanercept, etanercept-szzs, etanercept-ykro, Recombinant human TNF, rhu TNFR:Fc, rhu-TNFR:Fc, TNFR-Immunoadhesin]</data>
  <data key="d9">Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01336">
  <data key="d0">Metocurine</data>
  <data key="d1">drugbank.DB01336</data>
  <data key="d2">[drugbank.DB01336]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents producing tachycardia, Alkaloids, Amines, Ammonium Compounds, Anticholinergic Agents, Benzylisoquinolines, Central Nervous System Depressants, Curare Alkaloids, Drugs, Chinese Herbal, Isoquinolines, Muscarinic Antagonists, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular-Blocking Agents (Nondepolarizing), Nicotinic Antagonists, Nitrogen Compounds, Onium Compounds, Peripheral Nervous System Agents, Quaternary Ammonium Compounds, Tetrahydroisoquinolines]</data>
  <data key="d14">(1S,16R)-9,10,21,25-tetramethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.2^{3,6}.1^{8,12}.1^{18,22}.0^{27,31}.0^{16,34}]hexatriaconta-3,5,8(34),9,11,18(33),19,21,24,26,31,35-dodecaene-15,30-diium</data>
  <data key="d15">C40H48N2O6</data>
  <data key="d16">5152-30-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C40H48N2O6/c1-41(2)17-15-27-22-34(44-6)36-24-30(27)31(41)19-25-9-12-29(13-10-25)47-40-38-28(23-37(45-7)39(40)46-8)16-18-42(3,4)32(38)20-26-11-14-33(43-5)35(21-26)48-36/h9-14,21-24,31-32H,15-20H2,1-8H3/q+2/t31-,32+/m0/s1</data>
  <data key="d20">[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CC[N+]1(C)C)C2=C6)=C(OC)C=C5)=CC(OC)=C4OC)C=C3</data>
  <data key="d21">Metocurine is a muscle relaxant.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Dimethylchondrocurarine, O, O-Dimethylchondrocurarine]</data>
  <data key="d9">Dimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant. Patients on chronic anticonvulsant drugs are relatively resistant to metocurine. [A2393]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00001">
  <data key="d0">Lepirudin</data>
  <data key="d1">drugbank.DB00001</data>
  <data key="d2">[drugbank.DB00001, drugbank.BTD00024, drugbank.BIOD00024]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Anticoagulants, Antithrombin Proteins, Antithrombins, Blood and Blood Forming Organs, Cardiovascular Agents, Enzyme Inhibitors, Fibrin Modulating Agents, Hematologic Agents, Peptides, Protease Inhibitors, Proteins, Serine Proteinase Inhibitors, Serpins, Thrombin Inhibitors]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">138068-37-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">For the treatment of heparin-induced thrombocytopenia</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;e88eada4-f0d8-4e8b-a66d-5cc541c9dc6b DB00001 sequence\nLVYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIPEEYLQ]</data>
  <data key="d8">[Hirudin variant-1, Lepirudin recombinant]</data>
  <data key="d9">Lepirudin is identical to natural hirudin except for substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. It is produced via yeast cells. Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01340">
  <data key="d0">Cilazapril</data>
  <data key="d1">drugbank.DB01340</data>
  <data key="d2">[drugbank.DB01340]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[ACE Inhibitors and Diuretics, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Agents, Enzyme Inhibitors, Hypotensive Agents, P-glycoprotein/ABCB1 Inhibitors, Pyridazines]</data>
  <data key="d14">(1S,9S)-9-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-10-oxo-octahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid</data>
  <data key="d15">C22H31N3O5</data>
  <data key="d16">88768-40-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1</data>
  <data key="d20">CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O</data>
  <data key="d21">Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Cilazapril, Cilazapril anhydrous, Cilazaprilum]</data>
  <data key="d9">Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs.  It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. It is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB14641">
  <data key="d0">Estriol tripropionate</data>
  <data key="d1">drugbank.DB14641</data>
  <data key="d2">[drugbank.DB14641, drugbank.DBSALT000069]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(1R,2R,3aS,3bR,9bS,11aS)-11a-methyl-1,7-bis(propanoyloxy)-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-2-yl propanoate</data>
  <data key="d15">C27H36O6</data>
  <data key="d16">2236-31-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C27H36O6/c1-5-23(28)31-17-9-11-18-16(14-17)8-10-20-19(18)12-13-27(4)21(20)15-22(32-24(29)6-2)26(27)33-25(30)7-3/h9,11,14,19-22,26H,5-8,10,12-13,15H2,1-4H3/t19-,20-,21+,22-,26+,27+/m1/s1</data>
  <data key="d20">[H][C@]1(C[C@@]2([H])[C@]3([H])CCC4=CC(OC(=O)CC)=CC=C4[C@@]3([H])CC[C@]2(C)[C@@]1([H])OC(=O)CC)OC(=O)CC</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Estriol propionate, Estriol, tripropionate]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02715">
  <data key="d0">Compound 18</data>
  <data key="d1">drugbank.DB02715</data>
  <data key="d2">[drugbank.DB02715, drugbank.EXPT00473]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Acids, Carbocyclic, Benzene Derivatives, Benzoates, Iodobenzoates]</data>
  <data key="d14">(2S,3R)-3-(4-hydroxyphenyl)-2-{4-[(2S)-2-(pyrrolidin-1-yl)propoxy]phenyl}-2,3-dihydro-1,4-benzoxathiin-6-ol</data>
  <data key="d15">C27H29NO4S</data>
  <data key="d16">31112-66-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C27H29NO4S/c1-18(28-14-2-3-15-28)17-31-23-11-6-19(7-12-23)26-27(20-4-8-21(29)9-5-20)33-25-16-22(30)10-13-24(25)32-26/h4-13,16,18,26-27,29-30H,2-3,14-15,17H2,1H3/t18-,26-,27+/m0/s1</data>
  <data key="d20">[H][C@](C)(COC1=CC=C(C=C1)[C@]1([H])OC2=C(S[C@]1([H])C1=CC=C(O)C=C1)C=C(O)C=C2)N1CCCC1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02723">
  <data key="d0">4-Oxo-2-Phenylmethanesulfonyl-Octahydro-Pyrrolo[1,2-a]Pyrazine-6-Carboxylic Acid [1-(N-Hydroxycarbamimidoyl)-Piperidin-4-Ylmethyl]-Amide</data>
  <data key="d1">drugbank.DB02723</data>
  <data key="d2">[drugbank.DB02723, drugbank.EXPT00716]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(6S,8aS)-N-({1-[(E)-N'-hydroxycarbamimidoyl]piperidin-4-yl}methyl)-4-oxo-2-phenylmethanesulfonyl-octahydropyrrolo[1,2-a]piperazine-6-carboxamide</data>
  <data key="d15">C22H32N6O5S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H32N6O5S/c23-22(25-31)26-10-8-16(9-11-26)12-24-21(30)19-7-6-18-13-27(14-20(29)28(18)19)34(32,33)15-17-4-2-1-3-5-17/h1-5,16,18-19,31H,6-15H2,(H2,23,25)(H,24,30)/t18-,19-/m0/s1</data>
  <data key="d20">O\N=C(/N)N1CCC(CC1)CNC(=O)[C@@H]1CC[C@H]2CN(CC(=O)N12)S(=O)(=O)CC1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02726">
  <data key="d0">2-Phosphoglycolic Acid</data>
  <data key="d1">drugbank.DB02726</data>
  <data key="d2">[drugbank.DB02726, drugbank.EXPT02567, drugbank.DB02389]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-(phosphonooxy)acetic acid</data>
  <data key="d15">C2H5O6P</data>
  <data key="d16">13147-57-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C2H5O6P/c3-2(4)1-8-9(5,6)7/h1H2,(H,3,4)(H2,5,6,7)</data>
  <data key="d20">OC(=O)COP(O)(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01408">
  <data key="d0">Bambuterol</data>
  <data key="d1">drugbank.DB01408</data>
  <data key="d2">[drugbank.DB01408]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Adrenergic Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Adrenergics for Systemic Use, Agents producing tachycardia, Agents that produce hypertension, Agents to Treat Airway Disease, Alcohols, Amines, Amino Alcohols, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Cholinesterase Inhibitors, Cholinesterase substrates, Delayed-Action Preparations, Drugs for Obstructive Airway Diseases, Ethanolamines, Peripheral Nervous System Agents, Prodrugs, Respiratory System Agents, Selective Beta 2-adrenergic Agonists]</data>
  <data key="d14">3-[2-(tert-butylamino)-1-hydroxyethyl]-5-[(dimethylcarbamoyl)oxy]phenyl N,N-dimethylcarbamate</data>
  <data key="d15">C18H29N3O5</data>
  <data key="d16">81732-65-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3</data>
  <data key="d20">CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C</data>
  <data key="d21">For the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-5-(2-(tert-butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate), bambutrol, Bambuterol, Bambuterolum]</data>
  <data key="d9">Bambuterol is a long acting beta-adrenoceptor agonist used in the treatment of asthma. It is a prodrug of terbutaline.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01407">
  <data key="d0">Clenbuterol</data>
  <data key="d1">drugbank.DB01407</data>
  <data key="d2">[drugbank.DB01407]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Adrenergics for Systemic Use, Adrenergics, Inhalants, Agents producing tachycardia, Agents that produce hypertension, Agents to Treat Airway Disease, Alcohols, Amines, Amino Alcohols, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Drugs for Obstructive Airway Diseases, Ethanolamines, Neurotransmitter Agents, Peripheral Nervous System Agents, Respiratory System Agents, Selective Beta 2-adrenergic Agonists, Sympathomimetics]</data>
  <data key="d14">1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethan-1-ol</data>
  <data key="d15">C12H18Cl2N2O</data>
  <data key="d16">37148-27-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H18Cl2N2O/c1-12(2,3)16-6-10(17)7-4-8(13)11(15)9(14)5-7/h4-5,10,16-17H,6,15H2,1-3H3</data>
  <data key="d20">CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1</data>
  <data key="d21">Used as a bronchodilator in the treatment of asthma patients.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-clenbuterol, 1-(4-Amino-3, 5-dichloro-phenyl)-2-tert-butylamino-ethanol, 4-amino-3, 5-dichloro--(((1, 1-dimethylethyl)amino)methyl)benzenemethanol, 4-amino--((tert-butylamino)methyl)-3, 5-dichlorobenzyl alcohol, Clenbuterol, Clenbutrol, Clenbuterolum]</data>
  <data key="d9">A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01406">
  <data key="d0">Danazol</data>
  <data key="d1">drugbank.DB01406</data>
  <data key="d2">[drugbank.DB01406]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Androgens, Antigonadotropins and Similar Agents, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 Enzyme Inhibitors, Estrogen Antagonists, Genito Urinary System and Sex Hormones, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Pregnadienes, Pregnanes, Sex Hormones and Modulators of the Genital System, Steroids]</data>
  <data key="d14">(1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.0,.0,.0,]icosa-4(8),5,9-trien-17-ol</data>
  <data key="d15">C22H27NO2</data>
  <data key="d16">17230-88-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16-,17+,18+,20+,21+,22+/m1/s1</data>
  <data key="d20">[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3</data>
  <data key="d21">For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Danazol, Danazolum]</data>
  <data key="d9">A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01400">
  <data key="d0">Neostigmine</data>
  <data key="d1">drugbank.DB01400</data>
  <data key="d2">[drugbank.DB01400]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Amines, Ammonium Compounds, Antiglaucoma Preparations and Miotics, Autonomic Agents, Cholinergic Agents, Cholinesterase Inhibitors, Enzyme Inhibitors, Nervous System, Neurotransmitter Agents, Nitrogen Compounds, Onium Compounds, Ophthalmologicals, P-glycoprotein/ABCB1 Substrates, Parasympathomemetic (Cholinergic) Agents, Parasympathomimetics, Peripheral Nervous System Agents, Phenylammonium Compounds, Quaternary Ammonium Compounds, Sensory Organs]</data>
  <data key="d14">3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium</data>
  <data key="d15">C12H19N2O2</data>
  <data key="d16">59-99-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1</data>
  <data key="d20">CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C</data>
  <data key="d21">Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(m-Hydroxyphenyl)trimethylammonium dimethylcarbamate, 3-Trimethylammoniumphenyl N, N-dimethylcarbamate, Eustigmin, Eustigmine, m-Trimethylammoniumphenyldimethylcarbamate, Neostigmina]</data>
  <data key="d9">A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01411">
  <data key="d0">Pranlukast</data>
  <data key="d1">drugbank.DB01411</data>
  <data key="d2">[drugbank.DB01411]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Agents to Treat Airway Disease, Anti-Asthmatic Agents, Benzopyrans, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs for Obstructive Airway Diseases, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Leukotriene Antagonists, Pyrans, Respiratory System Agents]</data>
  <data key="d14">N-[4-oxo-2-(2H-1,2,3,4-tetrazol-5-yl)-4H-chromen-8-yl]-4-(4-phenylbutoxy)benzamide</data>
  <data key="d15">C27H23N5O4</data>
  <data key="d16">103177-37-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32)</data>
  <data key="d20">O=C(NC1=C2OC(=CC(=O)C2=CC=C1)C1=NNN=N1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1</data>
  <data key="d21">Used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02746">
  <data key="d0">Phthalic Acid</data>
  <data key="d1">drugbank.DB02746</data>
  <data key="d2">[drugbank.DB02746, drugbank.EXPT02595]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Acids, Carbocyclic]</data>
  <data key="d14">benzene-1,2-dicarboxylic acid</data>
  <data key="d15">C8H6O4</data>
  <data key="d16">88-99-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C8H6O4/c9-7(10)5-3-1-2-4-6(5)8(11)12/h1-4H,(H,9,10)(H,11,12)</data>
  <data key="d20">OC(=O)C1=CC=CC=C1C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02705">
  <data key="d0">6-[N-(1-Isopropyl-1,2,3,4-Tetrahydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine</data>
  <data key="d1">drugbank.DB02705</data>
  <data key="d2">[drugbank.DB02705, drugbank.EXPT00148]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">6-carbamimidoyl-N-[(1S)-1-(propan-2-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl]naphthalene-2-carboxamide</data>
  <data key="d15">C24H26N4O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H26N4O/c1-14(2)22-21-13-20(8-7-15(21)9-10-27-22)28-24(29)19-6-4-16-11-18(23(25)26)5-3-17(16)12-19/h3-8,11-14,22,27H,9-10H2,1-2H3,(H3,25,26)(H,28,29)/t22-/m0/s1</data>
  <data key="d20">[H][C@]1(NCCC2=C1C=C(NC(=O)C1=CC=C3C=C(C=CC3=C1)C(N)=N)C=C2)C(C)C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02709">
  <data key="d0">Resveratrol</data>
  <data key="d1">drugbank.DB02709</data>
  <data key="d2">[drugbank.DB02709, drugbank.EXPT02968]</data>
  <data key="d12">[approved, experimental, investigational]</data>
  <data key="d13">[Analgesics, Analgesics, Non-Narcotic, Angiogenesis Inhibitors, Anti-Inflammatory Agents, Anticarcinogenic Agents, Antimutagenic Agents, Antineoplastic Agents, Phytogenic, Antioxidants, Antiplatelet agents, Antirheumatic Agents, Benzene Derivatives, Benzylidene Compounds, Central Nervous System Agents, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Hematologic Agents, Peripheral Nervous System Agents, Phenols, Protective Agents, Ribonucleotide Reductases, antagonists &amp; inhibitors, Sensory System Agents, Vasodilating Agents]</data>
  <data key="d14">5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol</data>
  <data key="d15">C14H12O3</data>
  <data key="d16">501-36-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+</data>
  <data key="d20">OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1</data>
  <data key="d21">Being investigated for the treatment of Herpes labialis infections (cold sores).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1, 3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1, 3-benzenediol, (E)-resveratrol, 3, 4', 5-trihydroxy-trans-stilbene, 3, 4', 5-trihydroxystilbene, 3, 5, 4'-trihydroxystilbene, 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1, 3-diol, trans-resveratrol]</data>
  <data key="d9">Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as cis-(Z) and trans-(E) isomers. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of Science, Dr. Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation. It has been claimed that it is readily degraded by exposure to light, heat, and oxygen. However, studies find that Trans-resveratrol undergoes negligible oxidation in normal atmosphere at room temperature.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12598">
  <data key="d0">Nafamostat</data>
  <data key="d1">drugbank.DB12598</data>
  <data key="d2">[drugbank.DB12598]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Amidines, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anticoagulants, Antirheumatic Agents, Central Nervous System Agents, Complement Inactivating Agents, Enzyme Inhibitors, Fibrinolysin, antagonists &amp; inhibitors, Hematologic Agents, Immunologic Factors, Kallikreins, antagonists &amp; inhibitors, OCT1 substrates, OCT2 Substrates, OCT2 substrates with narrow therapeutic index, Peripheral Nervous System Agents, Protease Inhibitors, Sensory System Agents, Serine Proteinase Inhibitors, Trypsin Inhibitors]</data>
  <data key="d14">6-carbamimidoylnaphthalen-2-yl 4-carbamimidamidobenzoate</data>
  <data key="d15">C19H17N5O2</data>
  <data key="d16">81525-10-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24)</data>
  <data key="d20">NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N</data>
  <data key="d21">Used as an anticoagulant in patients with disseminative blood vessel coagulation, hemorrhagic lesions, and hemorrhagic tendencies. It prevents blood clot formation during extracorporeal circulation in patients undergoing continuous renal replacement therapy and extra corporeal membrane oxygenation.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Nafamostatum, p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine]</data>
  <data key="d9">Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties. It has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome. The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00573">
  <data key="d0">Fenoprofen</data>
  <data key="d1">drugbank.DB00573</data>
  <data key="d2">[drugbank.DB00573, drugbank.APRD00970]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acids, Carbocyclic, Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antirheumatic Agents, Central Nervous System Agents, Cyclooxygenase Inhibitors, Enzyme Inhibitors, Musculo-Skeletal System, Nephrotoxic agents, Non COX-2 selective NSAIDS, Nonsteroidal Anti-inflammatory Compounds, Peripheral Nervous System Agents, Phenylpropionates, Propionates, Sensory System Agents]</data>
  <data key="d14">2-(3-phenoxyphenyl)propanoic acid</data>
  <data key="d15">C15H14O3</data>
  <data key="d16">29679-58-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H14O3/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13/h2-11H,1H3,(H,16,17)</data>
  <data key="d20">CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1</data>
  <data key="d21">For relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Also for the relief of mild to moderate pain.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+/-)-fenoprofen, (+/-)-m-phenoxyhydratropic acid, ()-2-(3-phenoxyphenyl)propionic acid, 2-(3-phenoxyphenyl)propionic acid, 2-(m-phenoxyphenyl)propionic acid, 3-phenoxyhydratropic acid, DL-2-(3-phenoxyphenyl)propionic acid, Fenoprofen, Fnoprofne, Fenoprofeno, Fenoprofenum, -(m-phenoxyphenyl)propionic acid, -methyl-3-phenoxybenzeneacetic acid]</data>
  <data key="d9">An anti-inflammatory analgesic and antipyretic highly bound to plasma proteins. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00572">
  <data key="d0">Atropine</data>
  <data key="d1">drugbank.DB00572</data>
  <data key="d2">[drugbank.DB00572, drugbank.APRD00807, drugbank.EXPT02427]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Adjuvants, Anesthesia, Agents producing tachycardia, Agents that produce hypertension, Alimentary Tract and Metabolism, Alkaloids, Anti-Asthmatic Agents, Antiarrhythmic agents, Anticholinergic Agents, Antimuscarinics Antispasmodics, Atropine Derivatives, Autonomic Agents, Aza Compounds, Azabicyclo Compounds, Belladonna Alkaloids, Belladonna Alkaloids, Tertiary Amines, Belladonna and Derivatives, Plain, Bronchodilator Agents, BSEP/ABCB11 Substrates, Cardiovascular Agents, Central Nervous System Agents, Cholinergic Agents, Drugs for Functional Gastrointestinal Disorders, Moderate Risk QTc-Prolonging Agents, Muscarinic Antagonists, Mydriatics, Mydriatics and Cycloplegics, Neurotransmitter Agents, Ophthalmologicals, Parasympatholytics, Peripheral Nervous System Agents, QTc Prolonging Agents, Respiratory System Agents, Sensory Organs, Solanaceous Alkaloids, Tropanes]</data>
  <data key="d14">(1R,3R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate</data>
  <data key="d15">C17H23NO3</data>
  <data key="d16">51-55-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15+,16?</data>
  <data key="d20">CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1</data>
  <data key="d21">For the treatment of poisoning by susceptible organophosphorous nerve agents having anti-cholinesterase activity (cholinesterase inhibitors) as well as organophosphorous or carbamate insecticides.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-atropine, ()-hyoscyamine, Atropin, Atropina, Atropine, Atropinum, dl-Hyoscyamine, dl-tropyltropate, Tropine tropate]</data>
  <data key="d9">An alkaloid, originally from Atropa belladonna, but found in other plants, mainly solanaceae.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00589">
  <data key="d0">Lisuride</data>
  <data key="d1">drugbank.DB00589</data>
  <data key="d2">[drugbank.DB00589, drugbank.APRD00636]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents that produce hypertension, Alkaloids, Analgesics, Anti-Dyskinesia Agents, Anti-Parkinson Drugs, Antidepressive Agents, Antimigraine Preparations, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Dopamine Agents, Dopamine Agonists, Dopamine Antagonists, Ergolines, Ergot Alkaloids and Derivatives, Ergot-derivative Dopamine Receptor Agonists, Genito Urinary System and Sex Hormones, Nervous System, Neurotransmitter Agents, Prolactine Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Agonists, Serotonin Receptor Antagonists]</data>
  <data key="d14">3,3-diethyl-1-[(4S,7R)-6-methyl-6,11-diazatetracyclo[7.6.1.0,.0,]hexadeca-1(16),2,9,12,14-pentaen-4-yl]urea</data>
  <data key="d15">C20H26N4O</data>
  <data key="d16">18016-80-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18+/m0/s1</data>
  <data key="d20">[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC</data>
  <data key="d21">For the management of Parkinson's Disease</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Lisurid, Lisurida, Lisuride, Lisuridum, N'-((8alpha)-9, 10-Didehydro-6-methylergolin-8-yl)-N, N-diethylurea]</data>
  <data key="d9">An ergot derivative that acts as an agonist at dopamine D2 receptors (dopamine agonists). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (serotonin agonists).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00586">
  <data key="d0">Diclofenac</data>
  <data key="d1">drugbank.DB00586</data>
  <data key="d2">[drugbank.DB00586, drugbank.APRD00527]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Acetic Acid Derivatives and Related Substances, Acids, Carbocyclic, Agents causing angioedema, Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Allergic Agents, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antiinflammatory Preparations, Non-Steroids for Topical Use, Antirheumatic Agents, BSEP/ABCB11 Substrates, Central Nervous System Agents, Cyclooxygenase Inhibitors, Cyclooxygenase-2 (COX-2) Inhibitors, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Decreased Prostaglandin Production, Dermatologicals, Enzyme Inhibitors, Musculo-Skeletal System, Nephrotoxic agents, Non COX-2 selective NSAIDS, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OATP1B1/SLCO1B1 Inhibitors, Ophthalmologicals, Other Nonsteroidal Antiimflammatory Agents, P-glycoprotein/ABCB1 Inhibitors, Peripheral Nervous System Agents, Phenylacetates, Sensory Organs, Sensory System Agents, Topical Products for Joint and Muscular Pain, UGT1A1 Substrates, UGT2B7 substrates]</data>
  <data key="d14">2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid</data>
  <data key="d15">C14H11Cl2NO2</data>
  <data key="d16">15307-86-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)</data>
  <data key="d20">OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl</data>
  <data key="d21">For the acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[[2-(2, 6-dichloroanilino)phenyl]acetic acid, 2-((2, 6-dichlorophenyl)amino)benzeneacetic acid, Diclofenac, Diclofenac acid, Diclofenaco, Diclofenacum]</data>
  <data key="d9">A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00585">
  <data key="d0">Nizatidine</data>
  <data key="d1">drugbank.DB00585</data>
  <data key="d2">[drugbank.DB00585, drugbank.APRD00706]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acid Reducers, Agents Causing Muscle Toxicity, Alimentary Tract and Metabolism, Anti-Ulcer Agents, Cholinesterase Inhibitors, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Gastric Acid Lowering Agents, Gastrointestinal Agents, Histamine Agents, Histamine Antagonists, Histamine H2 Antagonists, Neurotransmitter Agents, P-glycoprotein/ABCB1 Substrates, Sulfur Compounds, Thiazoles]</data>
  <data key="d14">dimethyl[(4-{[(2-{[1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}-1,3-thiazol-2-yl)methyl]amine</data>
  <data key="d15">C12H21N5O2S2</data>
  <data key="d16">76963-41-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3</data>
  <data key="d20">CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O</data>
  <data key="d21">For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N, N-dimethylamine, Nizatidina, Nizatidine, Nizatidinum]</data>
  <data key="d9">A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00584">
  <data key="d0">Enalapril</data>
  <data key="d1">drugbank.DB00584</data>
  <data key="d2">[drugbank.DB00584, drugbank.APRD00510]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[ACE Inhibitors and Calcium Channel Blockers, ACE Inhibitors and Diuretics, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Agents Causing Muscle Toxicity, Amino Acids, Peptides, and Proteins, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Decreased Blood Pressure, Dipeptides, Enzyme Inhibitors, Hypotensive Agents, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OATP1B1/SLCO1B1 Substrates, Oligopeptides, P-glycoprotein/ABCB1 Inhibitors, Peptides, Protease Inhibitors]</data>
  <data key="d14">(2S)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]pyrrolidine-2-carboxylic acid</data>
  <data key="d15">C20H28N2O5</data>
  <data key="d16">75847-73-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1</data>
  <data key="d20">CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O</data>
  <data key="d21">Indicated for the management of essential or renovascular hypertension [L6586] as monotherapy or in combination with other antihypertensive agents, such as thiazide diuretics, for an additive effect.[label]\n\nIndicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis.[label]\n\nIndicated for the management of asymptomatic left ventricular dysfunction in patients with an ejection fraction of  to 35 percent to decrease the rate of development of overt heart failure and the incidence of hospitalization for heart failure.[label]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(S)-1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline, (S)-1-{(S)-2-[1-((S)-Ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid, 1-(N-((S)-1-carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester, nalapril, Enalapril, Enalaprila, Enalaprilum]</data>
  <data key="d9">Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-angiotensin-aldosterone system to lower blood pressure. It was developed from a targeted research programmed using molecular modelling.[A18459] Being a prodrug, enalapril is rapidly biotransformed into its active metabolite, [enalaprilat], which is responsible for the pharmacological actions of enalapril. The active metabolite of enalapril competitively inhibits the ACE to hinder the production of angiotensin II, a key component of the renin-angiotensin-aldosterone system that promotes vasoconstriction and renal reabsorption of sodium ions in the kidneys. Ultimately, enalaprilat works to reduce blood pressure and blood fluid volume.\n\nCommonly marketed under the trade name Vasotec, enalapril was first approved by the FDA in 1985 for the management of hypertension, heart failure, and asymptomatic left ventricular dysfunction. It is also found in a combination product containing [hydrochlorothiazide] that is used for the management of hypertension. The active metabolite enalaprilat is also available in oral tablets and intravenous formulations for injection.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00583">
  <data key="d0">Levocarnitine</data>
  <data key="d1">drugbank.DB00583</data>
  <data key="d2">[drugbank.DB00583, drugbank.APRD01070]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Amines, Amino Acids and Derivatives, Ammonium Compounds, Caloric Agents, Carnitine Analog, Dietary Supplements, Drugs that are Mainly Renally Excreted, Nitrogen Compounds, OAT3/SLC22A8 Substrates, OATP1B1/SLCO1B1 Inhibitors, Onium Compounds, Quaternary Ammonium Compounds, Trimethyl Ammonium Compounds]</data>
  <data key="d14">(3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate</data>
  <data key="d15">C7H15NO3</data>
  <data key="d16">541-15-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/t6-/m1/s1</data>
  <data key="d20">C[N+](C)(C)C[C@H](O)CC([O-])=O</data>
  <data key="d21">For treatment of primary systemic carnitine deficiency, a genetic impairment of normal biosynthesis or utilization of levocarnitine from dietary sources, or for the treatment of secondary carnitine deficiency resulting from an inborn error of metabolism such as glutaric aciduria II, methyl malonic aciduria, propionic acidemia, and medium chain fatty acylCoA dehydrogenase deficiency. Used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. Parenteral levocarnitine is indicated for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(-)-Carnitine, (-)-L-Carnitine, (R)-Carnitine, 3-Carboxy-2-hydroxy-N, N, N-trimethyl-1-propanaminium hydroxide, inner salt, Carnitina, Carnitine, L-Carnitine, Levocarnitin, Levocarnitina, Lvocarnitine, Levocarnitine, Levocarnitinum, Vitamin BT]</data>
  <data key="d9">Constituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00599">
  <data key="d0">Thiopental</data>
  <data key="d1">drugbank.DB00599</data>
  <data key="d2">[drugbank.DB00599, drugbank.APRD00660]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Anesthetics, Anesthetics, General, Anesthetics, Intravenous, Anticholinergic Agents, Anticonvulsants, Barbiturates, Barbiturates, Plain, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, GABA Agents, GABA Modulators, Hypnotics and Sedatives, Hypotensive Agents, Narrow Therapeutic Index Drugs, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones, Thiobarbiturates]</data>
  <data key="d14">5-ethyl-5-(pentan-2-yl)-2-sulfanylidene-1,3-diazinane-4,6-dione</data>
  <data key="d15">C11H18N2O2S</data>
  <data key="d16">76-75-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H18N2O2S/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)</data>
  <data key="d20">CCCC(C)C1(CC)C(=O)NC(=S)NC1=O</data>
  <data key="d21">For use as the sole anesthetic agent for brief (15 minute) procedures, for induction of anesthesia prior to administration of other anesthetic agents, to supplement regional anesthesia, to provide hypnosis during balanced anesthesia with other agents for analgesia or muscle relaxation, for the control of convulsive states during or following inhalation anesthesia or local anesthesia, in neurosurgical patients with increased intracranial pressure, and for narcoanalysis and narcosynthesis in psychiatric disorders.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-thiopental, 2-Thio-5-ethyl-5-sec-pentylbarbituric acid, 5-Ethyl-5-(1-methyl-butyl)-2-thioxo-dihydro-pyrimidine-4, 6-dione, Penthiobarbital, Pentothiobarbital, Thiopental, Thiopentobarbital, Thiopentobarbitone, Thiopentobarbituric acid, Thiopentone, Tiopentale]</data>
  <data key="d9">A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does not produce any excitation but has poor analgesic and muscle relaxant properties. Small doses have been shown to be anti-analgesic and lower the pain threshold. (From Martindale, The Extra Pharmacopoeia, 30th ed, p920)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00598">
  <data key="d0">Labetalol</data>
  <data key="d1">drugbank.DB00598</data>
  <data key="d2">[drugbank.DB00598, drugbank.APRD01062]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Agents producing tachycardia, Alcohols, Alpha and Beta Blocking Agents, Alpha and Beta Blocking Agents and Thiazides, Amides, Amines, Amino Alcohols, Antihypertensive Agents, Autonomic Agents, Beta Blocking Agents and Thiazides, Bradycardia-Causing Agents, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Ethanolamines, Hypotensive Agents, Neurotransmitter Agents, Peripheral alpha-1 blockers, Peripheral Nervous System Agents, Salicylamides, Sympathomimetics, Vasodilating Agents]</data>
  <data key="d14">2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide</data>
  <data key="d15">C19H24N2O3</data>
  <data key="d16">36894-69-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)</data>
  <data key="d20">CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1</data>
  <data key="d21">For the management of hypertension (alone or in combination with other classes of antihypertensive agents), as well as chronic stable angina pectoris and sympathetic overactivity syndrome associated with severe tetanus. Labetalol is used parenterally for immediate reduction in blood pressure in severe hypertension or in hypertensive crises when considered an emergency, for the control of blood pressure in patients with pheochromocytoma and pregnant women with preeclampsia, and to produce controlled hypotension during anesthesia to reduce bleeding resulting from surgical procedures.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol, 5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide, Labtalol, Labetalol, Labetalolum, Labetolol]</data>
  <data key="d9">Blocker of both alpha- and beta-adrenergic receptors that is used as an antihypertensive.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00594">
  <data key="d0">Amiloride</data>
  <data key="d1">drugbank.DB00594</data>
  <data key="d2">[drugbank.DB00594, drugbank.APRD00790, drugbank.EXPT00514]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acid Sensing Ion Channel Blockers, Agents causing hyperkalemia, Cardiovascular Agents, Decreased Renal K+ Excretion, Diuretics, Diuretics, Potassium Sparing, Epithelial Sodium Channel Blockers, Hypotensive Agents, Increased Diuresis, Membrane Transport Modulators, Natriuretic Agents, OCT2 Inhibitors, Potassium-Sparing Agents, Potassium-Sparing Diuretics, Pyrazines, Sodium Channel Blockers]</data>
  <data key="d14">3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide</data>
  <data key="d15">C6H8ClN7O</data>
  <data key="d16">2609-46-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15)</data>
  <data key="d20">NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1</data>
  <data key="d21">For use as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3, 5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide, Amilorid, Amilorida, Amiloride, Amiloridum, Amipramidin, Amipramidine, Amyloride, N-amidino-3, 5-diamino-6-chloropyrazinecarboxamide]</data>
  <data key="d9">A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00657">
  <data key="d0">Mecamylamine</data>
  <data key="d1">drugbank.DB00657</data>
  <data key="d2">[drugbank.DB00657, drugbank.APRD00458]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents that produce neuromuscular block (indirect), Antiadrenergic Agents, Ganglion-Blocking, Anticholinergic Agents, Antihypertensive Agents, Autonomic Agents, Autonomic Ganglionic Blocker, Cardiovascular Agents, Cholinergic Agents, Decreased Autonomic Ganglionic Activity, Drugs that are Mainly Renally Excreted, Ganglion Blockers, Hypotensive Agents, Monoterpenes, Neurotransmitter Agents, Nicotinic Antagonists, Norbornanes, Peripheral Nervous System Agents, Secondary and Tertiary Amines, Terpenes]</data>
  <data key="d14">N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine</data>
  <data key="d15">C11H21N</data>
  <data key="d16">60-40-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H21N/c1-10(2)8-5-6-9(7-8)11(10,3)12-4/h8-9,12H,5-7H2,1-4H3</data>
  <data key="d20">CNC1(C)C2CCC(C2)C1(C)C</data>
  <data key="d21">For the treatment of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Mecamylamine]</data>
  <data key="d9">A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00655">
  <data key="d0">Estrone</data>
  <data key="d1">drugbank.DB00655</data>
  <data key="d2">[drugbank.DB00655, drugbank.APRD00588]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[17-Ketosteroids, Adrenal Cortex Hormones, BCRP/ABCG2 Inhibitors, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Estradiol Congeners, Estranes, Estrenes, Estrogens, Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Ketosteroids, Natural and Semisynthetic Estrogens, Plain, OAT3/SLC22A8 Substrates, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Substrates, Sex Hormones and Modulators of the Genital System, Steroids]</data>
  <data key="d14">(1S,10R,11S,15S)-5-hydroxy-15-methyltetracyclo[8.7.0.0,.0,]heptadeca-2(7),3,5-trien-14-one</data>
  <data key="d15">C18H22O2</data>
  <data key="d16">53-16-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1</data>
  <data key="d20">[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3</data>
  <data key="d21">For management of perimenopausal and postmenopausal symptoms.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3-Hydroxy-1, 3, 5(10)-estratrien-17-one, Estrona, Estrone, Estronum, Follicular hormone, Folliculin, Oestrone]</data>
  <data key="d9">Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13961">
  <data key="d0">Fish oil</data>
  <data key="d1">drugbank.DB13961</data>
  <data key="d2">[drugbank.DB13961]</data>
  <data key="d12">[approved, nutraceutical]</data>
  <data key="d13">[Agents causing hyperkalemia, Antiarrhythmic agents, Bradycardia-Causing Agents, Calcium Channel Blockers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Lipids, Oils, Vasodilating Agents]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Under FDA approval, fish oil pharmaceuticals are typically products consisting of a combination of the omega-3-fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and are indicated primarily as an adjunct to diet to reduce triglyceride levels in adult patients with severe (&gt;=500 mg/dL) hypertriglyceridemia [FDA Label, F36].\n\nUnder EMA approval, such fish oil pharmaceuticals comprised of virtually the same fish and fish oil derived omega-3-fatty acids EPA and DHA are indicated specifically for (a) adjuvant treatment in secondary prevention after myocardial infarction, in addition to other standard therapy (ie. statins, antiplatelet medicinal products, beta blockers, ACE inhibitors), and (b) as a supplement to diet when dietary measures alone are insufficient to produce an adequate response, particularly with type IV hypertriglyceridemia in monotherapy or type IIb/III in combination with statins, when control of triglycerides is insufficient [L2661]. In addition, prescribing information for EMA approved fish oil pharmaceuticals are also indicated as an adjunct to diet to reduce very high (&gt;=500 mg/dL) triglyceride levels in adult patients, much like similar FDA approved indications [F37, FDA Label].</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Fish oil containing omega-3 acids, Fish oils, Omega-3 fish oil]</data>
  <data key="d9">Fish oil is a component of SMOFLIPID, which was FDA approved in July 2016. It is indicated in adults as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.\n\nMore commonly, fish oil refers to the omega-3-fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [FDA Label]. In general, dietary or pharmaceutical intake of these acids is primarily the only way to increase their levels in the human body where they are overall an essential element to dietary health as they have demonstrated abilities in minimizing or preventing hypertriglyceridemia when taken as an adjunct to a healthy diet [FDA Label].\n\nSuch fish oils are available in both non-prescription and prescription-only varieties at different concentrations. For many individuals, taking non-prescription fish oils as part of their multivitamin regimen is an effective way to supplement their diets with the healthy fatty acids. However, prescription-only fish oil products are sometimes prescribed for individuals who demonstrate severe (&gt;= 500 mg/dL) hypertriglyceridemia [FDA Label].\n\nFurthermore, a variety of studies regarding additional potential actions of fish oil omega-3-fatty acids EPA and DHA are ongoing. Such experimental actions include inflammation modulation, cardioprotective effects, the attenuation of oxidative stress, and more. Regardless, the specific mechanisms of action for these effects have yet to be formally elucidated.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00668">
  <data key="d0">Epinephrine</data>
  <data key="d1">drugbank.DB00668</data>
  <data key="d2">[drugbank.DB00668, drugbank.APRD00450, drugbank.EXPT00496]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic and Dopaminergic Agents, Adrenergic beta-1 Receptor Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-3 Receptor Agonists, Adrenergic beta-Agonists, Adrenergics, Inhalants, Agents producing tachycardia, Agents that produce hypertension, Alpha-and Beta-adrenergic Agonists, Amines, Anti-Asthmatic Agents, Antiglaucoma Preparations and Miotics, Autonomic Agents, Biogenic Amines, Biogenic Monoamines, Bronchodilator Agents, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiovascular Agents, Catecholamines, COMT Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dental Agents, Drugs for Obstructive Airway Diseases, Epinephrine and similars, Hemostatics, Hyperglycemia-Associated Agents, Local Hemostatics, Mydriatics, Nasal Preparations, Neurotransmitter Agents, OCT1 substrates, OCT2 Inhibitors, OCT2 Substrates, OCT2 substrates with narrow therapeutic index, Ophthalmologicals, Peripheral Nervous System Agents, Respiratory System Agents, Stomatological Preparations, Sympathomimetic (Adrenergic) Agents, Sympathomimetics, Sympathomimetics in Glaucoma Therapy, Sympathomimetics, Plain, Vasoconstrictor Agents]</data>
  <data key="d14">4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol</data>
  <data key="d15">C9H13NO3</data>
  <data key="d16">51-43-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3/t9-/m0/s1</data>
  <data key="d20">CNC[C@H](O)C1=CC(O)=C(O)C=C1</data>
  <data key="d21">Epinephrine injection is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. Injectable epinephrine is intended for immediate/urgent administration in patients, who are found to be at increased risk for anaphylaxis, including individuals with a history of anaphylaxis. Selection of the appropriate dosage strength is determined according to body weight [FDA label]. \n\nEpinephrine's cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes but is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock [F1247].\n\nEpinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis, and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics [F1247].\n\nIn addition to the above, epinephrine is used as an over the counter (OTC) agent for the intermittent symptoms of asthma, such as wheezing, tightness of chest and shortness of breath [F2131].  It is also used for the maintenance of mydriasis during intraocular surgery [L4825].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-(R)-epinephrine, ()-3, 4-dihydroxy--((methylamino)methyl)benzyl alcohol, ()-adrenaline, (R)-(-)-Adnephrine, (R)-(-)-Adrenaline, (R)-(-)-Epinephrine, (R)-(-)-Epirenamine, (R)-()-adrenaline, 4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1, 2-benzenediol, Adrnaline, Adrenaline, Epinefrin, Epinefrina, Epinephrin, Epinephrine, Epinephrinum, L-Adrenaline, Levoepinephrine]</data>
  <data key="d9">Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been available since 1987 in the USA. Many new products/biosimilars and dosage routes have been approved under various names over the last several decades [L4355], [L4356], [L4358].  On August 16, 2018, Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths [L4353]. Dosage delivery routes for epinephrine include intravenous, inhalation, nebulization, intramuscular injection, and subcutaneous injection.\n\nIn general, the most common uses of parenteral epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity (anaphylactic or anaphylactoid) reactions to drugs, animal serums and other allergens, and to prolong the action of infiltration anesthetics [F2136]. In addition to the above functions, epinephrine is the primary drug administered during cardiopulmonary resuscitation (CPR) to reverse cardiac arrest [A37697], [A37699].  It can be used in severe cases of croup [L4824].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01997">
  <data key="d0">3-Bromo-7-Nitroindazole</data>
  <data key="d1">drugbank.DB01997</data>
  <data key="d2">[drugbank.DB01997, drugbank.EXPT01883]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Nitric Oxide Synthase, antagonists &amp; inhibitors, Pyrazoles]</data>
  <data key="d14">3-bromo-7-nitro-1H-indazole</data>
  <data key="d15">C7H4BrN3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H4BrN3O2/c8-7-4-2-1-3-5(11(12)13)6(4)9-10-7/h1-3H,(H,9,10)</data>
  <data key="d20">BrC1=NNC2=C1C=CC=C2N(=O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09006">
  <data key="d0">Clinofibrate</data>
  <data key="d1">drugbank.DB09006</data>
  <data key="d2">[drugbank.DB09006]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Acetates, Acids, Acyclic, Fatty Acids, Fatty Acids, Volatile, Glycolates, Hydroxy Acids, Lipids]</data>
  <data key="d14">2-(4-{1-[4-(1-carboxy-1-methylpropoxy)phenyl]cyclohexyl}phenoxy)-2-methylbutanoic acid</data>
  <data key="d15">C28H36O6</data>
  <data key="d16">30299-08-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C28H36O6/c1-5-26(3,24(29)30)33-22-14-10-20(11-15-22)28(18-8-7-9-19-28)21-12-16-23(17-13-21)34-27(4,6-2)25(31)32/h10-17H,5-9,18-19H2,1-4H3,(H,29,30)(H,31,32)</data>
  <data key="d20">CCC(C)(OC1=CC=C(C=C1)C1(CCCCC1)C1=CC=C(OC(C)(CC)C(O)=O)C=C1)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Clinofibrate is a fibrate drug sold and marketed in Japan.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09010">
  <data key="d0">Carmofur</data>
  <data key="d1">drugbank.DB09010</data>
  <data key="d2">[drugbank.DB09010]</data>
  <data key="d12">[withdrawn]</data>
  <data key="d13">[Antimetabolites, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Fluoropyrimidines, Pyrimidine Analogues, Pyrimidines, Pyrimidinones, Uracil]</data>
  <data key="d14">5-fluoro-N-hexyl-4-hydroxy-2-oxo-1,2-dihydropyrimidine-1-carboximidic acid</data>
  <data key="d15">C11H16FN3O3</data>
  <data key="d16">61422-45-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H16FN3O3/c1-2-3-4-5-6-13-10(17)15-7-8(12)9(16)14-11(15)18/h7H,2-6H2,1H3,(H,13,17)(H,14,16,18)</data>
  <data key="d20">CCCCCCN=C(O)N1C=C(F)C(O)=NC1=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Carmofur is a derivative of fluorouracil, and is an antineoplastic agent that has been used in the treatment of breast and colorectal cancer. Carmofur has been known to induce leukoencephalopathy.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00679">
  <data key="d0">Thioridazine</data>
  <data key="d1">drugbank.DB00679</data>
  <data key="d2">[drugbank.DB00679, drugbank.APRD00596]</data>
  <data key="d12">[approved, withdrawn]</data>
  <data key="d13">[Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Antidepressive Agents, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Highest Risk QTc-Prolonging Agents, Hypotensive Agents, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Phenothiazines, Phenothiazines With Piperidine Structure, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Sulfur Compounds, Tranquilizing Agents]</data>
  <data key="d14">10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine</data>
  <data key="d15">C21H26N2S2</data>
  <data key="d16">50-52-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3</data>
  <data key="d20">CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1</data>
  <data key="d21">For the treatment of schizophrenia and generalized anxiety disorder.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine, 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine, 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine, Thioridazin, Thioridazine, Thioridazinum, Tioridazina]</data>
  <data key="d9">A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618).\n\nThioridazine was withdrawn worldwide in 2005 due to it's association with cardiac arrythmias.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00678">
  <data key="d0">Losartan</data>
  <data key="d1">drugbank.DB00678</data>
  <data key="d2">[drugbank.DB00678, drugbank.APRD00052]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin 2 Receptor Blocker, Angiotensin II receptor blockers (ARBs) and calcium channel blockers, Angiotensin II receptor blockers (ARBs) and diuretics, Angiotensin II receptor blockers (ARBs), plain, Angiotensin II Type 1 Receptor Blockers, Angiotensin II Type 2 Receptor Blockers, Angiotensin Receptor Antagonists, Antiarrhythmic agents, Antihypertensive Agents, Benzene Derivatives, Biphenyl Compounds, BSEP/ABCB11 Substrates, Cardiovascular Agents, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Hypotensive Agents, Imidazoles, OAT1/SLC22A6 inhibitors, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Tetrazoles, UGT1A1 Substrates, UGT1A3 substrates, UGT2B7 substrates]</data>
  <data key="d14">[2-butyl-4-chloro-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazol-5-yl]methanol</data>
  <data key="d15">C22H23ClN6O</data>
  <data key="d16">114798-26-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)</data>
  <data key="d20">CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1</data>
  <data key="d21">May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol, 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole, Losartan]</data>
  <data key="d9">Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. Losartan and its longer acting metabolite, E-3174, lower blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); they compete with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Losartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of systolic dysfunction, myocardial infarction, coronary artery disease, and heart failure.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00677">
  <data key="d0">Isoflurophate</data>
  <data key="d1">drugbank.DB00677</data>
  <data key="d2">[drugbank.DB00677, drugbank.APRD00763]</data>
  <data key="d12">[approved, investigational, withdrawn]</data>
  <data key="d13">[Cholinergic Agents, Cholinesterase Inhibitors, Enzyme Inhibitors, Neurotransmitter Agents, Ophthalmics, Organofluorophosphonates, Organophosphonates, Organophosphorus Compounds, Protease Inhibitors]</data>
  <data key="d14">bis(propan-2-yl) phosphorofluoridate</data>
  <data key="d15">C6H14FO3P</data>
  <data key="d16">55-91-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C6H14FO3P/c1-5(2)9-11(7,8)10-6(3)4/h5-6H,1-4H3</data>
  <data key="d20">CC(C)OP(F)(=O)OC(C)C</data>
  <data key="d21">For use in the eye to treat certain types of glaucoma and other eye conditions, such as accommodative esotropia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[DFP, Diisopropoxyphosphoryl fluoride, Diisopropyl fluorophosphate, Diisopropyl fluorophosphonate, Diisopropyl phosphofluoridate, Diisopropyl phosphorofluoridate, Diisopropylfluorophosphate, Diisopropylfluorophosphoric acid ester, Diisopropylphosphofluoridate, Diisopropylphosphorofluoridate, Fluorodiisopropyl phosphate, Fluorostigmine, Isofluorphate, Isoflurophate, Isoflurophosphate, Isopropyl fluophosphate, Isopropyl phosphorofluoridate, O, O'-diisopropyl phosphoryl fluoride]</data>
  <data key="d9">An irreversible cholinesterase inhibitor with actions similar to those of echothiophate. It is a powerful miotic used mainly in the treatment of glaucoma. Its vapor is highly toxic and it is recommended that only solutions in arachis oil be used therapeutically. (From Martindale, The Extra Pharmacopoeia, 29th ed, p1330)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00675">
  <data key="d0">Tamoxifen</data>
  <data key="d1">drugbank.DB00675</data>
  <data key="d2">[drugbank.DB00675, drugbank.APRD00123]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Anti-Estrogens, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Benzene Derivatives, Benzylidene Compounds, BSEP/ABCB11 Inhibitors, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (moderate), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Endocrine Therapy, Estrogen Agonist/Antagonist, Estrogen Antagonists, Estrogen Receptor Modulators, Hormone Antagonists, Hormone Antagonists and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Selective Estrogen Receptor Modulators, Stilbenes, Thyroxine-binding globulin inducers]</data>
  <data key="d14">(2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine</data>
  <data key="d15">C26H29NO</data>
  <data key="d16">10540-29-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-</data>
  <data key="d20">CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1</data>
  <data key="d21">Tamoxifen is indicated for the treatment of metastatic breast cancer in women and men and ductal carcinoma in Situ.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(Z)-2-(4-(1, 2-Diphenyl-1-butenyl)phenoxy)-N, N-dimethylethanamine, (Z)-2-(para-(1, 2-Diphenyl-1-butenyl)phenoxy)-N, N-dimethylamine, 1-p-beta-Dimethylaminoethoxyphenyl-trans-1, 2-diphenylbut-1-ene, 1-para-beta-Dimethylaminoethoxyphenyl-trans-1, 2-diphenylbut-1-ene, Tamoxifen, Tamoxifne, Tamoxifene, Tamoxifeno, Tamoxifenum, trans-Tamoxifen]</data>
  <data key="d9">One of the selective estrogen receptor modulators (SERM) with tissue-specific activities for the treatment and prevention of estrogen receptor positive breast cancer. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the endometrium.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00674">
  <data key="d0">Galantamine</data>
  <data key="d1">drugbank.DB00674</data>
  <data key="d2">[drugbank.DB00674, drugbank.APRD00206, drugbank.EXPT01628]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Alkaloids, Amaryllidaceae Alkaloids, Anti-Dementia Drugs, Autonomic Agents, Benzazepines, Bradycardia-Causing Agents, Central Nervous System Agents, Cholinergic Agents, Cholinesterase Inhibitors, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Nervous System, Neurotransmitter Agents, Nootropic Agents, Parasympathomemetic (Cholinergic) Agents, Parasympathomimetics, Peripheral Nervous System Agents, Potential QTc-Prolonging Agents, Psychoanaleptics, QTc Prolonging Agents]</data>
  <data key="d14">(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0,.0,]heptadeca-6(17),7,9,15-tetraen-14-ol</data>
  <data key="d15">C17H21NO3</data>
  <data key="d16">357-70-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1</data>
  <data key="d20">[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3</data>
  <data key="d21">For the treatment of mild to moderate dementia of the Alzheimer's type. Has also been investigated in patients with mild cognitive impairment who did not meet the diagnostic criteria for Alzheimer's disease.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(-)-Galanthamine, Galantamina, Galantamine, Galanthamine]</data>
  <data key="d9">A benzazepine derived from norbelladine. It is found in galanthus and other amaryllidaceae. Galantamine is a cholinesterase inhibitor that has been used to reverse the muscular effects of gallamine triethiodide and tubocurarine, and has been studied as a treatment for Alzheimer's disease and other central nervous system disorders.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09019">
  <data key="d0">Bromhexine</data>
  <data key="d1">drugbank.DB09019</data>
  <data key="d2">[drugbank.DB09019]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amines, Aniline Compounds, Cough and Cold Preparations, Cyclohexanes, Cyclohexylamines, Cycloparaffins, Expectorants, Respiratory System Agents]</data>
  <data key="d14">2,4-dibromo-6-{[cyclohexyl(methyl)amino]methyl}aniline</data>
  <data key="d15">C14H20Br2N2</data>
  <data key="d16">3572-43-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H20Br2N2/c1-18(12-5-3-2-4-6-12)9-10-7-11(15)8-13(16)14(10)17/h7-8,12H,2-6,9,17H2,1H3</data>
  <data key="d20">CN(CC1=CC(Br)=CC(Br)=C1N)C1CCCCC1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3, 5-dibromo-N(alpha)-cyclohexyl-N(alpha)-methyltoluene-alpha-2-diamine, Bromexina, Bromhexina, Bromhexine, Bromhexinum, N-cyclohexyl-N-methyl-(2-amino-3, 5-dibrombenzyl)amine]</data>
  <data key="d9">Bromhexine is an expectorant/mucolytic agent. Bromhexine is not available in the United States. It is marketed under the trade name Bisolvon(R) in Germany, England, Belgium, France, Italy, Netherlands, Norway, Sweden, Australia, and South Africa.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09018">
  <data key="d0">Bromopride</data>
  <data key="d1">drugbank.DB09018</data>
  <data key="d2">[drugbank.DB09018]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Carbocyclic, Alimentary Tract and Metabolism, Amides, Aminobenzoates, Antiemetics, Autonomic Agents, Benzamides and benzamide derivatives, Benzene Derivatives, Benzoates, Central Nervous System Agents, Chlorobenzoates, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs for Functional Gastrointestinal Disorders, Ethers, Gastrointestinal Agents, Hydroxy Acids, Hydroxybenzoate Ethers, Hydroxybenzoates, Neurotransmitter Agents, para-Aminobenzoates, Peripheral Nervous System Agents, Phenols, Phenyl Ethers, Propulsives]</data>
  <data key="d14">4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzene-1-carboximidic acid</data>
  <data key="d15">C14H22BrN3O2</data>
  <data key="d16">4093-35-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H22BrN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)</data>
  <data key="d20">CCN(CC)CCN=C(O)C1=C(OC)C=C(N)C(Br)=C1</data>
  <data key="d21">Bromopride in indicated in the treatment of nausea and vomiting, including PONV (post-operative nausea and vomiting), gastroesophageal reflux disease (GERD/GORD), as well as endoscopy preparation and radiographic studies of the GI tract.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide, Bromoprid, Bromoprida, Bromopride, Bromopridum]</data>
  <data key="d9">Bromopride is a dopamine antagonist used as an antiemetic. Its prokinetic properties are similar to those of metoclopramide. It is unavailable in America or the United Kingdom.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09028">
  <data key="d0">Cytisine</data>
  <data key="d1">drugbank.DB09028</data>
  <data key="d2">[drugbank.DB09028]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Drugs Used in Addictive Disorders, Drugs Used in Nicotine Dependence, Nervous System, Nicotine, antagonists &amp; inhibitors]</data>
  <data key="d14">(1R,9S)-7,11-diazatricyclo[7.3.1.0,]trideca-2,4-dien-6-one</data>
  <data key="d15">C11H14N2O</data>
  <data key="d16">485-35-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H14N2O/c14-11-3-1-2-10-9-4-8(5-12-6-9)7-13(10)11/h1-3,8-9,12H,4-7H2/t8-,9+/m0/s1</data>
  <data key="d20">O=C1C=CC=C2[C@H]3CNC[C@H](C3)CN12</data>
  <data key="d21">Indicated for use in smoking cessation.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(1R, 5S)-1, 2, 3, 4, 5, 6-Hexahydro-1, 5-methano-8H-pyrido[1, 2a][1, 5]diazocin-8-one, Baptitoxine, Sophorine, Ulexin]</data>
  <data key="d9">Cytisine is an alkaloid naturally derived from the Fabaceae family of plants including the genera Laburnum and Cytisus. Recent studies have shown it to be a more effective and significantly more affordable smoking cessation treatment than nicotine replacement therapy. Also known as baptitoxine or sophorine, cytisine has been used as a smoking cessation treatment since 1964, and is relatively unknown in regions outside of central and Eastern Europe. Cytisine is a partial nicotinic acetylcholine agonist with a half-life of 4.8 hours. Recent Phase III clinical trials using Tabex (a brand of Cytisine marketed by Sopharma AD) have shown similar efficacy to varenicline, but at a fraction of the cost.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00692">
  <data key="d0">Phentolamine</data>
  <data key="d1">drugbank.DB00692</data>
  <data key="d2">[drugbank.DB00692, drugbank.APRD00615]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Antidotes, Antihypertensive Agents, Cardiovascular Agents, Drugs that are Mainly Renally Excreted, Hypotensive Agents, Imidazoles, Imidazoline Derivatives, Neurotransmitter Agents, Non-selective Alfa-adrenergic Blocking Agents, Peripheral alpha-1 blockers, Peripheral Vasodilators, Sympatholytic (Adrenergic Blocking) Agents, Vasodilating Agents]</data>
  <data key="d14">3-[(4,5-dihydro-1H-imidazol-2-ylmethyl)(4-methylphenyl)amino]phenol</data>
  <data key="d15">C17H19N3O</data>
  <data key="d16">50-60-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)</data>
  <data key="d20">CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1</data>
  <data key="d21">Used as an aid for the diagnosis of pheochromocytoma, and may be administered immediately prior to or during pheochromocytomectomy to prevent or control paroxysmal hypertension resulting from anesthesia, stress, or operative manipulation of the tumor. Phentolamine has also been used to treat hypertensive crisis caused by sympathomimetic amines or catecholamine excess by certain foods or drugs in patients taking MAO inhibitors, or by clonidine withdrawal syndrome. Other indications include the prevention of dermal necrosis and sloughing following IV administration or extravasation of norepinephrine, decrease in impedance to left ventricular ejection and the infarct size in patients with MI associated with left ventricular failure, treatment of erectile dysfunction through self-injection of small doses combined with papaverine hydrochloride into the corpus cavernosum, and as an adjunct to the management of cocaine overdose to reverse coronary vasoconstriction following use of oxygen, benzodiazepines,and nitroglycerin.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazoline, Fentolamina, Phentolamin, Phentolamine, Phentolaminum]</data>
  <data key="d9">A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of raynaud disease and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00691">
  <data key="d0">Moexipril</data>
  <data key="d1">drugbank.DB00691</data>
  <data key="d2">[drugbank.DB00691, drugbank.APRD01120]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[ACE Inhibitors and Diuretics, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Agents, Enzyme Inhibitors, Hypotensive Agents, Isoquinolines, Potential QTc-Prolonging Agents, Protease Inhibitors, QTc Prolonging Agents]</data>
  <data key="d14">(3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid</data>
  <data key="d15">C27H34N2O7</data>
  <data key="d16">103775-10-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1</data>
  <data key="d20">CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[C@H]1C(O)=O</data>
  <data key="d21">For the treatment of hypertension.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Moexipril, Moexiprilum]</data>
  <data key="d9">Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12662">
  <data key="d0">Naveglitazar</data>
  <data key="d1">drugbank.DB12662</data>
  <data key="d2">[drugbank.DB12662, drugbank.DB06232]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Carbocyclic, PPAR alpha, agonists, PPAR gamma, agonists]</data>
  <data key="d14">(2S)-2-methoxy-3-{4-[3-(4-phenoxyphenoxy)propoxy]phenyl}propanoic acid</data>
  <data key="d15">C25H26O6</data>
  <data key="d16">476436-68-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C25H26O6/c1-28-24(25(26)27)18-19-8-10-20(11-9-19)29-16-5-17-30-21-12-14-23(15-13-21)31-22-6-3-2-4-7-22/h2-4,6-15,24H,5,16-18H2,1H3,(H,26,27)/t24-/m0/s1</data>
  <data key="d20">CO[C@@H](CC1=CC=C(OCCCOC2=CC=C(OC3=CC=CC=C3)C=C2)C=C1)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Naveglitazar has been used in trials studying the treatment of Diabetes Mellitus, Non-Insulin-Dependent.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00619">
  <data key="d0">Imatinib</data>
  <data key="d1">drugbank.DB00619</data>
  <data key="d2">[drugbank.DB00619, drugbank.APRD01028, drugbank.EXPT02967, drugbank.DB03261]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acids, Carbocyclic, Amides, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Benzamides and benzamide derivatives, Benzene Derivatives, Benzoates, BSEP/ABCB11 Substrates, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Highest Risk QTc-Prolonging Agents, Immunosuppressive Agents, Kinase Inhibitor, Miscellaneous Therapeutic Agents, Myelosuppressive Agents, OCT1 substrates, OCT2 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Piperazines, Protein Kinase Inhibitors, Pyrimidines, QTc Prolonging Agents, Tyrosine Kinase Inhibitors]</data>
  <data key="d14">N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide</data>
  <data key="d15">C29H31N7O</data>
  <data key="d16">152459-95-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)</data>
  <data key="d20">CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1</data>
  <data key="d21">For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Imatinib, Imatinibum, -(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide]</data>
  <data key="d9">Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.\n\nIt is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00616">
  <data key="d0">Candoxatril</data>
  <data key="d1">drugbank.DB00616</data>
  <data key="d2">[drugbank.DB00616, drugbank.APRD00027]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Acids, Acyclic, Antihypertensive Agents, Cardiovascular Agents, Enzyme Inhibitors, Fatty Acids, Fatty Acids, Volatile, Indenes, Lipids, Neprilysin, antagonists &amp; inhibitors, Prodrugs]</data>
  <data key="d14">(1s,4s)-4-{1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentaneamido}cyclohexane-1-carboxylic acid</data>
  <data key="d15">C29H41NO7</data>
  <data key="d16">123122-55-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C29H41NO7/c1-35-15-16-36-19-23(27(33)37-25-12-9-20-5-4-6-22(20)17-25)18-29(13-2-3-14-29)28(34)30-24-10-7-21(8-11-24)26(31)32/h9,12,17,21,23-24H,2-8,10-11,13-16,18-19H2,1H3,(H,30,34)(H,31,32)/t21-,23-,24+/m0/s1</data>
  <data key="d20">COCCOC[C@H](CC1(CCCC1)C(=O)N[C@H]1CC[C@H](CC1)C(O)=O)C(=O)OC1=CC2=C(CCC2)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[[4(S)-cis]-4-[[[1-[3-[(2, 3-dihydro-1H-Indeb5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid, 4-({1-[(S)-2-(indan-5-yloxycarbonyl)-3-(2-methoxy-ethoxy)-propyl]-cyclopentanecarbonyl}-amino)-cyclohexanecarboxylic acid, Candoxatril]</data>
  <data key="d9">Candoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01942">
  <data key="d0">Formic acid</data>
  <data key="d1">drugbank.DB01942</data>
  <data key="d2">[drugbank.DB01942, drugbank.EXPT01461]</data>
  <data key="d12">[experimental, investigational]</data>
  <data key="d13">[Acids, Acyclic, Blood Coagulation Factors, Hemostatics]</data>
  <data key="d14">formic acid</data>
  <data key="d15">CH2O2</data>
  <data key="d16">64-18-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/CH2O2/c2-1-3/h1H,(H,2,3)</data>
  <data key="d20">OC=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Acide formique, Ameisensure, Aminic acid, Bilorin, Formic acid, Formylic acid, Hydrogen carboxylic acid, Methanoic acid]</data>
  <data key="d9">Formic acid (systematically called methanoic acid) is the simplest carboxylic acid. It is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom of bee and ant stings. It is commonly used as a preservative and antibacterial agent in livestock feed.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00626">
  <data key="d0">Bacitracin</data>
  <data key="d1">drugbank.DB00626</data>
  <data key="d2">[drugbank.DB00626, drugbank.APRD00816]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Acids, Carbocyclic, Amino Acids, Peptides, and Proteins, Anti-Bacterial Agents, Anti-Infective Agents, Anti-Infective Agents, Local, Antibacterials for Systemic Use, Antibiotics for Topical Use, Antiinfectives for Systemic Use, Bacitracins, Benzene Derivatives, Benzoates, Decreased Cell Wall Synthesis &amp; Repair, Dermatologicals, Hydroxy Acids, Hydroxybenzoates, Nephrotoxic agents, Peptides, Peptides, Cyclic, Phenols, Throat Preparations]</data>
  <data key="d14">(4R)-4-[(2S)-2-{[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazol-4-yl]formamido}-4-methylpentanamido]-4-{[(1S,2S)-1-{[(3S,6R,9S,12R,15S,18R,21S)-18-(3-aminopropyl)-12-benzyl-15-[(2S)-butan-2-yl]-3-(carbamoylmethyl)-6-(carboxymethyl)-9-[(1H-imidazol-4-yl)methyl]-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclopentacosan-21-yl]carbamoyl}-2-methylbutyl]carbamoyl}butanoic acid</data>
  <data key="d15">C66H103N17O16S</data>
  <data key="d16">1405-87-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35-,36-,37-,40-,41+,42+,43-,44+,45-,46-,47+,48-,52-,53-,54-/m0/s1</data>
  <data key="d20">CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC</data>
  <data key="d21">For the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug. Also used in ointment form for topical treatment of a variety of localized skin and eye infections, as well as for the prevention of wound infections. Used against gram positive bacteria. Bacitracin is also used as an inhibitor of proteases and other enzymes. \nHowever, specific activity of bactracin's inhibition of protein disulfide isomerase has been called into question.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Bacitracin, Bacitracin A, Bacitracina]</data>
  <data key="d9">Bacitracin is a mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy. Its unique name derives from the fact that the bacillus producing it was first isolated in 1943 from a knee scrape from a girl named Margaret Tracy. It is synthesized via the activity of nonribosomal peptide synthetases (NRPSs). As a toxic and difficult-to-use antibiotic, bacitracin doesn't work well orally. However, it is very effective topically.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00624">
  <data key="d0">Testosterone</data>
  <data key="d1">drugbank.DB00624</data>
  <data key="d2">[drugbank.DB00624, drugbank.APRD00433, drugbank.DB05720, drugbank.DB05275]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[3-Oxoandrosten (4) Derivatives, Androgens, Androgens and Estrogens, Androstanes, Androstenes, Androstenols, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Drugs that are Mainly Renally Excreted, Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, OAT3/SLC22A8 Inducers, P-glycoprotein/ABCB1 Inhibitors, Sex Hormones and Modulators of the Genital System, Steroids, Testosterone and derivatives, Testosterone Congeners]</data>
  <data key="d14">(1S,3aS,3bR,9aR,9bS,11aS)-1-hydroxy-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one</data>
  <data key="d15">C19H28O2</data>
  <data key="d16">58-22-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C</data>
  <data key="d21">To be used as hormone replacement or substitution of diminished or absent endogenous testosterone. Use in males: For management of congenital or acquired hypogonadism, hypogonadism associated with HIV infection, and male climacteric (andopause). Use in females: For palliative treatment of androgen-responsive, advanced, inoperable, metastatis (skeletal) carcinoma of the breast  in women who are 1-5 years postmenopausal; testosterone esters may be used in combination with estrogens in the management of moderate to severe vasomotor symptoms associated with menopause in women who do not respond to adequately to estrogen therapy alone.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[17beta-hydroxy-4-androsten-3-one, 4-androsten-17-ol-3-one, Testosteron, Testosterona, Testosterone, Testostrone, Testosteronum, Virosterone]</data>
  <data key="d9">Testosterone is a steroid sex hormone found in both men and women. In men, testosterone is produced primarily by the Leydig (interstitial) cells of the testes when stimulated by luteinizing hormone (LH). It functions to stimulate spermatogenesis, promote physical and functional maturation of spermatozoa, maintain accessory organs of the male reproductive tract, support development of secondary sexual characteristics, stimulate growth and metabolism throughout the body and influence brain development by stimulating sexual behaviors and sexual drive. In women, testosterone is produced by the ovaries (25%), adrenals (25%) and via peripheral conversion from androstenedione (50%). Testerone in women functions to maintain libido and general wellbeing. Testosterone exerts a negative feedback mechanism on pituitary release of LH and follicle-stimulating hormone (FSH). Testosterone may be further converted to dihydrotestosterone or estradiol depending on the tissue.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00623">
  <data key="d0">Fluphenazine</data>
  <data key="d1">drugbank.DB00623</data>
  <data key="d2">[drugbank.DB00623, drugbank.APRD00633]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents that reduce seizure threshold, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Delayed-Action Preparations, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Nervous System, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein/ABCB1 Inhibitors, Phenothiazines, Phenothiazines With Piperazine Structure, Prodrugs, Psycholeptics, Psychotropic Drugs, Sulfur Compounds, Tranquilizing Agents]</data>
  <data key="d14">2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethan-1-ol</data>
  <data key="d15">C22H26F3N3OS</data>
  <data key="d16">69-23-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2</data>
  <data key="d20">OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1</data>
  <data key="d21">For management of manifestations of psychotic disorders.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-(2-hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine, 10-(3-(2-hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine, 10-(3'-(4''-(-hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine, 2-(4-(3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol, 2-(trifluoromethyl)-10-(3-(1-(-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine, 4-(3-(-trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol, 4-(3-(2-trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol, Flufenazina, Fluorfenazine, Fluorophenazine, Fluorphenazine, Fluphenazin, Fluphnazine, Fluphenazine, Fluphenazinum, Triflumethazine]</data>
  <data key="d9">A phenothiazine used in the treatment of psychoses. Its properties and uses are generally similar to those of chlorpromazine.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00622">
  <data key="d0">Nicardipine</data>
  <data key="d1">drugbank.DB00622</data>
  <data key="d2">[drugbank.DB00622, drugbank.APRD00088]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents causing hyperkalemia, Agents producing tachycardia, Antiarrhythmic agents, Anticholinergic Agents, Antihypertensive Agents, Bradycardia-Causing Agents, BSEP/ABCB11 Substrates, Calcium Channel Blockers, Calcium Channel Blockers (Dihydropyridine), Cardiovascular Agents, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strong), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (weak), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P450 2C19 Inhibitors, Cytochrome P450 3A4 Inhibitors, Dihydropyridine Derivatives, Dihydropyridines, Hypotensive Agents, Membrane Transport Modulators, Muscarinic Antagonists, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Potential QTc-Prolonging Agents, Pyridines, QTc Prolonging Agents, Selective Calcium Channel Blockers With Mainly Vascular Effects, Vasodilating Agents]</data>
  <data key="d14">3-{2-[benzyl(methyl)amino]ethyl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate</data>
  <data key="d15">C26H29N3O6</data>
  <data key="d16">55985-32-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3</data>
  <data key="d20">COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1</data>
  <data key="d21">Used for the management of patients with chronic stable angina and for the treatment of hypertension.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Nicardipine, Nicardipino, Nicardipinum]</data>
  <data key="d9">A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01950">
  <data key="d0">N-(4-Methoxybenzyl)-N'-(5-Nitro-1,3-Thiazol-2-Yl)Urea</data>
  <data key="d1">drugbank.DB01950</data>
  <data key="d2">[drugbank.DB01950, drugbank.EXPT03075]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Glycogen Synthase Kinase 3, antagonists &amp; inhibitors, Sulfur Compounds]</data>
  <data key="d14">1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea</data>
  <data key="d15">C12H12N4O4S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H12N4O4S/c1-20-9-4-2-8(3-5-9)6-13-11(17)15-12-14-7-10(21-12)16(18)19/h2-5,7H,6H2,1H3,(H2,13,14,15,17)</data>
  <data key="d20">COC1=CC=C(CNC(=O)NC2=NC=C(S2)[N+]([O-])=O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00637">
  <data key="d0">Astemizole</data>
  <data key="d1">drugbank.DB00637</data>
  <data key="d2">[drugbank.DB00637, drugbank.APRD00585]</data>
  <data key="d12">[approved, withdrawn]</data>
  <data key="d13">[Anti-Allergic Agents, Antihistamines for Systemic Use, Benzimidazoles, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Highest Risk QTc-Prolonging Agents, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine H1 Antagonists, Non-Sedating, Neurotransmitter Agents, P-glycoprotein/ABCB1 Inhibitors, QTc Prolonging Agents]</data>
  <data key="d14">1-[(4-fluorophenyl)methyl]-N-{1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl}-1H-1,3-benzodiazol-2-amine</data>
  <data key="d15">C28H31FN4O</data>
  <data key="d16">68844-77-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C28H31FN4O/c1-34-25-12-8-21(9-13-25)14-17-32-18-15-24(16-19-32)30-28-31-26-4-2-3-5-27(26)33(28)20-22-6-10-23(29)11-7-22/h2-13,24H,14-20H2,1H3,(H,30,31)</data>
  <data key="d20">COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1</data>
  <data key="d21">Astemizole was indicated for use in the relieving allergy symptoms, particularly rhinitis and conjunctivitis. It has been withdrawn from the market however due to concerns of arrhythmias.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-(p-Fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)piperid-4-yl)amino)benzimidazole, 1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazole, Astemizol, Astmizole, Astemizole, Astemizolum]</data>
  <data key="d9">Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when  when taken with CYP inhibitors or grapefruit juice.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13946">
  <data key="d0">Testosterone undecanoate</data>
  <data key="d1">drugbank.DB13946</data>
  <data key="d2">[drugbank.DB13946, drugbank.DBSALT001033]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Androgens, Androstanes, Androstenes, Androstenols, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, OAT3/SLC22A8 Inducers, P-glycoprotein/ABCB1 Inhibitors, Steroids, Testosterone and derivatives, Testosterone Congeners]</data>
  <data key="d14">(1S,3aS,3bR,9aR,9bS,11aS)-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl undecanoate</data>
  <data key="d15">C30H48O3</data>
  <data key="d16">5949-44-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C30H48O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h21,24-27H,4-20H2,1-3H3/t24-,25-,26-,27-,29-,30-/m0/s1</data>
  <data key="d20">CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C</data>
  <data key="d21">Testosterone undecanoate is indicated for replacement therapy in adult males with conditions that are linked with an absence or deficiency in endogenous testosterone production. [F4247][FDA Label]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Testosterone undecanoate, Testosterone undeconate, Testosterone undecylate]</data>
  <data key="d9">Testosterone undecanoate is the ester prodrug of testosterone and has a midchain fatty acid at the 17Beta position. [A176753]  It is available as an intramuscular injection and as an oral capsule, and is indicated for treatment of testosterone deficiency. [F4247][FDA Label]  It should be noted that testosterone undecanoate is only indicated for treatment of hypogonadal conditions with structural or genetic etiologies and should not be used to manage "age-related hypogonadism". [FDA Label]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13943">
  <data key="d0">Testosterone cypionate</data>
  <data key="d1">drugbank.DB13943</data>
  <data key="d2">[drugbank.DB13943, drugbank.DBSALT001298]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Anabolic Agents, Androgens, Androstanes, Androstenes, Androstenols, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Delayed-Action Preparations, Drugs that are Mainly Renally Excreted, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, OAT3/SLC22A8 Inducers, P-glycoprotein/ABCB1 Inhibitors, Steroids, Testosterone and derivatives, Testosterone Congeners]</data>
  <data key="d14">(1S,3aS,3bR,9aR,9bS,11aS)-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl 3-cyclopentylpropanoate</data>
  <data key="d15">C27H40O3</data>
  <data key="d16">58-20-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C27H40O3/c1-26-15-13-20(28)17-19(26)8-9-21-22-10-11-24(27(22,2)16-14-23(21)26)30-25(29)12-7-18-5-3-4-6-18/h17-18,21-24H,3-16H2,1-2H3/t21-,22-,23-,24-,26-,27-/m0/s1</data>
  <data key="d20">C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1</data>
  <data key="d21">Testosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone. These conditions are 1) primary hypogonadism, defined as the testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; and 2) hypogonadotropic hypogonadism characterized by idiopathic gonadotropin, LHRH deficiency or pituitary-hypothalamic injury from tumors, trauma or radiation.[L1153]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[testosterone 17-cyclopentanepropionate, testosterone 17-cyclopentylpropionate, testosterone 17-cypionate, Testosterone cipionate, Testosterone cyclopentanepropionate, Testosterone cyclopentylpropionate]</data>
  <data key="d9">Testosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester. Its benefit compared to other testosterone derivatives is the slow rate of release after injection and longer half-life. The characteristics of testosterone cypionate and testosterone enanthate are very similar, therefore both of them tend to be interchangeable.[L1152] It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13944">
  <data key="d0">Testosterone enanthate</data>
  <data key="d1">drugbank.DB13944</data>
  <data key="d2">[drugbank.DB13944, drugbank.DBSALT001030, drugbank.DBSALT001031, drugbank.DB13945]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenal Cortex Hormones, Androgens, Androstanes, Androstenes, Androstenols, BCRP/ABCG2 Substrates, Contraceptive Agents, Male, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Gonadal Hormones, Gonadal Steroid Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, OAT3/SLC22A8 Inducers, P-glycoprotein/ABCB1 Inhibitors, Steroids, Testosterone and derivatives, Testosterone Congeners]</data>
  <data key="d14">(1S,3aS,3bR,9aR,9bS,11aS)-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl heptanoate</data>
  <data key="d15">C26H40O3</data>
  <data key="d16">315-37-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h17,20-23H,4-16H2,1-3H3/t20-,21-,22-,23-,25-,26-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C</data>
  <data key="d21">Testosterone enanthate in males is indicated as a replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. Some of the treated conditions are 1) primary hypogonadism, defined as testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; 2) hypogonadotropic hypogonadism due to an idiopathic gonadotropin or luteinizing hormone-releasing hormone deficiency or due to a pituitary-hypothalamic injury from tumors, trauma or radiation, in this case it is important to accompany the treatment with adrenal cortical and thyroid hormone replacement therapy; 3) to stimulate puberty in patients with delayed puberty not secondary to a pathological disorder. If the conditions 1 and 2 occur prior to puberty, the androgen replacement therapy will be needed during adolescent years for the development of secondary sexual characteristics and prolonged androgen treatment might be needed it to maintain sexual characteristics after puberty.[FDA label]\n\nIn females, testosterone enanthate is indicated to be used secondarily in presence of advanced inoperable metastatic mammary cancer in women who are from one to five years postmenopausal. It has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormone-responsive tumor.[FDA label]\n\nTestosterone enanthate injections that are currently formulated for subcutaneous use are specifically indicated only for primary hypogonadism and hypogonadotropic hypogonadism [F1941]. The use of such formulations is limited because the safety and efficacy of these subcutaneous products in adult males with late-onset hypogonadism and males less than 18 years old have not yet been established [F1941]. Moreover, subcutaneously administered testosterone enanthate is indicated only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies, considering the medication could cause blood pressure increases that can raise the risk of major adverse cardiovascular events like non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death [F1941].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Testosterone heptanoate]</data>
  <data key="d9">Testosterone enanthate is an esterified variant of testosterone that comes as an injectable compound with a slow release rate. It is the first injectable ester preparation of testosterone.[L1158] This slow release is achieved by the presence of the enanthate ester functional group attached to the testosterone molecule.[A31615] This testosterone derivative was developed by Watson pharms Inc and FDA first approved on October 12, 1980.\n\nIn 2017, about 6.5 million retail prescriptions for testosterone therapy were filled [L4659]. The majority of the prescriptions written were for injectable (66%) and topical (32%) testosterone products. As recent as 1 October 2018, the US FDA approved Antares Pharma Inc.'s Xyosted - a subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable autoinjector [L4659]. As the first subcutaneous autoinjector product designed for testosterone replacement therapy, this innovative formulation removes transfer concerns commonly associated with testosterone gels and potentially reduces the need for in-office/in-clinic injection procedures that may inconvenience patients with frequent visits to the clinic [L4659].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00648">
  <data key="d0">Mitotane</data>
  <data key="d1">drugbank.DB00648</data>
  <data key="d2">[drugbank.DB00648, drugbank.APRD00494]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Antineoplastic Agents, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 Enzyme Inducers, Cytochrome P450 3A4 Inducers, Hydrocarbons, Chlorinated, Hydrocarbons, Halogenated, P-glycoprotein/ABCB1 Inhibitors, Thyroxine-binding globulin inducers]</data>
  <data key="d14">1-chloro-4-[2,2-dichloro-1-(2-chlorophenyl)ethyl]benzene</data>
  <data key="d15">C14H10Cl4</data>
  <data key="d16">53-19-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H</data>
  <data key="d20">ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl</data>
  <data key="d21">For treatment of inoperable adrenocortical tumours; Cushing's syndrome</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Mitotan, Mitotane, Mitotano, Mitotanum]</data>
  <data key="d9">A derivative of the insecticide  dichlorodiphenyldichloroethane that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01977">
  <data key="d0">6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine</data>
  <data key="d1">drugbank.DB01977</data>
  <data key="d2">[drugbank.DB01977, drugbank.EXPT00275]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">6-carbamimidoyl-N-phenylnaphthalene-2-carboxamide</data>
  <data key="d15">C18H15N3O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H15N3O/c19-17(20)14-8-6-13-11-15(9-7-12(13)10-14)18(22)21-16-4-2-1-3-5-16/h1-11H,(H3,19,20)(H,21,22)</data>
  <data key="d20">NC(=N)C1=CC=C2C=C(C=CC2=C1)C(=O)NC1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13956">
  <data key="d0">Estradiol valerate</data>
  <data key="d1">drugbank.DB13956</data>
  <data key="d2">[drugbank.DB13956, drugbank.DBSALT000068]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Adrenal Cortex Hormones, BCRP/ABCG2 Inhibitors, Contraceptive Agents, Female, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Estradiol Congeners, Estranes, Estrenes, Estrogen Contraceptives, Estrogens, Estrogens, Conjugated (USP), Gonadal Hormones, Gonadal Steroid Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, OATP1B1/SLCO1B1 Inhibitors, OCT1 inhibitors, OCT2 Inhibitors, P-glycoprotein/ABCB1 Substrates, Reproductive Control Agents, Steroids, UGT1A1 Substrates]</data>
  <data key="d14">(1S,3aS,3bR,9bS,11aS)-7-hydroxy-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl pentanoate</data>
  <data key="d15">C23H32O3</data>
  <data key="d16">979-32-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3/t18-,19-,20+,21+,23+/m1/s1</data>
  <data key="d20">[H][C@@]12CC[C@H](OC(=O)CCCC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3</data>
  <data key="d21">Estradiol valerate is commercially available as an intramuscular injection as the product Delestrogen and is indicated for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and for the treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). \n\nEstradiol valerate is also available in combination with [DB09123] as the commercially available product Natazia used for the prevention of pregnancy and for the treatment of heavy menstrual bleeding.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Estradiol valerate]</data>
  <data key="d9">Estradiol Valerate (also known as E2V) is a pro-drug ester of [DB00783], a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol acetate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ER and ER subtypes, which are located in various tissues including in the breasts, uterus, ovaries, skin, prostate, bone, fat, and brain.\n\n[DB00783] is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%). First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102]. Esterification of estradiol aims to improves absorption and bioavailability after oral administration (such as with Estradiol valerate) or to sustain release from depot intramuscular injections (such as with Estradiol Cypionate) through improved lipophilicity. Following absorption, the esters are cleaved, resulting in the release of endogenous estradiol, or 17-estradiol. Ester pro-drugs of estradiol are therefore considered to be bioidentical forms of estrogen [T84].\n\nEstradiol valerate is commercially available as an intramuscular injection as the product Delestrogen and is indicated for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and for the treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Estradiol valerate is also available in combination with [DB09123] as the commercially available product Natazia used for the prevention of pregnancy and for the treatment of heavy menstrual bleeding.\n\nThe primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. However, after menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women [FDA Label]. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol at the receptor level. Because of the difference in potency between estradiol and estrone, menopause (and a change in primary hormone from estradiol to estrone) is associated with a number of symptoms associated with this reduction in potency and in estrogenic effects. These include hot flashes, vaginal dryness, mood changes, irregular menses, chills, and sleeping problems. Administration of synthetic and bioidentical forms of estrogen, such as estradiol valerate, has shown to improve these menopausal symptoms.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13954">
  <data key="d0">Estradiol cypionate</data>
  <data key="d1">drugbank.DB13954</data>
  <data key="d2">[drugbank.DB13954, drugbank.DBSALT000067]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Adrenal Cortex Hormones, BCRP/ABCG2 Inhibitors, Contraceptive Agents, Female, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Estradiol Congeners, Estranes, Estrenes, Estrogen Contraceptives, Estrogens, Gonadal Hormones, Gonadal Steroid Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, OATP1B1/SLCO1B1 Inhibitors, OCT1 inhibitors, OCT2 Inhibitors, P-glycoprotein/ABCB1 Substrates, Reproductive Control Agents, Steroids, UGT1A1 Substrates]</data>
  <data key="d14">(1S,3aS,3bR,9bS,11aS)-7-hydroxy-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl 3-cyclopentylpropanoate</data>
  <data key="d15">C26H36O3</data>
  <data key="d16">313-06-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C26H36O3/c1-26-15-14-21-20-10-8-19(27)16-18(20)7-9-22(21)23(26)11-12-24(26)29-25(28)13-6-17-4-2-3-5-17/h8,10,16-17,21-24,27H,2-7,9,11-15H2,1H3/t21-,22-,23+,24+,26+/m1/s1</data>
  <data key="d20">[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1</data>
  <data key="d21">Depo-Estradiol intramuscular depot injection is indicated for the treatment of moderate to severe vasomotor symptoms and hypoestrogenism due to hypogonadism.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Estradiol Cypionate is a pro-drug ester of [DB00783], a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol cypionate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ER and ER subtypes, which are located in various tissues and organs such as the breasts, uterus, ovaries, skin, prostate, bone, fat, and brain.\n\n[DB00783] is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%). First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102]. Esterification of estradiol aims to improve absorption and bioavailability after oral administration (such as with Estradiol Valerate) or to sustain release from depot intramuscular injections (such as with Estradiol Cypionate) through improved lipophilicity. Following absorption, the esters are cleaved, resulting in the release of endogenous estradiol, or 17-estradiol. Ester pro-drugs of estradiol are therefore considered to be bioidentical forms of estrogen [T84].\n\nEstradiol cypionate is commercially available as Depo-Estradiol, an intramuscular depot injection used for the treatment of moderate to severe vasomotor symptoms associated with menopause and for the treatment of hypoestrogenism due to hypogonadism [FDA Label].\n\nThe primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. However, after menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women [FDA Label]. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol at the receptor level. Because of the difference in potency between estradiol and estrone, menopause (and a change in primary hormone from estradiol to estrone) is associated with a number of symptoms associated with this reduction in potency and in estrogenic effects. These include hot flashes, vaginal dryness, mood changes, irregular menses, chills, and sleeping problems. Administration of synthetic and bioidentical forms of estrogen, such as estradiol cypionate, has shown to improve these menopausal symptoms.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13955">
  <data key="d0">Estradiol dienanthate</data>
  <data key="d1">drugbank.DB13955</data>
  <data key="d2">[drugbank.DB13955, drugbank.DBSALT002570]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[BCRP/ABCG2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Estradiol Congeners, Estranes, Estrenes, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, OATP1B1/SLCO1B1 Inhibitors, OCT1 inhibitors, OCT2 Inhibitors, P-glycoprotein/ABCB1 Substrates, Steroids, UGT1A1 Substrates]</data>
  <data key="d14">(1S,3aS,3bR,9bS,11aS)-7-(heptanoyloxy)-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl heptanoate</data>
  <data key="d15">C32H48O4</data>
  <data key="d16">7732-97-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C32H48O4/c1-4-6-8-10-12-30(33)35-24-15-17-25-23(22-24)14-16-27-26(25)20-21-32(3)28(27)18-19-29(32)36-31(34)13-11-9-7-5-2/h15,17,22,26-29H,4-14,16,18-21H2,1-3H3/t26-,27-,28+,29+,32+/m1/s1</data>
  <data key="d20">CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(OC(=O)CCCCCC)=CC=C4[C@H]3CC[C@]12C</data>
  <data key="d21">Estradiol dienanthate is not currently available in any FDA or Health Canada approved products.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Estradiol dienantate]</data>
  <data key="d9">Estradiol Dienanthate is a pro-drug ester of [DB00783], a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol benzoate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ER and ER subtypes, which are located in various tissues including in the breasts, uterus, ovaries, skin, prostate, bone, fat, and brain.\n\nEstradiol is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%). First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102]. Esterification of estradiol aims to improves absorption and bioavailability after oral administration (such as with Estradiol valerate) or to sustain release from depot intramuscular injections (such as with Estradiol Cypionate) through improved lipophilicity. Following absorption, the esters are cleaved, resulting in the release of endogenous estradiol, or 17-estradiol. Ester pro-drugs of estradiol are therefore considered to be bioidentical forms of estrogen [T84].\n\nEstradiol dienanthate is not currently available in any commercially available products in Canada or the US.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13952">
  <data key="d0">Estradiol acetate</data>
  <data key="d1">drugbank.DB13952</data>
  <data key="d2">[drugbank.DB13952, drugbank.DBSALT000065]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[BCRP/ABCG2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Estrogens, OATP1B1/SLCO1B1 Inhibitors, OCT1 inhibitors, OCT2 Inhibitors, P-glycoprotein/ABCB1 Substrates, UGT1A1 Substrates]</data>
  <data key="d14">(1S,3aS,3bR,9bS,11aS)-1-hydroxy-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-yl acetate</data>
  <data key="d15">C20H26O3</data>
  <data key="d16">4245-41-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H26O3/c1-12(21)23-14-4-6-15-13(11-14)3-5-17-16(15)9-10-20(2)18(17)7-8-19(20)22/h4,6,11,16-19,22H,3,5,7-10H2,1-2H3/t16-,17-,18+,19+,20+/m1/s1</data>
  <data key="d20">[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(C)=O)C=C3CC[C@@]21[H]</data>
  <data key="d21">Femring is indicated for the treatment of vasomotor and urogenital symptoms associated with menopause. Use of Femring (estradiol acetate) has been shown to improve symptoms caused by atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[E3A, Estradiol 3-acetate, Estradiol acetate, Estradiol-3-acetate]</data>
  <data key="d9">Estradiol acetate is a pro-drug ester of [DB00783], a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol acetate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ER and ER subtypes, which are located in various tissues including in the breasts, uterus, ovaries, skin, prostate, bone, fat, and brain.\n\n[DB00783] is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%). First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102]. Esterification of estradiol aims to improves absorption and bioavailability after oral administration (such as with Estradiol valerate) or to sustain release from depot intramuscular injections (such as with Estradiol Cypionate) through improved lipophilicity. Following absorption, the esters are cleaved, resulting in the release of endogenous estradiol, or 17-estradiol. Ester pro-drugs of estradiol are therefore considered to be bioidentical forms of estrogen [T84].\n\nEstradiol acetate is commercially available as Femring, a vaginal ring used for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy due to menopause.\n\nThe primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. However, after menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women [FDA Label]. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol at the receptor level. Because of the difference in potency between estradiol and estrone, menopause (and a change in primary hormone from estradiol to estrone) is associated with a number of symptoms associated with this reduction in potency and in estrogenic effects. These include hot flashes, vaginal dryness, mood changes, irregular menses, chills, and sleeping problems. Administration of synthetic and bioidentical forms of estrogen, such as estradiol acetate, has shown to improve these menopausal symptoms.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13953">
  <data key="d0">Estradiol benzoate</data>
  <data key="d1">drugbank.DB13953</data>
  <data key="d2">[drugbank.DB13953, drugbank.DBSALT000066]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Adrenal Cortex Hormones, BCRP/ABCG2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Estradiol Congeners, Estranes, Estrenes, Estrogens, Gonadal Hormones, Gonadal Steroid Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, OATP1B1/SLCO1B1 Inhibitors, OCT1 inhibitors, OCT2 Inhibitors, P-glycoprotein/ABCB1 Substrates, Reproductive Control Agents, Steroids, UGT1A1 Substrates]</data>
  <data key="d14">(1S,3aS,3bR,9bS,11aS)-1-hydroxy-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-yl benzoate</data>
  <data key="d15">C25H28O3</data>
  <data key="d16">50-50-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C25H28O3/c1-25-14-13-20-19-10-8-18(28-24(27)16-5-3-2-4-6-16)15-17(19)7-9-21(20)22(25)11-12-23(25)26/h2-6,8,10,15,20-23,26H,7,9,11-14H2,1H3/t20-,21-,22+,23+,25+/m1/s1</data>
  <data key="d20">[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(OC(=O)C5=CC=CC=C5)=CC=C4[C@@]3([H])CC[C@]12C</data>
  <data key="d21">Estradiol benzoate is not currently available in any FDA or Health Canada approved products.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[benzoato de estradiol, Estradiol benzoate]</data>
  <data key="d9">Estradiol Benzoate is a pro-drug ester of [DB00783], a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol benzoate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ER and ER subtypes, which are located in various tissues including in the breasts, uterus, ovaries, skin, prostate, bone, fat, and brain.\n\n[DB00783] is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%). First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102]. Esterification of estradiol aims to improves absorption and bioavailability after oral administration (such as with Estradiol valerate) or to sustain release from depot intramuscular injections (such as with Estradiol Cypionate) through improved lipophilicity. Following absorption, the esters are cleaved, resulting in the release of endogenous estradiol, or 17-estradiol. Ester pro-drugs of estradiol are therefore considered to be bioidentical forms of estrogen [T84].\n\nEstradiol benzoate is not currently available in Canada or the US.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13951">
  <data key="d0">Stanolone acetate</data>
  <data key="d1">drugbank.DB13951</data>
  <data key="d2">[drugbank.DB13951, drugbank.DBSALT002357]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[P-glycoprotein/ABCB1 Substrates, Testosterone and derivatives]</data>
  <data key="d14">(1S,3aS,3bR,5aS,9aS,9bS,11aS)-9a,11a-dimethyl-7-oxo-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl acetate</data>
  <data key="d15">C21H32O3</data>
  <data key="d16">1164-91-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H32O3/c1-13(22)24-19-7-6-17-16-5-4-14-12-15(23)8-10-20(14,2)18(16)9-11-21(17,19)3/h14,16-19H,4-12H2,1-3H3/t14-,16-,17-,18-,19-,20-,21-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Androstanolone acetate, Dihydrotestosterone acetate]</data>
  <data key="d9">Stanolone acetate is a synthetic androgen and anabolic steroid and a dihydrotestosterone ester that was never marketed.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01905">
  <data key="d0">2-(2-Hydroxy-5-Methoxy-Phenyl)-1h-Benzoimidazole-5-Carboxamidine</data>
  <data key="d1">drugbank.DB01905</data>
  <data key="d2">[drugbank.DB01905, drugbank.EXPT00017]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">{amino[2-(2-hydroxy-5-methoxyphenyl)-1H-1,3-benzodiazol-5-yl]methylidene}azanium</data>
  <data key="d15">C15H15N4O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H14N4O2/c1-21-9-3-5-13(20)10(7-9)15-18-11-4-2-8(14(16)17)6-12(11)19-15/h2-7,20H,1H3,(H3,16,17)(H,18,19)/p+1</data>
  <data key="d20">COC1=CC=C(O)C(=C1)C1=NC2=C(N1)C=CC(=C2)C(N)=[NH2+]</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00608">
  <data key="d0">Chloroquine</data>
  <data key="d1">drugbank.DB00608</data>
  <data key="d2">[drugbank.DB00608, drugbank.APRD00468]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Agents Causing Muscle Toxicity, Agents that produce neuromuscular block (indirect), Agents that reduce seizure threshold, alpha-Galactosidase, antagonists &amp; inhibitors, Amebicides, Aminoquinolines, Analgesics, Analgesics, Non-Narcotic, Anti-Infective Agents, Anti-Inflammatory Agents, Antimalarials, Antinematodal Agents, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Antirheumatic Agents, Central Nervous System Agents, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Filaricides, Methemoglobinemia Associated Agents, Moderate Risk QTc-Prolonging Agents, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Peripheral Nervous System Agents, QTc Prolonging Agents, Quinolines, Sensory System Agents]</data>
  <data key="d14">7-chloro-N-[5-(diethylamino)pentan-2-yl]quinolin-4-amine</data>
  <data key="d15">C18H26ClN3</data>
  <data key="d16">54-05-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)</data>
  <data key="d20">CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1</data>
  <data key="d21">For the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum, Second-line agent in treatment of Rheumatoid Arthritis</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Chloraquine, Chlorochin, Chloroquina, Chloroquine, Chloroquinium, Chloroquinum, Cloroquina, N4-(7-chloro-4-quinolinyl)-N1, N1-diethyl-1, 4-pentanediamine]</data>
  <data key="d9">The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00604">
  <data key="d0">Cisapride</data>
  <data key="d1">drugbank.DB00604</data>
  <data key="d2">[drugbank.DB00604, drugbank.APRD00454]</data>
  <data key="d12">[approved, investigational, withdrawn]</data>
  <data key="d13">[Acids, Carbocyclic, Alimentary Tract and Metabolism, Amides, Aminobenzoates, Anti-Ulcer Agents, Antidepressive Agents, Benzamides and benzamide derivatives, Benzene Derivatives, Benzoates, Central Nervous System Depressants, Chlorobenzoates, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Drugs for Functional Gastrointestinal Disorders, Gastrointestinal Agents, Highest Risk QTc-Prolonging Agents, Neurotransmitter Agents, para-Aminobenzoates, Piperidines, Propulsives, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Receptor Agonists]</data>
  <data key="d14">4-amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide</data>
  <data key="d15">C23H29ClFN3O4</data>
  <data key="d16">81098-60-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m1/s1</data>
  <data key="d20">CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC</data>
  <data key="d21">For the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Cisaprid, Cisaprida, Cisapride, Cisapridum]</data>
  <data key="d9">In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00603">
  <data key="d0">Medroxyprogesterone acetate</data>
  <data key="d1">drugbank.DB00603</data>
  <data key="d2">[drugbank.DB00603, drugbank.APRD00627]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Adrenal Cortex Hormones, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, Combination Contraceptives (with Estrogen and derivatives), Contraceptive Agents, Female, Contraceptive Agents, Male, Contraceptives, Oral, Contraceptives, Oral, Synthetic, Corpus Luteum Hormones, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Endocrine Therapy, Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, Hydroxyprogesterones, Hyperglycemia-Associated Agents, Medroxyprogesterone, Pregnanes, Pregnen (4) Derivatives, Pregnenediones, Pregnenes, Progesterone, Progesterone Congeners, Progestin Contraceptives, Progestins, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids]</data>
  <data key="d14">(1S,2R,8S,10R,11S,14R,15S)-14-acetyl-2,8,15-trimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadec-6-en-14-yl acetate</data>
  <data key="d15">C24H34O4</data>
  <data key="d16">71-58-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C</data>
  <data key="d21">Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(6)-17-(Acetyloxy)-6-methylpreg-4-ene-3, 20-dione, 17-Acetoxy-6-methylprogesterone, 17-hydroxy-6-methylprogesterone acetate, 6-alpha-Methyl-17-alpha-acetoxyprogesterone, 6-alpha-Methyl-17-alpha-hydroxyprogesterone acetate, 6-Methyl-17-acetoxy progesterone, 6-Methyl-17-hydroxyprogesterone acetate, 6-Methyl-4-pregnene-3, 20-dion-17-ol acetate, Medroxyacetate progesterone, Medroxyprogesterone 17-acetate, Methylacetoxyprogesterone, Metigestrona, MPA]</data>
  <data key="d9">Medroxyprogesterone acetate (INN, USAN, BAN), also known as 17-hydroxy-6-methylprogesterone acetate, and commonly abbreviated as MPA, is a steroidal progestin, a synthetic variant of the human hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications.\nMPA is a more potent derivative of its parent compound medroxyprogesterone (MP). While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is normally being administered is MPA and not MP.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00602">
  <data key="d0">Ivermectin</data>
  <data key="d1">drugbank.DB00602</data>
  <data key="d2">[drugbank.DB00602, drugbank.APRD01058]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Agents Causing Muscle Toxicity, Agrochemicals, Anthelmintics, Anti-Bacterial Agents, Anti-Infective Agents, Antinematodal Agents, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Avermectines, BCRP/ABCG2 Substrates, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Insecticides, Lactones, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Pediculicides, Pesticides, Polyketides, Scabicides and Pediculicides, Toxic Actions]</data>
  <data key="d14">(1'R,2R,4'S,5S,6R,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'R,24'S)-21',24'-dihydroxy-12'-{[(2R,4S,5S,6S)-5-{[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,11',13',22'-tetramethyl-6-(propan-2-yl)-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1,.0,]pentacosane]-10',14',16',22'-tetraen-2'-one; (1'R,2R,4'S,5S,6R,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'R,24'S)-6-[(2R)-butan-2-yl]-21',24'-dihydroxy-12'-{[(2R,4S,5S,6S)-5-{[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1,.0,]pentacosane]-10',14',16',22'-tetraen-2'-one</data>
  <data key="d15">C95H146O28</data>
  <data key="d16">70288-86-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C48H74O14.C47H72O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38;1-24(2)41-27(5)16-17-46(61-41)22-33-19-32(60-46)15-14-26(4)42(25(3)12-11-13-31-23-54-44-39(48)28(6)18-34(45(50)57-33)47(31,44)51)58-38-21-36(53-10)43(30(8)56-38)59-37-20-35(52-9)40(49)29(7)55-37/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3;11-14,18,24-25,27,29-30,32-44,48-49,51H,15-17,19-23H2,1-10H3/b13-12+,27-15+,32-14+;12-11+,26-14+,31-13+/t25-,26+,28+,30+,31+,33-,34+,35+,36+,37+,38+,39+,40-,41+,42+,43-,44+,45-,47-,48-;25-,27-,29-,30-,32+,33-,34-,35-,36-,37-,38-,39+,40-,41+,42-,43-,44+,46+,47+/m10/s1</data>
  <data key="d20">CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@H]1[C@H](C)O[C@H](C[C@@H]1OC)O[C@H]1[C@@H](C)\C=C\C=C2/CO[C@@H]3[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]4C[C@@H](C\C=C1/C)O[C@@]1(CC[C@H](C)[C@@H](C(C)C)O1)C4)[C@]23O.CC[C@@H](C)[C@H]1O[C@@]2(CC[C@@H]1C)O[C@@H]1C\C=C(C)\[C@@H](O[C@@H]3O[C@@H](C)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](OC)C4)[C@@H](OC)C3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@@H](C1)C2)[C@]34O</data>
  <data key="d21">For the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite &lt;i&gt;Strongyloides stercoralis&lt;/i&gt;. Also for the treatment of onchocerciasis (river blindness) due to the nematode parasite &lt;i&gt;Onchocerca volvulus&lt;/i&gt;. Can be used to treat scabies caused by &lt;i&gt;Sarcoptes scabiei&lt;/i&gt;.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Ivermectin, Ivermectina, Ivermectine, Ivermectinum]</data>
  <data key="d9">Ivermectin is a broad-spectrum anti-parasite medication. It was first marketed under the name Stromectol and used against worms (except tapeworms), but, in 2012, it was approved for the topical treatment of head lice infestations in patients 6 months of age and older, and marketed under the name Sklice as well. Ivermectin is mainly used in humans in the treatment of onchocerciasis, but is also effective against other worm infestations (such as strongyloidiasis, ascariasis, trichuriasis and enterobiasis).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00601">
  <data key="d0">Linezolid</data>
  <data key="d1">drugbank.DB00601</data>
  <data key="d2">[drugbank.DB00601, drugbank.APRD01073, drugbank.DB08769]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acetamides, Acetates, Acids, Acyclic, Agents that produce hypertension, Agents that reduce seizure threshold, Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antidepressive Agents, Antiinfectives for Systemic Use, Central Nervous System Depressants, Enzyme Inhibitors, Fatty Acids, Fatty Acids, Volatile, Immunosuppressive Agents, Lipids, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase Inhibitors, Myelosuppressive Agents, Oxazoles, Oxazolidinone Antibacterial, Oxazolidinones, Protein Synthesis Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators]</data>
  <data key="d14">N-{[(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide</data>
  <data key="d15">C16H20FN3O4</data>
  <data key="d16">165800-03-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1</data>
  <data key="d20">CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1</data>
  <data key="d21">For the treatment of bacterial infections caused by susceptible strains of vancomycin resistant &lt;i&gt;Enterococcus faecium&lt;/i&gt;, &lt;i&gt;Staphylococcal aureus&lt;/i&gt; (methicillin resistant and susceptible strains), &lt;i&gt;Streptococcus pneumoniae&lt;/i&gt;, &lt;i&gt;Streptococcus pyogenes&lt;/i&gt;, &lt;i&gt;Streptococcus agalactiae&lt;/i&gt;.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Linezolid, Linezolide, Linezolidum, N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide]</data>
  <data key="d9">Linezolid is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi-resistant bacteria including streptococcus and methicillin-resistant Staphylococcus aureus (MRSA). The drug works by inhibiting the initiation of bacterial protein synthesis.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09070">
  <data key="d0">Tibolone</data>
  <data key="d1">drugbank.DB09070</data>
  <data key="d2">[drugbank.DB09070]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Anabolic Agents, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Cardiovascular Agents, Estrogen Receptor Modulators, Estrogens, Genito Urinary System and Sex Hormones, Hormone Antagonists, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Norpregnanes, Norsteroids, Sex Hormones and Modulators of the Genital System, Steroids]</data>
  <data key="d14">(1S,9R,10R,11S,14R,15S)-14-ethynyl-14-hydroxy-9,15-dimethyltetracyclo[8.7.0.0,.0,]heptadec-2(7)-en-5-one</data>
  <data key="d15">C21H28O2</data>
  <data key="d16">5630-53-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,13,17-19,23H,5-12H2,2-3H3/t13-,17-,18+,19-,20+,21+/m1/s1</data>
  <data key="d20">[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC(=O)CC3)C[C@@]([H])(C)[C@@]21[H]</data>
  <data key="d21">For the relief of post-menopausal symptoms and for the prevention of osteoporosis [L1724].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[17-hydroxy-7alpha-methyl-19-nor-17alpha-pregn-5(10)-en-20-yn-3-one, tibolona, Tibolone, tibolonum]</data>
  <data key="d9">Tibolone is a synthetic steroid hormone drug, which is mainly non-selective in its binding profile, acting as an agonist primarily at estrogen receptors (ER), with a preference for ER alpha [L1874].\n\nTibolone (Livial, Org OD 14), produced by Organon (West Orange, NJ), is a synthetic steroid that possesses estrogenic, androgenic and progestogenic properties. It has been used in Europe for almost 2 decades, primarily for the prevention of postmenopausal osteoporosis and the treatment of post-menopausal symptoms [L1720].  Tibolone is approved in 90 countries to manage menopausal symptoms and in 45 countries to prevent the development of osteoporosis [L1876].\n\nIn June 2006, Organon Pharmaceuticals announced the receipt of a Not Approvable Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for tibolone had not been approved [L1722].\n\nInterestingly, the use of tibolone in the treatment cardiovascular disease has been studied with inconclusive results [A32164]. Tibolone has been to have anti-resorptive effects on bone [L1874].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09079">
  <data key="d0">Nintedanib</data>
  <data key="d1">drugbank.DB09079</data>
  <data key="d2">[drugbank.DB09079]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Antifibrotic Agents, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Enzyme Inhibitors, Kinase Inhibitor, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d14">methyl (3Z)-3-[({4-[N-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate</data>
  <data key="d15">C31H33N5O4</data>
  <data key="d16">656247-17-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-</data>
  <data key="d20">COC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1</data>
  <data key="d21">Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2, 3-dihydro-1H-indole-6-carboxylate, Nintedanib]</data>
  <data key="d9">Nintedanib is a drug indicated for the treatment of idiopathic pulmonary fibrosis (IPF) that targets multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR)  and , fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, and Fms-like tyrosine kinase-3 (FLT3). Among them, FGFR, PDGFR, and VEGFR have been implicated in IPF pathogenesis. Nintedanib binds competitively to the adenosine triphosphate (ATP) binding pocket of these receptors and blocks the intracellular signaling which is crucial for the proliferation, migration, and transformation of fibroblasts representing essential mechanisms of the IPF pathology. In addition, nintedanib inhibits the following nRTKs: Lck, Lyn and Src kinases. The contribution of FLT3 and nRTK inhibition to IPF efficacy is unknown.\n\nIdiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease characterized by a progressive loss of lung function with worsening dyspnoea and cough. Development is thought to be instigated by repetitive lung injury (such as by cigarette smoke, industrial dusts, gastrooesophageal reflux and viral infection) leading to destruction of epithelial alveolar cells. Subsequent dysregulation of the repair process results in the proliferation/migration of fibroblasts and their differentiation into myofibroblasts, abnormal extracellular matrix deposition and excessive collagen accumulation in the lung interstitium and alveolar space, leading to progressive fibrosis and stiffening of the lungs. Vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) mediate various processes, including fibrogenesis and angiogenesis, and are implicated in the pathogenesis of IPF. By blocking substrate binding and downstream signalling cascades, nintedanib interferes with processes active in fibrosis such as fibroblast proliferation, migration and differentiation, and the secretion of extracellular matrix.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09081">
  <data key="d0">Idebenone</data>
  <data key="d1">drugbank.DB09081</data>
  <data key="d2">[drugbank.DB09081]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Antioxidants, Benzoquinones, Coenzymes, Compounds used in a research, industrial, or household setting, Drugs that are Mainly Renally Excreted, Enzymes and Coenzymes, Nervous System, Protective Agents, Psychoanaleptics, Psychostimulants, Agents Used for Adhd and Nootropics, Quinones]</data>
  <data key="d14">2-(12-hydroxydodecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione</data>
  <data key="d15">C21H34O5</data>
  <data key="d16">58186-27-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H34O5/c1-16-17(19(24)21(26-3)20(25-2)18(16)23)14-12-10-8-6-4-5-7-9-11-13-15-22/h22H,4-15H2,1-3H3</data>
  <data key="d20">COC1=C(OC)C(=O)C(CCCCCCCCCCCCO)=C(C)C1=O</data>
  <data key="d21">Idebenone is indicated for use by the European Medicines Agency (EMA) for the treatment of visual impairment in adolescent and adult patients with\nLebers Hereditary Optic Neuropathy (LHON). It is not currently approved for use by either the Food and Drug Administration (USA) or Health Canada [L885].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-(10-hydroxydecyl)-5, 6-dimethoxy-3-methyl-1, 4-benzoquinone, 2-(10-hydroxydecyl)-5, 6-dimethoxy-3-methyl-p-benzoquinone, 2-(10-hydroxydecyl)-5, 6-dimethoxy-3-methylcyclohexa-2, 5-diene-1, 4-dione, 2, 3-dimethoxy-5-methyl-6-(10'-hydroxydecyl)-1, 4-benzoquinone, 6-(10-hydroxydecyl)-2, 3-dimethoxy-5-methyl-1, 4-benzoquinone, 6-(10-hydroxydecyl)-2, 3-dimethoxy-5-methyl-p-benzoquinone, idebenona, Idebenone, idbnone]</data>
  <data key="d9">Idebenone is a synthetic analogue of ubiquinone (also known as Coenzyme Q10), a vital cell antioxidant and essential component of the Electron Transport Chain (ETC). It has been proposed that by interacting with the ETC, idebenone increases ATP production required for mitochondrial function, reduces free radicals, inhibits lipid peroxidation, and consequently protects the lipid membrane and mitochondria from oxidative damage [A19768]. More specifically, idebenone is thought to transfer electrons directly to complex III of the mitochondrial ETC, thereby circumventing complex I and restoring cellular energy (ATP) generation [L885]. \n\nDue to its ability to reduce oxidative damage and improve ATP production, idebenone was originally investigated for its potential use in Alzheimer's Disease and other cognitivie disorders [A19769]. Lack of improvement in cognitive function halted its production for these conditions, however it continues to be investigated for use in other conditions associated with mitochondrial damage. \n\nIdebenone is currently only indicated for use by the European Medicines Agency (EMA) for the treatment of visual impairment in adolescent and adult patients with\nLebers Hereditary Optic Neuropathy (LHON). LHON is a mitochondrially inherited degeneration of retinal ganglion cells, resulting in acute central vision loss. Due to its biochemical mode of action, it's thought that idebenone may re-activate viable-but-inactive retinal ganglion cells (RGCs) in LHON patients [L885]. It is not currently approved for use by either the Food and Drug Administration (USA) or Health Canada.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09086">
  <data key="d0">Eugenol</data>
  <data key="d1">drugbank.DB09086</data>
  <data key="d2">[drugbank.DB09086]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acids, Carbocyclic, Anti-Infective Agents, Caffeic Acids, Cell-mediated Immunity, Cinnamates, Compounds used in a research, industrial, or household setting, Increased Histamine Release, Solvents, Standardized Chemical Allergen]</data>
  <data key="d14">2-methoxy-4-(prop-2-en-1-yl)phenol</data>
  <data key="d15">C10H12O2</data>
  <data key="d16">97-53-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H12O2/c1-3-4-8-5-6-9(11)10(7-8)12-2/h3,5-7,11H,1,4H2,2H3</data>
  <data key="d20">COC1=C(O)C=CC(CC=C)=C1</data>
  <data key="d21">Eugenol is not currently available in any FDA-approved drug products. There are a number of unapproved OTC products that advertise it for the use of toothache.  Eugenol is is also commonly used in combination with zinc oxide in dental procedures for the cementation of temporary prostheses and the temporary restoration of teeth and cavities.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Eugenol is a naturally occurring phenolic molecule found in several plants such as cinnamon, clove, and bay leaves. It has been used as a topical antiseptic as a counter-irritant and in dental preparations with zinc oxide for root canal sealing and pain control. Although not currently available in any FDA-approved products (including OTC), eugenol has been found to have anti-inflammatory, neuroprotective, antipyretic, antioxidant, antifungal and analgesic properties. Its exact mechanism of action is unknown, however, it has been shown to interfere with action potential conduction. \nThere are a number of unapproved OTC products available containing eugenol that advertise its use for the treatment of toothache.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11397">
  <data key="d0">Dichlorvos</data>
  <data key="d1">drugbank.DB11397</data>
  <data key="d2">[drugbank.DB11397]</data>
  <data key="d12">[vet_approved]</data>
  <data key="d13">[Agrochemicals, Anthelmintics, Anti-Infective Agents, Antiparasitic Agents, Cholinergic Agents, Cholinesterase Inhibitors, Compounds used in a research, industrial, or household setting, Enzyme Inhibitors, Insecticides, Neurotransmitter Agents, Organophosphates, Organophosphorus Compounds, Pesticides, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Toxic Actions]</data>
  <data key="d14">2,2-dichloroethenyl dimethyl phosphate</data>
  <data key="d15">C4H7Cl2O4P</data>
  <data key="d16">62-73-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C4H7Cl2O4P/c1-8-11(7,9-2)10-3-4(5)6/h3H,1-2H3</data>
  <data key="d20">COP(=O)(OC)OC=C(Cl)Cl</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2, 2-Dichloroethenyl dimethyl phosphate, DDVP, Dichlorvos, Dimethyl 2, 2-dichlorovinyl phosphate, Dimethyl-2, 2-dichlorovinyl phosphate, Phosphoric acid, 2, 2-dichloroethenyl dimethyl ester, Phosphoric acid, 2, 2-dichlorovinyl dimethyl ester]</data>
  <data key="d9">Dichlorvos or 2,2-dichlorovinyl dimethyl phosphate is a drug of the _organophosphate_ class, frequently used as an insecticide for the control of  indoor pests and for the protection of stored products from insect infestations. The compound has been available on the market since 1961 and its use is a controversial topic due to environmental and health concerns. Dichlorvos is found in urban waterways and its toxicity may impact humans, leading to poisoning, neurotoxicity, and cancer.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09093">
  <data key="d0">Chlortetracycline</data>
  <data key="d1">drugbank.DB09093</data>
  <data key="d2">[drugbank.DB09093]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Agents that produce neuromuscular block (indirect), Alimentary Tract and Metabolism, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antibiotics for Topical Use, Antiinfectives and Antiseptics for Local Oral Treatment, Antiinfectives for Systemic Use, Antiparasitic Agents, Antiprotozoals, Dermatologicals, Enzyme Inhibitors, Naphthacenes, Ophthalmologicals, Protein Synthesis Inhibitors, Sensory Organs, Stomatological Preparations, Tetracyclines]</data>
  <data key="d14">(4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboximidic acid</data>
  <data key="d15">C22H23ClN2O8</data>
  <data key="d16">57-62-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H23ClN2O8/c1-21(32)7-6-8-15(25(2)3)17(28)13(20(24)31)19(30)22(8,33)18(29)11(7)16(27)12-10(26)5-4-9(23)14(12)21/h4-5,7-8,15,26,28-29,32-33H,6H2,1-3H3,(H2,24,31)/t7-,8-,15-,21-,22-/m0/s1</data>
  <data key="d20">[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O</data>
  <data key="d21">Used in the manufacuring of medicated animal feeds [FDA Label].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Chlortetracycline, clortetraciclina]</data>
  <data key="d9">Chlortetracycline is a _tetracycline_ antibiotic, and historically the first member of this class to be identified. It was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow. He discovered that this antibiotic was the product of an actinomycete strain he cultured and obtained from a soil sample from a field in Missouri. The organism was named _Streptomyces aureofaciens_ due to its gold-hued color.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09098">
  <data key="d0">Somatrem</data>
  <data key="d1">drugbank.DB09098</data>
  <data key="d2">[drugbank.DB09098]</data>
  <data key="d12">[approved, investigational, withdrawn]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Anterior Pituitary Lobe Hormones and Analogues, Growth Hormone, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Peptide Hormones, Peptides, Pituitary and Hypothalamic Hormones and Analogues, Pituitary Hormones, Pituitary Hormones, Anterior, Somatropin and Somatropin Agonists, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">82030-87-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Somatrem is a recombinant human growth hormone indicated for: (a) treatment of paediatric patients with growth failure due to growth hormone deficiency (GHD), (b) treatment of paediatric patients with growth failure due to idiopathic short stature (ISS),  (c) treatment of paediatric patients with growth failure due to Turner syndrome (TS), (d) treatment of paediatric patients with growth failure due to chronic kidney disease (CKD) up to the time of renal transplantation, (e) treatment of adults with childhood-onset GHD, or (f) treatment of adults with adult-onset GHD [FDA Label].</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Somatrem (genetical recombination)]</data>
  <data key="d9">In 1985 somatrem (methionyl-growth hormone) became the first recombinant growth hormone product to be marketed commercially (Protropin by Genentech) [L1909]. The agent has the same amino acid sequence as human growth hormone except for an extra methionine at the end of the sequence chain to facilitate its manufacturing process [L1909].\n\nAlthough the first commercially marketed recombinant growth hormone product Protropin was discontinued in 2004 owing to a relative explosion in brand and generic based releases of competing companies' own recombinant growth hormone products and the ensuing competition in product price over the years, many companies now produce and sell various approved formulations of methionyl-growth hormone, including Genetech's own current Nutropin product [L1909].\n\nDespite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate [A32292]. Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency [A32292].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11348">
  <data key="d0">Calcium Phosphate</data>
  <data key="d1">drugbank.DB11348</data>
  <data key="d2">[drugbank.DB11348, drugbank.DB11052, drugbank.DB11053]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acids, Acids, Noncarboxylic, Alimentary Tract and Metabolism, Anions, Biocompatible Materials, Biomedical and Dental Materials, Blood Coagulation Factors, Calcium Compounds, Calcium Salts, Ceramics, Compounds used in a research, industrial, or household setting, Electrolytes, Ions, Mineral Supplements, Phosphate Binder, Phosphate salts, Phosphoric Acids, Phosphorus Acids, Phosphorus Compounds]</data>
  <data key="d14">tricalcium diphosphate</data>
  <data key="d15">Ca3O8P2</data>
  <data key="d16">10103-46-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/3Ca.2H3O4P/c;;;2*1-5(2,3)4/h;;;2*(H3,1,2,3,4)/q3*+2;;/p-6</data>
  <data key="d20">[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O</data>
  <data key="d21">For use as an over the counter calcium and phosphate supplement, antacid, or a source of calcium and phosphate in toothpaste [FDA Label] [L851].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[calcio fosfato, Calcium phosphates, Phosphoric acid, calcium salt]</data>
  <data key="d9">Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] [L851].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09061">
  <data key="d0">Cannabidiol</data>
  <data key="d1">drugbank.DB09061</data>
  <data key="d2">[drugbank.DB09061]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents producing tachycardia, Agents that produce hypertension, Anticonvulsants, Antidepressive Agents, BCRP/ABCG2 Inhibitors, Cannabinoids and similars, Central Nervous System Depressants, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Nervous System, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT2 Receptor Agonists, Serotonin Agents, Serotonin Receptor Agonists, Terpenes]</data>
  <data key="d14">2-[(1R,6R)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol</data>
  <data key="d15">C21H30O2</data>
  <data key="d16">13956-29-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1</data>
  <data key="d20">CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1</data>
  <data key="d21">When used in combination with delta-9-tetrahydrocannabinol as the product Sativex, cannabidiol was given a standard marketing authorization (ie. a Notice of Compliance (NOC)) by Health Canada for the following indications: \n1) as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS) who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy [L886];\n\nDue to the need for confirmatory studies to verify the clinical benefit coupled with the promising nature of the clinical evidence, Sativex was also given a Notice of Compliance with Conditions (NOC/c) by Health Canada for the following indications: \n1) as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis; \n2) as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain [L886].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-trans-2-p-mentha-1, 8-dien-3-yl-5-pentylresorcinol, ()-trans-cannabidiol, (1'R, 2'R)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1', 2', 3', 4'-tetrahydrobiphenyl-2, 6-diol, Cannabidiol, CBD, 1(2)-trans-cannabidiol]</data>
  <data key="d9">Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investigated, CBD has shown promise as a therapeutic and pharmaceutical drug target. In particular, CBD has shown promise as an analgesic, anticonvulsant, muscle relaxant, anxiolytic, antipsychotic and has shown neuroprotective, anti-inflammatory, and antioxidant activity, among other currently investigated uses [A32477, A32469]. CBD's exact place within medical practice is still currently hotly debated, however as the body of evidence grows and legislation changes to reflect its wide-spread use, public and medical opinion have changed significantly with regards to its usefulness in a number of medical conditions ranging from anxiety to epilepsy.\n\nFrom a pharmacological perspective, Cannabis' (and CBD's) diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body [A32584]. Cannabinoid receptors are utilized endogenously by the body through the endocannabinoid system, which includes a group of lipid proteins, enzymes, and receptors that are involved in many physiological processes. Through its modulation of neurotransmitter release, the endocannabinoid system regulates cognition, pain sensation, appetite, memory, sleep, immune function, and mood among many other bodily systems. These effects are largely mediated through two members of the G-protein coupled receptor family, cannabinoid receptors 1 and 2 (CB1 and CB2)[A32585,A32824]. CB1 receptors are found in both the central and peripheral nervous systems, with the majority of receptors localized to the hippocampus and amygdala of the brain. Physiological effects of using cannabis make sense in the context of its receptor activity as the hippocampus and amygdala are primarily involved with regulation of memory, fear, and emotion. In contrast, CB2 receptors are mainly found peripherally in immune cells, lymphoid tissue, and peripheral nerve terminals [A32676].\n\nTetrahydrocannabinol (THC) and cannabidiol (CBD) are two types of cannabinoids found naturally in the resin of the marijuana plant, both of which interact with the cannabinoid receptors that are found throughout the body. Although THC and CBD have been the most studied cannabinoids, there are many others identified to date including cannabinol (CBN), cannabigerol (CBG), [DB14050] (CBDV), and [DB11755] (THCV) that can be found within the medical cannabis [A32830]. While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms of THC like [DB00470] or [DB00486]), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers.\n\nThe primary psychoactive component of Cannabis, delta 9-tetrahydrocannabinol (9-THC), demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors. This activity results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. In contrast to THC's weak agonist activity, CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body [A32469]. Allosteric regulation is achieved through the modulation of receptor activity on a functionally distinct site from the agonist or antagonist binding site which is clinically significant as direct agonists (such as THC) are limited by their psychomimetic effects such as changes to mood, memory, and anxiety[A32469]. \n\nIn addition to the well-known activity on CB1 and CB2 receptors, there is further evidence that CBD also activates 5-HT1A/2A/3A serotonergic and TRPV12 vanilloid receptors, antagonizes alpha-1 adrenergic and -opioid receptors, inhibits synaptosomal uptake of noradrenaline, dopamine, serotonin and gamma-aminobutyric acid (GABA), and cellular uptake of anandamide, acts on mitochondria Ca2+ stores, blocks low-voltage-activated (T-type) Ca2+ channels, stimulates activity of the inhibitory glycine-receptor, and inhibits activity of fatty amide hydrolase (FAAH) [A31555, A31574].\n\nCBD is currently available in Canada within a 1:1 formulation with tetrahydrocannbinol (THC) (as the formulation known as "nabiximols") as the brand name product Sativex. It is approved for use as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS). Sativex was also given a conditional Notice of Compliance (NOC/c) for use as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis and as adjunctive analgesic treatment for moderate to severe pain in adult patients with advanced cancer [L886].\n\nIn April 2018, a Food and Drug Administration advisory panel unanimously recommended approval of Epidiolex (cannabidiol oral solution) for the treatment of two rare forms of epilepsy - Lennox-Gastaut syndrome and Dravet syndrome, which are among the two most difficult types of epilepsy to treat [L2721, L2719]. Epidiolex was granted Orphan Drug designation as well as Fast Track Approval from the FDA for further study in these hard to treat conditions. Notably, phase 3 clinical trials of Epidiolex have demonstrated clinically significant improvement in Lennox-Gastaut syndrome and Dravet syndrome [L2720]. On June 25th, 2018, Epidiolex was approved by the FDA to be the first CBD-based product available on the US market.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09063">
  <data key="d0">Ceritinib</data>
  <data key="d1">drugbank.DB09063</data>
  <data key="d2">[drugbank.DB09063]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Bradycardia-Causing Agents, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P450 2C9 Inhibitors, Cytochrome P450 3A Inhibitors, Enzyme Inhibitors, Hyperglycemia-Associated Agents, Kinase Inhibitor, Moderate Risk QTc-Prolonging Agents, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, QTc Prolonging Agents, Receptor Protein-Tyrosine Kinases, antagonists &amp; inhibitors, Sulfur Compounds, Tyrosine Kinase Inhibitors]</data>
  <data key="d14">5-chloro-N2-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine</data>
  <data key="d15">C28H36ClN5O3S</data>
  <data key="d16">1032900-25-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)</data>
  <data key="d20">CC(C)OC1=C(NC2=NC=C(Cl)C(N2)=NC2=CC=CC=C2S(=O)(=O)C(C)C)C=C(C)C(=C1)C1CCNCC1</data>
  <data key="d21">Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Ceritinib, critinib, N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide]</data>
  <data key="d9">Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells. Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key "gatekeeper" residues of the enzyme. This occurrence led to development of novel second-generation ALK inhibitors such as ceritinib to overcome crizotinib resistance. The FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00772">
  <data key="d0">Malathion</data>
  <data key="d1">drugbank.DB00772</data>
  <data key="d2">[drugbank.DB00772, drugbank.APRD01081]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agrochemicals, Antiparasitic Products, Insecticides and Repellents, Cholinergic Agents, Cholinesterase Inhibitors, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Ectoparasiticides, Incl. Scabicides, Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents, Enzyme Inhibitors, Insecticides, Neurotransmitter Agents, Organophosphates, Organophosphorus Compounds, Organothiophosphates, Organothiophosphorus Compounds, Pesticides, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sulfur Compounds, Toxic Actions]</data>
  <data key="d14">1,4-diethyl 2-{[dimethoxy(sulfanylidene)--phosphanyl]sulfanyl}butanedioate</data>
  <data key="d15">C10H19O6PS2</data>
  <data key="d16">121-75-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H19O6PS2/c1-5-15-9(11)7-8(10(12)16-6-2)19-17(18,13-3)14-4/h8H,5-7H2,1-4H3</data>
  <data key="d20">CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC</data>
  <data key="d21">For patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[[(dimethoxyphosphinothioyl)thio]butanedioic acid diethyl ester, Carbophos, diethyl (dimethoxyphosphinothioylthio)succinate, Karbofos, Maldison, Mercaptothion, O, O-dimethyl S-(1, 2-bis(ethoxycarbonyl)ethyl), O, O-dimethyl S-(1, 2-dicarbethoxyethyl) dithiophosphate, O, O-dimethyl S-(1, 2-dicarbethoxyethyl)phosphorodithioate, O, O-dimethyl S-1, 2-di(ethoxycarbamyl)ethyl, O, O-dimethyldithiophosphate diethylmercaptosuccinate]</data>
  <data key="d9">Malathion is a parasympathomimetic organophosphate compound that is used as an insecticide for the treatment of head lice. Malathion is an irreversible cholinesterase inhibitor and has low human toxicity.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00780">
  <data key="d0">Phenelzine</data>
  <data key="d1">drugbank.DB00780</data>
  <data key="d2">[drugbank.DB00780, drugbank.APRD00099]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2E1 Inducers (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hydrazines, Hypotensive Agents, Monoamine Oxidase A Substrates, Monoamine Oxidase Inhibitors, Monoamine Oxidase Inhibitors, Non-Selective, Nervous System, Psychoanaleptics, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators]</data>
  <data key="d14">(2-phenylethyl)hydrazine</data>
  <data key="d15">C8H12N2</data>
  <data key="d16">51-71-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C8H12N2/c9-10-7-6-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2</data>
  <data key="d20">NNCCC1=CC=CC=C1</data>
  <data key="d21">Phenelzine is indicated for the treatment of nonendogenous, neurotic or atypical depression for patients that do not tolerate other forms of therapy.[L1356] \n\nAtypical depression has a high prevalence rate, starts in early life, tends to last longer, is more likely to occur in people with bipolar disorder, has a high comorbidity with anxiety disorder and carries more risk of suicidal behavior. It is important to specify the atypical feature to predict the clinical course of depression and hence generate the best treatment and service. The featuring symptoms of the atypical feature include mood reactivity, two or more of this symptoms: 1) increased appetite, 2) increased sleep, 3) leaden paralysis and 4) interpersonal rejection sensitivity and should not have melancholic or catatonic features of depression.[A31917]\n\nNeurotic depression is a depression of an emotionally unstable person. It is a secondary condition to major personality disorder, neuroses and drug use disorders. Likewise, a primary depression with a family history of depression spectrum disease would fit in this category.[A31922]\n\nA nonendogenous depression is characterized by a disturbance in mood and general outlook. The physical symptoms tend to be less severe and it often occurs in response to stressful life events that keep occurring over a large period of time generating a continuous stress in the daily living.[A31924]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Fenelzina, Phenelzin, Phenelzine, Phnelzine, Phenelzinum]</data>
  <data key="d9">Phenelzine, with the formula -phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder.[A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09109">
  <data key="d0">Turoctocog alfa</data>
  <data key="d1">drugbank.DB09109</data>
  <data key="d2">[drugbank.DB09109]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Biological Factors, Blood Coagulation Factors, Blood Proteins, Hemostatics, Proteins, Recombinant Proteins]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">1192451-26-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Turoctocog alfa is indicated for the treatment and prophylaxis of bleedings in patients presenting hemophilia A.[L1105] The treatment with turoctocog alfa is related with its use to control bleeding episodes or as a perioperative management.[L1106] Hemophilia A is a hereditary hemorrhagic disorder generated by the congenital deficit of the coagulation factor VIII. This disease is manifested as excessive spontaneous or trauma-driven bleeding. The coagulation factor VIII is a robust initiator of thrombin which is later required for the generation of fibrin to form a platelet plug and its gene is expressed in the X chromosome.[A31505]</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;9f4df3ab-ef5b-46cd-b5db-bb890456f71c &gt;Heavy chain&lt;&lt;&lt;\nATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHPSQNPPVLKRHQR, &gt;29f247f1-d5f6-46d6-82af-d06a8b9cb958 &gt;Light chain&lt;&lt;&lt;\nEITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY]</data>
  <data key="d8">[]</data>
  <data key="d9">Turoctocog alfa is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of the naturally occurring B-domain. Turoctocog alfa is produced in Chinese hamster ovary (CHO) cells without addition of any human- or animal-derived materials. During secretion, some rFVIII molecules are cleaved at the C-terminal of the heavy chain (HC) at amino acid 720, and a monoclonal antibody binding C-terminal to this position is used in the purification process allowing isolation of the intact rFVIII.[A31504] It was developped by Novo Nordisk and FDA approved in October 16, 2013.[L1104]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09129">
  <data key="d0">Chromic chloride</data>
  <data key="d1">drugbank.DB09129</data>
  <data key="d2">[drugbank.DB09129]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acids, Acids, Noncarboxylic, Anions, Antioxidants, Chlorine Compounds, Compounds used in a research, industrial, or household setting, Drugs that are Mainly Renally Excreted, Electrolytes, Hydrochloric Acid, Ions, Minerals, Protective Agents, Replacement Preparations]</data>
  <data key="d14">chromium(3+) ion trichloride</data>
  <data key="d15">Cl3Cr</data>
  <data key="d16">10025-73-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/3ClH.Cr/h3*1H;/q;;;+3/p-3</data>
  <data key="d20">[Cl-].[Cl-].[Cl-].[Cr+3]</data>
  <data key="d21">For use as a supplement to intravenous solutions given for total parenteral nutrition (TPN).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[anhydrous chromium(III) chloride, Chromium chloride, Chromium trichloride, chromium(3+) trichloride, Chromium(III) chloride, Puratronic chromium chloride, Trichlorochromium]</data>
  <data key="d9">Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00783">
  <data key="d0">Estradiol</data>
  <data key="d1">drugbank.DB00783</data>
  <data key="d2">[drugbank.DB00783, drugbank.APRD00311]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Adrenal Cortex Hormones, Androgens and Estrogens, Antiandrogens and Estrogens, BCRP/ABCG2 Inducers, BCRP/ABCG2 Inhibitors, Contraceptive Agents, Female, Contraceptives, Oral, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Estradiol Congeners, Estranes, Estrenes, Estrogen Contraceptives, Estrogens, Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Intravaginal Contraceptives, Natural and Semisynthetic Estrogens, Plain, OAT3/SLC22A8 Substrates, OATP1B1/SLCO1B1 Inhibitors, OCT1 inhibitors, OCT2 Inhibitors, P-glycoprotein/ABCB1 Substrates, Progestogens and Estrogens, Sequential Preparations, Sex Hormones and Modulators of the Genital System, Steroids, UGT1A1 Substrates]</data>
  <data key="d14">(1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0,.0,]heptadeca-2(7),3,5-triene-5,14-diol</data>
  <data key="d15">C18H24O2</data>
  <data key="d16">50-28-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1</data>
  <data key="d20">[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3</data>
  <data key="d21">Estradiol is indicated for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure, and for the prevention of post-menopausal osteoarthritis. It is also used for the treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease, and for the treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(17)-estra-1, 3, 5(10)-triene-3, 17-diol, 17beta oestradiol, 17-estra-1, 3, 5(10)-triene-3, 17-diol, 17-estradiol, 17-oestradiol, beta-Estradiol, cis-Estradiol, Estradiol, Estradiol-17beta, Estradiolum]</data>
  <data key="d9">Estradiol (also known as E2 or 17-estradiol) is a naturally occurring hormone that circulates endogenously within the human body. It is the most potent form of mammalian estrogenic steroids and acts as the major female sex hormone. As such, estradiol plays an essential role in the regulation of the menstrual cycle, in the development of puberty and secondary female sex characteristics, as well as in ageing and several hormonally-mediated disease states. Estrogen mediates its effects across the body through potent agonism of the Estrogen Receptor (ER), which is located in various tissues including in the breasts, uterus, ovaries, skin, prostate, bone, fat, and brain. Estradiol binds to both subtypes of the Estrogen Receptor: Estrogen Receptor Alpha (ER) and Estrogen Receptor Beta (ER). Estradiol also acts as a potent agonist of G Protein-coupled Estrogen Receptor (GPER), which has recently been recognized as a major mediator of estradiol's rapid cellular effects [A31620]. \n\nEstradiol is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen production such as menopausal and peri-menopausal symptoms as well as hypoestrogenism. It is also used in transgender hormone therapy, as a component of oral contraceptive pills for preventing pregnancy (most commonly as [DB00977], a synthetic form of estradiol), and is sometimes used for the palliative treatment of some hormone-sensitive cancers like breast and prostate cancer. Estradiol is available in a number of formulations including oral, transdermal, and injectable. \n\nThe primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. However, after menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. Thus, estrone and the sulphate conjugated form, estrone sulphate, are the most abundant circulating estrogens in postmenopausal women [FDA Label]. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol at the receptor level. Because of the difference in potency between estradiol and estrone, menopause (and a change in primary hormone from estradiol to estrone) is associated with a number of symptoms associated with this reduction in potency and in estrogenic effects. These include hot flashes, vaginal dryness, mood changes, irregular menses, chills, and sleeping problems.\n\nWhen used for oral or IM administration, estradiol is commonly synthesized as a pro-drug ester (such as [DB13952], [DB13953], [DB13954], [DB13955], and [DB13956]). It is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%). First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter the systemic circulation and exert its estrogenic effects [A12102]. Esterification of estradiol aims to improve absorption after oral administration (such as with Estradiol valerate) or to sustain release from intramuscular depot injections (such as with Estradiol Cypionate) through improved lipophilicity [T84]. Following absorption, the esters are cleaved, resulting in the release of endogenous estradiol, or 17-estradiol. \n\nRecommendations for treatment of menopausal symptoms changed drastically following the release of results and early termination of the Women's Health Initiative (WHI) studies in 2002 as a number of concerns were raised regarding the use of estrogen [A31626]. Specifically, the combined estrogenprogestin arm was discontinued after approximately five years of follow up due to a statistically significant increase in invasive breast cancer and in cardiovascular events [A31627]. Following extensive critique of the WHI results in the years following its release, Hormone Replacement Therapy (HRT) is now recommended to be used only for a short period (for 3-5 years post-menopause) in low doses, and in women without a history of breast cancer or at increased risk of cardiovascular or thromboembolic disease [A31628]. Notably, use of estrogen for menopausal symptoms should always be accompanied by a progestin component due to estrogen's effects on the endometrium; in women with an intact uterus, unopposed estrogen has been shown to promote the growth of the endometrium which can lead to endometrial hyperplasia and possibly cancer in the long-term. \n\n[DB00977] (EE) is a synthetic form of estradiol commonly used as the estrogenic component of most combination Oral Contraceptive Pills (OCPs). Ethinyl Estradiol differs from Estradiol in that it has improved biovailability and greater resistance to metabolism, making it more suitable for oral administration.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00790">
  <data key="d0">Perindopril</data>
  <data key="d1">drugbank.DB00790</data>
  <data key="d2">[drugbank.DB00790, drugbank.APRD01178]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[ACE Inhibitors and Calcium Channel Blockers, ACE Inhibitors and Diuretics, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Agents, Cholinesterase Inhibitors, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hypotensive Agents, Indoles, Lipid Modifying Agents, Protease Inhibitors]</data>
  <data key="d14">(2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid</data>
  <data key="d15">C19H32N2O5</data>
  <data key="d16">82834-16-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1</data>
  <data key="d20">[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O</data>
  <data key="d21">For the treatment of mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(2S, 3aS, 7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid, Perindopril, Perindoprilum]</data>
  <data key="d9">Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09130">
  <data key="d0">Copper</data>
  <data key="d1">drugbank.DB09130</data>
  <data key="d2">[drugbank.DB09130]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Copper-containing Intrauterine Device, Decreased Embryonic Implantation, Decreased Sperm Motility, Diet, Food, and Nutrition, Elements, Food, Food and Beverages, Growth Substances, Inhibit Ovum Fertilization, Metals, Metals, Heavy, Micronutrients, Minerals, Physiological Phenomena, Replacement Preparations, Trace Elements, Transition Elements]</data>
  <data key="d14">copper</data>
  <data key="d15">Cu</data>
  <data key="d16">7440-50-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/Cu</data>
  <data key="d20">[Cu]</data>
  <data key="d21">For use in the supplementation of total parenteral nutrition and in contraception with intrauterine devices [FDA Label] [L801].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[cobre, cuivre, cuprum, Kupfer]</data>
  <data key="d9">Copper is a transition metal and a trace element in the body. It is important to the function of many enzymes including cytochrome c oxidase, monoamine oxidase and superoxide dismutase [FDA Label]. Copper is commonly used in contraceptive intrauterine devices (IUD) [L801].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00795">
  <data key="d0">Sulfasalazine</data>
  <data key="d1">drugbank.DB00795</data>
  <data key="d2">[drugbank.DB00795, drugbank.APRD00152, drugbank.DB08518]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents causing hyperkalemia, Agents that produce hypertension, Alimentary Tract and Metabolism, Amides, Aminosalicylate, Analgesics, Analgesics, Non-Narcotic, Anti-Infective Agents, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antirheumatic Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Central Nervous System Agents, Gastrointestinal Agents, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Immunosuppressive Agents, Intestinal Antiinflammatory Agents, Methemoglobinemia Associated Agents, Nephrotoxic agents, Non COX-2 selective NSAIDS, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, Peripheral Nervous System Agents, Salicylates, Sensory System Agents, Sulfonamides, Sulfones, Sulfur Compounds]</data>
  <data key="d14">2-hydroxy-5-[(E)-2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl]benzoic acid</data>
  <data key="d15">C18H14N4O5S</data>
  <data key="d16">599-79-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+</data>
  <data key="d20">OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1</data>
  <data key="d21">For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid, 2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid, 4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene, 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid, 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid, 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid, Azopyrin, Salazosulfapiridina, Salazosulfapyridine, Salazosulfapyridinum, Salicylazosulfapyridine, Sulfasalazin, Sulfasalazina, Sulfasalazine, Sulfasalazinum]</data>
  <data key="d9">A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00794">
  <data key="d0">Primidone</data>
  <data key="d1">drugbank.DB00794</data>
  <data key="d2">[drugbank.DB00794, drugbank.APRD00549]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Anti-epileptic Agent, Anticholinergic Agents, Anticonvulsants, Barbiturates, Barbiturates and Derivatives, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strong), Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strong), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (unknown strength), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strong), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 Enzyme Inducers, Decreased Central Nervous System Disorganized Electrical Activity, Enzyme Inducing Antiepileptic Drugs, Hypnotics and Sedatives, Nervous System, Nicotinic Antagonists, Phenobarbital and similars, Psycholeptics, Pyrimidines, Pyrimidinones, UGT1A1 Inducers]</data>
  <data key="d14">5-ethyl-5-phenyl-1,3-diazinane-4,6-dione</data>
  <data key="d15">C12H14N2O2</data>
  <data key="d16">125-33-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16)</data>
  <data key="d20">CCC1(C(=O)NCNC1=O)C1=CC=CC=C1</data>
  <data key="d21">Primidone is commonly indicated for the management of grand mal, psychomotor, and focal epileptic seizures [L4645, FDA Label]. In addition, it has also been studied and utilized as an effective management of essential tremor [A39414, A39415, L4645].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-deoxyphenobarbital, 5-Phenyl-5-ethyl-Hexahydropyrimidine-4, 6-dione, Primidon, Primidona, Primidone, Primidonum]</data>
  <data key="d9">An antiepileptic agent related to the barbiturates; it is partly metabolized to phenobarbital in the body and owes some of its actions to this metabolite. Adverse effects are reported to be more frequent than with phenobarbital. (From Martindale, The Extra Pharmacopoeia, 30th ed, p309)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09149">
  <data key="d0">Florbetapir (18F)</data>
  <data key="d1">drugbank.DB09149</data>
  <data key="d2">[drugbank.DB09149]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alcohols, Amines, Central Nervous System, Diagnostic Radiopharmaceuticals, Drugs that are Mainly Renally Excreted, Fluorine Radioisotopes, Glycols, Positron Emitting Activity, Radioactive Diagnostic Agent]</data>
  <data key="d14">4-[(E)-2-[6-(2-{2-[2-(F)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl]-N-methylaniline</data>
  <data key="d15">C20H25FN2O3</data>
  <data key="d16">956103-76-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H25FN2O3/c1-22-19-7-4-17(5-8-19)2-3-18-6-9-20(23-16-18)26-15-14-25-13-12-24-11-10-21/h2-9,16,22H,10-15H2,1H3/b3-2+/i21-1</data>
  <data key="d20">[H]N(C1=C([H])C([H])=C(\C([H])=C(/[H])C2=C([H])N=C(OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])[18F])C([H])=C2[H])C([H])=C1[H])C([H])([H])[H]</data>
  <data key="d21">Florbetapir 18F is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate -amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[[18F]Florbetapir, 4-{(E)-2-[6-(2-{2-[2-(18F)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-N-methylaniline, Florbetapir (18F), Florbetapir F-18, Florbetapir F18, florbetapir-fluorine-18]</data>
  <data key="d9">Florbetapir (18F) is a radiopharmaceutical compound containing the radionuclide fluorine-18 bound to the compound florbetapir, a molecule that binds with high affinity to beta amyloid plaque, a peptide that plays a key role in Alzheimer's Disease pathogenesis. Marketed as the product Amyvid, florbetapir 18F is indicated for positron emission tomography (PET) imaging of the brain to estimate -amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.  \n\nThe radionucleide fluorine-18 was chosen as it has a half life of 110 minutes allowing it to accumulate sufficiently in the brain before undergoing positon emission decay.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09148">
  <data key="d0">Florbetaben (18F)</data>
  <data key="d1">drugbank.DB09148</data>
  <data key="d2">[drugbank.DB09148]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amines, Benzene Derivatives, Benzylidene Compounds, Central Nervous System, Diagnostic Radiopharmaceuticals, Drugs that are Mainly Renally Excreted, Fluorine Radioisotopes, Positron Emitting Activity, Radioactive Diagnostic Agent]</data>
  <data key="d14">4-[(E)-2-[4-(2-{2-[2-(F)fluoroethoxy]ethoxy}ethoxy)phenyl]ethenyl]-N-methylaniline</data>
  <data key="d15">C21H26FNO3</data>
  <data key="d16">902143-01-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H26FNO3/c1-23-20-8-4-18(5-9-20)2-3-19-6-10-21(11-7-19)26-17-16-25-15-14-24-13-12-22/h2-11,23H,12-17H2,1H3/b3-2+/i22-1</data>
  <data key="d20">CNC1=CC=C(\C=C\C2=CC=C(OCCOCCOCC[18F])C=C2)C=C1</data>
  <data key="d21">Florbetaben is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate -amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimers Disease (AD) and other causes of cognitive decline.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Florbetaben (18F), Florbetaben F-18]</data>
  <data key="d9">Florbetaben is a fluorine-18 (18F)-labeled stilbene derivative used for Positron Emission Tomography (PET) imaging of the brain. It is used for the non-invasive detection of the density of -amyloid neuritic plaques in the brain of adult patients with cognitive impairment.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00734">
  <data key="d0">Risperidone</data>
  <data key="d1">drugbank.DB00734</data>
  <data key="d2">[drugbank.DB00734, drugbank.APRD00187]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Antipsychotic Agents, Antipsychotic Agents (Second Generation [Atypical]), Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Histamine Antagonists, Histamine H1 Antagonists, Hyperglycemia-Associated Agents, Nervous System, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein/ABCB1 Substrates, Potential QTc-Prolonging Agents, Psycholeptics, Psychotropic Drugs, Pyrimidines, Pyrimidinones, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Tranquilizing Agents]</data>
  <data key="d14">3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one</data>
  <data key="d15">C23H27FN4O2</data>
  <data key="d16">106266-06-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3</data>
  <data key="d20">CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1</data>
  <data key="d21">Risperidone belongs to the class of medications known as second generation atypical antipsychotics [A1114, A1115, L1213].  It is widely used in the treatment of schizophrenia and mood disorders, including bipolar disorder and depression with pyschosis [A1115, A1116, L1212, L1213].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Risperidona, Risperidone, Rispridone, Risperidonum]</data>
  <data key="d9">Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively [L1212, L1213].\n \nRisperidone inhibits dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain. It is also said to block histamine receptors, and other neural receptors which are currently being studied [L1213, A1115].\n\nRisperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's binding affinity to D2 receptors [L1212, L1213, A1115].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00733">
  <data key="d0">Pralidoxime</data>
  <data key="d1">drugbank.DB00733</data>
  <data key="d2">[drugbank.DB00733, drugbank.APRD01193]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Amines, Antidotes, Cholinergic Agents, Cholinesterase Reactivators, Compounds used in a research, industrial, or household setting, Drugs that are Mainly Renally Excreted, Enzyme Reactivators, Hydroxylamines, Neurotransmitter Agents, Oximes, Protective Agents]</data>
  <data key="d14">2-[(1E)-(hydroxyimino)methyl]-1-methylpyridin-1-ium</data>
  <data key="d15">C7H9N2O</data>
  <data key="d16">6735-59-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H8N2O/c1-9-5-3-2-4-7(9)6-8-10/h2-6H,1H3/p+1</data>
  <data key="d20">C[N+]1=C(\C=N\O)C=CC=C1</data>
  <data key="d21">For the treatment of poisoning due to those pesticides and chemicals of the organophosphate class which have anticholinesterase activity and in the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-PAM, Pralidoxim, Pralidoxima, Pralidoxime, Pralidoximum]</data>
  <data key="d9">Pralidoxime is an antidote to organophosphate pesticides and chemicals. Organophosphates bind to the esteratic site of acetylcholinesterase, which results initially in reversible inactivation of the enzyme. If given within 24 hours,after organophosphate exposure, pralidoxime reactivates the enzyme cholinesterase by cleaving the phosphate-ester bond formed between the organophosphate and acetylcholinesterase.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00731">
  <data key="d0">Nateglinide</data>
  <data key="d1">drugbank.DB00731</data>
  <data key="d2">[drugbank.DB00731, drugbank.APRD00593]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Amino Acids, Amino Acids, Aromatic, Amino Acids, Cyclic, Amino Acids, Essential, Amino Acids, Peptides, and Proteins, Blood Glucose Lowering Agents, Cycloparaffins, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Drugs that are Mainly Renally Excreted, Drugs Used in Diabetes, Glinide, Hypoglycemia-Associated Agents, OAT1/SLC22A6 inhibitors, Oral Hypoglycemics, Potassium Channel Antagonists, UGT1A9 Substrates]</data>
  <data key="d14">(2R)-2-({hydroxy[(1r,4r)-4-(propan-2-yl)cyclohexyl]methylidene}amino)-3-phenylpropanoic acid</data>
  <data key="d15">C19H27NO3</data>
  <data key="d16">105816-04-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1</data>
  <data key="d20">[H][C@](CC1=CC=CC=C1)(N=C(O)[C@@]1([H])CC[C@@]([H])(CC1)C(C)C)C(O)=O</data>
  <data key="d21">For the treatment of non-insulin dependent-diabetes mellitus in conjunction with diet and exercise.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[nateglinida, Nateglinide]</data>
  <data key="d9">Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to  cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those nave to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00747">
  <data key="d0">Scopolamine</data>
  <data key="d1">drugbank.DB00747</data>
  <data key="d2">[drugbank.DB00747, drugbank.APRD00616]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Adjuvants, Adjuvants, Anesthesia, Agents producing tachycardia, Alimentary Tract and Metabolism, Alkaloids, Anticholinergic Agents, Antiemetics and Antinauseants, Antimuscarinics Antispasmodics, Autonomic Agents, Aza Compounds, Azabicyclo Compounds, Belladonna Alkaloids, Central Nervous System Agents, Central Nervous System Depressants, Cholinergic Agents, Hypnotics and Sedatives, Muscarinic Antagonists, Mydriatics, Mydriatics and Cycloplegics, Nervous System, Neurotransmitter Agents, Ophthalmologicals, P-glycoprotein/ABCB1 Inhibitors, Peripheral Nervous System Agents, Psycholeptics, Scopolamine Derivatives, Sensory Organs, Solanaceous Alkaloids, Tropanes]</data>
  <data key="d14">(1R,2R,4S,5S,7R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0,]nonan-7-yl (2S)-3-hydroxy-2-phenylpropanoate</data>
  <data key="d15">C17H21NO4</data>
  <data key="d16">51-34-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11-,12-,13-,14+,15-,16+/m1/s1</data>
  <data key="d20">CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1</data>
  <data key="d21">For the treatment of excessive salivation, colicky abdominal pain, bradycardia, sialorrhoea, diverticulitis, irritable bowel syndrome and motion sickness.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(-)-hyoscine, (-)-scopolamine, (1S, 3S, 5R, 6R, 7S)-6, 7-Epoxytropan-3-yl (2S)-3-hydroxy-2-phenylpropanoate, 6-beta, 7-beta-Epoxy-3-alpha-tropanyl S-(-)-tropate, 6, 7-Epoxytropine tropate, alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester, Hyoscine, scopine (-)-tropate, scopine ()-tropate, Scopolamine hydrobromide]</data>
  <data key="d9">An alkaloid from Solanaceae, especially Datura metel L. and Scopola carniolica. Scopolamine and its quaternary derivatives act as antimuscarinics like atropine, but may have more central nervous system effects. Among the many uses are as an anesthetic premedication, in urinary incontinence, in motion sickness, as an antispasmodic, and as a mydriatic and cycloplegic.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00746">
  <data key="d0">Deferoxamine</data>
  <data key="d1">drugbank.DB00746</data>
  <data key="d2">[drugbank.DB00746, drugbank.APRD00904]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Amines, Chelating Agents, Compounds used in a research, industrial, or household setting, Heavy Metal Antagonists, Hydroxamic Acids, Hydroxy Acids, Hydroxylamines, Iron Chelating Activity, Iron Chelating Agents, Sequestering Agents, Siderophores]</data>
  <data key="d14">N-(5-aminopentyl)-N-hydroxy-N'-[5-(N-hydroxy-3-{[5-(N-hydroxyacetamido)pentyl]carbamoyl}propanamido)pentyl]butanediamide</data>
  <data key="d15">C25H48N6O8</data>
  <data key="d16">70-51-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)</data>
  <data key="d20">CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN</data>
  <data key="d21">Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Deferoxamin, Deferoxamina, Dferoxamine, Deferoxamine, Deferoxaminum, Deferrioxamine, Deferrioxamine B, Desferrioxamine, DFO, DFOA, DFOM]</data>
  <data key="d9">Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00759">
  <data key="d0">Tetracycline</data>
  <data key="d1">drugbank.DB00759</data>
  <data key="d2">[drugbank.DB00759, drugbank.APRD00572]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Agents that produce neuromuscular block (indirect), Alimentary Tract and Metabolism, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antibiotics for Topical Use, Antiinfectives and Antiseptics for Local Oral Treatment, Antiinfectives for Systemic Use, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Naphthacenes, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, Ophthalmological and Otological Preparations, Ophthalmologicals, Otologicals, P-glycoprotein/ABCB1 Substrates, Protein Synthesis Inhibitors, Sensory Organs, Stomatological Preparations, Tetracyclines]</data>
  <data key="d14">(4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide</data>
  <data key="d15">C22H24N2O8</data>
  <data key="d16">60-54-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H24N2O8/c1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28/h4-6,9-10,15,25,27-28,31-32H,7H2,1-3H3,(H2,23,30)/t9-,10-,15-,21+,22-/m0/s1</data>
  <data key="d20">[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O</data>
  <data key="d21">Used to treat bacterial infections such as Rocky Mountain spotted fever, typhus fever, tick fevers, Q fever, rickettsialpox and Brill-Zinsser disease. May be used to treat infections caused by Chlamydiae spp., B. burgdorferi (Lyme disease), and upper respiratory infections caused by typical (S. pneumoniae, H. influenzae, and M. catarrhalis) and atypical organisms (C. pneumoniae, M. pneumoniae, L. pneumophila). May also be used to treat acne. Tetracycline may be an alternative drug for people who are allergic to penicillin.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(4S, 4aS, 5aS, 12aS)-4-(Dimethylamino)-1, 4, 4a, 5, 5a, 6, 11, 12a-octahydro-3, 6, 10, 12, 12a-pentahydroxy-6-methyl-1, 11-dioxo-2-naphthacenecarboxamide, Abramycin, Anhydrotetracycline, Deschlorobiomycin, Tetracyclin, Ttracycline, Tetracycline, Tetracyclinum, Tetrazyklin, Tsiklomitsin]</data>
  <data key="d9">Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00756">
  <data key="d0">Hexachlorophene</data>
  <data key="d1">drugbank.DB00756</data>
  <data key="d2">[drugbank.DB00756, drugbank.APRD00722]</data>
  <data key="d12">[approved, withdrawn]</data>
  <data key="d13">[Anti-Infective Agents, Anti-Infective Agents, Local, Antiseptics and Disinfectants, Benzene Derivatives, Chlorobenzenes, Chlorophenols, Dermatologicals, Hydrocarbons, Chlorinated, Hydrocarbons, Halogenated, Phenol and Derivatives, Phenols]</data>
  <data key="d14">3,4,6-trichloro-2-[(2,3,5-trichloro-6-hydroxyphenyl)methyl]phenol</data>
  <data key="d15">C13H6Cl6O2</data>
  <data key="d16">70-30-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H6Cl6O2/c14-6-2-8(16)12(20)4(10(6)18)1-5-11(19)7(15)3-9(17)13(5)21/h2-3,20-21H,1H2</data>
  <data key="d20">OC1=C(CC2=C(O)C(Cl)=CC(Cl)=C2Cl)C(Cl)=C(Cl)C=C1Cl</data>
  <data key="d21">For use as a surgical scrub and a bacteriostatic skin cleanser. It may also be used to control an outbreak of gram-positive infection where other infection control procedures have been unsuccessful.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2, 2'-dihydroxy-3, 3', 5, 5', 6, 6'-hexachlorodiphenylmethane, 2, 2'-dihydroxy-3, 5, 6, 3', 5', 6'-hexachlorodiphenylmethane, 2, 2'-methanediylbis(3, 4, 6-trichlorophenol), 2, 2'-methylenebis(3, 4, 6-trichlorophenol), 2, 2', 3, 3', 5, 5'-hexachloro-6, 6'-dihydroxydiphenylmethane, bis(2-hydroxy-3, 5, 6-trichlorophenyl)methane, bis(3, 5, 6-trichloro-2-hydroxyphenyl)methane, hexachlorophne, Hexachlorophene, Hexachlorophenum, Hexaclorofeno]</data>
  <data key="d9">A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00753">
  <data key="d0">Isoflurane</data>
  <data key="d1">drugbank.DB00753</data>
  <data key="d2">[drugbank.DB00753, drugbank.APRD00212]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Agents that produce hypertension, Agents that reduce seizure threshold, Anesthetics, Anesthetics, General, Anesthetics, Inhalation, Anticholinergic Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Ethers, Hydrocarbons, Halogenated, Hypotensive Agents, Methyl Ethers, Nervous System, Nicotinic Antagonists, Potential QTc-Prolonging Agents, QTc Prolonging Agents]</data>
  <data key="d14">2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane</data>
  <data key="d15">C3H2ClF5O</data>
  <data key="d16">26675-46-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C3H2ClF5O/c4-1(3(7,8)9)10-2(5)6/h1-2H</data>
  <data key="d20">FC(F)OC(Cl)C(F)(F)F</data>
  <data key="d21">For induction and maintenance of general anesthesia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-chloro-2, 2, 2-trifluoroethyl difluoromethyl ether, Isoflurane, Isoflurano, Isofluranum]</data>
  <data key="d9">A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00752">
  <data key="d0">Tranylcypromine</data>
  <data key="d1">drugbank.DB00752</data>
  <data key="d2">[drugbank.DB00752, drugbank.APRD00645]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents that produce hypertension, Agents that reduce seizure threshold, Amines, Anti-Anxiety Agents, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strong), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Hypotensive Agents, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase Inhibitors, Monoamine Oxidase Inhibitors, Non-Selective, Nervous System, Propylamines, Psychoanaleptics, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators, Tranquilizing Agents]</data>
  <data key="d14">2-phenylcyclopropan-1-amine</data>
  <data key="d15">C9H11N</data>
  <data key="d16">155-09-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2</data>
  <data key="d20">NC1CC1C1=CC=CC=C1</data>
  <data key="d21">For the treatment of major depressive episode without melancholia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-trans-2-phenylcyclopropylamine, (1R*, 2S*)-2-phenylcyclopropan-1-amine, dl-tranylcypromine, Racemic Tranylcypromine, Tranilcipromina, trans-2-phenylcyclopropylamine, trans-DL-2-Phenylcyclopropylamine, Transamine, Tranylcypromin, Tranylcypromine, Tranylcyprominum]</data>
  <data key="d9">A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311). \n\nTranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00762">
  <data key="d0">Irinotecan</data>
  <data key="d1">drugbank.DB00762</data>
  <data key="d2">[drugbank.DB00762, drugbank.APRD00579]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alkaloids, Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Carbohydrates, Cholinesterase substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Disaccharides, Enzyme Inhibitors, Immunosuppressive Agents, Myelosuppressive Agents, OATP1B1/SLCO1B1 Inhibitors, Oligosaccharides, P-glycoprotein/ABCB1 Substrates, Pharmaceutical Preparations, Polysaccharides, Prodrugs, Radiation-Sensitizing Agents, Topoisomerase I Inhibitors, Topoisomerase Inhibitors, UGT1A1 Substrates, UGT1A9 Substrates]</data>
  <data key="d14">(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl [1,4'-bipiperidine]-1'-carboxylate</data>
  <data key="d15">C33H38N4O6</data>
  <data key="d16">97682-44-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1</data>
  <data key="d20">CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12</data>
  <data key="d21">For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+)-Irinotecan, Irinotecan, Irinotecan lactone, Irinotecanum]</data>
  <data key="d9">Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00704">
  <data key="d0">Naltrexone</data>
  <data key="d1">drugbank.DB00704</data>
  <data key="d2">[drugbank.DB00704, drugbank.APRD00005, drugbank.DB05067]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Agents Causing Muscle Toxicity, Alimentary Tract and Metabolism, Alkaloids, Analgesics, Antiobesity Preparations, Excl. Diet Products, Central Nervous System Agents, Centrally Acting Antiobesity Products, Drugs Used in Addictive Disorders, Drugs Used in Alcohol Dependence, Morphinans, Naloxone, Natural Opium Alkaloids, Nervous System, Opiate Alkaloids, Opiate Antagonists, Opioid Antagonists, Opioids, Peripheral Nervous System Agents, Phenanthrenes, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, UGT1A1 Substrates]</data>
  <data key="d14">(1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0,.0,.0,]octadeca-7(18),8,10-trien-14-one</data>
  <data key="d15">C20H23NO4</data>
  <data key="d16">16590-41-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1</data>
  <data key="d20">[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O</data>
  <data key="d21">Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[17-(Cyclopropylmethyl)-4, 5-epoxy-3, 14-dihydroxymorphinan-6-one, 17-(Cyclopropylmethyl)-4, 5-epoxy-3, 14-dihydroxymorphinan-6-one, N-Cyclopropylmethyl-14-hydroxydihydromorphinone, N-Cyclopropylmethylnoroxymorphone, Naltrexon, Naltrexona, Naltrexone, Naltrexonum]</data>
  <data key="d9">Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00717">
  <data key="d0">Norethisterone</data>
  <data key="d1">drugbank.DB00717</data>
  <data key="d2">[drugbank.DB00717, drugbank.APRD00679]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenal Cortex Hormones, Combination Contraceptives (with Estrogen and derivatives), Contraceptive Agents, Female, Contraceptives, Oral, Contraceptives, Oral, Synthetic, Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (unknown strength), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Estren Derivatives, Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Hyperglycemia-Associated Agents, Norpregnanes, Norpregnenes, Norsteroids, P-glycoprotein/ABCB1 Inducers, Progestin Contraceptives, Progestins, Progestogens and Estrogens, Sequential Preparations, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids]</data>
  <data key="d14">(1R,3aS,3bR,9aR,9bS,11aS)-1-ethynyl-1-hydroxy-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one</data>
  <data key="d15">C20H26O2</data>
  <data key="d16">68-22-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]</data>
  <data key="d21">For the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(17alpha)-17-ethynyl-17-hydroxyestra-4, 8(14), 9-trien-3-one, 17-hydroxy-19-nor-17--pregn-4-en-20-yn-3-one, 17-hydroxy-19-nor-17-pregn-4-en-20-yn-3-one, 17--ethynyl-17-hydroxy-4-estren-3-one, 17--ethynyl-19-norandrost-4-en-17--ol-3-one, 17--ethynyl-19-nortestosterone, 17--ethynyl-4-estren-17-ol-3-one, 17--hydroxy-19-norpregn-4-en-20-yn-3-one, 17-ethinyl-19-nortestosterone, 17-ethinylestra-4-en-17-ol-3-one, 17-ethynyl-17-hydroxy-4-estren-3-one, 17-ethynyl-17-hydroxy-19-norandrost-4-en-3-one, 17-ethynyl-19-nor-4-androsten-17-ol-3-one, 17-ethynyl-19-norandrost-4-en-17-ol-3-one, 17-ethynyl-19-nortestosterone, 17-ethynyl-4-estren-17-ol-3-one, 17-hydroxy-19-norpregn-4-en-20-yn-3-one, 19-nor-17--ethynyl-17--hydroxy-4-androsten-3-one, 19-nor-17--ethynylandrosten-17--ol-3-one, 19-nor-17--ethynyltestosterone, 19-Nor-17alpha-ethynyl-17beta-hydroxy-4-androsten-3-one, 19-nor-17-ethynyl-17-hydroxy-4-androsten-3-one, 19-nor-17-ethynylandrosten-17-ol-3-one, 19-nor-17-ethynyltestosterone, 19-nor-ethindrone, 19-norethisterone, 4-estren-17-ethynyl-17-ol-3-one, Norethindrone, Norethisteron, Northistrone, Norethisterone, Norethisteronum, Noretisterona]</data>
  <data key="d9">Norethisterone (INN, BAN), also known as Norethindrone (USAN), is a synthetic progestational hormone with actions similar to those of progesterone but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for contraception.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00715">
  <data key="d0">Paroxetine</data>
  <data key="d1">drugbank.DB00715</data>
  <data key="d2">[drugbank.DB00715]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents producing tachycardia, Agents that reduce seizure threshold, Anticholinergic Agents, Antidepressive Agents, Antidepressive Agents, Second-Generation, Central Nervous System Agents, Central Nervous System Depressants, Chemically-Induced Disorders, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hypoglycemia-Associated Agents, Membrane Transport Modulators, Muscarinic Antagonists, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, P-glycoprotein/ABCB1 Inhibitors, Piperidines, Potential QTc-Prolonging Agents, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Selective Serotonin Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators]</data>
  <data key="d14">(3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine</data>
  <data key="d15">C19H20FNO3</data>
  <data key="d16">61869-08-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1</data>
  <data key="d20">FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1</data>
  <data key="d21">Labeled indications include: major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD). Unlabeled indications include: eating disorders, impulse control disorders, vasomotor symptoms of menopause, obsessive-compulsive disorder (OCD) in children, and mild dementia-associated agitation in nonpsychotic individuals. Brisdelle, which consists of paroxetine mesylate is indicated for the treatment of moderate to severe vasomotor symptoms (like hot flashes) associated with menopause.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-(3S, 4R)-4-(p-fluorophenyl)-3-((3, 4-(methylenedioxy)phenoxy)methyl)piperidine, (3S-trans)-3-((1, 3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine, Paroxetina, Paroxetine, Paroxetinum]</data>
  <data key="d9">Paroxetine hydrochloride and paroxetine mesylate belong to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize - or -adrenergic, dopamine D&lt;sub&gt;2&lt;/sub&gt; or histamine H&lt;sub&gt;1&lt;/sub&gt; receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT&lt;sub&gt;1A&lt;/sub&gt; and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT&lt;sub&gt;1A&lt;/sub&gt; and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. \n\nSide effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a complete listing of side effects). Side effects generally occur during the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Paroxetine hydrochloride and mesylate are considered therapeutic alternatives rather than generic equivalents by the US Food and Drug Administration (FDA); both agents contain the same active moiety (i.e. paroxetine), but are formulated as different salt forms. Clinical studies establishing the efficacy of paroxetine in various conditions were performed using paroxetine hydrochloride. Since both agents contain the same active moiety, the clinical efficacy of both agents is thought to be similar. Paroxetine may be used to treat major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD) and premenstrual dysphoric disorder (PMDD). Paroxetine has the most evidence supporting its use for anxiety-related disorders of the SSRIs. It has the greatest anticholinergic activity of the agents in this class and compared to other SSRIs, paroxetine may cause greater weight gain, sexual dysfunction, sedation and constipation.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00722">
  <data key="d0">Lisinopril</data>
  <data key="d1">drugbank.DB00722</data>
  <data key="d2">[drugbank.DB00722, drugbank.APRD00560]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[ACE Inhibitors and Calcium Channel Blockers, ACE Inhibitors and Diuretics, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Amino Acids, Peptides, and Proteins, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiotonic Agents, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Dipeptides, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hypotensive Agents, Lipid Modifying Agents, Oligopeptides, Peptides, Protease Inhibitors, Protective Agents]</data>
  <data key="d14">(2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid</data>
  <data key="d15">C21H31N3O5</data>
  <data key="d16">76547-98-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1</data>
  <data key="d20">NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O</data>
  <data key="d21">For the treatment of hypertension and symptomatic congestive heart failure. May be used in conjunction with thrombolytic agents, aspirin and/or &amp;beta;-blockers to improve survival in hemodynamically stable individuals following myocardial infarction. May be used to slow the progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline, [N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline, Lisinopril, Lisinopril anhydrous, Lisinoprilum]</data>
  <data key="d9">Lisinopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00721">
  <data key="d0">Procaine</data>
  <data key="d1">drugbank.DB00721</data>
  <data key="d2">[drugbank.DB00721, drugbank.APRD00650, drugbank.DB05342]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Acids, Carbocyclic, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Agents that reduce seizure threshold, Aminobenzoates, Anesthetics, Anesthetics, Local, Anticholinergic Agents, Antidepressive Agents, Benzene Derivatives, Benzoates, Central Nervous System Agents, Central Nervous System Depressants, Cholinesterase Inhibitors, Cholinesterase substrates, Esters of Aminobenzoic Acid, Monoamine Oxidase Inhibitors, Nervous System, Nicotinic Antagonists, NMDA Receptor Antagonists, Ophthalmologicals, para-Aminobenzoates, Peripheral Nervous System Agents, Procaine, Sensory Organs, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Vasoprotectives]</data>
  <data key="d14">2-(diethylamino)ethyl 4-aminobenzoate</data>
  <data key="d15">C13H20N2O2</data>
  <data key="d16">59-46-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H20N2O2/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3</data>
  <data key="d20">CCN(CC)CCOC(=O)C1=CC=C(N)C=C1</data>
  <data key="d21">Used as a local anesthetic primarily in oral surgery</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-Diethylaminoethyl p-aminobenzoate, 4-aminobenzoic acid 2-diethylaminoethyl ester, Novocaine, p-Aminobenzoic acid 2-diethylaminoethyl ester, Procaina, Procaine, Procainum, Vitamin H3, -(diethylamino)ethyl 4-aminobenzoate, -(diethylamino)ethyl p-aminobenzoate]</data>
  <data key="d9">A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). Procaine has also been investigated as an oral entry inhibitor in treatment-experienced HIV patients [L1215].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11095">
  <data key="d0">Desirudin</data>
  <data key="d1">drugbank.DB11095</data>
  <data key="d2">[drugbank.DB11095]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Anticoagulants, Antithrombin Proteins, Antithrombins, Blood and Blood Forming Organs, Cardiovascular Agents, Fibrin Modulating Agents, Hematologic Agents, Peptides, Proteins, Serpins, Thrombin Inhibitors]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">120993-53-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Indicated as prophylaxis of deep vein thrombosis for patients undergoing hip replacement surgery.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[63-Desulfohirudin, 63-Desulfohirudin (Hirudo Medicinalis Isoform HV1), 63-Desulfohirudin (recombinant), Desirudin recombinant, Desirudina, Hirudin desirudin]</data>
  <data key="d9">Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three disulfide bridges. Desirudin has a chemical formula of C287H440N80O110S6 with a molecular weight of 6963.52.\n\nIt is mainly indicated for the prevention of deep vein thrombosis in hip replacement surgery patients. \nCommon side effects include: Bleeding gums, collection of blood under the skin, coughing up blood, deep, dark purple bruise and difficulty with breathing or swallowing.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11093">
  <data key="d0">Calcium Citrate</data>
  <data key="d1">drugbank.DB11093</data>
  <data key="d2">[drugbank.DB11093]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Acyclic, Alimentary Tract and Metabolism, Blood Coagulation Factors, Calcium Compounds, Calcium Salts, Citrates, Citric Acid, Compounds used in a research, industrial, or household setting, Diet, Food, and Nutrition, Food, Food Additives, Food and Beverages, Mineral Supplements, Phosphate Binder, Physiological Phenomena, Polyvalent cation containing laxatives, antacids, oral supplements, Tricarboxylic Acids]</data>
  <data key="d14">tricalcium bis(2-hydroxypropane-1,2,3-tricarboxylate)</data>
  <data key="d15">C12H10Ca3O14</data>
  <data key="d16">813-94-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/2C6H8O7.3Ca/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;;3*+2/p-6</data>
  <data key="d20">[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O</data>
  <data key="d21">For use as an over the counter calcium supplement.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[tricalcium citrate]</data>
  <data key="d9">Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13694">
  <data key="d0">Distigmine</data>
  <data key="d1">drugbank.DB13694</data>
  <data key="d2">[drugbank.DB13694]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Cholinergic Agents, Cholinesterase Inhibitors, Enzyme Inhibitors, Nervous System, Neurotransmitter Agents, Parasympathomimetics, Pyridines]</data>
  <data key="d14">1-methyl-3-{[methyl({6-[methyl({[(1-methylpyridin-1-ium-3-yl)oxy]carbonyl})amino]hexyl})carbamoyl]oxy}pyridin-1-ium</data>
  <data key="d15">C22H32N4O4</data>
  <data key="d16">17299-00-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H32N4O4/c1-23-13-9-11-19(17-23)29-21(27)25(3)15-7-5-6-8-16-26(4)22(28)30-20-12-10-14-24(2)18-20/h9-14,17-18H,5-8,15-16H2,1-4H3/q+2</data>
  <data key="d20">CN(CCCCCCN(C)C(=O)OC1=C[N+](C)=CC=C1)C(=O)OC1=C[N+](C)=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Distigmine is a parasympathomimetic agent with a longer duration of action and enhanced drug accumulation compared to [DB00545] and [DB01400]. It is an anticholinergic drug and long-acting reversible carbamate cholinesterase inhibitor that binds directly and competitively to the agonist binding sites of muscurinic receptors. Distigmine is available in several countries as a treatment of underactive detrusor and voiding dysfunction in the urinary tract where the active ingredient is distigmine bromide. It improves detrusor function thereby restoring normal voiding patterns in patients suffering from detrusor underactivity [A27176].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00376">
  <data key="d0">Trihexyphenidyl</data>
  <data key="d1">drugbank.DB00376</data>
  <data key="d2">[drugbank.DB00376, drugbank.APRD00070]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents producing tachycardia, Anti-Dyskinesia Agents, Anti-Parkinson Drugs, Anticholinergic Agents, Central Nervous System Agents, Cholinergic Agents, Muscarinic Antagonists, Nervous System, Neurotransmitter Agents, Piperidines, Tertiary Amines]</data>
  <data key="d14">1-cyclohexyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol</data>
  <data key="d15">C20H31NO</data>
  <data key="d16">144-11-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H31NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1,4-5,10-11,19,22H,2-3,6-9,12-17H2</data>
  <data key="d20">OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1</data>
  <data key="d21">Indicated for the treatment of parkinson's disease and extrapyramidal reactions caused by drugs.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Trihexifenidilo, Trihexyphenidyl, Trihexyphnidyle, Trihexyphenidylum]</data>
  <data key="d9">One of the centrally acting muscarinic antagonists used for treatment of parkinsonian disorders and drug-induced extrapyramidal movement disorders and as an antispasmodic.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00384">
  <data key="d0">Triamterene</data>
  <data key="d1">drugbank.DB00384</data>
  <data key="d2">[drugbank.DB00384, drugbank.APRD00079]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents causing hyperkalemia, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Substrates, Decreased Renal K+ Excretion, Diuretics, Diuretics, Potassium Sparing, Epithelial Sodium Channel Blockers, Hypotensive Agents, Increased Diuresis, Membrane Transport Modulators, Natriuretic Agents, Nephrotoxic agents, Potassium-Sparing Agents, Potassium-Sparing Diuretics, Pteridines, Sodium Channel Blockers]</data>
  <data key="d14">6-phenylpteridine-2,4,7-triamine</data>
  <data key="d15">C12H11N7</data>
  <data key="d16">396-01-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)</data>
  <data key="d20">NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1</data>
  <data key="d21">Triamterene is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism.[Label]\n\nTriamterene in combination with hydrochlorothiazide is indicated for the managment of hypertension or treatment of edema in patients who develop hypokalemia following hydrochlorothiazide monotherapy, and in patients who require thiazide diuretic and in whom the development of hypokalemia cannot be risked.[L6169] Triamterene allows the maintenance of potassium balance when given in combination with loop diuretics and thiazides.[T28]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[6-phenylpteridine-2, 4, 7-triamine, Teridin, Triamteren, Triamterena, Triamtrne, Triamterene, Triamtereno, Triamterenum]</data>
  <data key="d9">Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side.[A177985] Since it acts on the distal nephron where only a small fraction of sodium ion reabsorption occurs, triamterene is reported to have limited diuretic efficacy.[T28] Due to its effects on increased serum potassium levels, triamterene is associated with a risk of producing hyperkalemia. Triamterene is a weak antagonist of folic acid, and a photosensitizing drug.[L6163] \n\nTriamterene was approved by the Food and Drug Administration in the U.S. in 1964.[L6163] Currently, triamterene is used in the treatment of edema associated with various conditions as monotherapy and is approved for use with other diuretics to enhance diuretic and potassium-sparing effects.[label] It is also found in a combination product with hydrochlorothiazide that is used for the management of hypertension or treatment of edema in patients who develop hypokalemia on hydrochlorothiazide alone.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00382">
  <data key="d0">Tacrine</data>
  <data key="d1">drugbank.DB00382</data>
  <data key="d2">[drugbank.DB00382, drugbank.APRD00690]</data>
  <data key="d12">[approved, investigational, withdrawn]</data>
  <data key="d13">[Acridines, Agents Causing Muscle Toxicity, Aminoacridines, Anti-Dementia Drugs, Autonomic Agents, Central Nervous System Agents, Cholinergic Agents, Cholinesterase Inhibitors, Cytochrome P-450 CYP1A2 Substrates, Enzyme Inhibitors, Nervous System, Neurotransmitter Agents, Nootropic Agents, P-glycoprotein/ABCB1 Substrates, Parasympathomimetics, Peripheral Nervous System Agents, Psychoanaleptics]</data>
  <data key="d14">1,2,3,4-tetrahydroacridin-9-amine</data>
  <data key="d15">C13H14N2</data>
  <data key="d16">321-64-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)</data>
  <data key="d20">NC1=C2CCCCC2=NC2=CC=CC=C12</data>
  <data key="d21">For the palliative treatment of mild to moderate dementia of the Alzheimer's type.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1, 2, 3, 4-tetrahydro-9-acridinamine, 1, 2, 3, 4-tetrahydro-9-aminoacridine, 1, 2, 3, 4-tetrahydroacridin-9-amine, 5-amino-6, 7, 8, 9-tetrahydroacridine, 9-amino-1, 2, 3, 4-tetrahydroacridine, Tacrin, Tacrine, Tacrinum, Tetrahydroaminacrine, Tetrahydroaminoacridine, THA]</data>
  <data key="d9">A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00392">
  <data key="d0">Profenamine</data>
  <data key="d1">drugbank.DB00392</data>
  <data key="d2">[drugbank.DB00392, drugbank.APRD00729]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic Antagonists, Agents producing tachycardia, Anti-Parkinson Drugs, Anticholinergic Agents, Cholinergic Agents, Cholinesterase Inhibitors, Histamine Agents, Muscarinic Antagonists, Nervous System, Neurotransmitter Agents, NMDA Receptor Antagonists, Sulfur Compounds, Tertiary Amines]</data>
  <data key="d14">diethyl[1-(10H-phenothiazin-10-yl)propan-2-yl]amine</data>
  <data key="d15">C19H24N2S</data>
  <data key="d16">522-00-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H24N2S/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21/h6-13,15H,4-5,14H2,1-3H3</data>
  <data key="d20">CCN(CC)C(C)CN1C2=CC=CC=C2SC2=CC=CC=C12</data>
  <data key="d21">For use in the treatment of Parkinson's disease and also used to control severe reactions to certain medicines such as reserpine.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[10-(2-diethylaminopropyl)phenothiazine, 10-[2-(diethylamino)-1-propyl]phenothiazine, 10-[2-(diethylamino)-2-methylethyl]phenothiazine, 10-[2-(diethylamino)propyl]phenothiazine, 2-diethylamino-1-propyl-N-dibenzoparathiazine, Ethopropazine, N, N-diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine, N, N-diethyl--methyl-10H-phenothiazine-10-ethanamine, Profenamina, Profnamine, Profenamine, Profenaminum]</data>
  <data key="d9">Profenamine is a medication derived from phenothiazine. It is primarily used as an antidyskinetic to treat parkinsonism. It is sold under the trade names Parsidol in the United States and Parsidan in Canada.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00398">
  <data key="d0">Sorafenib</data>
  <data key="d1">drugbank.DB00398</data>
  <data key="d2">[drugbank.DB00398, drugbank.APRD01304, drugbank.DB07438]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Benzene Derivatives, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (moderate), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strong), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Immunosuppressive Agents, Kinase Inhibitor, Miscellaneous Therapeutic Agents, Myelosuppressive Agents, Nicotinic Acids, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Potential QTc-Prolonging Agents, Protein Kinase Inhibitors, Pyridines, QTc Prolonging Agents, raf Kinases, Receptors, Vascular Endothelial Growth Factor, Tyrosine Kinase Inhibitors, UGT1A1 Inhibitors, UGT1A9 Inhibitors, UGT1A9 Substrates, Urea]</data>
  <data key="d14">4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide</data>
  <data key="d15">C21H16ClF3N4O3</data>
  <data key="d16">284461-73-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)</data>
  <data key="d20">CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1</data>
  <data key="d21">Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide, N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea, Sorafnib, Sorafenib, Sorafenibum]</data>
  <data key="d9">Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials.\nSorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 &amp; 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00396">
  <data key="d0">Progesterone</data>
  <data key="d1">drugbank.DB00396</data>
  <data key="d2">[drugbank.DB00396, drugbank.APRD00700]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Adrenal Cortex Hormones, BCRP/ABCG2 Inducers, BCRP/ABCG2 Inhibitors, BSEP/ABCB11 Inhibitors, Corpus Luteum Hormones, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inducers, OCT1 inhibitors, OCT2 Inhibitors, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Pregnanes, Pregnenediones, Pregnenes, Progesterone, Progestin-containing Intrauterine Device, Progestins, Sex Hormones and Modulators of the Genital System, Steroids]</data>
  <data key="d14">(1S,3aS,3bS,9aR,9bS,11aS)-1-acetyl-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one</data>
  <data key="d15">C21H30O2</data>
  <data key="d16">57-83-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C</data>
  <data key="d21">**Gelatinized capsules**\n\nThe gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea [FDA label]. \n\n**Vaginal gel**\n\nProgesterone gel (8%) is indicated as progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency.  The lower concentration progesterone gel (4%) is used in the treatment of secondary amenorrhea, with the use of the 8% concentration if there is no therapeutic response to the 4% gel [F3898].\n\n**Vaginal insert**\n\nThis form is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women [F3901].\n\n**Injection (intramuscular)**\n\nThis drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer [F3907]. \n\n**Tablets, contraceptive**\n\nThe tablet form of progesterone in contraceptive formulations is indicated for the prevention of pregnancy [F3904].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(S)-4-Pregnene-3, 20-dione, (S)-Pregn-4-en-3, 20-dione, (S)-Progesterone, 17alpha-Progesterone, 17-progesterone, 4-Pregnene-3, 20-dione, Agolutin, Akrolutin, Corpus Luteum Hormone, delta(4)-Pregnene-3, 20-dione, Gelbkrperhormon, Luteohormone, Lutogynon, Pregn-4-ene-3, 20-dione, Progesteron, Progesterona, Progestrone, Progesterone, Progesteronum]</data>
  <data key="d9">Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss [A175609]. Progesterone is used in various contraceptive preparations to prevent ovulation and fertilization [T481], [A175612] as well as in other formulations to promote and support pregnancy.  Please see [Medroxyprogesterone acetate], [Megestrol acetate], [Dydrogesterone] and [Hydroxyprogesterone] entries for information on various other forms of progesterone.\n\nPharmaceutical progesterone is made from a plant source as a starting material and is chemically identical to progesterone of human ovarian origin [FDA label]. Progesterone is available in gelatinized capsule form, vaginal gel form, tablet form, vaginal insert form, and injection form, all used for various purposes [Label,F3898,F3904,F3901,F3907].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11064">
  <data key="d0">Homosalate</data>
  <data key="d1">drugbank.DB11064</data>
  <data key="d2">[drugbank.DB11064]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Carbocyclic, Benzene Derivatives, Benzoates, Hydroxy Acids, Hydroxybenzoates, Phenols, Sunscreening Agents]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">As ingredient in many sunscreen for protection against sunburn, skin aging and skin cancer.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Homosalate]</data>
  <data key="d9">Homosalate is an organic compound that belongs to salicylates. It is an ester formed from salicylic acid and 3,3,5-trimethylcyclohexanol, a derivative of cyclohexanol. Salicylates prevent direct skin exposure to the suns harmful rays by absorbing ultraviolet (UV) light. Homosalate specifically absorbs short-wave UVB rays, which are associated with DNA damage and increased risk of skin cancer. \n\nIt is a common ingredient in many commercially available sunscreens.  There are no reported adverse effects from homosalate.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB02994">
  <data key="d0">Cacodylic acid</data>
  <data key="d1">drugbank.DB02994</data>
  <data key="d2">[drugbank.DB02994, drugbank.EXPT00823]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Agrochemicals, Arsenicals, Compounds used in a research, industrial, or household setting, Herbicides, Organometallic Compounds, Pesticides, Toxic Actions]</data>
  <data key="d14">dimethylarsinic acid</data>
  <data key="d15">C2H7AsO2</data>
  <data key="d16">75-60-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C2H7AsO2/c1-3(2,4)5/h1-2H3,(H,4,5)</data>
  <data key="d20">C[As](C)(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Dimethylarsenic acid, Dimethylarsinic acid, Hydroxydimethylarsine oxide]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12340">
  <data key="d0">Navitoclax</data>
  <data key="d1">drugbank.DB12340</data>
  <data key="d2">[drugbank.DB12340, drugbank.DB05764]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Amides, Amines, Antineoplastic Agents, Sulfones, Sulfur Compounds]</data>
  <data key="d14">4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-(4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-trifluoromethanesulfonylbenzenesulfonyl)benzamide</data>
  <data key="d15">C47H55ClF3N5O6S3</data>
  <data key="d16">923564-51-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1</data>
  <data key="d20">[H][C@@](CCN1CCOCC1)(CSC1=CC=CC=C1)NC1=C(C=C(C=C1)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC2=C(CCC(C)(C)C2)C2=CC=C(Cl)C=C2)CC1)S(=O)(=O)C(F)(F)F</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Navitoclax has been used in trials studying the treatment and basic science of Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies, among others.\n\nNavitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins. It is a substance being studied in the treatment of lymphomas and other types of cancer. It blocks some of the enzymes that keep cancer cells from dying.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00356">
  <data key="d0">Chlorzoxazone</data>
  <data key="d1">drugbank.DB00356</data>
  <data key="d2">[drugbank.DB00356, drugbank.APRD00308]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Benzoxazoles, Central Nervous System Agents, Central Nervous System Depressants, Centrally-mediated Muscle Relaxation, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Musculo-Skeletal System, Oxazol, Thiazine, and Triazine Derivatives, Peripheral Nervous System Agents]</data>
  <data key="d14">5-chloro-2,3-dihydro-1,3-benzoxazol-2-one</data>
  <data key="d15">C7H4ClNO2</data>
  <data key="d16">95-25-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)</data>
  <data key="d20">ClC1=CC2=C(OC(=O)N2)C=C1</data>
  <data key="d21">For the relief of discomfort associated with acute painful musculoskeletal conditions.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-hydroxy-5-chlorobenzoxazole, 5-chloro-2-benzoxazolinone, 5-chloro-2-benzoxazolol, 5-chloro-2-benzoxazolone, 5-chloro-2-hydroxybenzoxazole, 5-chloro-2(3H)-benzoxazolone, 5-chloro-3H-benzooxazol-2-one, 5-chlorobenzoxazolidone, 5-chlorobenzoxazolin-2-one, Chlorzoxane, Chlorzoxazon, Chlorzoxazona, Chlorzoxazone, Chlorzoxazonum, Clorzoxazona, Clorzoxazone]</data>
  <data key="d9">A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01686">
  <data key="d0">N,N-dimethylarginine</data>
  <data key="d1">drugbank.DB01686</data>
  <data key="d2">[drugbank.DB01686, drugbank.EXPT01101]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Amino Acids, Amino Acids, Basic, Amino Acids, Diamino, Amino Acids, Essential, Amino Acids, Peptides, and Proteins, Enzyme Inhibitors, Nitric Oxide Synthase, antagonists &amp; inhibitors]</data>
  <data key="d14">(2S)-2-amino-5-[(E)-[amino(dimethylamino)methylidene]amino]pentanoic acid</data>
  <data key="d15">C8H18N4O2</data>
  <data key="d16">30315-93-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C8H18N4O2/c1-12(2)8(10)11-5-3-4-6(9)7(13)14/h6H,3-5,9H2,1-2H3,(H2,10,11)(H,13,14)/t6-/m0/s1</data>
  <data key="d20">N[C@@H](CCC\N=C(/N)N(C)C)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[ADMA, Asymmetric dimethylarginine, dimethyl-L-arginine, guanidino-N, N-dimethylarginine, L-NG, NG-dimethylarginine, N(5)-((Dimethylamino)iminomethyl)-L-ornithine, N(G)-Dimethylarginine, N(G), N(G)-Dimethylarginine, N(G1), N(G1)-Dimethylarginine, NG, NG-Dimethyl-L-arginine]</data>
  <data key="d9">Asymmetric dimethylarginine (ADMA) is a naturally occurring chemical found in blood plasma. It is a metabolic by-product of continual protein modification processes in the cytoplasm of all human cells which is closely related to L-arginine, a conditionally-essential amino acid. ADMA interferes with L-arginine in the production of nitric oxide, a key chemical to endothelial and hence cardiovascular health.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00353">
  <data key="d0">Methylergometrine</data>
  <data key="d1">drugbank.DB00353</data>
  <data key="d2">[drugbank.DB00353, drugbank.APRD00739]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents that produce hypertension, Alkaloids, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dopamine Antagonists, Ergolines, Ergonovine, Ergot Alkaloids and Derivatives, Genito Urinary System and Sex Hormones, Reproductive Control Agents, Uterotonic agents]</data>
  <data key="d14">(4R,7R)-N-[(2S)-1-hydroxybutan-2-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0,.0,]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide</data>
  <data key="d15">C20H25N3O2</data>
  <data key="d16">113-42-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H25N3O2/c1-3-14(11-24)22-20(25)13-7-16-15-5-4-6-17-19(15)12(9-21-17)8-18(16)23(2)10-13/h4-7,9,13-14,18,21,24H,3,8,10-11H2,1-2H3,(H,22,25)/t13-,14+,18-/m1/s1</data>
  <data key="d20">[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO</data>
  <data key="d21">For the prevention and control of excessive bleeding following vaginal childbirth</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[9, 10-Didehydro-N-[1-(hydroxymethyl)-propyl]-D-lysergamide, D-lysergic acid 1-butanolamide, Ergotyl, Methylergobasin, Methylergometrin, Mthylergomtrine, Methylergometrine, Methylergometrinum, Methylergonovine, Metilergometrina, Metilergometrinio]</data>
  <data key="d9">A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00360">
  <data key="d0">Sapropterin</data>
  <data key="d1">drugbank.DB00360</data>
  <data key="d2">[drugbank.DB00360, drugbank.APRD01297, drugbank.EXPT00691, drugbank.DB02692]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Amines, Biological Factors, Breast Cancer Resistance Protein Inhibitors, Coenzymes, Dietary Supplements, Enzymes and Coenzymes, Ethylamines, Nitric Oxide, Nitric Oxide Synthase, Other Miscellaneous Therapeutic Agents, P-glycoprotein/ABCB1 Inhibitors, Phenethylamines, Phenylalanine Hydroxylase Activator, Phenylalanine Hydroxylase Activators, Pigments, Biological, Pteridines, Pterins, Supplements, Various Alimentary Tract and Metabolism Products]</data>
  <data key="d14">(6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-3,4,5,6,7,8-hexahydropteridin-4-one</data>
  <data key="d15">C9H15N5O3</data>
  <data key="d16">62989-33-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,4+,6-/m0/s1</data>
  <data key="d20">[H][C@@]1(CNC2=C(N1)C(=O)NC(N)=N2)[C@@H](O)[C@H](C)O</data>
  <data key="d21">For the treatment of tetrahydrobiopterin (BH4) deficiency.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-(6R)-2-amino-6-((1R, 2S)-1, 2-dihydroxypropyl)-5, 6, 7, 8-tetrahydro-4(3H)-pteridinone, (6R)-L-erythro-5, 6, 7, 8-tetrahydrobiopterin, (6R)-L-erythro-tetrahydrobiopterin, 2-Amino-6-(1, 2-dihydroxypropyl)-5, 6, 7, 8-tetrahydoro-4(1H)-pteridinone, 5, 6, 7, 8-Tetrahydrobiopterin, 6R-5, 6, 7, 8-tetrahydrobiopterin, 6R-BH4, 6R-L-5, 6, 7, 8-tetrahydrobiopterin, R-THBP, Sapropterin, Sapropterina, sapropterinum, Tetrahydrobiopterin]</data>
  <data key="d9">Sapropterin (tetrahydrobiopterin or BH4) is a cofactor in the synthesis of nitric oxide. It is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa by the enzyme tyrosine hydroxylase; and conversion of tryptophan to 5-hydroxytryptophan via tryptophan hydroxylase.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00367">
  <data key="d0">Levonorgestrel</data>
  <data key="d1">drugbank.DB00367</data>
  <data key="d2">[drugbank.DB00367, drugbank.APRD00754, drugbank.DB00506, drugbank.APRD00106]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Adrenal Cortex Hormones, Combination Contraceptives (with Estrogen and derivatives), Contraceptive Agents, Female, Contraceptives, Oral, Contraceptives, Oral, Synthetic, Contraceptives, Postcoital, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Hyperglycemia-Associated Agents, Inhibit Ovum Fertilization, Norgestrel, Norpregnanes, Norpregnenes, Norsteroids, Progestin Contraceptives, Progestin-containing Intrauterine Device, Progestins, Progestogens and Estrogens, Sequential Preparations, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids]</data>
  <data key="d14">(1S,2R,10R,11S,14R,15S)-15-ethyl-14-ethynyl-14-hydroxytetracyclo[8.7.0.0,.0,]heptadec-6-en-5-one</data>
  <data key="d15">C21H28O2</data>
  <data key="d16">797-63-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]</data>
  <data key="d21">For the treatment of menopausal and postmenopausal disorders and alone or in combination with other hormones as an oral contraceptive.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(-)-13-Ethyl-17-hydroxy-18, 19-dinor-17alpha-pregn-4-en-20-yn-3-one, (8R, 9S, 10R, 13S, 14S, 17R)-13-ethyl-17-ethynyl-17-hydroxy- 1, 2, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17- tetradecahydrocyclopenta[a] phenanthren-3-one, 13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one, 13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one, 13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one, 17-alpha-Ethinyl-13-beta-ethyl-17-beta-hydroxy-4-estren-3-one, 17-alpha-Ethynyl-13-ethyl-19-nortestosterone, 17-Ethynyl-18-methyl-19-nortestosterone, 17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol, 17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one, 17alpha-Ethynyl-18-homo-19-nortestosterone, 18-Methyl-17-alpha-ethynyl-19-nortestosterone, 18-Methylnorethisterone, d(-)-Norgestrel, Lvonorgestrel, Levonorgestrel, Levonorgestrelum]</data>
  <data key="d9">A synthetic progestational hormone with actions similar to those of progesterone and about twice as potent as its racemic or (+-)-isomer (norgestrel). It is used for contraception, control of menstrual disorders, and treatment of endometriosis. It is usually supplied in a racemic mixture (Norgestrel, 6533-00-2). Only the levonorgestrel isomer is active. Levonorgestrel is marketed mostly as a combination oral contraceptive under several brand names such as Alesse, Triphasil, and Min-Ovral.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01698">
  <data key="d0">Rutin</data>
  <data key="d1">drugbank.DB01698</data>
  <data key="d2">[drugbank.DB01698, drugbank.EXPT02824]</data>
  <data key="d12">[approved, experimental, investigational]</data>
  <data key="d13">[Benzopyrans, Capillary Stabilizing Agents, Chromones, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Flavonoids, Flavonols, Pyrans, Vasoprotectives]</data>
  <data key="d14">2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-({[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-4H-chromen-4-one</data>
  <data key="d15">C27H30O16</data>
  <data key="d16">153-18-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C27H30O16/c1-8-17(32)20(35)22(37)26(40-8)39-7-15-18(33)21(36)23(38)27(42-15)43-25-19(34)16-13(31)5-10(28)6-14(16)41-24(25)9-2-3-11(29)12(30)4-9/h2-6,8,15,17-18,20-23,26-33,35-38H,7H2,1H3/t8-,15+,17-,18+,20+,21-,22+,23+,26+,27-/m0/s1</data>
  <data key="d20">C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3-[[6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-2-(3, 4-dihydroxyphenyl)-5, 7-dihydroxy-4H-1-benzopyran-4-one, 3-Rhamnoglucosylquercetin, 3-Rutinosyl quercetin, Phytomelin, Quercetin 3-rutinoside, Quercetin-3-rutinoside, Rutin, Rutoside, Rutosido, Rutosidum, Sophorin, Vitamin P]</data>
  <data key="d9">A flavonol glycoside found in many plants, including buckwheat; tobacco; forsythia; hydrangea; viola, etc. It has been used therapeutically to decrease capillary fragility.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01695">
  <data key="d0">N-Hydroxy-4-Phosphono-Butanamide</data>
  <data key="d1">drugbank.DB01695</data>
  <data key="d2">[drugbank.DB01695, drugbank.EXPT00226]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">[3-(hydroxycarbamoyl)propyl]phosphonate</data>
  <data key="d15">C4H8NO5P</data>
  <data key="d16">146086-80-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C4H10NO5P/c6-4(5-7)2-1-3-11(8,9)10/h7H,1-3H2,(H,5,6)(H2,8,9,10)/p-2</data>
  <data key="d20">ONC(=O)CCCP([O-])([O-])=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00418">
  <data key="d0">Secobarbital</data>
  <data key="d1">drugbank.DB00418</data>
  <data key="d2">[drugbank.DB00418, drugbank.APRD00497]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Adjuvants, Adjuvants, Anesthesia, Anticholinergic Agents, Anticonvulsants, Barbiturates, Barbiturates, Plain, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (unknown strength), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (unknown strength), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strong), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Modulators, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones]</data>
  <data key="d14">5-(pentan-2-yl)-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione</data>
  <data key="d15">C12H18N2O3</data>
  <data key="d16">76-73-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H18N2O3/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)</data>
  <data key="d20">CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O</data>
  <data key="d21">For the Short-term treatment of intractable insomnia for patients habituated to barbiturates</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-secobarbital, 5-(1-methylbutyl)-5-(2-propenyl)-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione, 5-allyl-5-(1-methylbutyl)-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione, 5-allyl-5-(1-methylbutyl)barbituric acid, 5-allyl-5-(1-methylbutyl)pyrimidine-2, 4, 6(1H, 3H, 5H)-trione, Quinalbarbitone, Secobarbital, Secobarbitalum, Secobarbitone]</data>
  <data key="d9">Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00412">
  <data key="d0">Rosiglitazone</data>
  <data key="d1">drugbank.DB00412</data>
  <data key="d2">[drugbank.DB00412, drugbank.APRD00403]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Blood Glucose Lowering Agents, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Drugs Used in Diabetes, Hypoglycemia-Associated Agents, OATP1B1/SLCO1B1 Inhibitors, Oral Hypoglycemics, Peroxisome Proliferator Receptor gamma Agonist, Peroxisome Proliferator-activated Receptor Activity, PPAR gamma, Sulfur Compounds, Thiazoles, Thiazolidinediones, Vasodilating Agents]</data>
  <data key="d14">5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione</data>
  <data key="d15">C18H19N3O3S</data>
  <data key="d16">122320-73-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)</data>
  <data key="d20">CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1</data>
  <data key="d21">Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2, 4-thiazolidinedione, (RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2, 4-thiazolidinedion, Rosiglitazon, Rosiglitazona, Rosiglitazone, Rosiglitazonum]</data>
  <data key="d9">Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPAR. Rosiglitazone is a selective ligand of PPAR, and has no PPAR-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFB) levels fall and inhibitor (IB) levels increase in patients on rosiglitazone. Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. This is the subject of a clinical trial currently underway.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00411">
  <data key="d0">Carbamoylcholine</data>
  <data key="d1">drugbank.DB00411</data>
  <data key="d2">[drugbank.DB00411, drugbank.APRD00845, drugbank.DB02487]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Alcohols, Amines, Amino Alcohols, Ammonium Compounds, Analgesics, Analgesics, Non-Narcotic, Antiglaucoma Preparations and Miotics, Autonomic Agents, Cardiotonic Agents, Cardiovascular Agents, Central Nervous System Agents, Choline, Choline Esters, Cholinergic Agents, Cholinergic Agonists, Cholinergic Receptor Agonist, Compounds used in a research, industrial, or household setting, Ethanolamines, Miotics, Nervous System, Neurotransmitter Agents, Nitrogen Compounds, Onium Compounds, Ophthalmologicals, Parasympathomemetic (Cholinergic) Agents, Parasympathomimetics, Peripheral Nervous System Agents, Protective Agents, Quaternary Ammonium Compounds, Sensory Organs, Sensory System Agents, Trimethyl Ammonium Compounds]</data>
  <data key="d14">2-(trimethylazaniumyl)ethyl carbamate</data>
  <data key="d15">C6H15N2O2</data>
  <data key="d16">462-58-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C6H14N2O2/c1-8(2,3)4-5-10-6(7)9/h4-5H2,1-3H3,(H-,7,9)/p+1</data>
  <data key="d20">C[N+](C)(C)CCOC(N)=O</data>
  <data key="d21">Primarily used in the treatment of glaucoma, but is also used during ophthalmic surgery.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Carbacholine, carbacol, Carbamylcholine, Choline carbamate]</data>
  <data key="d9">A slowly hydrolyzed cholinergic agonist that acts at both muscarinic and nicotinic receptors.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00420">
  <data key="d0">Promazine</data>
  <data key="d1">drugbank.DB00420</data>
  <data key="d2">[drugbank.DB00420, drugbank.APRD00358]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents producing tachycardia, Agents that produce hypertension, Amino Acids, Amino Acids, Branched-Chain, Amino Acids, Essential, Amino Acids, Peptides, and Proteins, Anticholinergic Agents, Antidepressive Agents, Antiemetics, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Autonomic Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Gastrointestinal Agents, Histamine Antagonists, Histamine H1 Antagonists, Moderate Risk QTc-Prolonging Agents, Muscarinic Antagonists, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Phenothiazines, Phenothiazines With Aliphatic Side-Chain, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Sulfur Compounds, Tranquilizing Agents]</data>
  <data key="d14">dimethyl[3-(10H-phenothiazin-10-yl)propyl]amine</data>
  <data key="d15">C17H20N2S</data>
  <data key="d16">58-40-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3</data>
  <data key="d20">CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12</data>
  <data key="d21">Used as an adjunct for short term treatment of moderate and severe psychomotor agitation. Also used to treat agitation or restlessness in the elderly.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[10-(3-(Dimethylamino)propyl)phenothiazine, N-(3-Dimethylaminopropyl)phenothiazine, N-Dimethylamino-1-methylethyl thiodiphenylamine, N, N-dimethyl-3-(10H-phenothiazin-10-yl)-propan-1-amine, Promazin, Promazina, Promazine, Promazinum]</data>
  <data key="d9">A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01767">
  <data key="d0">Hemi-Babim</data>
  <data key="d1">drugbank.DB01767</data>
  <data key="d2">[drugbank.DB01767, drugbank.EXPT00622]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-(1H-1,3-benzodiazol-2-ylmethyl)-1H-1,3-benzodiazole-5-carboximidamide</data>
  <data key="d15">C16H14N6</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H14N6/c17-16(18)9-5-6-12-13(7-9)22-15(21-12)8-14-19-10-3-1-2-4-11(10)20-14/h1-7H,8H2,(H3,17,18)(H,19,20)(H,21,22)</data>
  <data key="d20">NC(=N)C1=CC2=C(NC(CC3=NC4=C(N3)C=CC=C4)=N2)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01766">
  <data key="d0">Beta-(2-Naphthyl)-Alanine</data>
  <data key="d1">drugbank.DB01766</data>
  <data key="d2">[drugbank.DB01766, drugbank.EXPT02291]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-2-amino-3-(naphthalen-2-yl)propanoic acid</data>
  <data key="d15">C13H13NO2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H13NO2/c14-12(13(15)16)8-9-5-6-10-3-1-2-4-11(10)7-9/h1-7,12H,8,14H2,(H,15,16)/t12-/m0/s1</data>
  <data key="d20">[H][C@](N)(CC1=CC=C2C=CC=CC2=C1)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00434">
  <data key="d0">Cyproheptadine</data>
  <data key="d1">drugbank.DB00434</data>
  <data key="d2">[drugbank.DB00434, drugbank.APRD00033]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents producing tachycardia, Agents that reduce seizure threshold, Anti-Allergic Agents, Anticholinergic Agents, Antidepressive Agents, Antihistamines for Systemic Use, Antipruritics, Benzocycloheptenes, Central Nervous System Depressants, Dermatologicals, Dibenzocycloheptenes, Gastrointestinal Agents, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Miscellaneous Derivatives, Muscarinic Antagonists, Neurotransmitter Agents, Piperidines, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Serotonin 5-HT2 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, UGT1A3 substrates]</data>
  <data key="d14">1-methyl-4-{tricyclo[9.4.0.0,]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-ylidene}piperidine</data>
  <data key="d15">C21H21N</data>
  <data key="d16">129-03-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3</data>
  <data key="d20">CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=CC=CC=C12</data>
  <data key="d21">For treatment of perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, amelioration of allergic reactions to blood or plasma, cold urticaria, dermatographism, and as therapy for anaphylactic reactions adjunctive to epinephrine.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-methyl-4-(5-dibenzo(a, e)cycloheptatrienylidene)piperidine, 1-Methyl-4-(5H-dibenzo(a, d)cycloheptenylidene)piperidine, 4-(5-dibenzo(a, d)cyclohepten-5-ylidine)-1-methylpiperidine, 4-(5H-dibenzo(a, d)cyclohepten-5-ylidene)-1-methylpiperidine, 4-Dibenzo[a, d]cyclohepten-5-ylidene-1-methyl-piperidine, 5-(1-methylpiperidylidene-4)-5H-dibenzo(a, d)cyclopheptene, Ciproheptadina, Cyproheptadin, Cyproheptadine, Cyproheptadinum]</data>
  <data key="d9">A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00433">
  <data key="d0">Prochlorperazine</data>
  <data key="d1">drugbank.DB00433</data>
  <data key="d2">[drugbank.DB00433, drugbank.APRD00624]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Antiemetics, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Autonomic Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Gastrointestinal Agents, Moderate Risk QTc-Prolonging Agents, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Phenothiazines, Phenothiazines With Piperazine Structure, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Schizophrenia, Sulfur Compounds, Tranquilizing Agents]</data>
  <data key="d14">2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine</data>
  <data key="d15">C20H24ClN3S</data>
  <data key="d16">58-38-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3</data>
  <data key="d20">CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1</data>
  <data key="d21">Indicated for the symptomatic treatment of severe nausea and vomiting.[label]\n\nIndicated for the management of manifestations of psychotic disorders, such as schizophrenia and generalized non-psychotic anxiety. The use of prochlorperazine for the management of generalized non-psychotic anxiety is typically not a first-line therapy and should be limited to doses of less than 20 mg per day or for shorter than 12 weeks.[label,L6634]\n\nOff-label uses include use in emergency settings for adult and pediatric migraines. The American Headache Society recommends the use of prochlorperazine as the first-line medication in this setting. In pediatric migraines, a non-steroidal anti-inflammatory agent is often used in combination with dopamine antagonist.[L6637]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine, 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine, 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine, 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine, Capazine, Chlormeprazine, Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine, Chloropernazine, N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine, Prochlorperazin, Prochlorprazine, Prochlorperazine, Prochlorperazinum, Prochlorpermazine, Prochlorpromazine, Procloperazine, Proclorperazina]</data>
  <data key="d9">Prochlorperazine, also known as compazine, is a piperazine phenothiazine and first-generation antipsychotic drug that is used for the treatment of severe nausea and vomiting, as well as short-term management of psychotic disorders such as generalized non-psychotic anxiety and schizophrenia.[label] It mainly works by depressing the chemoreceptor trigger zone and blocking D2 dopamine receptors in the brain. It was shown to also block histaminergic, cholinergic and noradrenergic receptors.[L6637] Prochlorperazine was first developed in the 1950s [L6643] and was first approved by the FDA in 1956. Although newer antiemetic agents such as 5-HT3 antagonists are more heavily promoted, prochlorperazine is still widely used in nausea and vomiting.[L6640]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00431">
  <data key="d0">Lindane</data>
  <data key="d1">drugbank.DB00431</data>
  <data key="d2">[drugbank.DB00431, drugbank.APRD01072]</data>
  <data key="d12">[approved, withdrawn]</data>
  <data key="d13">[Agents that reduce seizure threshold, Agrochemicals, Antiparasitic Products, Insecticides and Repellents, Chlorine Containing Products, Compounds used in a research, industrial, or household setting, Ectoparasiticides, Incl. Scabicides, Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents, Hydrocarbons, Chlorinated, Hydrocarbons, Halogenated, Insecticides, Pesticides, Toxic Actions]</data>
  <data key="d14">(1R,2S,3r,4R,5S,6r)-1,2,3,4,5,6-hexachlorocyclohexane</data>
  <data key="d15">C6H6Cl6</data>
  <data key="d16">58-89-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C6H6Cl6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-6H/t1-,2-,3-,4+,5+,6+</data>
  <data key="d20">Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl</data>
  <data key="d21">For the treatment of patients infested with Sarcoptes scabiei or pediculosis capitis who have either failed to respond to adequate doses, or are intolerant of other approved therapies.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(1r, 2c, 3t, 4c, 5c, 6t)-1, 2, 3, 4, 5, 6-hexachlorocyclohexane, (1, 2, 3, 4, 5, 6)-1, 2, 3, 4, 5, 6-hexachlorocyclohexane, 1, 2, 3, 4, 5, 6-hexachlorocyclohexane, Benzene hexachloride, gamma-1, 2, 3, 4, 5, 6-hexachlorocyclohexane, gamma-benzene hexachloride, gamma-BHC, gamma-HCH, gamma-Hexachlorocyclohexane, gamma-Lindane, Gammallin, Gammaxene, Lindan, Lindane, Lindano, Lindanum, -hexachlorocyclohexane, -Hexachlorzyklohexan, -lindane]</data>
  <data key="d9">An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical treatment of pediculosis capitis (head lice), pediculosis pubis (pubic lice), or scabies in patients greater than two years of age who cannot tolerate or have failed first-line treatment. Lindane is still allowed for pharmaceutical use until 2015.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00449">
  <data key="d0">Dipivefrin</data>
  <data key="d1">drugbank.DB00449</data>
  <data key="d2">[drugbank.DB00449, drugbank.APRD00930]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic beta-1 Receptor Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-3 Receptor Agonists, Adrenergic beta-Agonists, Alcohols, Amines, Amino Alcohols, Antiglaucoma Preparations and Miotics, Biogenic Amines, Biogenic Monoamines, Catecholamines, Cholinesterase substrates, Ethanolamines, Mydriatics, Neurotransmitter Agents, Ophthalmics, Ophthalmologicals, Sensory Organs, Sympathomimetics in Glaucoma Therapy]</data>
  <data key="d14">2-[(2,2-dimethylpropanoyl)oxy]-5-[1-hydroxy-2-(methylamino)ethyl]phenyl 2,2-dimethylpropanoate</data>
  <data key="d15">C19H29NO5</data>
  <data key="d16">52365-63-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H29NO5/c1-18(2,3)16(22)24-14-9-8-12(13(21)11-20-7)10-15(14)25-17(23)19(4,5)6/h8-10,13,20-21H,11H2,1-7H3</data>
  <data key="d20">CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1</data>
  <data key="d21">Dipivefrin is a prodrug which is used as initial therapy for the control of intraocular pressure in chronic open-angle glaucoma.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate, 1-(3', 4'-dipivaloyloxyphenyl)-2-methylamino-1-ethanol, 4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate, Dipivalyl epinephrine, Dipivefrin, Dipivefrina, Dipivefrine, Dipivfrine, Dipivefrinum]</data>
  <data key="d9">Dipivefrin is a prodrug of adrenaline, which is used to treat glaucoma. It is available as ophthalmic solution (eye drops).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00448">
  <data key="d0">Lansoprazole</data>
  <data key="d1">drugbank.DB00448</data>
  <data key="d2">[drugbank.DB00448, drugbank.APRD00077]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acid Reducers, Alimentary Tract and Metabolism, Anti-Ulcer Agents, BCRP/ABCG2 Inhibitors, Benzimidazoles, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Gastric Acid Lowering Agents, Gastrointestinal Agents, Inhibition Gastric Acid Secretion, OAT3/SLC22A8 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Proton Pump Inhibitors, Proton-pump Inhibitors, Pyridines, Sulfoxides, Sulfur Compounds]</data>
  <data key="d14">2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole</data>
  <data key="d15">C16H14F3N3O2S</data>
  <data key="d16">103577-45-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)</data>
  <data key="d20">CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1</data>
  <data key="d21">Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. [A4892][A177065][FDA Label]  It may be used in the maintenance and healing of several gastric conditions including duodenal ulcers, NSAID related gastric ulcers, and erosive esophagitis.[FDA Label] Lansoprazole prevents recurrence of gastric ulcers in patients who have a documented history of gastric ulcers who also use NSAIDs chronically. [FDA Label]  Predictably, it is also useful in the management of hypersecretory conditions including Zollinger-Ellison syndrome. [FDA Label]  Lansoprazole is effective at eradicating H. pylori when used in conjunction with amoxicillin and clarithromycin (triple therapy) or with amoxicillin alone (dual therapy). [FDA Label]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Lansoprazol, Lansoprazole, Lansoprazolum]</data>
  <data key="d9">Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole.[A177065] It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion.[A177053]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01776">
  <data key="d0">M-Cresol</data>
  <data key="d1">drugbank.DB01776</data>
  <data key="d2">[drugbank.DB01776, drugbank.EXPT01026]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Benzene Derivatives, Phenols]</data>
  <data key="d14">3-methylphenol</data>
  <data key="d15">C7H8O</data>
  <data key="d16">108-39-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H8O/c1-6-3-2-4-7(8)5-6/h2-5,8H,1H3</data>
  <data key="d20">CC1=CC=CC(O)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3-Cresol, 3-Methylphenol, m-Cresylic acid, m-Kresol, meta-Cresol, Metacresol]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01772">
  <data key="d0">3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione</data>
  <data key="d1">drugbank.DB01772</data>
  <data key="d2">[drugbank.DB01772, drugbank.EXPT01170]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-(3-{[(2S)-2,3-dihydroxypropyl]amino}phenyl)-4-(5-fluoro-1-methyl-1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione</data>
  <data key="d15">C22H20FN3O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H20FN3O4/c1-26-10-17(16-8-13(23)5-6-18(16)26)20-19(21(29)25-22(20)30)12-3-2-4-14(7-12)24-9-15(28)11-27/h2-8,10,15,24,27-28H,9,11H2,1H3,(H,25,29,30)/t15-/m0/s1</data>
  <data key="d20">[H][C@@](O)(CO)CNC1=CC=CC(=C1)C1=C(C(=O)NC1=O)C1=CN(C)C2=CC=C(F)C=C12</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13751">
  <data key="d0">Glycyrrhizic acid</data>
  <data key="d1">drugbank.DB13751</data>
  <data key="d2">[drugbank.DB13751]</data>
  <data key="d12">[approved, experimental]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Anti-Inflammatory Agents, Bile and Liver Therapy, BSEP/ABCB11 Substrates, Liver Therapy, Liver Therapy, Lipotropics, Pentacyclic Triterpenes, Terpenes, Triterpenes]</data>
  <data key="d14">(2S,3S,4S,5R,6S)-6-{[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}-5-{[(2R,3R,4S,5S,6S)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy}-3,4-dihydroxyoxane-2-carboxylic acid</data>
  <data key="d15">C42H62O16</data>
  <data key="d16">1405-86-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+/m0/s1</data>
  <data key="d20">[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O[C@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)C(O)=O)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O</data>
  <data key="d21">Glycyrrhizic acid is widely applied in foods as a natural sweetener. As a therapeutic agent, is has been used in a vast variety of formulations as it is reported to be anti-inflammatory, anti-ulcer, anti-allergic, antioxidant, anti-tumor, anti-diabetic and hepatoprotective. Due to this properties, its indications have been: treatment of premenstrual syndrome, treatment of viral infections, anti-lipidemic and antihyperglycemic.[A33063] It is also known to be used as a remedy for peptic ulcer and other stomach diseases.[T205]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[18-beta-Glycyrrhizic acid, Glizigen, Glycyrrhizin]</data>
  <data key="d9">Glycyrrhizic acid is extracted from the root of the licorice plant; _Glycyrrhiza glabra_.[F79] It is a triterpene glycoside with glycyrrhetinic acid that possesses a wide range of pharmacological and biological activities. When extracted from the plant, it can be obtained in the form of ammonium glycyrrhizin and mono-ammonium glycyrrhizin.[T204] Glycyrrhizic acid has been developed in Japan and China as a hepatoprotective drug in cases of chronic hepatitis.[A33062] From January 2014, glycyrrhizic acid as part of the licorice extract was approved by the FDA as an existing food sweetener.[F80] It was approved by Health Canada to be used in over-the-counter products but all the products are currently on the status canceled post marketed.[L1113]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01708">
  <data key="d0">Prasterone</data>
  <data key="d1">drugbank.DB01708</data>
  <data key="d2">[drugbank.DB01708, drugbank.EXPT00519, drugbank.DB06593]</data>
  <data key="d12">[approved, investigational, nutraceutical]</data>
  <data key="d13">[17-Ketosteroids, Adjuvants, Immunologic, Adrenal Cortex Hormones, Alimentary Tract and Metabolism, Anabolic Agents for Systemic Use, Anabolic Steroids, Androgens and Estrogens, Androstan Derivatives, Androstanes, Androstenes, Androstenols, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Immunologic Factors, Ketosteroids, Sex Hormones and Modulators of the Genital System, Steroids, Testosterone Congeners]</data>
  <data key="d14">(1S,2R,5S,10R,11S,15S)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0,.0,]heptadec-7-en-14-one</data>
  <data key="d15">C19H28O2</data>
  <data key="d16">53-43-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1</data>
  <data key="d20">[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C</data>
  <data key="d21">DHEA is taken as a supplement for a variety of unsubstantiated indications. The following indications have shown promise and are backed up by some scientific evidence: schizophrenia (DHEA may be more effective in women than men); improving the appearance of older peoples skin (taking DHEA by mouth seems to increase skin thickness and moisture, and decrease facial age spots in elderly men and women); improving ability to achieve an erection in men with sexual dysfunction. Additionally, DHEA has shown promise in improving symptoms of lupus (SLE). Taking DHEA by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed. DHEA may also help SLE symptoms such as muscle ache and mouth ulcers. DHEA also seems to strengthen bones in SLE patients being treated with high-dose steroids (corticosteroids).\nDHEA also shows promise in the treatment of osteoporosis. Taking DHEA by mouth daily seems to improve bone mineral density (BMD) in older women and men with osteoporosis or osteopenia (pre-osteoporosis). DHEA may also increase BMD in young women with the eating disorder called anorexia nervosa. DHEA is often prescribed in India for the induction of ovulation to improve chances of pregnancy.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3-beta-hydroxy-5-androsten-17-one, 3beta-hydroxyandrost-5-en-17-one, 3-hydroxyandrost-5-en-17-one, Dehydroandrosterone, Dehydroepiandrosterone, Dehydroisoandrosterone, DHEA, Prasterone]</data>
  <data key="d9">Prasterone, also known as dehydroepiandrosterone (DHEA) is a major C19 steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary. Dehydroepiandrosterone (DHEA) can be converted to testosterone; androstenedione; estradiol; and estrone. Most of DHEA is sulfated (dehydroepiandrosterone sulfate) before secretion.\n\nIn the United States, DHEA or DHEAS have been advertised with claims that they may be beneficial for a wide variety of ailments. DHEA and DHEAS are readily available in the United States, where they are marketed as over-the-counter dietary supplements. In November 2016, DHEA was approved (as Intrarosa) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.\n\nIn Canada, a prescription is required to buy DHEA.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01725">
  <data key="d0">2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1H-1,3-benzodiazole-5-carboximidamide</data>
  <data key="d1">drugbank.DB01725</data>
  <data key="d2">[drugbank.DB01725, drugbank.EXPT00301, drugbank.DB06854]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-(2-hydroxy-3-phenylphenyl)-1H-1,3-benzodiazole-5-carboximidamide</data>
  <data key="d15">C20H16N4O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H16N4O/c21-19(22)13-9-10-16-17(11-13)24-20(23-16)15-8-4-7-14(18(15)25)12-5-2-1-3-6-12/h1-11,25H,(H3,21,22)(H,23,24)</data>
  <data key="d20">NC(=N)C1=CC2=C(NC(=N2)C2=CC=CC(C3=CC=CC=C3)=C2O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-(2-HYDROXY-BIPHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE, 3-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-1, 1'-BIPHENYL-2-OLATE]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00406">
  <data key="d0">Gentian violet cation</data>
  <data key="d1">drugbank.DB00406</data>
  <data key="d2">[drugbank.DB00406, drugbank.APRD00998]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amines, Aniline Compounds, Anti-Infective Agents, Anti-Infective Agents, Local, Antifungals for Dermatological Use, Antifungals for Topical Use, Dermatologicals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Miscellaneous Antifungals]</data>
  <data key="d14">4-{bis[4-(dimethylamino)phenyl]methylidene}-N,N-dimethylcyclohexa-2,5-dien-1-iminium</data>
  <data key="d15">C25H30N3</data>
  <data key="d16">7438-46-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C25H30N3/c1-26(2)22-13-7-19(8-14-22)25(20-9-15-23(16-10-20)27(3)4)21-11-17-24(18-12-21)28(5)6/h7-18H,1-6H3/q+1</data>
  <data key="d20">CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C</data>
  <data key="d21">For the treatment of bacterial and fungal infections inside the mouth (thrush) and skin, also for the prevention of transmission of Chagas' disease (as a blood additive).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Crystal Violet, Crystal violet carbocation, Crystal violet ion(1), Crystal violet(1+), Gentian violet carbocation, Gentian violet cation, Gentian violet(1+), Methylrosaniline, Methylrosanilinium]</data>
  <data key="d9">A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12482">
  <data key="d0">Acotiamide</data>
  <data key="d1">drugbank.DB12482</data>
  <data key="d2">[drugbank.DB12482]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Carbocyclic, Amides, Benzene Derivatives, Benzoates, Sulfur Compounds]</data>
  <data key="d14">N-{2-[bis(propan-2-yl)amino]ethyl}-2-(2-hydroxy-4,5-dimethoxybenzamido)-1,3-thiazole-4-carboxamide</data>
  <data key="d15">C21H30N4O5S</data>
  <data key="d16">185106-16-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H30N4O5S/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27)</data>
  <data key="d20">COC1=C(OC)C=C(C(=O)NC2=NC(=CS2)C(=O)NCCN(C(C)C)C(C)C)C(O)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Acotiamide has been used in trials studying the treatment of Dyspepsia and Functional Dyspepsia.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00498">
  <data key="d0">Phenindione</data>
  <data key="d1">drugbank.DB00498</data>
  <data key="d2">[drugbank.DB00498, drugbank.APRD00166]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Anticoagulants, Blood and Blood Forming Organs, Hematologic Agents, Indans, Indenes, Narrow Therapeutic Index Drugs, Vitamin K Antagonists]</data>
  <data key="d14">2-phenyl-2,3-dihydro-1H-indene-1,3-dione</data>
  <data key="d15">C15H10O2</data>
  <data key="d16">83-12-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H10O2/c16-14-11-8-4-5-9-12(11)15(17)13(14)10-6-2-1-3-7-10/h1-9,13H</data>
  <data key="d20">O=C1C(C(=O)C2=CC=CC=C12)C1=CC=CC=C1</data>
  <data key="d21">For the treatment of pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, mural thrombosis, and thrombophili. Also used for anticoagulant prophylaxis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-phenyl-1, 3-diketohydrindene, 2-Phenyl-1, 3-indandione, 2-phenyl-1, 3(2H)-Indenedione, Fenindiona, Fenindione, Phenindion, Phnindione, Phenindione, Phenindionum, PID]</data>
  <data key="d9">An indandione that has been used as an anticoagulant. Phenindione has actions similar to warfarin, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11166">
  <data key="d0">Antithrombin Alfa</data>
  <data key="d1">drugbank.DB11166</data>
  <data key="d2">[drugbank.DB11166]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Anticoagulants, Decreased Coagulation Factor Activity, Factor Xa Inhibitors, Recombinant Antithrombin, Thrombin Inhibitors]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">84720-88-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Antithrombin alfa is a recombinant antithrombin it is indicated for the prevention of peri-operative and peri-partum thromboembolic events in patients with hereditary deficiency of antithrombin.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Antithrombin (recombinant), Antithrombin III, recombinant, Antithrombin III, recombinant]</data>
  <data key="d9">Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the  prevention of thromboembolic events in patients that have hereditary deficiency  of antithrombin in high risk situations.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00458">
  <data key="d0">Imipramine</data>
  <data key="d1">drugbank.DB00458</data>
  <data key="d2">[drugbank.DB00458, drugbank.APRD00672, drugbank.DB08002]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Adrenergic Uptake Inhibitors, Agents producing tachycardia, Agents that produce hypertension, Agents that reduce seizure threshold, Anticholinergic Agents, Antidepressive Agents, Antidepressive Agents, Tricyclic, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (moderate), Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Dibenzazepines, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index, Histamine Antagonists, Histamine H1 Antagonists, Hypotensive Agents, Membrane Transport Modulators, Moderate Risk QTc-Prolonging Agents, Muscarinic Antagonists, Narrow Therapeutic Index Drugs, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Non-Selective Monoamine Reuptake Inhibitors, OCT2 Inhibitors, P-glycoprotein/ABCB1 Substrates, P-glycoprotein/ABCB1 Substrates with narrow therapeutic index, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Antagonists, Tertiary amine tricyclic antidepressants, Tricyclics and Other Norepinephrine-reuptake Inhibitors]</data>
  <data key="d14">(3-{2-azatricyclo[9.4.0.0,]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)dimethylamine</data>
  <data key="d15">C19H24N2</data>
  <data key="d16">50-49-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3</data>
  <data key="d20">CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12</data>
  <data key="d21">For the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older [FDA Label]. \n\nMay also be used off-label to manage panic disorders with or without agoraphobia, as a second line agent for ADHD in children and adolescents, to manage bulimia nervosa, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, for the treatment of acute stress disorder and posttraumatic stress disorder, and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy [L1349,L1348,A31900,L1351,L1352,L1353,A31904].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[10, 11-dihydro-N, N-dimethyl-5H-dibenz[b, f]azepine-5-propanamine, 5-[3-(dimethylamino)propyl]-10, 11-dihydro-5H-dibenz[b, f]azepine, Imipramin, Imipramina, Imipramine, Imipraminum, Imizine, N-(gamma-Dimethylaminopropyl)iminodibenzyl, N-(-dimethylaminopropyl)iminodibenzyl]</data>
  <data key="d9">Imipramine, the prototypical tricyclic antidepressant (TCA), is a dibenzazepine-derivative TCA. TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as imipramine and amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also block histamine H&lt;sub&gt;1&lt;/sub&gt; receptors, &amp;alpha;&lt;sub&gt;1&lt;/sub&gt;-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively [A6584]. Imipramine has less sedative and anticholinergic effects than the tertiary amine TCAs, amitriptyline and clomipramine. Imipramine may be used to treat depression and nocturnal enuresis in children [FDA Label]. Unlabeled indications include chronic and neuropathic pain (including diabetic neuropathy), panic disorder, attention-deficit/hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD) [L1349,L1348,A31900,L1351,L1352,L1353,A31904].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12450">
  <data key="d0">Propyl Gallate</data>
  <data key="d1">drugbank.DB12450</data>
  <data key="d2">[drugbank.DB12450]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Carbocyclic, Antioxidants, Benzene Derivatives, Benzoates, Compounds used in a research, industrial, or household setting, Gallic Acid, Hydroxy Acids, Hydroxybenzoates, Phenols, Protective Agents]</data>
  <data key="d14">propyl 3,4,5-trihydroxybenzoate</data>
  <data key="d15">C10H12O5</data>
  <data key="d16">121-79-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H12O5/c1-2-3-15-10(14)6-4-7(11)9(13)8(12)5-6/h4-5,11-13H,2-3H2,1H3</data>
  <data key="d20">CCCOC(=O)C1=CC(O)=C(O)C(O)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Propyl Gallate is under investigation in clinical trial NCT01450098 (A Study of LY2484595 in Healthy Subjects).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00463">
  <data key="d0">Metharbital</data>
  <data key="d1">drugbank.DB00463</data>
  <data key="d2">[drugbank.DB00463, drugbank.APRD00757]</data>
  <data key="d12">[withdrawn]</data>
  <data key="d13">[Anticholinergic Agents, Anticonvulsants, Barbiturates and Derivatives, Central Nervous System Depressants, Nervous System, Nicotinic Antagonists, Pyrimidines, Pyrimidinones]</data>
  <data key="d14">5,5-diethyl-1-methyl-1,3-diazinane-2,4,6-trione</data>
  <data key="d15">C9H14N2O3</data>
  <data key="d16">50-11-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H14N2O3/c1-4-9(5-2)6(12)10-8(14)11(3)7(9)13/h4-5H2,1-3H3,(H,10,12,14)</data>
  <data key="d20">CCC1(CC)C(=O)NC(=O)N(C)C1=O</data>
  <data key="d21">Metharbital is used for the treatment of epilepsy.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Metarbital, Metharbital, Metharbitalum]</data>
  <data key="d9">Metharbital is a barbiturate anticonvulsant, similar to phenobarbital, marketed as Gemonil by Abbott Laboratories. It was patented in 1905 by Emil Fischer of Merck.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01793">
  <data key="d0">SB-409513</data>
  <data key="d1">drugbank.DB01793</data>
  <data key="d2">[drugbank.DB01793, drugbank.EXPT00277]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-chloro-5-{[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]amino}benzoic acid</data>
  <data key="d15">C17H10Cl2N2O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H10Cl2N2O4/c18-9-3-1-2-8(6-9)13-14(16(23)21-15(13)22)20-10-4-5-12(19)11(7-10)17(24)25/h1-7H,(H,24,25)(H2,20,21,22,23)</data>
  <data key="d20">OC(=O)C1=CC(NC2=C(C(=O)NC2=O)C2=CC(Cl)=CC=C2)=CC=C1Cl</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[I-5]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00472">
  <data key="d0">Fluoxetine</data>
  <data key="d1">drugbank.DB00472</data>
  <data key="d2">[drugbank.DB00472, drugbank.APRD00530]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Agents that reduce seizure threshold, Amines, Anticholinergic Agents, Antidepressive Agents, Antidepressive Agents, Second-Generation, Central Nervous System Agents, Central Nervous System Depressants, Chemically-Induced Disorders, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Highest Risk QTc-Prolonging Agents, Hypoglycemia-Associated Agents, Membrane Transport Modulators, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Nicotinic Antagonists, P-glycoprotein/ABCB1 Inhibitors, Propylamines, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Selective Serotonin Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Antagonists, Vasodilating Agents]</data>
  <data key="d14">methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine</data>
  <data key="d15">C17H18F3NO</data>
  <data key="d16">54910-89-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3</data>
  <data key="d20">CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1</data>
  <data key="d21">Labeled indication include: major depressive disorder (MDD), moderate to severe bulimia nervosa, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), panic disorder with or without agoraphobia, and combination treatment with olanzapine for treatment-resistant or bipolar I depression. Unlabeled indications include: selective mutism, mild dementia-associated agitation in nonpsychotic patients, post-traumatic stress disorder (PTSD), social anxiety disorder, chronic neuropathic pain, fibromyalgia, and Raynaud's phenomenon.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+-)-N-Methyl-3-phenyl-3-((alpha, alpha, alpha-trifluoro-P-tolyl)oxy)propylamine, (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine, Fluoxetin, Fluoxetina, Fluoxetine, Fluoxtine, Fluoxetinum]</data>
  <data key="d9">Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs). Fluoxetine is a racemic mixture of the R- and S- enantiomers and are of equivalent pharmacologic activity. Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize &amp;alpha;- or &amp;beta;-adrenergic, dopamine D&lt;sub&gt;2&lt;/sub&gt; or histamine H&lt;sub&gt;1&lt;/sub&gt; receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT&lt;sub&gt;1A&lt;/sub&gt; and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT&lt;sub&gt;1A&lt;/sub&gt; and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Fluoxetine may be used to treat major depressive disorder (MDD), moderate to severe bulimia nervosa, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), panic disorder with or without agoraphobia, and in combination with olanzapine for treatment-resistant or bipolar I depression. Fluoxetine is the most anorexic and stimulating SSRI.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00477">
  <data key="d0">Chlorpromazine</data>
  <data key="d1">drugbank.DB00477</data>
  <data key="d2">[drugbank.DB00477, drugbank.APRD00482]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents producing tachycardia, Agents that produce hypertension, Agents that reduce seizure threshold, Anticholinergic Agents, Antidepressive Agents, Antiemetics, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Autonomic Agents, BSEP/ABCB11 Inhibitors, Central Nervous System Agents, Central Nervous System Depressants, Cholinesterase Inhibitors, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs that are Mainly Renally Excreted, Gastrointestinal Agents, Histamine Antagonists, Histamine H1 Antagonists, Hyperglycemia-Associated Agents, Hypotensive Agents, Moderate Risk QTc-Prolonging Agents, Muscarinic Antagonists, Nervous System, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Peripheral Nervous System Agents, Phenothiazines, Phenothiazines With Aliphatic Side-Chain, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Sulfur Compounds, Tranquilizing Agents]</data>
  <data key="d14">[3-(2-chloro-10H-phenothiazin-10-yl)propyl]dimethylamine</data>
  <data key="d15">C17H19ClN2S</data>
  <data key="d16">50-53-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3</data>
  <data key="d20">CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2</data>
  <data key="d21">For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3-(2-chloro-10H-phenothiazin-10-yl)-N, N-dimethyl-1-propanamine, 3-(2-chlorophenothiazin-10-yl)-N, N-dimethyl-propan-1-amine, Chlorpromazine, Chlorpromazinum, Clorpromazina, CPZ, N-(3-dimethylaminopropyl)-3-chlorophenothiazine]</data>
  <data key="d9">The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00474">
  <data key="d0">Methohexital</data>
  <data key="d1">drugbank.DB00474</data>
  <data key="d2">[drugbank.DB00474, drugbank.APRD00058]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Anesthetics, Anesthetics, General, Anesthetics, Intravenous, Anticonvulsants, Barbiturates, Barbiturates, Plain, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P450 3A4 Inducers, Hypnotics and Sedatives, Nervous System, Psycholeptics, Pyrimidines, Pyrimidinones]</data>
  <data key="d14">5-(hex-3-yn-2-yl)-1-methyl-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione</data>
  <data key="d15">C14H18N2O3</data>
  <data key="d16">151-83-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H18N2O3/c1-5-7-8-10(3)14(9-6-2)11(17)15-13(19)16(4)12(14)18/h6,10H,2,5,9H2,1,3-4H3,(H,15,17,19)</data>
  <data key="d20">CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O</data>
  <data key="d21">Methohexital is indicated for use as an intravenous anaesthetic. It has also been commonly used to induce deep sedation.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-5-allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid, 5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione, 5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2, 4, 6-trione, 5-Allyl-5-(3-hexyn-2-yl)-1-methylbarbituric acid, Methohexital, Methohexitalum, Methohexitone, Metohexital, -DL-1-methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric acid]</data>
  <data key="d9">An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00483">
  <data key="d0">Gallamine Triethiodide</data>
  <data key="d1">drugbank.DB00483</data>
  <data key="d2">[drugbank.DB00483, drugbank.APRD00712]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents producing tachycardia, Amines, Ammonium Compounds, Anticholinergic Agents, Central Nervous System Depressants, Cholinergic Agents, Cholinesterase Inhibitors, Muscarinic Antagonists, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular-Blocking Agents (Nondepolarizing), Neurotransmitter Agents, Nicotinic Antagonists, Nitrogen Compounds, Onium Compounds, Peripheral Nervous System Agents, Quaternary Ammonium Compounds]</data>
  <data key="d14">(2-{2,3-bis[2-(triethylazaniumyl)ethoxy]phenoxy}ethyl)triethylazanium triiodide</data>
  <data key="d15">C30H60I3N3O3</data>
  <data key="d16">65-29-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C30H60N3O3.3HI/c1-10-31(11-2,12-3)22-25-34-28-20-19-21-29(35-26-23-32(13-4,14-5)15-6)30(28)36-27-24-33(16-7,17-8)18-9;;;/h19-21H,10-18,22-27H2,1-9H3;3*1H/q+3;;;/p-3</data>
  <data key="d20">[I-].[I-].[I-].CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC</data>
  <data key="d21">For use as adjuncts to anesthesia to induce skeletal muscle relaxation and to facilitate the management of patients undergoing mechanical ventilation</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Gallamin triethiodid, Gallamini Triethiodidum, Trithiodure de Gallamine, Trietioduro de galamina]</data>
  <data key="d9">A synthetic nondepolarizing blocking drug. The actions of gallamine triethiodide are similar to those of tubocurarine, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac output. It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00482">
  <data key="d0">Celecoxib</data>
  <data key="d1">drugbank.DB00482</data>
  <data key="d2">[drugbank.DB00482, drugbank.APRD00373]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents causing hyperkalemia, Agents that produce hypertension, Amides, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antineoplastic and Immunomodulating Agents, Antirheumatic Agents, BSEP/ABCB11 Substrates, Central Nervous System Agents, COX-2 Inhibitors, Cyclooxygenase Inhibitors, Cyclooxygenase-2 (COX-2) Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Methemoglobinemia Associated Agents, Musculo-Skeletal System, Nephrotoxic agents, Nonsteroidal Anti-inflammatory Compounds, Peripheral Nervous System Agents, Pyrazoles, Selective Cyclooxygenase 2 Inhibitors (NSAIDs), Sensory System Agents, Sulfonamides, Sulfones, Sulfur Compounds]</data>
  <data key="d14">4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide</data>
  <data key="d15">C17H14F3N3O2S</data>
  <data key="d16">169590-42-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)</data>
  <data key="d20">CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F</data>
  <data key="d21">For the relief and management of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis, acute pain, primary dysmenorrhea and oral adjunct to usual care for patients with familial adenomatous polyposis [FDA label].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Celecoxib, Clcoxib, Celecoxibum, p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide]</data>
  <data key="d9">_Celecoxib_ is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and is also used to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name _Celebrex_. Celecoxib is available by prescription in capsule form [A34124].\n\nBy inhibiting prostaglandin synthesis, non-steroidal anti-inflammatory drugs (NSAIDs) cause mucosal damage, ulceration and ulcer complication throughout the gastrointestinal tract.  Celecoxib, however, poses less of an ulceration risk, owing to its decreased effect on gastric mucosal prostaglandin synthesis, when compared to placebo [A34152].\n\nInterestingly, selective COX-2 inhibitors (especially _celecoxib_), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies [A34124].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00481">
  <data key="d0">Raloxifene</data>
  <data key="d1">drugbank.DB00481</data>
  <data key="d2">[drugbank.DB00481, drugbank.APRD00400]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[BCRP/ABCG2 Substrates, Benzene Derivatives, Benzylidene Compounds, Bone Density Conservation Agents, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strong), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Estrogen Agonist-antagonists, Estrogen Agonist/Antagonist, Estrogen Antagonists, Estrogen Receptor Modulators, Genito Urinary System and Sex Hormones, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, OATP1B1/SLCO1B1 Substrates, OATP1B3 substrates, P-glycoprotein/ABCB1 Substrates, Selective Estrogen Receptor Modulators, Sex Hormones and Modulators of the Genital System, Stilbenes, Tamoxifen, UGT1A1 Substrates]</data>
  <data key="d14">2-(4-hydroxyphenyl)-3-{4-[2-(piperidin-1-yl)ethoxy]benzoyl}-1-benzothiophen-6-ol</data>
  <data key="d15">C28H27NO4S</data>
  <data key="d16">84449-90-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2</data>
  <data key="d20">OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2</data>
  <data key="d21">Indicated for the prevention and treatment of osteoporosis in postmenopausal women, as well as prevention and treatment of corticosteroid-induced bone loss.[label]\n\nIndicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or postmenopausal women with a high risk for invasive breast cancer.[label]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone, Raloxifne, Raloxifene, Raloxifeno, Raloxifenum]</data>
  <data key="d9">Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation.[A4979,T28] Exhibiting tissue-specific effects distinct from [estradiol], raloxifene is the first of the benzothiophene group of antiestrogens to be labelled a SERM.[A4977] Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista for the management and prevention of osteoporosis in postmenopausal women and reduction in risk for invasive breast cancer in postmenopausal women with osteoporosis or those who are at high risk for invasive breast cancer. However, it has a negligible effect on altering the development and progression of breast cancer itself.[label] The most common causes of osteoporosis include postmenopausal deficiency of estrogen and age-related deterioration in bone homeostasis. Due to the risk of bone fractures that may lead to morbidities and reduced quality of life, the management of osteoporosis in postmenopausal women with the use of therapeutic agents in addition to concurrent therapies is critical. Due to the decline in estrogen levels in postmenopausal osteoporosis, hormone replacement therapy (HRT), such as estradiol, has been used to ameliorate the condition. However, due to the off-target actions by HRT, newer non-hormonal agents such as raloxifene and [tamoxifen] have been developed to reduce adverse events through selective pharmacological actions on tissue-specific therapeutic targets.[T28]\n\nThe main effects of raloxifene are to preserve the bone mineral density and decrease the risk of breast cancer in postmenopausal women. Compared to estrogen and tamoxifen, raloxifene was not associated with an increased risk of uterine cancer and it does not cause endometrial proliferation.[A716] Although rare, there was an increased risk of venous thromboembolism during clinical trials of postmenopausal women receiving raloxifene. In addition, a clinical study consisting of postmenopausal women with documented coronary heart disease or at increased risk for coronary events showed an increased risk for fatal stroke with raloxifene therapy compared to placebo.[label] It is strongly advised that the risk-benefit ratio is considered before starting raloxifene therapy in women at risk of thromboembolic disease or strokes, such as the prior history of stroke, transient ischemic attack, atrial fibrillation, hypertension, or cigarette smoking.[label]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00480">
  <data key="d0">Lenalidomide</data>
  <data key="d1">drugbank.DB00480</data>
  <data key="d2">[drugbank.DB00480, drugbank.APRD01303]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acids, Carbocyclic, Angiogenesis Inhibitors, Angiogenesis Modulating Agents, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Drugs that are Mainly Renally Excreted, Growth Inhibitors, Growth Substances, Imides, Immunologic Factors, Immunosuppressive Agents, Isoindoles, Myelosuppressive Agents, P-glycoprotein/ABCB1 Substrates, Phthalic Acids, Phthalimides, Piperidines, Piperidones, Thalidomide Analog]</data>
  <data key="d14">3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione</data>
  <data key="d15">C13H13N3O3</data>
  <data key="d16">191732-72-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)</data>
  <data key="d20">NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O</data>
  <data key="d21">Lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-oxo-2-(2, 6-dioxopiperidin-3-yl)-4-aminoisoindoline, 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2, 6-dione, Lenalidomida, Lenalidomide]</data>
  <data key="d9">Lenalidomide (initially known as CC-5013 and marketed as Revlimid by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. FDA approved on December 27, 2005.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11125">
  <data key="d0">Benzethonium</data>
  <data key="d1">drugbank.DB11125</data>
  <data key="d2">[drugbank.DB11125]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amines, Ammonium Compounds, Anti-Infective Agents, Anti-Infective Agents, Local, Antiseptics and Disinfectants, Benzylammonium Compounds, Dermatologicals, Miscellaneous Local Anti-infectives, Nitrogen Compounds, Onium Compounds, Quaternary Ammonium Compounds, Throat Preparations]</data>
  <data key="d14">benzyldimethyl(2-{2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy}ethyl)azanium</data>
  <data key="d15">C27H42NO2</data>
  <data key="d16">10172-60-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C27H42NO2/c1-26(2,3)22-27(4,5)24-13-15-25(16-14-24)30-20-19-29-18-17-28(6,7)21-23-11-9-8-10-12-23/h8-16H,17-22H2,1-7H3/q+1</data>
  <data key="d20">CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1</data>
  <data key="d21">Indicated as an antiseptic agent. No therapeutic indications for clinical use.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Benzethonium is a synthetic quaternary ammonium salt with surfactant, antiseptic, and broad spectrum antimicrobial properties. Its salt form, benzethonium chloride, is primarily used as a skin disinfectant at concentrations of 0.1-0.2 %, which are safe and effective concentrations for the compound specified by the U.S. Food and Drug Administration (FDA). It is additionally found in cosmetics and toiletries such as mouthwashes and anti-itch ointments. It is shown to be effective in mediating its antimicrobial action against bacteria, fungi, mold and viruses. There is evidence that benzethonium acts as a spermatocide but may cause vaginal irritation [A32304]. Benzethonium was identified as a novel cancer-specific compound by cell-based small-molecule screen [A32298].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00492">
  <data key="d0">Fosinopril</data>
  <data key="d1">drugbank.DB00492</data>
  <data key="d2">[drugbank.DB00492, drugbank.APRD00526]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[ACE Inhibitors and Diuretics, Acids, Acids, Acyclic, Acids, Noncarboxylic, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Amino Acids, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Agents, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hypotensive Agents, Imines, Imino Acids, Organophosphorus Compounds, Phosphinic Acids, Phosphorus Acids, Phosphorus Compounds, Proline, Protease Inhibitors]</data>
  <data key="d14">(2S,4S)-4-cyclohexyl-1-{2-[(R)-[(1S)-2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl]acetyl}pyrrolidine-2-carboxylic acid</data>
  <data key="d15">C30H46NO7P</data>
  <data key="d16">98048-97-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30+,39-/m1/s1</data>
  <data key="d20">CCC(=O)O[C@@H](O[P@](=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C</data>
  <data key="d21">For treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Fosenopril, Fosinopril]</data>
  <data key="d9">Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11133">
  <data key="d0">Omega-3 fatty acids</data>
  <data key="d1">drugbank.DB11133</data>
  <data key="d2">[drugbank.DB11133]</data>
  <data key="d12">[approved, nutraceutical]</data>
  <data key="d13">[Diet, Food, and Nutrition, Dietary Fats, Dietary Fats, Unsaturated, Fats, Fatty Acids, Fatty Acids, Omega-3, Fatty Acids, Unsaturated, Fish Oils, Food, Food and Beverages, Lipids, Membrane Lipids, Oils, Physiological Phenomena]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">329042-31-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Provided as daily supplements. Aa preparation of omega-3-acid ethyl esters is licensed in UK for prevention of recurrent events after myocardial infarction in addition to treatment of hypertriglyceridaemia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[n-3 fatty acids, Omega 3 fatty acids, Omega-3, Omega-3 acid, Omega-3 acid triglycerides, Omega-3 fatty acid, Omega-3 phospholipids, Omega-3 polyunsaturated fatty acids, Omega-3 polyunsaturates, Phospholipids, -3 fatty acids]</data>
  <data key="d9">Omega-3 fatty acids are polyunsaturated fatty acids (PUFAs) with a double bond at the third carbon atom from the end of the carbon chain. The three types of omega-3 fatty acids involved in human physiology are -linolenic acid (ALA) (found in plant oils), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) (both commonly found in fish oil that originally come from microalgae that is further consumed by phytoplankton, a source of diet for fish). Omega-3 fatty acids play a critical role in metabolism and cellular function and they are available as daily supplements. On September 8, 2004, the U.S. Food and Drug Administration gave "qualified health claim" status to EPA and DHA omega-3 fatty acids. Therapeutic products containing omega-3 fatty acid and its derivatives for treatment of hypertriglyceridemia include Lovaza, Omtryg, Epanova, and Vascepa.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00539">
  <data key="d0">Toremifene</data>
  <data key="d1">drugbank.DB00539</data>
  <data key="d2">[drugbank.DB00539, drugbank.APRD00391]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Anti-Estrogens, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, Benzene Derivatives, Benzylidene Compounds, Bone Density Conservation Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Endocrine Therapy, Estrogen Agonist/Antagonist, Estrogen Receptor Modulators, Highest Risk QTc-Prolonging Agents, Hormone Antagonists, Hormone Antagonists and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, QTc Prolonging Agents, Selective Estrogen Receptor Modulators, Stilbenes, Tamoxifen]</data>
  <data key="d14">(2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine</data>
  <data key="d15">C26H28ClNO</data>
  <data key="d16">89778-26-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-</data>
  <data key="d20">CN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1</data>
  <data key="d21">For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Toremifene, Toremifeno, Toremifenum]</data>
  <data key="d9">A first generation nonsteroidal selective estrogen receptor modulator (SERM) that is structurally related to tamoxifen. Like tamoxifen, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00535">
  <data key="d0">Cefdinir</data>
  <data key="d1">drugbank.DB00535</data>
  <data key="d2">[drugbank.DB00535, drugbank.APRD00644]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Aza Compounds, Azabicyclo Compounds, beta-Lactams, Cephalosporins, Lactams, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, Sulfur Compounds, Thiazines, Third-Generation Cephalosporins]</data>
  <data key="d14">(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(N-hydroxyimino)acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid</data>
  <data key="d15">C14H13N5O5S2</data>
  <data key="d16">91832-40-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1</data>
  <data key="d20">[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O</data>
  <data key="d21">For the treatment of the respiratory, skin, soft tissue, and ENT infections caused by &lt;i&gt;H. influenzae&lt;/i&gt; (including b-lactamase producing strains), &lt;i&gt;H. parainfluenzae&lt;/i&gt; (including b-lactamase producing strains), &lt;i&gt;S. pneumoniae&lt;/i&gt; (penicillin-susceptible strains), &lt;i&gt;S. pyogenes&lt;/i&gt;, &lt;i&gt;S. aureus&lt;/i&gt; (including b-lactamase producing strains), and &lt;i&gt;M. catarrhalis&lt;/i&gt;.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(6R, 7R, Z)-7-(2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid, (6R, 7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino}-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid, Cefdinir, Cefdinirum, CFDN]</data>
  <data key="d9">Cefdinir (marketed by Abbott Laboratories under the brand name Omnicef) is a semi-synthetic, broad-spectrum antibiotic in the third generation of the cephalosporin class, proven effective for common bacterial infections of the ear, sinus, throat, and skin. It was approved by the U.S. Food and Drug Administration (FDA) in December of 1997.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01878">
  <data key="d0">Benzophenone</data>
  <data key="d1">drugbank.DB01878</data>
  <data key="d2">[drugbank.DB01878, drugbank.EXPT00794]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Benzene Derivatives, Benzhydryl Compounds, Dermatologicals, Ketones, Photosensitizing Agents, Radiation-Sensitizing Agents]</data>
  <data key="d14">diphenylmethanone</data>
  <data key="d15">C13H10O</data>
  <data key="d16">119-61-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H10O/c14-13(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H</data>
  <data key="d20">O=C(C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Benzoylbenzene, Diphenyl ketone, Diphenylmethanone, -oxodiphenylmethane, -oxoditane]</data>
  <data key="d9">Benzophenone is the organic compound. Substituted benzophenones such as oxybenzone and dioxybenzone are used in sunscreen.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00545">
  <data key="d0">Pyridostigmine</data>
  <data key="d1">drugbank.DB00545</data>
  <data key="d2">[drugbank.DB00545, drugbank.APRD00380]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Cholinergic Agents, Cholinesterase Inhibitors, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Enzyme Inhibitors, Nervous System, Neurotransmitter Agents, Parasympathomemetic (Cholinergic) Agents, Parasympathomimetics, Pyridines, Pyridinium Compounds]</data>
  <data key="d14">3-[(dimethylcarbamoyl)oxy]-1-methylpyridin-1-ium</data>
  <data key="d15">C9H13N2O2</data>
  <data key="d16">155-97-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H13N2O2/c1-10(2)9(12)13-8-5-4-6-11(3)7-8/h4-7H,1-3H3/q+1</data>
  <data key="d20">CN(C)C(=O)OC1=C[N+](C)=CC=C1</data>
  <data key="d21">For the treatment of myasthenia gravis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Piridostigmina, Pyridostigmine cation]</data>
  <data key="d9">A cholinesterase inhibitor with a slightly longer duration of action than neostigmine. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00543">
  <data key="d0">Amoxapine</data>
  <data key="d1">drugbank.DB00543</data>
  <data key="d2">[drugbank.DB00543, drugbank.APRD00142]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Adrenergic Uptake Inhibitors, Agents producing tachycardia, Agents that produce hypertension, Agents that reduce seizure threshold, Anticholinergic Agents, Antidepressive Agents, Antidepressive Agents, Second-Generation, Antidepressive Agents, Tetracyclic, Antidepressive Agents, Tricyclic, Antipsychotic Agents, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Dibenzoxazepines, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Histamine Antagonists, Histamine H1 Antagonists, Loxapine, Membrane Transport Modulators, Muscarinic Antagonists, Narrow Therapeutic Index Drugs, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Non-Selective Monoamine Reuptake Inhibitors, P-glycoprotein/ABCB1 Inhibitors, Potential QTc-Prolonging Agents, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Antagonists]</data>
  <data key="d14">13-chloro-10-(piperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0,]pentadeca-1(11),3,5,7,9,12,14-heptaene</data>
  <data key="d15">C17H16ClN3O</data>
  <data key="d16">14028-44-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2</data>
  <data key="d20">ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1</data>
  <data key="d21">For the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. May also be used to treat depression accompanied by anxiety or agitation.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-Chloro-11-(1-piperazinyl)dibenz(b, f)(1, 4)oxazepine, Amoxapin, Amoxapina, Amoxapine, Amoxapinum, Amoxepine, Desmethylloxapin]</data>
  <data key="d9">Amoxapine, the &lt;i&gt;N&lt;/i&gt;-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical &amp;beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H&lt;sub&gt;1&lt;/sub&gt; receptors, &amp;alpha;&lt;sub&gt;1&lt;/sub&gt;-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Amoxapine may be used to treat neurotic and reactive depressive disorders, endogenous and psychotic depression, and mixed symptoms of depression and anxiety or agitation.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00542">
  <data key="d0">Benazepril</data>
  <data key="d1">drugbank.DB00542</data>
  <data key="d2">[drugbank.DB00542, drugbank.APRD00063]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[ACE Inhibitors and Diuretics, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Agents, Decreased Blood Pressure, Enzyme Inhibitors, Hypotensive Agents]</data>
  <data key="d14">2-[(3S)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid</data>
  <data key="d15">C24H28N2O5</data>
  <data key="d16">86541-75-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1</data>
  <data key="d20">[H][C@@]1(CCC2=CC=CC=C2N(CC(O)=O)C1=O)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC</data>
  <data key="d21">Benazepril is indicated for the treatment of hypertension[A840]. It may be used alone or in combination with thiazide diuretics[FDA Label].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Bnazpril, Benazepril, Benazeprilum]</data>
  <data key="d9">Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure[A838,A837]. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor[A836].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00540">
  <data key="d0">Nortriptyline</data>
  <data key="d1">drugbank.DB00540</data>
  <data key="d2">[drugbank.DB00540, drugbank.APRD00602]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Adrenergic Uptake Inhibitors, Agents producing tachycardia, Agents that produce hypertension, Agents that reduce seizure threshold, Anticholinergic Agents, Antidepressive Agents, Antidepressive Agents, Tricyclic, Benzocycloheptenes, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Dibenzocycloheptenes, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Histamine Antagonists, Histamine H1 Antagonists, Membrane Transport Modulators, Muscarinic Antagonists, Narrow Therapeutic Index Drugs, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Non-Selective Monoamine Reuptake Inhibitors, P-glycoprotein/ABCB1 Inhibitors, Potential QTc-Prolonging Agents, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Antagonists, Tricyclics and Other Norepinephrine-reuptake Inhibitors]</data>
  <data key="d14">methyl(3-{tricyclo[9.4.0.0,]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propyl)amine</data>
  <data key="d15">C19H21N</data>
  <data key="d16">72-69-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3</data>
  <data key="d20">CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12</data>
  <data key="d21">Primarily indicated for the relief of symptoms of depression.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[10, 11-dihydro-N-methyl-5H-dibenzo[a, d]cycloheptene-5, -propylamine, 3-(10, 11-dihydro-5H-dibenzo[a, d]cyclohepten-5-ylidene)-N-methyl-1-propanamine, Demethylamitriptyline, Desmethylamitriptyline, Nortriptylina, Nortriptyline, Nortriptylinum]</data>
  <data key="d9">Nortriptyline hydrochloride, the &lt;i&gt;N&lt;/i&gt;-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, nortriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, nortriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline. TCAs also down-regulate cerebral cortical &amp;beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H&lt;sub&gt;1&lt;/sub&gt; receptors, &amp;alpha;&lt;sub&gt;1&lt;/sub&gt;-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. Compared to other TCAs, nortriptyline is less toxic and displays less drug interactions [A6584]. As a more selective noadrenaline reuptake inhibitor, nortriptyline is less likely associated with the hypertensive cheese reaction' [A6584]. Nortriptyline exerts less anticholinergic and sedative side effects compared to the tertiary amine TCAs, amitriptyline and clomipramine. Apart from its indication to treat depression, nortriptyline has been investigated in chronic neuropathic pain (unlabeled use), fibromyalgia [A31911], irritable bowel syndrome (unlabeled use), diabetic neuropathy (unlabeled use) [A31912], post-traumatic stress disorder (unlabeled use), and migraine prophylaxis (unlabeled use).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00557">
  <data key="d0">Hydroxyzine</data>
  <data key="d1">drugbank.DB00557</data>
  <data key="d2">[drugbank.DB00557, drugbank.APRD00688]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Anti-Anxiety Agents, Antipruritics, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Diphenylmethane Derivatives, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine Receptor Antagonists, Miscellaneous Anxiolytics Sedatives and Hypnotics, Nervous System, Neurotransmitter Agents, Piperazines, Potential QTc-Prolonging Agents, Psycholeptics, QTc Prolonging Agents]</data>
  <data key="d14">2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethan-1-ol</data>
  <data key="d15">C21H27ClN2O2</data>
  <data key="d16">68-88-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2</data>
  <data key="d20">OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1</data>
  <data key="d21">For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Hidroxizina, Hychotine, Hydroksyzyny, Hydroxine, Hydroxizine, Hydroxizinum, Hydroxycine, Hydroxyzin, Hydroxyzine, Hydroxyzinum, Idrossizina]</data>
  <data key="d9">A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite cetirizine, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00553">
  <data key="d0">Methoxsalen</data>
  <data key="d1">drugbank.DB00553</data>
  <data key="d2">[drugbank.DB00553, drugbank.APRD00157]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Antipsoriatics, Antipsoriatics for Systemic Use, Antipsoriatics for Topical Use, Benzopyrans, Coloring Agents, Compounds used in a research, industrial, or household setting, Cross-Linking Reagents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strength unknown), Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Drugs that are Mainly Renally Excreted, Furocoumarins, Indicators and Reagents, Laboratory Chemicals, Photoabsorption, Photoactivated Radical Generator, Photosensitizing Activity, Photosensitizing Agents, Psoralens for Systemic Use, Psoralens for Topical Use, Pyrans, Radiation-Sensitizing Agents]</data>
  <data key="d14">9-methoxy-7H-furo[3,2-g]chromen-7-one</data>
  <data key="d15">C12H8O4</data>
  <data key="d16">298-81-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H8O4/c1-14-12-10-8(4-5-15-10)6-7-2-3-9(13)16-11(7)12/h2-6H,1H3</data>
  <data key="d20">COC1=C2OC(=O)C=CC2=CC2=C1OC=C2</data>
  <data key="d21">For the treatment of psoriasis and vitiligo</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[6-hydroxy-7-methoxy-5-benzofuranacrylic acid -lactone, 8-methoxy-[furano-3'.2':6.7-coumarin], 8-methoxy-2', 3', 6, 7-furocoumarin, 8-methoxy-4', 5':6, 7-furocoumarin, 8-Methoxyfuranocoumarin, 8-methoxypsoralen, 8-MOP, 8-MP, 9-methoxy-7H-furo[3, 2-g][1]benzopyran-7-one, Ammoidin, Methoxsalen, Mthoxsalne, Metoxaleno, O-methylxanthotoxol, Xanthotoxin, Xanthotoxine]</data>
  <data key="d9">A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00550">
  <data key="d0">Propylthiouracil</data>
  <data key="d1">drugbank.DB00550</data>
  <data key="d2">[drugbank.DB00550, drugbank.APRD00297]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents Causing Muscle Toxicity, Antimetabolites, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Immunosuppressive Agents, Myelosuppressive Agents, Noxae, Pyrimidines, Pyrimidinones, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Thiouracil, Thiouracils, Thyroid Hormone Synthesis Inhibitor, Thyroid Hormone Synthesis Inhibitors, Thyroid Products, Toxic Actions, Uracil]</data>
  <data key="d14">6-propyl-2-sulfanylidene-1,2,3,4-tetrahydropyrimidin-4-one</data>
  <data key="d15">C7H10N2OS</data>
  <data key="d16">51-52-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H10N2OS/c1-2-3-5-4-6(10)9-7(11)8-5/h4H,2-3H2,1H3,(H2,8,9,10,11)</data>
  <data key="d20">CCCC1=CC(=O)NC(=S)N1</data>
  <data key="d21">Used to manage hyperthyroidism which is due to an overactive thyroid gland (Grave's disease).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-Mercapto-6-propyl-4-pyrimidone, 2-Mercapto-6-propylpyrimid-4-one, 2-Thio-4-oxo-6-propyl-1, 3-pyrimidine, 2-Thio-6-propyl-1, 3-pyrimidin-4-one, 4-propyl-2-thiouracil, 6-Propyl-2-thio-2, 4(1H, 3H)pyrimidinedione, 6-propyl-2-thiouracil, 6-propyl-2-thioxo-2, 3-dihydropyrimidin-4(1H)-one, 6-Propylthiouracil, 6-Thio-4-propyluracil, Propiltiouracilo, Propylthiouracil, Propylthiouracile, Propylthiouracilum]</data>
  <data key="d9">A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01890">
  <data key="d0">N,N-Bis(3-(D-gluconamido)propyl)deoxycholamide</data>
  <data key="d1">drugbank.DB01890</data>
  <data key="d2">[drugbank.DB01890, drugbank.EXPT01003]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2R,3S,4R,5R)-N-{3-[(4R)-4-[(1S,2S,5R,7R,10R,11S,14R,15R,16S)-5,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0,.0,]heptadecan-14-yl]-N-(3-{[(2R,3S,4R,5R)-1,2,3,4,5,6-hexahydroxyhexylidene]amino}propyl)pentanamido]propyl}-2,3,4,5,6-pentahydroxyhexanimidic acid</data>
  <data key="d15">C42H75N3O15</data>
  <data key="d16">86303-23-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C42H75N3O15/c1-22(26-9-10-27-25-8-7-23-18-24(48)12-13-41(23,2)28(25)19-31(51)42(26,27)3)6-11-32(52)45(16-4-14-43-39(59)37(57)35(55)33(53)29(49)20-46)17-5-15-44-40(60)38(58)36(56)34(54)30(50)21-47/h22-31,33-38,46-51,53-58H,4-21H2,1-3H3,(H,43,59)(H,44,60)/t22-,23-,24-,25+,26-,27+,28+,29-,30-,31+,33-,34-,35+,36+,37-,38-,41+,42-/m1/s1</data>
  <data key="d20">[H][C@@](C)(CCC(=O)N(CCCN=C(O)[C@]([H])(O)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)CO)CCCN=C(O)[C@]([H])(O)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)CO)[C@@]1([H])CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[D-Gluconamide, N, N'-((((3alpha, 5beta, 12alpha)-3, 12-dihydroxy-24-oxocholan-24-yl)imino)di-3, 1-propanediyl)bis-, Deoxy-bigchap, N, N-Bis(3-(D-gluconamido)propyl)deoxycholamide, N, N'-((((3alpha, 5beta, 12alpha)-3, 12-Dihydroxy-24-oxocholan-24-yl)imino)di-3, 1-propandiyl)bis-D-gluconamide]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13869">
  <data key="d0">2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol</data>
  <data key="d1">drugbank.DB13869</data>
  <data key="d2">[drugbank.DB13869]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-methoxy-6-[(1E)-[(4-methylphenyl)imino]methyl]phenol</data>
  <data key="d15">C15H15NO2</data>
  <data key="d16">20772-64-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H15NO2/c1-11-6-8-13(9-7-11)16-10-12-4-3-5-14(18-2)15(12)17/h3-10,17H,1-2H3/b16-10+</data>
  <data key="d20">COC1=C(O)C(\C=N\C2=CC=C(C)C=C2)=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-Methoxy-6-[[(4-methylphenyl)imino]methyl]phenol, TIMBD]</data>
  <data key="d9">TIMBD is an azaresveratrol analog.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13866">
  <data key="d0">Etynodiol</data>
  <data key="d1">drugbank.DB13866</data>
  <data key="d2">[drugbank.DB13866]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Adrenal Cortex Hormones, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Estren Derivatives, Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Norpregnanes, Norpregnenes, Norsteroids, Progestins, Sex Hormones and Modulators of the Genital System, Steroids]</data>
  <data key="d14">(1S,2R,5S,10R,11S,14R,15S)-14-ethynyl-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-ene-5,14-diol</data>
  <data key="d15">C20H28O2</data>
  <data key="d16">1231-93-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H28O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,14-18,21-22H,4-11H2,2H3/t14-,15-,16+,17+,18-,19-,20-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](O)C=C3CC[C@@]21[H]</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(3, 17)-19-Norpregn-4-en-20-yne-3, 17-diol, 17-Ethynyl-19-norandrost-4-ene-3, 17-diol, 3-hydroxynorethisterone, Aethynodiolum, Ethinodiol, Ethynodiol, Etinodiol, tynodiol, Etynodiol, Etynodiolum]</data>
  <data key="d9">Etynodiol (INN), or ethynodiol (BAN) is a steroidal progestin related to norethisterone which was never marketed. While etynodiol is sometimes used as a synonym for etynodiol diacetate, it usually refers to etynodiol diacetate (see [DB00823]), not etynodiol.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00564">
  <data key="d0">Carbamazepine</data>
  <data key="d1">drugbank.DB00564</data>
  <data key="d2">[drugbank.DB00564, drugbank.APRD00337]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Analgesics, Analgesics, Non-Narcotic, Anticonvulsants, Antimanic Agents, Carboxamide Derivatives, Central Nervous System Agents, Central Nervous System Depressants, Chemically-Induced Disorders, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strong), Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strong), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (moderate), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (weak), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P450 1A2 Inducers, Cytochrome P450 2C19 Inducers, Cytochrome P450 2C9 Inducers, Cytochrome P450 3A4 Inducers, Decreased Central Nervous System Disorganized Electrical Activity, Dibenzazepines, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index, Enzyme Inducing Antiepileptic Drugs, Immunosuppressive Agents, Inducers of Drug Clearance, Miscellaneous Anticonvulsants, Mood Stabilizer, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Nervous System, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Substrates, P-glycoprotein/ABCB1 Substrates with narrow therapeutic index, Peripheral Nervous System Agents, Psychotropic Drugs, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Thyroxine-binding globulin substrates, Tranquilizing Agents, UGT1A1 Inducers, UGT2B7 substrates, UGT2B7 substrates with narrow therapeutic index]</data>
  <data key="d14">2-azatricyclo[9.4.0.0,]pentadeca-1(15),3,5,7,9,11,13-heptaene-2-carboxamide</data>
  <data key="d15">C15H12N2O</data>
  <data key="d16">298-46-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)</data>
  <data key="d20">NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12</data>
  <data key="d21">For the treatment of epilepsy and pain associated with true trigeminal neuralgia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[5-Carbamoyl-5H-dibenz(b, f)azepine, 5-carbamoyl-5H-dibenz[b, f]azepine, 5-Carbamoyl-5H-dibenzo(b, f)azepine, 5-Carbamyl-5H-dibenzo(b, f)azepine, 5H-Dibenz(b, f)azepine-5-carboxamide, Carbamazepen, Carbamazepin, Carbamazepina, Carbamazpine, Carbamazepine, Carbamazepinum, CBZ]</data>
  <data key="d9">An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00561">
  <data key="d0">Doxapram</data>
  <data key="d1">drugbank.DB00561</data>
  <data key="d2">[drugbank.DB00561, drugbank.APRD00935]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Agents that produce hypertension, Central Nervous System Agents, Central Nervous System Stimulants, Increased Medullary Respiratory Drive, Pyrrolidines, Pyrrolidinones, Respiratory System Agents]</data>
  <data key="d14">1-ethyl-4-[2-(morpholin-4-yl)ethyl]-3,3-diphenylpyrrolidin-2-one</data>
  <data key="d15">C24H30N2O2</data>
  <data key="d16">309-29-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H30N2O2/c1-2-26-19-22(13-14-25-15-17-28-18-16-25)24(23(26)27,20-9-5-3-6-10-20)21-11-7-4-8-12-21/h3-12,22H,2,13-19H2,1H3</data>
  <data key="d20">CCN1CC(CCN2CCOCC2)C(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d21">For use as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-doxapram, 1-ethyl-4-(2-morpholinoethyl)-3, 3-diphenyl-2-pyrrolidinone, Doxapram, Doxapramum]</data>
  <data key="d9">A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00571">
  <data key="d0">Propranolol</data>
  <data key="d1">drugbank.DB00571</data>
  <data key="d2">[drugbank.DB00571, drugbank.APRD00194]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Antiarrhythmic agents, Antihypertensive Agents, Beta Blocking Agents and Thiazides, Beta Blocking Agents, Non-Selective, Beta Blocking Agents, Non-Selective, and Thiazides, Bradycardia-Causing Agents, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Hypotensive Agents, Moderate Risk QTc-Prolonging Agents, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Naphthalenes, Neurotransmitter Agents, OCT2 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Phenoxypropanolamines, Propanolamines, Propanols, QTc Prolonging Agents, Vasodilating Agents]</data>
  <data key="d14">1-(naphthalen-1-yloxy)-3-[(propan-2-yl)amino]propan-2-ol</data>
  <data key="d15">C16H21NO2</data>
  <data key="d16">525-66-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3</data>
  <data key="d20">CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2</data>
  <data key="d21">Propranolol is indicated to treat hypertension.[L6907,L6904] Propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.[L6904,L6907]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol, 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol, beta-Propranolol, Propanalol, Propanolol, Propranolol, Propranololo, Propranololum, -Propranolol]</data>
  <data key="d9">A widely used non-cardioselective beta-adrenergic antagonist. Propranolol is used in the treatment or prevention of many disorders including acute myocardial infarction, arrhythmias, angina pectoris, hypertension, hypertensive emergencies, hyperthyroidism, migraine, pheochromocytoma, menopause, and anxiety.\n\nPropranolol was granted FDA approval on 13 November 1967.[L6904]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11219">
  <data key="d0">Enzacamene</data>
  <data key="d1">drugbank.DB11219</data>
  <data key="d2">[drugbank.DB11219]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Bornanes, Ketones, Monoterpenes, Norbornanes, Sunscreen Agents, Sunscreening Agents, Terpenes]</data>
  <data key="d14">(3E)-1,7,7-trimethyl-3-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-2-one</data>
  <data key="d15">C18H22O</data>
  <data key="d16">36861-47-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H22O/c1-12-5-7-13(8-6-12)11-14-15-9-10-18(4,16(14)19)17(15,2)3/h5-8,11,15H,9-10H2,1-4H3/b14-11+</data>
  <data key="d20">CC1=CC=C(\C=C2/C3CCC(C)(C2=O)C3(C)C)C=C1</data>
  <data key="d21">Indicated for use as an active sunscreen agent.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+/-)-3-(p-methylbenzylidene)camphor, 3-(4-methylbenzylidene)camphor, 3-(p-Methylbenzylidene)-DL-camphor, 4-MBC, 4-methylbenzylidene camphor, enzacamne, Enzacamene, Enzacamene D-L form, enzacameno, enzacamenum, Methyl benzylidene camphor]</data>
  <data key="d9">Commonly known as 4-methylbenzylidene-camphor (4-MBC), enzacamene is a camphor derivative and an organic chemical UV-B filter. It is used in cosmetic products such as sunscreen to provide skin protection against UV rays. While its effects on the human reproductive system as an endocrine disruptor are being investigated, its use in over-the-counter and cosmetic products is approved by Health Canada. Its tradenames include Eusolex 6300 (Merck) and Parsol 5000 (DSM).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13873">
  <data key="d0">Fenofibric acid</data>
  <data key="d1">drugbank.DB13873</data>
  <data key="d2">[drugbank.DB13873]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acids, Acyclic, Agents Causing Muscle Toxicity, Anticholesteremic Agents, Benzene Derivatives, Benzhydryl Compounds, Benzophenones, Butyrates, Drugs that are Mainly Renally Excreted, Ethers, Fatty Acids, Fatty Acids, Volatile, Fibric Acids, Hypolipidemic Agents, Isobutyrates, Ketones, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, Lipids, Noxae, Peroxisome Proliferator Receptor alpha Agonist, Phenols, Phenyl Ethers, Toxic Actions]</data>
  <data key="d14">2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid</data>
  <data key="d15">C17H15ClO4</data>
  <data key="d16">42017-89-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)</data>
  <data key="d20">CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O</data>
  <data key="d21">For use as an adjunctive therapy to diet to: (a) reduce triglyceride levels in adult patients with severe hypertriglyceridemia, and (b) reduce elevated total cholesterol, low-density-lipoprotein (LDL-C), triglycerides, and apolipoprotein B, and to increase high-density-lipoprotein (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). [FDA Label]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Fenofibrate is a third generation fibric acid derivative that is predominantly administered as monotherapy to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B and alternatively to increase high-density lipoprotein cholesterol in patients diagnosed with primary hyperlipidemia or mixed dyslipidemia and to reduce triglycerides in patients with severe hypertriglyceridemia [FDA Label, A32038]. Fenofibrate however is generally extremely lipophilic, largely insoluble in water, and poorly absorbed [A32038]. As the primary active metabolite of fenofibrate however, various hydrophilic salt formulations of fenofibric acid have since been developed, resulting in therapeutic agents that demonstrate far greater solubility, absorption throughout the gastrointestinal tract, bioavailability, and capability to be administered irrespective of  patient food intake [FDA Label, A32038].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01821">
  <data key="d0">L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide</data>
  <data key="d1">drugbank.DB01821</data>
  <data key="d2">[drugbank.DB01821, drugbank.EXPT01252]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-2-amino-N-[(1S)-3-amino-1-(C-hydroxycarbonimidoyl)propyl]-5-(1-nitrocarbamimidamido)pentanimidic acid</data>
  <data key="d15">C10H22N8O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H22N8O4/c11-4-3-7(8(13)19)16-9(20)6(12)2-1-5-15-10(14)17-18(21)22/h6-7H,1-5,11-12H2,(H2,13,19)(H,16,20)(H3,14,15,17)/t6-,7-/m0/s1</data>
  <data key="d20">[H][C@](N)(CCCNC(=N)NN(=O)=O)C(O)=N[C@@]([H])(CCN)C(O)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB13800">
  <data key="d0">Calcium levulinate</data>
  <data key="d1">drugbank.DB13800</data>
  <data key="d2">[drugbank.DB13800]</data>
  <data key="d12">[approved, experimental]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Calcium Salts, Enzyme Inhibitors, Keto Acids, Mineral Supplements]</data>
  <data key="d14">calcium bis(4-oxopentanoate)</data>
  <data key="d15">C10H14CaO6</data>
  <data key="d16">591-64-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/2C5H8O3.Ca/c2*1-4(6)2-3-5(7)8;/h2*2-3H2,1H3,(H,7,8);/q;;+2/p-2</data>
  <data key="d20">[Ca++].CC(=O)CCC([O-])=O.CC(=O)CCC([O-])=O</data>
  <data key="d21">This new application of calcium is intended for use as a food fortifier, to fortify foods like sauces, condiments, beer, beverages, soft drinks, milk and milk products, soy milk and soy products with calcium nutrition [L2765]. Calcium levulinate can be used alone, or with calcium lactate, calcium chloride, and other compounds, either for pharmaceutical tablets, capsules, or injections preparation [L2765]. In essence, calcium levulinate is ultimately a relatively new calcium supplementation option [L2767].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Calcium laevulate, Calcium levulinate anhydrous]</data>
  <data key="d9">The relatively new calcium levulinate is produced from a direct reaction between L- or levulinic acid levulose and calcium hydroxide [L2765]. The resultant calcium levulinate formulation, when used as a calcium supplement, possesses a high calcium content that is observed to be 14.8% higher than the content typically found in calcium lactate [L2765]. This formulation is considered a low molecular weight organic calcium ion type that is easily absorbed through the intestinal wall [L2765].\n\nThis new application of calcium is intended for use as a food fortifier, to fortify foods like sauces, condiments, beer, beverages, soft drinks, milk and milk products, soy milk and soy products with calcium nutrition [L2765]. Calcium levulinate can be used alone, or with calcium lactate, calcium chloride, and other compounds, either for pharmaceutical tablets, capsules, or injections preparation [L2765].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00503">
  <data key="d0">Ritonavir</data>
  <data key="d1">drugbank.DB00503</data>
  <data key="d2">[drugbank.DB00503, drugbank.APRD00312]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Acyclic, Agents Causing Muscle Toxicity, Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Antivirals for treatment of HCV infections, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Breast Cancer Resistance Protein Inhibitors, BSEP/ABCB11 Substrates, Chemically-Induced Disorders, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (unknown strength), Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (moderate), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (unknown strength), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inhibitors (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (moderate), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strong), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inducers, Cytochrome P-450 CYP3A7 Inducers (strength unknown), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strong), Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P450 1A2 Inducers, Cytochrome P450 2C19 Inducers, Cytochrome P450 2C9 Inducers, Cytochrome P450 2D6 Inhibitors, Cytochrome P450 3A Inducers, Cytochrome P450 3A Inhibitors, Cytochrome P450 3A4 Inhibitors, Direct Acting Antivirals, Enzyme Inhibitors, HIV Protease Inhibitors, Hyperglycemia-Associated Agents, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Potential QTc-Prolonging Agents, Protease Inhibitors, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Sulfur Compounds, Thiazoles, UDP Glucuronosyltransferases Inducers, UGT1A1 Inducers]</data>
  <data key="d14">1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[(2S)-3-methyl-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}butanamido]-1,6-diphenylhexan-2-yl]carbamate</data>
  <data key="d15">C37H48N6O5S2</data>
  <data key="d16">155213-67-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1</data>
  <data key="d20">CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1</data>
  <data key="d21">Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Ritonavir, Ritonavirum]</data>
  <data key="d9">Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulation and as capsules. \n\nWhile ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as [DB09297] and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as a first-line therapy for HCV Genotype 1a/b and 4 treatment-nave patients with or without cirrhosis. \n\nRitonavir is found in a fixed-dose combination product with [DB09296], [DB09183], and [DB09297] as the FDA-approved product Viekira Pak. First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis.\n\nRitonavir is also available as a fixed-dose combination product with [DB09296] and [DB09297] as the FDA- and Health Canada-approved product Technivie. First approved in July 2015, Technivie is indicated in combination with Ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis.\n\nIn Canada, ritonavir is also available as a fixed-dose combination product with [DB09296], [DB09183], and [DB09297] as the Health Canada-approved, commercially available product Holkira Pak. First approved in January 2015, Holkira Pak is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a with or without cirrhosis. Inclusion of ritonavir can can select for HIV-1 protease inhibitor resistance-associated substitutions. Any HCV/HIV-1 co-infected patients treated with ritonavir-containing combination therapies should also be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug resistance.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00502">
  <data key="d0">Haloperidol</data>
  <data key="d1">drugbank.DB00502</data>
  <data key="d2">[drugbank.DB00502, drugbank.APRD00538]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents that reduce seizure threshold, Anti-Dyskinesia Agents, Antiemetics, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Autonomic Agents, Butyrophenone Derivatives, Butyrophenones, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs that are Mainly Renally Excreted, Gastrointestinal Agents, Hyperglycemia-Associated Agents, Ketones, Moderate Risk QTc-Prolonging Agents, Nervous System, Neurotoxic agents, Neurotransmitter Agents, NMDA Receptor Antagonists, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Peripheral Nervous System Agents, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Tranquilizing Agents, UGT1A9 Substrates]</data>
  <data key="d14">4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one</data>
  <data key="d15">C21H23ClFNO2</data>
  <data key="d16">52-86-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2</data>
  <data key="d20">OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1</data>
  <data key="d21">For the treatment of schizophrenia [L2016]\n\nFor the treatment of acute psychosis in acutely agitated schizophrenic patients with moderately severe to very severe symptoms [L2016]\n\nFor the treatment of severe behavioral or psychological symptoms of dementia [L2016]\n\nFor the treatment of delirium in the pediatric intensive care unit [L2016]\n\nFor the treatment of agitation or delirium [L2016]\n\nFor agitation or delirium in adult patients with no underlying psychiatric illness [L2016]\n\nFor use as a second-line agent for rescue treatment of chemotherapy-induced nausea/vomiting [L2016]\n\nFor the treatment of irritability associated with autistic disorder [L2016]\n\nFor the treatment of tics and vocal utterances associated with Tourette's syndrome [L2016]\n\nFor the treatment of severe behavioral problems associated with oppositional defiant disorder or other disruptive behavioral disorders, or for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients who show excessive motor activity with accompanying conduct disorders [L2016]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine, 4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone, 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one, 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone, 4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone, Haloperidol, Haloperidolum, -(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone]</data>
  <data key="d9">A phenyl-piperidinyl-butyrophenone, traditional antipsychotic drug that is used primarily to treat schizophrenia and other psychoses. It is also used for the management of schizoaffective disorder, delusional disorders, ballism, and Tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea associated with Huntington's disease. It is a potent antiemetic and is used in the treatment of intractable hiccups [L1994], [L1996].\n\nThe efficacy of haloperidol was first established in controlled trials in the 1960s [L2014].\n\nInterestingly, in vivo pharmacogenetic studies have demonstrated that the metabolism of haloperidol may be modulated by genetically determined polymorphic _CYP2D6_ activity. However, these findings contradict the findings from studies in vitro with human liver microsomes and from drug interaction studies in vivo. Inter-ethnic and pharmacogenetic differences in haloperidol metabolism may possibly explain these observations [A32346].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01833">
  <data key="d0">L-2-Amino-4-(Guanidinooxy)Butyric Acid</data>
  <data key="d1">drugbank.DB01833</data>
  <data key="d2">[drugbank.DB01833, drugbank.EXPT01587]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-2-amino-4-(carbamimidamidooxy)butanoic acid</data>
  <data key="d15">C5H12N4O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C5H12N4O3/c6-3(4(10)11)1-2-12-9-5(7)8/h3H,1-2,6H2,(H,10,11)(H4,7,8,9)/t3-/m0/s1</data>
  <data key="d20">N[C@@H](CCONC(N)=N)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00519">
  <data key="d0">Trandolapril</data>
  <data key="d1">drugbank.DB00519</data>
  <data key="d2">[drugbank.DB00519, drugbank.APRD01269]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[ACE Inhibitors and Calcium Channel Blockers, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Agents, Enzyme Inhibitors, Hypotensive Agents, Protease Inhibitors]</data>
  <data key="d14">(2S,3aR,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid</data>
  <data key="d15">C24H34N2O5</data>
  <data key="d16">87679-37-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1</data>
  <data key="d20">[H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O</data>
  <data key="d21">For the treatment of mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure (CHF), to improve survival following myocardial infarction (MI) in individuals who are hemodynamically stable and demonstrate symptoms of left ventricular systolic dysfunction or signs of CHF within a few days following acute MI, and to slow progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Trandolapril, Trandolaprilum]</data>
  <data key="d9">Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00515">
  <data key="d0">Cisplatin</data>
  <data key="d1">drugbank.DB00515</data>
  <data key="d2">[drugbank.DB00515, drugbank.APRD00359]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Cardiotoxic antineoplastic agents, Chlorine Compounds, Cholinesterase Inhibitors, Compounds used in a research, industrial, or household setting, Cross-Linking Reagents, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index, Immunosuppressive Agents, Indicators and Reagents, Laboratory Chemicals, Myelosuppressive Agents, Nephrotoxic agents, Nitrogen Compounds, OCT2 Inhibitors, OCT2 Substrates, OCT2 substrates with narrow therapeutic index, P-glycoprotein/ABCB1 Substrates, Platinum Compounds, Radiation-Sensitizing Agents]</data>
  <data key="d14">NA</data>
  <data key="d15">Cl2H6N2Pt</data>
  <data key="d16">15663-27-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2</data>
  <data key="d20">[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]</data>
  <data key="d21">For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[CDDP, Cis-DDP, cis-diamminedichloroplatinum(II), Cisplatin, cisplatino]</data>
  <data key="d9">Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00514">
  <data key="d0">Dextromethorphan</data>
  <data key="d1">drugbank.DB00514</data>
  <data key="d2">[drugbank.DB00514, drugbank.APRD00655]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Alkaloids, Anticholinergic Agents, Antidepressive Agents, Antitussive Agents, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cough and Cold Preparations, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Excitatory Amino Acid Agents, Excitatory Amino Acid Antagonists, Expectorants, Morphinans, Narcotics, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, NMDA Receptor Antagonists, Opiate Alkaloids, Opium Alkaloids and Derivatives, Phenanthrenes, Respiratory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators, Sigma-1 Agonist, Sigma-1 Receptor Agonists, Uncompetitive N-methyl-D-aspartate Receptor Antagonist, Uncompetitive NMDA Receptor Antagonists]</data>
  <data key="d14">(1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.0,.0,]heptadeca-2(7),3,5-triene</data>
  <data key="d15">C18H25NO</data>
  <data key="d16">125-71-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1</data>
  <data key="d20">[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C</data>
  <data key="d21">For treatment and relief of dry cough.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+)-dextromethorphan, D-methorphan, delta-Methorphan, Dex, Dextromethorfan, Dextromethorphan, Dextromthorphane, Dextromethorphanum, Dextrometorfano, DM]</data>
  <data key="d9">The d-isomer of the codeine analog of levorphanol. Dextromethorphan shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (receptors, N-methyl-D-aspartate) and acts as a non-competitive channel blocker. It is one of the widely used antitussives, and is also used to study the involvement of glutamate receptors in neurotoxicity. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00527">
  <data key="d0">Cinchocaine</data>
  <data key="d1">drugbank.DB00527</data>
  <data key="d2">[drugbank.DB00527, drugbank.APRD00915]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Amides, Analgesics and Anesthetics, Anesthetics, Anesthetics for Topical Use, Anesthetics, Local, Antipruritics and Local Anesthetics, Antipruritics, Incl. Antihistamines, Anesthetics, Etc., Cell-mediated Immunity, Central Nervous System Agents, Cholinesterase Inhibitors, Dermatologicals, Increased Histamine Release, Nervous System, Ophthalmologicals, Otologicals, Peripheral Nervous System Agents, Quinolines, Sensory Organs, Sensory System Agents, Standardized Chemical Allergen, Vasoprotectives]</data>
  <data key="d14">2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide</data>
  <data key="d15">C20H29N3O2</data>
  <data key="d16">85-79-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)</data>
  <data key="d20">CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC</data>
  <data key="d21">For production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-butoxy-N-(2-(diethylamino)ethyl)cinchoninamide, 2-butoxy-N-(-diethylaminoethyl)cinchoninamide, 2-butoxy-N-(-diethylaminoethyl)cinchoninamide, 2-butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide, 2-Butoxy-quinoline-4-carboxylic acid (2-diethylamino-ethyl)-amide, 2-butoxyquinoline-4-carboxylic acid diethylaminoethylamide, 2-N-butoxy-N-(2-diethylaminoethyl)cinchoninamide, Cinchocaine, Cinchocainum, Cincocainio, Dibucaine, N-(2-(diethylamino)ethyl)-2-butoxycinchoninamide, -butyloxycinchonic acid--diethylethylenediamine, -butyloxycinchoninic acid diethylethylenediamide]</data>
  <data key="d9">A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB01805">
  <data key="d0">Monoisopropylphosphorylserine</data>
  <data key="d1">drugbank.DB01805</data>
  <data key="d2">[drugbank.DB01805, drugbank.EXPT02178]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-2-amino-3-{[hydroxy(propan-2-yloxy)phosphoryl]oxy}propanoic acid</data>
  <data key="d15">C6H14NO6P</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C6H14NO6P/c1-4(2)13-14(10,11)12-3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)(H,10,11)/t5-/m0/s1</data>
  <data key="d20">[H][C@](N)(COP(O)(=O)OC(C)C)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08061">
  <data key="d0">4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE</data>
  <data key="d1">drugbank.DB08061</data>
  <data key="d2">[drugbank.DB08061]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-[3-(4-chlorophenyl)-1H-pyrazol-5-yl]piperidine</data>
  <data key="d15">C14H16ClN3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H16ClN3/c15-12-3-1-10(2-4-12)13-9-14(18-17-13)11-5-7-16-8-6-11/h1-4,9,11,16H,5-8H2,(H,17,18)</data>
  <data key="d20">ClC1=CC=C(C=C1)C1=NNC(=C1)C1CCNCC1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08062">
  <data key="d0">3-(4-CHLOROPHENYL)-5-(METHYLTHIO)-4H-1,2,4-TRIAZOLE</data>
  <data key="d1">drugbank.DB08062</data>
  <data key="d2">[drugbank.DB08062]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-(4-chlorophenyl)-5-(methylsulfanyl)-4H-1,2,4-triazole</data>
  <data key="d15">C9H8ClN3S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H8ClN3S/c1-14-9-11-8(12-13-9)6-2-4-7(10)5-3-6/h2-5H,1H3,(H,11,12,13)</data>
  <data key="d20">CSC1=NN=C(N1)C1=CC=C(Cl)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08072">
  <data key="d0">4-(2-AMINOETHOXY)-3,5-DICHLORO-N-[3-(1-METHYLETHOXY)PHENYL]BENZAMIDE</data>
  <data key="d1">drugbank.DB08072</data>
  <data key="d2">[drugbank.DB08072]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-(2-aminoethoxy)-3,5-dichloro-N-[3-(propan-2-yloxy)phenyl]benzamide</data>
  <data key="d15">C18H20Cl2N2O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H20Cl2N2O3/c1-11(2)25-14-5-3-4-13(10-14)22-18(23)12-8-15(19)17(16(20)9-12)24-7-6-21/h3-5,8-11H,6-7,21H2,1-2H3,(H,22,23)</data>
  <data key="d20">CC(C)OC1=CC(NC(=O)C2=CC(Cl)=C(OCCN)C(Cl)=C2)=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08073">
  <data key="d0">(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE</data>
  <data key="d1">drugbank.DB08073</data>
  <data key="d2">[drugbank.DB08073]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-1-(1H-indol-3-yl)-3-{[5-(3-methyl-1H-indazol-5-yl)pyridin-3-yl]oxy}propan-2-amine</data>
  <data key="d15">C24H23N5O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H23N5O/c1-15-22-10-16(6-7-24(22)29-28-15)17-9-20(13-26-11-17)30-14-19(25)8-18-12-27-23-5-3-2-4-21(18)23/h2-7,9-13,19,27H,8,14,25H2,1H3,(H,28,29)/t19-/m0/s1</data>
  <data key="d20">[H][C@@](N)(COC1=CN=CC(=C1)C1=CC=C2NN=C(C)C2=C1)CC1=CNC2=CC=CC=C12</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08082">
  <data key="d0">N-(2-AMINOETHYL)-P-CHLOROBENZAMIDE</data>
  <data key="d1">drugbank.DB08082</data>
  <data key="d2">[drugbank.DB08082]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-chloro-N-(2-hydroxyethyl)benzamide</data>
  <data key="d15">C9H10ClNO2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H10ClNO2/c10-8-3-1-7(2-4-8)9(13)11-5-6-12/h1-4,12H,5-6H2,(H,11,13)</data>
  <data key="d20">OCCNC(=O)C1=CC=C(Cl)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09477">
  <data key="d0">Enalaprilat</data>
  <data key="d1">drugbank.DB09477</data>
  <data key="d2">[drugbank.DB09477]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Amino Acids, Peptides, and Proteins, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Agents, Decreased Blood Pressure, Dipeptides, Drugs that are Mainly Renally Excreted, Enalapril, Enzyme Inhibitors, Hypotensive Agents, Oligopeptides, Peptides, Protease Inhibitors]</data>
  <data key="d14">(2S)-1-[(2S)-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}propanoyl]pyrrolidine-2-carboxylic acid</data>
  <data key="d15">C18H24N2O5</data>
  <data key="d16">76420-72-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)/t12-,14-,15-/m0/s1</data>
  <data key="d20">[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@@]1([H])C(O)=O</data>
  <data key="d21">Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Enalaprilat, Enalaprilat anhydrous]</data>
  <data key="d9">Enalaprilat is the active metabolite of the orally available pro-drug, [enalapril]. Used in the treatment of hypertension, enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme (ACE) from transforming angiotensin I into angiotensin II. As angiotensin II is responsible for vasoconstriction and sodium reabsorption in the proximal tubule of the kidney, down-regulation of this protein results in reduced blood pressure and blood fluid volume. Enalaprilat was originally created to overcome the limitations of the first ACE inhibitor, captopril, which had numerous side effects and left a metallic taste in the mouth. Removal of the problematic thiol group from captopril resulted in enalaprilat, which was then modified further with an ester to create the orally available pro-drug enalapril.\n\nEnalaprilat is poorly orally available and is therefore only available as an intravenous injection for the treatment of hypertension when oral therapy is not possible.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11783">
  <data key="d0">Imidapril</data>
  <data key="d1">drugbank.DB11783</data>
  <data key="d2">[drugbank.DB11783]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Agents, Enzyme Inhibitors, Hypotensive Agents, Imidazoles, Protease Inhibitors]</data>
  <data key="d14">(4S)-3-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid</data>
  <data key="d15">C20H27N3O6</data>
  <data key="d16">89371-37-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1</data>
  <data key="d20">[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(=O)OCC)C(=O)N1C(=O)N(C)C[C@@]1([H])C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[imidapril]</data>
  <data key="d9">Imidapril has been investigated for the treatment of Kidney, Polycystic, Autosomal Dominant.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08152">
  <data key="d0">{(2S)-1-[N-(tert-butoxycarbonyl)glycyl]pyrrolidin-2-yl}methyl (3-chlorophenyl)acetate</data>
  <data key="d1">drugbank.DB08152</data>
  <data key="d2">[drugbank.DB08152]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">[(2S)-1-(2-{[(tert-butoxy)carbonyl]amino}acetyl)pyrrolidin-2-yl]methyl 2-(3-chlorophenyl)acetate</data>
  <data key="d15">C20H27ClN2O5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H27ClN2O5/c1-20(2,3)28-19(26)22-12-17(24)23-9-5-8-16(23)13-27-18(25)11-14-6-4-7-15(21)10-14/h4,6-7,10,16H,5,8-9,11-13H2,1-3H3,(H,22,26)/t16-/m0/s1</data>
  <data key="d20">[H][C@@]1(COC(=O)CC2=CC(Cl)=CC=C2)CCCN1C(=O)CNC(=O)OC(C)(C)C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08167">
  <data key="d0">Methylthioninium</data>
  <data key="d1">drugbank.DB08167</data>
  <data key="d2">[drugbank.DB08167]</data>
  <data key="d12">[experimental, investigational]</data>
  <data key="d13">[Oxidation-Reduction Activity, Oxidation-Reduction Agent, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome]</data>
  <data key="d14">3,7-bis(dimethylamino)-5-phenothiazin-5-ylium</data>
  <data key="d15">C16H18N3S</data>
  <data key="d16">7060-82-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H18N3S/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13/h5-10H,1-4H3/q+1</data>
  <data key="d20">CN(C)C1=CC2=[S+]C3=CC(=CC=C3N=C2C=C1)N(C)C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Methylene blue cation]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08176">
  <data key="d0">(1Z)-4-(4-FLUOROPHENYL)-2-METHYLIDENEBUTAN-1-IMINE</data>
  <data key="d1">drugbank.DB08176</data>
  <data key="d2">[drugbank.DB08176]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">1-(3-carboximidoylbut-3-en-1-yl)-4-fluorobenzene</data>
  <data key="d15">C11H12FN</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H12FN/c1-9(8-13)2-3-10-4-6-11(12)7-5-10/h4-8,13H,1-3H2/b13-8+</data>
  <data key="d20">[H]N=C([H])C(=C)CCC1=CC=C(F)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11742">
  <data key="d0">Ebastine</data>
  <data key="d1">drugbank.DB11742</data>
  <data key="d2">[drugbank.DB11742]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Antihistamines for Systemic Use, CYP3A Substrates (Sensitive), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Ketones, Neurotransmitter Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents]</data>
  <data key="d14">1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one</data>
  <data key="d15">C32H39NO2</data>
  <data key="d16">90729-43-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C32H39NO2/c1-32(2,3)28-18-16-25(17-19-28)30(34)15-10-22-33-23-20-29(21-24-33)35-31(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-9,11-14,16-19,29,31H,10,15,20-24H2,1-3H3</data>
  <data key="d20">CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Ebastina]</data>
  <data key="d9">Ebastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08121">
  <data key="d0">(2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid</data>
  <data key="d1">drugbank.DB08121</data>
  <data key="d2">[drugbank.DB08121]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-3-phenyl-2-(4-phenylphenoxy)propanoic acid</data>
  <data key="d15">C21H18O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H18O3/c22-21(23)20(15-16-7-3-1-4-8-16)24-19-13-11-18(12-14-19)17-9-5-2-6-10-17/h1-14,20H,15H2,(H,22,23)/t20-/m0/s1</data>
  <data key="d20">[H][C@@](CC1=CC=CC=C1)(OC1=CC=C(C=C1)C1=CC=CC=C1)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09401">
  <data key="d0">Isosorbide</data>
  <data key="d1">drugbank.DB09401</data>
  <data key="d2">[drugbank.DB09401, drugbank.DB05707]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Adrenal Cortex Hormones, Alcohols, Antianginal Agents, Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Antispermatogenic Agents, Carbohydrates, Cardiovascular Agents, Contraceptive Agents, Male, Diuretics, Diuretics, Osmotic, Hormonal Contraceptives for Systemic Use, Natriuretic Agents, Noxae, Organic Nitrates, Reproductive Control Agents, Sesquiterpenes, Sorbitol, Spermatocidal Agents, Sugar Alcohols, Terpenes, Toxic Actions, Vasodilating Agents]</data>
  <data key="d14">(3R,3aR,6S,6aR)-hexahydrofuro[3,2-b]furan-3,6-diol</data>
  <data key="d15">C6H10O4</data>
  <data key="d16">652-67-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C6H10O4/c7-3-1-9-6-4(8)2-10-5(3)6/h3-8H,1-2H2/t3-,4+,5-,6-/m1/s1</data>
  <data key="d20">[H][C@]1(O)CO[C@]2([H])[C@]([H])(O)CO[C@]12[H]</data>
  <data key="d21">Indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.[label]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Isosorbide is an organic nitrate with vasodilatory properties on both arteries and veins.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11726">
  <data key="d0">Encenicline</data>
  <data key="d1">drugbank.DB11726</data>
  <data key="d2">[drugbank.DB11726, drugbank.DB06341]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Nicotinic Agonists, Sulfur Compounds]</data>
  <data key="d14">N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophene-2-carboxamide</data>
  <data key="d15">C16H17ClN2OS</data>
  <data key="d16">550999-75-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H17ClN2OS/c17-12-3-1-2-11-8-14(21-15(11)12)16(20)18-13-9-19-6-4-10(13)5-7-19/h1-3,8,10,13H,4-7,9H2,(H,18,20)/t13-/m0/s1</data>
  <data key="d20">ClC1=C2SC(=CC2=CC=C1)C(=O)N[C@H]1CN2CCC1CC2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Encenicline has been investigated for the treatment of Cognition, Schizophrenia, Alzheimer's Disease, Cardiac Repolarization, and Central Nervous System Diseases.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08187">
  <data key="d0">METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE</data>
  <data key="d1">drugbank.DB08187</data>
  <data key="d2">[drugbank.DB08187]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-1-[(2R)-2-(methylamino)-3-phenylpropanoyl]-N-{[(1r,4r)-4-aminocyclohexyl]methyl}pyrrolidine-2-carboximidic acid</data>
  <data key="d15">C22H34N4O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H34N4O2/c1-24-19(14-16-6-3-2-4-7-16)22(28)26-13-5-8-20(26)21(27)25-15-17-9-11-18(23)12-10-17/h2-4,6-7,17-20,24H,5,8-15,23H2,1H3,(H,25,27)/t17-,18-,19-,20+/m1/s1</data>
  <data key="d20">[H][C@](CC1=CC=CC=C1)(NC)C(=O)N1CCC[C@@]1([H])C(O)=NC[C@@]1([H])CC[C@]([H])(N)CC1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09552">
  <data key="d0">Thonzonium</data>
  <data key="d1">drugbank.DB09552</data>
  <data key="d2">[drugbank.DB09552]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amines, Ammonium Compounds, Nitrogen Compounds, Onium Compounds]</data>
  <data key="d14">hexadecyl(2-{[(4-methoxyphenyl)methyl](pyrimidin-2-yl)amino}ethyl)dimethylazanium</data>
  <data key="d15">C32H55N4O</data>
  <data key="d16">25466-36-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C32H55N4O/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-27-36(2,3)28-26-35(32-33-24-19-25-34-32)29-30-20-22-31(37-4)23-21-30/h19-25H,5-18,26-29H2,1-4H3/q+1</data>
  <data key="d20">CCCCCCCCCCCCCCCC[N+](C)(C)CCN(CC1=CC=C(OC)C=C1)C1=NC=CC=N1</data>
  <data key="d21">Used as a monocationic surfactant and detergent to help penetration of active ingredients through cellular debris for its antibacterial action.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Tonzonium]</data>
  <data key="d9">Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication. A common pharmaceutical formulation of thonzonium bromide is cortisporin-TC ear drops. It is also reported that thonzonium also confers an antifungal property and antiresorptive effect on bone.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09564">
  <data key="d0">Insulin Degludec</data>
  <data key="d1">drugbank.DB09564</data>
  <data key="d2">[drugbank.DB09564]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Amino Acids, Peptides, and Proteins, Blood Glucose Lowering Agents, Drugs Used in Diabetes, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Insulin, Insulin Analog, Insulins and Analogues, Insulins and Analogues for Injection, Intermediate- or Long-Acting Combined With Fast-Acting, Insulins and Analogues for Injection, Long-Acting, Long-acting Insulins, Pancreatic Hormones, Peptide Hormones, Peptides]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">844439-96-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;59dea6ee-6cc5-467a-984f-4656e7173e5f A Chain\nFVNQHLCGSHLVEALYLVCGERGFFYTPK, &gt;3947f1d9-8ed4-4522-bc37-dbcb3d16c588 B Chain\nGIVEQCCTSICSLYQLENYCN]</data>
  <data key="d8">[Insulina degludec]</data>
  <data key="d9">Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.\n\nInsulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin degludec, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. \n\nMarketed as the brand name product Tresiba, insulin degludec has a duration of action up to 42 hours allowing for once-daily dosing, typically at bedtime. Due to its duration of action, Tresiba is considered "basal insulin" as it provides low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Basal insulin is often combined with short-acting "bolus insulin" such as [DB00046], [DB01309], or [DB01306] to provide higher doses of insulin required following meals. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia.\n\nCompared to endogenous insulin, insulin degludec has an added hexadecanedioic acid on lysine at the B29 position which allows for the formation of multi-hexamers. When injected subcutaneously, these multi-hexamers form a drug depot store from which monomers are slowly and continuously absorbed into the circulation. As a result, Insulin Degludec has a protracted time action profile due to the delayed absorption from subcutaneous tissue depots into the systemic circulation. Compared to available long-acting analogues such as [DB00047] and [DB01307], which have a duration of action of 20-24 hours, insulin degludec provides a consistent level of basal insulin over 42 hours with a low peak:trough ratio. Limitations of shorter acting analogues include more frequent dosing and less stable pharmacokinetics, which may negatively impact patient adherence and glucose control, particularly nocturnal control.\n\nWithout an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.\n\nInsulin Degludec was approved by the FDA in September 2015 as the product Tresiba, for use in providing glycemic control to adults with diabetes mellitus.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08231">
  <data key="d0">Myristic acid</data>
  <data key="d1">drugbank.DB08231</data>
  <data key="d2">[drugbank.DB08231]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Fatty Acids, Lipids, Myristic Acids]</data>
  <data key="d14">tetradecanoic acid</data>
  <data key="d15">C14H28O2</data>
  <data key="d16">544-63-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H28O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16/h2-13H2,1H3,(H,15,16)</data>
  <data key="d20">CCCCCCCCCCCCCC(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-tridecanecarboxylic acid, N-tetradecan-1-oic acid, N-tetradecanoic acid, Tetradecanoic acid]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08229">
  <data key="d0">[N-(3-DIBENZYLCARBAMOYL-OXIRANECARBONYL)-HYDRAZINO]-ACETIC ACID</data>
  <data key="d1">drugbank.DB08229</data>
  <data key="d2">[drugbank.DB08229]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-[(3S)-N-amino-3-(dibenzylcarbamoyl)-3-hydroxypropanamido]acetic acid</data>
  <data key="d15">C20H23N3O5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H23N3O5/c21-23(14-19(26)27)18(25)11-17(24)20(28)22(12-15-7-3-1-4-8-15)13-16-9-5-2-6-10-16/h1-10,17,24H,11-14,21H2,(H,26,27)/t17-/m0/s1</data>
  <data key="d20">[H][C@](O)(CC(=O)N(N)CC(O)=O)C(=O)N(CC1=CC=CC=C1)CC1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08251">
  <data key="d0">4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID</data>
  <data key="d1">drugbank.DB08251</data>
  <data key="d2">[drugbank.DB08251]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-(5-{[(2S)-1-carboxy-3-oxopropan-2-yl]carbamoyl}pyridin-3-yl)benzoic acid</data>
  <data key="d15">C17H14N2O6</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H14N2O6/c20-9-14(6-15(21)22)19-16(23)13-5-12(7-18-8-13)10-1-3-11(4-2-10)17(24)25/h1-5,7-9,14H,6H2,(H,19,23)(H,21,22)(H,24,25)/t14-/m0/s1</data>
  <data key="d20">[H][C@@](CC(O)=O)(NC(=O)C1=CN=CC(=C1)C1=CC=C(C=C1)C(O)=O)C=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08254">
  <data key="d0">2-NAPHTHALENESULFONIC ACID</data>
  <data key="d1">drugbank.DB08254</data>
  <data key="d2">[drugbank.DB08254]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Acids, Acids, Noncarboxylic, Arylsulfonates, Arylsulfonic Acids, Naphthalenes, Sulfonic Acids, Sulfur Acids, Sulfur Compounds]</data>
  <data key="d14">naphthalene-2-sulfonic acid</data>
  <data key="d15">C10H8O3S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H8O3S/c11-14(12,13)10-6-5-8-3-1-2-4-9(8)7-10/h1-7H,(H,11,12,13)</data>
  <data key="d20">OS(=O)(=O)C1=CC2=C(C=CC=C2)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11828">
  <data key="d0">Neratinib</data>
  <data key="d1">drugbank.DB11828</data>
  <data key="d2">[drugbank.DB11828]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Kinase Inhibitor, Kinase Inhibitors, P-glycoprotein/ABCB1 Inhibitors, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d14">(2E)-N-[4-({3-chloro-4-[(pyridin-2-yl)methoxy]phenyl}amino)-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide</data>
  <data key="d15">C30H29ClN6O3</data>
  <data key="d16">698387-09-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+</data>
  <data key="d20">CCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C(C=NC2=C1)C#N</data>
  <data key="d21">For use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy [FDA Label].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Neratinib]</data>
  <data key="d9">Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11829">
  <data key="d0">Ruboxistaurin</data>
  <data key="d1">drugbank.DB11829</data>
  <data key="d2">[drugbank.DB11829]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Acyclic, Dicarboxylic Acids, Enzyme Inhibitors, Imides, Maleates, Protein Kinase C, antagonists &amp; inhibitors]</data>
  <data key="d14">(18S)-18-[(dimethylamino)methyl]-3-hydroxy-17-oxa-4,14,21-triazahexacyclo[19.6.1.1,.0,.0,.0,]nonacosa-1(28),2(6),3,7(29),8,10,12,22,24,26-decaen-5-one</data>
  <data key="d15">C28H28N4O3</data>
  <data key="d16">169939-94-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1</data>
  <data key="d20">[H][C@@]1(CN(C)C)CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)N=C2O)C2=CN(CCO1)C1=CC=CC=C21</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Ruboxistaurin has been investigated for the basic science of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11823">
  <data key="d0">Esketamine</data>
  <data key="d1">drugbank.DB11823</data>
  <data key="d2">[drugbank.DB11823]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents producing tachycardia, Anesthetics, Anesthetics, General, Central Nervous System Depressants, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (weak), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inducers, Nervous System]</data>
  <data key="d14">(2S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one</data>
  <data key="d15">C13H16ClNO</data>
  <data key="d16">33643-46-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3/t13-/m0/s1</data>
  <data key="d20">CN[C@@]1(CCCCC1=O)C1=CC=CC=C1Cl</data>
  <data key="d21">This drug is indicated in conjunction with an oral antidepressant for the treatment of treatment-resistant depression (TRD) in adults [FDA label].\n\nNote: Esketamine is not approved as an anesthetic agent. The safety and effectiveness of esketamine as an anesthetic agent have not been established to this date [FDA label].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(-)-Ketamine, ()-ketamine, (S)-()-ketamine, (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone, (S)-ketamine, Esketamine, L-ketamine, S-(-)-Ketamine, S-ketamine]</data>
  <data key="d9">Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide [L5596], [A175462]. On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. \n\nEsketamine is the s-enantiomer of [Ketamine]. Ketamine is a mixture of two enantiomers (mirror image molecules). This is the first time that the FDA has approved esketamine for any use. The FDA approved ketamine (Ketalar) in 1970 [L5593].\n\nEsketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications and therapies.  The intranasal route of administration for this drug allows for easy administration and a fast onset of action, which sets it apart from many other antidepressant agents that may take several weeks to take effect.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08201">
  <data key="d0">(1S)-menthyl hexyl phosphonate group</data>
  <data key="d1">drugbank.DB08201</data>
  <data key="d2">[drugbank.DB08201]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">hexyl({[(1S,2R,5S)-5-methyl-2-(propan-2-yl)cyclohexyl]oxy})phosphinic acid</data>
  <data key="d15">C16H33O3P</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H33O3P/c1-5-6-7-8-11-20(17,18)19-16-12-14(4)9-10-15(16)13(2)3/h13-16H,5-12H2,1-4H3,(H,17,18)/t14-,15+,16-/m0/s1</data>
  <data key="d20">CCCCCCP(O)(=O)O[C@H]1C[C@@H](C)CC[C@@H]1C(C)C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08200">
  <data key="d0">(1R)-menthyl hexyl phosphonate group</data>
  <data key="d1">drugbank.DB08200</data>
  <data key="d2">[drugbank.DB08200]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">hexyl({[(1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexyl]oxy})phosphinic acid</data>
  <data key="d15">C16H33O3P</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H33O3P/c1-5-6-7-8-11-20(17,18)19-16-12-14(4)9-10-15(16)13(2)3/h13-16H,5-12H2,1-4H3,(H,17,18)/t14-,15+,16-/m1/s1</data>
  <data key="d20">CCCCCCP(O)(=O)O[C@@H]1C[C@H](C)CC[C@H]1C(C)C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09535">
  <data key="d0">Octocrylene</data>
  <data key="d1">drugbank.DB09535</data>
  <data key="d2">[drugbank.DB09535]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Acyclic, Sunscreen Agents, Sunscreening Agents]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">In the US, Octocrylene has been evaluated by the FDA and is considered safe for use up to 10% in the formula. Similarly, the EU allows its use up to 10% in a formula while Health Canada allows a maximum use level of 12%.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Octocrylene]</data>
  <data key="d9">Octocrylene is an organic compound used as an ingredient in sunscreens and cosmetics.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08213">
  <data key="d0">1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE</data>
  <data key="d1">drugbank.DB08213</data>
  <data key="d2">[drugbank.DB08213]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">1-methyl-5-{[(2S)-2-(phenoxymethyl)pyrrolidin-1-yl]sulfonyl}-2,3-dihydro-1H-indole-2,3-dione</data>
  <data key="d15">C20H20N2O5S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H20N2O5S/c1-21-18-10-9-16(12-17(18)19(23)20(21)24)28(25,26)22-11-5-6-14(22)13-27-15-7-3-2-4-8-15/h2-4,7-10,12,14H,5-6,11,13H2,1H3/t14-/m0/s1</data>
  <data key="d20">[H][C@@]1(COC2=CC=CC=C2)CCCN1S(=O)(=O)C1=CC2=C(C=C1)N(C)C(=O)C2=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11811">
  <data key="d0">Arhalofenate</data>
  <data key="d1">drugbank.DB11811</data>
  <data key="d2">[drugbank.DB11811, drugbank.DB06158]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acetates, Acids, Acyclic, Acids, Carbocyclic, Amides, Fatty Acids, Fatty Acids, Volatile, Lipids]</data>
  <data key="d14">2-acetamidoethyl (2R)-2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate</data>
  <data key="d15">C19H17ClF3NO4</data>
  <data key="d16">24136-23-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H17ClF3NO4/c1-12(25)24-9-10-27-18(26)17(13-5-7-15(20)8-6-13)28-16-4-2-3-14(11-16)19(21,22)23/h2-8,11,17H,9-10H2,1H3,(H,24,25)/t17-/m1/s1</data>
  <data key="d20">CC(=O)NCCOC(=O)[C@H](OC1=CC=CC(=C1)C(F)(F)F)C1=CC=C(Cl)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Arhalofenate has been investigated for the treatment of Gout and Hyperuricemia.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09198">
  <data key="d0">Lobeglitazone</data>
  <data key="d1">drugbank.DB09198</data>
  <data key="d2">[drugbank.DB09198]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Blood Glucose Lowering Agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (moderate), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, OATP1B1/SLCO1B1 Inhibitors, PPAR alpha, agonists, PPAR gamma, agonists, Sulfur Compounds, Thiazoles, Thiazolidinediones]</data>
  <data key="d14">5-{[4-(2-{[6-(4-methoxyphenoxy)pyrimidin-4-yl](methyl)amino}ethoxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione</data>
  <data key="d15">C24H24N4O5S</data>
  <data key="d16">607723-33-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H24N4O5S/c1-28(21-14-22(26-15-25-21)33-19-9-7-17(31-2)8-10-19)11-12-32-18-5-3-16(4-6-18)13-20-23(29)27-24(30)34-20/h3-10,14-15,20H,11-13H2,1-2H3,(H,27,29,30)</data>
  <data key="d20">COC1=CC=C(OC2=NC=NC(=C2)N(C)CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1</data>
  <data key="d21">Lobeglitazone was approved by the Ministry of Food and Drug Safety (South Korea) in 2013, and is being monitored by postmarketing surveillance until 2019. Lobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Lobeglitazone is an antidiabetic medication from the thiazolidinedione class of drugs. It primarily functions as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells. By activating PPAR-gamma and promoting the binding of insulin at fat cells, lobeglitazone thereby has been shown to reduce blood sugar levels, lower hemoglobain A1C (HbA1C) levels, and improve lipid and liver profiles [A19748]. Unlike [DB01132], which is a dual PPAR agonist at PPAR-alpha and PPAR-gamma, Lobeglitazone is a pure PPAR-alpha agonist. \n\nLobeglitazone was approved by the Ministry of Food and Drug Safety (South Korea) in 2013, and is being monitored by postmarketing surveillance until 2019. Lobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09151">
  <data key="d0">Flutemetamol (18F)</data>
  <data key="d1">drugbank.DB09151</data>
  <data key="d2">[drugbank.DB09151]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Central Nervous System, Diagnostic Radiopharmaceuticals, Radioactive Diagnostic Agent, Radiopharmaceutical Activity]</data>
  <data key="d14">2-[3-(F)fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol</data>
  <data key="d15">C14H11FN2OS</data>
  <data key="d16">765922-62-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H11FN2OS/c1-16-11-4-2-8(6-10(11)15)14-17-12-5-3-9(18)7-13(12)19-14/h2-7,16,18H,1H3/i15-1</data>
  <data key="d20">CNC1=C([18F])C=C(C=C1)C1=NC2=CC=C(O)C=C2S1</data>
  <data key="d21">Flutemetamol F18 is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate  amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[[18F]-Flutemetamol, 2-[3-(18F)fluoro-4-(methylamino)phenyl]-1, 3-benzothiazol-6-ol, Flutemetamol (18F), Flutemetamol F 18, Flutemetamol F-18, Flutemetamol F18]</data>
  <data key="d9">Flutemetamol (18F) is a PET scanning radiopharmaceutical containing the radionuclide fluorine-18. It is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate  amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11478">
  <data key="d0">Zeranol</data>
  <data key="d1">drugbank.DB11478</data>
  <data key="d2">[drugbank.DB11478]</data>
  <data key="d12">[experimental, vet_approved]</data>
  <data key="d13">[Benzene Derivatives, Biological Factors, Estrogens, Estrogens, Non-Steroidal, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Lactones, Mycotoxins, Phenols, Resorcinols, Toxins, Biological, Zearalenone]</data>
  <data key="d14">(3S,7R)-7,14,16-trihydroxy-3-methyl-3,4,5,6,7,8,9,10,11,12-decahydro-1H-2-benzoxacyclotetradecin-1-one</data>
  <data key="d15">C18H26O5</data>
  <data key="d16">26538-44-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H26O5/c1-12-6-5-9-14(19)8-4-2-3-7-13-10-15(20)11-16(21)17(13)18(22)23-12/h10-12,14,19-21H,2-9H2,1H3/t12-,14+/m0/s1</data>
  <data key="d20">C[C@H]1CCC[C@H](O)CCCCCC2=CC(O)=CC(O)=C2C(=O)O1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[alpha-Zeranol, Zeranol, Zeranolum, -zeranol]</data>
  <data key="d9">Zeranol is a non-steroidal estrogen agonist. It is a mycotoxin, derived from fungi in the Fusarium family, and may be found as a contaminant in fungus-infected crops. It is 3-4x more potent as an estrogen agonist than the related compound zearalenone.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00898">
  <data key="d0">Ethanol</data>
  <data key="d1">drugbank.DB00898</data>
  <data key="d2">[drugbank.DB00898, drugbank.APRD00738]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents Causing Muscle Toxicity, Alcohols, Anti-Infective Agents, Anti-Infective Agents, Local, Antidotes, Antiseptics and Disinfectants, Central Nervous System Agents, Central Nervous System Depressants, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2E1 Inducers (moderate), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Ethanol, Miscellaneous Local Anti-infectives, Miscellaneous Therapeutic Agents, Nerve Depressants, Neurotoxic agents, NMDA Receptor Antagonists, Solvents]</data>
  <data key="d14">ethanol</data>
  <data key="d15">C2H6O</data>
  <data key="d16">64-17-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C2H6O/c1-2-3/h3H,2H2,1H3</data>
  <data key="d20">CCO</data>
  <data key="d21">For therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (tic douloureux), in patients for whom neurosurgical procedures are contraindicated.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-Hydroxyethane, Alcohol, Alcohol (ethyl), Alcohol anhydrous, Alcohol denatured, Alcohol etlico, Alcohol, denatured, Alcool thylique, Alkohol, thanol, thylalkohol, Dehydrated ethanol, etanol, thanol, Ethyl Alcohol, Grain alcohol, Hydroxyethane, Methylcarbinol, Spiritus vini]</data>
  <data key="d9">A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09237">
  <data key="d0">Levamlodipine</data>
  <data key="d1">drugbank.DB09237</data>
  <data key="d2">[drugbank.DB09237]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Nicotinic Acids, Pyridines]</data>
  <data key="d14">3-ethyl 5-methyl (4S)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate</data>
  <data key="d15">C20H25ClN2O5</data>
  <data key="d16">103129-82-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3/t17-/m0/s1</data>
  <data key="d20">CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC</data>
  <data key="d21">For the treatment of hypertension and angina [L1483].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Levoamlodipine, S-amlodipine]</data>
  <data key="d9">Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of amlodipine, an antihypertensive and anti-anginal medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication is currently marketed in Russia and India [L1484].  The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however, with differing nomenclature. As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity [L1483].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11541">
  <data key="d0">Ractopamine</data>
  <data key="d1">drugbank.DB11541</data>
  <data key="d2">[drugbank.DB11541]</data>
  <data key="d12">[vet_approved]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic Agonists, Adrenergic beta-Agonists, Agents producing tachycardia, Agents that produce hypertension, Amines, Ethylamines, Growth Substances, Neurotransmitter Agents]</data>
  <data key="d14">4-(3-{[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino}butyl)phenol</data>
  <data key="d15">C18H23NO3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H23NO3/c1-13(2-3-14-4-8-16(20)9-5-14)19-12-18(22)15-6-10-17(21)11-7-15/h4-11,13,18-22H,2-3,12H2,1H3</data>
  <data key="d20">CC(CCC1=CC=C(O)C=C1)NCC(O)C1=CC=C(O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09241">
  <data key="d0">Methylene blue</data>
  <data key="d1">drugbank.DB09241</data>
  <data key="d2">[drugbank.DB09241]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Antidotes, Antipsychotic Agents, Central Nervous System Depressants, Diagnostic Agents, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Gastric Function, Miscellaneous Therapeutic Agents, Monoamine Oxidase Inhibitors, Neurotoxic agents, Oxidation-Reduction Agent, Phenothiazines, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Sulfur Compounds, Tests for Gastric Secretion]</data>
  <data key="d14">3,7-bis(dimethylamino)-5-phenothiazin-5-ylium chloride</data>
  <data key="d15">C16H18ClN3S</data>
  <data key="d16">61-73-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H18N3S.ClH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;/h5-10H,1-4H3;1H/q+1;/p-1</data>
  <data key="d20">[Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1</data>
  <data key="d21">Indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. \n\nOther clinical applications of methylene blue include improvement of hypotension associated with various clinical states, an antiseptic in urinary tract infections, treatment of hypoxia and hyperdynamic circulation in cirrhosis of liver and severe hepatopulmonary syndrome, and treatment of ifofosamide induced neurotoxicity.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Azul de metileno, Basic Blue 9, C.I. basic blue 9, Cloruro de metiltioninio, Lowacryl blue 9, Methylene blue, Methylene blue anhydrous, Methylenium ceruleum, Methylthioninium chloride]</data>
  <data key="d9">Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. Its use as an urinary tract antiseptic has also been investigated. \n\nMethylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation. The drug is of potential interest for the treatment of patients with Alzheimer's disease.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09245">
  <data key="d0">Toloxatone</data>
  <data key="d1">drugbank.DB09245</data>
  <data key="d2">[drugbank.DB09245]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Monoamine Oxidase A Inhibitors, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase Inhibitors, Nervous System, Oxazoles, Psychoanaleptics, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome]</data>
  <data key="d14">5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one</data>
  <data key="d15">C11H13NO3</data>
  <data key="d16">29218-27-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H13NO3/c1-8-3-2-4-9(5-8)12-6-10(7-13)15-11(12)14/h2-5,10,13H,6-7H2,1H3</data>
  <data key="d20">CC1=CC(=CC=C1)N1CC(CO)OC1=O</data>
  <data key="d21">For the treatment of major depressive disorder.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Toloxatone is an antidepressant agent, the first ever use of which was in France, 1984. It acts as a selective  and reversible inhibitor of monoamine oxidase-A (MOA) [L1388].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09248">
  <data key="d0">Mebanazine</data>
  <data key="d1">drugbank.DB09248</data>
  <data key="d2">[drugbank.DB09248]</data>
  <data key="d12">[withdrawn]</data>
  <data key="d13">[Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Central Nervous System Depressants, Monoamine Oxidase Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome]</data>
  <data key="d14">(1-phenylethyl)hydrazine</data>
  <data key="d15">C8H12N2</data>
  <data key="d16">65-64-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C8H12N2/c1-7(10-9)8-5-3-2-4-6-8/h2-7,10H,9H2,1H3</data>
  <data key="d20">CC(NN)C1=CC=CC=C1</data>
  <data key="d21">For the treatment of depression.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Mebanazine, also known as _Actomol_, is a monoamine oxidase inhibitor (MAOI) belonging to the _hydrazine_ class of chemicals. It was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09250">
  <data key="d0">Pheniprazine</data>
  <data key="d1">drugbank.DB09250</data>
  <data key="d2">[drugbank.DB09250]</data>
  <data key="d12">[withdrawn]</data>
  <data key="d13">[Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Central Nervous System Depressants, Monoamine Oxidase Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome]</data>
  <data key="d14">(1-phenylpropan-2-yl)hydrazine</data>
  <data key="d15">C9H14N2</data>
  <data key="d16">55-52-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H14N2/c1-8(11-10)7-9-5-3-2-4-6-9/h2-6,8,11H,7,10H2,1H3</data>
  <data key="d20">CC(CC1=CC=CC=C1)NN</data>
  <data key="d21">For the treatment of depression, schizophrenia, and angina pectoris.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Pheniprazine is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant in the 1960s. In addition, it was used for the treatment of other conditions, such as angina pectoris and schizophrenia. Pheniprazine was withdrawn by its manufacturer due to its ability to cause toxicity in the liver and its ability to cause optic neuritis.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11581">
  <data key="d0">Venetoclax</data>
  <data key="d1">drugbank.DB11581</data>
  <data key="d2">[drugbank.DB11581]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Amides, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCL-2 Inhibitor, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Increased Cellular Death, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Sulfones, Sulfur Compounds]</data>
  <data key="d14">4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzenesulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide</data>
  <data key="d15">C45H50ClN7O7S</data>
  <data key="d16">1257044-40-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)</data>
  <data key="d20">CC1(C)CCC(CN2CCN(CC2)C2=CC=C(C(=O)NS(=O)(=O)C3=CC=C(NCC4CCOCC4)C(=C3)[N+]([O-])=O)C(OC3=CN=C4NC=CC4=C3)=C2)=C(C1)C1=CC=C(Cl)C=C1</data>
  <data key="d21">A BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy [FDA label].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[4-{4-[(4'-chloro-5, 5-dimethyl[3, 4, 5, 6-tetrahydro[1, 1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2, 3-b]pyridin-5-yl)oxy]benzamide, Venetoclax]</data>
  <data key="d9">Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process [A18565], [A18566].  Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries [A40022]. Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax [A40022]. Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells [A40022]. A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy [FDA label].  Previously, this drug was indicated only for patients with 17p gene deletion [F2130].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00857">
  <data key="d0">Terbinafine</data>
  <data key="d1">drugbank.DB00857</data>
  <data key="d2">[drugbank.DB00857, drugbank.APRD00508]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Agents Causing Muscle Toxicity, Allylamine Antifungal, Allylamines, Anti-Infective Agents, Antifungal Agents, Antifungals for Dermatological Use, Antifungals for Systemic Use, Antifungals for Topical Use, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Enzyme Inhibitors, Trypanocidal Agents]</data>
  <data key="d14">[(2E)-6,6-dimethylhept-2-en-4-yn-1-yl](methyl)[(naphthalen-1-yl)methyl]amine</data>
  <data key="d15">C21H25N</data>
  <data key="d16">91161-71-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+</data>
  <data key="d20">CN(C\C=C\C#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12</data>
  <data key="d21">For the treatment of dermatophyte infections of the toenail or fingernail caused by susceptible fungi. Also for the treatment of tinea capitis (scalp ringworm) and tinea corporis (body ringworm) or tinea cruris (jock itch).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(E)-N-(6, 6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine, (E)-N-(6, 6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine, Terbinafina, Terbinafine, Terbinafinum]</data>
  <data key="d9">Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal. It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (squalene 2,3-epoxidase), an enzyme that is part of the fungal cell wall synthesis pathway.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00852">
  <data key="d0">Pseudoephedrine</data>
  <data key="d1">drugbank.DB00852</data>
  <data key="d2">[drugbank.DB00852, drugbank.APRD00634]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic beta-Agonists, Agents producing tachycardia, Agents that produce hypertension, Alcohols, Alpha-and Beta-adrenergic Agonists, Amines, Amino Alcohols, Amphetamines, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Substrates, Ethylamines, Hyperglycemia-Associated Agents, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Nasal Decongestants, Nasal Decongestants for Systemic Use, Nasal Preparations, Norepinephrine Releasing Agent, Peripheral Nervous System Agents, Phenethylamines, Propanolamines, Propanols, Respiratory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Sympathomimetic (Adrenergic) Agents, Sympathomimetics, Vasoconstrictor Agents]</data>
  <data key="d14">(1S,2S)-2-(methylamino)-1-phenylpropan-1-ol</data>
  <data key="d15">C10H15NO</data>
  <data key="d16">90-82-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10+/m0/s1</data>
  <data key="d20">CN[C@@H](C)[C@@H](O)C1=CC=CC=C1</data>
  <data key="d21">For the treatment of nasal congestion, sinus congestion, Eustachian tube congestion, and vasomotor rhinitis, and as an adjunct to other agents in the optimum treatment of allergic rhinitis, croup, sinusitis, otitis media, and tracheobronchitis. Also used as first-line therapy of priapism.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+) threo-2-(methylamino)-1-phenyl-1-propanol, (+)-(1S, 2S)-Pseudoephedrine, (+)-Pseudoephedrine, (+)-psi-Ephedrine, (+)-threo-Ephedrine, d-Isoephedrine, d-Pseudoephedrine, d-psi-2-Methylamino-1-phenyl-1-propanol, d-psi-Ephedrine, Isoephedrine, L-(+)-Pseudoephedrine, L(+)-psi-Ephedrine, Pseudoefedrina, Pseudoephedrine, pseudophdrine, Pseudoephedrine D-form, Pseudoephedrinum, Psi-ephedrin, Psi-ephedrine, trans-Ephedrine, -ephedrine]</data>
  <data key="d9">An alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used in the treatment of several disorders including asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00850">
  <data key="d0">Perphenazine</data>
  <data key="d1">drugbank.DB00850</data>
  <data key="d2">[drugbank.DB00850, drugbank.APRD00429]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Phenothiazines, Phenothiazines With Piperazine Structure, Psycholeptics, Psychotropic Drugs, Sulfur Compounds, Tranquilizing Agents]</data>
  <data key="d14">2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethan-1-ol</data>
  <data key="d15">C21H26ClN3OS</data>
  <data key="d16">58-39-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2</data>
  <data key="d20">OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1</data>
  <data key="d21">For use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-(4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol, 2-chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine, 4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol, 4-[3-(2-chlorophenothiazin-10-yl)propyl]-1-piperazineethanol, Chlorpiprazine, Etaperazin, Etaperazine, Ethaperazine, Perfenazina, Perfenazine, Perphenazin, Perphnazine, Perphenazine, Perphenazinum, -(4-(-hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine]</data>
  <data key="d9">An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12831">
  <data key="d0">Gabexate</data>
  <data key="d1">drugbank.DB12831</data>
  <data key="d2">[drugbank.DB12831]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Amidines, Anticoagulants, Enzyme Inhibitors, Guanidines, Hematologic Agents, Protease Inhibitors, Serine Proteinase Inhibitors]</data>
  <data key="d14">ethyl 4-[(6-carbamimidamidohexanoyl)oxy]benzoate</data>
  <data key="d15">C16H23N3O4</data>
  <data key="d16">39492-01-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H23N3O4/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18/h7-10H,2-6,11H2,1H3,(H4,17,18,19)</data>
  <data key="d20">CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1</data>
  <data key="d21">No approved indication.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines. Gabexate has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis [A19218] [A19219] [A19220].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09201">
  <data key="d0">Ciglitazone</data>
  <data key="d1">drugbank.DB09201</data>
  <data key="d2">[drugbank.DB09201]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Blood Glucose Lowering Agents, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Sulfur Compounds, Thiazoles, Thiazolidinediones]</data>
  <data key="d14">5-({4-[(1-methylcyclohexyl)methoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione</data>
  <data key="d15">C18H23NO3S</data>
  <data key="d16">74772-77-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H23NO3S/c1-18(9-3-2-4-10-18)12-22-14-7-5-13(6-8-14)11-15-16(20)19-17(21)23-15/h5-8,15H,2-4,9-12H2,1H3,(H,19,20,21)</data>
  <data key="d20">CC1(COC2=CC=C(CC3SC(=O)NC3=O)C=C2)CCCCC1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[ciglitazona, Ciglitazone]</data>
  <data key="d9">Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.\n\nCiglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. Several analogues were later developed, some of whichsuch as pioglitazone and troglitazonemade it to the market.\n\nCiglitazone significantly decreases VEGF production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstimulation syndrome. Ciglitazone is a potent and selective PPAR ligand with an EC50 of 3.0 M. It is also an anti-hyperglycemic agent in the ob/ob murine model in vivo. Ciglitazone increases adipogenesis, decreases differentiation and angiogenesis in human umbilical vein endothelial cell (HUVEC), and osteoblastogenesis in human mesenchymal stem cells.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00863">
  <data key="d0">Ranitidine</data>
  <data key="d1">drugbank.DB00863</data>
  <data key="d2">[drugbank.DB00863, drugbank.APRD00254]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acid Reducers, Agents Causing Muscle Toxicity, Alimentary Tract and Metabolism, Anti-Ulcer Agents, Cholinesterase Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (weak), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Drugs that are Mainly Renally Excreted, Furans, Gastric Acid Lowering Agents, Gastrointestinal Agents, Histamine Antagonists, Histamine H2 Antagonists, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Substrates, OCT1 substrates, OCT2 Inhibitors, OCT2 Substrates, OCT2 substrates with narrow therapeutic index, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates]</data>
  <data key="d14">[1-({2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}amino)-2-nitroethenyl](methyl)amine</data>
  <data key="d15">C13H22N4O3S</data>
  <data key="d16">66357-35-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3</data>
  <data key="d20">CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O</data>
  <data key="d21">This drug is used alone or with concomitant antacids for the following conditions [FDA label]:\n\n**Duodenal ulcer**\n\nTreatment of active duodenal ulcer (short-term), maintenance therapy of duodenal ulcers after healing (reduced dose)\n\n**Pathological hypersecretion of gastric acid**\n\nZollinger-Ellison syndrome, systemic mastocytosis, and other conditions causing gastric acid hypersecretion\n\n**Gastric ulcer**\n\nShort term treatment of active gastric ulcer (benign), maintenance of healing after gastric acid ulcer therapy (reduced dose)\n\n**Other conditions**: \n\nTreatment of GERD symptoms (symptoms usually improve within 24 hours), treatment of erosive esophagitis (endoscopically diagnosed) and maintenance of healing [FDA label]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Ranitidina, Ranitidine, Ranitidinum]</data>
  <data key="d9">Ranitidine is a commonly used drug, classified as a _histamine H2-receptor antagonist_. This drug helps to prevent and treat gastric-acid related conditions, including ulcers, because of its ability to decrease gastric acid secretion [A176759], [FDA label]. It is often referred to as _Zantac_, and is available in various forms, including a regular tablet, injection, and effervescent tablet [FDA label], [F4253].\n\nOne common use of this drug is to relieve the symptoms of gastric esophageal reflux disease (GERD) [FDA label], which often leads to heartburn symptoms and acid regurgitation. The prevalence of GERD is thought to be 10-20% in western countries [A176843]. Ranitidine has proven to be an effective agent in relieving the above symptoms and is therefore widely used in GERD and other gastric-acid related conditions [A176849], [FDA label].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09213">
  <data key="d0">Dexibuprofen</data>
  <data key="d1">drugbank.DB09213</data>
  <data key="d2">[drugbank.DB09213]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Carbocyclic, Agents causing hyperkalemia, Agents that produce hypertension, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Musculo-Skeletal System, Nephrotoxic agents, Non COX-2 selective NSAIDS, Phenylpropionates, Propionates]</data>
  <data key="d14">(2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid</data>
  <data key="d15">C13H18O2</data>
  <data key="d16">51146-56-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1</data>
  <data key="d20">CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O</data>
  <data key="d21">For more information, refer to [ibuprofen].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+)-(S)-p-isobutylhydratropic acid, (2S)-2-(4-isobutylphenyl)propanoic acid, (S)--methyl-4-(2-methylpropyl)benzeneacetic acid, d-ibuproten, Dexibuprofeno]</data>
  <data key="d9">Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. It is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. Dexibuprofen has a slower dissolution rate in the simulated gastric and enteric juices compared with the racemic ibuprofen and displays improved oral bioavilability [A19259]. For Metabolism, Enzymes, Carriers, Transporters Sections, refer to [Ibuprofen].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00889">
  <data key="d0">Granisetron</data>
  <data key="d1">drugbank.DB00889</data>
  <data key="d2">[drugbank.DB00889, drugbank.APRD01002]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Antidepressive Agents, Antiemetics, Antiemetics and Antinauseants, Autonomic Agents, Aza Compounds, Azabicyclo Compounds, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Gastrointestinal Agents, Indazoles, Moderate Risk QTc-Prolonging Agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Pyrazoles, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 3 Receptor Antagonists, Serotonin 5-HT3 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists]</data>
  <data key="d14">1-methyl-N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-1H-indazole-3-carboxamide</data>
  <data key="d15">C18H24N4O</data>
  <data key="d16">109889-09-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)/t12-,13+,14-</data>
  <data key="d20">CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2</data>
  <data key="d21">For the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Granistron, Granisetrn, Granisetron, Granisetronum]</data>
  <data key="d9">A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09224">
  <data key="d0">Melperone</data>
  <data key="d1">drugbank.DB09224</data>
  <data key="d2">[drugbank.DB09224]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Antiarrhythmic agents, Antipsychotic Agents, Antipsychotic Agents (Second Generation [Atypical]), Butyrophenone Derivatives, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs that are Mainly Renally Excreted, Ketones, Moderate Risk QTc-Prolonging Agents, Nervous System, Neurotoxic agents, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Tranquilizing Agents]</data>
  <data key="d14">1-(4-fluorophenyl)-4-(4-methylpiperidin-1-yl)butan-1-one</data>
  <data key="d15">C16H22FNO</data>
  <data key="d16">3575-80-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H22FNO/c1-13-8-11-18(12-9-13)10-2-3-16(19)14-4-6-15(17)7-5-14/h4-7,13H,2-3,8-12H2,1H3</data>
  <data key="d20">CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1</data>
  <data key="d21">For the treatment of schizophrenia, sleep, disorders, agitation and mentally confused states [L1317, L1319, L1322].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol.  Melperone has been used for a span of greater than 30 years in the European Union [L1316]. It has been well established in the treatment of confusion, anxiety, restlessness (particularly in the elderly) and schizophrenia as It is known to be well-tolerated with an excellent safety profile. Recently, it has been studied as a treatment of psychosis related to Parkinson's disease [L1316].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00886">
  <data key="d0">Omapatrilat</data>
  <data key="d1">drugbank.DB00886</data>
  <data key="d2">[drugbank.DB00886, drugbank.APRD00443]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Agents that produce hypertension, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Azepines, Cardiovascular Agents, Enzyme Inhibitors, Metalloendopeptidases, antagonists &amp; inhibitors, Protease Inhibitors, Sulfur Compounds, Thiepins]</data>
  <data key="d14">(4S,7S,10aS)-5-oxo-4-[(2S)-3-phenyl-2-sulfanylpropanamido]-octahydro-2H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid</data>
  <data key="d15">C19H24N2O4S2</data>
  <data key="d16">167305-00-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H24N2O4S2/c22-17(15(26)11-12-5-2-1-3-6-12)20-13-9-10-27-16-8-4-7-14(19(24)25)21(16)18(13)23/h1-3,5-6,13-16,26H,4,7-11H2,(H,20,22)(H,24,25)/t13-,14-,15-,16-/m0/s1</data>
  <data key="d20">[H][C@]12CCC[C@H](N1C(=O)[C@H](CCS2)NC(=O)[C@@H](S)CC1=CC=CC=C1)C(O)=O</data>
  <data key="d21">For the treatment of hypertension.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Omapatrilate]</data>
  <data key="d9">Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). The inhibition of NEP elevates natriuretic peptide levels, increasing excretion of sodium in urine, dilating blood vessels, and reducing preload and ventricular remodeling. This drug from BMS was not approved by the FDA due to angioedema safety concerns.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09221">
  <data key="d0">Polaprezinc</data>
  <data key="d1">drugbank.DB09221</data>
  <data key="d2">[drugbank.DB09221]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Anti-Ulcer Agents, Dipeptides, Gastrointestinal Agents, Metal cations, Metal divalent cations, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptides, Proteins, Zinc Compounds]</data>
  <data key="d14">zinc(2+) ion (2S)-2-[(3-aminopropanoyl)azanidyl]-3-(1H-imidazol-5-yl)propanoate</data>
  <data key="d15">C9H12N4O3Zn</data>
  <data key="d16">107667-60-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H14N4O3.Zn/c10-2-1-8(14)13-7(9(15)16)3-6-4-11-5-12-6;/h4-5,7H,1-3,10H2,(H3,11,12,13,14,15,16);/q;+2/p-2/t7-;/m0./s1</data>
  <data key="d20">[Zn++].[H][C@@](CC1=CN=CN1)([N-]C(=O)CCN)C([O-])=O</data>
  <data key="d21">Peptic ulcer disease, dyspepsia [L1308].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[beta-alanyl-l-histidinato zinc, Zinc L-carnosine]</data>
  <data key="d9">Polaprezinc is a chelated form of zinc and L-carnosine. It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1208].  It was determined that polaprezinc may be effective in pressure ulcer treatment [A31856]. A study in 2013 showed that CO-administration of polaprezinc may be effective against small intestine mucosal injury associated with long-term aspirin therapy [A7840].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09228">
  <data key="d0">Conestat alfa</data>
  <data key="d1">drugbank.DB09228</data>
  <data key="d2">[drugbank.DB09228]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Blood and Blood Forming Organs, C1 inhibitors, Drugs Used in Hereditary Angioedema, Protease Inhibitors]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">80295-38-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">For the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[C1 Esterase Inhibitor (Recombinant), C1 Inhibitor (Recombinant), Complement C1 esterase inhibitor, Human C1-inhibitor (recombinant, rabbit derived), Recombinant complement C1 esterase inhibitor, Recombinant human C1 inhibitor, Recombinant human C1-inhibitor, Recombinant human C1-inhibitor rabbit milk derived]</data>
  <data key="d9">C1 Esterase Inhibitor (Recombinant) is a recombinant analogue of endogenous complement component-1 esterase inhibitor (rhC1INH), purified from the milk of transgenic rabbits. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways. It does this through inhibition of several target proteases within these pathways including activated C1s, kallikrein, factor XIIa and factor XIa. C1 esterase inhibitor has also been shown to inhibit the action of thrombin within the coagulation pathway, and tPA and plasmin within the fibrinolytic pathway. Deficiency of C1-inhibitor allows for increased plasma kallikrein activation and subsequent production of bradykinin. Additionally, C4 and C2 cleavage occurs resulting in auto-activation of the complement system. Down-stream effects of the lack of enzyme inhibition by C1 esterase inhibitor results in swelling due to leakage of fluid from blood vessels into connective tissue and consequently the presentation of hereditary angioedema (HAE). \n\nMarketed as the product Ruconest (FDA), this drug is indicated for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults. Intravenous replacement of C1 esterase inhibitor results in reversal of acute symptoms of HAE.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00882">
  <data key="d0">Clomifene</data>
  <data key="d1">drugbank.DB00882</data>
  <data key="d2">[drugbank.DB00882, drugbank.APRD00880]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Benzene Derivatives, Benzylidene Compounds, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Estrogen Agonist-antagonists, Estrogen Agonist/Antagonist, Estrogen Antagonists, Estrogen Receptor Modulators, Fertility Agents, Fertility Agents, Female, Genito Urinary System and Sex Hormones, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Ovulation Stimulants, Synthetic, P-glycoprotein/ABCB1 Substrates, Reproductive Control Agents, Selective Estrogen Receptor Modulators, Sex Hormones and Modulators of the Genital System, Stilbenes]</data>
  <data key="d14">{2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]ethyl}diethylamine</data>
  <data key="d15">C26H28ClNO</data>
  <data key="d16">911-45-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C26H28ClNO/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23/h5-18H,3-4,19-20H2,1-2H3</data>
  <data key="d20">CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d21">Used mainly in female infertility due to anovulation (e.g. due to polycystic ovary syndrome) to induce ovulation.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-(4-(2-chloro-1, 2-diphenylethenyl)phenoxy)-N, N-diethylethanamine, 2-(p-(2-chloro-1, 2-diphenylvinyl)phenoxy)triethylamine, 2-(p-(-chloro--phenylstyryl)phenoxy)triethylamine, Clomifene, Clomifeno, Clomifenum, Clomiphene]</data>
  <data key="d9">A triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00881">
  <data key="d0">Quinapril</data>
  <data key="d1">drugbank.DB00881</data>
  <data key="d2">[drugbank.DB00881, drugbank.APRD00523]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[ACE Inhibitors and Diuretics, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Agents, Enzyme Inhibitors, Hypotensive Agents, Isoquinolines, OAT3/SLC22A8 Substrates, Protease Inhibitors]</data>
  <data key="d14">(3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid</data>
  <data key="d15">C25H30N2O5</data>
  <data key="d16">85441-61-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1</data>
  <data key="d20">CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O</data>
  <data key="d21">For the treatment of hypertension and as adjunct therapy in the treatment of congestive heart failure. May also be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Quinapril, Quinaprilum]</data>
  <data key="d9">Quinapril is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to quinaprilat (quinapril diacid) following oral administration. Quinaprilat is a competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Quinapril may be used to treat essential hypertension and congestive heart failure.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00890">
  <data key="d0">Dienestrol</data>
  <data key="d1">drugbank.DB00890</data>
  <data key="d2">[drugbank.DB00890, drugbank.APRD00917]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Benzene Derivatives, Estrogens, Estrogens, Non-Steroidal, Genito Urinary System and Sex Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Phenols, Sex Hormones and Modulators of the Genital System, Synthetic Estrogens, Plain]</data>
  <data key="d14">4-[(2E,4E)-4-(4-hydroxyphenyl)hexa-2,4-dien-3-yl]phenol</data>
  <data key="d15">C18H18O2</data>
  <data key="d16">13029-44-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H18O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h3-12,19-20H,1-2H3/b17-3+,18-4+</data>
  <data key="d20">[H]\C(C)=C(/C(=C(\[H])C)/C1=CC=C(O)C=C1)\C1=CC=C(O)C=C1</data>
  <data key="d21">For use in the treatment of atrophic vaginitis and kraurosis vulvae.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[4, 4'-Hydroxy-, -diphenyl-, -hexadiene, alpha-dienestrol diacetate, Cycladiene, Dehydrostilbestrol, Dienestrol, Dinestrol, Dienestrolum, p, p'-(Diethylideneethylene)diphenol]</data>
  <data key="d9">Dienestrol is a synthetic, non-steroidal estrogen. It is an estrogen receptor agonist. Estrogens work partly by increasing a normal clear discharge from the vagina and making the vulva and urethra healthy. Using or applying an estrogen relieves or lessens: dryness and soreness in the vagina, itching, redness, or soreness of the vulva. Conditions that are treated with vaginal estrogens include a genital skin condition (vulvar atrophy), inflammation of the vagina (atrophic vaginitis), and inflammation of the urethra (atrophic urethritis).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00813">
  <data key="d0">Fentanyl</data>
  <data key="d1">drugbank.DB00813</data>
  <data key="d2">[drugbank.DB00813, drugbank.APRD00347, drugbank.DB05853, drugbank.DB06055, drugbank.DB06220, drugbank.DB05564]</data>
  <data key="d12">[approved, illicit, investigational, vet_approved]</data>
  <data key="d13">[Adjuvants, Adjuvants, Anesthesia, Agents that produce hypertension, Agents that reduce seizure threshold, Analgesics, Anesthetics, Anesthetics, General, Anesthetics, Intravenous, Antidepressive Agents, Bradycardia-Causing Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index, Narcotics, Narrow Therapeutic Index Drugs, Nervous System, Neuraxial Anesthetics, Opiate Agonists, Opioid Agonist, Opioid Anesthetics, Opioids, Opioids, Anilidopiperidine, P-glycoprotein/ABCB1 Inhibitors, Peripheral Nervous System Agents, Phenylpiperidine Derivatives, Piperidines, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators]</data>
  <data key="d14">N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide</data>
  <data key="d15">C22H28N2O</data>
  <data key="d16">437-38-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3</data>
  <data key="d20">CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1</data>
  <data key="d21">Fentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction, maintenance, and recovery from general or regional anesthesia.[Label] These injections are also used with a neuroleptic for premedication, induction, and as an adjunct to maintenance of anesthesia.[Label] Finally, fentanyl intravenous or intramuscular injections are used with oxygen for anesthesia in high risk patients.[Label]\n\nFentanyl sublingual tablets, transmucosal lozenges, buccal tablets, sublingual sprays, transdermal systems, and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain management.[L6598,L6601,L6604,L6607,L922,L6610]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-Phenethyl-4-(N-phenylpropionamido)piperidine, 1-phenethyl-4-N-propionylanilinopiperidine, Fentanil, Fentanila, Fentanilo, Fentanyl, Fentanyl CII, Fentanylum, N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide, N-(1-phenethyl-4-piperidyl)propionanilide, N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide, N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide, N-phenethyl-4-(N-propionylanilino)piperidine, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide, Phentanyl]</data>
  <data key="d9">Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia.[A179542] Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and [oxycodone].\n\nFentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin.[A179542] In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths).[L6748] Opioid overdoses kill an average of 11 Canadians daily.[L6751]\n\nFentanyl was FDA approved in 1968.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00823">
  <data key="d0">Ethynodiol diacetate</data>
  <data key="d1">drugbank.DB00823</data>
  <data key="d2">[drugbank.DB00823, drugbank.APRD00760]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenal Cortex Hormones, Combination Contraceptives (with Estrogen and derivatives), Contraceptive Agents, Female, Contraceptives, Oral, Contraceptives, Oral, Synthetic, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Hyperglycemia-Associated Agents, Norpregnanes, Norpregnenes, Norsteroids, Progestin Contraceptives, Progestins, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids]</data>
  <data key="d14">(1S,2R,5S,10R,11S,14R,15S)-5-(acetyloxy)-14-ethynyl-15-methyltetracyclo[8.7.0.0,.0,]heptadec-6-en-14-yl acetate</data>
  <data key="d15">C24H32O4</data>
  <data key="d16">297-76-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H32O4/c1-5-24(28-16(3)26)13-11-22-21-8-6-17-14-18(27-15(2)25)7-9-19(17)20(21)10-12-23(22,24)4/h1,14,18-22H,6-13H2,2-4H3/t18-,19-,20+,21+,22-,23-,24-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](OC(C)=O)C=C3CC[C@@]21[H]</data>
  <data key="d21">For the prevention of pregnancy in women who elect to use this product as a method of contraception.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[17-Ethynyl-19-norandrost-4-ene-3, 17-beta-diol diacetate, 17-Ethynyl-3, 17-dihydroxy-4-estrene diacetate, 17-Ethynyl-4-estrene-3, 17-diol diacetate, 17-Ethynylestr-4-ene-3, 17-diol acetate, 19-Nor-17-pregn-4-en-20-yne-3, 17-diol diacetate, 3, 17-Diacetoxy-17-ethynyl-4-oestrene, 3, 17-Diacetoxy-19-nor-17-pregn-4-en-20-yne, Ethynodiol diacetate, Etynodiol acetate, Etynodiol diacetate]</data>
  <data key="d9">A synthetic progestational hormone used alone or in combination with estrogens as an oral contraceptive. Although etynodiol or ethynodiol are sometimes used as a synonym for ethynodiol diacetate, what is usually being referred to is actually ethynodiol diacetate and not ethynodiol (which is a separate drug that has never been marketed, see [DB13866]).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00836">
  <data key="d0">Loperamide</data>
  <data key="d1">drugbank.DB00836</data>
  <data key="d2">[drugbank.DB00836, drugbank.APRD00275]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents causing hyperkalemia, Alimentary Tract and Metabolism, Antiarrhythmic agents, Antidiarrheals, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antipropulsives, Bradycardia-Causing Agents, Calcium Channel Blockers, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inhibitors (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Gastrointestinal Agents, Moderate Risk QTc-Prolonging Agents, Opioid Agonist, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Piperidines, QTc Prolonging Agents]</data>
  <data key="d14">4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide</data>
  <data key="d15">C29H33ClN2O2</data>
  <data key="d16">53179-11-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3</data>
  <data key="d20">CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d21">For the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease or gastroenteritis. Also used for reducing the volume of discharge from ileostomies.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Loperamid, Loperamida, Lopramide, Loperamide, Loperamidum]</data>
  <data key="d9">One of the long-acting synthetic antidiarrheals; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00834">
  <data key="d0">Mifepristone</data>
  <data key="d1">drugbank.DB00834</data>
  <data key="d2">[drugbank.DB00834, drugbank.APRD00432]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Abortifacient Agents, Abortifacient Agents, Steroidal, Adrenal Cortex Hormones, Blood Glucose Lowering Agents, BSEP/ABCB11 Substrates, Contraceptive Agents, Female, Contraceptives, Oral, Contraceptives, Oral, Synthetic, Contraceptives, Postcoital, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (moderate), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Estranes, Estrenes, Genito Urinary System and Sex Hormones, Highest Risk QTc-Prolonging Agents, Hormonal Contraceptives for Systemic Use, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypoglycemia-Associated Agents, Luteolytic Agents, Menstruation-Inducing Agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Inhibitors, Progestational Hormone Receptor Antagonists, Progesterone Receptor Modulators, Progestin Antagonist, QTc Prolonging Agents, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids]</data>
  <data key="d14">(1S,3aS,3bS,10R,11aS)-10-[4-(dimethylamino)phenyl]-1-hydroxy-11a-methyl-1-(prop-1-yn-1-yl)-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,10H,11H,11aH-cyclopenta[a]phenanthren-7-one</data>
  <data key="d15">C29H35NO2</data>
  <data key="d16">84371-65-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]</data>
  <data key="d21">For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Mifepriston, Mifepristona, Mifpristone, Mifepristone, Mifepristonum]</data>
  <data key="d9">Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex (mifepristone 200mg) and Korlym (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00831">
  <data key="d0">Trifluoperazine</data>
  <data key="d1">drugbank.DB00831</data>
  <data key="d2">[drugbank.DB00831, drugbank.APRD00173, drugbank.DB08616]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Antiemetics, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Autonomic Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Gastrointestinal Agents, Nervous System, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Peripheral Nervous System Agents, Phenothiazines, Phenothiazines With Piperazine Structure, Psycholeptics, Psychotropic Drugs, Sulfur Compounds, Tranquilizing Agents, UGT1A4 substrates]</data>
  <data key="d14">10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine</data>
  <data key="d15">C21H24F3N3S</data>
  <data key="d16">117-89-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3</data>
  <data key="d20">CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1</data>
  <data key="d21">For the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine, Trifluoperazina, Trifluoprazine, Trifluoperazine, Trifluoperazinum, trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine, Trifluoroperazine, Trifluperazine]</data>
  <data key="d9">A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00849">
  <data key="d0">Methylphenobarbital</data>
  <data key="d1">drugbank.DB00849</data>
  <data key="d2">[drugbank.DB00849, drugbank.APRD00047]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Anticholinergic Agents, Anticonvulsants, Barbiturates, Barbiturates and Derivatives, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), GABA Agents, GABA Modulators, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, Phenobarbital and similars, Psycholeptics, Pyrimidines, Pyrimidinones]</data>
  <data key="d14">5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione</data>
  <data key="d15">C13H14N2O3</data>
  <data key="d16">115-38-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18)</data>
  <data key="d20">CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1</data>
  <data key="d21">For the relief of anxiety, tension, and apprehension, also used as an anticonvulsant for the treatment of epilepsy.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-Methylphenobarbital, 5-ethyl-1-methyl-5-phenyl-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione, 5-Ethyl-1-methyl-5-phenyl-pyrimidine-2, 4, 6-trione, 5-ethyl-1-methyl-5-phenylbarbituric acid, Enphenemal, Mephobarbital, Mephobarbitone, Mthylphnobarbital, Methylphenobarbital, Methylphenobarbitalum, Methylphenobarbitone, Metilfenobarbital, Metilfenobarbitale, N-Methylphenobarbital]</data>
  <data key="d9">A barbiturate that is metabolized to phenobarbital. It has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over phenobarbital.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00843">
  <data key="d0">Donepezil</data>
  <data key="d1">drugbank.DB00843</data>
  <data key="d2">[drugbank.DB00843, drugbank.APRD00039]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Anti-Dementia Drugs, Bradycardia-Causing Agents, Central Nervous System Agents, Central Nervous System Depressants, Cholinergic Agents, Cholinesterase Inhibitors, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Enzyme Inhibitors, Indenes, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Nervous System, Neurotransmitter Agents, Nootropic Agents, Parasympathomemetic (Cholinergic) Agents, Potential QTc-Prolonging Agents, Psychoanaleptics, QTc Prolonging Agents]</data>
  <data key="d14">2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one</data>
  <data key="d15">C24H29NO3</data>
  <data key="d16">120014-06-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3</data>
  <data key="d20">COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1</data>
  <data key="d21">For the palliative treatment of mild to moderate dementia of the Alzheimer's type.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Domepezil, Donepezil, Donepezilo, Donepezilum]</data>
  <data key="d9">Donepezil (Aricept), is a centrally acting reversible acetyl cholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine. Donepezil is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, donepezil's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. In other studies, domepezil has been investigated in other cognitive disorders, including Lewy body dementia and Vascular dementia, but the clinical use of domepezil in these conditions is limited and not yet approved. Donepezil has also been studied in patients with Mild Cognitive Impairment, schizophrenia, attention deficit disorder, post-coronary bypass cognitive impairment, cognitive impairment associated with multiple sclerosis, and Down syndrome.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00841">
  <data key="d0">Dobutamine</data>
  <data key="d1">drugbank.DB00841</data>
  <data key="d2">[drugbank.DB00841, drugbank.APRD00122]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic and Dopaminergic Agents, Adrenergic beta-1 Receptor Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Agents producing tachycardia, Agents that produce hypertension, Amines, Autonomic Agents, Biogenic Amines, Biogenic Monoamines, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Catecholamines, Compounds used in a research, industrial, or household setting, COMT Substrates, Drugs that are Mainly Renally Excreted, Ethylamines, Neurotransmitter Agents, Peripheral Nervous System Agents, Phenethylamines, Protective Agents, Selective Beta 1-adrenergic Agonists, Sympathomimetic (Adrenergic) Agents, Sympathomimetics]</data>
  <data key="d14">4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol</data>
  <data key="d15">C18H23NO3</data>
  <data key="d16">34368-04-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3</data>
  <data key="d20">CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1</data>
  <data key="d21">Indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[()-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol, 3, 4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]--phenylethylamine, 4-{2-[3-(4-Hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1, 2-diol, DL-dobutamine, Dobutamin, Dobutamina, Dobutamine, Dobutaminum, rac-dobutamine, racemic-dobutamine]</data>
  <data key="d9">A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00806">
  <data key="d0">Pentoxifylline</data>
  <data key="d1">drugbank.DB00806</data>
  <data key="d2">[drugbank.DB00806, drugbank.APRD00121]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alkaloids, Antioxidants, Antiplatelet agents, Blood Viscosity Reducer, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates, Drugs for Obstructive Airway Diseases, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Free Radical Scavengers, Hematologic Activity Alteration, Hematologic Agents, Hemorrheologic Agents, Peripheral Vasodilators, Phosphodiesterase 5 Inhibitors, Phosphodiesterase Inhibitors, Protective Agents, Purine Derivatives, Purines, Purinones, Radiation-Protective Agents, Theobromine, Vasodilating Agents, Xanthine derivatives]</data>
  <data key="d14">3,7-dimethyl-1-(5-oxohexyl)-2,3,6,7-tetrahydro-1H-purine-2,6-dione</data>
  <data key="d15">C13H18N4O3</data>
  <data key="d16">6493-05-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3</data>
  <data key="d20">CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C</data>
  <data key="d21">For the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Oxpentifylline, Pentoxifilina, Pentoxifyllin, Pentoxifylline, Pentoxifyllinum]</data>
  <data key="d9">A methylxanthine derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00805">
  <data key="d0">Minaprine</data>
  <data key="d1">drugbank.DB00805</data>
  <data key="d2">[drugbank.DB00805, drugbank.APRD00735]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Central Nervous System Stimulants, Cholinesterase Inhibitors, Cytochrome P-450 CYP2D6 Substrates, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase Inhibitors, Nervous System, Psychoanaleptics, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome]</data>
  <data key="d14">4-methyl-N-[2-(morpholin-4-yl)ethyl]-6-phenylpyridazin-3-amine</data>
  <data key="d15">C17H22N4O</data>
  <data key="d16">25905-77-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H22N4O/c1-14-13-16(15-5-3-2-4-6-15)19-20-17(14)18-7-8-21-9-11-22-12-10-21/h2-6,13H,7-12H2,1H3,(H,18,20)</data>
  <data key="d20">CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1</data>
  <data key="d21">For the treatment of depression</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[4-(2-((4-Methyl-6-phenyl-3-pyridazinyl)amino)ethyl)morpholine, 4-Methyl-3-(2-morpholinoethylamino)-6-phenylpyridazin, Minaprina, Minaprinum, N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine]</data>
  <data key="d9">Minaprine is a psychotropic drug which has proved to be effective in the treatment of various depressive states. Like most antidepressants minaprine antagonizes behavioral despair. Minaprine  is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11590">
  <data key="d0">Thimerosal</data>
  <data key="d1">drugbank.DB11590</data>
  <data key="d2">[drugbank.DB11590]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Alkylmercury Compounds, Antiseptics and Disinfectants, Cell-mediated Immunity, Compounds used in a research, industrial, or household setting, Dermatologicals, Ethylmercury Compounds, Increased Histamine Release, Mercurial Products, Organomercury Compounds, Organometallic Compounds, Pharmaceutic Aids, Pharmaceutical Preparations, Preservatives, Pharmaceutical, Standardized Chemical Allergen]</data>
  <data key="d14">ethyl({2-[(sodiooxy)carbonyl]phenyl}sulfanyl)mercury</data>
  <data key="d15">C9H9HgNaO2S</data>
  <data key="d16">54-64-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H6O2S.C2H5.Hg.Na/c8-7(9)5-3-1-2-4-6(5)10;1-2;;/h1-4,10H,(H,8,9);1H2,2H3;;/q;;2*+1/p-2</data>
  <data key="d20">CC[Hg]SC1=CC=CC=C1C(=O)O[Na]</data>
  <data key="d21">Used as preservative in some cosmetics, topical pharmaceuticals, and biological drug products, which includes vaccines [L1671, L1672, L1673].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[[(o-carboxyphenyl)thio]ethylmercury sodium salt, ethyl(2-mercaptobenzoato-S)mercury sodium salt, ethylmercurithiosalicylate sodium, ethylmercurithiosalicylic acid sodium salt, mercurothiolate, o-(ethylmercurithio)benzoic acid sodium salt, sodium ethylmercurithiosalicylate, sodium merthiolate, Thimerosal, Thiomersal, Thiomersalate, Thiomersalum, Tiomersal]</data>
  <data key="d9">Thiomersal (INN), commonly known in the U.S. as thimerosal, is an organomercury compound. This compound is a well-established and widely used antiseptic and antifungal agent. \n\nDeveloped in 1927, thimerosal has been and is still being used as a preservative in some cosmetics, topical pharmaceuticals, and biological drug products, which includes vaccines. There has been significant concern regarding its safety and toxicity in the last several decades. Although thimerosal is banned in several countries, it continues to be included as a preservative in some vaccines in the United States and many vaccines in the developing world [L1685].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09352">
  <data key="d0">Hydroxyamphetamine</data>
  <data key="d1">drugbank.DB09352</data>
  <data key="d2">[drugbank.DB09352]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenergic Agonists, Amines, Amphetamines, Autonomic Agents, Ethylamines, Mydriatics, Peripheral Nervous System Agents, Phenethylamines, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Sympathomimetics]</data>
  <data key="d14">4-(2-aminopropyl)phenol</data>
  <data key="d15">C9H13NO</data>
  <data key="d16">103-86-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H13NO/c1-7(10)6-8-2-4-9(11)5-3-8/h2-5,7,11H,6,10H2,1H3</data>
  <data key="d20">CC(N)CC1=CC=C(O)C=C1</data>
  <data key="d21">Mydriatic agent (eye pupil dilatation) for diagnosis of ophthalmic nerve lesions.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[4-(2-aminopropyl)phenol, 4-hydroxyamphetamine, dl-4-hydroxyamphetamine, dl-p-hydroxyamphetamine, Hydroxyamphetamine, p-hydroxyamphetamine]</data>
  <data key="d9">Hydroxyamphetamine is a derivative of amphetamines. Hydroxyamphetamine is intended mainly as local eye drops for diagnostic purposes. It is indirect sympathomimetic agent which cause dilation of the eye pupil before diagnostic test.  Among the minor side effects from its use are: change in color vision, difficulty seeing at night, dry mouth, headache, increased sensitivity of eyes to sunlight, muscle stiffness or tightness and temporary stinging in the eyes.\nThe main use of hydroxyamphetamines as eye drops is the diagnosis of Horner's syndrome which is characterized by nerve lesions.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08020">
  <data key="d0">(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL</data>
  <data key="d1">drugbank.DB08020</data>
  <data key="d2">[drugbank.DB08020]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2R,6S,7R)-7-(4-hydroxyphenyl)-10-(methoxymethyl)-8-oxatricyclo[7.4.0.0,]trideca-1(9),10,12-trien-12-ol</data>
  <data key="d15">C20H22O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H22O4/c1-23-11-13-9-15(22)10-18-16-3-2-4-17(16)19(24-20(13)18)12-5-7-14(21)8-6-12/h5-10,16-17,19,21-22H,2-4,11H2,1H3/t16-,17+,19+/m1/s1</data>
  <data key="d20">[H][C@@]12CCC[C@]1([H])[C@@]([H])(OC1=C2C=C(O)C=C1COC)C1=CC=C(O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08019">
  <data key="d0">N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine</data>
  <data key="d1">drugbank.DB08019</data>
  <data key="d2">[drugbank.DB08019]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">6-{[(3S,4R)-4-[(2-{[(3-chlorophenyl)methyl]amino}ethyl)amino]pyrrolidin-3-yl]methyl}-4-methylpyridin-2-amine</data>
  <data key="d15">C20H28ClN5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H28ClN5/c1-14-7-18(26-20(22)8-14)10-16-12-24-13-19(16)25-6-5-23-11-15-3-2-4-17(21)9-15/h2-4,7-9,16,19,23-25H,5-6,10-13H2,1H3,(H2,22,26)/t16-,19-/m0/s1</data>
  <data key="d20">[H][C@]1(CC2=NC(N)=CC(C)=C2)CNC[C@]1([H])NCCNCC1=CC(Cl)=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08039">
  <data key="d0">(3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE</data>
  <data key="d1">drugbank.DB08039</data>
  <data key="d2">[drugbank.DB08039]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(3Z)-N,N-dimethyl-2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylidene)-2,3-dihydro-1H-indole-5-sulfonamide</data>
  <data key="d15">C19H21N3O3S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H21N3O3S/c1-22(2)26(24,25)14-7-8-18-15(11-14)16(19(23)21-18)10-13-9-12-5-3-4-6-17(12)20-13/h7-11,20H,3-6H2,1-2H3,(H,21,23)/b16-10-</data>
  <data key="d20">CN(C)S(=O)(=O)C1=CC=C2NC(=O)\C(=C/C3=CC4=C(CCCC4)N3)C2=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09369">
  <data key="d0">Polyestradiol phosphate</data>
  <data key="d1">drugbank.DB09369</data>
  <data key="d2">[drugbank.DB09369]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Antineoplastic and Immunomodulating Agents, Endocrine Therapy, Estradiol Congeners, Estranes, Estrenes, Estrogens, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, Steroids]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">28014-46-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(17-beta)-Estra-1, 3, 5(10)-triene-3, 17-diol polymer with phosphoric acid, Estradiol phosphate polymer, Fosfato de poliestradiol, Oestradiol phosphate polymer, Phosphate de polyestradiol, Poly(estradiol phosphate), Polyestradioli phosphas]</data>
  <data key="d9">Polymeric phosphoric acid ester of estradiol.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11672">
  <data key="d0">Curcumin</data>
  <data key="d1">drugbank.DB11672</data>
  <data key="d2">[drugbank.DB11672]</data>
  <data key="d12">[approved, experimental, investigational]</data>
  <data key="d13">[Alkanes, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Antineoplastic Agents, Antirheumatic Agents, Benzene Derivatives, Catechols, Central Nervous System Agents, Coloring Agents, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (moderate), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strong), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inhibitors (strong), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 Enzyme Inhibitors, Diarylheptanoids, Enzyme Inhibitors, Heptanes, Hydrocarbons, Acyclic, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Peripheral Nervous System Agents, Phenols, Sensory System Agents]</data>
  <data key="d14">(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione</data>
  <data key="d15">C21H20O6</data>
  <data key="d16">458-37-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+</data>
  <data key="d20">COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(O)C=C2)=CC=C1O</data>
  <data key="d21">No approved therapeutic indications.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Curcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in [DB11265]. It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities [A33166]. Due to these properties, curcumin has been investigated for the treatment and supportive care of clinical conditions including proteinuria, breast cancer, multiple myeloma, depression, and Non Small Cell Lung Cancer (NSCLC). Despite proven efficacy against numerous experimental models, poor bioavailability due to poor absorption, rapid metabolism, and rapid systemic elimination have been shown to limit the therapeutic efficacy of curcumin [A33166]. Curcumin is under investigation for the treatment and supportive care of various clinical conditions including mucositis, rectal cancer, prostate cancer, chronic schizophrenia, and Mild Cognitive Impairment (MCI) [A33166].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09371">
  <data key="d0">Norethynodrel</data>
  <data key="d1">drugbank.DB09371</data>
  <data key="d2">[drugbank.DB09371]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenal Cortex Hormones, Combination Contraceptives (with Estrogen and derivatives), Contraceptive Agents, Female, Contraceptives, Oral, Contraceptives, Oral, Synthetic, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Norpregnanes, Norpregnenes, Norsteroids, Progestin Contraceptives, Progestins, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids]</data>
  <data key="d14">(1R,3aS,3bR,9bS,11aS)-1-ethynyl-1-hydroxy-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,6H,7H,8H,9H,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one</data>
  <data key="d15">C20H26O2</data>
  <data key="d16">68-23-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,16-18,22H,4-12H2,2H3/t16-,17-,18+,19+,20+/m1/s1</data>
  <data key="d20">[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])CC(=O)CC3</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Noretynodrel, Noretynodrelum]</data>
  <data key="d9">A synthetic progestational hormone with actions and uses similar to those of PROGESTERONE. It has been used in the treatment of functional uterine bleeding and endometriosis. As a contraceptive, it has usually been administered in combination with MESTRANOL.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08047">
  <data key="d0">4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol</data>
  <data key="d1">drugbank.DB08047</data>
  <data key="d2">[drugbank.DB08047]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-[1-(prop-2-en-1-yl)-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol</data>
  <data key="d15">C17H13F3N2O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H13F3N2O2/c1-2-8-22-16-12(4-3-5-13(16)17(18,19)20)15(21-22)11-7-6-10(23)9-14(11)24/h2-7,9,23-24H,1,8H2</data>
  <data key="d20">OC1=CC(O)=C(C=C1)C1=NN(CC=C)C2=C1C=CC=C2C(F)(F)F</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08048">
  <data key="d0">4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL</data>
  <data key="d1">drugbank.DB08048</data>
  <data key="d2">[drugbank.DB08048]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-(6-hydroxy-1H-indazol-3-yl)benzene-1,3-diol</data>
  <data key="d15">C13H10N2O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H10N2O3/c16-7-1-3-9-11(5-7)14-15-13(9)10-4-2-8(17)6-12(10)18/h1-6,16-18H,(H,14,15)</data>
  <data key="d20">OC1=CC=C2C(NN=C2C2=CC=C(O)C=C2O)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09389">
  <data key="d0">Norgestrel</data>
  <data key="d1">drugbank.DB09389</data>
  <data key="d2">[drugbank.DB09389]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenal Cortex Hormones, Combination Contraceptives (with Estrogen and derivatives), Contraceptive Agents, Female, Contraceptives, Oral, Contraceptives, Oral, Synthetic, Contraceptives, Postcoital, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Norpregnanes, Norpregnenes, Norsteroids, Progestin Contraceptives, Progestins, Progestogens and Estrogens, Sequential Preparations, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids]</data>
  <data key="d14">15-ethyl-14-ethynyl-14-hydroxytetracyclo[8.7.0.0,.0,]heptadec-6-en-5-one</data>
  <data key="d15">C21H28O2</data>
  <data key="d16">6533-00-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3</data>
  <data key="d20">CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C</data>
  <data key="d21">Norgestrel in combination with ethinyl estradiol is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[17-ethynyl-17-hydroxy-18a-homoestr-4-en-3-one, LD norgestrel, Methylnorethindrone, Norgestrel, Norgestrelum]</data>
  <data key="d9">Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel.  However, only the levorotary enantiomer ([levonorgestrel]) is biologically active.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11699">
  <data key="d0">Tropisetron</data>
  <data key="d1">drugbank.DB11699</data>
  <data key="d2">[drugbank.DB11699]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Anti-Inflammatory Agents, Antiarrhythmic agents, Antidepressive Agents, Antiemetics, Antiemetics and Antinauseants, Autonomic Agents, Central Nervous System Agents, Central Nervous System Depressants, Drugs that are Mainly Renally Excreted, Gastrointestinal Agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Serotonin 5-HT3 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists]</data>
  <data key="d14">(1R,3R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 1H-indole-3-carboxylate</data>
  <data key="d15">C17H20N2O2</data>
  <data key="d16">89565-68-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H20N2O2/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16/h2-5,10-13,18H,6-9H2,1H3/t11-,12+,13+</data>
  <data key="d20">[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(=O)C1=CNC3=CC=CC=C13)N2C</data>
  <data key="d21">For the prevention of nausea and vomiting induced by cytotoxic therapy and postoperative.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Tropisetron]</data>
  <data key="d9">Tropisetron is an indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy-and radiotherapy-induced nausea and vomiting.\n\nTropisetron appears to be well tolerated with the most frequently reported adverse effect being headache. Extrapyramidal side effects are rare upon using tropisetron.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00977">
  <data key="d0">Ethinylestradiol</data>
  <data key="d1">drugbank.DB00977</data>
  <data key="d2">[drugbank.DB00977, drugbank.APRD00691]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenal Cortex Hormones, Antineoplastic and Immunomodulating Agents, BSEP/ABCB11 inducers, BSEP/ABCB11 Inhibitors, Contraceptive Agents, Female, Contraceptives, Oral, Contraceptives, Postcoital, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Endocrine Therapy, Estradiol Congeners, Estrogen Contraceptives, Estrogenic Steroids, Alkylated, Estrogens, Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Natural and Semisynthetic Estrogens, Plain, Norpregnanes, Norpregnatrienes, Norsteroids, P-glycoprotein/ABCB1 Substrates, Progestogens and Estrogens, Sequential Preparations, Sex Hormones and Modulators of the Genital System, Steroids, UGT1A1 Inducers, UGT1A1 Substrates]</data>
  <data key="d14">(1S,10R,11S,14R,15S)-14-ethynyl-15-methyltetracyclo[8.7.0.0,.0,]heptadeca-2(7),3,5-triene-5,14-diol</data>
  <data key="d15">C20H24O2</data>
  <data key="d16">57-63-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1</data>
  <data key="d20">[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3</data>
  <data key="d21">For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[17-ethinyl-3, 17-estradiol, 17-ethinyl-3, 17-oestradiol, 17-ethinylestradiol, 17alpha-Ethinyl estradiol, 17-ethynylestradiol, Ethinyl estradiol, Ethinylestradiol, Ethinylestradiolum, Ethinyloestradiol, Ethynyl estradiol, Etinilestradiol]</data>
  <data key="d9">A semisynthetic alkylated estradiol with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally and is often used as the estrogenic component in oral contraceptives. Ethinyl estradiol is marketed mostly as a combination oral contraceptive under several brand names such as Alesse, Tri-Cyclen, Triphasil, and Yasmin. The FDA label includes a black box warning that states that combination oral contraceptives should not be used in women over 35 years old who smoke due to the increased risk of serious cardiovascular side effects.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00989">
  <data key="d0">Rivastigmine</data>
  <data key="d1">drugbank.DB00989</data>
  <data key="d2">[drugbank.DB00989, drugbank.APRD00321]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Acyclic, Anti-Dementia Drugs, Bradycardia-Causing Agents, Carbamates, Central Nervous System Agents, Cholinergic Agents, Cholinesterase Inhibitors, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Enzyme Inhibitors, Nervous System, Neuroprotective Agents, Neurotransmitter Agents, Parasympathomemetic (Cholinergic) Agents, Phenylcarbamates, Protective Agents, Psychoanaleptics]</data>
  <data key="d14">3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate</data>
  <data key="d15">C14H22N2O2</data>
  <data key="d16">123441-03-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1</data>
  <data key="d20">CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C</data>
  <data key="d21">For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate, m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate, Rivastigmina, Rivastigmine]</data>
  <data key="d9">Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00985">
  <data key="d0">Dimenhydrinate</data>
  <data key="d1">drugbank.DB00985</data>
  <data key="d2">[drugbank.DB00985, drugbank.APRD00924]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Alkaloids, Amines, Antiemetics, Autonomic Agents, Benzene Derivatives, Benzhydryl Compounds, Central Nervous System Agents, Central Nervous System Depressants, Diphenhydramine, Ethylamines, Gastrointestinal Agents, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Moderate Risk QTc-Prolonging Agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Pharmaceutical Preparations, Purines, Purinones, QTc Prolonging Agents]</data>
  <data key="d14">8-chloro-1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-7-ide; [2-(diphenylmethoxy)ethyl]dimethylazanium</data>
  <data key="d15">C24H28ClN5O3</data>
  <data key="d16">523-87-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H21NO.C7H7ClN4O2/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h3-12,17H,13-14H2,1-2H3;1-2H3,(H,9,10,13)</data>
  <data key="d20">CN1C2=C([N-]C(Cl)=N2)C(=O)N(C)C1=O.C[NH+](C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d21">Dimenhydrinate is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(O-benzhydryl(dimethylamino)ethanol) 8-chlorotheophyllinate, 8-chloro-1, 3-dimethyl-3, 7-dihydro-1H-purine-2, 6-dione - 2-(diphenylmethoxy)-N, N-dimethylethanamine (1:1), Benzhydryl--dimethylaminoethylether 8-chlorotheophylline, Dimenhidrinato, Dimenhydrinate, Dimenhydrinatum, diphenhydramine 8-chlorotheophyllinate, diphenhydramine 8-chlorotheophylline, Diphenhydramine theoclate, N, N-dimethyl-2-diphenylmethoxyethylamine 8-chlorotheophyllinate, O-benzhydryldimethylaminoethanol 8-chlorotheophyllinate, -dimethylaminoethyl benzhydryl ether 1, 3-dimethyl-8-chloroxanthine]</data>
  <data key="d9">Dimenhydrinate, also known as Dramamine or Gravol, is an over-the-counter drug used to prevent nausea, vomiting, and dizziness caused by motion sickness. Dimenhydrinate is a combination drug composed of [DB01075] and [DB14132] in a salt form, with 53%-55.5% of diphenhydramine, and not less than 44%-47% of 8-chlorotheophylline, calculated on the dried basis. \n\nThe antiemetic properties of dimenhydrinate are primarily thought to be produced by diphenhydramine's antagonism of H1 histamine receptors in the vestibular system [A1540] while the excitatory effects are thought to be produced by 8-chlorotheophylline's adenosine receptor blockade [A33889]. The addition of 8-chlorotheophylline was initially intended to counteract the sedative effects of diphenhydramine.\n\nWhen used in large doses, dimenhydrinate has been shown to cause a "high" characterized by hallucinations, excitement, incoordination, and disorientation [A1539].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00981">
  <data key="d0">Physostigmine</data>
  <data key="d1">drugbank.DB00981</data>
  <data key="d2">[drugbank.DB00981, drugbank.APRD00406]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Acyclic, Alkaloids, Antidotes, Antiglaucoma Preparations and Miotics, Autonomic Agents, Carbamates, Cholinergic Agents, Cholinesterase Inhibitors, Enzyme Inhibitors, Indole Alkaloids, Indoles, Miotics, Neurotransmitter Agents, Ophthalmologicals, Parasympathomimetics, Peripheral Nervous System Agents, Phenylcarbamates, Sensory Organs]</data>
  <data key="d14">(3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-methylcarbamate</data>
  <data key="d15">C15H21N3O2</data>
  <data key="d16">57-47-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H21N3O2/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2/h5-6,9,13H,7-8H2,1-4H3,(H,16,19)/t13-,15+/m1/s1</data>
  <data key="d20">[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC)=C1)N2C</data>
  <data key="d21">For the treatment of glaucoma, and in the treatment of severe anticholinergic toxicity.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Eserine, Physostigmine, Physostol]</data>
  <data key="d9">A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09318">
  <data key="d0">Synthetic Conjugated Estrogens, B</data>
  <data key="d1">drugbank.DB09318</data>
  <data key="d2">[drugbank.DB09318]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Drugs that are Mainly Renally Excreted, Estrogens, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Thyroxine-binding globulin inducers]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">746658-13-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">For the treatment of moderate to severe vasomotor symptoms due to menopause and for the treatment of moderate to severe vaginal dryness, pain with intercourse, and symptoms of vulvar and vaginal atrophy due to menopause.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Estrogens, Conjugated Synthetic B, Synthetic Conjugated Estrogens, B]</data>
  <data key="d9">Synthetic conjugated estrogens, B tablets contain a blend of ten synthetic estrogenic substances. The estrogenic substances are: sodium estrone sulfate, sodium equilin sulfate, sodium 17-dihydroequilin sulfate, sodium 17-estradiol sulfate, sodium 17 dihydroequilin sulfate, sodium 17-dihydroequilenin sulfate, sodium 17-dihydroequilenin sulfate, sodium equilenin sulfate, sodium 17-estradiol sulfate, and sodium 8,9-dehydroestrone sulfate. This blend of ten estrogen derivatives are plant-derived forms of endogenous estrogens and contain many of the same compounds as the Conjugated Equine Estrogens (CEEs), although they are not considered to be equivalent. Available as the product Cenestin (FDA), this combination of plant-derived estrogenic compounds is indicated for the treatment of moderate to severe vasomotor symptoms, vulvovaginal atrophy, vaginal dryness, and paint with intercourse associated with menopause. \n\nAll estrogen products mimic the effects of endogenous estrogens in the body which are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estrogens act by binding to estrogen receptors on a wide variety of tissues in the body and modulating the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism. Prior to menopause, the primary source of estrogen is the ovarian follicle, which secretes 70-500 micrograms of estradiol daily, depending on the phase of the menstrual cycle. However, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control. This shift in hormone production is largely responsible for many of the symptoms experienced during and after menopause and includes hot flashes and other vasomotor symptoms, painful intercourse, vaginal dryness, and vulvovaginal atrophy. These symptoms are able to be reduced by replacing many of the hormones lost during and following menopause with synthetic or naturally occurring forms, in a therapy known as Hormone Replacement Therapy (HRT).\n\nPharmacologic estrogen products are available in a variety of formats. Although many of them contain several compounds in common (such as the estrogen derivatives sodium estrone sulfate and sodium equilin sulfate), they vary by their original source (such as horse-, human-, or plant-derived), and the remaining mixture of estrogenic derivatives. Conjugated Equine Estrogens (CEEs) are derived from the urine of pregnant mares and contain a blend of at least 10 estrogen derivatives. Marketed under the brand name Premarin, CEEs are the most frequently used form of conjugated estrogens. There is currently no generic form of CEEs available as a detailed analytical characterization of the active ingredients or of their estrogenic activity is not available at this time. Conjugated estrogens are also available in a plant-derived synthetic form that replicates the naturally occurring, horse-derived forms. Available as either "Synthetic Conjugated Estrogens, A" containing 9 estrogen derivatives (available as Cenestin) or as "Synthetic Conjugated Estrogens, B" containing 10 estrogen derivatives (available as Enjuvia), these products are isolated as precursors from yam or soy plants and then chemically modified to mimic the products available in their naturally occurring form.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09317">
  <data key="d0">Synthetic Conjugated Estrogens, A</data>
  <data key="d1">drugbank.DB09317</data>
  <data key="d2">[drugbank.DB09317]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Drugs that are Mainly Renally Excreted, Estrogens, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Thyroxine-binding globulin inducers]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">For the treatment of moderate to severe vasomotor symptoms due to menopause and for treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Estrogens, Conjugated Synthetic A]</data>
  <data key="d9">Synthetic conjugated estrogens A are composed of a blend of the following nine synthetic estrogenic substances: estrone sulfate, sodium equilin sulfate, sodium 17-dihydroequilin sulfate, sodium 17-estradiol sulfate, sodium 17 dihydroequilin sulfate, sodium 17-dihydroequilenin sulfate, sodium 17-dihydroequilenin sulfate, sodium equilenin sulfate, and sodium 17-estradiol sulfate. This blend of nine estrogen derivatives are plant-derived forms of endogenous estrogens and contain many of the same compounds as the Conjugated Equine Estrogens (CEEs), although they are not considered to be equivalent. Available as the product Enjuvia (FDA), this combination of plant-derived estrogenic compounds is indicated for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy associated with menopause. \n\nAll estrogen products mimic the effects of endogenous estrogens in the body which are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estrogens act by binding to estrogen receptors on a wide variety of tissues in the body and modulating the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism. Prior to menopause, the primary source of estrogen is the ovarian follicle, which secretes 70-500 micrograms of estradiol daily, depending on the phase of the menstrual cycle. However, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control. This shift in hormone production is largely responsible for many of the symptoms experienced during and after menopause and includes hot flashes and other vasomotor symptoms, painful intercourse, vaginal dryness, and vulvovaginal atrophy. These symptoms are able to be reduced by replacing many of the hormones lost during and following menopause with synthetic or naturally occurring forms, in a therapy known as Hormone Replacement Therapy (HRT).\n\nPharmacologic estrogen products are available in a variety of formats. Although many of them contain several compounds in common (such as the estrogen derivatives sodium estrone sulfate and sodium equilin sulfate), they vary by their original source (such as horse-, human-, or plant-derived), and the remaining mixture of estrogenic derivatives. Conjugated Equine Estrogens (CEEs) are derived from the urine of pregnant mares and contain a blend of at least 10 estrogen derivatives. Marketed under the brand name Premarin, CEEs are the most frequently used form of conjugated estrogens. There is currently no generic form of CEEs available as a detailed analytical characterization of the active ingredients or of their estrogenic activity is not available at this time. Conjugated estrogens are also available in a plant-derived synthetic form that replicates the naturally occurring, horse-derived forms. Available as either "Synthetic Conjugated Estrogens, A" containing 9 estrogen derivatives (available as Cenestin) or as "Synthetic Conjugated Estrogens, B" containing 10 estrogen derivatives (available as Enjuvia), these products are isolated as precursors from yam or soy plants and then chemically modified to mimic the products available in their naturally occurring form.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11638">
  <data key="d0">Artenimol</data>
  <data key="d1">drugbank.DB11638</data>
  <data key="d2">[drugbank.DB11638]</data>
  <data key="d12">[experimental, investigational]</data>
  <data key="d13">[Anions, Anti-Infective Agents, Antimalarials, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Artemisia, Artemisinin and Derivatives, Plain, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Electrolytes, Free Radicals, Ions, Oxides, Oxygen Compounds, Peroxides, Reactive Oxygen Species, Sesquiterpenes, Terpenes, UGT1A9 Substrates, UGT2B7 substrates]</data>
  <data key="d14">(1R,4S,5R,8S,9R,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecan-10-ol</data>
  <data key="d15">C15H24O5</data>
  <data key="d16">71939-50-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12?,13-,14-,15-/m1/s1</data>
  <data key="d20">[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4</data>
  <data key="d21">For the treatment of uncomplicated *Plasmodium falciparum* infection in adults, children, and infants aged 6 months and up weighing over 5 kg [FDA Label]. Used in combination with [DB13941].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[beta-Dihydroartemisinin, Dihydroartemisinin]</data>
  <data key="d9">Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim. Artemisinin combination therapy is highly effective against malaria and stongly recommended by the World Health Organization [L1156].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12965">
  <data key="d0">Silver</data>
  <data key="d1">drugbank.DB12965</data>
  <data key="d2">[drugbank.DB12965]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Antiseptics and Disinfectants, Dermatologicals, Elements, Metals, Metals, Heavy, Silver Compounds, Transition Elements]</data>
  <data key="d14">silver</data>
  <data key="d15">Ag</data>
  <data key="d16">7440-22-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/Ag</data>
  <data key="d20">[Ag]</data>
  <data key="d21">Indicated for the treatment of acne for topical use or the management of dental caries for dental use.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Argentum metallicum, Colloidal silver, Nanosilver, Silver colloidal, Silver nanoparticles, Silver, colloidal]</data>
  <data key="d9">Silver (Ag) is a chemical element that belongs in the family of transition metals in the periodic table. It has a high electrical conductivity, thermal conductivity, and reflectivity. Silver exists as a pure elemental form, alloy with other metals, and mineral. Having critical roles in various applications inducing chemical and industrial fields, silver compounds have also been used in the field of medicine for centuries due to their broad-spectrum biological actions. Silver nanoparticles especially have been widely used in industrial, household, and healthcare-related products due to their potent antimicrobial activity. [DB11080] and [DB05245] have been used as topical antibacterial agents for the treatment of skin infections, while [DB05245] has also been valued for topical burn treatment [A33141]. Silver and its compounds have been used in trials studying the management of dental caries since the 1800s, and they may be found in dental pastes as an active ingredients. However, some drawbacks of dental use of silver compounds include tooth discolouration and pulp irritation [A33141].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09330">
  <data key="d0">Osimertinib</data>
  <data key="d1">drugbank.DB09330</data>
  <data key="d2">[drugbank.DB09330]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acids, Acyclic, Acrylates, Amides, Amines, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Breast Cancer Resistance Protein Inhibitors, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (unknown strength), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P450 1A2 Inducers, Cytochrome P450 3A Inhibitors, Cytochrome P450 3A4 Inducers, Enzyme Inhibitors, Kinase Inhibitor, Kinase Inhibitors, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d14">N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide</data>
  <data key="d15">C28H33N7O2</data>
  <data key="d16">1421373-65-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)</data>
  <data key="d20">COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C</data>
  <data key="d21">Osimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA- approved test, who have progressed on or after EGFR-TKI therapy.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Mereletinib, N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide, Osimertinib, Osimertinibum]</data>
  <data key="d9">Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. \n\nDevelopment of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09332">
  <data key="d0">Kappadione</data>
  <data key="d1">drugbank.DB09332</data>
  <data key="d2">[drugbank.DB09332]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[]</data>
  <data key="d14">tetrasodium 3-methyl-4-(phosphonatooxy)naphthalen-1-yl phosphate</data>
  <data key="d15">C11H8Na4O8P2</data>
  <data key="d16">131-13-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H12O8P2.4Na/c1-7-6-10(18-20(12,13)14)8-4-2-3-5-9(8)11(7)19-21(15,16)17;;;;/h2-6H,1H3,(H2,12,13,14)(H2,15,16,17);;;;/q;4*+1/p-4</data>
  <data key="d20">[Na+].[Na+].[Na+].[Na+].CC1=C(OP([O-])([O-])=O)C2=CC=CC=C2C(OP([O-])([O-])=O)=C1</data>
  <data key="d21">Anticoagulant-induced prothrombin deficiency caused by coumadin or indanedione derivatives,\nprophylaxis and therapy of hemorrhagic disease of the newborn, hypoprothrombinemia due to antibacterial therapy,\nhypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K (for example, obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis, other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism) [L1545, L1546].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Menadiol sodium diphosphate]</data>
  <data key="d9">Kappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued and is not available in North America [L1543]. It has been found to have carcinogenic potential in mammalian cells as well as cytotoxic properties [L1544]. Studies involving the active metabolite of this formulation, menadione, showed oocyte toxicity in a study of mice [L1544].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08018">
  <data key="d0">N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE</data>
  <data key="d1">drugbank.DB08018</data>
  <data key="d2">[drugbank.DB08018]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">6-{[(3S,4S)-4-[(2-{[(4-chlorophenyl)methyl]amino}ethyl)amino]pyrrolidin-3-yl]methyl}-4-methylpyridin-2-amine</data>
  <data key="d15">C20H28ClN5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H28ClN5/c1-14-8-18(26-20(22)9-14)10-16-12-24-13-19(16)25-7-6-23-11-15-2-4-17(21)5-3-15/h2-5,8-9,16,19,23-25H,6-7,10-13H2,1H3,(H2,22,26)/t16-,19+/m0/s1</data>
  <data key="d20">[H][C@]1(CC2=NC(N)=CC(C)=C2)CNC[C@@]1([H])NCCNCC1=CC=C(Cl)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00935">
  <data key="d0">Oxymetazoline</data>
  <data key="d1">drugbank.DB00935</data>
  <data key="d2">[drugbank.DB00935, drugbank.APRD01158]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Agents producing tachycardia, Agents that produce hypertension, Autonomic Agents, Cardiovascular Agents, Decongestants and Antiallergics, Imidazoles, Increased Sympathetic Activity, Nasal Decongestants, Nasal Preparations, Neurotransmitter Agents, Ophthalmologicals, Peripheral Nervous System Agents, Respiratory System Agents, Sensory Organs, Sympathomimetics, Sympathomimetics Used as Decongestants, Sympathomimetics, Plain, Vasoconstriction, Vasoconstrictor Agents]</data>
  <data key="d14">6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol</data>
  <data key="d15">C16H24N2O</data>
  <data key="d16">1491-59-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)</data>
  <data key="d20">CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C</data>
  <data key="d21">For treatment of nasal congestion and redness associated with minor irritations of the eye</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-(4-tert-butyl-2, 6-dimethyl-3-hydroxybenzyl)-2-imidazoline, 3-[(4, 5-dihydro-1H-imidazol-2-yl)methyl]-6-(1, 1-dimethylethyl)-2, 4-dimethylphenol, 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2, 4-dimethylphenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2, 4-dimethylphenol, Oximetazolinum, Oxymetazolina, Oxymetazoline, Oxymtazoline, Oxymetazolinum, Oxymethazoline, Oxymetozoline]</data>
  <data key="d9">A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00948">
  <data key="d0">Mezlocillin</data>
  <data key="d1">drugbank.DB00948</data>
  <data key="d2">[drugbank.DB00948, drugbank.APRD01113]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Aza Compounds, Azabicyclo Compounds, Beta-Lactam Antibacterials, beta-Lactams, Lactams, Penicillin G, Penicillins, Penicillins With Extended Spectrum, Sulfur Compounds]</data>
  <data key="d14">(2S,5R,6R)-6-[(2R)-2-[(3-methanesulfonyl-2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid</data>
  <data key="d15">C21H25N5O8S2</data>
  <data key="d16">51481-65-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H25N5O8S2/c1-21(2)14(18(29)30)26-16(28)13(17(26)35-21)22-15(27)12(11-7-5-4-6-8-11)23-19(31)24-9-10-25(20(24)32)36(3,33)34/h4-8,12-14,17H,9-10H2,1-3H3,(H,22,27)(H,23,31)(H,29,30)/t12-,13-,14+,17-/m1/s1</data>
  <data key="d20">[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(C1=O)S(C)(=O)=O)C1=CC=CC=C1)C(O)=O</data>
  <data key="d21">Used to treat serious gram&amp;ndash;negative infections of the lungs, urinary tract, and skin.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(2S, 5R, 6R)-3, 3-dimethyl-6-{[(2R)-2-({[3-(methylsulfonyl)-2-oxoimidazolidin-1-yl]carbonyl}amino)-2-phenylacetyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-{(2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}penicillanic acid, Mezlocilina, Mezlocillin, Mezlocilline, Mezlocillinum]</data>
  <data key="d9">Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00947">
  <data key="d0">Fulvestrant</data>
  <data key="d1">drugbank.DB00947</data>
  <data key="d2">[drugbank.DB00947, drugbank.APRD00654]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Anti-Estrogens, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Endocrine Therapy, Estradiol Congeners, Estranes, Estrenes, Estrogen Antagonists, Estrogen Receptor Antagonists, Gonadal Hormones, Gonadal Steroid Hormones, Hormone Antagonists, Hormone Antagonists and Related Agents, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Selective Estrogen Receptor Modulators, Steroids, UGT1A1 Substrates]</data>
  <data key="d14">(1S,3aS,3bR,4R,9bS,11aS)-11a-methyl-4-[9-(4,4,5,5,5-pentafluoropentanesulfinyl)nonyl]-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1,7-diol</data>
  <data key="d15">C32H47F5O3S</data>
  <data key="d16">129453-61-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1</data>
  <data key="d20">[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]</data>
  <data key="d21">For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(7, 17)-7-{9-[(4, 4, 5, 5, 5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10), 2, 4-triene-3, 17-diol, Fulvestrant]</data>
  <data key="d9">Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with [alpelisib] for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00945">
  <data key="d0">Acetylsalicylic acid</data>
  <data key="d1">drugbank.DB00945</data>
  <data key="d2">[drugbank.DB00945, drugbank.APRD00264, drugbank.EXPT00475]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Acids, Carbocyclic, Agents causing angioedema, Agents causing hyperkalemia, Agents that produce hypertension, Alimentary Tract and Metabolism, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Anticoagulants, Antiinflammatory and Antirheumatic Products, Antiplatelet agents, Antipyretics, Benzene Derivatives, Blood and Blood Forming Organs, Cardiovascular Agents, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (unknown strength), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inducers, Decreased Platelet Aggregation, Decreased Prostaglandin Production, Drugs that are Mainly Renally Excreted, Hematologic Agents, Hydroxybenzoates, Musculo-Skeletal System, Nephrotoxic agents, Non COX-2 selective NSAIDS, Nonsteroidal Anti-inflammatory Compounds, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, P-glycoprotein/ABCB1 Inducers, P-glycoprotein/ABCB1 Substrates, Peripheral Nervous System Agents, Platelet Aggregation Inhibitors Excl. Heparin, Salicylates, Salicylic Acid and Derivatives, Sensory System Agents, Stomatological Preparations, UGT1A6 substrate]</data>
  <data key="d14">2-(acetyloxy)benzoic acid</data>
  <data key="d15">C9H8O4</data>
  <data key="d16">50-78-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)</data>
  <data key="d20">CC(=O)OC1=CC=CC=C1C(O)=O</data>
  <data key="d21">**Pain, fever, and inflammation**\n\nAcetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures [FDA label]. \n\nThe _extra strength_ formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound)[FDA label].\n\n**Other indications**\n\nASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include: \n\nReducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) [FDA label]. \n\nReducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction [FDA label].\n\nFor reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) [FDA label].\n\nFor the prevention of thromboembolism after hip replacement surgery [FDA label]. \n\nFor decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) [FDA label].\n\nUsed for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site [FDA Label]. \n\n**Important note regarding use of the extended-release formulation [F4405]**\n\nIn the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action [Label, F4405]. The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA [F4405].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-Acetoxybenzenecarboxylic acid, 2-Acetoxybenzoic acid, Acetylsalicylate, Acetylsalicylsure, acide 2-(actyloxy)benzoque, Acide actylsalicylique, cido acetilsaliclico, Acidum acetylsalicylicum, ASA, Aspirin, Aspirina, Azetylsalizylsure, o-acetoxybenzoic acid, O-acetylsalicylic acid, o-carboxyphenyl acetate, Polopiryna, salicylic acid acetate]</data>
  <data key="d9">Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects.  This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) [FDA label].  \n\nInterestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer [A177325]. Aspirin is classified as a _non-selective cyclooxygenase (COX) inhibitor_ [A32682, A177268] and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others [L5968]. \n\nAcetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants [FDA label].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00944">
  <data key="d0">Demecarium</data>
  <data key="d1">drugbank.DB00944</data>
  <data key="d2">[drugbank.DB00944, drugbank.APRD00905]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amines, Ammonium Compounds, Antiglaucoma Preparations and Miotics, Cholinergic Agents, Cholinesterase Inhibitors, Enzyme Inhibitors, Neurotransmitter Agents, Nitrogen Compounds, Onium Compounds, Ophthalmologicals, Parasympathomimetics, Sensory Organs]</data>
  <data key="d14">N,N,N-trimethyl-3-{[methyl({10-[methyl({[3-(trimethylazaniumyl)phenoxy]carbonyl})amino]decyl})carbamoyl]oxy}anilinium</data>
  <data key="d15">C32H52N4O4</data>
  <data key="d16">16505-84-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C32H52N4O4/c1-33(31(37)39-29-21-17-19-27(25-29)35(3,4)5)23-15-13-11-9-10-12-14-16-24-34(2)32(38)40-30-22-18-20-28(26-30)36(6,7)8/h17-22,25-26H,9-16,23-24H2,1-8H3/q+2</data>
  <data key="d20">CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C</data>
  <data key="d21">For the topical treatment of chronic open-angle glaucoma.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Demecarium, Demecarium cation, Demecarium ion]</data>
  <data key="d9">Demecarium is an indirect-acting parasympathomimetic agent that is used to treat glaucoma. It is a cholinesterase inhibitor or an anticholinesterase. Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the neuroeffector junction of parasympathetic postganglion nerves, by inactivating the cholinesterases that break it down. Demecarium inactivates both pseudocholinesterase and acetylcholinesterase. In the eye, this causes constriction of the iris sphincter muscle (causing miosis) and the ciliary muscle. The outflow of the aqueous humor is facilitated, which leads to a reduction in intraocular pressure.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00941">
  <data key="d0">Hexafluronium</data>
  <data key="d1">drugbank.DB00941</data>
  <data key="d2">[drugbank.DB00941, drugbank.APRD01013]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amines, Ammonium Compounds, Bis-Trimethylammonium Compounds, Central Nervous System Depressants, Cholinesterase Inhibitors, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Nitrogen Compounds, Onium Compounds, Quaternary Ammonium Compounds]</data>
  <data key="d14">N-{6-[(9H-fluoren-9-yl)dimethylazaniumyl]hexyl}-N,N-dimethyl-9H-fluoren-9-aminium</data>
  <data key="d15">C36H42N2</data>
  <data key="d16">4844-10-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C36H42N2/c1-37(2,35-31-21-11-7-17-27(31)28-18-8-12-22-32(28)35)25-15-5-6-16-26-38(3,4)36-33-23-13-9-19-29(33)30-20-10-14-24-34(30)36/h7-14,17-24,35-36H,5-6,15-16,25-26H2,1-4H3/q+2</data>
  <data key="d20">C[N+](C)(CCCCCC[N+](C)(C)C1C2=C(C=CC=C2)C2=C1C=CC=C2)C1C2=C(C=CC=C2)C2=C1C=CC=C2</data>
  <data key="d21">Used as an adjunct with succinylcholine (or suxamethonium chloride) to prolong muscle relaxation and to prevent succinylcholine-induced muscle fasciculations.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Hexafluorenium, Hexafluorenium cation, Hexafluorenium ion, Hexamethylenebis(fluoren-9-yldimethylammonium)]</data>
  <data key="d9">Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery. It is known to bind and block the activity of plasma cholinesterases.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00957">
  <data key="d0">Norgestimate</data>
  <data key="d1">drugbank.DB00957</data>
  <data key="d2">[drugbank.DB00957, drugbank.APRD00569]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Adrenal Cortex Hormones, Combination Contraceptives (with Estrogen and derivatives), Contraceptive Agents, Female, Contraceptives, Oral, Contraceptives, Oral, Synthetic, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Hyperglycemia-Associated Agents, Norpregnanes, Norpregnenes, Norsteroids, Progestin Contraceptives, Progestins, Progestogens and Estrogens, Sequential Preparations, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids]</data>
  <data key="d14">(1R,3aS,3bR,7E,9aR,9bS,11aS)-11a-ethyl-1-ethynyl-7-(hydroxyimino)-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl acetate</data>
  <data key="d15">C23H31NO3</data>
  <data key="d16">35189-28-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H31NO3/c1-4-22-12-10-19-18-9-7-17(24-26)14-16(18)6-8-20(19)21(22)11-13-23(22,5-2)27-15(3)25/h2,14,18-21,26H,4,6-13H2,1,3H3/b24-17+/t18-,19+,20+,21-,22-,23-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\C(C=C3CC[C@@]21[H])=N/O</data>
  <data key="d21">For the prevention of pregnancy</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+)-13-Ethyl-17-hydroxy-18, 19-dinor-17-pregn-4-en-20-yn-3-one oxime acetate (ester), (17)-17-(Acetyloxy)-13-ethyl-18, 19-dinorpregn-4-en-20-yn-3-one 3-oxime, d-13-Ethyl-17-ethynyl-17-acetoxygon-4-en-3-one oxime, Dexnorgestrel Acetime, Norgestimate, Norgestimato, Norgestimatum]</data>
  <data key="d9">Norgestimate is a form of progesterone, which is a female hormone important for the regulation of ovulation and menstruation. Norgestimate is used with estradiol to treat the symptoms of menopause.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00953">
  <data key="d0">Rizatriptan</data>
  <data key="d1">drugbank.DB00953</data>
  <data key="d2">[drugbank.DB00953, drugbank.APRD00008]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents that produce hypertension, Amines, Analgesics, Antidepressive Agents, Antimigraine Preparations, Biogenic Amines, Biogenic Monoamines, Central Nervous System Depressants, Drugs that are Mainly Renally Excreted, Indoles, Migraine Disorders, Monoamine Oxidase A Substrates, Nervous System, Neurotransmitter Agents, Selective Serotonin 5-HT1 Receptor Agonists, Selective Serotonin Agonists, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 1b Receptor Agonists, Serotonin 1d Receptor Agonists, Serotonin 5-HT1 Receptor Agonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Agonists, Serotonin-1b and Serotonin-1d Receptor Agonist, Triptans]</data>
  <data key="d14">dimethyl({2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethyl})amine</data>
  <data key="d15">C15H19N5</data>
  <data key="d16">144034-80-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3</data>
  <data key="d20">CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2</data>
  <data key="d21">For treatment of acute migraine attacks with or without aura.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[N, N-Dimethyl-2-[5-(1, 2, 4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine, N, N-Dimethyl-5-(1H-1, 2, 4-triazol-1-ylmethyl)-1H-indole-3-ethanamine, Risatriptan, Rizatriptn, Rizatriptan, Rizatriptanum]</data>
  <data key="d9">Rizatriptan is a triptan drug used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00966">
  <data key="d0">Telmisartan</data>
  <data key="d1">drugbank.DB00966</data>
  <data key="d2">[drugbank.DB00966, drugbank.APRD01247]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Carbocyclic, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin 2 Receptor Blocker, Angiotensin II receptor blockers (ARBs) and calcium channel blockers, Angiotensin II receptor blockers (ARBs) and diuretics, Angiotensin II receptor blockers (ARBs), plain, Angiotensin II Type 1 Receptor Blockers, Angiotensin II Type 2 Receptor Blockers, Angiotensin Receptor Antagonists, Antihypertensive Agents, BCRP/ABCG2 Inhibitors, Benzene Derivatives, BSEP/ABCB11 Substrates, Cardiovascular Agents, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 Enzyme Inhibitors, Hypotensive Agents, P-glycoprotein/ABCB1 Inhibitors, UGT1A3 substrates]</data>
  <data key="d14">2-(4-{[4-methyl-6-(1-methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl]methyl}phenyl)benzoic acid</data>
  <data key="d15">C33H30N4O2</data>
  <data key="d16">144701-48-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)</data>
  <data key="d20">CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O</data>
  <data key="d21">Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[4'-((1, 4'-dimethyl-2'-propyl(2, 6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1, 1'-biphenyl)-2-carboxylic acid, 4'-((4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid, 4'-[(1, 4'-dimethyl-2'propyl[2, 6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1, 1'-biphenyl]-2-carboxylic acid, 4'-[(1, 7'-dimethyl-2'-propyl-1H, 3'H-2, 5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid, Telmisartan]</data>
  <data key="d9">Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB09301">
  <data key="d0">Chondroitin sulfate</data>
  <data key="d1">drugbank.DB09301</data>
  <data key="d2">[drugbank.DB09301, drugbank.DB11353, drugbank.DB11339]</data>
  <data key="d12">[approved, investigational, nutraceutical]</data>
  <data key="d13">[Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Carbohydrates, Chondroitin, Drugs that are Mainly Renally Excreted, Glycosaminoglycans, Musculo-Skeletal System, Polysaccharides]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">24967-93-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Chondroitin sulfate, used with glucosamine, is indicated to alleviate pain and inflammation from primary osteoarthritis.[L1527] This supplement is reported to improve joint function and slow disease progression.[L1528] Osteoarthritis is characterized by progressive structural and metabolic changes in joint tissues, mainly cartilage degradation, subchondral bone sclerosis and inflammation of synovial membrane.[A32066]\n\nStudies have proposed the potential use of chondroitin sulfate as a nutraceutical in dietary supplements.[A32065]</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Chondroitin sulfates, Condroitn sulfato]</data>
  <data key="d9">Chondroitin sulfate is a glycosaminoglycan considered as a symptomatic slow-acting drug for osteoarthritis (SYSADOA).[A7906] The SYSADOA status suggested a pain relief and increased joint mobility after a relative long regular administration, as well as a long-lasting effect after the end of the treatment. Chondroitin sulfate is composed of alternating 1,3-N-acetyl--d-galactosamine and 1,4--d-glucuronic acid units which bear 4-O- and/or 6-O-sulfations at the N-acetylgalactosamine units disposed of in specific patterns. Depending on the predominating disaccharide unit, it will present different biological activities.[A32063] Chondroitin sulfate is sold as an OTC dietary supplement in North America and it is a prescription drug under the EMA in Europe.[A32066]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11619">
  <data key="d0">Gestrinone</data>
  <data key="d1">drugbank.DB11619</data>
  <data key="d2">[drugbank.DB11619]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenal Cortex Hormones, Antigonadotropins and Similar Agents, Contraceptive Agents, Female, Contraceptives, Oral, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Norgestrienone, Norpregnanes, Norpregnatrienes, Norsteroids, Progestin Contraceptives, Progestins, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids]</data>
  <data key="d14">(10S,11S,14R,15S)-15-ethyl-14-ethynyl-14-hydroxytetracyclo[8.7.0.0,.0,]heptadeca-1,6,16-trien-5-one</data>
  <data key="d15">C21H24O2</data>
  <data key="d16">16320-04-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H24O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,9,11,13,18-19,23H,3,5-8,10,12H2,1H3/t18-,19+,20+,21+/m1/s1</data>
  <data key="d20">[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]</data>
  <data key="d21">Endometriosis with or without accompanying sterility. Treatment is limited to a single course of 6 months duration per lifetime [L1699, L1700].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Ethylnorgestrienone, Gestrinona, Gestrinone, Gestrinonum]</data>
  <data key="d9">Gestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and is used primarily in the treatment of endometriosis.\n\nGestrinone was developed in the early 1970s and was tested clinically as a weekly oral contraceptive in Europe and North America. Without significant advantages over other oral contraceptives and with its high cost, gestrinone was no longer used after the Stage II clinical trials. However, from 1982 this drug attracted increased interest due to significant therapeutic effects in the treatment endometriosis. Under different endocrine conditions, gestrinone possesses estrogenic, progestational, androgenic, antiestrogenic and antiprogesterone actions [L1696].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB12944">
  <data key="d0">Phloroglucinol</data>
  <data key="d1">drugbank.DB12944</data>
  <data key="d2">[drugbank.DB12944]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Benzene Derivatives, Compounds used in a research, industrial, or household setting, Drugs for Functional Gastrointestinal Disorders, Indicators and Reagents, Laboratory Chemicals, Phenols]</data>
  <data key="d14">benzene-1,3,5-triol</data>
  <data key="d15">C6H6O3</data>
  <data key="d16">108-73-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C6H6O3/c7-4-1-5(8)3-6(9)2-4/h1-3,7-9H</data>
  <data key="d20">OC1=CC(O)=CC(O)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Phloroglucin]</data>
  <data key="d9">Phloroglucinol has been used in trials studying the diagnostic of Colonoscopy.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00904">
  <data key="d0">Ondansetron</data>
  <data key="d1">drugbank.DB00904</data>
  <data key="d2">[drugbank.DB00904, drugbank.APRD00481]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Anti-Anxiety Agents, Antidepressive Agents, Antiemetics, Antiemetics and Antinauseants, Carbazoles, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Imidazoles, Indoles, Moderate Risk QTc-Prolonging Agents, P-glycoprotein/ABCB1 Substrates, Peripheral Nervous System Agents, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 3 Receptor Antagonists, Serotonin 5-HT3 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists]</data>
  <data key="d14">9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one</data>
  <data key="d15">C18H19N3O</data>
  <data key="d16">99614-02-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3</data>
  <data key="d20">CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2</data>
  <data key="d21">In the adult patient population:\ni) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:\n- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and\n- the prevention and treatment of postoperative nausea and vomiting\n\nii) intravenously administered ondansetron injection formulations are indicated for:\n- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and\n- the prevention and treatment of postoperative nausea and vomiting\n\nIn the pediatric (4-18 years of age) patient population:\ni) ondansetron was effective and well tolerated when given to children 4-12 years of age for the treatment of post-chemotherapy induced nausea and vomiting,\nii) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for the treatment of children 3 years of age or younger,\niii) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of post-radiotherapy induced nausea and vomiting, and\niV) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of postoperative nausea and vomiting\n\nIn the geriatric (&gt;65 years of age) patient population:\ni) efficacy and tolerance of ondansetron were similar to that observed in younger adults for the treatment of post-chemotherapy and radiotherapy-induced nausea and vomiting, and\nii) clinical experience in the use of ondansetron in the prevention and treatment of postoperative nausea and vomiting is limited and is not indicated for use in the geriatric patient population</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Ondansetron]</data>
  <data key="d9">A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. [PubChem]\n\nHaving been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy. Commonly formulated as oral tablets, orally disintegrating tablets (ODT), and injections, and available as generic products as well, ondansetron continues to see contemporary innovations in its formulation and use, including the development of orally soluble films that are both discreet in administration and less of a burden in comparison to having patients attempt to swallow pills during emesis [L5221].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00909">
  <data key="d0">Zonisamide</data>
  <data key="d1">drugbank.DB00909</data>
  <data key="d2">[drugbank.DB00909, drugbank.APRD00004]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents causing hyperkalemia, Anti-epileptic Agent, Antiarrhythmic agents, Anticonvulsants, Antioxidants, Bradycardia-Causing Agents, Calcium Channel Blockers, Carbonic Anhydrase Inhibitors, Central Nervous System Agents, Central Nervous System Depressants, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Decreased Central Nervous System Disorganized Electrical Activity, Diuretics, Drugs that are Mainly Renally Excreted, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Nervous System, P-glycoprotein/ABCB1 Inhibitors, Potential QTc-Prolonging Agents, Protective Agents, QTc Prolonging Agents, Sulfonamides, UGT1A1 Substrates]</data>
  <data key="d14">1,2-benzoxazol-3-ylmethanesulfonamide</data>
  <data key="d15">C8H8N2O3S</data>
  <data key="d16">68291-97-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)</data>
  <data key="d20">NS(=O)(=O)CC1=NOC2=CC=CC=C12</data>
  <data key="d21">For use as adjunctive treatment of partial seizures in adults with epilepsy.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1, 2-Benzisoxazole-3-methanesulfonamide, 3-(Sulfamoylmethyl)-1, 2-benzisoxazole, Benzo[d]isoxazol-3-yl-methanesulfonamide, Zonisamida, Zonisamide, Zonisamidum]</data>
  <data key="d9">Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may be a carbonic anhydrase inhibitor although this is not one of the primary mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels leading to a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00908">
  <data key="d0">Quinidine</data>
  <data key="d1">drugbank.DB00908</data>
  <data key="d2">[drugbank.DB00908, drugbank.APRD00136]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents producing tachycardia, Agents that produce hypertension, Agents that produce neuromuscular block (indirect), Agents that reduce seizure threshold, Alkaloids, Anti-Infective Agents, Antiarrhythmic agents, Antiarrhythmics, Class I, Antiarrhythmics, Class Ia, Anticholinergic Agents, Antimalarials, Antiparasitic Agents, Antiprotozoals, Biological Products, Biomedical and Dental Materials, Biopolymers, BSEP/ABCB11 Inhibitors, Carbohydrates, Cardiac Therapy, Cardiovascular Agents, Chemically-Induced Disorders, Cholinergic Agents, Cinchona Alkaloids, Complex Mixtures, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strong), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (weak), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P450 2D6 Inhibitors, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index, Enzyme Inhibitors, Highest Risk QTc-Prolonging Agents, Macromolecular Substances, Membrane Transport Modulators, Muscarinic Antagonists, Narrow Therapeutic Index Drugs, Neurotransmitter Agents, OAT3/SLC22A8 Inhibitors, OATP1B1/SLCO1B1 Inhibitors, OCT1 inhibitors, OCT2 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, P-glycoprotein/ABCB1 Substrates with narrow therapeutic index, Pharmaceutical Preparations, Plant Extracts, Plant Preparations, Polymers, Polysaccharides, QTc Prolonging Agents, Quinolines, Quinuclidines, Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers]</data>
  <data key="d14">(S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol</data>
  <data key="d15">C20H24N2O2</data>
  <data key="d16">56-54-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1</data>
  <data key="d20">[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1</data>
  <data key="d21">For the treatment of ventricular pre-excitation and cardiac dysrhythmias</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+)-quinidine, (8R, 9S)-Quinidine, (R)-(6-Methoxyquinolin-4-yl)((3S, 4R, 7S)-3-vinylquinuclidin-7-yl)methanol, (S)-(6-Methoxy-quinolin-4-yl)-((2R, 5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol, (S)-(6-Methoxyquinolin-4-yl)((2R, 5R)-5-vinylquinuclidin-2-yl)methanol, 6-methoxy--(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol, beta-Quinine, Chinidin, Chinidinum, CIN-QUIN, Conchinin, Conquinine, Pitayine, Quinidina, -(6-methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol, -quinine]</data>
  <data key="d9">An optical isomer of quinine, extracted from the bark of the Cinchona tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular action potential, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00915">
  <data key="d0">Amantadine</data>
  <data key="d1">drugbank.DB00915</data>
  <data key="d2">[drugbank.DB00915, drugbank.APRD00787]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adamantane, Adamantane Derivatives, Adamantanes, Analgesics, Analgesics, Non-Narcotic, Anti-Dyskinesia Agents, Anti-Infective Agents, Anti-Parkinson Drugs, Anticholinergic Agents, Antiviral Agents, Central Nervous System Agents, Cycloparaffins, Dopamine Agents, Drugs that are Mainly Renally Excreted, Influenza A M2 Protein Inhibitor, M2 Protein Inhibitors, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, NMDA Receptor Antagonists, OCT1 inhibitors, OCT1 substrates, OCT2 Inhibitors, OCT2 Substrates, OCT2 substrates with narrow therapeutic index, Peripheral Nervous System Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome]</data>
  <data key="d14">adamantan-1-amine</data>
  <data key="d15">C10H17N</data>
  <data key="d16">768-94-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2</data>
  <data key="d20">NC12CC3CC(CC(C3)C1)C2</data>
  <data key="d21">For the chemoprophylaxis, prophylaxis, and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Also for the treatment of parkinsonism and drug-induced extrapyramidal reactions.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1-adamantanamine, 1-adamantylamine, 1-aminoadamantane, Amantadina, Amantadine, Amantadinum, Amantidine, Aminoadamantane]</data>
  <data key="d9">An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00912">
  <data key="d0">Repaglinide</data>
  <data key="d1">drugbank.DB00912</data>
  <data key="d2">[drugbank.DB00912, drugbank.APRD00439]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Acids, Acyclic, Alimentary Tract and Metabolism, Blood Glucose Lowering Agents, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Drugs Used in Diabetes, Glinide, Hypoglycemia-Associated Agents, Meglitinides, OATP1B1/SLCO1B1 Substrates, Oral Hypoglycemics, Potassium Channel Antagonists, Stereoisomerism]</data>
  <data key="d14">2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbamoyl}methyl)benzoic acid</data>
  <data key="d15">C27H36N2O4</data>
  <data key="d16">135062-02-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1</data>
  <data key="d20">CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O</data>
  <data key="d21">As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Repaglinida, Repaglinide, Repaglinidum]</data>
  <data key="d9">Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to  cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those nave to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB00925">
  <data key="d0">Phenoxybenzamine</data>
  <data key="d1">drugbank.DB00925</data>
  <data key="d2">[drugbank.DB00925, drugbank.APRD00651]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Amines, Antihypertensive Agents, Cardiovascular Agents, Ethylamines, Hypotensive Agents, Neurotransmitter Agents, OCT1 inhibitors, OCT2 Inhibitors, Peripheral alpha-1 blockers, Peripheral Vasodilators, Vasodilating Agents]</data>
  <data key="d14">benzyl(2-chloroethyl)(1-phenoxypropan-2-yl)amine</data>
  <data key="d15">C18H22ClNO</data>
  <data key="d16">59-96-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3</data>
  <data key="d20">CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1</data>
  <data key="d21">For the treatment of phaeochromocytoma (malignant), benign prostatic hypertrophy and malignant essential hypertension.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Fenossibenzamina, Fenoxibenzamina, Phenoxybenzamine, Phenoxybenzaminum, POB]</data>
  <data key="d9">An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08595">
  <data key="d0">4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL</data>
  <data key="d1">drugbank.DB08595</data>
  <data key="d2">[drugbank.DB08595]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-[(1S,2R,5S)-4,4,8-trimethyl-3-oxabicyclo[3.3.1]non-7-en-2-yl]phenol</data>
  <data key="d15">C17H22O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H22O2/c1-11-4-7-13-10-15(11)16(19-17(13,2)3)12-5-8-14(18)9-6-12/h4-6,8-9,13,15-16,18H,7,10H2,1-3H3/t13-,15-,16-/m0/s1</data>
  <data key="d20">[H][C@]12CC=C(C)[C@]([H])(C1)[C@@]([H])(OC2(C)C)C1=CC=C(O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07277">
  <data key="d0">2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHANESULFONAMIDE</data>
  <data key="d1">drugbank.DB07277</data>
  <data key="d2">[drugbank.DB07277]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-(5-chlorothiophen-2-yl)-N-[(3S)-1-[(2S)-1-(morpholin-4-yl)-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl]ethane-1-sulfonamide</data>
  <data key="d15">C17H24ClN3O5S2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H24ClN3O5S2/c1-12(16(22)20-7-9-26-10-8-20)21-6-4-14(17(21)23)19-28(24,25)11-5-13-2-3-15(18)27-13/h2-3,12,14,19H,4-11H2,1H3/t12-,14-/m0/s1</data>
  <data key="d20">[H][C@@](C)(N1CC[C@]([H])(NS(=O)(=O)CCC2=CC=C(Cl)S2)C1=O)C(=O)N1CCOCC1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07278">
  <data key="d0">2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHENESULFONAMIDE</data>
  <data key="d1">drugbank.DB07278</data>
  <data key="d2">[drugbank.DB07278]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(E)-2-(5-chlorothiophen-2-yl)-N-[(3S)-1-[(2S)-1-(morpholin-4-yl)-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl]ethene-1-sulfonamide</data>
  <data key="d15">C17H22ClN3O5S2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H22ClN3O5S2/c1-12(16(22)20-7-9-26-10-8-20)21-6-4-14(17(21)23)19-28(24,25)11-5-13-2-3-15(18)27-13/h2-3,5,11-12,14,19H,4,6-10H2,1H3/b11-5+/t12-,14-/m0/s1</data>
  <data key="d20">O=C([C@@](C)([H])N1CC[C@]([H])(NS(=O)(=O)\C=C\C2=CC=C(Cl)S2)C1=O)N1CCOCC1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07279">
  <data key="d0">N-ETHYL-N-ISOPROPYL-3-METHYL-5-{[(2S)-2-(PYRIDIN-4-YLAMINO)PROPYL]OXY}BENZAMIDE</data>
  <data key="d1">drugbank.DB07279</data>
  <data key="d2">[drugbank.DB07279]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-ethyl-3-methyl-N-(propan-2-yl)-5-[(2S)-2-[(pyridin-4-yl)amino]propoxy]benzamide</data>
  <data key="d15">C21H29N3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H29N3O2/c1-6-24(15(2)3)21(25)18-11-16(4)12-20(13-18)26-14-17(5)23-19-7-9-22-10-8-19/h7-13,15,17H,6,14H2,1-5H3,(H,22,23)/t17-/m0/s1</data>
  <data key="d20">[H][C@](C)(COC1=CC(=CC(C)=C1)C(=O)N(CC)C(C)C)NC1=CC=NC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07284">
  <data key="d0">N~3~-(3-PYRIDIN-3-YLBENZYL)PYRIDINE-2,3-DIAMINE</data>
  <data key="d1">drugbank.DB07284</data>
  <data key="d2">[drugbank.DB07284]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N3-{[3-(pyridin-3-yl)phenyl]methyl}pyridine-2,3-diamine</data>
  <data key="d15">C17H16N4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H16N4/c18-17-16(7-3-9-20-17)21-11-13-4-1-5-14(10-13)15-6-2-8-19-12-15/h1-10,12,21H,11H2,(H2,18,20)</data>
  <data key="d20">NC1=NC=CC=C1NCC1=CC=CC(=C1)C1=CN=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07281">
  <data key="d0">N~3~-BENZYLPYRIDINE-2,3-DIAMINE</data>
  <data key="d1">drugbank.DB07281</data>
  <data key="d2">[drugbank.DB07281]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N3-benzylpyridine-2,3-diamine</data>
  <data key="d15">C12H13N3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H13N3/c13-12-11(7-4-8-14-12)15-9-10-5-2-1-3-6-10/h1-8,15H,9H2,(H2,13,14)</data>
  <data key="d20">NC1=NC=CC=C1NCC1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07211">
  <data key="d0">(2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDE</data>
  <data key="d1">drugbank.DB07211</data>
  <data key="d2">[drugbank.DB07211]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(1E)-2-(5-chlorothiophen-2-yl)-N-[(3S)-1-[(2S)-1-(morpholin-4-yl)-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl]prop-1-ene-1-sulfonamide</data>
  <data key="d15">C18H24ClN3O5S2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H24ClN3O5S2/c1-12(15-3-4-16(19)28-15)11-29(25,26)20-14-5-6-22(18(14)24)13(2)17(23)21-7-9-27-10-8-21/h3-4,11,13-14,20H,5-10H2,1-2H3/b12-11+/t13-,14-/m0/s1</data>
  <data key="d20">C\C(=C/S(=O)(=O)N[C@@]1([H])CCN([C@](C)([H])C(=O)N2CCOCC2)C1=O)C1=CC=C(Cl)S1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08546">
  <data key="d0">4-[(3AS,4R,7R,8AS,8BR)-2-(1,3-BENZODIOXOL-5-YLMETHYL)-7-HYDROXY-1,3-DIOXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZENECARBOXIMIDAMIDE</data>
  <data key="d1">drugbank.DB08546</data>
  <data key="d2">[drugbank.DB08546]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-[(3aS,4R,7R,8aS,8bR)-2-(2H-1,3-benzodioxol-5-ylmethyl)-7-hydroxy-1,3-dioxo-decahydropyrrolo[3,4-a]pyrrolizin-4-yl]benzene-1-carboximidamide</data>
  <data key="d15">C24H24N4O5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H24N4O5/c25-22(26)14-4-2-13(3-5-14)21-20-19(16-8-15(29)10-27(16)21)23(30)28(24(20)31)9-12-1-6-17-18(7-12)33-11-32-17/h1-7,15-16,19-21,29H,8-11H2,(H3,25,26)/t15-,16+,19+,20+,21+/m1/s1</data>
  <data key="d20">[H][C@]1(O)C[N@]2[C@@]([H])(C1)[C@]1([H])C(=O)N(CC3=CC=C4OCOC4=C3)C(=O)[C@]1([H])[C@]2([H])C1=CC=C(C=C1)C(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07208">
  <data key="d0">(8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid</data>
  <data key="d1">drugbank.DB07208</data>
  <data key="d2">[drugbank.DB07208]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid</data>
  <data key="d15">C18H30O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H30O4/c1-2-3-4-5-6-7-11-16(19)13-10-14-17(20)12-8-9-15-18(21)22/h6-7,10,13,16,19H,2-5,8-9,11-12,14-15H2,1H3,(H,21,22)/b7-6-,13-10+/t16-/m0/s1</data>
  <data key="d20">[H][C@](O)(C\C=C/CCCCC)\C=C\CC(=O)CCCCC(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07206">
  <data key="d0">6-[2-(1H-INDOL-6-YL)ETHYL]PYRIDIN-2-AMINE</data>
  <data key="d1">drugbank.DB07206</data>
  <data key="d2">[drugbank.DB07206]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">6-[2-(1H-indol-6-yl)ethyl]pyridin-2-amine</data>
  <data key="d15">C15H15N3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H15N3/c16-15-3-1-2-13(18-15)7-5-11-4-6-12-8-9-17-14(12)10-11/h1-4,6,8-10,17H,5,7H2,(H2,16,18)</data>
  <data key="d20">NC1=NC(CCC2=CC=C3C=CNC3=C2)=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07209">
  <data key="d0">(8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid</data>
  <data key="d1">drugbank.DB07209</data>
  <data key="d2">[drugbank.DB07209]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid</data>
  <data key="d15">C18H30O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H30O4/c1-2-3-4-5-6-7-8-9-12-16(19)15-17(20)13-10-11-14-18(21)22/h6-7,9,12,16,19H,2-5,8,10-11,13-15H2,1H3,(H,21,22)/b7-6-,12-9-/t16-/m0/s1</data>
  <data key="d20">[H][C@@](O)(CC(=O)CCCCC(O)=O)\C=C/C\C=C/CCCCC</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08560">
  <data key="d0">3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE</data>
  <data key="d1">drugbank.DB08560</data>
  <data key="d2">[drugbank.DB08560]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-fluoro-N-[1-(4-fluorophenyl)-3-(thiophen-2-yl)-1H-pyrazol-5-yl]benzene-1-sulfonamide</data>
  <data key="d15">C19H13F2N3O2S2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H13F2N3O2S2/c20-13-6-8-15(9-7-13)24-19(12-17(22-24)18-5-2-10-27-18)23-28(25,26)16-4-1-3-14(21)11-16/h1-12,23H</data>
  <data key="d20">FC1=CC=C(C=C1)N1N=C(C=C1NS(=O)(=O)C1=CC=CC(F)=C1)C1=CC=CS1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07244">
  <data key="d0">5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE</data>
  <data key="d1">drugbank.DB07244</data>
  <data key="d2">[drugbank.DB07244]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">5-(4-{[(3,5-difluorophenyl)methyl]amino}phenyl)-6-ethylpyrimidine-2,4-diamine</data>
  <data key="d15">C19H19F2N5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H19F2N5/c1-2-16-17(18(22)26-19(23)25-16)12-3-5-15(6-4-12)24-10-11-7-13(20)9-14(21)8-11/h3-9,24H,2,10H2,1H3,(H4,22,23,25,26)</data>
  <data key="d20">CCC1=C(C(N)=NC(N)=N1)C1=CC=C(NCC2=CC(F)=CC(F)=C2)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07245">
  <data key="d0">6-[2-(3'-METHOXYBIPHENYL-3-YL)ETHYL]PYRIDIN-2-AMINE</data>
  <data key="d1">drugbank.DB07245</data>
  <data key="d2">[drugbank.DB07245]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">6-{2-[3-(3-methoxyphenyl)phenyl]ethyl}pyridin-2-amine</data>
  <data key="d15">C20H20N2O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H20N2O/c1-23-19-9-3-7-17(14-19)16-6-2-5-15(13-16)11-12-18-8-4-10-20(21)22-18/h2-10,13-14H,11-12H2,1H3,(H2,21,22)</data>
  <data key="d20">COC1=CC=CC(=C1)C1=CC(CCC2=CC=CC(N)=N2)=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08513">
  <data key="d0">[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID</data>
  <data key="d1">drugbank.DB08513</data>
  <data key="d2">[drugbank.DB08513]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-[4-({5-carbamoyl-4-[(3-methylphenyl)amino]pyrimidin-2-yl}amino)phenyl]acetic acid</data>
  <data key="d15">C20H19N5O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H19N5O3/c1-12-3-2-4-15(9-12)23-19-16(18(21)28)11-22-20(25-19)24-14-7-5-13(6-8-14)10-17(26)27/h2-9,11H,10H2,1H3,(H2,21,28)(H,26,27)(H2,22,23,24,25)</data>
  <data key="d20">CC1=CC(NC2=NC(NC3=CC=C(CC(O)=O)C=C3)=NC=C2C(N)=O)=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08516">
  <data key="d0">(S)-(+)-2-[4-(FLUOROBENZYLOXY-BENZYLAMINO)PROPIONAMIDE]</data>
  <data key="d1">drugbank.DB08516</data>
  <data key="d2">[drugbank.DB08516]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-2-[(E)-({4-[(3-fluorophenyl)methoxy]phenyl}methylidene)amino]propanamide</data>
  <data key="d15">C17H17FN2O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H17FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-10,12H,11H2,1H3,(H2,19,21)/b20-10+/t12-/m0/s1</data>
  <data key="d20">[H][C@@](C)(\N=C\C1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08604">
  <data key="d0">Triclosan</data>
  <data key="d1">drugbank.DB08604</data>
  <data key="d2">[drugbank.DB08604]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Anti-Infective Agents, Anti-Infective Agents, Local, Antiseptics and Disinfectants, Benzene Derivatives, Dermatologicals, Ethers, Fatty Acid Synthesis Inhibitors, Hypolipidemic Agents, Lipid Regulating Agents, Medicated Dressings, Medicated Dressings With Antiinfectives, Miscellaneous Local Anti-infectives, Noxae, Phenol and Derivatives, Phenols, Phenyl Ethers, Toxic Actions]</data>
  <data key="d14">5-chloro-2-(2,4-dichlorophenoxy)phenol</data>
  <data key="d15">C12H7Cl3O2</data>
  <data key="d16">3380-34-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H7Cl3O2/c13-7-1-3-11(9(15)5-7)17-12-4-2-8(14)6-10(12)16/h1-6,16H</data>
  <data key="d20">OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1</data>
  <data key="d21">Triclosan is used in a variety of common household products, including soaps, mouthwashes, dish detergents, toothpastes, deodorants, and hand sanitizers.  It is also used in health care settings in surgical scrubs and personnel hand washes.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2, 4, 4'-Trichloro-2'-hydroxydiphenyl ether, 5-Chloro-2-(2, 4-dichloro-phenoxy)-phenol, Triclosn, Triclosan, Triclosanum]</data>
  <data key="d9">An aromatic ether that is phenol which is substituted at C-5 by a chloro group and at C-2 by a 2,4-dichlorophenoxy group. It is widely used as a preservative and antimicrobial agent in personal care products such as soaps, skin creams, toothpaste and deodorants as well as in household items such as plastic chopping boards, sports equipment and shoes.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07376">
  <data key="d0">5-(DIMETHYLAMINO)-1-NAPHTHALENESULFONIC ACID(DANSYL ACID)</data>
  <data key="d1">drugbank.DB07376</data>
  <data key="d2">[drugbank.DB07376]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">5-(dimethylamino)naphthalene-1-sulfonic acid</data>
  <data key="d15">C12H13NO3S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H13NO3S/c1-13(2)11-7-3-6-10-9(11)5-4-8-12(10)17(14,15)16/h3-8H,1-2H3,(H,14,15,16)</data>
  <data key="d20">CN(C)C1=C2C=CC=C(C2=CC=C1)S(O)(=O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07387">
  <data key="d0">3-(BUTYLSULPHONYL)-PROPANOIC ACID</data>
  <data key="d1">drugbank.DB07387</data>
  <data key="d2">[drugbank.DB07387]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-(butane-1-sulfonyl)propanoic acid</data>
  <data key="d15">C7H14O4S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C7H14O4S/c1-2-3-5-12(10,11)6-4-7(8)9/h2-6H2,1H3,(H,8,9)</data>
  <data key="d20">CCCCS(=O)(=O)CCC(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07384">
  <data key="d0">1-ACETYL-2-CARBOXYPIPERIDINE</data>
  <data key="d1">drugbank.DB07384</data>
  <data key="d2">[drugbank.DB07384]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-1-acetylpiperidine-2-carboxylic acid</data>
  <data key="d15">C8H13NO3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C8H13NO3/c1-6(10)9-5-3-2-4-7(9)8(11)12/h7H,2-5H2,1H3,(H,11,12)/t7-/m0/s1</data>
  <data key="d20">[H][C@]1(CCCCN1C(C)=O)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07388">
  <data key="d0">ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE</data>
  <data key="d1">drugbank.DB07388</data>
  <data key="d2">[drugbank.DB07388]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">ethyl 4-[(4-methylpyridin-2-yl)amino]piperidine-1-carboxylate</data>
  <data key="d15">C14H21N3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H21N3O2/c1-3-19-14(18)17-8-5-12(6-9-17)16-13-10-11(2)4-7-15-13/h4,7,10,12H,3,5-6,8-9H2,1-2H3,(H,15,16)</data>
  <data key="d20">CCOC(=O)N1CCC(CC1)NC1=NC=CC(C)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07394">
  <data key="d0">AUROVERTIN B</data>
  <data key="d1">drugbank.DB07394</data>
  <data key="d2">[drugbank.DB07394]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Pyrans]</data>
  <data key="d14">(1S,3S,4S,5S,7R,8S)-7-ethyl-4-hydroxy-3-[(1E,3E,5E)-6-(4-methoxy-5-methyl-2-oxo-2H-pyran-6-yl)hexa-1,3,5-trien-1-yl]-1,5-dimethyl-2,6-dioxabicyclo[3.2.1]octan-8-yl acetate</data>
  <data key="d15">C25H32O8</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C25H32O8/c1-7-20-24(4)23(30-16(3)26)25(5,33-20)22(28)18(32-24)13-11-9-8-10-12-17-15(2)19(29-6)14-21(27)31-17/h8-14,18,20,22-23,28H,7H2,1-6H3/b9-8+,12-10+,13-11+/t18-,20+,22-,23+,24-,25-/m0/s1</data>
  <data key="d20">[H][C@]1(CC)O[C@]2(C)[C@]([H])(OC(C)=O)[C@@]1(C)O[C@@]([H])(\C=C\C=C\C=C\C1=C(C)C(OC)=CC(=O)O1)[C@]2([H])O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06073">
  <data key="d0">CTS-21166</data>
  <data key="d1">drugbank.DB06073</data>
  <data key="d2">[drugbank.DB06073]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in alzheimer's disease.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability, and oral availability; all of these have met the requirements of an ideal oral drug candidate.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06075">
  <data key="d0">Linsitinib</data>
  <data key="d1">drugbank.DB06075</data>
  <data key="d2">[drugbank.DB06075]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">(1s,3r)-3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol</data>
  <data key="d15">C26H23N5O</data>
  <data key="d16">867160-71-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)/t19-,26+</data>
  <data key="d20">C[C@@]1(O)C[C@@H](C1)C1=NC(=C2N1C=CN=C2N)C1=CC=C2C=CC(=NC2=C1)C1=CC=CC=C1</data>
  <data key="d21">Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08658">
  <data key="d0">ETHYL HYDROGEN DIETHYLAMIDOPHOSPHATE</data>
  <data key="d1">drugbank.DB08658</data>
  <data key="d2">[drugbank.DB08658]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(diethylamino)(ethoxy)phosphinic acid</data>
  <data key="d15">C6H16NO3P</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C6H16NO3P/c1-4-7(5-2)11(8,9)10-6-3/h4-6H2,1-3H3,(H,8,9)</data>
  <data key="d20">CCO[P@](O)(=O)N(CC)CC</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07342">
  <data key="d0">1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone</data>
  <data key="d1">drugbank.DB07342</data>
  <data key="d2">[drugbank.DB07342]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Cycloparaffins, Heme Oxygenase-1, antagonists &amp; inhibitors]</data>
  <data key="d14">1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethan-1-one</data>
  <data key="d15">C15H20N2O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H20N2O/c18-14(9-17-2-1-16-10-17)15-6-11-3-12(7-15)5-13(4-11)8-15/h1-2,10-13H,3-9H2/t11-,12+,13-,15-</data>
  <data key="d20">[H]C12CC3([H])CC([H])(C1)CC(C2)(C3)C(=O)CN1C=CN=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07346">
  <data key="d0">4-(2-aminoethyl)-2-ethylphenol</data>
  <data key="d1">drugbank.DB07346</data>
  <data key="d2">[drugbank.DB07346]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-(2-aminoethyl)-2-ethylphenol</data>
  <data key="d15">C10H15NO</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H15NO/c1-2-9-7-8(5-6-11)3-4-10(9)12/h3-4,7,12H,2,5-6,11H2,1H3</data>
  <data key="d20">CCC1=CC(CCN)=CC=C1O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07345">
  <data key="d0">4-(2-aminoethyl)-2-cyclohexylphenol</data>
  <data key="d1">drugbank.DB07345</data>
  <data key="d2">[drugbank.DB07345]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-(2-aminoethyl)-2-cyclohexylphenol</data>
  <data key="d15">C14H21NO</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H21NO/c15-9-8-11-6-7-14(16)13(10-11)12-4-2-1-3-5-12/h6-7,10,12,16H,1-5,8-9,15H2</data>
  <data key="d20">NCCC1=CC=C(O)C(=C1)C1CCCCC1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07353">
  <data key="d0">4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL</data>
  <data key="d1">drugbank.DB07353</data>
  <data key="d2">[drugbank.DB07353]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-[(2R,5S)-2,5-diamino-5-hydroxypentyl]phenol</data>
  <data key="d15">C11H18N2O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H18N2O2/c12-9(3-6-11(13)15)7-8-1-4-10(14)5-2-8/h1-2,4-5,9,11,14-15H,3,6-7,12-13H2/t9-,11+/m1/s1</data>
  <data key="d20">[H][C@](N)(O)CC[C@@]([H])(N)CC1=CC=C(O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07366">
  <data key="d0">2-[N'-(4-AMINO-BUTYL)-HYDRAZINOCARBONYL]-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER</data>
  <data key="d1">drugbank.DB07366</data>
  <data key="d2">[drugbank.DB07366]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">benzyl (2S)-2-[N'-(4-aminobutyl)hydrazinecarbonyl]pyrrolidine-1-carboxylate</data>
  <data key="d15">C17H26N4O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H26N4O3/c18-10-4-5-11-19-20-16(22)15-9-6-12-21(15)17(23)24-13-14-7-2-1-3-8-14/h1-3,7-8,15,19H,4-6,9-13,18H2,(H,20,22)/t15-/m0/s1</data>
  <data key="d20">[H][C@]1(CCCN1C(=O)OCC1=CC=CC=C1)C(=O)NNCCCCN</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08697">
  <data key="d0">4-(2-aminoethoxy)-N-(3-chloro-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide</data>
  <data key="d1">drugbank.DB08697</data>
  <data key="d2">[drugbank.DB08697]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-(2-aminoethoxy)-N-[3-chloro-5-(piperidin-1-yl)phenyl]-3,5-dimethylbenzamide</data>
  <data key="d15">C22H28ClN3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H28ClN3O2/c1-15-10-17(11-16(2)21(15)28-9-6-24)22(27)25-19-12-18(23)13-20(14-19)26-7-4-3-5-8-26/h10-14H,3-9,24H2,1-2H3,(H,25,27)</data>
  <data key="d20">CC1=CC(=CC(C)=C1OCCN)C(=O)NC1=CC(Cl)=CC(=C1)N1CCCCC1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08615">
  <data key="d0">2-[4-(DIMETHYLAMINO)PHENYL]-6-HYDROXY-3-METHYL-1,3-BENZOTHIAZOL-3-IUM</data>
  <data key="d1">drugbank.DB08615</data>
  <data key="d2">[drugbank.DB08615]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-[4-(dimethylamino)phenyl]-6-hydroxy-3-methyl-1,3-benzothiazol-3-ium</data>
  <data key="d15">C16H17N2OS</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H16N2OS/c1-17(2)12-6-4-11(5-7-12)16-18(3)14-9-8-13(19)10-15(14)20-16/h4-10H,1-3H3/p+1</data>
  <data key="d20">CN(C)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(O)C=C2S1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07302">
  <data key="d0">(9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid</data>
  <data key="d1">drugbank.DB07302</data>
  <data key="d2">[drugbank.DB07302]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid</data>
  <data key="d15">C18H32O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H32O3/c1-2-3-4-5-6-8-11-14-17(19)15-12-9-7-10-13-16-18(20)21/h6,8,11,14,17,19H,2-5,7,9-10,12-13,15-16H2,1H3,(H,20,21)/b8-6-,14-11+/t17-/m1/s1</data>
  <data key="d20">[H][C@](O)(CCCCCCCC(O)=O)\C=C\C=C/CCCCC</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07303">
  <data key="d0">N~3~-[3-(5-METHOXYPYRIDIN-3-YL)BENZYL]PYRIDINE-2,3-DIAMINE</data>
  <data key="d1">drugbank.DB07303</data>
  <data key="d2">[drugbank.DB07303]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N3-{[3-(5-methoxypyridin-3-yl)phenyl]methyl}pyridine-2,3-diamine</data>
  <data key="d15">C18H18N4O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H18N4O/c1-23-16-9-15(11-20-12-16)14-5-2-4-13(8-14)10-22-17-6-3-7-21-18(17)19/h2-9,11-12,22H,10H2,1H3,(H2,19,21)</data>
  <data key="d20">COC1=CN=CC(=C1)C1=CC(CNC2=CC=CN=C2N)=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08626">
  <data key="d0">Thiorphan</data>
  <data key="d1">drugbank.DB08626</data>
  <data key="d2">[drugbank.DB08626, drugbank.DB01654]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Amino Acids, Amino Acids, Peptides, and Proteins, Amino Acids, Sulfur, Enzyme Inhibitors, Glycine, N-substituted Glycines, Peptides, Peptoids, Protease Inhibitors, Sulfur Compounds]</data>
  <data key="d14">2-[(2S)-2-benzyl-3-sulfanylpropanamido]acetic acid</data>
  <data key="d15">C12H15NO3S</data>
  <data key="d16">76721-89-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H15NO3S/c14-11(15)7-13-12(16)10(8-17)6-9-4-2-1-3-5-9/h1-5,10,17H,6-8H2,(H,13,16)(H,14,15)/t10-/m1/s1</data>
  <data key="d20">[H][C@](CS)(CC1=CC=CC=C1)C(=O)NCC(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">A potent inhibitor of membrane metalloendopeptidase (enkephalinase). Thiorphan potentiates morphine-induced analgesia and attenuates naloxone-precipitated withdrawal symptoms.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08624">
  <data key="d0">BENZOTHIAZOLE</data>
  <data key="d1">drugbank.DB08624</data>
  <data key="d2">[drugbank.DB08624]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Sulfur Compounds, Thiazoles]</data>
  <data key="d14">1-[(4S)-4-amino-5-(1,3-benzothiazol-2-yl)-5-oxopentyl]guanidine</data>
  <data key="d15">C13H17N5OS</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H17N5OS/c14-8(4-3-7-17-13(15)16)11(19)12-18-9-5-1-2-6-10(9)20-12/h1-2,5-6,8H,3-4,7,14H2,(H4,15,16,17)/t8-/m0/s1</data>
  <data key="d20">[H][C@](N)(CCCNC(N)=N)C(=O)C1=NC2=CC=CC=C2S1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08629">
  <data key="d0">N1-(2-AMINO-4-METHYLPENTYL)OCTAHYDRO-PYRROLO[1,2-A] PYRIMIDINE</data>
  <data key="d1">drugbank.DB08629</data>
  <data key="d2">[drugbank.DB08629]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-1-[(8aR)-octahydropyrrolo[1,2-a]pyrimidin-1-yl]-4-methylpentan-2-amine</data>
  <data key="d15">C13H27N3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H27N3/c1-11(2)9-12(14)10-16-8-4-7-15-6-3-5-13(15)16/h11-13H,3-10,14H2,1-2H3/t12-,13+/m0/s1</data>
  <data key="d20">[H][C@](N)(CC(C)C)CN1CCC[N@@]2CCC[C@@]12[H]</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07053">
  <data key="d0">2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID</data>
  <data key="d1">drugbank.DB07053</data>
  <data key="d2">[drugbank.DB07053]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-[5-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzoxazol-6-yl]oxy}propoxy)-1H-indol-1-yl]acetic acid</data>
  <data key="d15">C24H23F3N2O5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H23F3N2O5/c1-2-4-17-20(8-6-18-22(17)34-28-23(18)24(25,26)27)33-12-3-11-32-16-5-7-19-15(13-16)9-10-29(19)14-21(30)31/h5-10,13H,2-4,11-12,14H2,1H3,(H,30,31)</data>
  <data key="d20">CCCC1=C2ON=C(C2=CC=C1OCCCOC1=CC2=C(C=C1)N(CC(O)=O)C=C2)C(F)(F)F</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07058">
  <data key="d0">5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione</data>
  <data key="d1">drugbank.DB07058</data>
  <data key="d2">[drugbank.DB07058]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">5-[1-(4-methoxyphenyl)-1H-1,3-benzodiazol-6-yl]-2,3-dihydro-1,3,4-oxadiazole-2-thione</data>
  <data key="d15">C16H12N4O2S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H12N4O2S/c1-21-12-5-3-11(4-6-12)20-9-17-13-7-2-10(8-14(13)20)15-18-19-16(23)22-15/h2-9H,1H3,(H,19,23)</data>
  <data key="d20">COC1=CC=C(C=C1)N1C=NC2=C1C=C(C=C2)C1=NNC(=S)O1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08399">
  <data key="d0">PICEATANNOL</data>
  <data key="d1">drugbank.DB08399</data>
  <data key="d2">[drugbank.DB08399]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Benzene Derivatives, Benzylidene Compounds, Tyrosine Kinase Inhibitors]</data>
  <data key="d14">4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,2-diol</data>
  <data key="d15">C14H12O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H12O4/c15-11-5-10(6-12(16)8-11)2-1-9-3-4-13(17)14(18)7-9/h1-8,15-18H/b2-1+</data>
  <data key="d20">OC1=CC(\C=C\C2=CC=C(O)C(O)=C2)=CC(O)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08398">
  <data key="d0">2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine</data>
  <data key="d1">drugbank.DB08398</data>
  <data key="d2">[drugbank.DB08398, drugbank.DB12735]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Carcinogens, Mutagens, Noxae, Toxic Actions]</data>
  <data key="d14">1-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2-amine</data>
  <data key="d15">C13H12N4</data>
  <data key="d16">105650-23-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H12N4/c1-17-11-7-10(9-5-3-2-4-6-9)8-15-12(11)16-13(17)14/h2-8H,1H3,(H2,14,15,16)</data>
  <data key="d20">CN1C(N)=NC2=NC=C(C=C12)C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine, PhIP]</data>
  <data key="d9">PhIP (2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine) has been used in trials studying the basic science of Pancreas Cancer.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07076">
  <data key="d0">6-[(Z)-AMINO(IMINO)METHYL]-N-[3-(CYCLOPENTYLOXY)PHENYL]-2-NAPHTHAMIDE</data>
  <data key="d1">drugbank.DB07076</data>
  <data key="d2">[drugbank.DB07076]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">6-carbamimidoyl-N-[3-(cyclopentyloxy)phenyl]naphthalene-2-carboxamide</data>
  <data key="d15">C23H23N3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H23N3O2/c24-22(25)17-10-8-16-13-18(11-9-15(16)12-17)23(27)26-19-4-3-7-21(14-19)28-20-5-1-2-6-20/h3-4,7-14,20H,1-2,5-6H2,(H3,24,25)(H,26,27)</data>
  <data key="d20">NC(=N)C1=CC2=CC=C(C=C2C=C1)C(=O)NC1=CC=CC(OC2CCCC2)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07086">
  <data key="d0">4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL</data>
  <data key="d1">drugbank.DB07086</data>
  <data key="d2">[drugbank.DB07086]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-[(1S,2S,5S)-5-(hydroxymethyl)-8-methyl-3-oxabicyclo[3.3.1]non-7-en-2-yl]phenol</data>
  <data key="d15">C16H20O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H20O3/c1-11-6-7-16(9-17)8-14(11)15(19-10-16)12-2-4-13(18)5-3-12/h2-6,14-15,17-18H,7-10H2,1H3/t14-,15+,16-/m0/s1</data>
  <data key="d20">[H][C@@]12C[C@@](CO)(CO[C@]1([H])C1=CC=C(O)C=C1)CC=C2C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07083">
  <data key="d0">beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide</data>
  <data key="d1">drugbank.DB07083</data>
  <data key="d2">[drugbank.DB07083]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-1-[(2R)-2-amino-3,3-diphenylpropanoyl]-N-propylpyrrolidine-2-carboxamide</data>
  <data key="d15">C23H29N3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H29N3O2/c1-2-15-25-22(27)19-14-9-16-26(19)23(28)21(24)20(17-10-5-3-6-11-17)18-12-7-4-8-13-18/h3-8,10-13,19-21H,2,9,14-16,24H2,1H3,(H,25,27)/t19-,21+/m0/s1</data>
  <data key="d20">[H][C@@](N)(C(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCCC</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07089">
  <data key="d0">N-[amino(imino)methyl]-2-[2-(2-chlorophenyl)-4-(4-propoxyphenyl)-3-thienyl]acetamide</data>
  <data key="d1">drugbank.DB07089</data>
  <data key="d2">[drugbank.DB07089]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-carbamimidoyl-2-[2-(2-chlorophenyl)-4-(4-propoxyphenyl)thiophen-3-yl]acetamide</data>
  <data key="d15">C22H22ClN3O2S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H22ClN3O2S/c1-2-11-28-15-9-7-14(8-10-15)18-13-29-21(16-5-3-4-6-19(16)23)17(18)12-20(27)26-22(24)25/h3-10,13H,2,11-12H2,1H3,(H4,24,25,26,27)</data>
  <data key="d20">CCCOC1=CC=C(C=C1)C1=CSC(=C1CC(=O)NC(N)=N)C1=CC=CC=C1Cl</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07087">
  <data key="d0">4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL</data>
  <data key="d1">drugbank.DB07087</data>
  <data key="d2">[drugbank.DB07087]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-[(1R,2S,5S,8S,9R)-5-(hydroxymethyl)-8,9-dimethyl-3-oxabicyclo[3.3.1]nonan-2-yl]phenol</data>
  <data key="d15">C17H24O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H24O3/c1-11-7-8-17(9-18)10-20-16(15(11)12(17)2)13-3-5-14(19)6-4-13/h3-6,11-12,15-16,18-19H,7-10H2,1-2H3/t11-,12+,15+,16+,17-/m0/s1</data>
  <data key="d20">[H][C@]1(C)CC[C@]2(CO)CO[C@]([H])(C3=CC=C(O)C=C3)[C@@]1([H])[C@@]2([H])C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07088">
  <data key="d0">(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide</data>
  <data key="d1">drugbank.DB07088</data>
  <data key="d2">[drugbank.DB07088]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-N-[(4-carbamimidoylphenyl)methyl]-1-[2-(cyclopentyloxy)acetyl]pyrrolidine-2-carboxamide</data>
  <data key="d15">C20H28N4O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H28N4O3/c21-19(22)15-9-7-14(8-10-15)12-23-20(26)17-6-3-11-24(17)18(25)13-27-16-4-1-2-5-16/h7-10,16-17H,1-6,11-13H2,(H3,21,22)(H,23,26)/t17-/m0/s1</data>
  <data key="d20">[H][C@]1(CCCN1C(=O)COC1CCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07016">
  <data key="d0">(3R)-8-(dioxidosulfanyl)-3-methyl-1,2,3,4-tetrahydroquinoline</data>
  <data key="d1">drugbank.DB07016</data>
  <data key="d2">[drugbank.DB07016]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(3R)-3-methyl-8-sulfonyl-1,2,3,4-tetrahydroquinoline</data>
  <data key="d15">C10H13NO2S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H13NO2S/c1-7-5-8-3-2-4-9(14(12)13)10(8)11-6-7/h2-4,7,11,14H,5-6H2,1H3/t7-/m1/s1</data>
  <data key="d20">[H][C@]1(C)CNC2=C(C1)C=CC=C2S(=O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07014">
  <data key="d0">2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole</data>
  <data key="d1">drugbank.DB07014</data>
  <data key="d2">[drugbank.DB07014]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-(2H-1,3-benzodioxol-5-yl)-5-{[(3-fluoro-4-methoxyphenyl)methyl]sulfanyl}-1,3,4-oxadiazole</data>
  <data key="d15">C17H13FN2O4S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H13FN2O4S/c1-21-13-4-2-10(6-12(13)18)8-25-17-20-19-16(24-17)11-3-5-14-15(7-11)23-9-22-14/h2-7H,8-9H2,1H3</data>
  <data key="d20">COC1=C(F)C=C(CSC2=NN=C(O2)C2=CC3=C(OCO3)C=C2)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07027">
  <data key="d0">D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide</data>
  <data key="d1">drugbank.DB07027</data>
  <data key="d2">[drugbank.DB07027]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-[(3-fluorophenyl)methyl]pyrrolidine-2-carboxamide</data>
  <data key="d15">C21H24FN3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H24FN3O2/c22-17-9-4-8-16(12-17)14-24-20(26)19-10-5-11-25(19)21(27)18(23)13-15-6-2-1-3-7-15/h1-4,6-9,12,18-19H,5,10-11,13-14,23H2,(H,24,26)/t18-,19+/m1/s1</data>
  <data key="d20">[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=CC(F)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08357">
  <data key="d0">1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE</data>
  <data key="d1">drugbank.DB08357</data>
  <data key="d2">[drugbank.DB08357]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">1-ethoxy-2-(2-ethoxyethoxy)ethane</data>
  <data key="d15">C8H18O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C8H18O3/c1-3-9-5-7-11-8-6-10-4-2/h3-8H2,1-2H3</data>
  <data key="d20">CCOCCOCCOCC</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07019">
  <data key="d0">N-[(5R,14R)-5-AMINO-5,14-DIMETHYL-4-OXO-3-OXA-18-AZATRICYCLO[15.3.1.1~7,11~]DOCOSA-1(21),7(22),8,10,17,19-HEXAEN-19-YL]-N-METHYLMETHANESULFONAMIDE</data>
  <data key="d1">drugbank.DB07019</data>
  <data key="d2">[drugbank.DB07019]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-[(5R,14R)-5-amino-5,14-dimethyl-4-oxo-3-oxa-18-azatricyclo[15.3.1.1,]docosa-1(21),7,9,11(22),17,19-hexaen-19-yl]-N-methylmethanesulfonamide</data>
  <data key="d15">C24H33N3O4S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H33N3O4S/c1-17-8-10-18-6-5-7-19(12-18)15-24(2,25)23(28)31-16-20-13-21(11-9-17)26-22(14-20)27(3)32(4,29)30/h5-7,12-14,17H,8-11,15-16,25H2,1-4H3/t17-,24-/m1/s1</data>
  <data key="d20">[H][C@@]1(C)CCC2=CC(C[C@@](C)(N)C(=O)OCC3=CC(CC1)=NC(=C3)N(C)S(C)(=O)=O)=CC=C2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11994">
  <data key="d0">Diacerein</data>
  <data key="d1">drugbank.DB11994</data>
  <data key="d2">[drugbank.DB11994]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Anthracenes, Anti-Inflammatory Agents, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Musculo-Skeletal System, Quinones]</data>
  <data key="d14">4,5-bis(acetyloxy)-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid</data>
  <data key="d15">C19H12O8</data>
  <data key="d16">13739-02-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H12O8/c1-8(20)26-13-5-3-4-11-15(13)18(23)16-12(17(11)22)6-10(19(24)25)7-14(16)27-9(2)21/h3-7H,1-2H3,(H,24,25)</data>
  <data key="d20">CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O</data>
  <data key="d21">For the treatment of osteoarthritis affecting the hip or knee [L780].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Diacerena]</data>
  <data key="d9">Diacerein is a prodrug which is metabolized to rhein. It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including sevre diarrhea [L780]. Diacerein is under investigation for the treatment of Insulin Resistance, Diabetes Mellitus (Type 2), and Diabetes-Related Complications.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08302">
  <data key="d0">3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid</data>
  <data key="d1">drugbank.DB08302</data>
  <data key="d2">[drugbank.DB08302]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-{5-[(1Z)-2-nitropent-1-en-1-yl]furan-2-yl}benzoic acid</data>
  <data key="d15">C16H15NO5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H15NO5/c1-2-4-13(17(20)21)10-14-7-8-15(22-14)11-5-3-6-12(9-11)16(18)19/h3,5-10H,2,4H2,1H3,(H,18,19)/b13-10-</data>
  <data key="d20">CCC\C(=C\C1=CC=C(O1)C1=CC(=CC=C1)C(O)=O)[N+]([O-])=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08320">
  <data key="d0">DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE</data>
  <data key="d1">drugbank.DB08320</data>
  <data key="d2">[drugbank.DB08320]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2,3-diethyl (1R,2S,3R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate</data>
  <data key="d15">C24H24O7</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H24O7/c1-3-29-23(27)19-20(24(28)30-4-2)22-18(14-7-11-16(26)12-8-14)17(21(19)31-22)13-5-9-15(25)10-6-13/h5-12,19-22,25-26H,3-4H2,1-2H3/t19-,20+,21-,22+</data>
  <data key="d20">[H][C@]12O[C@]([H])(C(=C1C1=CC=C(O)C=C1)C1=CC=C(O)C=C1)[C@]([H])(C(=O)OCC)[C@]2([H])C(=O)OCC</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB11967">
  <data key="d0">Binimetinib</data>
  <data key="d1">drugbank.DB11967</data>
  <data key="d2">[drugbank.DB11967, drugbank.DB05985]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP1A2 Substrates, MAP Kinase Kinase 1, antagonists &amp; inhibitors, MAP Kinase Kinase 2, antagonists &amp; inhibitors, Protein Kinase Inhibitors, UGT1A1 Substrates]</data>
  <data key="d14">5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboxamide</data>
  <data key="d15">C17H15BrF2N4O3</data>
  <data key="d16">606143-89-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)</data>
  <data key="d20">CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO</data>
  <data key="d21">On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test [L3335].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Binimetinib]</data>
  <data key="d9">Binimetinib, also known as _Mektovi_, is a potent is a potent and selective oral mitogen-activated protein kinase 1/2   (MEK 1/2) inhibitor which is combined with [Encorafenib] [A34275],[L3335].\n\nOn June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test [L3335].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07001">
  <data key="d0">(3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine</data>
  <data key="d1">drugbank.DB07001</data>
  <data key="d2">[drugbank.DB07001]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(3S)-3-propyl-2H,3H,4H,5H-thieno[2,3-f][1,4]oxazepin-5-imine</data>
  <data key="d15">C10H14N2OS</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H14N2OS/c1-2-3-7-6-13-8-4-5-14-9(8)10(11)12-7/h4-5,7H,2-3,6H2,1H3,(H2,11,12)/t7-/m0/s1</data>
  <data key="d20">[H][C@]1(CCC)COC2=C(SC=C2)C(=N)N1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07005">
  <data key="d0">D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide</data>
  <data key="d1">drugbank.DB07005</data>
  <data key="d2">[drugbank.DB07005]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">{amino[4-({[(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}methyl)phenyl]methylidene}azanium</data>
  <data key="d15">C22H28N5O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H27N5O2/c23-18(13-15-5-2-1-3-6-15)22(29)27-12-4-7-19(27)21(28)26-14-16-8-10-17(11-9-16)20(24)25/h1-3,5-6,8-11,18-19H,4,7,12-14,23H2,(H3,24,25)(H,26,28)/p+1/t18-,19+/m1/s1</data>
  <data key="d20">[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=C(C=C1)C(N)=[NH2+]</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07091">
  <data key="d0">(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide</data>
  <data key="d1">drugbank.DB07091</data>
  <data key="d2">[drugbank.DB07091]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-N-[(4-carbamimidoylphenyl)methyl]-1-[2-(cyclohexyloxy)acetyl]pyrrolidine-2-carboxamide</data>
  <data key="d15">C21H30N4O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H30N4O3/c22-20(23)16-10-8-15(9-11-16)13-24-21(27)18-7-4-12-25(18)19(26)14-28-17-5-2-1-3-6-17/h8-11,17-18H,1-7,12-14H2,(H3,22,23)(H,24,27)/t18-/m0/s1</data>
  <data key="d20">[H][C@]1(CCCN1C(=O)COC1CCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07095">
  <data key="d0">(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide</data>
  <data key="d1">drugbank.DB07095</data>
  <data key="d2">[drugbank.DB07095]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-N-[(4-carbamimidoylphenyl)methyl]-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide</data>
  <data key="d15">C21H30N4O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H30N4O2/c22-20(23)17-10-7-16(8-11-17)14-24-21(27)18-6-3-13-25(18)19(26)12-9-15-4-1-2-5-15/h7-8,10-11,15,18H,1-6,9,12-14H2,(H3,22,23)(H,24,27)/t18-/m0/s1</data>
  <data key="d20">[H][C@]1(CCCN1C(=O)CCC1CCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07172">
  <data key="d0">(5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid</data>
  <data key="d1">drugbank.DB07172</data>
  <data key="d2">[drugbank.DB07172]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid</data>
  <data key="d15">C20H30O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H30O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(21)17-15-18-20(22)23/h3-4,6-7,9-10,12-14,16,19,21H,2,5,8,11,15,17-18H2,1H3,(H,22,23)/b4-3-,7-6-,10-9-,13-12-,16-14+/t19-/m0/s1</data>
  <data key="d20">[H][C@@](O)(CCCC(O)=O)\C=C\C=C/C\C=C/C\C=C/C\C=C/CC</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07175">
  <data key="d0">N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide</data>
  <data key="d1">drugbank.DB07175</data>
  <data key="d2">[drugbank.DB07175]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide</data>
  <data key="d15">C18H18N4O2S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H18N4O2S/c1-13-8-9-15(10-16(13)22-25(2,23)24)21-18-11-17(19-12-20-18)14-6-4-3-5-7-14/h3-12,22H,1-2H3,(H,19,20,21)</data>
  <data key="d20">CC1=CC=C(NC2=CC(=NC=N2)C2=CC=CC=C2)C=C1NS(C)(=O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07190">
  <data key="d0">3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide</data>
  <data key="d1">drugbank.DB07190</data>
  <data key="d2">[drugbank.DB07190]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-1-[(2R)-2-amino-3-cyclohexylpropanoyl]-N-[(3-chlorophenyl)methyl]pyrrolidine-2-carboxamide</data>
  <data key="d15">C21H30ClN3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H30ClN3O2/c22-17-9-4-8-16(12-17)14-24-20(26)19-10-5-11-25(19)21(27)18(23)13-15-6-2-1-3-7-15/h4,8-9,12,15,18-19H,1-3,5-7,10-11,13-14,23H2,(H,24,26)/t18-,19+/m1/s1</data>
  <data key="d20">[H][C@@](N)(CC1CCCCC1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC(Cl)=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07195">
  <data key="d0">4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL</data>
  <data key="d1">drugbank.DB07195</data>
  <data key="d2">[drugbank.DB07195]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-[(1S,2S,5S,6S,9S)-5-(hydroxymethyl)-6,8,9-trimethyl-3-oxabicyclo[3.3.1]non-7-en-2-yl]phenol</data>
  <data key="d15">C18H24O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H24O3/c1-11-8-12(2)18(9-19)10-21-17(16(11)13(18)3)14-4-6-15(20)7-5-14/h4-8,12-13,16-17,19-20H,9-10H2,1-3H3/t12-,13-,16+,17+,18-/m0/s1</data>
  <data key="d20">[H][C@]1(C)C=C(C)[C@]2([H])[C@]([H])(C)[C@@]1(CO)CO[C@]2([H])C1=CC=C(O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07133">
  <data key="d0">D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide</data>
  <data key="d1">drugbank.DB07133</data>
  <data key="d2">[drugbank.DB07133]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-[(3-methylphenyl)methyl]pyrrolidine-2-carboxamide</data>
  <data key="d15">C22H27N3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H27N3O2/c1-16-7-5-10-18(13-16)15-24-21(26)20-11-6-12-25(20)22(27)19(23)14-17-8-3-2-4-9-17/h2-5,7-10,13,19-20H,6,11-12,14-15,23H2,1H3,(H,24,26)/t19-,20+/m1/s1</data>
  <data key="d20">[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC(C)=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07131">
  <data key="d0">(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide</data>
  <data key="d1">drugbank.DB07131</data>
  <data key="d2">[drugbank.DB07131]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-N-[(4-carbamimidoylphenyl)methyl]-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide</data>
  <data key="d15">C22H32N4O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H32N4O2/c23-21(24)18-11-8-17(9-12-18)15-25-22(28)19-7-4-14-26(19)20(27)13-10-16-5-2-1-3-6-16/h8-9,11-12,16,19H,1-7,10,13-15H2,(H3,23,24)(H,25,28)/t19-/m0/s1</data>
  <data key="d20">[H][C@]1(CCCN1C(=O)CCC1CCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07128">
  <data key="d0">N7-BUTYL-N2-(5-CHLORO-2-METHYLPHENYL)-5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE-2,7-DIAMINE</data>
  <data key="d1">drugbank.DB07128</data>
  <data key="d2">[drugbank.DB07128]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N7-butyl-N2-(5-chloro-2-methylphenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2,7-diamine</data>
  <data key="d15">C17H21ClN6</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H21ClN6/c1-4-5-8-19-15-9-12(3)20-17-22-16(23-24(15)17)21-14-10-13(18)7-6-11(14)2/h6-7,9-10,19H,4-5,8H2,1-3H3,(H,21,23)</data>
  <data key="d20">CCCCNC1=CC(C)=NC2=NC(NC3=CC(Cl)=CC=C3C)=NN12</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07129">
  <data key="d0">(2R)-1-(2,6-dimethylphenoxy)propan-2-amine</data>
  <data key="d1">drugbank.DB07129</data>
  <data key="d2">[drugbank.DB07129]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2R)-1-(2,6-dimethylphenoxy)propan-2-amine</data>
  <data key="d15">C11H17NO</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3/t10-/m1/s1</data>
  <data key="d20">[H][C@](C)(N)COC1=C(C)C=CC=C1C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB10770">
  <data key="d0">Foreskin fibroblast (neonatal)</data>
  <data key="d1">drugbank.DB10770</data>
  <data key="d2">[drugbank.DB10770]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Allogeneic Cultured Cell Scaffold]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">This device is indicated for use for the treatment of full-thickness,  diabetic foot ulcers greater than six weeks duration which extends through the dermis, but without tendon, muscle, joint capsule or bone exposure. This drug should be used in conjunction with standard wound care regimens and in patients with an adequate blood supply to the involved foot [L2418].</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[foreskin fibroblast, neonatal]</data>
  <data key="d9">Foreskin fibroblast-like stromal cells (FDSCs) are progenitors isolated from human tissue that can differentiate into various cell types [A32660].\n\nAlso known as Dermagraft, this device is a cryopreserved human fibroblast-derived dermal substitute. Composed of fibroblasts, extracellular matrix, and a bioabsorbable scaffold, it effectively supports wound healing [L2418].\n\nDermagraft has only been available in the United States as an investigational device (IDE). Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997. Dermagraft was introduced in the United Kingdom in October 1997, and several other European countries, as well as New Zealand and Australia. The device is available for commercial distribution in Australia, Canada, Finland, France, Hong Kong, Ireland, The Netherlands, New Zealand, Singapore, and The United Kingdom [L2418].\n\nThe impact of diabetic foot ulcers (DFU) on individuals and society is devastating. Failure to observe proper wound care in this condition often results in amputation. If wound closure is achieved, it is likely to delay the need for surgical intervention and provide other benefits such as improvements in productivity, mental outlook, social interactions, and time at work, in addition to decreased mortality [L2438].\n\nInterestingly, it has been shown that human foreskin cells possess immunosuppressive properties, which are mediated by other processes than that reported for bone marrow/stromal stem cells [A32655].  Dermagraft has been combined with [DB10772] to create a drug beneficial to patients with open burn wounds [L2427].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB10772">
  <data key="d0">Foreskin keratinocyte (neonatal)</data>
  <data key="d1">drugbank.DB10772</data>
  <data key="d2">[drugbank.DB10772]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Allogeneic Cultured Cell Scaffold]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">For chronic leg ulcers and diabetic foot [L2439].  \n\nOrcel is indicated for use with standard therapeutic compression for the treatment of non-infected partial and full-thickness skin ulcers due to venous insufficiency of greater than 1 month in duration and which have not effectively responded to conventional ulcer therapy. Orcel is also for use with standard diabetic foot ulcer care for the treatment of full-thickness neuropathic diabetic foot ulcers of greater than 3 weeks in duration which have not effectively responded to conventional ulcer therapy, and which extend through the dermis but without tendon, muscle, capsule or bone involvement [L2459].</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[foreskin keratinocyte, neonatal]</data>
  <data key="d9">Skin, the largest organ of the human body, plays the main role in protecting the body from mechanical damage. It is composed of epidermal, dermal and hypodermal layers. The barrier function of the skin owed to its avascular epidermal layer, which is made mainly of keratinocytes. The keratinocytes form a stratified epithelium, with growing basal cells at the innermost layer and the keratinized, and mostly impermeable outer stratum corneum layer on the surface [L2452].\n\nForeskin keratinocytes are a form of skin cells that are cultured as a skin cell replacement for wounds, to accelerate wound closure and healing [L2434], [L2460]. \n\nThe defining moment in skin culture was in 1975 when Rheinwald and Green successfully grew human keratinocytes on lethally irradiated murine fibroblasts. In 1981, OConner and his group utilized cultured autologous epithelium to coat burn defects for the first time. To construct a "living" alternative, a dermal substitute based on collagen I gel was created with mesenchymal cells such as fibroblasts. When an epidermal layer was added, this approach became known as "skin equivalent", "composite culture" or "organotypical culture" [L2453].\n\nForeskin keratinocytes are an important ingredient in several skin substitutes [L2460], used for various indications. \nKeratinocytes are derived from neonatal foreskins and used to create a drug called _Apligraf_, a mixture of [DB10770] and keratinocytes. A gel made of bovine collagen is used as the matrix for cell growth and differentiation. Apligraf has been useful in the treatment of venous leg ulcers and diabetic foot ulcers, by increasing rates of wound healing and decreasing the time required for closure of wounds [L2452].\n\nOrcel, another skin substitute,  is similar to Apligraf since it contains both fibroblasts and keratinocytes derived from neonatal foreskin, but in addition, utilizes a type I collagen sponge as its matrix. It is used for grafting onto partial-thickness wounds, where it offers a favorable matrix for host cell migration [L2452].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07143">
  <data key="d0">D-phenylalanyl-N-benzyl-L-prolinamide</data>
  <data key="d1">drugbank.DB07143</data>
  <data key="d2">[drugbank.DB07143]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-benzylpyrrolidine-2-carboxamide</data>
  <data key="d15">C21H25N3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H25N3O2/c22-18(14-16-8-3-1-4-9-16)21(26)24-13-7-12-19(24)20(25)23-15-17-10-5-2-6-11-17/h1-6,8-11,18-19H,7,12-15,22H2,(H,23,25)/t18-,19+/m1/s1</data>
  <data key="d20">[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07149">
  <data key="d0">(7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one</data>
  <data key="d1">drugbank.DB07149</data>
  <data key="d2">[drugbank.DB07149]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-4-one</data>
  <data key="d15">C13H14FN5O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H14FN5O/c14-3-1-7-6-17-12(20)8-5-10(18-11(7)8)9-2-4-16-13(15)19-9/h2,4-5,7,18H,1,3,6H2,(H,17,20)(H2,15,16,19)/t7-/m0/s1</data>
  <data key="d20">[H][C@]1(CCF)CNC(=O)C2=C1NC(=C2)C1=NC(N)=NC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08480">
  <data key="d0">4-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN</data>
  <data key="d1">drugbank.DB08480</data>
  <data key="d2">[drugbank.DB08480]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(1R)-1-[(E)-(prop-2-en-1-ylidene)amino]-2,3-dihydro-1H-inden-4-ol</data>
  <data key="d15">C12H13NO</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H13NO/c1-2-8-13-11-7-6-10-9(11)4-3-5-12(10)14/h2-5,8,11,14H,1,6-7H2/b13-8+/t11-/m1/s1</data>
  <data key="d20">[H][C@]1(CCC2=C1C=CC=C2O)\N=C\C=C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07156">
  <data key="d0">(4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione</data>
  <data key="d1">drugbank.DB07156</data>
  <data key="d2">[drugbank.DB07156]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)-1,2,3,4-tetrahydroisoquinoline-1,3-dione</data>
  <data key="d15">C21H20BrN3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H20BrN3O2/c22-15-5-8-17-18(11-15)19(21(27)24-20(17)26)12-23-16-6-3-14(4-7-16)13-25-9-1-2-10-25/h3-8,11-12,23H,1-2,9-10,13H2,(H,24,26,27)/b19-12-</data>
  <data key="d20">BrC1=CC=C2C(=O)NC(=O)\C(=C/NC3=CC=C(CN4CCCC4)C=C3)C2=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08498">
  <data key="d0">(1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate</data>
  <data key="d1">drugbank.DB08498</data>
  <data key="d2">[drugbank.DB08498]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(S)-(3-chlorophenyl)[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)carbamoyl]methyl acetate</data>
  <data key="d15">C19H13ClN2O6</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H13ClN2O6/c1-9(23)28-16(10-4-2-5-11(20)8-10)19(27)21-13-7-3-6-12-14(13)15(24)18(26)22-17(12)25/h2-8,16H,1H3,(H,21,27)(H,22,25,26)/t16-/m0/s1</data>
  <data key="d20">[H][C@@](OC(C)=O)(C(=O)NC1=CC=CC2=C1C(=O)C(=O)NC2=O)C1=CC=CC(Cl)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08497">
  <data key="d0">(1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate</data>
  <data key="d1">drugbank.DB08497</data>
  <data key="d2">[drugbank.DB08497]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(S)-phenyl[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)carbamoyl]methyl acetate</data>
  <data key="d15">C19H14N2O6</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H14N2O6/c1-10(22)27-16(11-6-3-2-4-7-11)19(26)20-13-9-5-8-12-14(13)15(23)18(25)21-17(12)24/h2-9,16H,1H3,(H,20,26)(H,21,24,25)/t16-/m0/s1</data>
  <data key="d20">[H][C@@](OC(C)=O)(C(=O)NC1=CC=CC2=C1C(=O)C(=O)NC2=O)C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07165">
  <data key="d0">N-(5-CHLORO-BENZO[B]THIOPHEN-3-YLMETHYL)-2-[6-CHLORO-OXO-3-(2-PYRIDIN-2-YL-ETHYLAMINO)-2H-PYRAZIN-1-YL]-ACETAMIDE</data>
  <data key="d1">drugbank.DB07165</data>
  <data key="d2">[drugbank.DB07165]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-[(5-chloro-1-benzothiophen-3-yl)methyl]-2-[(2R,6S)-2-chloro-6-hydroxy-5-{[2-(pyridin-2-yl)ethyl]amino}-1,2,3,6-tetrahydropyrazin-1-yl]acetamide</data>
  <data key="d15">C22H23Cl2N5O2S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H23Cl2N5O2S/c23-15-4-5-18-17(9-15)14(13-32-18)10-27-20(30)12-29-19(24)11-28-21(22(29)31)26-8-6-16-3-1-2-7-25-16/h1-5,7,9,13,19,22,31H,6,8,10-12H2,(H,26,28)(H,27,30)/t19-,22-/m0/s1</data>
  <data key="d20">[H][C@@]1(Cl)CN=C(NCCC2=NC=CC=C2)[C@]([H])(O)N1CC(=O)NCC1=CSC2=CC=C(Cl)C=C12</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08499">
  <data key="d0">N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide</data>
  <data key="d1">drugbank.DB08499</data>
  <data key="d2">[drugbank.DB08499]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide</data>
  <data key="d15">C21H18FN3O6</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H18FN3O6/c22-8-9-31-14-3-1-2-12(10-14)23-17(26)6-7-18(27)24-13-4-5-15-16(11-13)19(28)21(30)25-20(15)29/h1-5,10-11H,6-9H2,(H,23,26)(H,24,27)(H,25,29,30)</data>
  <data key="d20">FCCOC1=CC=CC(NC(=O)CCC(=O)NC2=CC=C3C(=O)NC(=O)C(=O)C3=C2)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08422">
  <data key="d0">[PHENYLALANINYL-PROLINYL]-[2-(PYRIDIN-4-YLAMINO)-ETHYL]-AMINE</data>
  <data key="d1">drugbank.DB08422</data>
  <data key="d2">[drugbank.DB08422]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-{2-[(pyridin-4-yl)amino]ethyl}pyrrolidine-2-carboxamide</data>
  <data key="d15">C21H27N5O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H27N5O2/c22-18(15-16-5-2-1-3-6-16)21(28)26-14-4-7-19(26)20(27)25-13-12-24-17-8-10-23-11-9-17/h1-3,5-6,8-11,18-19H,4,7,12-15,22H2,(H,23,24)(H,25,27)/t18-,19+/m1/s1</data>
  <data key="d20">[H][C@@](N)(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(=O)NCCNC1=CC=NC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07105">
  <data key="d0">2-[2-(4-CHLORO-PHENYLSULFANYL)-ACETYLAMINO]-3-(4-GUANIDINO-PHENYL)-PROPIONAMIDE</data>
  <data key="d1">drugbank.DB07105</data>
  <data key="d2">[drugbank.DB07105]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-3-(4-carbamimidamidophenyl)-2-{2-[(4-chlorophenyl)sulfanyl]acetamido}propanamide</data>
  <data key="d15">C18H20ClN5O2S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H20ClN5O2S/c19-12-3-7-14(8-4-12)27-10-16(25)24-15(17(20)26)9-11-1-5-13(6-2-11)23-18(21)22/h1-8,15H,9-10H2,(H2,20,26)(H,24,25)(H4,21,22,23)/t15-/m0/s1</data>
  <data key="d20">[H][C@@](CC1=CC=C(NC(N)=N)C=C1)(NC(=O)CSC1=CC=C(Cl)C=C1)C(N)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08435">
  <data key="d0">(5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid</data>
  <data key="d1">drugbank.DB08435</data>
  <data key="d2">[drugbank.DB08435]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(5E)-7-[(1S,5Z)-5-[(2E)-oct-2-en-1-ylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid</data>
  <data key="d15">C20H28O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H28O3/c1-2-3-4-5-6-10-13-18-17(15-16-19(18)21)12-9-7-8-11-14-20(22)23/h6-7,9-10,13,15-17H,2-5,8,11-12,14H2,1H3,(H,22,23)/b9-7+,10-6+,18-13-/t17-/m0/s1</data>
  <data key="d20">[H][C@]1(C\C=C\CCCC(O)=O)C=CC(=O)\C1=C/C=C/CCCCC</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07111">
  <data key="d0">(4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid</data>
  <data key="d1">drugbank.DB07111</data>
  <data key="d2">[drugbank.DB07111]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid</data>
  <data key="d15">C22H32O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-21(23)19-20-22(24)25/h3-4,6-7,9-10,12-13,15-18,21,23H,2,5,8,11,14,19-20H2,1H3,(H,24,25)/b4-3-,7-6-,10-9-,13-12-,16-15-,18-17+/t21-/m1/s1</data>
  <data key="d20">[H][C@](O)(CCC(O)=O)\C=C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07110">
  <data key="d0">4-(4-FLUOROBENZYL)PIPERIDINE</data>
  <data key="d1">drugbank.DB07110</data>
  <data key="d2">[drugbank.DB07110]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-[(4-fluorophenyl)methyl]piperidine</data>
  <data key="d15">C12H16FN</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H16FN/c13-12-3-1-10(2-4-12)9-11-5-7-14-8-6-11/h1-4,11,14H,5-9H2</data>
  <data key="d20">FC1=CC=C(CC2CCNCC2)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07122">
  <data key="d0">1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine</data>
  <data key="d1">drugbank.DB07122</data>
  <data key="d2">[drugbank.DB07122]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine</data>
  <data key="d15">C15H15N3O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H15N3O/c16-15(17)18-13-8-6-11(7-9-13)10-14(19)12-4-2-1-3-5-12/h1-9H,10H2,(H4,16,17,18)</data>
  <data key="d20">NC(=N)NC1=CC=C(CC(=O)C2=CC=CC=C2)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07120">
  <data key="d0">N4-(N,N-DIPHENYLCARBAMOYL)-AMINOGUANIDINE</data>
  <data key="d1">drugbank.DB07120</data>
  <data key="d2">[drugbank.DB07120]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-carbamimidamido-1,1-diphenylurea</data>
  <data key="d15">C14H15N5O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H15N5O/c15-13(16)17-18-14(20)19(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H,18,20)(H4,15,16,17)</data>
  <data key="d20">NC(=N)NNC(=O)N(C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07118">
  <data key="d0">Hymecromone</data>
  <data key="d1">drugbank.DB07118</data>
  <data key="d2">[drugbank.DB07118]</data>
  <data key="d12">[experimental, investigational]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Benzopyrans, Bile and Liver Therapy, Bile Therapy, Compounds used in a research, industrial, or household setting, Coumarins, Indicators and Reagents, Laboratory Chemicals, Narrow Therapeutic Index Drugs, Pyrans, Umbelliferones]</data>
  <data key="d14">7-hydroxy-4-methyl-2H-chromen-2-one</data>
  <data key="d15">C10H8O3</data>
  <data key="d16">90-33-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H8O3/c1-6-4-10(12)13-9-5-7(11)2-3-8(6)9/h2-5,11H,1H3</data>
  <data key="d20">CC1=CC(=O)OC2=C1C=CC(O)=C2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[himecromona, Hymecromone]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08402">
  <data key="d0">2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID</data>
  <data key="d1">drugbank.DB08402</data>
  <data key="d2">[drugbank.DB08402]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-(2,4-dichlorobenzamido)-5-(pyrimidin-2-yloxy)benzoic acid</data>
  <data key="d15">C18H11Cl2N3O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H11Cl2N3O4/c19-10-2-4-12(14(20)8-10)16(24)23-15-5-3-11(9-13(15)17(25)26)27-18-21-6-1-7-22-18/h1-9H,(H,23,24)(H,25,26)</data>
  <data key="d20">OC(=O)C1=C(NC(=O)C2=C(Cl)C=C(Cl)C=C2)C=CC(OC2=NC=CC=N2)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08936">
  <data key="d0">Chlorcyclizine</data>
  <data key="d1">drugbank.DB08936</data>
  <data key="d2">[drugbank.DB08936]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Antihistamines for Systemic Use, Histamine Antagonists, Histamine H1 Antagonists, Piperazine Derivatives, Potential QTc-Prolonging Agents, QTc Prolonging Agents]</data>
  <data key="d14">1-[(4-chlorophenyl)(phenyl)methyl]-4-methylpiperazine</data>
  <data key="d15">C18H21ClN2</data>
  <data key="d16">82-93-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H21ClN2/c1-20-11-13-21(14-12-20)18(15-5-3-2-4-6-15)16-7-9-17(19)10-8-16/h2-10,18H,11-14H2,1H3</data>
  <data key="d20">CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Chlorcyclizin, Chlorcyclizine, Chlorcyclizinum, Clorciclicina, Clorciclizina, Clorciclizinio]</data>
  <data key="d9">Chlorcyclizine is a first generation phenylpiperazine class antihistamine used to treat urticaria, rhinitis, pruritus, and other allergy symptoms. Chlorcyclizine also has some local anesthetic, anticholinergic, and antiserotonergic properties, and can be used as an antiemetic.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08960">
  <data key="d0">Hexamethonium</data>
  <data key="d1">drugbank.DB08960</data>
  <data key="d2">[drugbank.DB08960]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Amines, Ammonium Compounds, Anticholinergic Agents, Antihypertensive Agents, Autonomic Agents, Bis-Trimethylammonium Compounds, Cardiovascular Agents, Central Nervous System Depressants, Cholinergic Agents, Ganglion Blockers, Hexamethonium Compounds, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Neurotransmitter Agents, Nicotinic Antagonists, Nitrogen Compounds, Onium Compounds, Peripheral Nervous System Agents, Quaternary Ammonium Compounds]</data>
  <data key="d14">trimethyl[6-(trimethylazaniumyl)hexyl]azanium</data>
  <data key="d15">C12H30N2</data>
  <data key="d16">60-26-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H30N2/c1-13(2,3)11-9-7-8-10-12-14(4,5)6/h7-12H2,1-6H3/q+2</data>
  <data key="d20">C[N+](C)(C)CCCCCC[N+](C)(C)C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[N, N, N, N', N', N'-hexamethylhexane-1, 6-diaminium]</data>
  <data key="d9">A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07625">
  <data key="d0">4-(2-aminoethoxy)-N-(2,5-diethoxyphenyl)-3,5-dimethylbenzamide</data>
  <data key="d1">drugbank.DB07625</data>
  <data key="d2">[drugbank.DB07625]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-(2-aminoethoxy)-N-(2,5-diethoxyphenyl)-3,5-dimethylbenzamide</data>
  <data key="d15">C21H28N2O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H28N2O4/c1-5-25-17-7-8-19(26-6-2)18(13-17)23-21(24)16-11-14(3)20(15(4)12-16)27-10-9-22/h7-8,11-13H,5-6,9-10,22H2,1-4H3,(H,23,24)</data>
  <data key="d20">CCOC1=CC=C(OCC)C(NC(=O)C2=CC(C)=C(OCCN)C(C)=C2)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07626">
  <data key="d0">4-(2-aminoethoxy)-N-(3-chloro-2-ethoxy-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide</data>
  <data key="d1">drugbank.DB07626</data>
  <data key="d2">[drugbank.DB07626]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-(2-aminoethoxy)-N-[3-chloro-2-ethoxy-5-(piperidin-1-yl)phenyl]-3,5-dimethylbenzamide</data>
  <data key="d15">C24H32ClN3O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H32ClN3O3/c1-4-30-23-20(25)14-19(28-9-6-5-7-10-28)15-21(23)27-24(29)18-12-16(2)22(17(3)13-18)31-11-8-26/h12-15H,4-11,26H2,1-3H3,(H,27,29)</data>
  <data key="d20">CCOC1=C(NC(=O)C2=CC(C)=C(OCCN)C(C)=C2)C=C(C=C1Cl)N1CCCCC1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06307">
  <data key="d0">Apoptone</data>
  <data key="d1">drugbank.DB06307</data>
  <data key="d2">[drugbank.DB06307]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Androstanes, Steroids]</data>
  <data key="d14">(1S,2S,5R,7S,10R,11S,14R,15S)-14-ethynyl-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecane-5,14-diol</data>
  <data key="d15">C21H32O2</data>
  <data key="d16">183387-50-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H32O2/c1-4-21(23)12-9-18-16-6-5-14-13-15(22)7-10-19(14,2)17(16)8-11-20(18,21)3/h1,14-18,22-23H,5-13H2,2-3H3/t14-,15+,16+,17-,18-,19-,20-,21-/m0/s1</data>
  <data key="d20">C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C</data>
  <data key="d21">Investigated for use/treatment in cancer/tumors (unspecified).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07638">
  <data key="d0">(3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL</data>
  <data key="d1">drugbank.DB07638</data>
  <data key="d2">[drugbank.DB07638]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2R,6S,7R)-4,4-difluoro-7-(4-hydroxyphenyl)-8-oxatricyclo[7.4.0.0,]trideca-1(9),10,12-trien-12-ol</data>
  <data key="d15">C18H16F2O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H16F2O3/c19-18(20)8-14-13-7-12(22)5-6-16(13)23-17(15(14)9-18)10-1-3-11(21)4-2-10/h1-7,14-15,17,21-22H,8-9H2/t14-,15-,17-/m0/s1</data>
  <data key="d20">[H][C@@]12CC(F)(F)C[C@]1([H])[C@@]([H])(OC1=C2C=C(O)C=C1)C1=CC=C(O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07639">
  <data key="d0">3-(7-DIAMINOMETHYL-NAPHTHALEN-2-YL)-PROPIONIC ACID ETHYL ESTER</data>
  <data key="d1">drugbank.DB07639</data>
  <data key="d2">[drugbank.DB07639]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">ethyl 3-[7-(diaminomethyl)naphthalen-2-yl]-2-[4-(pyrrolidin-3-yloxy)phenyl]propanoate</data>
  <data key="d15">C26H31N3O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C26H31N3O3/c1-2-31-26(30)24(19-7-9-22(10-8-19)32-23-11-12-29-16-23)14-17-3-4-18-5-6-20(25(27)28)15-21(18)13-17/h3-10,13,15,23-25,29H,2,11-12,14,16,27-28H2,1H3</data>
  <data key="d20">CCOC(=O)C(CC1=CC2=C(C=C1)C=CC(=C2)C(N)N)C1=CC=C(OC2CCNC2)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08904">
  <data key="d0">Certolizumab pegol</data>
  <data key="d1">drugbank.DB08904</data>
  <data key="d2">[drugbank.DB08904]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents reducing cytokine levels, Alcohols, Amino Acids, Peptides, and Proteins, Antibodies, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic and Immunomodulating Agents, Antirheumatic Agents, Biologics for Rheumatoid Arthritis Treatment, Disease-modifying Antirheumatic Agents, Drugs that are Mainly Renally Excreted, Ethylene Glycols, Globulins, Glycols, Immunoglobulin Fab Fragments, Immunoglobulin Fragments, Immunoglobulins, Immunologic Factors, Immunoproteins, Immunosuppressive Agents, Macromolecular Substances, Pegylated agents, Peptide Fragments, Peptides, Polyethylene Glycols, Polymers, Proteins, Serum Globulins, Tumor Necrosis Factor Alpha (TNF-) Inhibitors, Tumor Necrosis Factor Blocker, Tumor Necrosis Factor Receptor Blocking Activity]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">428863-50-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Certolizumab pegol has been approved for several different conditions listed below:\n\n- Symptomatic management of Chron's disease patients and for the maintenance of clinical response in patients with moderate to severe disease with inadequate response to conventional therapy.\n- Treatment of adult patients with moderate to severely active rheumatoid arthritis.\n- Treatment of adult patients with active psoriatic arthritis.\n- Treatment of adult patients with active ankylosing spondylitis.\n- Treatment of adult patients with moderate-to-severe plaque psoriasis that are candidates for systemic therapy or phototherapy.[FDA label]\n- Treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation.[L5819]\n\nIn Canada, certolizumab pegol is additionally approved in combination with [methotrexate] for the symptomatic treatment, including major clinical response, and for the reduction of joint damage in adult patients with moderately to severely active rheumatoid arthritis and psoriatic arthritis.[L5825]\n\nInflammation is a biological response against a potential threat. This response can be normal but in certain conditions, the immune system can attack the body's normal cells or tissues which causes an abnormal inflammation.[L5840] TNF-alpha has been identified as a key regulator of the inflammatory response. The signaling cascades of this inflammatory mediator can produce a wide range of reactions including cell death, survival, differentiation, proliferation and migration.[A176660]</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;15a0fb53-48d4-401d-b36d-e8dc88588bed Amino acid sequence of the light chain\nDIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPYRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC, &gt;04a57ec0-e379-49de-ad3e-bb138df233e4 Amino acid sequence of the heavy chain\nEVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIYADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCAA]</data>
  <data key="d8">[Certolizumab pegol]</data>
  <data key="d9">Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha).[A176585] It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life.[A176606] \n\nCertolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_.[A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L4894] and updated for a new indication on March 28, 2019.[L5819]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08910">
  <data key="d0">Pomalidomide</data>
  <data key="d1">drugbank.DB08910</data>
  <data key="d2">[drugbank.DB08910]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acids, Carbocyclic, Angiogenesis Inhibitors, Angiogenesis Modulating Agents, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Drugs that are Mainly Renally Excreted, Growth Inhibitors, Growth Substances, Imides, Immunologic Factors, Immunosuppressive Agents, Isoindoles, Myelosuppressive Agents, P-glycoprotein/ABCB1 Substrates, Phthalic Acids, Phthalimides, Piperidines, Piperidones, Thalidomide Analog]</data>
  <data key="d14">4-amino-2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione</data>
  <data key="d15">C13H11N3O4</data>
  <data key="d16">19171-19-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)</data>
  <data key="d20">NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O</data>
  <data key="d21">Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Pomalidomida, Pomalidomide]</data>
  <data key="d9">Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08915">
  <data key="d0">Aleglitazar</data>
  <data key="d1">drugbank.DB08915</data>
  <data key="d2">[drugbank.DB08915, drugbank.DB08483]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Sulfur Compounds]</data>
  <data key="d14">(2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid</data>
  <data key="d15">C24H23NO5S</data>
  <data key="d16">475479-34-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H23NO5S/c1-15-19(25-23(30-15)16-6-4-3-5-7-16)10-12-29-20-9-8-17(14-21(28-2)24(26)27)22-18(20)11-13-31-22/h3-9,11,13,21H,10,12,14H2,1-2H3,(H,26,27)/t21-/m0/s1</data>
  <data key="d20">CO[C@@H](CC1=CC=C(OCCC2=C(C)OC(=N2)C2=CC=CC=C2)C2=C1SC=C2)C(O)=O</data>
  <data key="d21">Investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Aleglitazar is an investigational drug from the company HoffmannLa Roche and is currently in a phase III clinical trial called ALECARDIO. It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPAR and PPAR receptor subtypes. In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects and toxicity.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05088">
  <data key="d0">Tetrathiomolybdate</data>
  <data key="d1">drugbank.DB05088</data>
  <data key="d2">[drugbank.DB05088]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Adenosine Triphosphatases, antagonists &amp; inhibitors, Angiogenesis Modulating Agents, Antineoplastic Agents, Chelating Agents, Compounds used in a research, industrial, or household setting, Elements, Enzyme Inhibitors, Growth Inhibitors, Growth Substances, Metals, Metals, Heavy, Sequestering Agents, Transition Elements]</data>
  <data key="d14">(sulfanidyldisulfanylidenemolybdenio)sulfanide</data>
  <data key="d15">MoS4</data>
  <data key="d16">16330-92-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/Mo.4S/q;;;2*-1</data>
  <data key="d20">[S-][Mo]([S-])(=S)=S</data>
  <data key="d21">Investigated for use/treatment in liver disease and pulmonary fibrosis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Thiomolybdate, Tiomolibdate ion]</data>
  <data key="d9">Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is dependent upon the availability of free copper in the body.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07696">
  <data key="d0">methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate</data>
  <data key="d1">drugbank.DB07696</data>
  <data key="d2">[drugbank.DB07696]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">methyl (3S)-3-{[(tert-butoxy)carbonyl]amino}-4-oxopentanoate</data>
  <data key="d15">C11H19NO5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H19NO5/c1-7(13)8(6-9(14)16-5)12-10(15)17-11(2,3)4/h8H,6H2,1-5H3,(H,12,15)/t8-/m0/s1</data>
  <data key="d20">[H][C@@](CC(=O)OC)(NC(=O)OC(C)(C)C)C(C)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06374">
  <data key="d0">Elacestrant</data>
  <data key="d1">drugbank.DB06374</data>
  <data key="d2">[drugbank.DB06374]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">(6R)-6-{2-[ethyl({4-[2-(ethylamino)ethyl]phenyl}methyl)amino]-4-methoxyphenyl}-5,6,7,8-tetrahydronaphthalen-2-ol</data>
  <data key="d15">C30H38N2O2</data>
  <data key="d16">722533-56-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C30H38N2O2/c1-4-31-17-16-22-6-8-23(9-7-22)21-32(5-2)30-20-28(34-3)14-15-29(30)26-11-10-25-19-27(33)13-12-24(25)18-26/h6-9,12-15,19-20,26,31,33H,4-5,10-11,16-18,21H2,1-3H3/t26-/m1/s1</data>
  <data key="d20">CCNCCC1=CC=C(CN(CC)C2=C(C=CC(OC)=C2)[C@@H]2CCC3=CC(O)=CC=C3C2)C=C1</data>
  <data key="d21">Investigated for use/treatment in menopause and female hormonal deficiencies/abnormalities.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06372">
  <data key="d0">Rilonacept</data>
  <data key="d1">drugbank.DB06372</data>
  <data key="d2">[drugbank.DB06372]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents reducing cytokine levels, Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating Agents, Immunosuppressive Agents, Interleukin Inhibitors, Interleukin-1 Receptor Accessory Protein, Proteins, Receptors, Interleukin-1 Type I, Recombinant Proteins]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">501081-76-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Rilonacept is currently used in the treatment of cryopyrin-associated periodic syndrome. In May 2012, an advisory panel for the FDA voted 11-0 against the use of Rilonacept for the treatment of gout.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;81ba12e0-2415-4fb4-a0ab-f0c621e6a949 8750_M|rilonacept|Homo sapiens||FUSION-IL1RAP-IL1R1-GAMMA-1 (IL1RAP+(Pr21-359)(1-339)+IL1R1+(Pr22-333)(340-651)+HINGE-REGION(652-663)+CH2(664-773)+CH3(774-880))|||||||880||||MW 100630.6|MW 100630.6|\nSERCDDWGLDTMRQIQVFEDEPARIKCPLFEHFLKFNYSTAHSAGLTLIWYWTRQDRDLEEPINFRLPENRISKEKDVLWFRPTLLNDTGNYTCMLRNTTYCSKVAFPLEVVQKDSCFNSPMKLPVHKLYIEYGIQRITCPNVDGYFPSSVKPTITWYMGCYKIQNFNNVIPEGMNLSFLIALISNNGNYTCVVTYPENGRTFHLTRTLTVKVVGSPKNAVPPVIHSPNDHVVYEKEPGEELLIPCTVYFSFLMDSRNEVWWTIDGKKPDDITIDVTINESISHSRTEDETRTQILSIKKVTSEDLKRSYVCHARSAKGEVAKAAKVKQKVPAPRYTVEKCKEREEKIILVSSANEIDVRPCPLNPNEHKGTITWYKDDSKTPVSTEQASRIHQHKEKLWFVPAKVEDSGHYYCVVRNSSYCLRIKISAKFVENEPNLCYNAQAIFKQKLPVAGDGGLVCPYMEFFKNENNELPKLQWYKDCKPLLLDNIHFSGVKDRLIVMNVAEKHRGNYTCHASYTYLGKQYPITRVIEFITLEENKPTRPVIVSPANETMEVDLGSQIQLICNVTGQLSDIAYWKWNGSVIDEDDPVLGEDYYSVENPANKRRSTLITVLNISEIESRFYKHPFTCFAKNTHGIDAAYIQLIYPVTNSGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK]</data>
  <data key="d8">[interleukin-1 (IL-1) trap]</data>
  <data key="d9">Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05047">
  <data key="d0">CX717</data>
  <data key="d1">drugbank.DB05047</data>
  <data key="d2">[drugbank.DB05047]</data>
  <data key="d12">[illicit, investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">5-(morpholine-4-carbonyl)-2,1,3-benzoxadiazole</data>
  <data key="d15">C11H11N3O3</data>
  <data key="d16">867276-98-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H11N3O3/c15-11(14-3-5-16-6-4-14)8-1-2-9-10(7-8)13-17-12-9/h1-2,7H,3-6H2</data>
  <data key="d20">O=C(N1CCOCC1)C1=CC2=NON=C2C=C1</data>
  <data key="d21">April 18 2007 Cortex Pharmaceuticals submitted two large data packages to the FDA regarding CX717. One data set went to the FDA's Division of Neurology Drug Products for the treatment of Alzheimer's disease, while the other went to the Division of Psychiatry Products where the company intends to file a second CX717 IND for the treatment of ADHD. On 18 April 2007 Cortex Pharmaeuticals submitted data to the FDA for the treatment of Alzheimer's disease as well as ADHD. The data shows that histopathological changes seen in animal studies were an artifact of postmortem fixation methods and not a change that occurred in the living animals as a result of the drug.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">CX717 is an ampakine compound created by Dr. Gary Lynch at UCI in 1993 and further developed by Cortex Pharmaceuticals, an Irvine company created to explore possible applications. It is one of a class of synthetic compounds that amplify the signal of glutamate, a neurotransmitter important for learning and memory.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06318">
  <data key="d0">AVE9633</data>
  <data key="d1">drugbank.DB06318</data>
  <data key="d2">[drugbank.DB06318]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Amides, Amino Acids, Peptides, and Proteins, Anti-Bacterial Agents, Antibodies, Antibodies, Monoclonal, Blood Proteins, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Globulins, Immunoglobulins, Immunoproteins, Lactams, Lactams, Macrocyclic, Lactones, Macrolides, Polyketides, Proteins, Serum Globulins]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in leukemia (myeloid).</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[huMy9-6-DM4]</data>
  <data key="d9">AVE9633 is an anti-CD33 monoclonal antibody-DM4 conjugate.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08992">
  <data key="d0">Eperisone</data>
  <data key="d1">drugbank.DB08992</data>
  <data key="d2">[drugbank.DB08992]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Agents causing hyperkalemia, Antiarrhythmic agents, Autonomic Agents, Bradycardia-Causing Agents, Calcium Channel Blockers, Cardiovascular Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Ketones, Membrane Transport Modulators, Moderate Risk QTc-Prolonging Agents, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Parasympatholytics, Peripheral Nervous System Agents, QTc Prolonging Agents, Vasodilating Agents]</data>
  <data key="d14">1-(4-ethylphenyl)-2-methyl-3-(piperidin-1-yl)propan-1-one</data>
  <data key="d15">C17H25NO</data>
  <data key="d16">64840-90-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H25NO/c1-3-15-7-9-16(10-8-15)17(19)14(2)13-18-11-5-4-6-12-18/h7-10,14H,3-6,11-13H2,1-2H3</data>
  <data key="d20">CCC1=CC=C(C=C1)C(=O)C(C)CN1CCCCC1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(2RS)-1-(4-ethylphenyl)-2-methyl-3-(1-piperidyl)propan-1-one, Eperison, Eperisona, Eperisone, Eprisone, Eperisonum]</data>
  <data key="d9">Eperisone is an antispasmodic drug which relaxes both skeletal muscles and vascular smooth muscles, and demonstrates a variety of effects such as reduction of myotonia, improvement of circulation, and suppression of the pain reflex. It is not approved for use in the United States, but is available in other countries like India, South Korea, and Bangladesh.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07660">
  <data key="d0">AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH</data>
  <data key="d1">drugbank.DB07660</data>
  <data key="d2">[drugbank.DB07660]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">[(1R)-4-amino-1-{[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}butyl]boronic acid</data>
  <data key="d15">C20H31BN4O5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H31BN4O5/c1-14(26)23-16(13-15-7-3-2-4-8-15)20(28)25-12-6-9-17(25)19(27)24-18(21(29)30)10-5-11-22/h2-4,7-8,16-18,29-30H,5-6,9-13,22H2,1H3,(H,23,26)(H,24,27)/t16-,17+,18+/m1/s1</data>
  <data key="d20">[H][C@@](CCCN)(NC(=O)[C@]1([H])CCCN1C(=O)[C@@]([H])(CC1=CC=CC=C1)NC(C)=O)B(O)O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07665">
  <data key="d0">N-[2-(carbamimidamidooxy)ethyl]-2-{6-cyano-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-fluorophenyl}acetamide</data>
  <data key="d1">drugbank.DB07665</data>
  <data key="d2">[drugbank.DB07665]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-[2-(carbamimidamidooxy)ethyl]-2-(6-cyano-3-{[2,2-difluoro-2-(pyridin-2-yl)ethyl]amino}-2-fluorophenyl)acetamide</data>
  <data key="d15">C19H20F3N7O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H20F3N7O2/c20-17-13(9-16(30)27-7-8-31-29-18(24)25)12(10-23)4-5-14(17)28-11-19(21,22)15-3-1-2-6-26-15/h1-6,28H,7-9,11H2,(H,27,30)(H4,24,25,29)</data>
  <data key="d20">NC(=N)NOCCNC(=O)CC1=C(C=CC(NCC(F)(F)C2=NC=CC=C2)=C1F)C#N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08996">
  <data key="d0">Dimetacrine</data>
  <data key="d1">drugbank.DB08996</data>
  <data key="d2">[drugbank.DB08996]</data>
  <data key="d12">[experimental, withdrawn]</data>
  <data key="d13">[Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Antidepressive Agents, Tricyclic, Central Nervous System Depressants, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with Narrow Therapeutic Index, Narrow Therapeutic Index Drugs, Nervous System, Neurotoxic agents, Non-Selective Monoamine Reuptake Inhibitors, Psychoanaleptics, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome]</data>
  <data key="d14">[3-(9,9-dimethyl-9,10-dihydroacridin-10-yl)propyl]dimethylamine</data>
  <data key="d15">C20H26N2</data>
  <data key="d16">4757-55-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H26N2/c1-20(2)16-10-5-7-12-18(16)22(15-9-14-21(3)4)19-13-8-6-11-17(19)20/h5-8,10-13H,9,14-15H2,1-4H3</data>
  <data key="d20">CN(C)CCCN1C2=CC=CC=C2C(C)(C)C2=CC=CC=C12</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3-(9, 9-dimethylacridin-10-yl)-N, N-dimethyl-propan-1-amine, Dimetacrine, Istonil, Istonyl, Linostil, Miroistonil]</data>
  <data key="d9">Dimetacrine is also known as dimethacrine or acripamine. It is marketed under the names Istonil, Istonyl, Linostil, and Miroistonil. Dimetacrine is a tricyclic antidepressant (TCA) with imipramine-like effects used in Europe for the treatment of depression. Dimetacrine is no longer used in Japan.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07658">
  <data key="d0">AC-(D)PHE-PRO-BOROLYS-OH</data>
  <data key="d1">drugbank.DB07658</data>
  <data key="d2">[drugbank.DB07658]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">[(1R)-5-amino-1-{[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}pentyl]boronic acid</data>
  <data key="d15">C21H33BN4O5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H33BN4O5/c1-15(27)24-17(14-16-8-3-2-4-9-16)21(29)26-13-7-10-18(26)20(28)25-19(22(30)31)11-5-6-12-23/h2-4,8-9,17-19,30-31H,5-7,10-14,23H2,1H3,(H,24,27)(H,25,28)/t17-,18+,19+/m1/s1</data>
  <data key="d20">[H][C@@](CCCCN)(NC(=O)[C@]1([H])CCCN1C(=O)[C@@]([H])(CC1=CC=CC=C1)NC(C)=O)B(O)O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07659">
  <data key="d0">AC-(D)PHE-PRO-BOROHOMOLYS-OH</data>
  <data key="d1">drugbank.DB07659</data>
  <data key="d2">[drugbank.DB07659]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">[(1R)-6-amino-1-{[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}hexyl]boronic acid</data>
  <data key="d15">C22H35BN4O5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H35BN4O5/c1-16(28)25-18(15-17-9-4-2-5-10-17)22(30)27-14-8-11-19(27)21(29)26-20(23(31)32)12-6-3-7-13-24/h2,4-5,9-10,18-20,31-32H,3,6-8,11-15,24H2,1H3,(H,25,28)(H,26,29)/t18-,19+,20+/m1/s1</data>
  <data key="d20">[H][C@@](CCCCCN)(NC(=O)[C@]1([H])CCCN1C(=O)[C@@]([H])(CC1=CC=CC=C1)NC(C)=O)B(O)O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07676">
  <data key="d0">3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one</data>
  <data key="d1">drugbank.DB07676</data>
  <data key="d2">[drugbank.DB07676]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-(3-{[(3S)-3,4-dihydroxybutoxy]amino}-1H-indol-2-yl)-2H-indol-2-one</data>
  <data key="d15">C20H19N3O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H19N3O4/c24-11-12(25)9-10-27-23-18-14-6-2-4-8-16(14)21-19(18)17-13-5-1-3-7-15(13)22-20(17)26/h1-8,12,21,23-25H,9-11H2/t12-/m0/s1</data>
  <data key="d20">[H][C@@](O)(CO)CCONC1=C(NC2=CC=CC=C12)C1=C2C=CC=CC2=NC1=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06343">
  <data key="d0">Teprotumumab</data>
  <data key="d1">drugbank.DB06343</data>
  <data key="d2">[drugbank.DB06343]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Antibodies, Blood Proteins, Globulins, Immunoglobulins, Immunoproteins, Proteins, Serum Globulins]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">1036734-93-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in solid tumors.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Immunoglobulin G1, anti-(human insulin-like growth factor I receptor) (human monoclonal heavy chain), disulfide with human monoclonal light chain, dimer]</data>
  <data key="d9">A fully human IgG1 type monoclonal antibody directed against the human insulin-like growth factor-I receptor.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07675">
  <data key="d0">(2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID</data>
  <data key="d1">drugbank.DB07675</data>
  <data key="d2">[drugbank.DB07675]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-2-ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoic acid</data>
  <data key="d15">C25H25NO5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C25H25NO5/c1-2-29-24(25(27)28)17-18-11-13-19(14-12-18)30-16-15-26-20-7-3-5-9-22(20)31-23-10-6-4-8-21(23)26/h3-14,24H,2,15-17H2,1H3,(H,27,28)/t24-/m0/s1</data>
  <data key="d20">[H][C@@](CC1=CC=C(OCCN2C3=C(OC4=C2C=CC=C4)C=CC=C3)C=C1)(OCC)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07681">
  <data key="d0">DODECANESULFONATE ION</data>
  <data key="d1">drugbank.DB07681</data>
  <data key="d2">[drugbank.DB07681]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">dodecane-1-sulfonate</data>
  <data key="d15">C12H25O3S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H26O3S/c1-2-3-4-5-6-7-8-9-10-11-12-16(13,14)15/h2-12H2,1H3,(H,13,14,15)/p-1</data>
  <data key="d20">CCCCCCCCCCCCS([O-])(=O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05023">
  <data key="d0">ATL1101</data>
  <data key="d1">drugbank.DB05023</data>
  <data key="d2">[drugbank.DB05023]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in psoriasis and psoriatic disorders.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis. ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05017">
  <data key="d0">YSIL6</data>
  <data key="d1">drugbank.DB05017</data>
  <data key="d2">[drugbank.DB05017]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in crohn's disease, psoriasis and psoriatic disorders, and rheumatoid arthritis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis. The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07678">
  <data key="d0">(9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL</data>
  <data key="d1">drugbank.DB07678</data>
  <data key="d2">[drugbank.DB07678]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(1S,10R,11S,14S,15S)-4-[(1Z)-but-1-en-1-yl]-15-methyltetracyclo[8.7.0.0,.0,]heptadeca-2,4,6-triene-5,14-diol</data>
  <data key="d15">C22H30O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H30O2/c1-3-4-5-15-12-18-14(13-20(15)23)6-7-17-16(18)10-11-22(2)19(17)8-9-21(22)24/h4-5,12-13,16-17,19,21,23-24H,3,6-11H2,1-2H3/b5-4-/t16-,17+,19-,21-,22-/m0/s1</data>
  <data key="d20">[H]\C(CC)=C(/[H])C1=C(O)C=C2CC[C@@]3([H])[C@]4([H])CC[C@]([H])(O)[C@@]4(C)CC[C@]3([H])C2=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06401">
  <data key="d0">Bazedoxifene</data>
  <data key="d1">drugbank.DB06401</data>
  <data key="d2">[drugbank.DB06401]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Bone Density Conservation Agents, Estrogen Agonist/Antagonist, Estrogen Receptor Modulators, Genito Urinary System and Sex Hormones, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Selective Estrogen Receptor Modulators, Sex Hormones and Modulators of the Genital System, UGT1A1 Substrates]</data>
  <data key="d14">1-({4-[2-(azepan-1-yl)ethoxy]phenyl}methyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol</data>
  <data key="d15">C30H34N2O3</data>
  <data key="d16">198481-32-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3</data>
  <data key="d20">CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1</data>
  <data key="d21">Indicated for following conditions alone or in combination with conjugated estrogens in women with a uterus:\n\n- Treatment of moderate to severe vasomotor symptoms associated with menopause\n\n- Prevention of postmenopausal osteoporosis</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Bazedoxifene, Bazedoxifeno]</data>
  <data key="d9">Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. It is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. In 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as the prevention of postmenopausal osteoporosis in women.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07724">
  <data key="d0">Indeglitazar</data>
  <data key="d1">drugbank.DB07724</data>
  <data key="d2">[drugbank.DB07724]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-[5-methoxy-1-(4-methoxybenzenesulfonyl)-1H-indol-3-yl]propanoic acid</data>
  <data key="d15">C19H19NO6S</data>
  <data key="d16">835619-41-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H19NO6S/c1-25-14-4-7-16(8-5-14)27(23,24)20-12-13(3-10-19(21)22)17-11-15(26-2)6-9-18(17)20/h4-9,11-12H,3,10H2,1-2H3,(H,21,22)</data>
  <data key="d20">COC1=CC=C(C=C1)S(=O)(=O)N1C=C(CCC(O)=O)C2=CC(OC)=CC=C12</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07723">
  <data key="d0">3-(5-methoxy-1H-indol-3-yl)propanoic acid</data>
  <data key="d1">drugbank.DB07723</data>
  <data key="d2">[drugbank.DB07723]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-(5-methoxy-1H-indol-3-yl)propanoic acid</data>
  <data key="d15">C12H13NO3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H13NO3/c1-16-9-3-4-11-10(6-9)8(7-13-11)2-5-12(14)15/h3-4,6-7,13H,2,5H2,1H3,(H,14,15)</data>
  <data key="d20">COC1=CC=C2NC=C(CCC(O)=O)C2=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06412">
  <data key="d0">Oxymetholone</data>
  <data key="d1">drugbank.DB06412</data>
  <data key="d2">[drugbank.DB06412]</data>
  <data key="d12">[approved, illicit]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Anabolic Agents, Anabolic Agents for Systemic Use, Anabolic Steroids, Androgens, Androstan Derivatives, Androstanes, Androstanols, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Steroids]</data>
  <data key="d14">(1S,2S,4Z,7S,10R,11S,14S,15S)-14-hydroxy-4-(hydroxymethylidene)-2,14,15-trimethyltetracyclo[8.7.0.0,.0,]heptadecan-5-one</data>
  <data key="d15">C21H32O3</data>
  <data key="d16">434-07-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H32O3/c1-19-11-13(12-22)18(23)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,22,24H,4-11H2,1-3H3/b13-12-/t14-,15+,16-,17-,19-,20-,21-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)\C(C[C@]12C)=C/O</data>
  <data key="d21">Indicated in the treatment of anemias caused by deficient red cell production. Acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond. Oxymetholone should not replace other supportive measures such as transfusion, correction of iron, folic acid, vitamin B12 or pyridoxine deficiency, antibacterial therapy and the appropriate use of corticosteroids.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[17-Hydroxy-2-hydroxymethylidene-17-methyl-3-androstanone, Oximetolona, Oxymetholon, Oxymtholone, Oxymetholone, Oxymetholonum]</data>
  <data key="d9">Oxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limitedand used in the treatment of osteoporosis, anaemia, and as an agent to stimulate muscle growth in malnourished or underdeveloped patients. Anabolic-androgenic steroids (AAS), such as oxymetholone, have been abused by bodybuilders and athletes. The uncontrolled misuse of oxymetholone can lead to a large variety of detrimental effects, the most often reported of which are cardiovascular events. In 2009, no producers of oxymetholone were identified worldwide (SRI 2009), but it was available from 14 suppliers, including 8 U.S. suppliers (ChemSources 2009).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07741">
  <data key="d0">4-(1R,3AS,4R,8AS,8BR)-[1-DIFLUOROMETHYL-2-(4-FLUOROBENZYL)-3-OXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZAMIDINE</data>
  <data key="d1">drugbank.DB07741</data>
  <data key="d2">[drugbank.DB07741]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(1S,3aS,4R,8aS,8bR)-4-[4-(diaminomethyl)phenyl]-1-(difluoromethyl)-2-[(4-fluorophenyl)methyl]-decahydropyrrolo[3,4-a]pyrrolizin-3-one</data>
  <data key="d15">C24H27F3N4O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H27F3N4O/c25-16-9-3-13(4-10-16)12-31-21(22(26)27)18-17-2-1-11-30(17)20(19(18)24(31)32)14-5-7-15(8-6-14)23(28)29/h3-10,17-23H,1-2,11-12,28-29H2/t17-,18-,19-,20-,21-/m0/s1</data>
  <data key="d20">[H][C@@]12CCC[N@@]1[C@@]([H])(C1=CC=C(C=C1)C(N)N)[C@@]1([H])C(=O)N(CC3=CC=C(F)C=C3)[C@]([H])(C(F)F)[C@@]21[H]</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06404">
  <data key="d0">Human C1-esterase inhibitor</data>
  <data key="d1">drugbank.DB06404</data>
  <data key="d2">[drugbank.DB06404, drugbank.DB05341]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Blood and Blood Forming Organs, Blood Proteins, C1 inhibitors, Carbohydrates, Complement C1 Inactivator Proteins, Complement Inactivating Agents, Complement Inactivator Proteins, Complement System Proteins, Decreased Vascular Permeability, Drugs Used in Hereditary Angioedema, Glycoconjugates, Glycoproteins, Immunologic Factors, Immunoproteins, Kallikrein Inhibitors, Peptides, Protease Inhibitors, Proteins, Serpins]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">For routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[C1 Esterase Inhibitor (Human), C1 inhibitor, C1 inhibitor (human), C1 inhibitor human, C1-esterase inhibitor, human, C1-INH, C1-inhibiting factor, C1-inhibitor, plasma derived, Human C1 inhibitor, Human C1-esterase inhibitor, Plasma protease C1 inhibitor]</data>
  <data key="d9">C1 Esterase Inhibitor (Human) is composed of purified endogenous complement component-1 esterase inhibitor (hC1INH) isolated from human plasma. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways. It does this through inhibition of several target proteases within these pathways including activated C1s, kallikrein, factor XIIa and factor XIa. C1 esterase inhibitor has also been shown to inhibit the action of thrombin within the coagulation pathway, and tPA and plasmin within the fibrinolytic pathway. Deficiency of C1-inhibitor allows increased plasma kallikrein activation resulting in increased production of bradykinin. Additionally, C4 and C2 cleavage is uninhibited leading to auto-activation of the complement system. Down-stream effects of the lack of enzyme inhibition by C1 esterase inhibitor results in swelling due to leakage of fluid from blood vessels into connective tissue and consequently the presentation of hereditary angioedema (HAE). \n\nMarketed as the product Cyrinze (FDA), this drug is indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE), a human genetic disorder caused by a shortage of C1 inhibitor activity that results in an overreaction of the immune system. The disease is characterized by acute attacks of painful and in some cases fatal swelling of several soft tissues (edema), which may last up to five days when untreated.\n\nIn June 2017 the FDA approved a formulation of human C1-esterase inhibitor for subcutaneous administration under the tradename Haegarda.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07735">
  <data key="d0">N-[1-(2,6-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide</data>
  <data key="d1">drugbank.DB07735</data>
  <data key="d2">[drugbank.DB07735]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-{1-[(2,6-dimethoxyphenyl)methyl]piperidin-4-yl}-4-sulfanylbutanamide</data>
  <data key="d15">C18H28N2O3S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H28N2O3S/c1-22-16-5-3-6-17(23-2)15(16)13-20-10-8-14(9-11-20)19-18(21)7-4-12-24/h3,5-6,14,24H,4,7-13H2,1-2H3,(H,19,21)</data>
  <data key="d20">COC1=CC=CC(OC)=C1CN1CCC(CC1)NC(=O)CCCS</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07736">
  <data key="d0">(2S)-4-(4-fluorobenzyl)-N-(2-sulfanylethyl)piperazine-2-carboxamide</data>
  <data key="d1">drugbank.DB07736</data>
  <data key="d2">[drugbank.DB07736]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-4-[(4-fluorophenyl)methyl]-N-(2-sulfanylethyl)piperazine-2-carboxamide</data>
  <data key="d15">C14H20FN3OS</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H20FN3OS/c15-12-3-1-11(2-4-12)9-18-7-5-16-13(10-18)14(19)17-6-8-20/h1-4,13,16,20H,5-10H2,(H,17,19)/t13-/m0/s1</data>
  <data key="d20">[H][C@]1(CN(CC2=CC=C(F)C=C2)CCN1)C(=O)NCCS</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07734">
  <data key="d0">N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide</data>
  <data key="d1">drugbank.DB07734</data>
  <data key="d2">[drugbank.DB07734]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide</data>
  <data key="d15">C16H24N2OS</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H24N2OS/c19-16(7-4-12-20)17-15-8-10-18(11-9-15)13-14-5-2-1-3-6-14/h1-3,5-6,15,20H,4,7-13H2,(H,17,19)</data>
  <data key="d20">SCCCC(=O)NC1CCN(CC2=CC=CC=C2)CC1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07737">
  <data key="d0">(2S)-4-(4-fluorobenzyl)-N-(3-sulfanylpropyl)piperazine-2-carboxamide</data>
  <data key="d1">drugbank.DB07737</data>
  <data key="d2">[drugbank.DB07737]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-4-[(4-fluorophenyl)methyl]-N-(3-sulfanylpropyl)piperazine-2-carboxamide</data>
  <data key="d15">C15H22FN3OS</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H22FN3OS/c16-13-4-2-12(3-5-13)10-19-8-7-17-14(11-19)15(20)18-6-1-9-21/h2-5,14,17,21H,1,6-11H2,(H,18,20)/t14-/m0/s1</data>
  <data key="d20">[H][C@]1(CN(CC2=CC=C(F)C=C2)CCN1)C(=O)NCCCS</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07738">
  <data key="d0">N-[1-(5-bromo-2,3-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide</data>
  <data key="d1">drugbank.DB07738</data>
  <data key="d2">[drugbank.DB07738]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-{1-[(5-bromo-2,3-dimethoxyphenyl)methyl]piperidin-4-yl}-4-sulfanylbutanamide</data>
  <data key="d15">C18H27BrN2O3S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H27BrN2O3S/c1-23-16-11-14(19)10-13(18(16)24-2)12-21-7-5-15(6-8-21)20-17(22)4-3-9-25/h10-11,15,25H,3-9,12H2,1-2H3,(H,20,22)</data>
  <data key="d20">COC1=C(OC)C(CN2CCC(CC2)NC(=O)CCCS)=CC(Br)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07756">
  <data key="d0">1-[3-({[(4-AMINO-5-FLUORO-2-METHYLQUINOLIN-3-YL)METHYL]THIO}METHYL)PHENYL]-2,2,2-TRIFLUOROETHANE-1,1-DIOL</data>
  <data key="d1">drugbank.DB07756</data>
  <data key="d2">[drugbank.DB07756]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">1-[3-({[(4-amino-5-fluoro-2-methylquinolin-3-yl)methyl]sulfanyl}methyl)phenyl]-2,2,2-trifluoroethane-1,1-diol</data>
  <data key="d15">C20H18F4N2O2S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H18F4N2O2S/c1-11-14(18(25)17-15(21)6-3-7-16(17)26-11)10-29-9-12-4-2-5-13(8-12)19(27,28)20(22,23)24/h2-8,27-28H,9-10H2,1H3,(H2,25,26)</data>
  <data key="d20">CC1=C(CSCC2=CC(=CC=C2)C(O)(O)C(F)(F)F)C(N)=C2C(F)=CC=CC2=N1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07701">
  <data key="d0">1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON-2-YL)METHYL]PIPERIDINE</data>
  <data key="d1">drugbank.DB07701</data>
  <data key="d2">[drugbank.DB07701]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2R)-2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one</data>
  <data key="d15">C24H29NO3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3/t20-/m1/s1</data>
  <data key="d20">[H][C@@]1(CC2CCN(CC3=CC=CC=C3)CC2)CC2=CC(OC)=C(OC)C=C2C1=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07707">
  <data key="d0">(9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL</data>
  <data key="d1">drugbank.DB07707</data>
  <data key="d2">[drugbank.DB07707]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(1R,10S,11S,14S,15S,17S)-17-(methoxymethyl)-15-methyltetracyclo[8.7.0.0,.0,]heptadeca-2,4,6-triene-5,14-diol</data>
  <data key="d15">C20H28O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H28O3/c1-20-10-13(11-23-2)19-15-6-4-14(21)9-12(15)3-5-16(19)17(20)7-8-18(20)22/h4,6,9,13,16-19,21-22H,3,5,7-8,10-11H2,1-2H3/t13-,16+,17+,18+,19-,20+/m1/s1</data>
  <data key="d20">[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])[C@@]([H])(COC)C[C@]12C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07708">
  <data key="d0">3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL</data>
  <data key="d1">drugbank.DB07708</data>
  <data key="d2">[drugbank.DB07708]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-chloro-2-(4-hydroxyphenyl)-2H-indazol-5-ol</data>
  <data key="d15">C13H9ClN2O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H9ClN2O2/c14-13-11-7-10(18)5-6-12(11)15-16(13)8-1-3-9(17)4-2-8/h1-7,17-18H</data>
  <data key="d20">OC1=CC=C(C=C1)N1N=C2C=CC(O)=CC2=C1Cl</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07720">
  <data key="d0">Epibatidine</data>
  <data key="d1">drugbank.DB07720</data>
  <data key="d2">[drugbank.DB07720]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Analgesics, Analgesics, Non-Narcotic, Central Nervous System Agents, Cholinergic Agents, Cholinergic Agonists, Neurotransmitter Agents, Nicotinic Agonists, Peripheral Nervous System Agents, Sensory System Agents]</data>
  <data key="d14">(1R,2R,4S)-2-(6-chloropyridin-3-yl)-7-azabicyclo[2.2.1]heptane</data>
  <data key="d15">C11H13ClN2</data>
  <data key="d16">140111-52-0</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H13ClN2/c12-11-4-1-7(6-13-11)9-5-8-2-3-10(9)14-8/h1,4,6,8-10,14H,2-3,5H2/t8-,9+,10+/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@@]([H])(N1)[C@]([H])(C2)C1=CC=C(Cl)N=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(+)-epibatidine, (1R, 2R, 4S)-epibatidine]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07712">
  <data key="d0">3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL</data>
  <data key="d1">drugbank.DB07712</data>
  <data key="d2">[drugbank.DB07712]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-ethyl-2-(4-hydroxyphenyl)-2H-indazol-5-ol</data>
  <data key="d15">C15H14N2O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H14N2O2/c1-2-15-13-9-12(19)7-8-14(13)16-17(15)10-3-5-11(18)6-4-10/h3-9,18-19H,2H2,1H3</data>
  <data key="d20">CCC1=C2C=C(O)C=CC2=NN1C1=CC=C(O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07718">
  <data key="d0">3-(4-HYDROXY-PHENYL)PYRUVIC ACID</data>
  <data key="d1">drugbank.DB07718</data>
  <data key="d2">[drugbank.DB07718]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-(4-hydroxyphenyl)-2-oxopropanoic acid</data>
  <data key="d15">C9H8O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H8O4/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,10H,5H2,(H,12,13)</data>
  <data key="d20">OC(=O)C(=O)CC1=CC=C(O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05150">
  <data key="d0">CAD106</data>
  <data key="d1">drugbank.DB05150</data>
  <data key="d2">[drugbank.DB05150]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in alzheimer's disease.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06495">
  <data key="d0">Onercept</data>
  <data key="d1">drugbank.DB06495</data>
  <data key="d2">[drugbank.DB06495]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Antigens, Antigens, CD, Antigens, Differentiation, Antigens, Surface, Biological Factors, Biomarkers, Membrane Proteins, Polyethylene Glycols, Proteins, Receptors, Cell Surface, Receptors, Cytokine, Receptors, Death Domain, Receptors, Immunologic, Receptors, Tumor Necrosis Factor, Recombinant Proteins]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">199685-57-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[R-HTBP-1]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05184">
  <data key="d0">XL228</data>
  <data key="d1">drugbank.DB05184</data>
  <data key="d2">[drugbank.DB05184]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in leukemia (lymphoid) and leukemia (myeloid).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases  targets that play crucial roles in cancer cell proliferation, survival and metastasis.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05187">
  <data key="d0">Elafibranor</data>
  <data key="d1">drugbank.DB05187</data>
  <data key="d2">[drugbank.DB05187]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Acyclic, Benzopyrans, Chromones, Fatty Acids, Fatty Acids, Volatile, Flavonoids, Ketones, Lipids, PPAR alpha, agonists, PPAR delta, agonists, Propiophenones, Pyrans]</data>
  <data key="d14">2-{2,6-dimethyl-4-[(1E)-3-[4-(methylsulfanyl)phenyl]-3-oxoprop-1-en-1-yl]phenoxy}-2-methylpropanoic acid</data>
  <data key="d15">C22H24O4S</data>
  <data key="d16">923978-27-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+</data>
  <data key="d20">CSC1=CC=C(C=C1)C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1</data>
  <data key="d21">Investigated for use/treatment in atherosclerosis and diabetes mellitus type 2.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Elafibranor (code name GFT505) is a multimodal and pluripotent medication for treatment of atherogenic dyslipidemia for an overweight patient with or without diabetes. It is an oral treatment that acts on the 3 sub-types of PPAR (PPARa, PPARg, PPARd) with a preferential action on PPARa. As of February 2016, elafibranor has completed 8 clinical trials and a phase III is in progress.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06444">
  <data key="d0">Dexanabinol</data>
  <data key="d1">drugbank.DB06444</data>
  <data key="d2">[drugbank.DB06444]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Antiemetics, Autonomic Agents, Cannabinoids and similars, Cardiovascular Agents, Central Nervous System Agents, Compounds used in a research, industrial, or household setting, Excitatory Amino Acid Agents, Excitatory Amino Acid Antagonists, Gastrointestinal Agents, Neuroprotective Agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Protective Agents, Terpenes]</data>
  <data key="d14">(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6H,6aH,7H,10H,10aH-benzo[c]isochromen-1-ol</data>
  <data key="d15">C25H38O3</data>
  <data key="d16">112924-45-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C25H38O3/c1-6-7-8-9-12-24(2,3)18-14-21(27)23-19-13-17(16-26)10-11-20(19)25(4,5)28-22(23)15-18/h10,14-15,19-20,26-27H,6-9,11-13,16H2,1-5H3/t19-,20-/m0/s1</data>
  <data key="d20">CCCCCCC(C)(C)C1=CC(O)=C2[C@H]3CC(CO)=CC[C@@H]3C(C)(C)OC2=C1</data>
  <data key="d21">Investigated for use/treatment in traumatic brain injuries and neurologic disorders.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Sinnabidol]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05120">
  <data key="d0">AT1391</data>
  <data key="d1">drugbank.DB05120</data>
  <data key="d2">[drugbank.DB05120]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in diabetes mellitus type 1 and 2.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05115">
  <data key="d0">NN344</data>
  <data key="d1">drugbank.DB05115</data>
  <data key="d2">[drugbank.DB05115]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Blood Glucose Lowering Agents, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Insulin, Pancreatic Hormones, Peptide Hormones, Peptides, Proinsulin, Protein Precursors, Proteins]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in diabetes mellitus type 1 and 2.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile. The product is intended for basal insulin treatment of diabetes mellitus.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05133">
  <data key="d0">VP025</data>
  <data key="d1">drugbank.DB05133</data>
  <data key="d2">[drugbank.DB05133]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in alzheimer's disease and inflammatory disorders (unspecified).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation. VP025 may inhibit immune system activation and protect motoneurons from injury. It also shows the ability to reduce inflammation across the blood-brain barrier and improve correlates of memory and learning function. It is being developed to target the chronic inflammation within the central nervous system that is associated with a number of neurological diseases, including Alzheimers disease, Parkinsons disease, and amyotrophic lateral sclerosis (Lou Gehrigs disease). It is considered to be a systemic anti-inflammatory and neuroprotective agent.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07796">
  <data key="d0">(3ASR,4RS,8ASR,8BRS)-4-(2-(4-FLUOROBENZYL)-1,3-DIOXODEACAHYDROPYRROLO[3,4-A] PYRROLIZIN-4-YL)BENZAMIDINE</data>
  <data key="d1">drugbank.DB07796</data>
  <data key="d2">[drugbank.DB07796]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">({4-[(3aS,4R,8aS,8bR)-2-[(4-fluorophenyl)methyl]-1,3-dioxo-decahydropyrrolo[3,4-a]pyrrolizin-4-yl]phenyl}(amino)methylidene)azanium</data>
  <data key="d15">C23H24FN4O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H23FN4O2/c24-16-9-3-13(4-10-16)12-28-22(29)18-17-2-1-11-27(17)20(19(18)23(28)30)14-5-7-15(8-6-14)21(25)26/h3-10,17-20H,1-2,11-12H2,(H3,25,26)/p+1/t17-,18-,19-,20-/m0/s1</data>
  <data key="d20">[H][C@@]12CCC[N@@]1[C@@]([H])(C1=CC=C(C=C1)C(N)=[NH2+])[C@@]1([H])C(=O)N(CC3=CC=C(F)C=C3)C(=O)[C@@]21[H]</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05137">
  <data key="d0">Lobeline</data>
  <data key="d1">drugbank.DB05137</data>
  <data key="d2">[drugbank.DB05137]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Alkaloids, Autonomic Agents, Cholinergic Agents, Cholinergic Agonists, Ganglionic Stimulants, Neurotransmitter Agents, Nicotinic Agonists, Peripheral Nervous System Agents, Piperidines, Respiratory System Agents]</data>
  <data key="d14">2-[(2R,6S)-6-[(2S)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethan-1-one</data>
  <data key="d15">C22H27NO2</data>
  <data key="d16">90-69-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H27NO2/c1-23-19(15-21(24)17-9-4-2-5-10-17)13-8-14-20(23)16-22(25)18-11-6-3-7-12-18/h2-7,9-12,19-21,24H,8,13-16H2,1H3/t19-,20+,21-/m0/s1</data>
  <data key="d20">CN1[C@H](C[C@H](O)C2=CC=CC=C2)CCC[C@@H]1CC(=O)C1=CC=CC=C1</data>
  <data key="d21">Investigated for use/treatment in addictions.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Lobelina]</data>
  <data key="d9">An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07400">
  <data key="d0">1-ETHOXYCARBONYL-D-PHE-PRO-2(4-AMINOBUTYL)HYDRAZINE</data>
  <data key="d1">drugbank.DB07400</data>
  <data key="d2">[drugbank.DB07400]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">ethyl N-[(2R)-1-[(2S)-2-[N'-(4-aminobutyl)hydrazinecarbonyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]carbamate</data>
  <data key="d15">C21H33N5O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H33N5O4/c1-2-30-21(29)24-17(15-16-9-4-3-5-10-16)20(28)26-14-8-11-18(26)19(27)25-23-13-7-6-12-22/h3-5,9-10,17-18,23H,2,6-8,11-15,22H2,1H3,(H,24,29)(H,25,27)/t17-,18+/m1/s1</data>
  <data key="d20">[H][C@](CC1=CC=CC=C1)(NC(=O)OCC)C(=O)N1CCC[C@@]1([H])C(=O)NNCCCCN</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06168">
  <data key="d0">Canakinumab</data>
  <data key="d1">drugbank.DB06168</data>
  <data key="d2">[drugbank.DB06168]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents reducing cytokine levels, Amino Acids, Peptides, and Proteins, Antibodies, Antineoplastic and Immunomodulating Agents, Blood Proteins, Globulins, Immunoglobulins, Immunoproteins, Immunosuppressive Agents, Interleukin Inhibitors, Interleukin-1beta, antagonists &amp; inhibitors, Proteins, Serum Globulins]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">914613-48-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Used in patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA).</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;c4d7a32d-fcd2-4195-83c9-fbacb052b59f 8836_H|canakinumab|Homo sapiens||H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217-231)+CH2(232-341)+CH3(342-448))|||||||448||||MW 49253.6|MW 49253.6|\nQVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK, &gt;cd245236-d63c-4bb5-b3da-c276131dcec1 8836_L|canakinumab|Homo sapiens||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23357.9|MW 23357.9|\nQVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLEIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC]</data>
  <data key="d8">[]</data>
  <data key="d9">Canakinumab is a recombinant, human anti-human-IL-1 monoclonal antibody that belongs to the IgG1/ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1 and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07461">
  <data key="d0">3-AMINO-3-BENZYL-9-CARBOXAMIDE[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE</data>
  <data key="d1">drugbank.DB07461</data>
  <data key="d2">[drugbank.DB07461]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(1S,7S)-7-amino-7-benzyl-8-oxo-hexahydro-1H-pyrazolidino[1,2-a]pyridazine-1-carbaldehyde</data>
  <data key="d15">C15H19N3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H19N3O2/c16-15(10-12-4-2-1-3-5-12)7-9-17-8-6-13(11-19)18(17)14(15)20/h1-5,11,13H,6-10,16H2/t13-,15+/m0/s1</data>
  <data key="d20">[H][C@]1(CCN2CC[C@@](N)(CC3=CC=CC=C3)C(=O)N12)C=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07474">
  <data key="d0">3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE</data>
  <data key="d1">drugbank.DB07474</data>
  <data key="d2">[drugbank.DB07474]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-[6-(1H-imidazol-1-yl)-4-methyl-1H-1,3-benzodiazol-2-yl]-4-[(pyridin-2-ylmethyl)amino]-1,2-dihydropyridin-2-one</data>
  <data key="d15">C22H19N7O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H19N7O/c1-14-10-16(29-9-8-23-13-29)11-18-20(14)28-21(27-18)19-17(5-7-25-22(19)30)26-12-15-4-2-3-6-24-15/h2-11,13H,12H2,1H3,(H,27,28)(H2,25,26,30)</data>
  <data key="d20">CC1=CC(=CC2=C1N=C(N2)C1=C(NCC2=NC=CC=C2)C=CNC1=O)N1C=CN=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06151">
  <data key="d0">Acetylcysteine</data>
  <data key="d1">drugbank.DB06151</data>
  <data key="d2">[drugbank.DB06151, drugbank.DB05436]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Amino Acids, Amino Acids, Neutral, Amino Acids, Peptides, and Proteins, Amino Acids, Sulfur, Anti-Infective Agents, Antidote for Acetaminophen Overdose, Antidotes, Antioxidants, Compounds used in a research, industrial, or household setting, Cough and Cold Preparations, Cysteine, Decreased Respiratory Secretion Viscosity, Expectorants, Free Radical Scavengers, Increased Glutathione Concentration, OATP1B1/SLCO1B1 Inhibitors, Ophthalmologicals, Protective Agents, Reduction Activity, Respiratory System Agents, Sensory Organs, Sulfhydryl Compounds, Sulfur Compounds]</data>
  <data key="d14">(2R)-2-acetamido-3-sulfanylpropanoic acid</data>
  <data key="d15">C5H9NO3S</data>
  <data key="d16">616-91-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1</data>
  <data key="d20">CC(=O)N[C@@H](CS)C(O)=O</data>
  <data key="d21">Acetylcysteine is used mainly as a mucolytic and in the management of paracetamol (acetaminophen) overdose.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(2R)-2-acetylamino-3-sulfanylpropanoic acid, (R)-2-acetylamino-3-mercaptopropanoic acid, (R)-mercapturic acid, Acetilcisteina, Acetylcysteine, Acetylcysteinum, L-acetylcysteine, L--acetamido--mercaptopropionic acid, Mercapturic acid, N-acetyl-L-(+)-cysteine, N-acetyl-L-cysteine, N-acetylcysteine, NAC]</data>
  <data key="d9">Acetylcysteine (also known as N-acetylcysteine or N-acetyl-L-cysteine or NAC) is primarily used as a mucolytic agent and in the management of acetaminophen poisoning.  It is a derivative of cysteine with an acetyl group attached to the amino group of cysteine.  NAC is essentially a prodrug that is converted to cysteine (in the intestine by the enzyme aminoacylase 1) and absorbed in the intestine into the blood stream.  Cysteine is a key constituent to glutathione and hence administration of acetylcysteine replenishes glutathione stores. Acetylcysteine can also be used as a general antioxidant which can help mitigate symptoms for a variety of diseases exacerbated by reactive oxygen species (ROS). For instance, acetylcysteine is commonly used in individuals with renal impairment to prevent the precipitation of acute renal failure. Acetylcysteine has been shown to have efficacy in treating mild to moderate traumatic brain injury including ischemic brain injury, particularly in reducing neuronal losses, and also reducing cognitive and neurological symptoms when administered promptly after injury. N-acetylcysteine is now widely used in the treatment of HIV, and it has reported efficacy in chronic obstructive pulmonary disease and contrast-induced nephropathy. Acetylcysteine is also being successfully used to treat a variety of neuropsychiatric and neurodegenerative disorders including cocaine, cannabis, and smoking addictions, Alzheimer's and Parkinson's diseases, autism, compulsive and grooming disorders, schizophrenia, depression, and bipolar disorder.  Recent data also shows that N-acetylcysteine inhibits muscle fatigue and can be used to enhance performance in endurance events and in exercise and endurance training.\n\nAcetylcysteine is also undergoing clinical trials as RK-0202, an oral rinse for the prevention and treatment of mucositis. It is comprised of acetylcysteine in a polymer matrix.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06155">
  <data key="d0">Rimonabant</data>
  <data key="d1">drugbank.DB06155</data>
  <data key="d2">[drugbank.DB06155]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents producing tachycardia, Alimentary Tract and Metabolism, Antiobesity Preparations, Excl. Diet Products, Cannabinoid Receptor Antagonists, Cannabinoids and similars, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Neurotransmitter Agents, Receptor, Cannabinoid, CB1, antagonists &amp; inhibitors]</data>
  <data key="d14">5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide</data>
  <data key="d15">C22H21Cl3N4O</data>
  <data key="d16">168273-06-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)</data>
  <data key="d20">CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(Cl)C=C1</data>
  <data key="d21">For use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m&lt;sup&gt;2&lt;/sup&gt;, or patients wih a BMI greater than 27 kg/m&lt;sup&gt;2&lt;/sup&gt; with associated risk factors, such as type 2 diabetes or dyslipidaemia.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil.  It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08737">
  <data key="d0">(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL</data>
  <data key="d1">drugbank.DB08737</data>
  <data key="d2">[drugbank.DB08737]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2R,6S,7R)-7-(4-hydroxyphenyl)-8-oxatricyclo[7.4.0.0,]trideca-1(13),9,11-trien-13-ol</data>
  <data key="d15">C18H18O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H18O3/c19-12-9-7-11(8-10-12)18-14-4-1-3-13(14)17-15(20)5-2-6-16(17)21-18/h2,5-10,13-14,18-20H,1,3-4H2/t13-,14+,18+/m1/s1</data>
  <data key="d20">[H][C@@]12CCC[C@]1([H])[C@@]([H])(OC1=CC=CC(O)=C21)C1=CC=C(O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07415">
  <data key="d0">4-[(1S)-1-(3-fluoro-4-methoxyphenyl)-2-(2-methoxy-5-nitrophenyl)ethyl]-1H-imidazol-2-amine</data>
  <data key="d1">drugbank.DB07415</data>
  <data key="d2">[drugbank.DB07415]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-[(1S)-1-(3-fluoro-4-methoxyphenyl)-2-(2-methoxy-5-nitrophenyl)ethyl]-1H-imidazol-2-amine</data>
  <data key="d15">C19H19FN4O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H19FN4O4/c1-27-17-6-4-13(24(25)26)7-12(17)8-14(16-10-22-19(21)23-16)11-3-5-18(28-2)15(20)9-11/h3-7,9-10,14H,8H2,1-2H3,(H3,21,22,23)/t14-/m0/s1</data>
  <data key="d20">[H][C@@](CC1=CC(=CC=C1OC)[N+]([O-])=O)(C1=CNC(N)=N1)C1=CC=C(OC)C(F)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08749">
  <data key="d0">3-(2-AMINO-6-BENZOYLQUINAZOLIN-3(4H)-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE</data>
  <data key="d1">drugbank.DB08749</data>
  <data key="d2">[drugbank.DB08749]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-(2-amino-6-benzoyl-3,4-dihydroquinazolin-3-yl)-N-cyclohexyl-N-methylpropanamide</data>
  <data key="d15">C25H30N4O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C25H30N4O2/c1-28(21-10-6-3-7-11-21)23(30)14-15-29-17-20-16-19(12-13-22(20)27-25(29)26)24(31)18-8-4-2-5-9-18/h2,4-5,8-9,12-13,16,21H,3,6-7,10-11,14-15,17H2,1H3,(H2,26,27)</data>
  <data key="d20">CN(C1CCCCC1)C(=O)CCN1CC2=CC(=CC=C2N=C1N)C(=O)C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08760">
  <data key="d0">(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid</data>
  <data key="d1">drugbank.DB08760</data>
  <data key="d2">[drugbank.DB08760]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid</data>
  <data key="d15">C15H13ClO3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H13ClO3/c16-12-6-8-13(9-7-12)19-14(15(17)18)10-11-4-2-1-3-5-11/h1-9,14H,10H2,(H,17,18)/t14-/m0/s1</data>
  <data key="d20">[H][C@@](CC1=CC=CC=C1)(OC1=CC=C(Cl)C=C1)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08773">
  <data key="d0">RALOXIFENE CORE</data>
  <data key="d1">drugbank.DB08773</data>
  <data key="d2">[drugbank.DB08773]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-(4-hydroxyphenyl)-1-benzothiophen-6-ol</data>
  <data key="d15">C14H10O2S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H10O2S/c15-11-4-1-9(2-5-11)13-7-10-3-6-12(16)8-14(10)17-13/h1-8,15-16H</data>
  <data key="d20">OC1=CC=C(C=C1)C1=CC2=C(S1)C=C(O)C=C2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07440">
  <data key="d0">4-TERT-BUTYLBENZENESULFONIC ACID</data>
  <data key="d1">drugbank.DB07440</data>
  <data key="d2">[drugbank.DB07440]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-tert-butylbenzene-1-sulfonic acid</data>
  <data key="d15">C10H14O3S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H14O3S/c1-10(2,3)8-4-6-9(7-5-8)14(11,12)13/h4-7H,1-3H3,(H,11,12,13)</data>
  <data key="d20">CC(C)(C)C1=CC=C(C=C1)S(O)(=O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07512">
  <data key="d0">7-[(3-CHLOROBENZYL)OXY]-2-OXO-2H-CHROMENE-4-CARBALDEHYDE</data>
  <data key="d1">drugbank.DB07512</data>
  <data key="d2">[drugbank.DB07512]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">7-[(3-chlorophenyl)methoxy]-2-oxo-2H-chromene-4-carbaldehyde</data>
  <data key="d15">C17H11ClO4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H11ClO4/c18-13-3-1-2-11(6-13)10-21-14-4-5-15-12(9-19)7-17(20)22-16(15)8-14/h1-9H,10H2</data>
  <data key="d20">ClC1=CC=CC(COC2=CC=C3C(OC(=O)C=C3C=O)=C2)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08841">
  <data key="d0">Tyramine</data>
  <data key="d1">drugbank.DB08841</data>
  <data key="d2">[drugbank.DB08841]</data>
  <data key="d12">[investigational, nutraceutical]</data>
  <data key="d13">[Adrenergic Agents, Agents producing tachycardia, Agents that produce hypertension, Amines, Autonomic Agents, Biogenic Amines, Biogenic Monoamines, Membrane Transport Modulators, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Peripheral Nervous System Agents, Sympathomimetics]</data>
  <data key="d14">4-(2-aminoethyl)phenol</data>
  <data key="d15">C8H11NO</data>
  <data key="d16">51-67-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C8H11NO/c9-6-5-7-1-3-8(10)4-2-7/h1-4,10H,5-6,9H2</data>
  <data key="d20">NCCC1=CC=C(O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Tyramine (4-hydroxyphenethylamine; para-tyramine, mydrial or uteramin) is a naturally occurring monoamine compound and trace amine derived from the amino acid tyrosine. Tyramine acts by inducing the release of catecholamine. An important characteristic of this product is its impediment to cross the blood-brain barrier which restrains its side effects to only nonpsychoactive peripheral sympathomimetic effects. There have been reports of hypertensive crisis in patients ingesting tyramine-rich diet in conjunction with monoamine oxidase inhibitors (MAOIs).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08836">
  <data key="d0">Temocapril</data>
  <data key="d1">drugbank.DB08836</data>
  <data key="d2">[drugbank.DB08836]</data>
  <data key="d12">[experimental, investigational]</data>
  <data key="d13">[Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Azepines, Cardiovascular Agents, Enzyme Inhibitors, OATP1B1/SLCO1B1 Substrates, Protease Inhibitors, Sulfur Compounds, Thiepins]</data>
  <data key="d14">2-[(2S,6R)-6-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-5-oxo-2-(thiophen-2-yl)-1,4-thiazepan-4-yl]acetic acid</data>
  <data key="d15">C23H28N2O5S2</data>
  <data key="d16">111902-57-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)/t17-,18-,20-/m0/s1</data>
  <data key="d20">CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)C1=CC=CS1</data>
  <data key="d21">Temocapril is an ACE inhibitor primarily indicated in the treatment of hypertension and congestive heart failure, diabetic nephropathy, and improvement of prognosis for coronary artery diseases (including acute myocardial infarction).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Temocaprilum]</data>
  <data key="d9">Temocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea. Temocapril can also be used in hemodialysis patients without risk of serious accumulation.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07508">
  <data key="d0">4-(5-BENZENESULFONYLAMINO-1-METHYL-1H-BENZOIMIDAZOL-2-YLMETHYL)-BENZAMIDINE</data>
  <data key="d1">drugbank.DB07508</data>
  <data key="d2">[drugbank.DB07508]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-[(5-benzenesulfonamido-1-methyl-1H-1,3-benzodiazol-2-yl)methyl]benzene-1-carboximidamide</data>
  <data key="d15">C22H21N5O2S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H21N5O2S/c1-27-20-12-11-17(26-30(28,29)18-5-3-2-4-6-18)14-19(20)25-21(27)13-15-7-9-16(10-8-15)22(23)24/h2-12,14,26H,13H2,1H3,(H3,23,24)</data>
  <data key="d20">CN1C(CC2=CC=C(C=C2)C(N)=N)=NC2=C1C=CC(NS(=O)(=O)C1=CC=CC=C1)=C2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07509">
  <data key="d0">difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron</data>
  <data key="d1">drugbank.DB07509</data>
  <data key="d2">[drugbank.DB07509]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">12-(4-carboxybutyl)-2,2-difluoro-4-octyl-1,3-diaza-2-boratricyclo[7.3.0.0,]dodeca-1(12),4,6,8,10-pentaen-1-ylium-2-uide</data>
  <data key="d15">C22H31BF2N2O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H31BF2N2O2/c1-2-3-4-5-6-7-10-18-13-15-20-17-21-16-14-19(11-8-9-12-22(28)29)27(21)23(24,25)26(18)20/h13-17H,2-12H2,1H3,(H,28,29)</data>
  <data key="d20">CCCCCCCCC1=CC=C2C=C3C=CC(CCCCC(O)=O)=[N+]3[B-](F)(F)N12</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07522">
  <data key="d0">N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]NAPHTHALENE-2-SULFONAMIDE</data>
  <data key="d1">drugbank.DB07522</data>
  <data key="d2">[drugbank.DB07522]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2R,3S)-3-amino-2-hydroxy-S-(naphthalen-2-yl)-4-phenylbutane-1-sulfonamido</data>
  <data key="d15">C20H22N2O3S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H22N2O3S/c21-19(12-15-6-2-1-3-7-15)20(23)14-22-26(24,25)18-11-10-16-8-4-5-9-17(16)13-18/h1-11,13,19-20,22-23H,12,14,21H2/t19-,20+/m0/s1</data>
  <data key="d20">[H][C@](N)(CC1=CC=CC=C1)[C@]([H])(O)CNS(=O)(=O)C1=CC=C2C=CC=CC2=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07521">
  <data key="d0">6-CHLORO-1-(2-{[(5-CHLORO-1-BENZOTHIEN-3-YL)METHYL]AMINO}ETHYL)-3-[(2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL</data>
  <data key="d1">drugbank.DB07521</data>
  <data key="d2">[drugbank.DB07521]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(6S)-6-chloro-1-(2-{[(5-chloro-1-benzothiophen-3-yl)methyl]amino}ethyl)-3-({2-[(2R)-piperidin-2-yl]ethyl}imino)piperazin-2-ol</data>
  <data key="d15">C22H31Cl2N5OS</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H31Cl2N5OS/c23-16-4-5-19-18(11-16)15(14-31-19)12-25-9-10-29-20(24)13-28-21(22(29)30)27-8-6-17-3-1-2-7-26-17/h4-5,11,14,17,20,22,25-26,30H,1-3,6-10,12-13H2,(H,27,28)/t17-,20-,22?/m1/s1</data>
  <data key="d20">[H][C@]1(CCN=C2NC[C@]([H])(Cl)N(CCNCC3=CSC4=C3C=C(Cl)C=C4)C2([H])O)CCCCN1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07515">
  <data key="d0">1-(2-{[(6-AMINO-2-METHYLPYRIDIN-3-YL)METHYL]AMINO}ETHYL)-6-CHLORO-3-[(2,2-DIFLUORO-2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL</data>
  <data key="d1">drugbank.DB07515</data>
  <data key="d2">[drugbank.DB07515]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">1-[2-({[(6R)-6-amino-2-methylpiperidin-3-yl]methyl}amino)ethyl]-6-chloro-3-{[2,2-difluoro-2-(pyridin-2-yl)ethyl]amino}-1,2-dihydropyrazin-2-ol</data>
  <data key="d15">C20H30ClF2N7O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H30ClF2N7O/c1-13-14(5-6-17(24)29-13)10-25-8-9-30-16(21)11-27-18(19(30)31)28-12-20(22,23)15-4-2-3-7-26-15/h2-4,7,11,13-14,17,19,25,29,31H,5-6,8-10,12,24H2,1H3,(H,27,28)/t13?,14?,17-,19?/m1/s1</data>
  <data key="d20">[H][C@]1(N)CCC([H])(CNCCN2C(Cl)=CN=C(NCC(F)(F)C3=CC=CC=N3)C2([H])O)C([H])(C)N1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07513">
  <data key="d0">7-[(3-CHLOROBENZYL)OXY]-4-[(METHYLAMINO)METHYL]-2H-CHROMEN-2-ONE</data>
  <data key="d1">drugbank.DB07513</data>
  <data key="d2">[drugbank.DB07513]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">7-[(3-chlorophenyl)methoxy]-4-[(methylamino)methyl]-2H-chromen-2-one</data>
  <data key="d15">C18H16ClNO3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H16ClNO3/c1-20-10-13-8-18(21)23-17-9-15(5-6-16(13)17)22-11-12-3-2-4-14(19)7-12/h2-9,20H,10-11H2,1H3</data>
  <data key="d20">CNCC1=CC(=O)OC2=C1C=CC(OCC1=CC=CC(Cl)=C1)=C2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07519">
  <data key="d0">(6R)-2-amino-6-[2-(3'-methoxybiphenyl-3-yl)ethyl]-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one</data>
  <data key="d1">drugbank.DB07519</data>
  <data key="d2">[drugbank.DB07519]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(6R)-2-amino-6-{2-[3-(3-methoxyphenyl)phenyl]ethyl}-3,6-dimethyl-3,4,5,6-tetrahydropyrimidin-4-one</data>
  <data key="d15">C21H25N3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H25N3O2/c1-21(14-19(25)24(2)20(22)23-21)11-10-15-6-4-7-16(12-15)17-8-5-9-18(13-17)26-3/h4-9,12-13H,10-11,14H2,1-3H3,(H2,22,23)/t21-/m1/s1</data>
  <data key="d20">COC1=CC(=CC=C1)C1=CC(CC[C@]2(C)CC(=O)N(C)C(N)=N2)=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08807">
  <data key="d0">Bopindolol</data>
  <data key="d1">drugbank.DB08807</data>
  <data key="d2">[drugbank.DB08807]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Beta Blocking Agents, Non-Selective, Bradycardia-Causing Agents, Cytochrome P-450 CYP2D6 Substrates, Neurotransmitter Agents, Phenoxypropanolamines, Propanolamines, Propanols]</data>
  <data key="d14">1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate</data>
  <data key="d15">C23H28N2O3</data>
  <data key="d16">62658-63-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H28N2O3/c1-16-13-19-20(25-16)11-8-12-21(19)27-15-18(14-24-23(2,3)4)28-22(26)17-9-6-5-7-10-17/h5-13,18,24-25H,14-15H2,1-4H3</data>
  <data key="d20">CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1</data>
  <data key="d21">For the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Bopindolol, Bopindololum]</data>
  <data key="d9">Bopindolol (INN) is an ester prodrug for the beta blocker [pindolol].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07573">
  <data key="d0">(2S)-1-(2,5-dimethylphenoxy)-3-morpholin-4-ylpropan-2-ol</data>
  <data key="d1">drugbank.DB07573</data>
  <data key="d2">[drugbank.DB07573]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-1-(2,5-dimethylphenoxy)-3-(morpholin-4-yl)propan-2-ol</data>
  <data key="d15">C15H23NO3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H23NO3/c1-12-3-4-13(2)15(9-12)19-11-14(17)10-16-5-7-18-8-6-16/h3-4,9,14,17H,5-8,10-11H2,1-2H3/t14-/m0/s1</data>
  <data key="d20">[H][C@@](O)(COC1=C(C)C=CC(C)=C1)CN1CCOCC1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07584">
  <data key="d0">N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine</data>
  <data key="d1">drugbank.DB07584</data>
  <data key="d2">[drugbank.DB07584]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine</data>
  <data key="d15">C15H13N7</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H13N7/c1-9-19-15(22-21-9)10-4-2-3-5-12(10)20-14-11-6-7-16-13(11)17-8-18-14/h2-8H,1H3,(H,19,21,22)(H2,16,17,18,20)</data>
  <data key="d20">CC1=NN=C(N1)C1=CC=CC=C1NC1=NC=NC2=C1C=CN2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07585">
  <data key="d0">5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine</data>
  <data key="d1">drugbank.DB07585</data>
  <data key="d2">[drugbank.DB07585]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">5-chloro-4-{1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl}-7H-pyrrolo[2,3-d]pyrimidine</data>
  <data key="d15">C12H11ClN6</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H11ClN6/c13-7-3-14-11-10(7)12(18-6-17-11)19-2-1-8-9(4-19)16-5-15-8/h3,5-6H,1-2,4H2,(H,15,16)(H,14,17,18)</data>
  <data key="d20">ClC1=CNC2=C1C(=NC=N2)N1CCC2=C(C1)N=CN2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06249">
  <data key="d0">Arzoxifene</data>
  <data key="d1">drugbank.DB06249</data>
  <data key="d2">[drugbank.DB06249]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Sulfur Compounds]</data>
  <data key="d14">2-(4-methoxyphenyl)-3-{4-[2-(piperidin-1-yl)ethoxy]phenoxy}-1-benzothiophen-6-ol</data>
  <data key="d15">C28H29NO4S</data>
  <data key="d16">182133-25-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C28H29NO4S/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29/h5-14,19,30H,2-4,15-18H2,1H3</data>
  <data key="d20">COC1=CC=C(C=C1)C1=C(OC2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2</data>
  <data key="d21">Investigated for use/treatment in breast cancer, osteoporosis, and endometrial cancer.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06202">
  <data key="d0">Lasofoxifene</data>
  <data key="d1">drugbank.DB06202</data>
  <data key="d2">[drugbank.DB06202]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Genito Urinary System and Sex Hormones, Naphthalenes, Selective Estrogen Receptor Modulators, Sex Hormones and Modulators of the Genital System]</data>
  <data key="d14">(5R,6S)-6-phenyl-5-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-5,6,7,8-tetrahydronaphthalen-2-ol</data>
  <data key="d15">C28H31NO2</data>
  <data key="d16">180916-16-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2/t26-,28+/m1/s1</data>
  <data key="d20">[H][C@@]1(CCC2=CC(O)=CC=C2[C@@]1([H])C1=CC=C(OCCN2CCCC2)C=C1)C1=CC=CC=C1</data>
  <data key="d21">Investigated for use/treatment in postmenopausal osteoporosis to reduce the risk of both vertebral and novertebral fractures, as well as address other postmenopausal conditions, including reduction in risk of breast cancer and treatment of vulvar and vaginal atrophy (VVA)</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(-)-cis-5, 6, 7, 8-Tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol]</data>
  <data key="d9">Lasofoxifene is a non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ER and ER with high affinity. It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment of vaginal atrophy. It was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal atrophy, in which were both rejected for approval by FDA. Later Fablyn was developed as a result of a research collaboration between Pfizer and Ligand Pharmaceuticals with a newly submitted New Drug Application in 2008. It gained approval by European Commission in March 2009. Ligand Pharmaceuticals signed a license agreement with Sermonix Pharmaceuticals for the development and commercialization of oral lasofoxifene in the USA.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08865">
  <data key="d0">Crizotinib</data>
  <data key="d1">drugbank.DB08865</data>
  <data key="d2">[drugbank.DB08865, drugbank.DB08700]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Bradycardia-Causing Agents, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P450 3A Inhibitors, Enzyme Inhibitors, Kinase Inhibitor, Moderate Risk QTc-Prolonging Agents, OCT2 Inhibitors, Organic Cation Transporter 1 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, QTc Prolonging Agents, Receptor Tyrosine Kinase Inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d14">3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine</data>
  <data key="d15">C21H22Cl2FN5O</data>
  <data key="d16">877399-52-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1</data>
  <data key="d20">C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl</data>
  <data key="d21">Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(R)-crizotinib, Crizotinib, Crizotinibum]</data>
  <data key="d9">Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07527">
  <data key="d0">N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]-4-METHOXY-2,3,6-TRIMETHYLBENZENESULFONAMIDE</data>
  <data key="d1">drugbank.DB07527</data>
  <data key="d2">[drugbank.DB07527]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2R,3S)-3-amino-2-hydroxy-S-(4-methoxy-2,3,6-trimethylphenyl)-4-phenylbutane-1-sulfonamido</data>
  <data key="d15">C20H28N2O4S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H28N2O4S/c1-13-10-19(26-4)14(2)15(3)20(13)27(24,25)22-12-18(23)17(21)11-16-8-6-5-7-9-16/h5-10,17-18,22-23H,11-12,21H2,1-4H3/t17-,18+/m0/s1</data>
  <data key="d20">[H][C@](N)(CC1=CC=CC=C1)[C@]([H])(O)CNS(=O)(=O)C1=C(C)C=C(OC)C(C)=C1C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08871">
  <data key="d0">Eribulin</data>
  <data key="d1">drugbank.DB08871</data>
  <data key="d2">[drugbank.DB08871, drugbank.DB04940]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Immunosuppressive Agents, Microtubule Inhibition, Microtubule Inhibitors, Myelosuppressive Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents]</data>
  <data key="d14">(1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.1,.1,.1,.1,.0,.0,.0,]hentetracontan-24-one</data>
  <data key="d15">C40H59NO11</data>
  <data key="d16">253128-41-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C40H59NO11/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41/h19,23-39,43H,2-3,5-18,41H2,1,4H3/t19-,23+,24+,25?,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+/m1/s1</data>
  <data key="d20">[H][C@@]12O[C@@]3([H])CCC4CC(=O)C[C@H]5[C@H](C[C@H]6O[C@H](C[C@@H](C)C6=C)CC[C@@H]6O[C@H](CC6=C)CC[C@@]67C[C@@H](O[C@H]1[C@@H](O6)[C@@]3([H])O4)[C@@H]2O7)O[C@H](C[C@H](O)CN)[C@@H]5OC</data>
  <data key="d21">For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Eribulin, Eribulina]</data>
  <data key="d9">Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors [A7439].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07535">
  <data key="d0">2-amino-6-[2-(1H-indol-6-yl)ethyl]pyrimidin-4(3H)-one</data>
  <data key="d1">drugbank.DB07535</data>
  <data key="d2">[drugbank.DB07535]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-amino-6-[2-(1H-indol-6-yl)ethyl]-3,4-dihydropyrimidin-4-one</data>
  <data key="d15">C14H14N4O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H14N4O/c15-14-17-11(8-13(19)18-14)4-2-9-1-3-10-5-6-16-12(10)7-9/h1,3,5-8,16H,2,4H2,(H3,15,17,18,19)</data>
  <data key="d20">NC1=NC(CCC2=CC3=C(C=CN3)C=C2)=CC(=O)N1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07550">
  <data key="d0">2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(1-OXIDO-2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUOROPHENYL)METHYL]ACETAMIDE</data>
  <data key="d1">drugbank.DB07550</data>
  <data key="d2">[drugbank.DB07550]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-(2-{[5-chloro-4-({[(2-fluorophenyl)methyl]carbamoyl}methyl)-3-oxo-3,4-dihydropyrazin-2-yl]amino}-1,1-difluoroethyl)pyridin-1-ium-1-olate</data>
  <data key="d15">C20H17ClF3N5O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H17ClF3N5O3/c21-16-10-26-18(27-12-20(23,24)15-7-3-4-8-29(15)32)19(31)28(16)11-17(30)25-9-13-5-1-2-6-14(13)22/h1-8,10H,9,11-12H2,(H,25,30)(H,26,27)</data>
  <data key="d20">[O-][N+]1=CC=CC=C1C(F)(F)CNC1=NC=C(Cl)N(CC(=O)NCC2=C(F)C=CC=C2)C1=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07555">
  <data key="d0">Hydroxy(oxo)(2-{(1S)-2,2,2-trifluoro-1-[2-(trimethylarsonio)ethoxy]ethyl}phenyl)ammonium</data>
  <data key="d1">drugbank.DB07555</data>
  <data key="d2">[drugbank.DB07555]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">trimethyl({2-[(1S)-2,2,2-trifluoro-1-{2-[hydroxy(oxo)azaniumyl]phenyl}ethoxy]ethyl})arsanium</data>
  <data key="d15">C13H19AsF3NO3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H19AsF3NO3/c1-14(2,3)8-9-21-12(13(15,16)17)10-6-4-5-7-11(10)18(19)20/h4-7,12H,8-9H2,1-3H3,(H,19,20)/q+2/t12-/m0/s1</data>
  <data key="d20">[H][C@](OCC[As+](C)(C)C)(C1=CC=CC=C1[N+](O)=O)C(F)(F)F</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08885">
  <data key="d0">Aflibercept</data>
  <data key="d1">drugbank.DB08885</data>
  <data key="d2">[drugbank.DB08885]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Antineovascularisation Agents, EENT Drugs, Miscellaneous, Enzymes, Enzymes and Coenzymes, Membrane Proteins, Ocular Vascular Disorder Agents, Ophthalmics, Ophthalmologicals, Phosphotransferases, Phosphotransferases (Alcohol Group Acceptor), Protein Kinases, Protein-Tyrosine Kinases, Proteins, Receptor Protein-Tyrosine Kinases, Receptors, Cell Surface, Receptors, Growth Factor, Receptors, Peptide, Recombinant Proteins, Sensory Organs, Transferases, Vascular Endothelial Growth Factor Inhibitor, Vascular Endothelial Growth Factor Inhibitors]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">862111-32-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">The opthalmic agent is used for the treatment of neovascular (wet) age-related mascular degeneration (AMD) and macular edema following central retinal vein occulsion (CRVO). The systemic injection, known as ziv-aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;a4977eea-2753-44b6-91f5-595bb2304e6f  Protein sequence for aflibercept\nSDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG]</data>
  <data key="d8">[Aflibercept, Aflibercept (genetical recombination), Ziv-aflibercept]</data>
  <data key="d9">Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15% glycosylation to give a total molecular weight of 115 kDa. All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrate and exhibit some degree of chain heterogeneity, including heterogeneity in terminal sialic acid residues, except at the single unsialylated site associated with the Fc domain. Aflibercept, as an ophthalmic agent, is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Ziv-aflibercept, under the brand name Zaltrap, was developed as an injection for treatment of metastatic colorectal cancer. FDA approved in November 18, 2011 and EMA approved in November 2012.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07548">
  <data key="d0">2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-6-PYRIDINYL)METHYL]ACETAMIDE</data>
  <data key="d1">drugbank.DB07548</data>
  <data key="d2">[drugbank.DB07548]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-(3-{[2,2-difluoro-2-(pyridin-2-yl)ethyl]amino}-6-methyl-2-oxo-1,2-dihydropyrazin-1-yl)-N-[(3-fluoropyridin-2-yl)methyl]acetamide</data>
  <data key="d15">C20H19F3N6O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H19F3N6O2/c1-13-9-27-18(28-12-20(22,23)16-6-2-3-7-25-16)19(31)29(13)11-17(30)26-10-15-14(21)5-4-8-24-15/h2-9H,10-12H2,1H3,(H,26,30)(H,27,28)</data>
  <data key="d20">CC1=CN=C(NCC(F)(F)C2=CC=CC=N2)C(=O)N1CC(=O)NCC1=C(F)C=CC=N1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06218">
  <data key="d0">Lacosamide</data>
  <data key="d1">drugbank.DB06218</data>
  <data key="d2">[drugbank.DB06218]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Acetates, Acids, Acyclic, Alkanes, Amides, Anti-epileptic Agent, Anticonvulsants, Bradycardia-Causing Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Decreased Central Nervous System Disorganized Electrical Activity, Fatty Acids, Fatty Acids, Volatile, Hydrocarbons, Acyclic, Lipids, Miscellaneous Anticonvulsants, Nervous System]</data>
  <data key="d14">(2R)-N-benzyl-2-acetamido-3-methoxypropanamide</data>
  <data key="d15">C13H18N2O3</data>
  <data key="d16">175481-36-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1</data>
  <data key="d20">COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1</data>
  <data key="d21">Lacosamide is indicated for adjunctive therapy for partial onset seizures in patients with epilepsy over 17 years old. Injection is indicated for short term use when oral therapy is not feasible.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Erlosamide, Harkoseride, Lacosamida, Lacosamide]</data>
  <data key="d9">Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focus of an epileptic seizure, as opposed to other antiepileptic drugs such as carbamazepine or lamotrigine which slow the recovery from inactivation and reduce the ability of neurons to fire action potentials.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07549">
  <data key="d0">2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-3-METHYL-6-PYRIDINYL)METHYL]ACETAMIDE</data>
  <data key="d1">drugbank.DB07549</data>
  <data key="d2">[drugbank.DB07549]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-{[2,2-difluoro-2-(pyridin-1-ium-2-yl)ethyl]amino}-4-({[(3-fluoro-4-methylpyridin-2-yl)methyl]carbamoyl}methyl)-5-methyl-3-oxo-3,4-dihydropyrazin-1-ium</data>
  <data key="d15">C21H23F3N6O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H21F3N6O2/c1-13-6-8-25-15(18(13)22)10-27-17(31)11-30-14(2)9-28-19(20(30)32)29-12-21(23,24)16-5-3-4-7-26-16/h3-9H,10-12H2,1-2H3,(H,27,31)(H,28,29)/p+2</data>
  <data key="d20">CC1=C[NH+]=C(NCC(F)(F)C2=[NH+]C=CC=C2)C(=O)N1CC(=O)NCC1=C(F)C(C)=CC=N1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07567">
  <data key="d0">(2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL</data>
  <data key="d1">drugbank.DB07567</data>
  <data key="d2">[drugbank.DB07567]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2R,3R,4S)-3-(4-hydroxyphenyl)-4-methyl-2-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-3,4-dihydro-2H-1-benzopyran-6-ol</data>
  <data key="d15">C28H31NO4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C28H31NO4/c1-19-25-18-23(31)10-13-26(25)33-28(27(19)20-4-8-22(30)9-5-20)21-6-11-24(12-7-21)32-17-16-29-14-2-3-15-29/h4-13,18-19,27-28,30-31H,2-3,14-17H2,1H3/t19-,27-,28+/m1/s1</data>
  <data key="d20">[H][C@@]1(C)C2=CC(O)=CC=C2O[C@@]([H])(C2=CC=C(OCCN3CCCC3)C=C2)[C@@]1([H])C1=CC=C(O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB08888">
  <data key="d0">Ocriplasmin</data>
  <data key="d1">drugbank.DB08888</data>
  <data key="d2">[drugbank.DB08888, drugbank.DB05028]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, EENT Drugs, Miscellaneous, Endopeptidases, Enzymes, Enzymes and Coenzymes, Hydrolases, Ophthalmics, Ophthalmologicals, Peptide Hydrolases, Peptides, Sensory Organs, Serine Endopeptidases, Serine Proteases]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">1048016-09-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Ocriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;5b1caa45-8fb0-434e-b72d-d7d1fcd41018 Protein sequence for the truncated heavy chain\nAPSFDCGKPQVEPKKCPGR, &gt;6ba48747-2fc8-4c50-b17a-686e284a50ba Protein sequence for the light chain \nVVGGCVAHPHSWPWQVSLRTRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLEPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSRFVTWIEGVMRNN]</data>
  <data key="d8">[Microplasmin, Microplasmin (synthetic human), Ocriplasmina, Recombinant human microplasmin]</data>
  <data key="d9">Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains.  Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06756">
  <data key="d0">Glycine betaine</data>
  <data key="d1">drugbank.DB06756</data>
  <data key="d2">[drugbank.DB06756]</data>
  <data key="d12">[approved, nutraceutical]</data>
  <data key="d13">[Acid Preparations, Alimentary Tract and Metabolism, Amines, Amino Acids and Derivatives, Ammonium Compounds, Cholinesterase Inhibitors, Digestives, Incl. Enzymes, Gastrointestinal Agents, Hypolipidemic Agents, Lipid Regulating Agents, Lipotropic Agents, Methylating Activity, Methylating Agent, Nitrogen Compounds, Noxae, Onium Compounds, Other Miscellaneous Therapeutic Agents, Quaternary Ammonium Compounds, Toxic Actions, Trimethyl Ammonium Compounds]</data>
  <data key="d14">2-(trimethylazaniumyl)acetate</data>
  <data key="d15">C5H11NO2</data>
  <data key="d16">107-43-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C5H11NO2/c1-6(2,3)4-5(7)8/h4H2,1-3H3</data>
  <data key="d20">C[N+](C)(C)CC([O-])=O</data>
  <data key="d21">Betaine is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. Included within the category of homocystinuria are deficiencies or defects in: 1. cystathionine beta-synthase (CBS), 2. 5,10-methylenetetrahydrofolate reductase (MTHFR), 3. cobalamin cofactor metabolism (cbl).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-(Trimethylammonio)Acetate, 2-N, N, N-trimethylammonio acetate, 2-trimethylammonioacetate, abromine, acidol, betana anhidra, Betaine, Betaine, anhydrous, Glycinebetaine, N, N, N-trimethylammonioacetate, N, N, N-Trimethylglycine, TMG, Trimethylaminoacetate, Trimethylammonioacetate, Trimethylglycine, trimethylglycocoll]</data>
  <data key="d9">Betaine is a methyl group donor that functions in the normal metabolic cycle of methionine and reduces homocystinuria in patients with inborn errors of methionine metabolism. In the United States, betaine is distributed under the brand name Cystadane by Rare Disease Therapeutics. Many reports have shown that betaine's therapeutic effectiveness is limited, and does not lower tHcy levels or prevent clinical symptoms [2].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06757">
  <data key="d0">Manganese</data>
  <data key="d1">drugbank.DB06757</data>
  <data key="d2">[drugbank.DB06757]</data>
  <data key="d12">[approved, nutraceutical]</data>
  <data key="d13">[Acids, Acids, Noncarboxylic, Anions, Chlorine Compounds, Diet, Food, and Nutrition, Electrolytes, Elements, Food, Food and Beverages, Growth Substances, Hydrochloric Acid, Ions, Magnetic Resonance Contrast Activity, Metals, Metals, Heavy, Micronutrients, Minerals, Paramagnetic Contrast Agent, Physiological Phenomena, Replacement Preparations, Sulfur Acids, Sulfur Compounds, Sulfuric Acids, Trace Elements, Transition Elements]</data>
  <data key="d14">manganese(2+) ion</data>
  <data key="d15">Mn</data>
  <data key="d16">7439-96-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/Mn/q+2</data>
  <data key="d20">[Mn++]</data>
  <data key="d21">Indicated for use as a supplement to intravenous solutions given for Total Parenteral Nutrition (TPN). Administration helps to maintain plasma levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Manganese is a transition metal with a molar mass of 54.94g/mol. Manganese is considered critical for human health, and plays important roles in development, metabolism, and the antioxidant system. That said, excessive manganese intake is associated with manganism, a neurodegenerative disorder that causes dopaminergic neuronal death and parkinsonian-like symptoms.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05442">
  <data key="d0">Etiprednol dicloacetate</data>
  <data key="d1">drugbank.DB05442</data>
  <data key="d2">[drugbank.DB05442]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists]</data>
  <data key="d14">ethyl (1S,2R,10S,11S,14R,15S,17S)-14-[(2,2-dichloroacetyl)oxy]-17-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-3,6-diene-14-carboxylate</data>
  <data key="d15">C24H30Cl2O6</data>
  <data key="d16">199331-40-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H30Cl2O6/c1-4-31-21(30)24(32-20(29)19(25)26)10-8-16-15-6-5-13-11-14(27)7-9-22(13,2)18(15)17(28)12-23(16,24)3/h7,9,11,15-19,28H,4-6,8,10,12H2,1-3H3/t15-,16-,17-,18+,22-,23-,24-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@](OC(=O)C(Cl)Cl)(C(=O)OCC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C</data>
  <data key="d21">Investigated for use/treatment in asthma and crohn's disease.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Etiprednol dicloacetate (BNP-166) is a soft corticosteroid with anti-inflammatory properties that has been indicated in the treatment of asthma and Chron's disease. Anti-asthmatic effects were associated with decreased cytokine production in lipopolysaccharide-stimulated lymphocytes and attenuated lectin-induced proliferation of blood mononuclear cells in tissue culture.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05434">
  <data key="d0">ABT-510</data>
  <data key="d1">drugbank.DB05434</data>
  <data key="d2">[drugbank.DB05434]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Amino Acids, Peptides, and Proteins, Peptides]</data>
  <data key="d14">(2S)-1-[(2S)-5-[(diaminomethylidene)amino]-2-[(2S,3S)-2-[(2S)-2-[(2S,3R)-3-hydroxy-2-[(2R,3S)-3-methyl-2-[(2S)-3-methyl-2-{2-[2-(N-methylacetamido)acetamido]acetamido}butanamido]pentanamido]butanamido]pentanamido]-3-methylpentanamido]pentanoyl]-N-ethylpyrrolidine-2-carboxamide</data>
  <data key="d15">C46H83N13O11</data>
  <data key="d16">251579-55-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C46H83N13O11/c1-12-18-30(39(64)55-36(26(7)13-2)42(67)53-31(19-16-21-50-46(47)48)45(70)59-22-17-20-32(59)40(65)49-15-4)52-44(69)38(28(9)60)57-43(68)37(27(8)14-3)56-41(66)35(25(5)6)54-33(62)23-51-34(63)24-58(11)29(10)61/h25-28,30-32,35-38,60H,12-24H2,1-11H3,(H,49,65)(H,51,63)(H,52,69)(H,53,67)(H,54,62)(H,55,64)(H,56,66)(H,57,68)(H4,47,48,50)/t26-,27-,28+,30-,31-,32-,35-,36-,37+,38-/m0/s1</data>
  <data key="d20">CCC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN(C)C(C)=O)C(C)C)[C@@H](C)CC)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC</data>
  <data key="d21">Investigated for use/treatment in lymphoma (unspecified), melanoma, and solid tumors.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">ABT-510 is peptide mimetics of thrombospondin-1 (TSP-1), block angiogenesis in vitro and in vivo and slow tumor growth. It is developed by Abbott Laboratories for the treatment of Solid Tumors, Lymphoma and Melanoma.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06782">
  <data key="d0">Dimercaprol</data>
  <data key="d1">drugbank.DB06782</data>
  <data key="d2">[drugbank.DB06782]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Antidotes, Chelating Agents, Compounds used in a research, industrial, or household setting, Drugs that are Mainly Renally Excreted, Heavy Metal Antagonists, Metal Chelating Activity, Metal Chelator, Sequestering Agents, Sulfhydryl Compounds, Sulfur Compounds]</data>
  <data key="d14">2,3-disulfanylpropan-1-ol</data>
  <data key="d15">C3H8OS2</data>
  <data key="d16">59-52-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C3H8OS2/c4-1-3(6)2-5/h3-6H,1-2H2</data>
  <data key="d20">OCC(S)CS</data>
  <data key="d21">For the treatment of arsenic, gold and mercury poisoning. Indicated in acute lead poisoning when used concomitantly with edetate calcium disodium (DB00974).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[1, 2-dimercapto-3-propanol, 1, 2-dithioglycerol, 2, 3-dimercapto-1-propanol, 2, 3-dimercaptol-1-propanol, 2, 3-dimercaptopropanol, 2, 3-dithiopropanol, 2, 3-mercaptopropan-1-ol, 2, 3-Mercaptopropanol, 3-hydroxy-1, 2-propanedithiol, BAL, British anti-lewisite, British antilewisite, Dimercaprol, Dimercaprolum, Dimercaptopropanol, Dithioglycerine, Dithioglycerol, Sulfactin, , -dithioglycerol]</data>
  <data key="d9">Dimercaprol is a traditional chelating agent developed by British biochemists at Oxford University during World War II. It was developed as an experimental antidote against the arsenic-based poison gas Lewisite. It has been used clinically since 1949 in arsenic, cadmium and mercury poisoning. In addition, it has in the past been used for the treatment of Wilson's disease, a genetic disorder in which the body tends to retain copper. Dimercaprol has toxic potential, and its use may be followed by a variety of adverse effects.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04114">
  <data key="d0">3-Chloro-9-Ethyl-6,7,8,9,10,11-Hexahydro-7,11-Methanocycloocta[B]Quinolin-12-Amine</data>
  <data key="d1">drugbank.DB04114</data>
  <data key="d2">[drugbank.DB04114, drugbank.EXPT01796]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(1S,13S)-7-chloro-15-ethyl-10-azatetracyclo[11.3.1.0,.0,]heptadeca-2(11),3,5,7,9,14-hexaen-3-amine</data>
  <data key="d15">C18H19ClN2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H19ClN2/c1-2-10-5-11-7-12(6-10)17-16(8-11)21-15-9-13(19)3-4-14(15)18(17)20/h3-5,9,11-12H,2,6-8H2,1H3,(H2,20,21)/t11-,12+/m0/s1</data>
  <data key="d20">[H][C@]12CC3=C(C(N)=C4C=CC(Cl)=CC4=N3)[C@]([H])(CC(CC)=C1)C2</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06779">
  <data key="d0">Dalteparin</data>
  <data key="d1">drugbank.DB06779</data>
  <data key="d2">[drugbank.DB06779]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents causing hyperkalemia, Anticoagulants, Blood and Blood Forming Organs, Carbohydrates, Cardiovascular Agents, Fibrin Modulating Agents, Fibrinolytic Agents, Glycosaminoglycans, Hematologic Agents, Heparin (Low Molecular Weight), Heparin and similars, Polysaccharides]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">9005-49-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Dalteparin is used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in patients undergoing general surgery (e.g., abdominal, gynecologic, urologic), and in patients with acute medical conditions (e.g. cancer, bed rest, heart failure, severe lung disease). It is also used in patients who have severely restricted mobility, which poses a risk for thromboembolic complications. \n\nDalteparin is also used concomitantly with aspirin and/or other therapy (e.g., nitrates, -adrenergic blockers, clopidogrel, platelet glycoprotein [GP] IIb/IIIa-receptor inhibitors) to reduce the risk of acute cardiac ischemic events. The patients who undergo this treatment combination have unstable angina or non-ST-segment elevation/non-Q-wave myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes).\n\nIt is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[alpha-heparin]</data>
  <data key="d9">Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05458">
  <data key="d0">Pozanicline</data>
  <data key="d1">drugbank.DB05458</data>
  <data key="d2">[drugbank.DB05458]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">2-methyl-3-[(2S)-pyrrolidin-2-ylmethoxy]pyridine</data>
  <data key="d15">C11H16N2O</data>
  <data key="d16">161417-03-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C11H16N2O/c1-9-11(5-3-6-12-9)14-8-10-4-2-7-13-10/h3,5-6,10,13H,2,4,7-8H2,1H3/t10-/m0/s1</data>
  <data key="d20">CC1=C(OC[C@@H]2CCCN2)C=CC=N1</data>
  <data key="d21">Investigated for use/treatment in Alzheimer's disease, Attention Deficit/Hyperactivity Disorder (ADHD), and Schizophrenia and schizoaffective disorders.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">ABT-089 is a neuronal nicotinic acetylcholine receptor agonist that may have therapeutic utility for the treatment of several neurological disorders including Alzheimer, Attention Deficit Hyperactivity Disorder and Schizophrenia/Schizoaffective disorders. In radioligand binding studies, ABT-089 has shown selectivity toward the alpha4beta2 nAChR subtype as compared to the alpha7 and alpha1beta1deltagamma nAChR subtypes. Neuronal nicotinic acetylcholine receptors (nAChRs) modulate the release of several important neurotransmitters, such as acetylcholine and dopamine.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06710">
  <data key="d0">Methyltestosterone</data>
  <data key="d1">drugbank.DB06710</data>
  <data key="d2">[drugbank.DB06710]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[3-Oxoandrosten (4) Derivatives, Anabolic Agents, Androgens, Androgens and Estrogens, Androstanes, Androstenes, Androstenols, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Drugs that are Mainly Renally Excreted, Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, OAT3/SLC22A8 Inducers, Sex Hormones and Modulators of the Genital System, Steroids, Testosterone Congeners]</data>
  <data key="d14">(1S,2R,10R,11S,14S,15S)-14-hydroxy-2,14,15-trimethyltetracyclo[8.7.0.0,.0,]heptadec-6-en-5-one</data>
  <data key="d15">C20H30O2</data>
  <data key="d16">58-18-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,15-17,22H,4-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1</data>
  <data key="d20">[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C</data>
  <data key="d21">Methyltestosterone is an anabolic steroid hormone used to treat men with a testosterone deficiency. It is also used in women to treat breast cancer, breast pain, swelling due to pregnancy, and with the addition of estrogen it can treat symptoms of menopause.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[17-beta-Hydroxy-17-methylandrost-4-en-3-one, 17-methyltestosterone, 17alpha-Methyl-3-oxo-4-androsten-17beta-ol, 17alpha-Methyltestosterone, 17beta-Hydroxy-17-methylandrost-4-en-3-one, 17-methyl-4-androsten-17-ol-3-one, 17-methyltestosterone, 4-Androstene-17alpha-methyl-17beta-ol-3-one, Methyltestosterone, Methyltestosteronum, Metiltestosterona]</data>
  <data key="d9">A synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement therapies. Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Methyltestosterone is a schedule III drug in the US.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06718">
  <data key="d0">Stanozolol</data>
  <data key="d1">drugbank.DB06718</data>
  <data key="d2">[drugbank.DB06718]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Anabolic Agents, Anabolic Agents for Systemic Use, Anabolic Steroids, Androgens, Androstan Derivatives, Androstanes, Androstanols, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Steroids]</data>
  <data key="d14">(1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.0,.0,.0,]icosa-4,7-dien-17-ol</data>
  <data key="d15">C21H32N2O</data>
  <data key="d16">10418-03-8</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H32N2O/c1-19-11-13-12-22-23-18(13)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,24H,4-11H2,1-3H3,(H,22,23)/t14-,15+,16-,17-,19-,20-,21-/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=NNC=C3C[C@]12C</data>
  <data key="d21">Stanozolol is a synthetic anabolic steroid with therapeutic uses in treating C1-inhibitor deficient hereditary angioedema. C1-inhibitor is a protease that inhibits the complement system (part of the innate immune system), a biochemical chain of reactions which assists the body in removing pathogens from the body. Stanozolol may help control attacks of hereditary angioedema.  Stanozolol can be administered orally or intramuscularly.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[androstanazol, androstanazole, estanozolol]</data>
  <data key="d9">Stanozolol is a synthetic anabolic steroid with therapeutic uses in treating hereditary angioedema. Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06726">
  <data key="d0">Bufuralol</data>
  <data key="d1">drugbank.DB06726</data>
  <data key="d2">[drugbank.DB06726]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Bradycardia-Causing Agents, Cytochrome P-450 CYP2D6 Substrates, Neurotransmitter Agents]</data>
  <data key="d14">2-(tert-butylamino)-1-(7-ethyl-1-benzofuran-2-yl)ethan-1-ol</data>
  <data key="d15">C16H23NO2</data>
  <data key="d16">54340-62-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H23NO2/c1-5-11-7-6-8-12-9-14(19-15(11)12)13(18)10-17-16(2,3)4/h6-9,13,17-18H,5,10H2,1-4H3</data>
  <data key="d20">CCC1=CC=CC2=C1OC(=C2)C(O)CNC(C)(C)C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Bufuralol, Bufuralolum]</data>
  <data key="d9">Bufuralol is a new, non-selective -adrenoceptor blocking agent.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06742">
  <data key="d0">Ambroxol</data>
  <data key="d1">drugbank.DB06742</data>
  <data key="d2">[drugbank.DB06742]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Adrenergics for Systemic Use, Amines, Aniline Compounds, Bromhexine, Cough and Cold Preparations, Cyclohexanes, Cyclohexylamines, Cycloparaffins, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Drugs for Obstructive Airway Diseases, Expectorants, Respiratory System Agents, Selective Beta 2-adrenergic Agonists]</data>
  <data key="d14">(1r,4r)-4-{[(2-amino-3,5-dibromophenyl)methyl]amino}cyclohexan-1-ol</data>
  <data key="d15">C13H18Br2N2O</data>
  <data key="d16">18683-91-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H18Br2N2O/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10/h5-6,10-11,17-18H,1-4,7,16H2/t10-,11-</data>
  <data key="d20">NC1=C(Br)C=C(Br)C=C1CN[C@H]1CC[C@H](O)CC1</data>
  <data key="d21">Ambroxol is indicated for secretolytic therapy in bronchoplmonary diseaes with abnormal mucus secretion and transport. It allows the mucus to be more easily cleared and ease a patient's breathing.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Ambroxolum, Bisolvon metabolite vIII, Bromhexine metabolite vIII, Bromhexine-metabolite vIII, Cyclohexanol, 4-((2-amino-3, 5-dibromobenzyl)amino)- (E)-, N-(2-Amino-3, 4-dibromociclohexil)-trans-4-aminociclohexanol, N-(2-Amino-3, 4-dibromocyclohexyl)-trans-4-aminocyclohexanol, trans-4-((2-Amino-3, 5-dibromobencil)amino)ciclohexanol, trans-4-((2-Amino-3, 5-dibromobenzyl)amine)cyclohexanol, trans-4-((2-Amino-3, 5-dibromobenzyl)amino)cyclohexanol]</data>
  <data key="d9">Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin. The substance is a mucoactive drug with several properties including secretolytic and secretomotoric actions that restore the physiological clearance mechanisms of the respiratory tract which play an important role in the bodys natural defence mechanisms. It stimulates synthesis and release of surfactant by type II pneumocytes. Surfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06732">
  <data key="d0">beta-Naphthoflavone</data>
  <data key="d1">drugbank.DB06732</data>
  <data key="d2">[drugbank.DB06732]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Benzoflavones, Benzopyrans, Chromones, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (unknown strength), Cytochrome P-450 Enzyme Inducers, Enzyme Inhibitors, Flavonoids, Pyrans]</data>
  <data key="d14">3-phenyl-1H-benzo[f]chromen-1-one</data>
  <data key="d15">C19H12O2</data>
  <data key="d16">6051-87-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H12O2/c20-16-12-18(14-7-2-1-3-8-14)21-17-11-10-13-6-4-5-9-15(13)19(16)17/h1-12H</data>
  <data key="d20">O=C1C=C(OC2=C1C1=CC=CC=C1C=C2)C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[3-phenyl-1H-naphtho(2, 1-b)pyran-1-one, 5, 6-benzoflavone, beta-NF, -NF]</data>
  <data key="d9">-Naphthoflavone, also known as 5,6-benzoflavone, is a potent agonist of the aryl hydrocarbon receptor and induces cytochromes P450 (CYPs) and uridine 5'-diphospho-glucuronosyltransferases (UGTs). It may be a chemopreventive agent.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05408">
  <data key="d0">Emricasan</data>
  <data key="d1">drugbank.DB05408</data>
  <data key="d2">[drugbank.DB05408]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Acyclic, Fatty Acids, Fatty Acids, Volatile, Lipids, Valerates]</data>
  <data key="d14">(3S)-3-[(2S)-2-{[(2-tert-butylphenyl)carbamoyl]formamido}propanamido]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid</data>
  <data key="d15">C26H27F4N3O7</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C26H27F4N3O7/c1-12(31-24(38)25(39)32-16-8-6-5-7-13(16)26(2,3)4)23(37)33-17(10-19(35)36)18(34)11-40-22-20(29)14(27)9-15(28)21(22)30/h5-9,12,17H,10-11H2,1-4H3,(H,31,38)(H,32,39)(H,33,37)(H,35,36)/t12-,17-/m0/s1</data>
  <data key="d20">C[C@H](NC(=O)C(=O)NC1=CC=CC=C1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COC1=C(F)C(F)=CC(F)=C1F</data>
  <data key="d21">Investigated for use/treatment in hepatitis (viral, C), liver disease, and transplantation (organ or tissue).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA. It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05412">
  <data key="d0">Talmapimod</data>
  <data key="d1">drugbank.DB05412</data>
  <data key="d2">[drugbank.DB05412]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">2-{6-chloro-5-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine-1-carbonyl]-1-methyl-1H-indol-3-yl}-N,N-dimethyl-2-oxoacetamide</data>
  <data key="d15">C27H30ClFN4O3</data>
  <data key="d16">309913-83-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C27H30ClFN4O3/c1-16-13-33(17(2)12-32(16)14-18-6-8-19(29)9-7-18)26(35)21-10-20-22(25(34)27(36)30(3)4)15-31(5)24(20)11-23(21)28/h6-11,15-17H,12-14H2,1-5H3/t16-,17+/m0/s1</data>
  <data key="d20">[H][C@]1(C)CN(C(=O)C2=C(Cl)C=C3N(C)C=C(C(=O)C(=O)N(C)C)C3=C2)[C@]([H])(C)CN1CC1=CC=C(F)C=C1</data>
  <data key="d21">Investigated for use/treatment in pain (acute or chronic) and rheumatoid arthritis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Talmapimod]</data>
  <data key="d9">Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05470">
  <data key="d0">VX-702</data>
  <data key="d1">drugbank.DB05470</data>
  <data key="d2">[drugbank.DB05470]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Benzene Derivatives, Urea]</data>
  <data key="d14">2-(2,4-difluorophenyl)-6-[1-(2,6-difluorophenyl)carbamoylamino]pyridine-3-carboxamide</data>
  <data key="d15">C19H12F4N4O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H12F4N4O2/c20-9-4-5-10(14(23)8-9)16-11(18(24)28)6-7-15(26-16)27(19(25)29)17-12(21)2-1-3-13(17)22/h1-8H,(H2,24,28)(H2,25,29)</data>
  <data key="d20">NC(=O)N(C1=CC=C(C(N)=O)C(=N1)C1=CC=C(F)C=C1F)C1=C(F)C=CC=C1F</data>
  <data key="d21">Investigated for use/treatment in coronary artery disease, inflammatory disorders (unspecified), and rheumatoid arthritis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor. In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04136">
  <data key="d0">Lysophosphotidylserine</data>
  <data key="d1">drugbank.DB04136</data>
  <data key="d2">[drugbank.DB04136, drugbank.EXPT02059]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-2-amino-3-({hydroxy[(2R)-2-hydroxy-3-{[(1R)-1-hydroxypentadecyl]oxy}propoxy]phosphoryl}oxy)propanoic acid</data>
  <data key="d15">C21H44NO9P</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H44NO9P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-20(24)29-15-18(23)16-30-32(27,28)31-17-19(22)21(25)26/h18-20,23-24H,2-17,22H2,1H3,(H,25,26)(H,27,28)/t18-,19+,20-/m1/s1</data>
  <data key="d20">[H][C@@](O)(CO[C@@]([H])(O)CCCCCCCCCCCCCC)COP(O)(=O)OC[C@]([H])(N)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05487">
  <data key="d0">Custirsen</data>
  <data key="d1">drugbank.DB05487</data>
  <data key="d2">[drugbank.DB05487]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Carbohydrates, Glycosides, Nucleic Acids, Nucleotides, and Nucleosides, Nucleotides, Oligonucleotides, Antisense, Pyrans, Sulfur Compounds]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in brain cancer and breast cancer.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Custirsen is a benzopyran with potential antineoplastic activity. Custirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor-related mechanisms. Custirsen is also being investigated in the treatment of primary brain tumors.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04147">
  <data key="d0">Lauryl Dimethylamine-N-Oxide</data>
  <data key="d1">drugbank.DB04147</data>
  <data key="d2">[drugbank.DB04147, drugbank.EXPT02013]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N,N-dimethyldodecanamine oxide</data>
  <data key="d15">C14H31NO</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C14H31NO/c1-4-5-6-7-8-9-10-11-12-13-14-15(2,3)16/h4-14H2,1-3H3</data>
  <data key="d20">CCCCCCCCCCCC[N+](C)(C)[O-]</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05490">
  <data key="d0">AMG-131</data>
  <data key="d1">drugbank.DB05490</data>
  <data key="d2">[drugbank.DB05490]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Amides, PPAR gamma, agonists, Sulfones, Sulfur Compounds]</data>
  <data key="d14">2,4-dichloro-N-[3,5-dichloro-4-(quinolin-3-yloxy)phenyl]benzene-1-sulfonamide</data>
  <data key="d15">C21H12Cl4N2O3S</data>
  <data key="d16">315224-26-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H12Cl4N2O3S/c22-13-5-6-20(16(23)8-13)31(28,29)27-14-9-17(24)21(18(25)10-14)30-15-7-12-3-1-2-4-19(12)26-11-15/h1-11,27H</data>
  <data key="d20">ClC1=CC=C(C(Cl)=C1)S(=O)(=O)NC1=CC(Cl)=C(OC2=CN=C3C=CC=CC3=C2)C(Cl)=C1</data>
  <data key="d21">Investigated for use/treatment in diabetes mellitus type 2.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">AMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the bodys ability to respond to insulin. T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the bodys ability to respond to insulin. T131 is not structurally related to the thiazolidinedione class of PPARg agonists, which includes Actos and Avandia.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04172">
  <data key="d0">[2,4,6-Triisopropyl-Phenylsulfonyl-L-[3-Amidino-Phenylalanine]]-Piperazine-N'-Beta-Alanine</data>
  <data key="d1">drugbank.DB04172</data>
  <data key="d2">[drugbank.DB04172, drugbank.EXPT03181]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-[(2S)-3-[4-(3-aminopropanoyl)piperazin-1-yl]-3-oxo-2-[2,4,6-tris(propan-2-yl)benzenesulfonamido]propyl]benzene-1-carboximidamide</data>
  <data key="d15">C32H48N6O4S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C32H48N6O4S/c1-20(2)25-18-26(21(3)4)30(27(19-25)22(5)6)43(41,42)36-28(17-23-8-7-9-24(16-23)31(34)35)32(40)38-14-12-37(13-15-38)29(39)10-11-33/h7-9,16,18-22,28,36H,10-15,17,33H2,1-6H3,(H3,34,35)/t28-/m0/s1</data>
  <data key="d20">[H][C@@](CC1=CC(=CC=C1)C(N)=N)(NS(=O)(=O)C1=C(C=C(C=C1C(C)C)C(C)C)C(C)C)C(=O)N1CCN(CC1)C(=O)CCN</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04223">
  <data key="d0">Nitroarginine</data>
  <data key="d1">drugbank.DB04223</data>
  <data key="d2">[drugbank.DB04223, drugbank.EXPT02387]</data>
  <data key="d12">[experimental, investigational]</data>
  <data key="d13">[Amino Acids, Amino Acids, Basic, Amino Acids, Diamino, Amino Acids, Essential, Amino Acids, Peptides, and Proteins, Arginine, Enzyme Inhibitors]</data>
  <data key="d14">(2S)-2-amino-5-(1-nitrocarbamimidamido)pentanoic acid</data>
  <data key="d15">C6H13N5O4</data>
  <data key="d16">2149-70-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C6H13N5O4/c7-4(5(12)13)2-1-3-9-6(8)10-11(14)15/h4H,1-3,7H2,(H,12,13)(H3,8,9,10)/t4-/m0/s1</data>
  <data key="d20">N[C@@H](CCCNC(=N)N[N+]([O-])=O)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[N(gamma)-nitro-L-arginine, Ngamma-Nitro-L-arginine]</data>
  <data key="d9">An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity. Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06878">
  <data key="d0">1-[(2R)-2-aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide</data>
  <data key="d1">drugbank.DB06878</data>
  <data key="d2">[drugbank.DB06878]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-1-[(2R)-2-aminobutanoyl]-N-[(3-chlorophenyl)methyl]pyrrolidine-2-carboxamide</data>
  <data key="d15">C16H22ClN3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H22ClN3O2/c1-2-13(18)16(22)20-8-4-7-14(20)15(21)19-10-11-5-3-6-12(17)9-11/h3,5-6,9,13-14H,2,4,7-8,10,18H2,1H3,(H,19,21)/t13-,14+/m1/s1</data>
  <data key="d20">[H][C@@](N)(CC)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=CC=CC(Cl)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04216">
  <data key="d0">Quercetin</data>
  <data key="d1">drugbank.DB04216</data>
  <data key="d2">[drugbank.DB04216, drugbank.EXPT02732]</data>
  <data key="d12">[experimental, investigational]</data>
  <data key="d13">[Antioxidants, BCRP/ABCG2 Inhibitors, Benzopyrans, Chromones, Compounds used in a research, industrial, or household setting, COMT Inhibitors, COMT Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Flavonoids, Flavonols, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, Protective Agents, Pyrans]</data>
  <data key="d14">2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one</data>
  <data key="d15">C15H10O7</data>
  <data key="d16">117-39-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H</data>
  <data key="d20">OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C1=CC=C(O)C(O)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[2-(3, 4-dihydroxyphenyl)-3, 5, 7-trihydroxy-4H-1-benzopyran-4-one, 3, 3', 4', 5, 7-pentahydroxyflavone, 3, 5, 7, 3', 4'-Pentahydroxyflavone, Sophoretin, Xanthaurine]</data>
  <data key="d9">Quercetin is a flavonol widely distributed in plants. It is an antioxidant, like many other phenolic heterocyclic compounds. Glycosylated forms include RUTIN and quercetrin.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04224">
  <data key="d0">Oleic Acid</data>
  <data key="d1">drugbank.DB04224</data>
  <data key="d2">[drugbank.DB04224, drugbank.EXPT02430]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Fatty Acids, Fatty Acids, Monounsaturated, Fatty Acids, Unsaturated, Lipids, Oleic Acids]</data>
  <data key="d14">(9E)-octadec-9-enoic acid</data>
  <data key="d15">C18H34O2</data>
  <data key="d16">112-80-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h9-10H,2-8,11-17H2,1H3,(H,19,20)/b10-9+</data>
  <data key="d20">CCCCCCCC\C=C\CCCCCCCC(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed)</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06898">
  <data key="d0">4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol</data>
  <data key="d1">drugbank.DB06898</data>
  <data key="d2">[drugbank.DB06898]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-{2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl}phenol</data>
  <data key="d15">C13H12N4O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H12N4O/c1-17-11-6-9(7-15-12(11)16-13(17)14)8-2-4-10(18)5-3-8/h2-7,18H,1H3,(H2,14,15,16)</data>
  <data key="d20">CN1C(N)=NC2=C1C=C(C=N2)C1=CC=C(O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04250">
  <data key="d0">Butyrylthiocholine</data>
  <data key="d1">drugbank.DB04250</data>
  <data key="d2">[drugbank.DB04250, drugbank.EXPT00639]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[Alcohols, Amines, Amino Alcohols, Ammonium Compounds, Choline, Ethanolamines, Nitrogen Compounds, Onium Compounds, Quaternary Ammonium Compounds, Sulfhydryl Compounds, Sulfur Compounds, Thiocholine, Trimethyl Ammonium Compounds]</data>
  <data key="d14">[2-(butanoylsulfanyl)ethyl]trimethylazanium</data>
  <data key="d15">C9H20NOS</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H20NOS/c1-5-6-9(11)12-8-7-10(2,3)4/h5-8H2,1-4H3/q+1</data>
  <data key="d20">CCCC(=O)SCC[N+](C)(C)C</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">A sulfur-containing analog of butyrylcholine which is hydrolyzed by butyrylcholinesterase to butyrate and thiocholine. It is used as a reagent in the determination of butyrylcholinesterase activity. [PubChem]</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06841">
  <data key="d0">D-phenylalanyl-N-[(1S)-4-{[amino(iminio)methyl]amino}-1-(chloroacetyl)butyl]-L-prolinamide</data>
  <data key="d1">drugbank.DB06841</data>
  <data key="d2">[drugbank.DB06841]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2R)-1-[(2S)-2-{[(2S,3S)-6-carbamimidamido-1-chloro-2-hydroxyhexan-3-yl]-C-hydroxycarbonimidoyl}pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-aminium</data>
  <data key="d15">C21H34ClN6O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H33ClN6O3/c22-13-18(29)16(8-4-10-26-21(24)25)27-19(30)17-9-5-11-28(17)20(31)15(23)12-14-6-2-1-3-7-14/h1-3,6-7,15-18,29H,4-5,8-13,23H2,(H,27,30)(H4,24,25,26)/p+1/t15-,16+,17+,18-/m1/s1</data>
  <data key="d20">[H][C@@]([NH3+])(CC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(O)=N[C@@]([H])(CCCNC(N)=N)[C@]([H])(O)CCl</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06838">
  <data key="d0">methyl L-phenylalaninate</data>
  <data key="d1">drugbank.DB06838</data>
  <data key="d2">[drugbank.DB06838]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">methyl (2S)-2-amino-3-phenylpropanoate</data>
  <data key="d15">C10H13NO2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C10H13NO2/c1-13-10(12)9(11)7-8-5-3-2-4-6-8/h2-6,9H,7,11H2,1H3/t9-/m0/s1</data>
  <data key="d20">[H][C@](N)(CC1=CC=CC=C1)C(=O)OC</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05507">
  <data key="d0">VX-765</data>
  <data key="d1">drugbank.DB05507</data>
  <data key="d2">[drugbank.DB05507]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Carbocyclic, Amino Acids, Peptides, and Proteins, Aminobenzoates, Benzene Derivatives, Benzoates, Oligopeptides, Peptides]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in inflammatory disorders (unspecified) and psoriasis and psoriatic disorders.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198). VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06850">
  <data key="d0">(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide</data>
  <data key="d1">drugbank.DB06850</data>
  <data key="d2">[drugbank.DB06850]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-N-[(4-carbamimidoylphenyl)methyl]-1-[2-(cyclohexylamino)acetyl]pyrrolidine-2-carboxamide</data>
  <data key="d15">C21H31N5O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H31N5O2/c22-20(23)16-10-8-15(9-11-16)13-25-21(28)18-7-4-12-26(18)19(27)14-24-17-5-2-1-3-6-17/h8-11,17-18,24H,1-7,12-14H2,(H3,22,23)(H,25,28)/t18-/m0/s1</data>
  <data key="d20">[H][C@]1(CCCN1C(=O)CNC1CCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06845">
  <data key="d0">(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide</data>
  <data key="d1">drugbank.DB06845</data>
  <data key="d2">[drugbank.DB06845]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-N-[(4-carbamimidoylphenyl)methyl]-1-[2-(cyclopentylamino)acetyl]pyrrolidine-2-carboxamide</data>
  <data key="d15">C20H29N5O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H29N5O2/c21-19(22)15-9-7-14(8-10-15)12-24-20(27)17-6-3-11-25(17)18(26)13-23-16-4-1-2-5-16/h7-10,16-17,23H,1-6,11-13H2,(H3,21,22)(H,24,27)/t17-/m0/s1</data>
  <data key="d20">[H][C@]1(CCCN1C(=O)CNC1CCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05513">
  <data key="d0">Atiprimod</data>
  <data key="d1">drugbank.DB05513</data>
  <data key="d2">[drugbank.DB05513]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">(3-{8,8-dipropyl-2-azaspiro[4.5]decan-2-yl}propyl)diethylamine</data>
  <data key="d15">C22H44N2</data>
  <data key="d16">123018-47-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H44N2/c1-5-10-21(11-6-2)12-14-22(15-13-21)16-19-24(20-22)18-9-17-23(7-3)8-4/h5-20H2,1-4H3</data>
  <data key="d20">CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1</data>
  <data key="d21">Investigated for use/treatment in cancer/tumors (unspecified), multiple myeloma, and rheumatoid arthritis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Atiprimod, Azaspirane, N, N-Diethyl-8, 8-dipropyl-2-azaspiro(4.5)decane-2-propanamine]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06862">
  <data key="d0">2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID</data>
  <data key="d1">drugbank.DB06862</data>
  <data key="d2">[drugbank.DB06862]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-hydroxy-5-[(2-sulfanylethyl)sulfamoyl]benzoic acid</data>
  <data key="d15">C9H11NO5S2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H11NO5S2/c11-8-2-1-6(5-7(8)9(12)13)17(14,15)10-3-4-16/h1-2,5,10-11,16H,3-4H2,(H,12,13)</data>
  <data key="d20">OC(=O)C1=C(O)C=CC(=C1)S(=O)(=O)NCCS</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06861">
  <data key="d0">6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE</data>
  <data key="d1">drugbank.DB06861</data>
  <data key="d2">[drugbank.DB06861]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(6R)-6-[(1R,2S)-2-hydroxycyclopentyl]-7-oxoheptanimidamide</data>
  <data key="d15">C12H22N2O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C12H22N2O2/c13-12(14)7-2-1-4-9(8-15)10-5-3-6-11(10)16/h8-11,16H,1-7H2,(H3,13,14)/t9-,10+,11-/m0/s1</data>
  <data key="d20">[H][C@](CCCCC(N)=N)(C=O)[C@@]1([H])CCC[C@]1([H])O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06855">
  <data key="d0">6-fluoro-2-(2-hydroxy-3-isobutoxy-phenyl)-1H-benzoimidazole-5-carboxamidine</data>
  <data key="d1">drugbank.DB06855</data>
  <data key="d2">[drugbank.DB06855, drugbank.EXPT00343, drugbank.DB03494]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-{5-[amino(iminiumyl)methyl]-6-fluoro-1H-1,3-benzodiazol-2-yl}-6-(2-methylpropoxy)benzen-1-olate</data>
  <data key="d15">C18H19FN4O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H19FN4O2/c1-9(2)8-25-15-5-3-4-10(16(15)24)18-22-13-6-11(17(20)21)12(19)7-14(13)23-18/h3-7,9,24H,8H2,1-2H3,(H3,20,21)(H,22,23)</data>
  <data key="d20">CC(C)COC1=C(O)C(=CC=C1)C1=NC2=CC(C(N)=N)=C(F)C=C2N1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06856">
  <data key="d0">6-FLUORO-2-[2-HYDROXY-3-(2-METHYL-CYCLOHEXYLOXY)-PHENYL]-1H-INDOLE-5-CARBOXAMIDINE</data>
  <data key="d1">drugbank.DB06856</data>
  <data key="d2">[drugbank.DB06856]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">6-fluoro-2-(2-hydroxy-3-{[(1S,2S)-2-methylcyclohexyl]oxy}phenyl)-1H-indole-5-carboximidamide</data>
  <data key="d15">C22H24FN3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H24FN3O2/c1-12-5-2-3-7-19(12)28-20-8-4-6-14(21(20)27)18-10-13-9-15(22(24)25)16(23)11-17(13)26-18/h4,6,8-12,19,26-27H,2-3,5,7H2,1H3,(H3,24,25)/t12-,19-/m0/s1</data>
  <data key="d20">[H][C@]1(C)CCCC[C@]1([H])OC1=C(O)C(=CC=C1)C1=CC2=CC(C(N)=N)=C(F)C=C2N1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06853">
  <data key="d0">N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide</data>
  <data key="d1">drugbank.DB06853</data>
  <data key="d2">[drugbank.DB06853]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-N-[(4-carbamimidoylphenyl)methyl]-1-[2-(cycloheptylamino)acetyl]pyrrolidine-2-carboxamide</data>
  <data key="d15">C22H33N5O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H33N5O2/c23-21(24)17-11-9-16(10-12-17)14-26-22(29)19-8-5-13-27(19)20(28)15-25-18-6-3-1-2-4-7-18/h9-12,18-19,25H,1-8,13-15H2,(H3,23,24)(H,26,29)/t19-/m0/s1</data>
  <data key="d20">[H][C@]1(CCCN1C(=O)CNC1CCCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06859">
  <data key="d0">N-ALLYL-5-AMIDINOAMINOOXY-PROPYLOXY-3-CHLORO-N-CYCLOPENTYLBENZAMIDE</data>
  <data key="d1">drugbank.DB06859</data>
  <data key="d2">[drugbank.DB06859]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">3-[3-(carbamimidamidooxy)propoxy]-5-chloro-N-cyclopentyl-N-(prop-2-en-1-yl)benzamide</data>
  <data key="d15">C19H27ClN4O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H27ClN4O3/c1-2-8-24(16-6-3-4-7-16)18(25)14-11-15(20)13-17(12-14)26-9-5-10-27-23-19(21)22/h2,11-13,16H,1,3-10H2,(H4,21,22,23)</data>
  <data key="d20">NC(=N)NOCCCOC1=CC(Cl)=CC(=C1)C(=O)N(CC=C)C1CCCC1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06857">
  <data key="d0">N-(4-CARBAMIMIDOYL-3-CHORO-PHENYL)-2-HYDROXY-3-IODO-5-METHYL-BENZAMIDE</data>
  <data key="d1">drugbank.DB06857</data>
  <data key="d2">[drugbank.DB06857]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-(4-carbamimidoyl-3-chlorophenyl)-2-hydroxy-3-iodo-5-methylbenzamide</data>
  <data key="d15">C15H13ClIN3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H13ClIN3O2/c1-7-4-10(13(21)12(17)5-7)15(22)20-8-2-3-9(14(18)19)11(16)6-8/h2-6,21H,1H3,(H3,18,19)(H,20,22)</data>
  <data key="d20">CC1=CC(I)=C(O)C(=C1)C(=O)NC1=CC(Cl)=C(C=C1)C(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06858">
  <data key="d0">N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide</data>
  <data key="d1">drugbank.DB06858</data>
  <data key="d2">[drugbank.DB06858]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-N-[(4-carbamimidoylphenyl)methyl]-1-[2-(cyclooctylamino)acetyl]pyrrolidine-2-carboxamide</data>
  <data key="d15">C23H35N5O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H35N5O2/c24-22(25)18-12-10-17(11-13-18)15-27-23(30)20-9-6-14-28(20)21(29)16-26-19-7-4-2-1-3-5-8-19/h10-13,19-20,26H,1-9,14-16H2,(H3,24,25)(H,27,30)/t20-/m0/s1</data>
  <data key="d20">[H][C@]1(CCCN1C(=O)CNC1CCCCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06871">
  <data key="d0">17-METHYL-17-ALPHA-DIHYDROEQUILENIN</data>
  <data key="d1">drugbank.DB06871</data>
  <data key="d2">[drugbank.DB06871]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(11S,14R,15S)-14,15-dimethyltetracyclo[8.7.0.0,.0,]heptadeca-1(10),2,4,6,8-pentaene-5,14-diol</data>
  <data key="d15">C19H22O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H22O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h3-6,11,17,20-21H,7-10H2,1-2H3/t17-,18-,19+/m0/s1</data>
  <data key="d20">[H][C@@]12CC[C@@](C)(O)[C@@]1(C)CCC1=C2C=CC2=CC(O)=CC=C12</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06866">
  <data key="d0">6-CARBAMIMIDOYL-2-[2-HYDROXY-5-(3-METHOXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID</data>
  <data key="d1">drugbank.DB06866</data>
  <data key="d2">[drugbank.DB06866]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2R)-6-carbamimidoyl-2-[(1S,2S)-2-hydroxy-5-(3-methoxyphenyl)-2,3-dihydro-1H-inden-1-yl]hexanoic acid</data>
  <data key="d15">C23H28N2O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C23H28N2O4/c1-29-17-6-4-5-14(12-17)15-9-10-18-16(11-15)13-20(26)22(18)19(23(27)28)7-2-3-8-21(24)25/h4-6,9-12,19-20,22,26H,2-3,7-8,13H2,1H3,(H3,24,25)(H,27,28)/t19-,20+,22-/m1/s1</data>
  <data key="d20">[H][C@](CCCCC(N)=N)(C(O)=O)[C@@]1([H])C2=C(C[C@]1([H])O)C=C(C=C2)C1=CC(OC)=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06865">
  <data key="d0">6-CARBAMIMIDOYL-2-[2-HYDROXY-6-(4-HYDROXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID</data>
  <data key="d1">drugbank.DB06865</data>
  <data key="d2">[drugbank.DB06865]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2R)-6-carbamimidoyl-2-[(1S,2S)-2-hydroxy-6-(4-hydroxyphenyl)-2,3-dihydro-1H-inden-1-yl]hexanoic acid</data>
  <data key="d15">C22H26N2O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H26N2O4/c23-20(24)4-2-1-3-17(22(27)28)21-18-11-14(5-6-15(18)12-19(21)26)13-7-9-16(25)10-8-13/h5-11,17,19,21,25-26H,1-4,12H2,(H3,23,24)(H,27,28)/t17-,19+,21+/m1/s1</data>
  <data key="d20">[H][C@](CCCCC(N)=N)(C(O)=O)[C@@]1([H])C2=C(C[C@]1([H])O)C=CC(=C2)C1=CC=C(O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06868">
  <data key="d0">N-(3-chlorobenzyl)-1-(4-methylpentanoyl)-L-prolinamide</data>
  <data key="d1">drugbank.DB06868</data>
  <data key="d2">[drugbank.DB06868]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-N-[(3-chlorophenyl)methyl]-1-(4-methylpentanoyl)pyrrolidine-2-carboxamide</data>
  <data key="d15">C18H25ClN2O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H25ClN2O2/c1-13(2)8-9-17(22)21-10-4-7-16(21)18(23)20-12-14-5-3-6-15(19)11-14/h3,5-6,11,13,16H,4,7-10,12H2,1-2H3,(H,20,23)/t16-/m0/s1</data>
  <data key="d20">[H][C@]1(CCCN1C(=O)CCC(C)C)C(=O)NCC1=CC(Cl)=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06869">
  <data key="d0">1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE</data>
  <data key="d1">drugbank.DB06869</data>
  <data key="d2">[drugbank.DB06869]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-1-[(2R)-2-amino-2-cyclohexylacetyl]-N-({5-chloro-2-[(ethylcarbamoyl)methoxy]phenyl}methyl)pyrrolidine-2-carboxamide</data>
  <data key="d15">C24H35ClN4O4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C24H35ClN4O4/c1-2-27-21(30)15-33-20-11-10-18(25)13-17(20)14-28-23(31)19-9-6-12-29(19)24(32)22(26)16-7-4-3-5-8-16/h10-11,13,16,19,22H,2-9,12,14-15,26H2,1H3,(H,27,30)(H,28,31)/t19-,22+/m0/s1</data>
  <data key="d20">[H][C@@](N)(C1CCCCC1)C(=O)N1CCC[C@@]1([H])C(=O)NCC1=C(OCC(=O)NCC)C=CC(Cl)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06800">
  <data key="d0">Methylnaltrexone</data>
  <data key="d1">drugbank.DB06800</data>
  <data key="d2">[drugbank.DB06800]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Alimentary Tract and Metabolism, Alkaloids, Amines, Ammonium Compounds, Central Nervous System Agents, Drugs for Constipation, Drugs that are Mainly Renally Excreted, Miscellaneous GI Drugs, Morphinans, Naloxone, Nitrogen Compounds, Onium Compounds, Opiate Alkaloids, Opioid Antagonists, Peripheral Nervous System Agents, Peripheral Opioid Receptor Antagonists, Phenanthrenes, Sensory System Agents]</data>
  <data key="d14">(1S,4R,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-4-methyl-14-oxo-12-oxa-4-azapentacyclo[9.6.1.0,.0,.0,]octadeca-7(18),8,10-trien-4-ium</data>
  <data key="d15">C21H26NO4</data>
  <data key="d16">916055-93-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H25NO4/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13/h4-5,12,16,19,25H,2-3,6-11H2,1H3/p+1/t16-,19+,20+,21-,22-/m1/s1</data>
  <data key="d20">C[N@+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35</data>
  <data key="d21">Treatment of opioids induced constipation in palliative patients that are inadequately responding to laxative therapy.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[MNTX]</data>
  <data key="d9">Methylnaltrexone is a pheriphally-acting -opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. FDA approved in 2008.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06803">
  <data key="d0">Niclosamide</data>
  <data key="d1">drugbank.DB06803</data>
  <data key="d2">[drugbank.DB06803]</data>
  <data key="d12">[approved, investigational, vet_approved]</data>
  <data key="d13">[Agrochemicals, Amides, Anilides, Anthelmintics, Anti-Infective Agents, Anticestodal Agents, Anticestodals, Antinematodal Agents, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiplatyhelmintic Agents, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inhibitors, Molluscacides, Pesticides, Salicylamides, Salicylanilides, Salicylic Acid Derivatives, Toxic Actions]</data>
  <data key="d14">5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide</data>
  <data key="d15">C13H8Cl2N2O4</data>
  <data key="d16">50-65-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H8Cl2N2O4/c14-7-1-4-12(18)9(5-7)13(19)16-11-3-2-8(17(20)21)6-10(11)15/h1-6,18H,(H,16,19)</data>
  <data key="d20">OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O</data>
  <data key="d21">For the treatment of tapeworm and intestinal fluke infections: Taenia saginata (Beef Tapeworm), Taenia solium (Pork Tapeworm), Diphyllobothrium latum (Fish Tapeworm), Fasciolopsis buski (large intestinal fluke). Niclosamide is also used as a molluscicide in the control of schistosomiasis.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Niclosamide is used for the treatment of most tapeworm infections. Helminths (worms) are multicellular organisms that infect very large numbers of humans and cause a broad range of diseases. Over 1 billion people are infected with intestinal nematodes, and many millions are infected with filarial nematodes, flukes, and tapeworms. They are an even greater problem in domestic animals.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06820">
  <data key="d0">Sulconazole</data>
  <data key="d1">drugbank.DB06820</data>
  <data key="d2">[drugbank.DB06820]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Anti-Infective Agents, Antifungal Agents, Antifungals for Dermatological Use, Antifungals for Topical Use, Azole Antifungals, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Imidazole and Triazole Derivatives]</data>
  <data key="d14">1-(2-{[(4-chlorophenyl)methyl]sulfanyl}-2-(2,4-dichlorophenyl)ethyl)-1H-imidazole</data>
  <data key="d15">C18H15Cl3N2S</data>
  <data key="d16">61318-90-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H15Cl3N2S/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21/h1-9,12,18H,10-11H2</data>
  <data key="d20">ClC1=CC=C(CSC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1</data>
  <data key="d21">Sulconazole solution 1.0% is indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athletes foot).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Sulconazole]</data>
  <data key="d9">Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes making it an effective treatment for tinea cruris and tinea corporis infections.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04270">
  <data key="d0">(S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid</data>
  <data key="d1">drugbank.DB04270</data>
  <data key="d2">[drugbank.DB04270, drugbank.EXPT03276]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-3-{4-[2-(9H-carbazol-9-yl)ethoxy]phenyl}-2-ethoxypropanoic acid</data>
  <data key="d15">C25H25NO4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C25H25NO4/c1-2-29-24(25(27)28)17-18-11-13-19(14-12-18)30-16-15-26-22-9-5-3-7-20(22)21-8-4-6-10-23(21)26/h3-14,24H,2,15-17H2,1H3,(H,27,28)/t24-/m0/s1</data>
  <data key="d20">[H][C@@](CC1=CC=C(OCCN2C3=C(C=CC=C3)C3=C2C=CC=C3)C=C1)(OCC)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06521">
  <data key="d0">Ertiprotafib</data>
  <data key="d1">drugbank.DB06521</data>
  <data key="d2">[drugbank.DB06521]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Carbocyclic, Sulfur Compounds]</data>
  <data key="d14">(2R)-2-(4-{9-bromo-2,3-dimethylnaphtho[2,3-b]thiophen-4-yl}-2,6-dimethylphenoxy)-3-phenylpropanoic acid</data>
  <data key="d15">C31H27BrO3S</data>
  <data key="d16">251303-04-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C31H27BrO3S/c1-17-14-22(15-18(2)29(17)35-25(31(33)34)16-21-10-6-5-7-11-21)27-23-12-8-9-13-24(23)28(32)30-26(27)19(3)20(4)36-30/h5-15,25H,16H2,1-4H3,(H,33,34)/t25-/m1/s1</data>
  <data key="d20">CC1=C(C)C2=C(C3=CC(C)=C(O[C@H](CC4=CC=CC=C4)C(O)=O)C(C)=C3)C3=CC=CC=C3C(Br)=C2S1</data>
  <data key="d21">Investigated for use/treatment in diabetes mellitus type 2.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Ertiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 diabetes. In insulin-resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improved glycemic excursion during an oral glucose tolerance test.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07846">
  <data key="d0">1S,3AS,8AS-TRIMETHYL-1-OXIDO-1,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL 2-ETHYLPHENYLCARBAMATE</data>
  <data key="d1">drugbank.DB07846</data>
  <data key="d2">[drugbank.DB07846]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">1-({1,3a,8-trimethyl-1-oxo-1H,2H,3H,3aH,8H,8aH-1-pyrrolo[2,3-b]indol-5-yl}oxy)-N-(2-ethylphenyl)methanimidic acid</data>
  <data key="d15">C22H27N3O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H27N3O3/c1-5-15-8-6-7-9-18(15)23-21(26)28-16-10-11-19-17(14-16)22(2)12-13-25(4,27)20(22)24(19)3/h6-11,14,20H,5,12-13H2,1-4H3,(H,23,26)</data>
  <data key="d20">CCC1=CC=CC=C1N=C(O)OC1=CC2=C(C=C1)N(C)C1C2(C)CCN1(C)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07863">
  <data key="d0">2-chloro-5-nitro-N-phenylbenzamide</data>
  <data key="d1">drugbank.DB07863</data>
  <data key="d2">[drugbank.DB07863]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2-chloro-5-nitro-N-phenylbenzamide</data>
  <data key="d15">C13H9ClN2O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C13H9ClN2O3/c14-12-7-6-10(16(18)19)8-11(12)13(17)15-9-4-2-1-3-5-9/h1-8H,(H,15,17)</data>
  <data key="d20">[O-][N+](=O)C1=CC=C(Cl)C(=C1)C(=O)NC1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06533">
  <data key="d0">Ragaglitazar</data>
  <data key="d1">drugbank.DB06533</data>
  <data key="d2">[drugbank.DB06533]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Carbocyclic]</data>
  <data key="d14">(2R)-2-ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoic acid</data>
  <data key="d15">C25H25NO5</data>
  <data key="d16">222834-30-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C25H25NO5/c1-2-29-24(25(27)28)17-18-11-13-19(14-12-18)30-16-15-26-20-7-3-5-9-22(20)31-23-10-6-4-8-21(23)26/h3-14,24H,2,15-17H2,1H3,(H,27,28)/t24-/m1/s1</data>
  <data key="d20">CCO[C@H](CC1=CC=C(OCCN2C3=CC=CC=C3OC3=C2C=CC=C3)C=C1)C(O)=O</data>
  <data key="d21">Investigated for use/treatment in diabetes mellitus type 2.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06525">
  <data key="d0">Ganstigmine</data>
  <data key="d1">drugbank.DB06525</data>
  <data key="d2">[drugbank.DB06525]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Acyclic, Carbamates]</data>
  <data key="d14">(4aS,9aS)-2,4a,9-trimethyl-2H,3H,4H,4aH,9H,9aH-[1,2]oxazino[6,5-b]indol-6-yl N-(2-ethylphenyl)carbamate</data>
  <data key="d15">C22H27N3O3</data>
  <data key="d16">457075-21-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H27N3O3/c1-5-15-8-6-7-9-18(15)23-21(26)27-16-10-11-19-17(14-16)22(2)12-13-24(3)28-20(22)25(19)4/h6-11,14,20H,5,12-13H2,1-4H3,(H,23,26)/t20-,22-/m0/s1</data>
  <data key="d20">CCC1=C(NC(=O)OC2=CC3=C(C=C2)N(C)[C@H]2ON(C)CC[C@@]32C)C=CC=C1</data>
  <data key="d21">Investigated for use/treatment in alzheimer's disease.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Ganstigmine]</data>
  <data key="d9">Ganstigmine is an orally active, geneserine derived, carbamate-based acetylcholinesterase inhibitor developed for the treatment of Alzheimer's disease.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07859">
  <data key="d0">4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE</data>
  <data key="d1">drugbank.DB07859</data>
  <data key="d2">[drugbank.DB07859]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-(4-chlorophenyl)-4-[4-(1H-pyrazol-4-yl)phenyl]piperidine</data>
  <data key="d15">C20H20ClN3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H20ClN3/c21-19-7-5-18(6-8-19)20(9-11-22-12-10-20)17-3-1-15(2-4-17)16-13-23-24-14-16/h1-8,13-14,22H,9-12H2,(H,23,24)</data>
  <data key="d20">ClC1=CC=C(C=C1)C1(CCNCC1)C1=CC=C(C=C1)C1=CNN=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07874">
  <data key="d0">(6S)-2-amino-6-(3'-methoxybiphenyl-3-yl)-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one</data>
  <data key="d1">drugbank.DB07874</data>
  <data key="d2">[drugbank.DB07874]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(6S)-2-amino-6-[3-(3-methoxyphenyl)phenyl]-3,6-dimethyl-3,4,5,6-tetrahydropyrimidin-4-one</data>
  <data key="d15">C19H21N3O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H21N3O2/c1-19(12-17(23)22(2)18(20)21-19)15-8-4-6-13(10-15)14-7-5-9-16(11-14)24-3/h4-11H,12H2,1-3H3,(H2,20,21)/t19-/m0/s1</data>
  <data key="d20">COC1=CC(=CC=C1)C1=CC(=CC=C1)[C@]1(C)CC(=O)N(C)C(N)=N1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06536">
  <data key="d0">Tesaglitazar</data>
  <data key="d1">drugbank.DB06536</data>
  <data key="d2">[drugbank.DB06536, drugbank.DB07399]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Acids, Carbocyclic, Acids, Noncarboxylic, Alkanes, Alkanesulfonic Acids, Hydrocarbons, Acyclic, Sulfonic Acids, Sulfur Acids, Sulfur Compounds]</data>
  <data key="d14">(2S)-2-ethoxy-3-(4-{2-[4-(methanesulfonyloxy)phenyl]ethoxy}phenyl)propanoic acid</data>
  <data key="d15">C20H24O7S</data>
  <data key="d16">251565-85-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H24O7S/c1-3-25-19(20(21)22)14-16-6-8-17(9-7-16)26-13-12-15-4-10-18(11-5-15)27-28(2,23)24/h4-11,19H,3,12-14H2,1-2H3,(H,21,22)/t19-/m0/s1</data>
  <data key="d20">CCO[C@@H](CC1=CC=C(OCCC2=CC=C(OS(C)(=O)=O)C=C2)C=C1)C(O)=O</data>
  <data key="d21">Investigated for use/treatment in diabetes mellitus type 2.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05207">
  <data key="d0">SD118</data>
  <data key="d1">drugbank.DB05207</data>
  <data key="d2">[drugbank.DB05207]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Central Nervous System - Neuropathic pain</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">SD118 was previously under investigation in Japan for a different indication and now, following re-profiling and evaluation in experimental animal models, has demonstrated its potential as a new oral therapy for neuropathic pain.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05218">
  <data key="d0">PN0621</data>
  <data key="d1">drugbank.DB05218</data>
  <data key="d2">[drugbank.DB05218]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Intended for the treatment of auto-immune diseases such as rheumatoid arthritis, psoriasis and Crohn's disease.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07809">
  <data key="d0">4-({[4-(3-METHYLBENZOYL)PYRIDIN-2-YL]AMINO}METHYL)BENZENECARBOXIMIDAMIDE</data>
  <data key="d1">drugbank.DB07809</data>
  <data key="d2">[drugbank.DB07809]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-({[4-(3-methylbenzoyl)pyridin-2-yl]amino}methyl)benzene-1-carboximidamide</data>
  <data key="d15">C21H20N4O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C21H20N4O/c1-14-3-2-4-17(11-14)20(26)18-9-10-24-19(12-18)25-13-15-5-7-16(8-6-15)21(22)23/h2-12H,13H2,1H3,(H3,22,23)(H,24,25)</data>
  <data key="d20">CC1=CC=CC(=C1)C(=O)C1=CC=NC(NCC2=CC=C(C=C2)C(N)=N)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07812">
  <data key="d0">N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide</data>
  <data key="d1">drugbank.DB07812</data>
  <data key="d2">[drugbank.DB07812]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-[(1S)-2-amino-1-phenylethyl]-5-{1H-pyrrolo[2,3-b]pyridin-4-yl}thiophene-2-carboxamide</data>
  <data key="d15">C20H18N4OS</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H18N4OS/c21-12-16(13-4-2-1-3-5-13)24-20(25)18-7-6-17(26-18)14-8-10-22-19-15(14)9-11-23-19/h1-11,16H,12,21H2,(H,22,23)(H,24,25)/t16-/m1/s1</data>
  <data key="d20">[H][C@](CN)(NC(=O)C1=CC=C(S1)C1=C2C=CNC2=NC=C1)C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06510">
  <data key="d0">Muraglitazar</data>
  <data key="d1">drugbank.DB06510</data>
  <data key="d2">[drugbank.DB06510]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Amino Acids, Amino Acids, Peptides, and Proteins, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Substrates, Phenoxybenzamine, PPAR alpha, agonists, PPAR gamma, agonists, UGT1A1 Substrates, UGT1A3 substrates]</data>
  <data key="d14">2-{[(4-methoxyphenoxy)carbonyl]({4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}methyl)amino}acetic acid</data>
  <data key="d15">C29H28N2O7</data>
  <data key="d16">331741-94-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33)</data>
  <data key="d20">COC1=CC=C(OC(=O)N(CC(O)=O)CC2=CC=C(OCCC3=C(C)OC(=N3)C3=CC=CC=C3)C=C2)C=C1</data>
  <data key="d21">Investigated for use/treatment in diabetes mellitus type 2.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes. In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease in LDL-C levels.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07842">
  <data key="d0">(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid</data>
  <data key="d1">drugbank.DB07842</data>
  <data key="d2">[drugbank.DB07842]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid</data>
  <data key="d15">C17H18O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H18O3/c1-2-13-8-10-15(11-9-13)20-16(17(18)19)12-14-6-4-3-5-7-14/h3-11,16H,2,12H2,1H3,(H,18,19)/t16-/m0/s1</data>
  <data key="d20">[H][C@@](CC1=CC=CC=C1)(OC1=CC=C(CC)C=C1)C(O)=O</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05294">
  <data key="d0">Vandetanib</data>
  <data key="d1">drugbank.DB05294</data>
  <data key="d2">[drugbank.DB05294, drugbank.DB08764]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Highest Risk QTc-Prolonging Agents, Kinase Inhibitor, OCT2 Inhibitors, P-glycoprotein/ABCB1 Inhibitors, Protein Kinase Inhibitors, QTc Prolonging Agents, Tyrosine Kinase Inhibitors]</data>
  <data key="d14">N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine</data>
  <data key="d15">C22H24BrFN4O2</data>
  <data key="d16">443913-73-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)</data>
  <data key="d20">COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1</data>
  <data key="d21">Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine, Vandetanib]</data>
  <data key="d9">Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.\n\nOn April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05297">
  <data key="d0">Paclitaxel docosahexaenoic acid</data>
  <data key="d1">drugbank.DB05297</data>
  <data key="d2">[drugbank.DB05297]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Cyclodecanes, Cycloparaffins, Diterpenes, Taxoids, Terpenes]</data>
  <data key="d14">(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-15-{[(2R,3S)-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]-3-phenyl-3-(phenylformamido)propanoyl]oxy}-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0,.0,]heptadec-13-en-2-yl benzoate</data>
  <data key="d15">C69H81NO15</data>
  <data key="d16">199796-52-6</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C69H81NO15/c1-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-35-42-55(74)83-59(57(49-36-29-26-30-37-49)70-63(76)50-38-31-27-32-39-50)65(78)82-52-44-69(79)62(84-64(77)51-40-33-28-34-41-51)60-67(7,53(73)43-54-68(60,45-80-54)85-48(4)72)61(75)58(81-47(3)71)56(46(52)2)66(69,5)6/h9-10,12-13,15-16,18-19,21-22,24-34,36-41,52-54,57-60,62,73,79H,8,11,14,17,20,23,35,42-45H2,1-7H3,(H,70,76)/b10-9-,13-12-,16-15-,19-18-,22-21-,25-24-/t52-,53-,54+,57-,58+,59+,60-,62-,67+,68-,69+/m0/s1</data>
  <data key="d20">CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@@]3([H])[C@@](C)([C@@H](O)C[C@@]4([H])OC[C@@]34OC(=O)C)C(=O)[C@H](OC(=O)C)C(=C1C)C2(C)C)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1</data>
  <data key="d21">Investigated for use/treatment in breast cancer, colorectal cancer, gastric cancer, kidney cancer, lung cancer, pancreatic cancer, prostate cancer, and skin cancer.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[DHA Paclitaxel, DHA-paclitaxel, Paclitaxel 2'-(all-cis-4, 7, 10, 13, 16, 19-docosahexaenoate), Paclitaxel docosahexaenoic acid ester]</data>
  <data key="d9">A combination of DHA (a natural fatty acid) and paclitaxel (an anticancer drug) being studied in the treatment of cancer. It is a type of mitotic inhibitor.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05233">
  <data key="d0">AP1081</data>
  <data key="d1">drugbank.DB05233</data>
  <data key="d2">[drugbank.DB05233]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">For use as a female contraceptive.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">A transdermal gel containing ethinyl estradiol and norelgestromin being investigated by Antares Pharma for use as a female contraceptive.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07897">
  <data key="d0">1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE</data>
  <data key="d1">drugbank.DB07897</data>
  <data key="d2">[drugbank.DB07897]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">8-[(hydroxymethyl)amino]octan-1-ol</data>
  <data key="d15">C9H21NO2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C9H21NO2/c11-8-6-4-2-1-3-5-7-10-9-12/h10-12H,1-9H2</data>
  <data key="d20">OCCCCCCCCNCO</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05254">
  <data key="d0">Fibrinolysin</data>
  <data key="d1">drugbank.DB05254</data>
  <data key="d2">[drugbank.DB05254, drugbank.DB08977]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Anticoagulants, Blood and Blood Forming Organs, Cardiovascular Agents, Endopeptidases, Enzymes, Enzymes and Coenzymes, Fibrin Modulating Agents, Fibrinolytic Agents, Hematologic Agents, Hydrolases, Peptide Hydrolases, Serine Endopeptidases, Serine Proteases]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">9004-09-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Fibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[&gt;93e3e0dd-0785-442f-8f39-399255ab5dd3 Fibrinolysin heavy chain\nDLLDDYVNTQGASLLSLSRKNLAGRSVEDCAAKCEEETDFVCRAFQYHSKEQQCVVMAENSKNTPVFRMRDVILYEKRIYLLECKTGNGQTYRGTTAETKSGVTCQKWSATSPHVPKFSPEKFPLAGLEENYCRNPDNDENGPWCYTTDPDKRYDYCDIPECEDKCMHCSGENYEGKIAKTMSGRDCQAWDSQSPHAHGYIPSKFPNKNLKMNYCRNPDGEPRPWCFTTDPQKRWEFCDIPRCTTPPPSSGPKYQCLKGTGKNYGGTVAVTESGHTCQRWSEQTPHKHNRTPENFPCKNLEENYCRNPNGEKAPWCYTTNSEVRWEYCTIPSCESSPLSTERMDVPVPPEQTPVPQDCYHGNGQSYRGTSSTTITGRKCQSWSSMTPHRHLKTPENYPNAGLTMNYCRNPDADKSPWCYTTDPRVRWEFCNLKKCSETPEQVPAAPQAPGVENPPEADCMIGTGKSYRGKKATTVAGVPCQEWAAQEPHQHSIFTPETNPQSGLERNYCRNPDGDVNGPWCYTMNPRKPFDYCDVPQCESSFDCGKPKVEPKKCSGR, &gt;73a84c6c-783f-464a-b099-f99e82602743 Fibrinolysin light chain\nIVGGCVSKPHSWPWQVSLRRSSRHFCGGTLISPKWVLTAAHCLDNILALSFYKVILGAHNEKVREQSVQEIPVSRLFREPSQADIALLKLSRPAIITKEVIPACLPPPNYMVAARTECYITGWGETQGTFGEGLLKEAHLPVIENKVCNRNEYLDGRVKPTELCAGHLIGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSPYVPWIEETMRRN]</data>
  <data key="d8">[Bovine Fibrinolysin, Bovine Plasmin, Fibrinolysin (human), Fibrinolysin, human, Plasmin (bos taurus), Plasmin (bovine), Plasmin bovine]</data>
  <data key="d9">Fibrinolysin (also known as bovine plasmin) is a bovine enzyme derived from bovine plasma or extracted from bacterial cultures. It is a globular protein with a molecular weight of ~90,000 daltons. Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin; the heavy chain has a molecular weight of approximately 57,000 Da. Fibrinolysin is used as a local healing ointment when combined together with the enzyme deoxyribonuclease I (extracted from bovine pancreas). Fibrinolysin and deoxyribonuclease both act as lytic enzymes. The combination is available as ointment containing 1 BU (Biological Unit) Fibrinolysin and 666 BUs desoxyribonuclease per gram. The ointment is marketed by Pfizer under the brand name Fibrolan in a variety of countries (e.g. Switzerland). It is currently not approved in the USA.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05260">
  <data key="d0">Gallium nitrate</data>
  <data key="d1">drugbank.DB05260</data>
  <data key="d2">[drugbank.DB05260]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Antineoplastic Agents, Bone Resorption Inhibition, Calcium Resorption Inhibitor, Elements, Immunosuppressive Agents, Metals, Metals, Heavy]</data>
  <data key="d14">gallium(3+) ion trinitrate</data>
  <data key="d15">GaN3O9</data>
  <data key="d16">13494-90-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/Ga.3NO3/c;3*2-1(3)4/q+3;3*-1</data>
  <data key="d20">[Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O</data>
  <data key="d21">For the treatment of hypercalcemia. Also intended for the treatment of non-hodgkin's lymphoma.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Gallium nitrate (anhydrous), Nitric acid, gallium salt, anhydrate]</data>
  <data key="d9">Gallium nitrate is a drug that is used to treat hyper-calcemia, or too much calcium in the blood. This condition may occur when individuals develop various types of cancer. Gallium nitrate is also known by the common brand name Ganite.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06595">
  <data key="d0">Midostaurin</data>
  <data key="d1">drugbank.DB06595</data>
  <data key="d2">[drugbank.DB06595]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Alkaloids, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Carbazoles, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (unknown strength), Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strong), Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (unknown strength), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strong), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inhibitors (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 CYP3A7 Inducers, Cytochrome P-450 CYP3A7 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Indole Alkaloids, Indoles, Kinase Inhibitor, Protein Kinase C, antagonists &amp; inhibitors, Protein Kinase Inhibitors, Receptor Tyrosine Kinase Inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d14">N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8(13),9,11,14(28),15(19),20(27),21(26),22,24-nonaen-4-yl]-N-methylbenzamide</data>
  <data key="d15">C35H30N4O4</data>
  <data key="d16">120685-11-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1</data>
  <data key="d20">CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O)N(C)C(=O)C1=CC=CC=C1</data>
  <data key="d21">Investigated for use/treatment in adult patients with high-risk acute myeloid leukemia (AML) who are FLT3 mutation-positive, agressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[4'-N-benzoylstaurosporine, Midostaurin]</data>
  <data key="d9">Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors [A19108]. It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06642">
  <data key="d0">Bevasiranib</data>
  <data key="d1">drugbank.DB06642</data>
  <data key="d2">[drugbank.DB06642]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Antisense Elements (Genetics), Compounds used in a research, industrial, or household setting, Diagnostic Uses of Chemicals, Laboratory Chemicals, Molecular Probes, Nucleic Acid Probes, Nucleic Acids, Nucleic Acids, Nucleotides, and Nucleosides, RNA, RNA, Antisense, RNA, Small Untranslated, RNA, Untranslated]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">959961-96-7</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in macular degeneration and diabetic retinopathy.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Bevasiranib]</data>
  <data key="d9">Bevasiranib is a small interfering RNA (siRNA) targeting vascular endothelial growth factor A (VEGF-A).</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB05303">
  <data key="d0">OMS-103HP</data>
  <data key="d1">drugbank.DB05303</data>
  <data key="d2">[drugbank.DB05303]</data>
  <data key="d12">[investigational]</data>
  <data key="d13">[Acids, Carbocyclic, Benzocycloheptenes, Dibenzocycloheptenes, Imidazoles, Pharmaceutical Preparations, Phenylpropionates]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Investigated for use/treatment in inflammatory disorders (unspecified), knee replacement, orthopedic surgery, and pain (acute or chronic).</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">OMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of the most common procedures performed today by orthopedic surgeons.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06654">
  <data key="d0">Safinamide</data>
  <data key="d1">drugbank.DB06654</data>
  <data key="d2">[drugbank.DB06654]</data>
  <data key="d12">[approved, investigational]</data>
  <data key="d13">[Agents that produce hypertension, Agents that reduce seizure threshold, Amines, Amino Acids, Amino Acids, Peptides, and Proteins, Anti-Parkinson Drugs, Antidepressive Agents, BCRP/ABCG2 Inhibitors, Benzene Derivatives, Benzyl Compounds, Breast Cancer Resistance Protein Inhibitors, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (unknown strength), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (unknown strength), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dopamine Agents, Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase B Inhibitors, Monoamine Oxidase Inhibitors, Monoamine Oxidase-B Inhibitors, Nervous System, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome]</data>
  <data key="d14">(2S)-2-[({4-[(3-fluorophenyl)methoxy]phenyl}methyl)amino]propanamide</data>
  <data key="d15">C17H19FN2O2</data>
  <data key="d16">133865-89-1</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1</data>
  <data key="d20">C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O</data>
  <data key="d21">Safinamide is indicated as an add-on treatment to levodopa with or without other medicines for Parkinsons disease</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Safinamida, Safinamide]</data>
  <data key="d9">Safinamide is  for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07991">
  <data key="d0">N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE</data>
  <data key="d1">drugbank.DB07991</data>
  <data key="d2">[drugbank.DB07991]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-[(2R)-4-(4-hydroxyphenyl)butan-2-yl]-2-(2-phenyl-1H-indol-3-yl)acetamide</data>
  <data key="d15">C26H26N2O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C26H26N2O2/c1-18(11-12-19-13-15-21(29)16-14-19)27-25(30)17-23-22-9-5-6-10-24(22)28-26(23)20-7-3-2-4-8-20/h2-10,13-16,18,28-29H,11-12,17H2,1H3,(H,27,30)/t18-/m1/s1</data>
  <data key="d20">[H][C@@](C)(CCC1=CC=C(O)C=C1)NC(=O)CC1=C(NC2=C1C=CC=C2)C1=CC=CC=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07993">
  <data key="d0">N~3~-[3-(1H-INDOL-6-YL)BENZYL]PYRIDINE-2,3-DIAMINE</data>
  <data key="d1">drugbank.DB07993</data>
  <data key="d2">[drugbank.DB07993]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N3-{[3-(1H-indol-6-yl)phenyl]methyl}pyridine-2,3-diamine</data>
  <data key="d15">C20H18N4</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H18N4/c21-20-18(5-2-9-23-20)24-13-14-3-1-4-16(11-14)17-7-6-15-8-10-22-19(15)12-17/h1-12,22,24H,13H2,(H2,21,23)</data>
  <data key="d20">NC1=NC=CC=C1NCC1=CC=CC(=C1)C1=CC2=C(C=CN2)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07994">
  <data key="d0">N~3~-[5-(1H-INDOL-6-YL)-2-(PYRIDIN-2-YLMETHOXY)BENZYL]PYRIDINE-2,3-DIAMINE</data>
  <data key="d1">drugbank.DB07994</data>
  <data key="d2">[drugbank.DB07994]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N3-{[5-(1H-indol-6-yl)-2-(pyridin-2-ylmethoxy)phenyl]methyl}pyridine-2,3-diamine</data>
  <data key="d15">C26H23N5O</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C26H23N5O/c27-26-23(5-3-12-30-26)31-16-21-14-19(20-7-6-18-10-13-29-24(18)15-20)8-9-25(21)32-17-22-4-1-2-11-28-22/h1-15,29,31H,16-17H2,(H2,27,30)</data>
  <data key="d20">NC1=NC=CC=C1NCC1=C(OCC2=NC=CC=C2)C=CC(=C1)C1=CC2=C(C=CN2)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04014">
  <data key="d0">Alsterpaullone</data>
  <data key="d1">drugbank.DB04014</data>
  <data key="d2">[drugbank.DB04014, drugbank.EXPT00590]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[CDC2 Protein Kinase, Cyclin B]</data>
  <data key="d14">14-nitro-8,18-diazatetracyclo[9.7.0.0,.0,]octadeca-1(11),2(7),3,5,12(17),13,15-heptaen-9-one</data>
  <data key="d15">C16H11N3O3</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C16H11N3O3/c20-15-8-12-11-7-9(19(21)22)5-6-14(11)18-16(12)10-3-1-2-4-13(10)17-15/h1-7,18H,8H2,(H,17,20)</data>
  <data key="d20">[O-][N+](=O)C1=CC2=C(NC3=C2CC(=O)NC2=C3C=CC=C2)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06674">
  <data key="d0">Golimumab</data>
  <data key="d1">drugbank.DB06674</data>
  <data key="d2">[drugbank.DB06674]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Agents reducing cytokine levels, Amino Acids, Peptides, and Proteins, Antibodies, Antibodies, Monoclonal, Antineoplastic and Immunomodulating Agents, Antirheumatic Agents, Biologics for Rheumatoid Arthritis Treatment, Blood Proteins, Disease-modifying Antirheumatic Agents, Globulins, Immunoglobulins, Immunoproteins, Immunosuppressive Agents, Proteins, Serum Globulins, Tumor Necrosis Factor Alpha (TNF-) Inhibitors, Tumor Necrosis Factor Blocker, Tumor Necrosis Factor Receptor Blocking Activity]</data>
  <data key="d14">NA</data>
  <data key="d15">NA</data>
  <data key="d16">476181-74-5</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">NA</data>
  <data key="d20">NA</data>
  <data key="d21">Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.</data>
  <data key="d22">BiotechDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9">Golimumab is a human IgG1 monoclonal antibody derived from immunizing genetically engineered mice with human TNF. Golimumab binds and inhibits soluble and transmembrane human TNF. Increased TNF is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07940">
  <data key="d0">9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE</data>
  <data key="d1">drugbank.DB07940</data>
  <data key="d2">[drugbank.DB07940]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-[(3-iodophenyl)methyl]-1,2,3,4-tetrahydroacridin-9-amine</data>
  <data key="d15">C20H19IN2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H19IN2/c21-15-7-5-6-14(12-15)13-22-20-16-8-1-3-10-18(16)23-19-11-4-2-9-17(19)20/h1,3,5-8,10,12H,2,4,9,11,13H2,(H,22,23)</data>
  <data key="d20">IC1=CC=CC(CNC2=C3CCCCC3=NC3=C2C=CC=C3)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07933">
  <data key="d0">Erteberel</data>
  <data key="d1">drugbank.DB07933</data>
  <data key="d2">[drugbank.DB07933, drugbank.DB12801]</data>
  <data key="d12">[experimental, investigational]</data>
  <data key="d13">[Pyrans]</data>
  <data key="d14">(2R,6S,7R)-7-(4-hydroxyphenyl)-8-oxatricyclo[7.4.0.0,]trideca-1(9),10,12-trien-12-ol</data>
  <data key="d15">C18H18O3</data>
  <data key="d16">533884-09-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H18O3/c19-12-6-4-11(5-7-12)18-15-3-1-2-14(15)16-10-13(20)8-9-17(16)21-18/h4-10,14-15,18-20H,1-3H2/t14-,15+,18+/m1/s1</data>
  <data key="d20">[H][C@@]12CCC[C@]1([H])[C@@]([H])(OC1=C2C=C(O)C=C1)C1=CC=C(O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[(3aS, 4R, 9bR)-4-(4-Hydroxyphenyl)-1, 2, 3, 3a, 4, 9b-hexahydrocyclopenta(c)(1) benzopyran-8-ol]</data>
  <data key="d9">Erteberel is an estrogen receptor beta agonist that  has been used in trials studying the treatment of Benign Prostatic Hyperplasia.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07934">
  <data key="d0">[[CYCLOHEXANESULFONYL-GLYCYL]-3[PYRIDIN-4-YL-AMINOMETHYL]ALANYL]PIPERIDINE</data>
  <data key="d1">drugbank.DB07934</data>
  <data key="d2">[drugbank.DB07934]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-{[(3R)-3-(2-cyclohexanesulfonamidoacetamido)-4-oxo-4-(piperidin-1-yl)butyl]amino}pyridin-1-ium</data>
  <data key="d15">C22H36N5O4S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H35N5O4S/c28-21(17-25-32(30,31)19-7-3-1-4-8-19)26-20(22(29)27-15-5-2-6-16-27)11-14-24-18-9-12-23-13-10-18/h9-10,12-13,19-20,25H,1-8,11,14-17H2,(H,23,24)(H,26,28)/p+1/t20-/m1/s1</data>
  <data key="d20">[H][C@](CCNC1=CC=[NH+]C=C1)(NC(=O)CNS(=O)(=O)C1CCCCC1)C(=O)N1CCCCC1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07931">
  <data key="d0">Hexestrol</data>
  <data key="d1">drugbank.DB07931</data>
  <data key="d2">[drugbank.DB07931, drugbank.DB08959]</data>
  <data key="d12">[withdrawn]</data>
  <data key="d13">[Antineoplastic Agents, Antineoplastic Agents, Hormonal, Benzene Derivatives, Benzylidene Compounds, Diethylstilbestrol, Estrogens, Estrogens, Non-Steroidal, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Stilbenes]</data>
  <data key="d14">4-[(3R,4S)-4-(4-hydroxyphenyl)hexan-3-yl]phenol</data>
  <data key="d15">C18H22O2</data>
  <data key="d16">84-16-2</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C18H22O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,17-20H,3-4H2,1-2H3/t17-,18+</data>
  <data key="d20">[H][C@](CC)(C1=CC=C(O)C=C1)[C@]([H])(CC)C1=CC=C(O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[4, 4'-(1, 2-diethylethylene)diphenol, Erythrohexestrol, Hexanoestrol, Hexoestrolum, Meso-3, 4-di(p-hydroxyphenyl)-n-hexane, Meso-hexestrol, Mesohexestrol, Synoestrolum]</data>
  <data key="d9">A synthetic estrogen that has been used as a hormonal antineoplastic agent.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07932">
  <data key="d0">dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate</data>
  <data key="d1">drugbank.DB07932</data>
  <data key="d2">[drugbank.DB07932]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">2,3-dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate</data>
  <data key="d15">C22H18O7</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C22H18O7/c1-27-21(25)17-18(22(26)28-2)20-16(12-5-9-14(24)10-6-12)15(19(17)29-20)11-3-7-13(23)8-4-11/h3-10,19-20,23-24H,1-2H3/t19-,20+</data>
  <data key="d20">[H][C@]12O[C@]([H])(C(C(=O)OC)=C1C(=O)OC)C(=C2C1=CC=C(O)C=C1)C1=CC=C(O)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06605">
  <data key="d0">Apixaban</data>
  <data key="d1">drugbank.DB06605</data>
  <data key="d2">[drugbank.DB06605, drugbank.DB07828]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Anticoagulants, Antithrombins, BCRP/ABCG2 Substrates, Blood and Blood Forming Organs, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Enzyme Inhibitors, Factor Xa Inhibitors, Hematologic Agents, P-glycoprotein/ABCB1 Substrates, Pyridines, Serine Proteinase Inhibitors]</data>
  <data key="d14">1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridine-3-carboxamide</data>
  <data key="d15">C25H25N5O4</data>
  <data key="d16">503612-47-3</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)</data>
  <data key="d20">COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O</data>
  <data key="d21">Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence[Label,A177565,A6897].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[apixabn, Apixaban, apixabanum]</data>
  <data key="d9">Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07944">
  <data key="d0">N-{3-METHYL-5-[2-(PYRIDIN-4-YLAMINO)-ETHOXY]-PHENYL}-BENZENESULFONAMIDE</data>
  <data key="d1">drugbank.DB07944</data>
  <data key="d2">[drugbank.DB07944]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">4-{[2-(3-benzenesulfonamido-5-methylphenoxy)ethyl]amino}pyridin-1-ium</data>
  <data key="d15">C20H22N3O3S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H21N3O3S/c1-16-13-18(23-27(24,25)20-5-3-2-4-6-20)15-19(14-16)26-12-11-22-17-7-9-21-10-8-17/h2-10,13-15,23H,11-12H2,1H3,(H,21,22)/p+1</data>
  <data key="d20">CC1=CC(OCCNC2=CC=[NH+]C=C2)=CC(NS(=O)(=O)C2=CC=CC=C2)=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07946">
  <data key="d0">N-[2-({[amino(imino)methyl]amino}oxy)ethyl]-2-{6-chloro-3-[(2,2-difluoro-2-phenylethyl)amino]-2-fluorophenyl}acetamide</data>
  <data key="d1">drugbank.DB07946</data>
  <data key="d2">[drugbank.DB07946]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-[2-(carbamimidamidooxy)ethyl]-2-{6-chloro-3-[(2,2-difluoro-2-phenylethyl)amino]-2-fluorophenyl}acetamide</data>
  <data key="d15">C19H21ClF3N5O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C19H21ClF3N5O2/c20-14-6-7-15(27-11-19(22,23)12-4-2-1-3-5-12)17(21)13(14)10-16(29)26-8-9-30-28-18(24)25/h1-7,27H,8-11H2,(H,26,29)(H4,24,25,28)</data>
  <data key="d20">NC(=N)NOCCNC(=O)CC1=C(Cl)C=CC(NCC(F)(F)C2=CC=CC=C2)=C1F</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06616">
  <data key="d0">Bosutinib</data>
  <data key="d1">drugbank.DB06616</data>
  <data key="d2">[drugbank.DB06616]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Amines, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Immunosuppressive Agents, Kinase Inhibitor, Myelosuppressive Agents, P-glycoprotein/ABCB1 Inhibitors, P-glycoprotein/ABCB1 Substrates, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors]</data>
  <data key="d14">4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile</data>
  <data key="d15">C26H29Cl2N5O3</data>
  <data key="d16">380843-75-4</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)</data>
  <data key="d20">COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl</data>
  <data key="d21">Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[4-((2, 4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile, Bosutinib]</data>
  <data key="d9">Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB07947">
  <data key="d0">ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE</data>
  <data key="d1">drugbank.DB07947</data>
  <data key="d2">[drugbank.DB07947]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-[2-({2-[(4-chlorophenyl)methoxy]ethyl}amino)ethyl]isoquinoline-5-sulfonamide</data>
  <data key="d15">C20H22ClN3O3S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C20H22ClN3O3S/c21-18-6-4-16(5-7-18)15-27-13-12-22-10-11-24-28(25,26)20-3-1-2-17-14-23-9-8-19(17)20/h1-9,14,22,24H,10-13,15H2</data>
  <data key="d20">ClC1=CC=C(COCCNCCNS(=O)(=O)C2=CC=CC3=CN=CC=C23)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04059">
  <data key="d0">8-(Pyrimidin-2-Ylamino)Naphthalene-2-Carboximidamide</data>
  <data key="d1">drugbank.DB04059</data>
  <data key="d2">[drugbank.DB04059, drugbank.EXPT03179]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">8-[(pyrimidin-2-yl)amino]naphthalene-2-carboximidamide</data>
  <data key="d15">C15H13N5</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H13N5/c16-14(17)11-6-5-10-3-1-4-13(12(10)9-11)20-15-18-7-2-8-19-15/h1-9H,(H3,16,17)(H,18,19,20)</data>
  <data key="d20">NC(=N)C1=CC2=C(C=CC=C2NC2=NC=CC=N2)C=C1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04021">
  <data key="d0">MF268</data>
  <data key="d1">drugbank.DB04021</data>
  <data key="d2">[drugbank.DB04021, drugbank.EXPT02157]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">N-{8-[(2R,6S)-2,6-dimethylmorpholin-4-yl]octyl}formamide</data>
  <data key="d15">C15H30N2O2</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C15H30N2O2/c1-14-11-17(12-15(2)19-14)10-8-6-4-3-5-7-9-16-13-18/h13-15H,3-12H2,1-2H3,(H,16,18)/t14-,15+</data>
  <data key="d20">[H][C@]1(C)CN(CCCCCCCCNC=O)C[C@@]([H])(C)O1</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB04018">
  <data key="d0">S-Isopropyl-Isothiourea</data>
  <data key="d1">drugbank.DB04018</data>
  <data key="d2">[drugbank.DB04018, drugbank.EXPT01925]</data>
  <data key="d12">[experimental]</data>
  <data key="d13">[]</data>
  <data key="d14">(propan-2-ylsulfanyl)methanimidamide</data>
  <data key="d15">C4H10N2S</data>
  <data key="d16"></data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C4H10N2S/c1-3(2)7-4(5)6/h3H,1-2H3,(H3,5,6)</data>
  <data key="d20">CC(C)SC(N)=N</data>
  <data key="d21"></data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[]</data>
  <data key="d9"></data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06691">
  <data key="d0">Mepyramine</data>
  <data key="d1">drugbank.DB06691</data>
  <data key="d2">[drugbank.DB06691]</data>
  <data key="d12">[approved, vet_approved]</data>
  <data key="d13">[Amines, Aminopyridines, Anti-Allergic Agents, Antihistamines for Systemic Use, Antihistamines for Topical Use, Antipruritics, Incl. Antihistamines, Anesthetics, Etc., Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Neurotransmitter Agents, Potential QTc-Prolonging Agents, Pyridines, QTc Prolonging Agents, Sleep Aids, Pharmaceutical, Substituted Ethylene Diamines]</data>
  <data key="d14">N-[2-(dimethylamino)ethyl]-N-[(4-methoxyphenyl)methyl]pyridin-2-amine</data>
  <data key="d15">C17H23N3O</data>
  <data key="d16">91-84-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C17H23N3O/c1-19(2)12-13-20(17-6-4-5-11-18-17)14-15-7-9-16(21-3)10-8-15/h4-11H,12-14H2,1-3H3</data>
  <data key="d20">COC1=CC=C(CN(CCN(C)C)C2=NC=CC=C2)C=C1</data>
  <data key="d21">Indicated for the treatment of allergic conditions, symptomatic relief of hypersensitivity reaction, and treatment of pruritic skin disorders.</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Mepiramina, Mepyramine, N-(p-methoxybenzyl)-N', N'-dimethyl-N-(-pyridyl)ethylenediamine, N-[(4-methoxyphenyl)methyl]-N', N'-dimethyl-N-2-pyridinyl-1, 2-ethanediamine, N', N'-dimethyl-N-(p-methoxybenzyl)-N-(2-pyridyl)ethylenediamine, Pyranisamine, Pyrilamine]</data>
  <data key="d9">Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions.</data>
  <data key="d10">drug</data>
</node>
<node id="drugbank.DB06695">
  <data key="d0">Dabigatran etexilate</data>
  <data key="d1">drugbank.DB06695</data>
  <data key="d2">[drugbank.DB06695]</data>
  <data key="d12">[approved]</data>
  <data key="d13">[Anticoagulants, Antithrombins, Benzimidazoles, Blood and Blood Forming Organs, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hematologic Agents, Narrow Therapeutic Index Drugs, P-glycoprotein/ABCB1 Substrates, P-glycoprotein/ABCB1 Substrates with narrow therapeutic index, Protease Inhibitors, Pyridines, Serine Proteinase Inhibitors, UGT1A9 Substrates, UGT1A9 substrates with narrow therapeutic index]</data>
  <data key="d14">ethyl 3-(1-{2-[({4-[(1E)-amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate</data>
  <data key="d15">C34H41N7O5</data>
  <data key="d16">211915-06-9</data>
  <data key="d17">DrugBank</data>
  <data key="d18">[DrugBank]</data>
  <data key="d19">InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)</data>
  <data key="d20">CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1</data>
  <data key="d21">Dabigatran is indicated for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery (based on RE-NOVATE, RE-MODEL, and RE-MOBILIZE trials)[A177463,A6978,A6977]. In 2010, it was approved in the US and Canada for prevention of stroke and systemic embolism in patients with atrial fibrillation (approval based on the RE-LY trial)[Label,A177463].</data>
  <data key="d22">SmallMoleculeDrug</data>
  <data key="d23">[]</data>
  <data key="d8">[Dabigatran etexilate]</data>
  <data key="d9">Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor [dabigatran][Label,A177463,A6970]. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated[A177463]. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary[A177463]. Dabigatran etexilate was approved by the FDA in 2010[L6022].</data>
  <data key="d10">drug</data>
</node>
<edge source="entrez.2" target="mondo.0004975">
  <data key="d24">131</data>
  <data key="d25">9604</data>
  <data key="d26">A2M</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.2</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.2" target="mondo.0007088">
  <data key="d24">131</data>
  <data key="d25">23400</data>
  <data key="d26">A2M</data>
  <data key="d27">Alzheimer disease type 1</data>
  <data key="d28">entrez.2</data>
  <data key="d29">mondo.0007088</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.2" target="drugbank.DB14487">
  <data key="d24">2394</data>
  <data key="d25">131</data>
  <data key="d26">Zinc acetate</data>
  <data key="d27">A2M</data>
  <data key="d28">drugbank.DB14487</data>
  <data key="d29">entrez.2</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2" target="drugbank.DB00102">
  <data key="d24">3851</data>
  <data key="d25">131</data>
  <data key="d26">Becaplermin</data>
  <data key="d27">A2M</data>
  <data key="d28">drugbank.DB00102</data>
  <data key="d29">entrez.2</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2" target="drugbank.DB01593">
  <data key="d24">4227</data>
  <data key="d25">131</data>
  <data key="d26">Zinc</data>
  <data key="d27">A2M</data>
  <data key="d28">drugbank.DB01593</data>
  <data key="d29">entrez.2</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2" target="drugbank.DB14533">
  <data key="d24">5035</data>
  <data key="d25">131</data>
  <data key="d26">Zinc chloride</data>
  <data key="d27">A2M</data>
  <data key="d28">drugbank.DB14533</data>
  <data key="d29">entrez.2</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2" target="drugbank.DB00626">
  <data key="d24">6437</data>
  <data key="d25">131</data>
  <data key="d26">Bacitracin</data>
  <data key="d27">A2M</data>
  <data key="d28">drugbank.DB00626</data>
  <data key="d29">entrez.2</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2" target="drugbank.DB00515">
  <data key="d24">8119</data>
  <data key="d25">131</data>
  <data key="d26">Cisplatin</data>
  <data key="d27">A2M</data>
  <data key="d28">drugbank.DB00515</data>
  <data key="d29">entrez.2</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2" target="drugbank.DB12965">
  <data key="d24">9586</data>
  <data key="d25">131</data>
  <data key="d26">Silver</data>
  <data key="d27">A2M</data>
  <data key="d28">drugbank.DB12965</data>
  <data key="d29">entrez.2</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2" target="drugbank.DB08888">
  <data key="d24">12226</data>
  <data key="d25">131</data>
  <data key="d26">Ocriplasmin</data>
  <data key="d27">A2M</data>
  <data key="d28">drugbank.DB08888</data>
  <data key="d29">entrez.2</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.498" target="mondo.0004975">
  <data key="d24">322</data>
  <data key="d25">9604</data>
  <data key="d26">ATP5F1A</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.498</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.32</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.498" target="drugbank.DB11638">
  <data key="d24">9575</data>
  <data key="d25">322</data>
  <data key="d26">Artenimol</data>
  <data key="d27">ATP5F1A</data>
  <data key="d28">drugbank.DB11638</data>
  <data key="d29">entrez.498</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.498" target="drugbank.DB07384">
  <data key="d24">10216</data>
  <data key="d25">322</data>
  <data key="d26">1-ACETYL-2-CARBOXYPIPERIDINE</data>
  <data key="d27">ATP5F1A</data>
  <data key="d28">drugbank.DB07384</data>
  <data key="d29">entrez.498</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.498" target="drugbank.DB07394">
  <data key="d24">10224</data>
  <data key="d25">322</data>
  <data key="d26">AUROVERTIN B</data>
  <data key="d27">ATP5F1A</data>
  <data key="d28">drugbank.DB07394</data>
  <data key="d29">entrez.498</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.498" target="drugbank.DB08629">
  <data key="d24">10393</data>
  <data key="d25">322</data>
  <data key="d26">N1-(2-AMINO-4-METHYLPENTYL)OCTAHYDRO-PYRROLO[1,2-A] PYRIMIDINE</data>
  <data key="d27">ATP5F1A</data>
  <data key="d28">drugbank.DB08629</data>
  <data key="d29">entrez.498</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.498" target="drugbank.DB08399">
  <data key="d24">10496</data>
  <data key="d25">322</data>
  <data key="d26">PICEATANNOL</data>
  <data key="d27">ATP5F1A</data>
  <data key="d28">drugbank.DB08399</data>
  <data key="d29">entrez.498</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.498" target="drugbank.DB04216">
  <data key="d24">12527</data>
  <data key="d25">322</data>
  <data key="d26">Quercetin</data>
  <data key="d27">ATP5F1A</data>
  <data key="d28">drugbank.DB04216</data>
  <data key="d29">entrez.498</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.627" target="mondo.0004975">
  <data key="d24">567</data>
  <data key="d25">9604</data>
  <data key="d26">BDNF</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.627</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.6</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.627" target="drugbank.DB09130">
  <data key="d24">6850</data>
  <data key="d25">567</data>
  <data key="d26">Copper</data>
  <data key="d27">BDNF</data>
  <data key="d28">drugbank.DB09130</data>
  <data key="d29">entrez.627</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.627" target="drugbank.DB11823">
  <data key="d24">8795</data>
  <data key="d25">567</data>
  <data key="d26">Esketamine</data>
  <data key="d27">BDNF</data>
  <data key="d28">drugbank.DB11823</data>
  <data key="d29">entrez.627</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.627" target="drugbank.DB09301">
  <data key="d24">9778</data>
  <data key="d25">567</data>
  <data key="d26">Chondroitin sulfate</data>
  <data key="d27">BDNF</data>
  <data key="d28">drugbank.DB09301</data>
  <data key="d29">entrez.627</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.627" target="drugbank.DB05047">
  <data key="d24">11321</data>
  <data key="d25">567</data>
  <data key="d26">CX717</data>
  <data key="d27">BDNF</data>
  <data key="d28">drugbank.DB05047</data>
  <data key="d29">entrez.627</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.581" target="mondo.0004975">
  <data key="d24">755</data>
  <data key="d25">9604</data>
  <data key="d26">BAX</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.581</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.51</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.590" target="mondo.0004975">
  <data key="d24">783</data>
  <data key="d25">9604</data>
  <data key="d26">BCHE</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.590</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.590" target="drugbank.DB14006">
  <data key="d24">695</data>
  <data key="d25">783</data>
  <data key="d26">Choline salicylate</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB14006</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB01069">
  <data key="d24">1661</data>
  <data key="d25">783</data>
  <data key="d26">Promethazine</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB01069</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB01057">
  <data key="d24">1907</data>
  <data key="d25">783</data>
  <data key="d26">Echothiophate</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB01057</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB03672">
  <data key="d24">2015</data>
  <data key="d25">783</data>
  <data key="d26">9-N-Phenylmethylamino-Tacrine</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB03672</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB01010">
  <data key="d24">2023</data>
  <data key="d25">783</data>
  <data key="d26">Edrophonium</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB01010</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB03814">
  <data key="d24">2675</data>
  <data key="d25">783</data>
  <data key="d26">2-(N-Morpholino)-Ethanesulfonic Acid</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB03814</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB03822">
  <data key="d24">2683</data>
  <data key="d25">783</data>
  <data key="d26">Ethyl Dihydrogen Phosphate</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB03822</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB03568">
  <data key="d24">3217</data>
  <data key="d25">783</data>
  <data key="d26">Butyric Acid</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB03568</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB04892">
  <data key="d24">3397</data>
  <data key="d25">783</data>
  <data key="d26">Phenserine</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB04892</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB00122">
  <data key="d24">3953</data>
  <data key="d25">783</data>
  <data key="d26">Choline</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB00122</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB02845">
  <data key="d24">4041</data>
  <data key="d25">783</data>
  <data key="d26">Methylphosphinic Acid</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB02845</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB02811">
  <data key="d24">4151</data>
  <data key="d25">783</data>
  <data key="d26">Diethylphosphono Group</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB02811</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB01226">
  <data key="d24">4991</data>
  <data key="d25">783</data>
  <data key="d26">Mivacurium</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB01226</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB01221">
  <data key="d24">5001</data>
  <data key="d25">783</data>
  <data key="d26">Ketamine</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB01221</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB01408">
  <data key="d24">5978</data>
  <data key="d25">783</data>
  <data key="d26">Bambuterol</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB01408</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB01400">
  <data key="d24">5985</data>
  <data key="d25">783</data>
  <data key="d26">Neostigmine</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB01400</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB00677">
  <data key="d24">6315</data>
  <data key="d25">783</data>
  <data key="d26">Isoflurophate</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB00677</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB00674">
  <data key="d24">6321</data>
  <data key="d25">783</data>
  <data key="d26">Galantamine</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB00674</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB11397">
  <data key="d24">6643</data>
  <data key="d25">783</data>
  <data key="d26">Dichlorvos</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB11397</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB00772">
  <data key="d24">6778</data>
  <data key="d25">783</data>
  <data key="d26">Malathion</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB00772</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB00733">
  <data key="d24">6916</data>
  <data key="d25">783</data>
  <data key="d26">Pralidoxime</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB00733</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB00382">
  <data key="d24">7100</data>
  <data key="d25">783</data>
  <data key="d26">Tacrine</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB00382</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB00392">
  <data key="d24">7139</data>
  <data key="d25">783</data>
  <data key="d26">Profenamine</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB00392</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB00449">
  <data key="d24">7530</data>
  <data key="d25">783</data>
  <data key="d26">Dipivefrin</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB00449</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB00545">
  <data key="d24">7939</data>
  <data key="d25">783</data>
  <data key="d26">Pyridostigmine</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB00545</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB08201">
  <data key="d24">8819</data>
  <data key="d25">783</data>
  <data key="d26">(1S)-menthyl hexyl phosphonate group</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB08201</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB08200">
  <data key="d24">8821</data>
  <data key="d25">783</data>
  <data key="d26">(1R)-menthyl hexyl phosphonate group</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB08200</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB00863">
  <data key="d24">9124</data>
  <data key="d25">783</data>
  <data key="d26">Ranitidine</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB00863</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB00843">
  <data key="d24">9272</data>
  <data key="d25">783</data>
  <data key="d26">Donepezil</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB00843</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB00989">
  <data key="d24">9552</data>
  <data key="d25">783</data>
  <data key="d26">Rivastigmine</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB00989</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB00981">
  <data key="d24">9564</data>
  <data key="d25">783</data>
  <data key="d26">Physostigmine</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB00981</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB00944">
  <data key="d24">9729</data>
  <data key="d25">783</data>
  <data key="d26">Demecarium</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB00944</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB00941">
  <data key="d24">9732</data>
  <data key="d25">783</data>
  <data key="d26">Hexafluronium</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB00941</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB00908">
  <data key="d24">9814</data>
  <data key="d25">783</data>
  <data key="d26">Quinidine</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB00908</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB08658">
  <data key="d24">10260</data>
  <data key="d25">783</data>
  <data key="d26">ETHYL HYDROGEN DIETHYLAMIDOPHOSPHATE</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB08658</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB07681">
  <data key="d24">11437</data>
  <data key="d25">783</data>
  <data key="d26">DODECANESULFONATE ION</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB07681</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB04216">
  <data key="d24">12527</data>
  <data key="d25">783</data>
  <data key="d26">Quercetin</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB04216</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB04250">
  <data key="d24">12576</data>
  <data key="d25">783</data>
  <data key="d26">Butyrylthiocholine</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB04250</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.590" target="drugbank.DB07940">
  <data key="d24">13092</data>
  <data key="d25">783</data>
  <data key="d26">9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE</data>
  <data key="d27">BCHE</data>
  <data key="d28">drugbank.DB07940</data>
  <data key="d29">entrez.590</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.596" target="mondo.0004975">
  <data key="d24">813</data>
  <data key="d25">9604</data>
  <data key="d26">BCL2</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.596</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.6</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.596" target="drugbank.DB01050">
  <data key="d24">1876</data>
  <data key="d25">813</data>
  <data key="d26">Ibuprofen</data>
  <data key="d27">BCL2</data>
  <data key="d28">drugbank.DB01050</data>
  <data key="d29">entrez.596</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.596" target="drugbank.DB13044">
  <data key="d24">1888</data>
  <data key="d25">813</data>
  <data key="d26">Gossypol</data>
  <data key="d27">BCL2</data>
  <data key="d28">drugbank.DB13044</data>
  <data key="d29">entrez.596</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.596" target="drugbank.DB12191">
  <data key="d24">3592</data>
  <data key="d25">813</data>
  <data key="d26">Obatoclax</data>
  <data key="d27">BCL2</data>
  <data key="d28">drugbank.DB12191</data>
  <data key="d29">entrez.596</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.596" target="drugbank.DB01229">
  <data key="d24">4988</data>
  <data key="d25">813</data>
  <data key="d26">Paclitaxel</data>
  <data key="d27">BCL2</data>
  <data key="d28">drugbank.DB01229</data>
  <data key="d29">entrez.596</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.596" target="drugbank.DB01248">
  <data key="d24">5097</data>
  <data key="d25">813</data>
  <data key="d26">Docetaxel</data>
  <data key="d27">BCL2</data>
  <data key="d28">drugbank.DB01248</data>
  <data key="d29">entrez.596</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.596" target="drugbank.DB01367">
  <data key="d24">5685</data>
  <data key="d25">813</data>
  <data key="d26">Rasagiline</data>
  <data key="d27">BCL2</data>
  <data key="d28">drugbank.DB01367</data>
  <data key="d29">entrez.596</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.596" target="drugbank.DB12340">
  <data key="d24">7317</data>
  <data key="d25">813</data>
  <data key="d26">Navitoclax</data>
  <data key="d27">BCL2</data>
  <data key="d28">drugbank.DB12340</data>
  <data key="d29">entrez.596</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.596" target="drugbank.DB09401">
  <data key="d24">8527</data>
  <data key="d25">813</data>
  <data key="d26">Isosorbide</data>
  <data key="d27">BCL2</data>
  <data key="d28">drugbank.DB09401</data>
  <data key="d29">entrez.596</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.596" target="drugbank.DB11581">
  <data key="d24">9074</data>
  <data key="d25">813</data>
  <data key="d26">Venetoclax</data>
  <data key="d27">BCL2</data>
  <data key="d28">drugbank.DB11581</data>
  <data key="d29">entrez.596</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.596" target="drugbank.DB09213">
  <data key="d24">9152</data>
  <data key="d25">813</data>
  <data key="d26">Dexibuprofen</data>
  <data key="d27">BCL2</data>
  <data key="d28">drugbank.DB09213</data>
  <data key="d29">entrez.596</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.596" target="drugbank.DB08936">
  <data key="d24">11154</data>
  <data key="d25">813</data>
  <data key="d26">Chlorcyclizine</data>
  <data key="d27">BCL2</data>
  <data key="d28">drugbank.DB08936</data>
  <data key="d29">entrez.596</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.596" target="drugbank.DB06307">
  <data key="d24">11226</data>
  <data key="d25">813</data>
  <data key="d26">Apoptone</data>
  <data key="d27">BCL2</data>
  <data key="d28">drugbank.DB06307</data>
  <data key="d29">entrez.596</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.596" target="drugbank.DB08871">
  <data key="d24">12143</data>
  <data key="d25">813</data>
  <data key="d26">Eribulin</data>
  <data key="d27">BCL2</data>
  <data key="d28">drugbank.DB08871</data>
  <data key="d29">entrez.596</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.596" target="drugbank.DB06756">
  <data key="d24">12240</data>
  <data key="d25">813</data>
  <data key="d26">Glycine betaine</data>
  <data key="d27">BCL2</data>
  <data key="d28">drugbank.DB06756</data>
  <data key="d29">entrez.596</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.596" target="drugbank.DB05297">
  <data key="d24">12891</data>
  <data key="d25">813</data>
  <data key="d26">Paclitaxel docosahexaenoic acid</data>
  <data key="d27">BCL2</data>
  <data key="d28">drugbank.DB05297</data>
  <data key="d29">entrez.596</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.274" target="mondo.0004975">
  <data key="d24">1286</data>
  <data key="d25">9604</data>
  <data key="d26">BIN1</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.274</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.267" target="mondo.0004975">
  <data key="d24">1293</data>
  <data key="d25">9604</data>
  <data key="d26">AMFR</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.267</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.3</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.23607" target="mondo.0004975">
  <data key="d24">1351</data>
  <data key="d25">9604</data>
  <data key="d26">CD2AP</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.23607</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.5</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.23621" target="mondo.0004975">
  <data key="d24">1385</data>
  <data key="d25">9604</data>
  <data key="d26">BACE1</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.23621</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB06930">
  <data key="d24">1130</data>
  <data key="d25">1385</data>
  <data key="d26">N-[amino(imino)methyl]-2-(2,5-diphenyl-1H-pyrrol-1-yl)acetamide</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB06930</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB02378">
  <data key="d24">1873</data>
  <data key="d25">1385</data>
  <data key="d26">MMI-175</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB02378</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB12285">
  <data key="d24">4178</data>
  <data key="d25">1385</data>
  <data key="d26">Verubecestat</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB12285</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB00843">
  <data key="d24">9272</data>
  <data key="d25">1385</data>
  <data key="d26">Donepezil</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB00843</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB09352">
  <data key="d24">9361</data>
  <data key="d25">1385</data>
  <data key="d26">Hydroxyamphetamine</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB09352</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB12944">
  <data key="d24">9797</data>
  <data key="d25">1385</data>
  <data key="d26">Phloroglucinol</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB12944</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07284">
  <data key="d24">9928</data>
  <data key="d25">1385</data>
  <data key="d26">N~3~-(3-PYRIDIN-3-YLBENZYL)PYRIDINE-2,3-DIAMINE</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07284</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07281">
  <data key="d24">9929</data>
  <data key="d25">1385</data>
  <data key="d26">N~3~-BENZYLPYRIDINE-2,3-DIAMINE</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07281</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07206">
  <data key="d24">9958</data>
  <data key="d25">1385</data>
  <data key="d26">6-[2-(1H-INDOL-6-YL)ETHYL]PYRIDIN-2-AMINE</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07206</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07245">
  <data key="d24">10043</data>
  <data key="d25">1385</data>
  <data key="d26">6-[2-(3'-METHOXYBIPHENYL-3-YL)ETHYL]PYRIDIN-2-AMINE</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07245</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB06073">
  <data key="d24">10235</data>
  <data key="d25">1385</data>
  <data key="d26">CTS-21166</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB06073</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07346">
  <data key="d24">10281</data>
  <data key="d25">1385</data>
  <data key="d26">4-(2-aminoethyl)-2-ethylphenol</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07346</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07345">
  <data key="d24">10290</data>
  <data key="d25">1385</data>
  <data key="d26">4-(2-aminoethyl)-2-cyclohexylphenol</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07345</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07303">
  <data key="d24">10378</data>
  <data key="d25">1385</data>
  <data key="d26">N~3~-[3-(5-METHOXYPYRIDIN-3-YL)BENZYL]PYRIDINE-2,3-DIAMINE</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07303</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07089">
  <data key="d24">10521</data>
  <data key="d25">1385</data>
  <data key="d26">N-[amino(imino)methyl]-2-[2-(2-chlorophenyl)-4-(4-propoxyphenyl)-3-thienyl]acetamide</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07089</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07019">
  <data key="d24">10585</data>
  <data key="d25">1385</data>
  <data key="d26">N-[(5R,14R)-5-AMINO-5,14-DIMETHYL-4-OXO-3-OXA-18-AZATRICYCLO[15.3.1.1~7,11~]DOCOSA-1(21),7(22),8,10,17,19-HEXAEN-19-YL]-N-METHYLMETHANESULFONAMIDE</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07019</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07175">
  <data key="d24">10852</data>
  <data key="d25">1385</data>
  <data key="d26">N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07175</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07110">
  <data key="d24">11033</data>
  <data key="d25">1385</data>
  <data key="d26">4-(4-FLUOROBENZYL)PIPERIDINE</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07110</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07735">
  <data key="d24">11474</data>
  <data key="d25">1385</data>
  <data key="d26">N-[1-(2,6-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07735</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07736">
  <data key="d24">11476</data>
  <data key="d25">1385</data>
  <data key="d26">(2S)-4-(4-fluorobenzyl)-N-(2-sulfanylethyl)piperazine-2-carboxamide</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07736</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07734">
  <data key="d24">11480</data>
  <data key="d25">1385</data>
  <data key="d26">N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07734</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07737">
  <data key="d24">11485</data>
  <data key="d25">1385</data>
  <data key="d26">(2S)-4-(4-fluorobenzyl)-N-(3-sulfanylpropyl)piperazine-2-carboxamide</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07737</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07738">
  <data key="d24">11486</data>
  <data key="d25">1385</data>
  <data key="d26">N-[1-(5-bromo-2,3-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07738</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07415">
  <data key="d24">11920</data>
  <data key="d25">1385</data>
  <data key="d26">4-[(1S)-1-(3-fluoro-4-methoxyphenyl)-2-(2-methoxy-5-nitrophenyl)ethyl]-1H-imidazol-2-amine</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07415</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB08749">
  <data key="d24">11924</data>
  <data key="d25">1385</data>
  <data key="d26">3-(2-AMINO-6-BENZOYLQUINAZOLIN-3(4H)-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB08749</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB08841">
  <data key="d24">11993</data>
  <data key="d25">1385</data>
  <data key="d26">Tyramine</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB08841</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07519">
  <data key="d24">12022</data>
  <data key="d25">1385</data>
  <data key="d26">(6R)-2-amino-6-[2-(3'-methoxybiphenyl-3-yl)ethyl]-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07519</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07573">
  <data key="d24">12052</data>
  <data key="d25">1385</data>
  <data key="d26">(2S)-1-(2,5-dimethylphenoxy)-3-morpholin-4-ylpropan-2-ol</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07573</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07535">
  <data key="d24">12163</data>
  <data key="d25">1385</data>
  <data key="d26">2-amino-6-[2-(1H-indol-6-yl)ethyl]pyrimidin-4(3H)-one</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07535</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB04216">
  <data key="d24">12527</data>
  <data key="d25">1385</data>
  <data key="d26">Quercetin</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB04216</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07874">
  <data key="d24">12786</data>
  <data key="d25">1385</data>
  <data key="d26">(6S)-2-amino-6-(3'-methoxybiphenyl-3-yl)-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07874</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07993">
  <data key="d24">13038</data>
  <data key="d25">1385</data>
  <data key="d26">N~3~-[3-(1H-INDOL-6-YL)BENZYL]PYRIDINE-2,3-DIAMINE</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07993</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23621" target="drugbank.DB07994">
  <data key="d24">13042</data>
  <data key="d25">1385</data>
  <data key="d26">N~3~-[5-(1H-INDOL-6-YL)-2-(PYRIDIN-2-YLMETHOXY)BENZYL]PYRIDINE-2,3-DIAMINE</data>
  <data key="d27">BACE1</data>
  <data key="d28">drugbank.DB07994</data>
  <data key="d29">entrez.23621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23646" target="mondo.0014316">
  <data key="d24">1420</data>
  <data key="d25">9343</data>
  <data key="d26">PLD3</data>
  <data key="d27">Alzheimer disease 19</data>
  <data key="d28">entrez.23646</data>
  <data key="d29">mondo.0014316</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.3</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.323" target="mondo.0004975">
  <data key="d24">1564</data>
  <data key="d25">9604</data>
  <data key="d26">APBB2</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.323</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.34</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.351" target="mondo.0004975">
  <data key="d24">1601</data>
  <data key="d25">9604</data>
  <data key="d26">APP</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.351</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.9</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.351" target="mondo.0007088">
  <data key="d24">1601</data>
  <data key="d25">23400</data>
  <data key="d26">APP</data>
  <data key="d27">Alzheimer disease type 1</data>
  <data key="d28">entrez.351</data>
  <data key="d29">mondo.0007088</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.351" target="drugbank.DB05846">
  <data key="d24">283</data>
  <data key="d25">1601</data>
  <data key="d26">Mito-4509</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB05846</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB05938">
  <data key="d24">809</data>
  <data key="d25">1601</data>
  <data key="d26">Edonerpic</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB05938</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB14487">
  <data key="d24">2394</data>
  <data key="d25">1601</data>
  <data key="d26">Zinc acetate</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB14487</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB01136">
  <data key="d24">2544</data>
  <data key="d25">1601</data>
  <data key="d26">Carvedilol</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB01136</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB02235">
  <data key="d24">3210</data>
  <data key="d25">1601</data>
  <data key="d26">L-methionine (R)-S-oxide</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB02235</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB04892">
  <data key="d24">3397</data>
  <data key="d25">1601</data>
  <data key="d26">Phenserine</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB04892</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB04815">
  <data key="d24">3440</data>
  <data key="d25">1601</data>
  <data key="d26">Clioquinol</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB04815</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB01593">
  <data key="d24">4227</data>
  <data key="d25">1601</data>
  <data key="d26">Zinc</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB01593</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB14533">
  <data key="d24">5035</data>
  <data key="d25">1601</data>
  <data key="d26">Zinc chloride</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB14533</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB14518">
  <data key="d24">5252</data>
  <data key="d25">1601</data>
  <data key="d26">Aluminum acetate</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB14518</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB14517">
  <data key="d24">5255</data>
  <data key="d25">1601</data>
  <data key="d26">Aluminium phosphate</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB14517</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB01370">
  <data key="d24">5701</data>
  <data key="d25">1601</data>
  <data key="d26">Aluminium</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB01370</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB02709">
  <data key="d24">6040</data>
  <data key="d25">1601</data>
  <data key="d26">Resveratrol</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB02709</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB09130">
  <data key="d24">6850</data>
  <data key="d25">1601</data>
  <data key="d26">Copper</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB09130</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB09149">
  <data key="d24">6893</data>
  <data key="d25">1601</data>
  <data key="d26">Florbetapir (18F)</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB09149</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB09148">
  <data key="d24">6894</data>
  <data key="d25">1601</data>
  <data key="d26">Florbetaben (18F)</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB09148</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB00746">
  <data key="d24">6933</data>
  <data key="d25">1601</data>
  <data key="d26">Deferoxamine</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB00746</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB09151">
  <data key="d24">8920</data>
  <data key="d25">1601</data>
  <data key="d26">Flutemetamol (18F)</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB09151</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB09241">
  <data key="d24">9023</data>
  <data key="d25">1601</data>
  <data key="d26">Methylene blue</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB09241</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB05088">
  <data key="d24">11271</data>
  <data key="d25">1601</data>
  <data key="d26">Tetrathiomolybdate</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB05088</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB05150">
  <data key="d24">11556</data>
  <data key="d25">1601</data>
  <data key="d26">CAD106</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB05150</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.351" target="drugbank.DB06782">
  <data key="d24">12281</data>
  <data key="d25">1601</data>
  <data key="d26">Dimercaprol</data>
  <data key="d27">APP</data>
  <data key="d28">drugbank.DB06782</data>
  <data key="d29">entrez.351</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.348" target="mondo.0011743">
  <data key="d24">1606</data>
  <data key="d25">258</data>
  <data key="d26">APOE</data>
  <data key="d27">Alzheimer disease 4</data>
  <data key="d28">entrez.348</data>
  <data key="d29">mondo.0011743</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.3</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.348" target="mondo.0004975">
  <data key="d24">1606</data>
  <data key="d25">9604</data>
  <data key="d26">APOE</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.348</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.7</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.348" target="mondo.0007089">
  <data key="d24">1606</data>
  <data key="d25">23397</data>
  <data key="d26">APOE</data>
  <data key="d27">Alzheimer disease 2</data>
  <data key="d28">entrez.348</data>
  <data key="d29">mondo.0007089</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.7</data>
  <data key="d32">[disgenet, omim]</data>
</edge>
<edge source="entrez.348" target="mondo.0011913">
  <data key="d24">1606</data>
  <data key="d25">23540</data>
  <data key="d26">APOE</data>
  <data key="d27">Alzheimer disease 3</data>
  <data key="d28">entrez.348</data>
  <data key="d29">mondo.0011913</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.348" target="drugbank.DB14487">
  <data key="d24">2394</data>
  <data key="d25">1606</data>
  <data key="d26">Zinc acetate</data>
  <data key="d27">APOE</data>
  <data key="d28">drugbank.DB14487</data>
  <data key="d29">entrez.348</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.348" target="drugbank.DB01593">
  <data key="d24">4227</data>
  <data key="d25">1606</data>
  <data key="d26">Zinc</data>
  <data key="d27">APOE</data>
  <data key="d28">drugbank.DB01593</data>
  <data key="d29">entrez.348</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.348" target="drugbank.DB14533">
  <data key="d24">5035</data>
  <data key="d25">1606</data>
  <data key="d26">Zinc chloride</data>
  <data key="d27">APOE</data>
  <data key="d28">drugbank.DB14533</data>
  <data key="d29">entrez.348</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.348" target="drugbank.DB09130">
  <data key="d24">6850</data>
  <data key="d25">1606</data>
  <data key="d26">Copper</data>
  <data key="d27">APOE</data>
  <data key="d28">drugbank.DB09130</data>
  <data key="d29">entrez.348</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.945" target="mondo.0004975">
  <data key="d24">1975</data>
  <data key="d25">9604</data>
  <data key="d26">CD33</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.945</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.945" target="drugbank.DB00056">
  <data key="d24">5441</data>
  <data key="d25">1975</data>
  <data key="d26">Gemtuzumab ozogamicin</data>
  <data key="d27">CD33</data>
  <data key="d28">drugbank.DB00056</data>
  <data key="d29">entrez.945</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.945" target="drugbank.DB06318">
  <data key="d24">11371</data>
  <data key="d25">1975</data>
  <data key="d26">AVE9633</data>
  <data key="d27">CD33</data>
  <data key="d28">drugbank.DB06318</data>
  <data key="d29">entrez.945</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23385" target="mondo.0004975">
  <data key="d24">3390</data>
  <data key="d25">9604</data>
  <data key="d26">NCSTN</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.23385</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.642" target="mondo.0004975">
  <data key="d24">3427</data>
  <data key="d25">9604</data>
  <data key="d26">BLMH</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.642</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.39</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.801" target="mondo.0004975">
  <data key="d24">3732</data>
  <data key="d25">9604</data>
  <data key="d26">CALM1</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.801</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.801" target="drugbank.DB04513">
  <data key="d24">279</data>
  <data key="d25">3732</data>
  <data key="d26">N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB04513</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB01069">
  <data key="d24">1661</data>
  <data key="d25">3732</data>
  <data key="d26">Promethazine</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB01069</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB01023">
  <data key="d24">1767</data>
  <data key="d25">3732</data>
  <data key="d26">Felodipine</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB01023</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB01065">
  <data key="d24">1912</data>
  <data key="d25">3732</data>
  <data key="d26">Melatonin</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB01065</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB14481">
  <data key="d24">2339</data>
  <data key="d25">3732</data>
  <data key="d26">Calcium phosphate dihydrate</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB14481</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB01184">
  <data key="d24">2384</data>
  <data key="d25">3732</data>
  <data key="d26">Domperidone</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB01184</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB01100">
  <data key="d24">2407</data>
  <data key="d25">3732</data>
  <data key="d26">Pimozide</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB01100</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB01115">
  <data key="d24">2443</data>
  <data key="d25">3732</data>
  <data key="d26">Nifedipine</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB01115</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB04825">
  <data key="d24">3448</data>
  <data key="d25">3732</data>
  <data key="d26">Prenylamine</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB04825</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB04841">
  <data key="d24">3475</data>
  <data key="d25">3732</data>
  <data key="d26">Flunarizine</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB04841</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB01429">
  <data key="d24">3796</data>
  <data key="d25">3732</data>
  <data key="d26">Aprindine</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB01429</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB02868">
  <data key="d24">4126</data>
  <data key="d25">3732</data>
  <data key="d26">3''-(Beta-Chloroethyl)-2'',4''-Dioxo-3, 5''-Spiro-Oxazolidino-4-Deacetoxy-Vinblastine</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB02868</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB01244">
  <data key="d24">5104</data>
  <data key="d25">3732</data>
  <data key="d26">Bepridil</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB01244</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB03900">
  <data key="d24">5383</data>
  <data key="d25">3732</data>
  <data key="d26">2-Methyl-2-Propanol</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB03900</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB01373">
  <data key="d24">5695</data>
  <data key="d25">3732</data>
  <data key="d26">Calcium</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB01373</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB03977">
  <data key="d24">5824</data>
  <data key="d25">3732</data>
  <data key="d26">N-Trimethyllysine</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB03977</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB00623">
  <data key="d24">6443</data>
  <data key="d25">3732</data>
  <data key="d26">Fluphenazine</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB00623</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB00622">
  <data key="d24">6445</data>
  <data key="d25">3732</data>
  <data key="d26">Nicardipine</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB00622</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB00637">
  <data key="d24">6473</data>
  <data key="d25">3732</data>
  <data key="d26">Astemizole</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB00637</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB11348">
  <data key="d24">6683</data>
  <data key="d25">3732</data>
  <data key="d26">Calcium Phosphate</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB11348</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB00753">
  <data key="d24">6955</data>
  <data key="d25">3732</data>
  <data key="d26">Isoflurane</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB00753</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB11093">
  <data key="d24">7075</data>
  <data key="d25">3732</data>
  <data key="d26">Calcium Citrate</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB11093</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB00434">
  <data key="d24">7498</data>
  <data key="d25">3732</data>
  <data key="d26">Cyproheptadine</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB00434</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB00477">
  <data key="d24">7827</data>
  <data key="d25">3732</data>
  <data key="d26">Chlorpromazine</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB00477</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB13800">
  <data key="d24">8082</data>
  <data key="d25">3732</data>
  <data key="d26">Calcium levulinate</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB13800</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB00502">
  <data key="d24">8096</data>
  <data key="d25">3732</data>
  <data key="d26">Haloperidol</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB00502</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB00527">
  <data key="d24">8143</data>
  <data key="d25">3732</data>
  <data key="d26">Cinchocaine</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB00527</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB08231">
  <data key="d24">8692</data>
  <data key="d25">3732</data>
  <data key="d26">Myristic acid</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB08231</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB00850">
  <data key="d24">9103</data>
  <data key="d25">3732</data>
  <data key="d26">Perphenazine</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB00850</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB00836">
  <data key="d24">9250</data>
  <data key="d25">3732</data>
  <data key="d26">Loperamide</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB00836</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB00831">
  <data key="d24">9255</data>
  <data key="d25">3732</data>
  <data key="d26">Trifluoperazine</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB00831</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB08039">
  <data key="d24">9418</data>
  <data key="d25">3732</data>
  <data key="d26">(3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB08039</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB00925">
  <data key="d24">9829</data>
  <data key="d25">3732</data>
  <data key="d26">Phenoxybenzamine</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB00925</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.801" target="drugbank.DB04216">
  <data key="d24">12527</data>
  <data key="d25">3732</data>
  <data key="d26">Quercetin</data>
  <data key="d27">CALM1</data>
  <data key="d28">drugbank.DB04216</data>
  <data key="d29">entrez.801</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.836" target="mondo.0004975">
  <data key="d24">3869</data>
  <data key="d25">9604</data>
  <data key="d26">CASP3</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.836</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.836" target="drugbank.DB03124">
  <data key="d24">1327</data>
  <data key="d25">3869</data>
  <data key="d26">5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid</data>
  <data key="d27">CASP3</data>
  <data key="d28">drugbank.DB03124</data>
  <data key="d29">entrez.836</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.836" target="drugbank.DB01017">
  <data key="d24">2056</data>
  <data key="d25">3869</data>
  <data key="d26">Minocycline</data>
  <data key="d27">CASP3</data>
  <data key="d28">drugbank.DB01017</data>
  <data key="d29">entrez.836</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.836" target="drugbank.DB13751">
  <data key="d24">7570</data>
  <data key="d25">3869</data>
  <data key="d26">Glycyrrhizic acid</data>
  <data key="d27">CASP3</data>
  <data key="d28">drugbank.DB13751</data>
  <data key="d29">entrez.836</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.836" target="drugbank.DB08229">
  <data key="d24">8699</data>
  <data key="d25">3869</data>
  <data key="d26">[N-(3-DIBENZYLCARBAMOYL-OXIRANECARBONYL)-HYDRAZINO]-ACETIC ACID</data>
  <data key="d27">CASP3</data>
  <data key="d28">drugbank.DB08229</data>
  <data key="d29">entrez.836</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.836" target="drugbank.DB08251">
  <data key="d24">8756</data>
  <data key="d25">3869</data>
  <data key="d26">4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID</data>
  <data key="d27">CASP3</data>
  <data key="d28">drugbank.DB08251</data>
  <data key="d29">entrez.836</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.836" target="drugbank.DB08213">
  <data key="d24">8859</data>
  <data key="d25">3869</data>
  <data key="d26">1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE</data>
  <data key="d27">CASP3</data>
  <data key="d28">drugbank.DB08213</data>
  <data key="d29">entrez.836</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.836" target="drugbank.DB00945">
  <data key="d24">9728</data>
  <data key="d25">3869</data>
  <data key="d26">Acetylsalicylic acid</data>
  <data key="d27">CASP3</data>
  <data key="d28">drugbank.DB00945</data>
  <data key="d29">entrez.836</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.836" target="drugbank.DB11994">
  <data key="d24">10596</data>
  <data key="d25">3869</data>
  <data key="d26">Diacerein</data>
  <data key="d27">CASP3</data>
  <data key="d28">drugbank.DB11994</data>
  <data key="d29">entrez.836</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.836" target="drugbank.DB08498">
  <data key="d24">10973</data>
  <data key="d25">3869</data>
  <data key="d26">(1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate</data>
  <data key="d27">CASP3</data>
  <data key="d28">drugbank.DB08498</data>
  <data key="d29">entrez.836</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.836" target="drugbank.DB08497">
  <data key="d24">10975</data>
  <data key="d25">3869</data>
  <data key="d26">(1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate</data>
  <data key="d27">CASP3</data>
  <data key="d28">drugbank.DB08497</data>
  <data key="d29">entrez.836</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.836" target="drugbank.DB08499">
  <data key="d24">10982</data>
  <data key="d25">3869</data>
  <data key="d26">N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide</data>
  <data key="d27">CASP3</data>
  <data key="d28">drugbank.DB08499</data>
  <data key="d29">entrez.836</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.836" target="drugbank.DB07696">
  <data key="d24">11300</data>
  <data key="d25">3869</data>
  <data key="d26">methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate</data>
  <data key="d27">CASP3</data>
  <data key="d28">drugbank.DB07696</data>
  <data key="d29">entrez.836</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.836" target="drugbank.DB05408">
  <data key="d24">12380</data>
  <data key="d25">3869</data>
  <data key="d26">Emricasan</data>
  <data key="d27">CASP3</data>
  <data key="d28">drugbank.DB05408</data>
  <data key="d29">entrez.836</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.836" target="drugbank.DB06862">
  <data key="d24">12628</data>
  <data key="d25">3869</data>
  <data key="d26">2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID</data>
  <data key="d27">CASP3</data>
  <data key="d28">drugbank.DB06862</data>
  <data key="d29">entrez.836</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.23237" target="mondo.0004975">
  <data key="d24">3875</data>
  <data key="d25">9604</data>
  <data key="d26">ARC</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.23237</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.32</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.102" target="mondo.0014265">
  <data key="d24">6694</data>
  <data key="d25">10192</data>
  <data key="d26">ADAM10</data>
  <data key="d27">Alzheimer disease 18</data>
  <data key="d28">entrez.102</data>
  <data key="d29">mondo.0014265</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.6</data>
  <data key="d32">[disgenet, omim]</data>
</edge>
<edge source="entrez.102" target="drugbank.DB04991">
  <data key="d24">1962</data>
  <data key="d25">6694</data>
  <data key="d26">XL784</data>
  <data key="d27">ADAM10</data>
  <data key="d28">drugbank.DB04991</data>
  <data key="d29">entrez.102</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4852" target="mondo.0004975">
  <data key="d24">12779</data>
  <data key="d25">9604</data>
  <data key="d26">NPY</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.4852</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.55</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.4852" target="drugbank.DB03380">
  <data key="d24">425</data>
  <data key="d25">12779</data>
  <data key="d26">L-tyrosinamide</data>
  <data key="d27">NPY</data>
  <data key="d28">drugbank.DB03380</data>
  <data key="d29">entrez.4852</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4852" target="drugbank.DB00191">
  <data key="d24">3566</data>
  <data key="d25">12779</data>
  <data key="d26">Phentermine</data>
  <data key="d27">NPY</data>
  <data key="d28">drugbank.DB00191</data>
  <data key="d29">entrez.4852</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4852" target="drugbank.DB02952">
  <data key="d24">4590</data>
  <data key="d25">12779</data>
  <data key="d26">Alpha-Aminoisobutyric Acid</data>
  <data key="d27">NPY</data>
  <data key="d28">drugbank.DB02952</data>
  <data key="d29">entrez.4852</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="mondo.0004975">
  <data key="d24">12789</data>
  <data key="d25">9604</data>
  <data key="d26">NOS3</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.4846</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.4846" target="mondo.0007088">
  <data key="d24">12789</data>
  <data key="d25">23400</data>
  <data key="d26">NOS3</data>
  <data key="d27">Alzheimer disease type 1</data>
  <data key="d28">entrez.4846</data>
  <data key="d29">mondo.0007088</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB04534">
  <data key="d24">124</data>
  <data key="d25">12789</data>
  <data key="d26">5-Nitroindazole</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB04534</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB04559">
  <data key="d24">197</data>
  <data key="d25">12789</data>
  <data key="d26">N-(Chlorophenyl)-N'-Hydroxyguanidine</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB04559</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB02044">
  <data key="d24">388</data>
  <data key="d25">12789</data>
  <data key="d26">N-(3-(Aminomethyl)Benzyl)Acetamidine</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB02044</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB02048">
  <data key="d24">442</data>
  <data key="d25">12789</data>
  <data key="d26">1,2,4-Triazole-Carboxamidine</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB02048</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB02077">
  <data key="d24">518</data>
  <data key="d25">12789</data>
  <data key="d26">L-N(omega)-Nitroarginine-(4R)-Amino-L-Proline Amide</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB02077</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB03332">
  <data key="d24">537</data>
  <data key="d25">12789</data>
  <data key="d26">5,6-Cyclic-Tetrahydropteridine</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB03332</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB02027">
  <data key="d24">684</data>
  <data key="d25">12789</data>
  <data key="d26">N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N'-Nitroguanidine</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB02027</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB03305">
  <data key="d24">745</data>
  <data key="d25">12789</data>
  <data key="d26">N5-Iminoethyl-L-Ornithine</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB03305</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB05676">
  <data key="d24">937</data>
  <data key="d25">12789</data>
  <data key="d26">Apremilast</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB05676</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB03065">
  <data key="d24">1254</data>
  <data key="d25">12789</data>
  <data key="d26">7-Nitroindazole-2-Carboxamidine</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB03065</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB03144">
  <data key="d24">1360</data>
  <data key="d25">12789</data>
  <data key="d26">N-Omega-Hydroxy-L-Arginine</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB03144</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB03100">
  <data key="d24">1462</data>
  <data key="d25">12789</data>
  <data key="d26">6-Nitroindazole</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB03100</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB02335">
  <data key="d24">2028</data>
  <data key="d25">12789</data>
  <data key="d26">2-Aminothiazoline</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB02335</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB03707">
  <data key="d24">2182</data>
  <data key="d25">12789</data>
  <data key="d26">S-Ethyl-N-Phenyl-Isothiourea</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB03707</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB01110">
  <data key="d24">2410</data>
  <data key="d25">12789</data>
  <data key="d26">Miconazole</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB01110</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB02141">
  <data key="d24">2891</data>
  <data key="d25">12789</data>
  <data key="d26">S,S'-(1,4-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB02141</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB02234">
  <data key="d24">3207</data>
  <data key="d25">12789</data>
  <data key="d26">S-Ethylisothiourea</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB02234</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB02207">
  <data key="d24">3358</data>
  <data key="d25">12789</data>
  <data key="d26">7-Nitroindazole</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB02207</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB00155">
  <data key="d24">3728</data>
  <data key="d25">12789</data>
  <data key="d26">L-Citrulline</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB00155</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB00125">
  <data key="d24">3947</data>
  <data key="d25">12789</data>
  <data key="d26">L-Arginine</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB00125</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB02979">
  <data key="d24">4704</data>
  <data key="d25">12789</data>
  <data key="d26">N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB02979</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB02911">
  <data key="d24">4776</data>
  <data key="d25">12789</data>
  <data key="d26">2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB02911</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB02589">
  <data key="d24">5160</data>
  <data key="d25">12789</data>
  <data key="d26">Se-Ethyl-Isoselenourea</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB02589</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB03910">
  <data key="d24">5393</data>
  <data key="d25">12789</data>
  <data key="d26">S,S'-(1,3-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB03910</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB03918">
  <data key="d24">5401</data>
  <data key="d25">12789</data>
  <data key="d26">6S-5,6,7,8-Tetrahydrobiopterin</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB03918</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB03963">
  <data key="d24">5785</data>
  <data key="d25">12789</data>
  <data key="d26">S-(Dimethylarsenic)Cysteine</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB03963</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB03974">
  <data key="d24">5817</data>
  <data key="d25">12789</data>
  <data key="d26">L-Homoarginine</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB03974</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB01997">
  <data key="d24">6262</data>
  <data key="d25">12789</data>
  <data key="d26">3-Bromo-7-Nitroindazole</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB01997</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB02994">
  <data key="d24">7231</data>
  <data key="d25">12789</data>
  <data key="d26">Cacodylic acid</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB02994</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB00356">
  <data key="d24">7328</data>
  <data key="d25">12789</data>
  <data key="d26">Chlorzoxazone</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB00356</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB01686">
  <data key="d24">7331</data>
  <data key="d25">12789</data>
  <data key="d26">N,N-dimethylarginine</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB01686</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB00360">
  <data key="d24">7341</data>
  <data key="d25">12789</data>
  <data key="d26">Sapropterin</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB00360</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB01821">
  <data key="d24">8072</data>
  <data key="d25">12789</data>
  <data key="d26">L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB01821</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB01833">
  <data key="d24">8097</data>
  <data key="d25">12789</data>
  <data key="d26">L-2-Amino-4-(Guanidinooxy)Butyric Acid</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB01833</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB09237">
  <data key="d24">8999</data>
  <data key="d25">12789</data>
  <data key="d26">Levamlodipine</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB09237</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB08019">
  <data key="d24">9376</data>
  <data key="d25">12789</data>
  <data key="d26">N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB08019</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB08018">
  <data key="d24">9665</data>
  <data key="d25">12789</data>
  <data key="d26">N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB08018</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB07244">
  <data key="d24">10033</data>
  <data key="d25">12789</data>
  <data key="d26">5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB07244</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB07388">
  <data key="d24">10218</data>
  <data key="d25">12789</data>
  <data key="d26">ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB07388</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB07001">
  <data key="d24">10750</data>
  <data key="d25">12789</data>
  <data key="d26">(3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB07001</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB04223">
  <data key="d24">12517</data>
  <data key="d25">12789</data>
  <data key="d26">Nitroarginine</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB04223</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4846" target="drugbank.DB04018">
  <data key="d24">13233</data>
  <data key="d25">12789</data>
  <data key="d26">S-Isopropyl-Isothiourea</data>
  <data key="d27">NOS3</data>
  <data key="d28">drugbank.DB04018</data>
  <data key="d29">entrez.4846</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4353" target="mondo.0004975">
  <data key="d24">14631</data>
  <data key="d25">9604</data>
  <data key="d26">MPO</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.4353</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.4353" target="mondo.0007088">
  <data key="d24">14631</data>
  <data key="d25">23400</data>
  <data key="d26">MPO</data>
  <data key="d27">Alzheimer disease type 1</data>
  <data key="d28">entrez.4353</data>
  <data key="d29">mondo.0007088</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.4353" target="drugbank.DB01065">
  <data key="d24">1912</data>
  <data key="d25">14631</data>
  <data key="d26">Melatonin</data>
  <data key="d27">MPO</data>
  <data key="d28">drugbank.DB01065</data>
  <data key="d29">entrez.4353</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4353" target="drugbank.DB04743">
  <data key="d24">2979</data>
  <data key="d25">14631</data>
  <data key="d26">Nimesulide</data>
  <data key="d27">MPO</data>
  <data key="d28">drugbank.DB04743</data>
  <data key="d29">entrez.4353</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4353" target="drugbank.DB02266">
  <data key="d24">3303</data>
  <data key="d25">14631</data>
  <data key="d26">Flufenamic Acid</data>
  <data key="d27">MPO</data>
  <data key="d28">drugbank.DB02266</data>
  <data key="d29">entrez.4353</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4353" target="drugbank.DB04821">
  <data key="d24">3444</data>
  <data key="d25">14631</data>
  <data key="d26">Nomifensine</data>
  <data key="d27">MPO</data>
  <data key="d28">drugbank.DB04821</data>
  <data key="d29">entrez.4353</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4353" target="drugbank.DB00244">
  <data key="d24">4538</data>
  <data key="d25">14631</data>
  <data key="d26">Mesalazine</data>
  <data key="d27">MPO</data>
  <data key="d28">drugbank.DB00244</data>
  <data key="d29">entrez.4353</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4353" target="drugbank.DB00583">
  <data key="d24">6130</data>
  <data key="d25">14631</data>
  <data key="d26">Levocarnitine</data>
  <data key="d27">MPO</data>
  <data key="d28">drugbank.DB00583</data>
  <data key="d29">entrez.4353</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4353" target="drugbank.DB00535">
  <data key="d24">7900</data>
  <data key="d25">14631</data>
  <data key="d26">Cefdinir</data>
  <data key="d27">MPO</data>
  <data key="d28">drugbank.DB00535</data>
  <data key="d29">entrez.4353</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4353" target="drugbank.DB00550">
  <data key="d24">7988</data>
  <data key="d25">14631</data>
  <data key="d26">Propylthiouracil</data>
  <data key="d27">MPO</data>
  <data key="d28">drugbank.DB00550</data>
  <data key="d29">entrez.4353</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4353" target="drugbank.DB04216">
  <data key="d24">12527</data>
  <data key="d25">14631</data>
  <data key="d26">Quercetin</data>
  <data key="d27">MPO</data>
  <data key="d28">drugbank.DB04216</data>
  <data key="d29">entrez.4353</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4524" target="mondo.0004975">
  <data key="d24">15974</data>
  <data key="d25">9604</data>
  <data key="d26">MTHFR</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.4524</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.4524" target="drugbank.DB00116">
  <data key="d24">3892</data>
  <data key="d25">15974</data>
  <data key="d26">Tetrahydrofolic acid</data>
  <data key="d27">MTHFR</data>
  <data key="d28">drugbank.DB00116</data>
  <data key="d29">entrez.4524</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4524" target="drugbank.DB00115">
  <data key="d24">3894</data>
  <data key="d25">15974</data>
  <data key="d26">Cyanocobalamin</data>
  <data key="d27">MTHFR</data>
  <data key="d28">drugbank.DB00115</data>
  <data key="d29">entrez.4524</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4137" target="mondo.0004975">
  <data key="d24">16153</data>
  <data key="d25">9604</data>
  <data key="d26">MAPT</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.4137</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.4137" target="drugbank.DB01229">
  <data key="d24">4988</data>
  <data key="d25">16153</data>
  <data key="d26">Paclitaxel</data>
  <data key="d27">MAPT</data>
  <data key="d28">drugbank.DB01229</data>
  <data key="d29">entrez.4137</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4137" target="drugbank.DB01248">
  <data key="d24">5097</data>
  <data key="d25">16153</data>
  <data key="d26">Docetaxel</data>
  <data key="d27">MAPT</data>
  <data key="d28">drugbank.DB01248</data>
  <data key="d29">entrez.4137</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4137" target="drugbank.DB00637">
  <data key="d24">6473</data>
  <data key="d25">16153</data>
  <data key="d26">Astemizole</data>
  <data key="d27">MAPT</data>
  <data key="d28">drugbank.DB00637</data>
  <data key="d29">entrez.4137</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4137" target="drugbank.DB00448">
  <data key="d24">7531</data>
  <data key="d25">16153</data>
  <data key="d26">Lansoprazole</data>
  <data key="d27">MAPT</data>
  <data key="d28">drugbank.DB00448</data>
  <data key="d29">entrez.4137</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4137" target="drugbank.DB09241">
  <data key="d24">9023</data>
  <data key="d25">16153</data>
  <data key="d26">Methylene blue</data>
  <data key="d27">MAPT</data>
  <data key="d28">drugbank.DB09241</data>
  <data key="d29">entrez.4137</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="mondo.0004975">
  <data key="d24">16179</data>
  <data key="d25">9604</data>
  <data key="d26">MAOB</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.4129</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.38</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB04677">
  <data key="d24">635</data>
  <data key="d25">16179</data>
  <data key="d26">N-METHYL-N-[(1R)-1-METHYL-2-PHENYLETHYL]PROP-2-EN-1-AMINE</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB04677</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB02095">
  <data key="d24">862</data>
  <data key="d25">16179</data>
  <data key="d26">Isatin</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB02095</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB04307">
  <data key="d24">1049</data>
  <data key="d25">16179</data>
  <data key="d26">5-Hydroxy-N-Propargyl-1(R)-Aminoindan</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB04307</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB03147">
  <data key="d24">1404</data>
  <data key="d25">16179</data>
  <data key="d26">Flavin adenine dinucleotide</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB03147</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB01087">
  <data key="d24">1701</data>
  <data key="d25">16179</data>
  <data key="d26">Primaquine</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB01087</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB01037">
  <data key="d24">1812</data>
  <data key="d25">16179</data>
  <data key="d26">Selegiline</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB01037</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB01168">
  <data key="d24">2342</data>
  <data key="d25">16179</data>
  <data key="d26">Procarbazine</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB01168</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB01176">
  <data key="d24">2345</data>
  <data key="d25">16179</data>
  <data key="d26">Cyclizine</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB01176</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB01171">
  <data key="d24">2353</data>
  <data key="d25">16179</data>
  <data key="d26">Moclobemide</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB01171</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB01132">
  <data key="d24">2501</data>
  <data key="d25">16179</data>
  <data key="d26">Pioglitazone</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB01132</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB02509">
  <data key="d24">2709</data>
  <data key="d25">16179</data>
  <data key="d26">Farnesol</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB02509</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB02211">
  <data key="d24">3372</data>
  <data key="d25">16179</data>
  <data key="d26">N-Methyl-N-Propargyl-1(R)-Aminoindan</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB02211</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB04818">
  <data key="d24">3441</data>
  <data key="d25">16179</data>
  <data key="d26">Iproniazid</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB04818</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB04821">
  <data key="d24">3444</data>
  <data key="d25">16179</data>
  <data key="d26">Nomifensine</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB04821</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB04820">
  <data key="d24">3445</data>
  <data key="d25">16179</data>
  <data key="d26">Nialamide</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB04820</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB04832">
  <data key="d24">3456</data>
  <data key="d25">16179</data>
  <data key="d26">Zimelidine</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB04832</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB04840">
  <data key="d24">3477</data>
  <data key="d25">16179</data>
  <data key="d26">Debrisoquine</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB04840</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB00182">
  <data key="d24">3539</data>
  <data key="d25">16179</data>
  <data key="d26">Amphetamine</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB00182</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB00197">
  <data key="d24">3560</data>
  <data key="d25">16179</data>
  <data key="d26">Troglitazone</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB00197</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB00191">
  <data key="d24">3566</data>
  <data key="d25">16179</data>
  <data key="d26">Phentermine</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB00191</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB01472">
  <data key="d24">3624</data>
  <data key="d25">16179</data>
  <data key="d26">4-Methoxyamphetamine</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB01472</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB00170">
  <data key="d24">3784</data>
  <data key="d25">16179</data>
  <data key="d26">Menadione</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB00170</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB01442">
  <data key="d24">3904</data>
  <data key="d25">16179</data>
  <data key="d26">MMDA</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB01442</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB01577">
  <data key="d24">4535</data>
  <data key="d25">16179</data>
  <data key="d26">Metamfetamine</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB01577</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB01626">
  <data key="d24">4578</data>
  <data key="d25">16179</data>
  <data key="d26">Pargyline</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB01626</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB03894">
  <data key="d24">5059</data>
  <data key="d25">16179</data>
  <data key="d26">N-Propargyl-1(S)-Aminoindan</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB03894</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB01247">
  <data key="d24">5098</data>
  <data key="d25">16179</data>
  <data key="d26">Isocarboxazid</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB01247</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB01363">
  <data key="d24">5636</data>
  <data key="d25">16179</data>
  <data key="d26">Ephedra sinica root</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB01363</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB01367">
  <data key="d24">5685</data>
  <data key="d25">16179</data>
  <data key="d26">Rasagiline</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB01367</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB02643">
  <data key="d24">5816</data>
  <data key="d25">16179</data>
  <data key="d26">N-Dodecyl-N,N-Dimethyl-3-Ammonio-1-Propanesulfonate</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB02643</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB00601">
  <data key="d24">6597</data>
  <data key="d25">16179</data>
  <data key="d26">Linezolid</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB00601</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB00780">
  <data key="d24">6784</data>
  <data key="d25">16179</data>
  <data key="d26">Phenelzine</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB00780</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB00752">
  <data key="d24">6956</data>
  <data key="d25">16179</data>
  <data key="d26">Tranylcypromine</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB00752</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB00721">
  <data key="d24">7036</data>
  <data key="d25">16179</data>
  <data key="d26">Procaine</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB00721</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB00412">
  <data key="d24">7435</data>
  <data key="d25">16179</data>
  <data key="d26">Rosiglitazone</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB00412</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB08082">
  <data key="d24">8245</data>
  <data key="d25">16179</data>
  <data key="d26">N-(2-AMINOETHYL)-P-CHLOROBENZAMIDE</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB08082</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB08176">
  <data key="d24">8378</data>
  <data key="d25">16179</data>
  <data key="d26">(1Z)-4-(4-FLUOROPHENYL)-2-METHYLIDENEBUTAN-1-IMINE</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB08176</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB09241">
  <data key="d24">9023</data>
  <data key="d25">16179</data>
  <data key="d26">Methylene blue</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB09241</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB09245">
  <data key="d24">9026</data>
  <data key="d25">16179</data>
  <data key="d26">Toloxatone</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB09245</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB09248">
  <data key="d24">9030</data>
  <data key="d25">16179</data>
  <data key="d26">Mebanazine</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB09248</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB09250">
  <data key="d24">9052</data>
  <data key="d25">16179</data>
  <data key="d26">Pheniprazine</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB09250</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB00813">
  <data key="d24">9223</data>
  <data key="d25">16179</data>
  <data key="d26">Fentanyl</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB00813</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB00843">
  <data key="d24">9272</data>
  <data key="d25">16179</data>
  <data key="d26">Donepezil</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB00843</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB00909">
  <data key="d24">9813</data>
  <data key="d25">16179</data>
  <data key="d26">Zonisamide</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB00909</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB08516">
  <data key="d24">10101</data>
  <data key="d25">16179</data>
  <data key="d26">(S)-(+)-2-[4-(FLUOROBENZYLOXY-BENZYLAMINO)PROPIONAMIDE]</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB08516</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB08480">
  <data key="d24">10941</data>
  <data key="d25">16179</data>
  <data key="d26">4-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB08480</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB07118">
  <data key="d24">11079</data>
  <data key="d25">16179</data>
  <data key="d26">Hymecromone</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB07118</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB07512">
  <data key="d24">11991</data>
  <data key="d25">16179</data>
  <data key="d26">7-[(3-CHLOROBENZYL)OXY]-2-OXO-2H-CHROMENE-4-CARBALDEHYDE</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB07512</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB07513">
  <data key="d24">12018</data>
  <data key="d25">16179</data>
  <data key="d26">7-[(3-CHLOROBENZYL)OXY]-4-[(METHYLAMINO)METHYL]-2H-CHROMEN-2-ONE</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB07513</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB04147">
  <data key="d24">12474</data>
  <data key="d25">16179</data>
  <data key="d26">Lauryl Dimethylamine-N-Oxide</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB04147</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB04216">
  <data key="d24">12527</data>
  <data key="d25">16179</data>
  <data key="d26">Quercetin</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB04216</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.4129" target="drugbank.DB06654">
  <data key="d24">13006</data>
  <data key="d25">16179</data>
  <data key="d26">Safinamide</data>
  <data key="d27">MAOB</data>
  <data key="d28">drugbank.DB06654</data>
  <data key="d29">entrez.4129</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.10347" target="mondo.0004975">
  <data key="d24">18785</data>
  <data key="d25">9604</data>
  <data key="d26">ABCA7</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.10347</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.5</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.3952" target="mondo.0004975">
  <data key="d24">19250</data>
  <data key="d25">9604</data>
  <data key="d26">LEP</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.3952</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.58</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.8301" target="mondo.0004975">
  <data key="d24">20417</data>
  <data key="d25">9604</data>
  <data key="d26">PICALM</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.8301</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.5</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.780912" target="mondo.0012321">
  <data key="d24">20785</data>
  <data key="d25">5141</data>
  <data key="d26">entrez.780912</data>
  <data key="d27">Alzheimer disease 10</data>
  <data key="d28">entrez.780912</data>
  <data key="d29">mondo.0012321</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.114475" target="mondo.0011647">
  <data key="d24">22400</data>
  <data key="d25">656</data>
  <data key="d26">entrez.114475</data>
  <data key="d27">Alzheimer disease 7</data>
  <data key="d28">entrez.114475</data>
  <data key="d29">mondo.0011647</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.8081" target="mondo.0011194">
  <data key="d24">22507</data>
  <data key="d25">4002</data>
  <data key="d26">entrez.8081</data>
  <data key="d27">Alzheimer disease 5</data>
  <data key="d28">entrez.8081</data>
  <data key="d29">mondo.0011194</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.7782" target="mondo.0004975">
  <data key="d24">25336</data>
  <data key="d25">9604</data>
  <data key="d26">SLC30A4</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.7782</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.31</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.7422" target="mondo.0004975">
  <data key="d24">26036</data>
  <data key="d25">9604</data>
  <data key="d26">VEGFA</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.7422</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB05890">
  <data key="d24">172</data>
  <data key="d25">26036</data>
  <data key="d26">Veglin</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB05890</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB05969">
  <data key="d24">749</data>
  <data key="d25">26036</data>
  <data key="d26">SNS-032</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB05969</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB05932">
  <data key="d24">799</data>
  <data key="d25">26036</data>
  <data key="d26">Denibulin</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB05932</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB03088">
  <data key="d24">1304</data>
  <data key="d25">26036</data>
  <data key="d26">Pidolic Acid</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB03088</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB01017">
  <data key="d24">2056</data>
  <data key="d25">26036</data>
  <data key="d26">Minocycline</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB01017</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB01120">
  <data key="d24">2458</data>
  <data key="d25">26036</data>
  <data key="d26">Gliclazide</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB01120</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB01136">
  <data key="d24">2544</data>
  <data key="d25">26036</data>
  <data key="d26">Carvedilol</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB01136</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB03754">
  <data key="d24">2641</data>
  <data key="d25">26036</data>
  <data key="d26">Tromethamine</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB03754</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB04895">
  <data key="d24">3209</data>
  <data key="d25">26036</data>
  <data key="d26">Pegaptanib</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB04895</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB00112">
  <data key="d24">3900</data>
  <data key="d25">26036</data>
  <data key="d26">Bevacizumab</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB00112</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB01270">
  <data key="d24">4907</data>
  <data key="d25">26036</data>
  <data key="d26">Ranibizumab</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB01270</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB09301">
  <data key="d24">9778</data>
  <data key="d25">26036</data>
  <data key="d26">Chondroitin sulfate</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB09301</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB10772">
  <data key="d24">10903</data>
  <data key="d25">26036</data>
  <data key="d26">Foreskin keratinocyte (neonatal)</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB10772</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB06151">
  <data key="d24">11864</data>
  <data key="d25">26036</data>
  <data key="d26">Acetylcysteine</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB06151</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB08885">
  <data key="d24">12183</data>
  <data key="d25">26036</data>
  <data key="d26">Aflibercept</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB08885</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB05434">
  <data key="d24">12268</data>
  <data key="d25">26036</data>
  <data key="d26">ABT-510</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB05434</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB06779">
  <data key="d24">12302</data>
  <data key="d25">26036</data>
  <data key="d26">Dalteparin</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB06779</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB05294">
  <data key="d24">12890</data>
  <data key="d25">26036</data>
  <data key="d26">Vandetanib</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB05294</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7422" target="drugbank.DB06642">
  <data key="d24">12973</data>
  <data key="d25">26036</data>
  <data key="d26">Bevasiranib</data>
  <data key="d27">VEGFA</data>
  <data key="d28">drugbank.DB06642</data>
  <data key="d29">entrez.7422</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7447" target="mondo.0004975">
  <data key="d24">26087</data>
  <data key="d25">9604</data>
  <data key="d26">VSNL1</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.7447</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.45</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.54209" target="mondo.0004975">
  <data key="d24">28150</data>
  <data key="d25">9604</data>
  <data key="d26">TREM2</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.54209</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.5</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.3553" target="mondo.0004975">
  <data key="d24">28668</data>
  <data key="d25">9604</data>
  <data key="d26">IL1B</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.3553</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.6</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.3553" target="drugbank.DB05767">
  <data key="d24">1495</data>
  <data key="d25">28668</data>
  <data key="d26">Andrographolide</data>
  <data key="d27">IL1B</data>
  <data key="d28">drugbank.DB05767</data>
  <data key="d29">entrez.3553</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3553" target="drugbank.DB01017">
  <data key="d24">2056</data>
  <data key="d25">28668</data>
  <data key="d26">Minocycline</data>
  <data key="d27">IL1B</data>
  <data key="d28">drugbank.DB01017</data>
  <data key="d29">entrez.3553</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3553" target="drugbank.DB12119">
  <data key="d24">3633</data>
  <data key="d25">28668</data>
  <data key="d26">Gevokizumab</data>
  <data key="d27">IL1B</data>
  <data key="d28">drugbank.DB12119</data>
  <data key="d29">entrez.3553</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3553" target="drugbank.DB12140">
  <data key="d24">3716</data>
  <data key="d25">28668</data>
  <data key="d26">Dilmapimod</data>
  <data key="d27">IL1B</data>
  <data key="d28">drugbank.DB12140</data>
  <data key="d29">entrez.3553</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3553" target="drugbank.DB11967">
  <data key="d24">10734</data>
  <data key="d25">28668</data>
  <data key="d26">Binimetinib</data>
  <data key="d27">IL1B</data>
  <data key="d28">drugbank.DB11967</data>
  <data key="d29">entrez.3553</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3553" target="drugbank.DB10772">
  <data key="d24">10903</data>
  <data key="d25">28668</data>
  <data key="d26">Foreskin keratinocyte (neonatal)</data>
  <data key="d27">IL1B</data>
  <data key="d28">drugbank.DB10772</data>
  <data key="d29">entrez.3553</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3553" target="drugbank.DB06372">
  <data key="d24">11314</data>
  <data key="d25">28668</data>
  <data key="d26">Rilonacept</data>
  <data key="d27">IL1B</data>
  <data key="d28">drugbank.DB06372</data>
  <data key="d29">entrez.3553</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3553" target="drugbank.DB05133">
  <data key="d24">11680</data>
  <data key="d25">28668</data>
  <data key="d26">VP025</data>
  <data key="d27">IL1B</data>
  <data key="d28">drugbank.DB05133</data>
  <data key="d29">entrez.3553</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3553" target="drugbank.DB06168">
  <data key="d24">11767</data>
  <data key="d25">28668</data>
  <data key="d26">Canakinumab</data>
  <data key="d27">IL1B</data>
  <data key="d28">drugbank.DB06168</data>
  <data key="d29">entrez.3553</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3553" target="drugbank.DB05442">
  <data key="d24">12254</data>
  <data key="d25">28668</data>
  <data key="d26">Etiprednol dicloacetate</data>
  <data key="d27">IL1B</data>
  <data key="d28">drugbank.DB05442</data>
  <data key="d29">entrez.3553</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3553" target="drugbank.DB05412">
  <data key="d24">12394</data>
  <data key="d25">28668</data>
  <data key="d26">Talmapimod</data>
  <data key="d27">IL1B</data>
  <data key="d28">drugbank.DB05412</data>
  <data key="d29">entrez.3553</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3553" target="drugbank.DB05470">
  <data key="d24">12436</data>
  <data key="d25">28668</data>
  <data key="d26">VX-702</data>
  <data key="d27">IL1B</data>
  <data key="d28">drugbank.DB05470</data>
  <data key="d29">entrez.3553</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3553" target="drugbank.DB05507">
  <data key="d24">12602</data>
  <data key="d25">28668</data>
  <data key="d26">VX-765</data>
  <data key="d27">IL1B</data>
  <data key="d28">drugbank.DB05507</data>
  <data key="d29">entrez.3553</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3553" target="drugbank.DB05260">
  <data key="d24">12955</data>
  <data key="d25">28668</data>
  <data key="d26">Gallium nitrate</data>
  <data key="d27">IL1B</data>
  <data key="d28">drugbank.DB05260</data>
  <data key="d29">entrez.3553</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="mondo.0004975">
  <data key="d24">29038</data>
  <data key="d25">9604</data>
  <data key="d26">INSR</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.3643</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.59</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB04868">
  <data key="d24">3359</data>
  <data key="d25">29038</data>
  <data key="d26">Nilotinib</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB04868</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB14751">
  <data key="d24">3935</data>
  <data key="d25">29038</data>
  <data key="d26">Mecasermin rinfabate</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB14751</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB12267">
  <data key="d24">4340</data>
  <data key="d25">29038</data>
  <data key="d26">Brigatinib</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB12267</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB01268">
  <data key="d24">4894</data>
  <data key="d25">29038</data>
  <data key="d26">Sunitinib</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB01268</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB01277">
  <data key="d24">4934</data>
  <data key="d25">29038</data>
  <data key="d26">Mecasermin</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB01277</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB01259">
  <data key="d24">5140</data>
  <data key="d25">29038</data>
  <data key="d26">Lapatinib</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB01259</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB03909">
  <data key="d24">5392</data>
  <data key="d25">29038</data>
  <data key="d26">Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB03909</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB00071">
  <data key="d24">5493</data>
  <data key="d25">29038</data>
  <data key="d26">Insulin Pork</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB00071</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB12010">
  <data key="d24">5608</data>
  <data key="d25">29038</data>
  <data key="d26">Fostamatinib</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB12010</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB00030">
  <data key="d24">5641</data>
  <data key="d25">29038</data>
  <data key="d26">Insulin Human</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB00030</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB00047">
  <data key="d24">5740</data>
  <data key="d25">29038</data>
  <data key="d26">Insulin glargine</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB00047</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB00046">
  <data key="d24">5742</data>
  <data key="d25">29038</data>
  <data key="d26">Insulin Lispro</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB00046</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB01309">
  <data key="d24">5774</data>
  <data key="d25">29038</data>
  <data key="d26">Insulin Glulisine</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB01309</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB01307">
  <data key="d24">5775</data>
  <data key="d25">29038</data>
  <data key="d26">Insulin Detemir</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB01307</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB01306">
  <data key="d24">5776</data>
  <data key="d25">29038</data>
  <data key="d26">Insulin Aspart</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB01306</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB00619">
  <data key="d24">6404</data>
  <data key="d25">29038</data>
  <data key="d26">Imatinib</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB00619</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB09079">
  <data key="d24">6627</data>
  <data key="d25">29038</data>
  <data key="d26">Nintedanib</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB09079</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB09063">
  <data key="d24">6756</data>
  <data key="d25">29038</data>
  <data key="d26">Ceritinib</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB09063</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB09129">
  <data key="d24">6819</data>
  <data key="d25">29038</data>
  <data key="d26">Chromic chloride</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB09129</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB00398">
  <data key="d24">7170</data>
  <data key="d25">29038</data>
  <data key="d26">Sorafenib</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB00398</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB09564">
  <data key="d24">8689</data>
  <data key="d25">29038</data>
  <data key="d26">Insulin Degludec</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB09564</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB11828">
  <data key="d24">8787</data>
  <data key="d25">29038</data>
  <data key="d26">Neratinib</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB11828</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB09330">
  <data key="d24">9595</data>
  <data key="d25">29038</data>
  <data key="d26">Osimertinib</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB09330</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB08513">
  <data key="d24">10073</data>
  <data key="d25">29038</data>
  <data key="d26">[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB08513</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB05120">
  <data key="d24">11642</data>
  <data key="d25">29038</data>
  <data key="d26">AT1391</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB05120</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB05115">
  <data key="d24">11658</data>
  <data key="d25">29038</data>
  <data key="d26">NN344</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB05115</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3643" target="drugbank.DB08865">
  <data key="d24">12120</data>
  <data key="d25">29038</data>
  <data key="d26">Crizotinib</data>
  <data key="d27">INSR</data>
  <data key="d28">drugbank.DB08865</data>
  <data key="d29">entrez.3643</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3630" target="mondo.0004975">
  <data key="d24">29056</data>
  <data key="d25">9604</data>
  <data key="d26">INS</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.3630</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.52</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.3630" target="drugbank.DB14487">
  <data key="d24">2394</data>
  <data key="d25">29056</data>
  <data key="d26">Zinc acetate</data>
  <data key="d27">INS</data>
  <data key="d28">drugbank.DB14487</data>
  <data key="d29">entrez.3630</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3630" target="drugbank.DB01593">
  <data key="d24">4227</data>
  <data key="d25">29056</data>
  <data key="d26">Zinc</data>
  <data key="d27">INS</data>
  <data key="d28">drugbank.DB01593</data>
  <data key="d29">entrez.3630</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3630" target="drugbank.DB14533">
  <data key="d24">5035</data>
  <data key="d25">29056</data>
  <data key="d26">Zinc chloride</data>
  <data key="d27">INS</data>
  <data key="d28">drugbank.DB14533</data>
  <data key="d29">entrez.3630</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3630" target="drugbank.DB01776">
  <data key="d24">7538</data>
  <data key="d25">29056</data>
  <data key="d26">M-Cresol</data>
  <data key="d27">INS</data>
  <data key="d28">drugbank.DB01776</data>
  <data key="d29">entrez.3630</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3630" target="drugbank.DB08231">
  <data key="d24">8692</data>
  <data key="d25">29056</data>
  <data key="d26">Myristic acid</data>
  <data key="d27">INS</data>
  <data key="d28">drugbank.DB08231</data>
  <data key="d29">entrez.3630</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3481" target="mondo.0004975">
  <data key="d24">30245</data>
  <data key="d25">9604</data>
  <data key="d26">IGF2</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.3481</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.55</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.3482" target="mondo.0004975">
  <data key="d24">30246</data>
  <data key="d25">9604</data>
  <data key="d26">IGF2R</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.3482</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.32</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.3482" target="drugbank.DB13173">
  <data key="d24">2207</data>
  <data key="d25">30246</data>
  <data key="d26">Cerliponase alfa</data>
  <data key="d27">IGF2R</data>
  <data key="d28">drugbank.DB13173</data>
  <data key="d29">entrez.3482</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3482" target="drugbank.DB14751">
  <data key="d24">3935</data>
  <data key="d25">30246</data>
  <data key="d26">Mecasermin rinfabate</data>
  <data key="d27">IGF2R</data>
  <data key="d28">drugbank.DB14751</data>
  <data key="d29">entrez.3482</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3482" target="drugbank.DB02900">
  <data key="d24">4861</data>
  <data key="d25">30246</data>
  <data key="d26">alpha-D-mannose 6-phosphate</data>
  <data key="d27">IGF2R</data>
  <data key="d28">drugbank.DB02900</data>
  <data key="d29">entrez.3482</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3482" target="drugbank.DB01277">
  <data key="d24">4934</data>
  <data key="d25">30246</data>
  <data key="d26">Mecasermin</data>
  <data key="d27">IGF2R</data>
  <data key="d28">drugbank.DB01277</data>
  <data key="d29">entrez.3482</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="mondo.0004975">
  <data key="d24">30249</data>
  <data key="d25">9604</data>
  <data key="d26">IGF1R</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.3480</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.52</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB05897">
  <data key="d24">226</data>
  <data key="d25">30249</data>
  <data key="d26">rhIGFBP-3</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB05897</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB04395">
  <data key="d24">1251</data>
  <data key="d25">30249</data>
  <data key="d26">Phosphoaminophosphonic Acid-Adenylate Ester</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB04395</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB00179">
  <data key="d24">3531</data>
  <data key="d25">30249</data>
  <data key="d26">Masoprocol</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB00179</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB14751">
  <data key="d24">3935</data>
  <data key="d25">30249</data>
  <data key="d26">Mecasermin rinfabate</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB14751</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB12250">
  <data key="d24">4258</data>
  <data key="d25">30249</data>
  <data key="d26">Cixutumumab</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB12250</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB12267">
  <data key="d24">4340</data>
  <data key="d25">30249</data>
  <data key="d26">Brigatinib</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB12267</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB01268">
  <data key="d24">4894</data>
  <data key="d25">30249</data>
  <data key="d26">Sunitinib</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB01268</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB01277">
  <data key="d24">4934</data>
  <data key="d25">30249</data>
  <data key="d26">Mecasermin</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB01277</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB00071">
  <data key="d24">5493</data>
  <data key="d25">30249</data>
  <data key="d26">Insulin Pork</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB00071</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB00030">
  <data key="d24">5641</data>
  <data key="d25">30249</data>
  <data key="d26">Insulin Human</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB00030</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB00047">
  <data key="d24">5740</data>
  <data key="d25">30249</data>
  <data key="d26">Insulin glargine</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB00047</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB00046">
  <data key="d24">5742</data>
  <data key="d25">30249</data>
  <data key="d26">Insulin Lispro</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB00046</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB01309">
  <data key="d24">5774</data>
  <data key="d25">30249</data>
  <data key="d26">Insulin Glulisine</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB01309</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB01307">
  <data key="d24">5775</data>
  <data key="d25">30249</data>
  <data key="d26">Insulin Detemir</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB01307</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB01306">
  <data key="d24">5776</data>
  <data key="d25">30249</data>
  <data key="d26">Insulin Aspart</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB01306</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB09079">
  <data key="d24">6627</data>
  <data key="d25">30249</data>
  <data key="d26">Nintedanib</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB09079</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB09098">
  <data key="d24">6652</data>
  <data key="d25">30249</data>
  <data key="d26">Somatrem</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB09098</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB09063">
  <data key="d24">6756</data>
  <data key="d25">30249</data>
  <data key="d26">Ceritinib</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB09063</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB09564">
  <data key="d24">8689</data>
  <data key="d25">30249</data>
  <data key="d26">Insulin Degludec</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB09564</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB06075">
  <data key="d24">10238</data>
  <data key="d25">30249</data>
  <data key="d26">Linsitinib</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB06075</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB07156">
  <data key="d24">10944</data>
  <data key="d25">30249</data>
  <data key="d26">(4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB07156</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB06343">
  <data key="d24">11419</data>
  <data key="d25">30249</data>
  <data key="d26">Teprotumumab</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB06343</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB05023">
  <data key="d24">11442</data>
  <data key="d25">30249</data>
  <data key="d26">ATL1101</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB05023</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB05184">
  <data key="d24">11602</data>
  <data key="d25">30249</data>
  <data key="d26">XL228</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB05184</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB07474">
  <data key="d24">11849</data>
  <data key="d25">30249</data>
  <data key="d26">3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB07474</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB08865">
  <data key="d24">12120</data>
  <data key="d25">30249</data>
  <data key="d26">Crizotinib</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB08865</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3480" target="drugbank.DB04216">
  <data key="d24">12527</data>
  <data key="d25">30249</data>
  <data key="d26">Quercetin</data>
  <data key="d27">IGF1R</data>
  <data key="d28">drugbank.DB04216</data>
  <data key="d29">entrez.3480</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3479" target="mondo.0004975">
  <data key="d24">30259</data>
  <data key="d25">9604</data>
  <data key="d26">IGF1</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.3479</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.3479" target="drugbank.DB02643">
  <data key="d24">5816</data>
  <data key="d25">30259</data>
  <data key="d26">N-Dodecyl-N,N-Dimethyl-3-Ammonio-1-Propanesulfonate</data>
  <data key="d27">IGF1</data>
  <data key="d28">drugbank.DB02643</data>
  <data key="d29">entrez.3479</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3479" target="drugbank.DB01890">
  <data key="d24">7992</data>
  <data key="d25">30259</data>
  <data key="d26">N,N-Bis(3-(D-gluconamido)propyl)deoxycholamide</data>
  <data key="d27">IGF1</data>
  <data key="d28">drugbank.DB01890</data>
  <data key="d29">entrez.3479</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3416" target="mondo.0004975">
  <data key="d24">30305</data>
  <data key="d25">9604</data>
  <data key="d26">IDE</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.3416</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.3416" target="drugbank.DB00121">
  <data key="d24">3956</data>
  <data key="d25">30305</data>
  <data key="d26">Biotin</data>
  <data key="d27">IDE</data>
  <data key="d28">drugbank.DB00121</data>
  <data key="d29">entrez.3416</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3416" target="drugbank.DB00071">
  <data key="d24">5493</data>
  <data key="d25">30305</data>
  <data key="d26">Insulin Pork</data>
  <data key="d27">IDE</data>
  <data key="d28">drugbank.DB00071</data>
  <data key="d29">entrez.3416</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3416" target="drugbank.DB00626">
  <data key="d24">6437</data>
  <data key="d25">30305</data>
  <data key="d26">Bacitracin</data>
  <data key="d27">IDE</data>
  <data key="d28">drugbank.DB00626</data>
  <data key="d29">entrez.3416</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3416" target="drugbank.DB09552">
  <data key="d24">8655</data>
  <data key="d25">30305</data>
  <data key="d26">Thonzonium</data>
  <data key="d27">IDE</data>
  <data key="d28">drugbank.DB09552</data>
  <data key="d29">entrez.3416</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3077" target="mondo.0004975">
  <data key="d24">30483</data>
  <data key="d25">9604</data>
  <data key="d26">HFE</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.3077</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.3077" target="mondo.0007088">
  <data key="d24">30483</data>
  <data key="d25">23400</data>
  <data key="d26">HFE</data>
  <data key="d27">Alzheimer disease type 1</data>
  <data key="d28">entrez.3077</data>
  <data key="d29">mondo.0007088</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.3127" target="mondo.0004975">
  <data key="d24">30753</data>
  <data key="d25">9604</data>
  <data key="d26">HLA-DRB5</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.3127</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.31</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.3162" target="mondo.0004975">
  <data key="d24">31025</data>
  <data key="d25">9604</data>
  <data key="d26">HMOX1</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.3162</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.3162" target="drugbank.DB02073">
  <data key="d24">514</data>
  <data key="d25">31025</data>
  <data key="d26">Biliverdine IX Alpha</data>
  <data key="d27">HMOX1</data>
  <data key="d28">drugbank.DB02073</data>
  <data key="d29">entrez.3162</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3162" target="drugbank.DB06914">
  <data key="d24">1109</data>
  <data key="d25">31025</data>
  <data key="d26">1-({2-[2-(4-CHLOROPHENYL)ETHYL]-1,3-DIOXOLAN-2-YL}METHYL)-1H-IMIDAZOLE</data>
  <data key="d27">HMOX1</data>
  <data key="d28">drugbank.DB06914</data>
  <data key="d29">entrez.3162</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3162" target="drugbank.DB02468">
  <data key="d24">2564</data>
  <data key="d25">31025</data>
  <data key="d26">12-Phenylheme</data>
  <data key="d27">HMOX1</data>
  <data key="d28">drugbank.DB02468</data>
  <data key="d29">entrez.3162</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3162" target="drugbank.DB04803">
  <data key="d24">3099</data>
  <data key="d25">31025</data>
  <data key="d26">Verdoheme</data>
  <data key="d27">HMOX1</data>
  <data key="d28">drugbank.DB04803</data>
  <data key="d29">entrez.3162</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3162" target="drugbank.DB04912">
  <data key="d24">3504</data>
  <data key="d25">31025</data>
  <data key="d26">Stannsoporfin</data>
  <data key="d27">HMOX1</data>
  <data key="d28">drugbank.DB04912</data>
  <data key="d29">entrez.3162</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3162" target="drugbank.DB00157">
  <data key="d24">3724</data>
  <data key="d25">31025</data>
  <data key="d26">NADH</data>
  <data key="d27">HMOX1</data>
  <data key="d28">drugbank.DB00157</data>
  <data key="d29">entrez.3162</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3162" target="drugbank.DB03906">
  <data key="d24">5389</data>
  <data key="d25">31025</data>
  <data key="d26">2-Phenylheme</data>
  <data key="d27">HMOX1</data>
  <data key="d28">drugbank.DB03906</data>
  <data key="d29">entrez.3162</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3162" target="drugbank.DB01942">
  <data key="d24">6419</data>
  <data key="d25">31025</data>
  <data key="d26">Formic acid</data>
  <data key="d27">HMOX1</data>
  <data key="d28">drugbank.DB01942</data>
  <data key="d29">entrez.3162</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.3162" target="drugbank.DB07342">
  <data key="d24">10273</data>
  <data key="d25">31025</data>
  <data key="d26">1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone</data>
  <data key="d27">HMOX1</data>
  <data key="d28">drugbank.DB07342</data>
  <data key="d29">entrez.3162</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.10858" target="mondo.0004975">
  <data key="d24">31449</data>
  <data key="d25">9604</data>
  <data key="d26">CYP46A1</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.10858</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.2932" target="mondo.0004975">
  <data key="d24">33460</data>
  <data key="d25">9604</data>
  <data key="d26">GSK3B</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.2932</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.6</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB02052">
  <data key="d24">429</data>
  <data key="d25">33460</data>
  <data key="d26">Indirubin-3'-Monoxime</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB02052</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB02010">
  <data key="d24">567</data>
  <data key="d25">33460</data>
  <data key="d26">Staurosporine</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB02010</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB04395">
  <data key="d24">1251</data>
  <data key="d25">33460</data>
  <data key="d26">Phosphoaminophosphonic Acid-Adenylate Ester</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB04395</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB01094">
  <data key="d24">1729</data>
  <data key="d25">33460</data>
  <data key="d26">Hesperetin</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB01094</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB03444">
  <data key="d24">2824</data>
  <data key="d25">33460</data>
  <data key="d26">(3e)-6'-Bromo-2,3'-Biindole-2',3(1h,1'h)-Dione 3-Oxime</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB03444</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB12129">
  <data key="d24">3693</data>
  <data key="d25">33460</data>
  <data key="d26">Tideglusib</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB12129</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB14509">
  <data key="d24">5204</data>
  <data key="d25">33460</data>
  <data key="d26">Lithium carbonate</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB14509</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB14508">
  <data key="d24">5207</data>
  <data key="d25">33460</data>
  <data key="d26">Lithium succinate</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB14508</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB14507">
  <data key="d24">5210</data>
  <data key="d25">33460</data>
  <data key="d26">Lithium citrate</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB14507</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB12010">
  <data key="d24">5608</data>
  <data key="d25">33460</data>
  <data key="d26">Fostamatinib</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB12010</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB01356">
  <data key="d24">5625</data>
  <data key="d25">33460</data>
  <data key="d26">Lithium cation</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB01356</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB01950">
  <data key="d24">6451</data>
  <data key="d25">33460</data>
  <data key="d26">N-(4-Methoxybenzyl)-N'-(5-Nitro-1,3-Thiazol-2-Yl)Urea</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB01950</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB09079">
  <data key="d24">6627</data>
  <data key="d25">33460</data>
  <data key="d26">Nintedanib</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB09079</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB01772">
  <data key="d24">7546</data>
  <data key="d25">33460</data>
  <data key="d26">3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB01772</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB01793">
  <data key="d24">7785</data>
  <data key="d25">33460</data>
  <data key="d26">SB-409513</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB01793</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB08073">
  <data key="d24">8234</data>
  <data key="d25">33460</data>
  <data key="d26">(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB08073</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB11829">
  <data key="d24">8788</data>
  <data key="d25">33460</data>
  <data key="d26">Ruboxistaurin</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB11829</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB07058">
  <data key="d24">10474</data>
  <data key="d25">33460</data>
  <data key="d26">5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB07058</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB07014">
  <data key="d24">10536</data>
  <data key="d25">33460</data>
  <data key="d26">2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB07014</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB07149">
  <data key="d24">10920</data>
  <data key="d25">33460</data>
  <data key="d26">(7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB07149</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB07676">
  <data key="d24">11414</data>
  <data key="d25">33460</data>
  <data key="d26">3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB07676</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB07584">
  <data key="d24">12075</data>
  <data key="d25">33460</data>
  <data key="d26">N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB07584</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB07585">
  <data key="d24">12076</data>
  <data key="d25">33460</data>
  <data key="d26">5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB07585</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB04216">
  <data key="d24">12527</data>
  <data key="d25">33460</data>
  <data key="d26">Quercetin</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB04216</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB06803">
  <data key="d24">12674</data>
  <data key="d25">33460</data>
  <data key="d26">Niclosamide</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB06803</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB07859">
  <data key="d24">12781</data>
  <data key="d25">33460</data>
  <data key="d26">4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB07859</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB07812">
  <data key="d24">12842</data>
  <data key="d25">33460</data>
  <data key="d26">N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB07812</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB06595">
  <data key="d24">12958</data>
  <data key="d25">33460</data>
  <data key="d26">Midostaurin</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB06595</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB04014">
  <data key="d24">13062</data>
  <data key="d25">33460</data>
  <data key="d26">Alsterpaullone</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB04014</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2932" target="drugbank.DB07947">
  <data key="d24">13128</data>
  <data key="d25">33460</data>
  <data key="d26">ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE</data>
  <data key="d27">GSK3B</data>
  <data key="d28">drugbank.DB07947</data>
  <data key="d29">entrez.2932</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7019" target="mondo.0004975">
  <data key="d24">36096</data>
  <data key="d25">9604</data>
  <data key="d26">TFAM</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.7019</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.35</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.7018" target="mondo.0004975">
  <data key="d24">36097</data>
  <data key="d25">9604</data>
  <data key="d26">TF</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.7018</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.35</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.7018" target="drugbank.DB14491">
  <data key="d24">2375</data>
  <data key="d25">36097</data>
  <data key="d26">Ferrous fumarate</data>
  <data key="d27">TF</data>
  <data key="d28">drugbank.DB14491</data>
  <data key="d29">entrez.7018</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7018" target="drugbank.DB14490">
  <data key="d24">2377</data>
  <data key="d25">36097</data>
  <data key="d26">Ferrous ascorbate</data>
  <data key="d27">TF</data>
  <data key="d28">drugbank.DB14490</data>
  <data key="d29">entrez.7018</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7018" target="drugbank.DB14489">
  <data key="d24">2390</data>
  <data key="d25">36097</data>
  <data key="d26">Ferrous succinate</data>
  <data key="d27">TF</data>
  <data key="d28">drugbank.DB14489</data>
  <data key="d29">entrez.7018</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7018" target="drugbank.DB14488">
  <data key="d24">2392</data>
  <data key="d25">36097</data>
  <data key="d26">Ferrous gluconate</data>
  <data key="d27">TF</data>
  <data key="d28">drugbank.DB14488</data>
  <data key="d29">entrez.7018</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7018" target="drugbank.DB14487">
  <data key="d24">2394</data>
  <data key="d25">36097</data>
  <data key="d26">Zinc acetate</data>
  <data key="d27">TF</data>
  <data key="d28">drugbank.DB14487</data>
  <data key="d29">entrez.7018</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7018" target="drugbank.DB01593">
  <data key="d24">4227</data>
  <data key="d25">36097</data>
  <data key="d26">Zinc</data>
  <data key="d27">TF</data>
  <data key="d28">drugbank.DB01593</data>
  <data key="d29">entrez.7018</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7018" target="drugbank.DB01592">
  <data key="d24">4229</data>
  <data key="d25">36097</data>
  <data key="d26">Iron</data>
  <data key="d27">TF</data>
  <data key="d28">drugbank.DB01592</data>
  <data key="d29">entrez.7018</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7018" target="drugbank.DB14533">
  <data key="d24">5035</data>
  <data key="d25">36097</data>
  <data key="d26">Zinc chloride</data>
  <data key="d27">TF</data>
  <data key="d28">drugbank.DB14533</data>
  <data key="d29">entrez.7018</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7018" target="drugbank.DB14501">
  <data key="d24">5223</data>
  <data key="d25">36097</data>
  <data key="d26">Ferrous glycine sulfate</data>
  <data key="d27">TF</data>
  <data key="d28">drugbank.DB14501</data>
  <data key="d29">entrez.7018</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7018" target="drugbank.DB14518">
  <data key="d24">5252</data>
  <data key="d25">36097</data>
  <data key="d26">Aluminum acetate</data>
  <data key="d27">TF</data>
  <data key="d28">drugbank.DB14518</data>
  <data key="d29">entrez.7018</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7018" target="drugbank.DB14517">
  <data key="d24">5255</data>
  <data key="d25">36097</data>
  <data key="d26">Aluminium phosphate</data>
  <data key="d27">TF</data>
  <data key="d28">drugbank.DB14517</data>
  <data key="d29">entrez.7018</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7018" target="drugbank.DB01370">
  <data key="d24">5701</data>
  <data key="d25">36097</data>
  <data key="d26">Aluminium</data>
  <data key="d27">TF</data>
  <data key="d28">drugbank.DB01370</data>
  <data key="d29">entrez.7018</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7018" target="drugbank.DB00677">
  <data key="d24">6315</data>
  <data key="d25">36097</data>
  <data key="d26">Isoflurophate</data>
  <data key="d27">TF</data>
  <data key="d28">drugbank.DB00677</data>
  <data key="d29">entrez.7018</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7018" target="drugbank.DB11397">
  <data key="d24">6643</data>
  <data key="d25">36097</data>
  <data key="d26">Dichlorvos</data>
  <data key="d27">TF</data>
  <data key="d28">drugbank.DB11397</data>
  <data key="d29">entrez.7018</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7018" target="drugbank.DB09130">
  <data key="d24">6850</data>
  <data key="d25">36097</data>
  <data key="d26">Copper</data>
  <data key="d27">TF</data>
  <data key="d28">drugbank.DB09130</data>
  <data key="d29">entrez.7018</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7018" target="drugbank.DB00515">
  <data key="d24">8119</data>
  <data key="d25">36097</data>
  <data key="d26">Cisplatin</data>
  <data key="d27">TF</data>
  <data key="d28">drugbank.DB00515</data>
  <data key="d29">entrez.7018</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7018" target="drugbank.DB06757">
  <data key="d24">12242</data>
  <data key="d25">36097</data>
  <data key="d26">Manganese</data>
  <data key="d27">TF</data>
  <data key="d28">drugbank.DB06757</data>
  <data key="d29">entrez.7018</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7167" target="mondo.0004975">
  <data key="d24">36689</data>
  <data key="d25">9604</data>
  <data key="d26">TPI1</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.7167</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.31</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.7167" target="drugbank.DB04510">
  <data key="d24">277</data>
  <data key="d25">36689</data>
  <data key="d26">3-phospho-D-glyceric acid</data>
  <data key="d27">TPI1</data>
  <data key="d28">drugbank.DB04510</data>
  <data key="d29">entrez.7167</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7167" target="drugbank.DB03379">
  <data key="d24">443</data>
  <data key="d25">36689</data>
  <data key="d26">2-Carboxyethylphosphonic Acid</data>
  <data key="d27">TPI1</data>
  <data key="d28">drugbank.DB03379</data>
  <data key="d29">entrez.7167</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7167" target="drugbank.DB03314">
  <data key="d24">771</data>
  <data key="d25">36689</data>
  <data key="d26">5-fluorotryptophan</data>
  <data key="d27">TPI1</data>
  <data key="d28">drugbank.DB03314</data>
  <data key="d29">entrez.7167</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7167" target="drugbank.DB03026">
  <data key="d24">969</data>
  <data key="d25">36689</data>
  <data key="d26">Phosphoglycolohydroxamic Acid</data>
  <data key="d27">TPI1</data>
  <data key="d28">drugbank.DB03026</data>
  <data key="d29">entrez.7167</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7167" target="drugbank.DB04326">
  <data key="d24">1097</data>
  <data key="d25">36689</data>
  <data key="d26">Dihydroxyacetone phosphate</data>
  <data key="d27">TPI1</data>
  <data key="d28">drugbank.DB04326</data>
  <data key="d29">entrez.7167</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7167" target="drugbank.DB03132">
  <data key="d24">1318</data>
  <data key="d25">36689</data>
  <data key="d26">3-(2-Benzothiazolylthio)-1-Propanesulfonic Acid</data>
  <data key="d27">TPI1</data>
  <data key="d28">drugbank.DB03132</data>
  <data key="d29">entrez.7167</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7167" target="drugbank.DB03135">
  <data key="d24">1363</data>
  <data key="d25">36689</data>
  <data key="d26">[2(Formyl-Hydroxy-Amino)-Ethyl]-Phosphonic Acid</data>
  <data key="d27">TPI1</data>
  <data key="d28">drugbank.DB03135</data>
  <data key="d29">entrez.7167</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7167" target="drugbank.DB04447">
  <data key="d24">1526</data>
  <data key="d25">36689</data>
  <data key="d26">1,4-Dithiothreitol</data>
  <data key="d27">TPI1</data>
  <data key="d28">drugbank.DB04447</data>
  <data key="d29">entrez.7167</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7167" target="drugbank.DB14487">
  <data key="d24">2394</data>
  <data key="d25">36689</data>
  <data key="d26">Zinc acetate</data>
  <data key="d27">TPI1</data>
  <data key="d28">drugbank.DB14487</data>
  <data key="d29">entrez.7167</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7167" target="drugbank.DB01593">
  <data key="d24">4227</data>
  <data key="d25">36689</data>
  <data key="d26">Zinc</data>
  <data key="d27">TPI1</data>
  <data key="d28">drugbank.DB01593</data>
  <data key="d29">entrez.7167</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7167" target="drugbank.DB14533">
  <data key="d24">5035</data>
  <data key="d25">36689</data>
  <data key="d26">Zinc chloride</data>
  <data key="d27">TPI1</data>
  <data key="d28">drugbank.DB14533</data>
  <data key="d29">entrez.7167</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7167" target="drugbank.DB03900">
  <data key="d24">5383</data>
  <data key="d25">36689</data>
  <data key="d26">2-Methyl-2-Propanol</data>
  <data key="d27">TPI1</data>
  <data key="d28">drugbank.DB03900</data>
  <data key="d29">entrez.7167</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7167" target="drugbank.DB02726">
  <data key="d24">5970</data>
  <data key="d25">36689</data>
  <data key="d26">2-Phosphoglycolic Acid</data>
  <data key="d27">TPI1</data>
  <data key="d28">drugbank.DB02726</data>
  <data key="d29">entrez.7167</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7167" target="drugbank.DB01695">
  <data key="d24">7395</data>
  <data key="d25">36689</data>
  <data key="d26">N-Hydroxy-4-Phosphono-Butanamide</data>
  <data key="d27">TPI1</data>
  <data key="d28">drugbank.DB01695</data>
  <data key="d29">entrez.7167</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7167" target="drugbank.DB11638">
  <data key="d24">9575</data>
  <data key="d25">36689</data>
  <data key="d26">Artenimol</data>
  <data key="d27">TPI1</data>
  <data key="d28">drugbank.DB11638</data>
  <data key="d29">entrez.7167</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7167" target="drugbank.DB07387">
  <data key="d24">10215</data>
  <data key="d25">36689</data>
  <data key="d26">3-(BUTYLSULPHONYL)-PROPANOIC ACID</data>
  <data key="d27">TPI1</data>
  <data key="d28">drugbank.DB07387</data>
  <data key="d29">entrez.7167</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="mondo.0004975">
  <data key="d24">36780</data>
  <data key="d25">9604</data>
  <data key="d26">TNF</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.7124</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB05869">
  <data key="d24">135</data>
  <data key="d25">36780</data>
  <data key="d26">Ethyl pyruvate</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB05869</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB05879">
  <data key="d24">162</data>
  <data key="d25">36780</data>
  <data key="d26">AME-527</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB05879</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB05992">
  <data key="d24">531</data>
  <data key="d25">36780</data>
  <data key="d26">Plinabulin</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB05992</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB05968">
  <data key="d24">752</data>
  <data key="d25">36780</data>
  <data key="d26">PR-104</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB05968</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB05676">
  <data key="d24">937</data>
  <data key="d25">36780</data>
  <data key="d26">Apremilast</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB05676</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB05744">
  <data key="d24">1452</data>
  <data key="d25">36780</data>
  <data key="d26">CRx-139</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB05744</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB05758">
  <data key="d24">1475</data>
  <data key="d25">36780</data>
  <data key="d26">CYT007-TNFQb</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB05758</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB05767">
  <data key="d24">1495</data>
  <data key="d25">36780</data>
  <data key="d26">Andrographolide</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB05767</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB01041">
  <data key="d24">1829</data>
  <data key="d25">36780</data>
  <data key="d26">Thalidomide</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB01041</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB02325">
  <data key="d24">1979</data>
  <data key="d25">36780</data>
  <data key="d26">Isopropyl alcohol</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB02325</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB04956">
  <data key="d24">2139</data>
  <data key="d25">36780</data>
  <data key="d26">Afelimomab</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB04956</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB13170">
  <data key="d24">2208</data>
  <data key="d25">36780</data>
  <data key="d26">Plecanatide</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB13170</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB12140">
  <data key="d24">3716</data>
  <data key="d25">36780</data>
  <data key="d26">Dilmapimod</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB12140</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB01427">
  <data key="d24">3798</data>
  <data key="d25">36780</data>
  <data key="d26">Amrinone</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB01427</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB01296">
  <data key="d24">4961</data>
  <data key="d25">36780</data>
  <data key="d26">Glucosamine</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB01296</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB00065">
  <data key="d24">5443</data>
  <data key="d25">36780</data>
  <data key="d26">Infliximab</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB00065</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB00051">
  <data key="d24">5751</data>
  <data key="d25">36780</data>
  <data key="d26">Adalimumab</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB00051</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB00005">
  <data key="d24">5900</data>
  <data key="d25">36780</data>
  <data key="d26">Etanercept</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB00005</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB01407">
  <data key="d24">5979</data>
  <data key="d25">36780</data>
  <data key="d26">Clenbuterol</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB01407</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB01411">
  <data key="d24">6011</data>
  <data key="d25">36780</data>
  <data key="d26">Pranlukast</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB01411</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB00668">
  <data key="d24">6257</data>
  <data key="d25">36780</data>
  <data key="d26">Epinephrine</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB00668</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB00608">
  <data key="d24">6583</data>
  <data key="d25">36780</data>
  <data key="d26">Chloroquine</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB00608</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB13751">
  <data key="d24">7570</data>
  <data key="d25">36780</data>
  <data key="d26">Glycyrrhizic acid</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB13751</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB00480">
  <data key="d24">7835</data>
  <data key="d25">36780</data>
  <data key="d26">Lenalidomide</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB00480</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB00852">
  <data key="d24">9101</data>
  <data key="d25">36780</data>
  <data key="d26">Pseudoephedrine</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB00852</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB09221">
  <data key="d24">9195</data>
  <data key="d25">36780</data>
  <data key="d26">Polaprezinc</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB09221</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB11967">
  <data key="d24">10734</data>
  <data key="d25">36780</data>
  <data key="d26">Binimetinib</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB11967</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB10770">
  <data key="d24">10902</data>
  <data key="d25">36780</data>
  <data key="d26">Foreskin fibroblast (neonatal)</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB10770</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB10772">
  <data key="d24">10903</data>
  <data key="d25">36780</data>
  <data key="d26">Foreskin keratinocyte (neonatal)</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB10772</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB08904">
  <data key="d24">11235</data>
  <data key="d25">36780</data>
  <data key="d26">Certolizumab pegol</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB08904</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB08910">
  <data key="d24">11243</data>
  <data key="d25">36780</data>
  <data key="d26">Pomalidomide</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB08910</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB05017">
  <data key="d24">11449</data>
  <data key="d25">36780</data>
  <data key="d26">YSIL6</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB05017</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB06495">
  <data key="d24">11575</data>
  <data key="d25">36780</data>
  <data key="d26">Onercept</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB06495</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB06444">
  <data key="d24">11614</data>
  <data key="d25">36780</data>
  <data key="d26">Dexanabinol</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB06444</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB05412">
  <data key="d24">12394</data>
  <data key="d25">36780</data>
  <data key="d26">Talmapimod</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB05412</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB05470">
  <data key="d24">12436</data>
  <data key="d25">36780</data>
  <data key="d26">VX-702</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB05470</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB05513">
  <data key="d24">12619</data>
  <data key="d25">36780</data>
  <data key="d26">Atiprimod</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB05513</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB05207">
  <data key="d24">12802</data>
  <data key="d25">36780</data>
  <data key="d26">SD118</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB05207</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB05218">
  <data key="d24">12829</data>
  <data key="d25">36780</data>
  <data key="d26">PN0621</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB05218</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB05303">
  <data key="d24">12983</data>
  <data key="d25">36780</data>
  <data key="d26">OMS-103HP</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB05303</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.7124" target="drugbank.DB06674">
  <data key="d24">13067</data>
  <data key="d25">36780</data>
  <data key="d26">Golimumab</data>
  <data key="d27">TNF</data>
  <data key="d28">drugbank.DB06674</data>
  <data key="d29">entrez.7124</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.406938" target="mondo.0004975">
  <data key="d24">36978</data>
  <data key="d25">9604</data>
  <data key="d26">MIR146A</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.406938</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.64851" target="mondo.0011561">
  <data key="d24">38133</data>
  <data key="d25">1991</data>
  <data key="d26">entrez.64851</data>
  <data key="d27">Alzheimer disease 6</data>
  <data key="d28">entrez.64851</data>
  <data key="d29">mondo.0011561</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.43" target="mondo.0004975">
  <data key="d24">38289</data>
  <data key="d25">9604</data>
  <data key="d26">ACHE</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.43</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.43" target="drugbank.DB03283">
  <data key="d24">96</data>
  <data key="d25">38289</data>
  <data key="d26">beta-L-fucose</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB03283</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB04556">
  <data key="d24">194</data>
  <data key="d25">38289</data>
  <data key="d26">3-[(1s)-1-(Dimethylamino)Ethyl]Phenol</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB04556</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB03348">
  <data key="d24">637</data>
  <data key="d25">38289</data>
  <data key="d26">Huperzine B</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB03348</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB03359">
  <data key="d24">688</data>
  <data key="d25">38289</data>
  <data key="d26">M-(N,N,N-Trimethylammonio)-2,2,2-Trifluoro-1,1-Dihydroxyethylbenzene</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB03359</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB14006">
  <data key="d24">695</data>
  <data key="d25">38289</data>
  <data key="d26">Choline salicylate</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB14006</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB04614">
  <data key="d24">708</data>
  <data key="d25">38289</data>
  <data key="d26">(R)-tacrine(10)-hupyridone</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB04614</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB04616">
  <data key="d24">712</data>
  <data key="d25">38289</data>
  <data key="d26">TACRINE(8)-4-AMINOQUINOLINE</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB04616</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB04615">
  <data key="d24">713</data>
  <data key="d25">38289</data>
  <data key="d26">(S)-tacrine(10)-hupyridone</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB04615</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB04617">
  <data key="d24">715</data>
  <data key="d25">38289</data>
  <data key="d26">(9S)-9-[(8-AMMONIOOCTYL)AMINO]-1,2,3,4,9,10-HEXAHYDROACRIDINIUM</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB04617</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB03005">
  <data key="d24">904</data>
  <data key="d25">38289</data>
  <data key="d26">3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-5-Yl]Hexyl]-Phenanthridinium</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB03005</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB03128">
  <data key="d24">1338</data>
  <data key="d25">38289</data>
  <data key="d26">Acetylcholine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB03128</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB01091">
  <data key="d24">1732</data>
  <data key="d25">38289</data>
  <data key="d26">Butenafine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB01091</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB01035">
  <data key="d24">1816</data>
  <data key="d25">38289</data>
  <data key="d26">Procainamide</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB01035</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB01057">
  <data key="d24">1907</data>
  <data key="d25">38289</data>
  <data key="d26">Echothiophate</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB01057</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB01010">
  <data key="d24">2023</data>
  <data key="d25">38289</data>
  <data key="d26">Edrophonium</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB01010</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB02343">
  <data key="d24">2069</data>
  <data key="d25">38289</data>
  <data key="d26">3,6,9,12,15-Pentaoxaheptadecane</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB02343</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB01199">
  <data key="d24">2231</data>
  <data key="d25">38289</data>
  <data key="d26">Tubocurarine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB01199</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB01103">
  <data key="d24">2402</data>
  <data key="d25">38289</data>
  <data key="d26">Quinacrine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB01103</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB01110">
  <data key="d24">2410</data>
  <data key="d25">38289</data>
  <data key="d26">Miconazole</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB01110</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB01113">
  <data key="d24">2446</data>
  <data key="d25">38289</data>
  <data key="d26">Papaverine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB01113</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB01127">
  <data key="d24">2486</data>
  <data key="d25">38289</data>
  <data key="d26">Econazole</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB01127</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB01122">
  <data key="d24">2498</data>
  <data key="d25">38289</data>
  <data key="d26">Ambenonium</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB01122</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB02404">
  <data key="d24">2600</data>
  <data key="d25">38289</data>
  <data key="d26">1-Deoxy-1-Thio-Heptaethylene Glycol</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB02404</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB03740">
  <data key="d24">2612</data>
  <data key="d25">38289</data>
  <data key="d26">N-acetyl-alpha-D-glucosamine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB03740</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB03814">
  <data key="d24">2675</data>
  <data key="d25">38289</data>
  <data key="d26">2-(N-Morpholino)-Ethanesulfonic Acid</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB03814</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB02166">
  <data key="d24">2728</data>
  <data key="d25">38289</data>
  <data key="d26">Propidium</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB02166</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB04859">
  <data key="d24">3332</data>
  <data key="d25">38289</data>
  <data key="d26">Zanapezil</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB04859</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB04864">
  <data key="d24">3350</data>
  <data key="d25">38289</data>
  <data key="d26">Huperzine A</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB04864</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB04892">
  <data key="d24">3397</data>
  <data key="d25">38289</data>
  <data key="d26">Phenserine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB04892</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB02226">
  <data key="d24">3416</data>
  <data key="d25">38289</data>
  <data key="d26">3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-4-Yl]Hexyl]-Phenanthridinium</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB02226</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB04924">
  <data key="d24">3512</data>
  <data key="d25">38289</data>
  <data key="d26">Itopride</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB04924</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB01493">
  <data key="d24">3736</data>
  <data key="d25">38289</data>
  <data key="d26">Ethylestrenol</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB01493</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00166">
  <data key="d24">3775</data>
  <data key="d25">38289</data>
  <data key="d26">Lipoic Acid</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00166</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00122">
  <data key="d24">3953</data>
  <data key="d25">38289</data>
  <data key="d26">Choline</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00122</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB02845">
  <data key="d24">4041</data>
  <data key="d25">38289</data>
  <data key="d26">Methylphosphinic Acid</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB02845</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB13503">
  <data key="d24">4078</data>
  <data key="d25">38289</data>
  <data key="d26">Tyrothricin</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB13503</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00201">
  <data key="d24">4106</data>
  <data key="d25">38289</data>
  <data key="d26">Caffeine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00201</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB02825">
  <data key="d24">4172</data>
  <data key="d25">38289</data>
  <data key="d26">Methylphosphonic Acid Ester Group</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB02825</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00257">
  <data key="d24">4215</data>
  <data key="d25">38289</data>
  <data key="d26">Clotrimazole</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00257</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00255">
  <data key="d24">4219</data>
  <data key="d25">38289</data>
  <data key="d26">Diethylstilbestrol</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00255</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB13520">
  <data key="d24">4398</data>
  <data key="d25">38289</data>
  <data key="d26">Metergoline</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB13520</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00239">
  <data key="d24">4468</data>
  <data key="d25">38289</data>
  <data key="d26">Oxiconazole</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00239</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00251">
  <data key="d24">4546</data>
  <data key="d25">38289</data>
  <data key="d26">Terconazole</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00251</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB01233">
  <data key="d24">5053</data>
  <data key="d25">38289</data>
  <data key="d26">Metoclopramide</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB01233</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB01245">
  <data key="d24">5102</data>
  <data key="d25">38289</data>
  <data key="d26">Decamethonium</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB01245</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB02673">
  <data key="d24">5582</data>
  <data key="d25">38289</data>
  <data key="d26">(4ar,6s,8ar)-11-[8-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Octyl]-6-Hydroxy-3-Methoxy-5,6,9,10-Tetrahydro-4ah-[1]Benzofuro[3a,3,2-Ef][2]Benzazepin-11-Ium</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB02673</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB01364">
  <data key="d24">5691</data>
  <data key="d25">38289</data>
  <data key="d26">Ephedrine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB01364</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB01408">
  <data key="d24">5978</data>
  <data key="d25">38289</data>
  <data key="d26">Bambuterol</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB01408</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB01400">
  <data key="d24">5985</data>
  <data key="d25">38289</data>
  <data key="d26">Neostigmine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB01400</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00585">
  <data key="d24">6128</data>
  <data key="d25">38289</data>
  <data key="d26">Nizatidine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00585</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00677">
  <data key="d24">6315</data>
  <data key="d25">38289</data>
  <data key="d26">Isoflurophate</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00677</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00674">
  <data key="d24">6321</data>
  <data key="d25">38289</data>
  <data key="d26">Galantamine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00674</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB09018">
  <data key="d24">6324</data>
  <data key="d25">38289</data>
  <data key="d26">Bromopride</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB09018</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00733">
  <data key="d24">6916</data>
  <data key="d25">38289</data>
  <data key="d26">Pralidoxime</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00733</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00756">
  <data key="d24">6952</data>
  <data key="d25">38289</data>
  <data key="d26">Hexachlorophene</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00756</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00762">
  <data key="d24">6985</data>
  <data key="d25">38289</data>
  <data key="d26">Irinotecan</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00762</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB13694">
  <data key="d24">7084</data>
  <data key="d25">38289</data>
  <data key="d26">Distigmine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB13694</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00382">
  <data key="d24">7100</data>
  <data key="d25">38289</data>
  <data key="d26">Tacrine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00382</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00392">
  <data key="d24">7139</data>
  <data key="d25">38289</data>
  <data key="d26">Profenamine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00392</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB01698">
  <data key="d24">7390</data>
  <data key="d25">38289</data>
  <data key="d26">Rutin</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB01698</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00411">
  <data key="d24">7436</data>
  <data key="d25">38289</data>
  <data key="d26">Carbamoylcholine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00411</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00449">
  <data key="d24">7530</data>
  <data key="d25">38289</data>
  <data key="d26">Dipivefrin</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00449</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00406">
  <data key="d24">7615</data>
  <data key="d25">38289</data>
  <data key="d26">Gentian violet cation</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00406</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB12482">
  <data key="d24">7657</data>
  <data key="d25">38289</data>
  <data key="d26">Acotiamide</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB12482</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00472">
  <data key="d24">7786</data>
  <data key="d25">38289</data>
  <data key="d26">Fluoxetine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00472</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00483">
  <data key="d24">7832</data>
  <data key="d25">38289</data>
  <data key="d26">Gallamine Triethiodide</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00483</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00481">
  <data key="d24">7834</data>
  <data key="d25">38289</data>
  <data key="d26">Raloxifene</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00481</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB11125">
  <data key="d24">7840</data>
  <data key="d25">38289</data>
  <data key="d26">Benzethonium</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB11125</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00545">
  <data key="d24">7939</data>
  <data key="d25">38289</data>
  <data key="d26">Pyridostigmine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00545</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00553">
  <data key="d24">7982</data>
  <data key="d25">38289</data>
  <data key="d26">Methoxsalen</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00553</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB13873">
  <data key="d24">8057</data>
  <data key="d25">38289</data>
  <data key="d26">Fenofibric acid</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB13873</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB01805">
  <data key="d24">8181</data>
  <data key="d25">38289</data>
  <data key="d26">Monoisopropylphosphorylserine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB01805</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB08167">
  <data key="d24">8354</data>
  <data key="d25">38289</data>
  <data key="d26">Methylthioninium</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB08167</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB11742">
  <data key="d24">8412</data>
  <data key="d25">38289</data>
  <data key="d26">Ebastine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB11742</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00863">
  <data key="d24">9124</data>
  <data key="d25">38289</data>
  <data key="d26">Ranitidine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00863</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00843">
  <data key="d24">9272</data>
  <data key="d25">38289</data>
  <data key="d26">Donepezil</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00843</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00806">
  <data key="d24">9286</data>
  <data key="d25">38289</data>
  <data key="d26">Pentoxifylline</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00806</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00805">
  <data key="d24">9287</data>
  <data key="d25">38289</data>
  <data key="d26">Minaprine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00805</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00989">
  <data key="d24">9552</data>
  <data key="d25">38289</data>
  <data key="d26">Rivastigmine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00989</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00981">
  <data key="d24">9564</data>
  <data key="d25">38289</data>
  <data key="d26">Physostigmine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00981</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00944">
  <data key="d24">9729</data>
  <data key="d25">38289</data>
  <data key="d26">Demecarium</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00944</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB00941">
  <data key="d24">9732</data>
  <data key="d25">38289</data>
  <data key="d26">Hexafluronium</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB00941</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB08615">
  <data key="d24">10364</data>
  <data key="d25">38289</data>
  <data key="d26">2-[4-(DIMETHYLAMINO)PHENYL]-6-HYDROXY-3-METHYL-1,3-BENZOTHIAZOL-3-IUM</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB08615</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB08357">
  <data key="d24">10581</data>
  <data key="d25">38289</data>
  <data key="d26">1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB08357</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB08996">
  <data key="d24">11388</data>
  <data key="d25">38289</data>
  <data key="d26">Dimetacrine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB08996</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB07756">
  <data key="d24">11521</data>
  <data key="d25">38289</data>
  <data key="d26">1-[3-({[(4-AMINO-5-FLUORO-2-METHYLQUINOLIN-3-YL)METHYL]THIO}METHYL)PHENYL]-2,2,2-TRIFLUOROETHANE-1,1-DIOL</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB07756</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB07701">
  <data key="d24">11528</data>
  <data key="d25">38289</data>
  <data key="d26">1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON-2-YL)METHYL]PIPERIDINE</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB07701</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB06155">
  <data key="d24">11869</data>
  <data key="d25">38289</data>
  <data key="d26">Rimonabant</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB06155</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB07555">
  <data key="d24">12177</data>
  <data key="d25">38289</data>
  <data key="d26">Hydroxy(oxo)(2-{(1S)-2,2,2-trifluoro-1-[2-(trimethylarsonio)ethoxy]ethyl}phenyl)ammonium</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB07555</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB04114">
  <data key="d24">12300</data>
  <data key="d25">38289</data>
  <data key="d26">3-Chloro-9-Ethyl-6,7,8,9,10,11-Hexahydro-7,11-Methanocycloocta[B]Quinolin-12-Amine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB04114</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB04216">
  <data key="d24">12527</data>
  <data key="d25">38289</data>
  <data key="d26">Quercetin</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB04216</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB07846">
  <data key="d24">12752</data>
  <data key="d25">38289</data>
  <data key="d26">1S,3AS,8AS-TRIMETHYL-1-OXIDO-1,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL 2-ETHYLPHENYLCARBAMATE</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB07846</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB06525">
  <data key="d24">12772</data>
  <data key="d25">38289</data>
  <data key="d26">Ganstigmine</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB06525</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.43" target="drugbank.DB04021">
  <data key="d24">13217</data>
  <data key="d25">38289</data>
  <data key="d26">MF268</data>
  <data key="d27">ACHE</data>
  <data key="d28">drugbank.DB04021</data>
  <data key="d29">entrez.43</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.101290498" target="mondo.0014036">
  <data key="d24">39057</data>
  <data key="d25">11726</data>
  <data key="d26">entrez.101290498</data>
  <data key="d27">Alzheimer disease 17</data>
  <data key="d28">entrez.101290498</data>
  <data key="d29">mondo.0014036</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.353128" target="mondo.0011777">
  <data key="d24">39598</data>
  <data key="d25">57</data>
  <data key="d26">entrez.353128</data>
  <data key="d27">Alzheimer disease 8</data>
  <data key="d28">entrez.353128</data>
  <data key="d29">mondo.0011777</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.6653" target="mondo.0004975">
  <data key="d24">40302</data>
  <data key="d25">9604</data>
  <data key="d26">SORL1</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.6653</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.7</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.6648" target="mondo.0004975">
  <data key="d24">40311</data>
  <data key="d25">9604</data>
  <data key="d26">SOD2</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.6648</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.35</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.6648" target="drugbank.DB03297">
  <data key="d24">346</data>
  <data key="d25">40311</data>
  <data key="d26">Benzylsulfinic Acid</data>
  <data key="d27">SOD2</data>
  <data key="d28">drugbank.DB03297</data>
  <data key="d29">entrez.6648</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.6648" target="drugbank.DB04436">
  <data key="d24">1494</data>
  <data key="d25">40311</data>
  <data key="d26">3-Fluoro-L-tyrosine</data>
  <data key="d27">SOD2</data>
  <data key="d28">drugbank.DB04436</data>
  <data key="d29">entrez.6648</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.6648" target="drugbank.DB06151">
  <data key="d24">11864</data>
  <data key="d25">40311</data>
  <data key="d26">Acetylcysteine</data>
  <data key="d27">SOD2</data>
  <data key="d28">drugbank.DB06151</data>
  <data key="d29">entrez.6648</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.6517" target="mondo.0004975">
  <data key="d24">41438</data>
  <data key="d25">9604</data>
  <data key="d26">SLC2A4</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.6517</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.3</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.100271718" target="mondo.0010422">
  <data key="d24">43114</data>
  <data key="d25">151</data>
  <data key="d26">entrez.100271718</data>
  <data key="d27">Alzheimer disease 16</data>
  <data key="d28">entrez.100271718</data>
  <data key="d29">mondo.0010422</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.55676" target="mondo.0004975">
  <data key="d24">43191</data>
  <data key="d25">9604</data>
  <data key="d26">SLC30A6</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.55676</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.34</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.2023" target="mondo.0004975">
  <data key="d24">44987</data>
  <data key="d25">9604</data>
  <data key="d26">ENO1</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.2023</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.32</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.2023" target="drugbank.DB14487">
  <data key="d24">2394</data>
  <data key="d25">44987</data>
  <data key="d26">Zinc acetate</data>
  <data key="d27">ENO1</data>
  <data key="d28">drugbank.DB14487</data>
  <data key="d29">entrez.2023</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2023" target="drugbank.DB01593">
  <data key="d24">4227</data>
  <data key="d25">44987</data>
  <data key="d26">Zinc</data>
  <data key="d27">ENO1</data>
  <data key="d28">drugbank.DB01593</data>
  <data key="d29">entrez.2023</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2023" target="drugbank.DB14533">
  <data key="d24">5035</data>
  <data key="d25">44987</data>
  <data key="d26">Zinc chloride</data>
  <data key="d27">ENO1</data>
  <data key="d28">drugbank.DB14533</data>
  <data key="d29">entrez.2023</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2023" target="drugbank.DB09130">
  <data key="d24">6850</data>
  <data key="d25">44987</data>
  <data key="d26">Copper</data>
  <data key="d27">ENO1</data>
  <data key="d28">drugbank.DB09130</data>
  <data key="d29">entrez.2023</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2023" target="drugbank.DB11638">
  <data key="d24">9575</data>
  <data key="d25">44987</data>
  <data key="d26">Artenimol</data>
  <data key="d27">ENO1</data>
  <data key="d28">drugbank.DB11638</data>
  <data key="d29">entrez.2023</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="mondo.0004975">
  <data key="d24">45094</data>
  <data key="d25">9604</data>
  <data key="d26">ESR1</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.2099</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB05882">
  <data key="d24">141</data>
  <data key="d25">45094</data>
  <data key="d26">CHF 4227</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB05882</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB04573">
  <data key="d24">217</data>
  <data key="d25">45094</data>
  <data key="d26">Estriol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB04573</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB04575">
  <data key="d24">221</data>
  <data key="d25">45094</data>
  <data key="d26">Quinestrol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB04575</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB04574">
  <data key="d24">223</data>
  <data key="d25">45094</data>
  <data key="d26">Estrone sulfate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB04574</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB05966">
  <data key="d24">746</data>
  <data key="d25">45094</data>
  <data key="d26">TAS-108</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB05966</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB05662">
  <data key="d24">1082</data>
  <data key="d25">45094</data>
  <data key="d26">NP-50301</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB05662</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB06927">
  <data key="d24">1125</data>
  <data key="d25">45094</data>
  <data key="d26">[5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB06927</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB04471">
  <data key="d24">1355</data>
  <data key="d25">45094</data>
  <data key="d26">2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB04471</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB04468">
  <data key="d24">1372</data>
  <data key="d25">45094</data>
  <data key="d26">Afimoxifene</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB04468</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB13044">
  <data key="d24">1888</data>
  <data key="d25">45094</data>
  <data key="d26">Gossypol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB13044</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB01065">
  <data key="d24">1912</data>
  <data key="d25">45094</data>
  <data key="d26">Melatonin</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB01065</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB04930">
  <data key="d24">2092</data>
  <data key="d25">45094</data>
  <data key="d26">Permethrin</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB04930</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB04938">
  <data key="d24">2105</data>
  <data key="d25">45094</data>
  <data key="d26">Ospemifene</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB04938</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB01196">
  <data key="d24">2214</data>
  <data key="d25">45094</data>
  <data key="d26">Estramustine</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB01196</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB13169">
  <data key="d24">2221</data>
  <data key="d25">45094</data>
  <data key="d26">Nandrolone</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB13169</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB01185">
  <data key="d24">2383</data>
  <data key="d25">45094</data>
  <data key="d26">Fluoxymesterone</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB01185</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB01183">
  <data key="d24">2385</data>
  <data key="d25">45094</data>
  <data key="d26">Naloxone</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB01183</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB14487">
  <data key="d24">2394</data>
  <data key="d25">45094</data>
  <data key="d26">Zinc acetate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB14487</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB01108">
  <data key="d24">2397</data>
  <data key="d25">45094</data>
  <data key="d26">Trilostane</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB01108</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB03742">
  <data key="d24">2616</data>
  <data key="d25">45094</data>
  <data key="d26">Compound 4-D</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB03742</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB03802">
  <data key="d24">2665</data>
  <data key="d25">45094</data>
  <data key="d26">1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB03802</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB02187">
  <data key="d24">2778</data>
  <data key="d25">45094</data>
  <data key="d26">Equilin</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB02187</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB03467">
  <data key="d24">2905</data>
  <data key="d25">45094</data>
  <data key="d26">Naringenin</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB03467</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB04813">
  <data key="d24">3438</data>
  <data key="d25">45094</data>
  <data key="d26">Bithionol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB04813</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB04824">
  <data key="d24">3449</data>
  <data key="d25">45094</data>
  <data key="d26">Phenolphthalein</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB04824</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00179">
  <data key="d24">3531</data>
  <data key="d25">45094</data>
  <data key="d26">Masoprocol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00179</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB01493">
  <data key="d24">3736</data>
  <data key="d25">45094</data>
  <data key="d26">Ethylestrenol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB01493</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB01428">
  <data key="d24">3797</data>
  <data key="d25">45094</data>
  <data key="d26">Oxybenzone</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB01428</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB02757">
  <data key="d24">3819</data>
  <data key="d25">45094</data>
  <data key="d26">Pyrazole</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB02757</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB01431">
  <data key="d24">3855</data>
  <data key="d25">45094</data>
  <data key="d26">Allylestrenol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB01431</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB01524">
  <data key="d24">4057</data>
  <data key="d25">45094</data>
  <data key="d26">Androstenediol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB01524</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00255">
  <data key="d24">4219</data>
  <data key="d25">45094</data>
  <data key="d26">Diethylstilbestrol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00255</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB01593">
  <data key="d24">4227</data>
  <data key="d25">45094</data>
  <data key="d26">Zinc</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB01593</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00269">
  <data key="d24">4263</data>
  <data key="d25">45094</data>
  <data key="d26">Chlorotrianisene</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00269</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00286">
  <data key="d24">4331</data>
  <data key="d25">45094</data>
  <data key="d26">Conjugated estrogens</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00286</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00294">
  <data key="d24">4334</data>
  <data key="d25">45094</data>
  <data key="d26">Etonogestrel</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00294</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00304">
  <data key="d24">4624</data>
  <data key="d25">45094</data>
  <data key="d26">Desogestrel</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00304</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB01645">
  <data key="d24">4675</data>
  <data key="d25">45094</data>
  <data key="d26">Genistein</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB01645</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB02901">
  <data key="d24">4862</data>
  <data key="d25">45094</data>
  <data key="d26">Stanolone</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB02901</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB14533">
  <data key="d24">5035</data>
  <data key="d25">45094</data>
  <data key="d26">Zinc chloride</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB14533</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB02615">
  <data key="d24">5345</data>
  <data key="d25">45094</data>
  <data key="d26">Compound 19</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB02615</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB01357">
  <data key="d24">5622</data>
  <data key="d25">45094</data>
  <data key="d26">Mestranol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB01357</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB14641">
  <data key="d24">5947</data>
  <data key="d25">45094</data>
  <data key="d26">Estriol tripropionate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB14641</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB02715">
  <data key="d24">5953</data>
  <data key="d25">45094</data>
  <data key="d26">Compound 18</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB02715</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB01406">
  <data key="d24">5980</data>
  <data key="d25">45094</data>
  <data key="d26">Danazol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB01406</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB02746">
  <data key="d24">6022</data>
  <data key="d25">45094</data>
  <data key="d26">Phthalic Acid</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB02746</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB02709">
  <data key="d24">6040</data>
  <data key="d25">45094</data>
  <data key="d26">Resveratrol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB02709</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00655">
  <data key="d24">6213</data>
  <data key="d25">45094</data>
  <data key="d26">Estrone</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00655</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00675">
  <data key="d24">6319</data>
  <data key="d25">45094</data>
  <data key="d26">Tamoxifen</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00675</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00624">
  <data key="d24">6441</data>
  <data key="d25">45094</data>
  <data key="d26">Testosterone</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00624</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB13946">
  <data key="d24">6499</data>
  <data key="d25">45094</data>
  <data key="d26">Testosterone undecanoate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB13946</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB13943">
  <data key="d24">6501</data>
  <data key="d25">45094</data>
  <data key="d26">Testosterone cypionate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB13943</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB13944">
  <data key="d24">6503</data>
  <data key="d25">45094</data>
  <data key="d26">Testosterone enanthate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB13944</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00648">
  <data key="d24">6509</data>
  <data key="d25">45094</data>
  <data key="d26">Mitotane</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00648</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB13956">
  <data key="d24">6534</data>
  <data key="d25">45094</data>
  <data key="d26">Estradiol valerate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB13956</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB13954">
  <data key="d24">6538</data>
  <data key="d25">45094</data>
  <data key="d26">Estradiol cypionate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB13954</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB13955">
  <data key="d24">6540</data>
  <data key="d25">45094</data>
  <data key="d26">Estradiol dienanthate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB13955</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB13952">
  <data key="d24">6542</data>
  <data key="d25">45094</data>
  <data key="d26">Estradiol acetate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB13952</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB13953">
  <data key="d24">6544</data>
  <data key="d25">45094</data>
  <data key="d26">Estradiol benzoate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB13953</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB13951">
  <data key="d24">6547</data>
  <data key="d25">45094</data>
  <data key="d26">Stanolone acetate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB13951</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00603">
  <data key="d24">6593</data>
  <data key="d25">45094</data>
  <data key="d26">Medroxyprogesterone acetate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00603</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB09070">
  <data key="d24">6620</data>
  <data key="d25">45094</data>
  <data key="d26">Tibolone</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB09070</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB09086">
  <data key="d24">6639</data>
  <data key="d25">45094</data>
  <data key="d26">Eugenol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB09086</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00783">
  <data key="d24">6820</data>
  <data key="d25">45094</data>
  <data key="d26">Estradiol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00783</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00756">
  <data key="d24">6952</data>
  <data key="d25">45094</data>
  <data key="d26">Hexachlorophene</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00756</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00717">
  <data key="d24">7021</data>
  <data key="d25">45094</data>
  <data key="d26">Norethisterone</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00717</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00396">
  <data key="d24">7172</data>
  <data key="d25">45094</data>
  <data key="d26">Progesterone</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00396</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB11064">
  <data key="d24">7189</data>
  <data key="d25">45094</data>
  <data key="d26">Homosalate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB11064</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00367">
  <data key="d24">7389</data>
  <data key="d25">45094</data>
  <data key="d26">Levonorgestrel</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00367</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00431">
  <data key="d24">7504</data>
  <data key="d25">45094</data>
  <data key="d26">Lindane</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00431</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB01708">
  <data key="d24">7572</data>
  <data key="d25">45094</data>
  <data key="d26">Prasterone</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB01708</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB12450">
  <data key="d24">7765</data>
  <data key="d25">45094</data>
  <data key="d26">Propyl Gallate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB12450</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00481">
  <data key="d24">7834</data>
  <data key="d25">45094</data>
  <data key="d26">Raloxifene</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00481</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00539">
  <data key="d24">7895</data>
  <data key="d25">45094</data>
  <data key="d26">Toremifene</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00539</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB01878">
  <data key="d24">7936</data>
  <data key="d25">45094</data>
  <data key="d26">Benzophenone</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB01878</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB13869">
  <data key="d24">8001</data>
  <data key="d25">45094</data>
  <data key="d26">2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB13869</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB13866">
  <data key="d24">8004</data>
  <data key="d25">45094</data>
  <data key="d26">Etynodiol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB13866</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB11219">
  <data key="d24">8047</data>
  <data key="d25">45094</data>
  <data key="d26">Enzacamene</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB11219</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB09535">
  <data key="d24">8825</data>
  <data key="d25">45094</data>
  <data key="d26">Octocrylene</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB09535</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB11478">
  <data key="d24">8952</data>
  <data key="d25">45094</data>
  <data key="d26">Zeranol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB11478</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB11541">
  <data key="d24">9013</data>
  <data key="d25">45094</data>
  <data key="d26">Ractopamine</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB11541</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00882">
  <data key="d24">9198</data>
  <data key="d25">45094</data>
  <data key="d26">Clomifene</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00882</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00890">
  <data key="d24">9204</data>
  <data key="d25">45094</data>
  <data key="d26">Dienestrol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00890</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00823">
  <data key="d24">9234</data>
  <data key="d25">45094</data>
  <data key="d26">Ethynodiol diacetate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00823</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00834">
  <data key="d24">9252</data>
  <data key="d25">45094</data>
  <data key="d26">Mifepristone</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00834</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00841">
  <data key="d24">9274</data>
  <data key="d25">45094</data>
  <data key="d26">Dobutamine</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00841</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB08020">
  <data key="d24">9362</data>
  <data key="d25">45094</data>
  <data key="d26">(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB08020</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB09369">
  <data key="d24">9420</data>
  <data key="d25">45094</data>
  <data key="d26">Polyestradiol phosphate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB09369</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB09371">
  <data key="d24">9452</data>
  <data key="d25">45094</data>
  <data key="d26">Norethynodrel</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB09371</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB08047">
  <data key="d24">9453</data>
  <data key="d25">45094</data>
  <data key="d26">4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB08047</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB08048">
  <data key="d24">9461</data>
  <data key="d25">45094</data>
  <data key="d26">4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB08048</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB09389">
  <data key="d24">9492</data>
  <data key="d25">45094</data>
  <data key="d26">Norgestrel</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB09389</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00977">
  <data key="d24">9513</data>
  <data key="d25">45094</data>
  <data key="d26">Ethinylestradiol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00977</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB09318">
  <data key="d24">9570</data>
  <data key="d25">45094</data>
  <data key="d26">Synthetic Conjugated Estrogens, B</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB09318</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB09317">
  <data key="d24">9572</data>
  <data key="d25">45094</data>
  <data key="d26">Synthetic Conjugated Estrogens, A</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB09317</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00947">
  <data key="d24">9726</data>
  <data key="d25">45094</data>
  <data key="d26">Fulvestrant</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00947</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB00957">
  <data key="d24">9745</data>
  <data key="d25">45094</data>
  <data key="d26">Norgestimate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB00957</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB11619">
  <data key="d24">9788</data>
  <data key="d25">45094</data>
  <data key="d26">Gestrinone</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB11619</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB08595">
  <data key="d24">9908</data>
  <data key="d25">45094</data>
  <data key="d26">4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB08595</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB08398">
  <data key="d24">10498</data>
  <data key="d25">45094</data>
  <data key="d26">2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB08398</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB07086">
  <data key="d24">10518</data>
  <data key="d25">45094</data>
  <data key="d26">4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB07086</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB07087">
  <data key="d24">10522</data>
  <data key="d25">45094</data>
  <data key="d26">4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB07087</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB08320">
  <data key="d24">10721</data>
  <data key="d25">45094</data>
  <data key="d26">DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB08320</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB07195">
  <data key="d24">10867</data>
  <data key="d25">45094</data>
  <data key="d26">4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB07195</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB07638">
  <data key="d24">11227</data>
  <data key="d25">45094</data>
  <data key="d26">(3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB07638</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB06374">
  <data key="d24">11312</data>
  <data key="d25">45094</data>
  <data key="d26">Elacestrant</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB06374</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB07678">
  <data key="d24">11453</data>
  <data key="d25">45094</data>
  <data key="d26">(9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB07678</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB06401">
  <data key="d24">11458</data>
  <data key="d25">45094</data>
  <data key="d26">Bazedoxifene</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB06401</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB06412">
  <data key="d24">11468</data>
  <data key="d25">45094</data>
  <data key="d26">Oxymetholone</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB06412</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB07707">
  <data key="d24">11530</data>
  <data key="d25">45094</data>
  <data key="d26">(9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB07707</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB07708">
  <data key="d24">11533</data>
  <data key="d25">45094</data>
  <data key="d26">3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB07708</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB07712">
  <data key="d24">11539</data>
  <data key="d25">45094</data>
  <data key="d26">3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB07712</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB08737">
  <data key="d24">11892</data>
  <data key="d25">45094</data>
  <data key="d26">(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB08737</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB08773">
  <data key="d24">11949</data>
  <data key="d25">45094</data>
  <data key="d26">RALOXIFENE CORE</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB08773</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB06249">
  <data key="d24">12090</data>
  <data key="d25">45094</data>
  <data key="d26">Arzoxifene</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB06249</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB06202">
  <data key="d24">12118</data>
  <data key="d25">45094</data>
  <data key="d26">Lasofoxifene</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB06202</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB07567">
  <data key="d24">12211</data>
  <data key="d25">45094</data>
  <data key="d26">(2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB07567</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB06710">
  <data key="d24">12346</data>
  <data key="d25">45094</data>
  <data key="d26">Methyltestosterone</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB06710</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB06718">
  <data key="d24">12352</data>
  <data key="d25">45094</data>
  <data key="d26">Stanozolol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB06718</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB06732">
  <data key="d24">12373</data>
  <data key="d25">45094</data>
  <data key="d26">beta-Naphthoflavone</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB06732</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB05487">
  <data key="d24">12472</data>
  <data key="d25">45094</data>
  <data key="d26">Custirsen</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB05487</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB04216">
  <data key="d24">12527</data>
  <data key="d25">45094</data>
  <data key="d26">Quercetin</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB04216</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB06898">
  <data key="d24">12574</data>
  <data key="d25">45094</data>
  <data key="d26">4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB06898</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB06871">
  <data key="d24">12651</data>
  <data key="d25">45094</data>
  <data key="d26">17-METHYL-17-ALPHA-DIHYDROEQUILENIN</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB06871</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB05233">
  <data key="d24">12902</data>
  <data key="d25">45094</data>
  <data key="d26">AP1081</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB05233</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB07991">
  <data key="d24">13027</data>
  <data key="d25">45094</data>
  <data key="d26">N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB07991</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB07933">
  <data key="d24">13096</data>
  <data key="d25">45094</data>
  <data key="d26">Erteberel</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB07933</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB07931">
  <data key="d24">13100</data>
  <data key="d25">45094</data>
  <data key="d26">Hexestrol</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB07931</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2099" target="drugbank.DB07932">
  <data key="d24">13101</data>
  <data key="d25">45094</data>
  <data key="d26">dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate</data>
  <data key="d27">ESR1</data>
  <data key="d28">drugbank.DB07932</data>
  <data key="d29">entrez.2099</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2041" target="mondo.0004975">
  <data key="d24">45261</data>
  <data key="d25">9604</data>
  <data key="d26">EPHA1</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.2041</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.2041" target="drugbank.DB04868">
  <data key="d24">3359</data>
  <data key="d25">45261</data>
  <data key="d26">Nilotinib</data>
  <data key="d27">EPHA1</data>
  <data key="d28">drugbank.DB04868</data>
  <data key="d29">entrez.2041</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2041" target="drugbank.DB00317">
  <data key="d24">4668</data>
  <data key="d25">45261</data>
  <data key="d26">Gefitinib</data>
  <data key="d27">EPHA1</data>
  <data key="d28">drugbank.DB00317</data>
  <data key="d29">entrez.2041</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2041" target="drugbank.DB01254">
  <data key="d24">5149</data>
  <data key="d25">45261</data>
  <data key="d26">Dasatinib</data>
  <data key="d27">EPHA1</data>
  <data key="d28">drugbank.DB01254</data>
  <data key="d29">entrez.2041</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2041" target="drugbank.DB12010">
  <data key="d24">5608</data>
  <data key="d25">45261</data>
  <data key="d26">Fostamatinib</data>
  <data key="d27">EPHA1</data>
  <data key="d28">drugbank.DB12010</data>
  <data key="d29">entrez.2041</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2041" target="drugbank.DB09079">
  <data key="d24">6627</data>
  <data key="d25">45261</data>
  <data key="d26">Nintedanib</data>
  <data key="d27">EPHA1</data>
  <data key="d28">drugbank.DB09079</data>
  <data key="d29">entrez.2041</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2041" target="drugbank.DB00398">
  <data key="d24">7170</data>
  <data key="d25">45261</data>
  <data key="d26">Sorafenib</data>
  <data key="d27">EPHA1</data>
  <data key="d28">drugbank.DB00398</data>
  <data key="d29">entrez.2041</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2041" target="drugbank.DB08865">
  <data key="d24">12120</data>
  <data key="d25">45261</data>
  <data key="d26">Crizotinib</data>
  <data key="d27">EPHA1</data>
  <data key="d28">drugbank.DB08865</data>
  <data key="d29">entrez.2041</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2041" target="drugbank.DB05294">
  <data key="d24">12890</data>
  <data key="d25">45261</data>
  <data key="d26">Vandetanib</data>
  <data key="d27">EPHA1</data>
  <data key="d28">drugbank.DB05294</data>
  <data key="d29">entrez.2041</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2041" target="drugbank.DB06616">
  <data key="d24">13127</data>
  <data key="d25">45261</data>
  <data key="d26">Bosutinib</data>
  <data key="d27">EPHA1</data>
  <data key="d28">drugbank.DB06616</data>
  <data key="d29">entrez.2041</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="mondo.0004975">
  <data key="d24">45592</data>
  <data key="d25">9604</data>
  <data key="d26">F2</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.2147</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.32</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB04591">
  <data key="d24">40</data>
  <data key="d25">45592</data>
  <data key="d26">N-{2,2-DIFLUORO-2-[(2R)-PIPERIDIN-2-YL]ETHYL}-2-[2-(1H-1,2,4-TRIAZOL-1-YL)BENZYL][1,3]OXAZOLO[4,5-C]PYRIDIN-4-AMINE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB04591</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB04697">
  <data key="d24">396</data>
  <data key="d25">45592</data>
  <data key="d26">TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB04697</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06996">
  <data key="d24">907</data>
  <data key="d25">45592</data>
  <data key="d26">D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06996</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06911">
  <data key="d24">1108</data>
  <data key="d25">45592</data>
  <data key="d26">D-leucyl-N-(3-chlorobenzyl)-L-prolinamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06911</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06919">
  <data key="d24">1114</data>
  <data key="d25">45592</data>
  <data key="d26">D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06919</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06929">
  <data key="d24">1124</data>
  <data key="d25">45592</data>
  <data key="d26">1-butanoyl-N-(4-carbamimidoylbenzyl)-L-prolinamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06929</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06936">
  <data key="d24">1132</data>
  <data key="d25">45592</data>
  <data key="d26">N-(4-carbamimidoylbenzyl)-1-(4-methylpentanoyl)-L-prolinamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06936</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06942">
  <data key="d24">1148</data>
  <data key="d25">45592</data>
  <data key="d26">N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-L-prolinamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06942</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06947">
  <data key="d24">1149</data>
  <data key="d25">45592</data>
  <data key="d26">1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06947</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB03136">
  <data key="d24">1366</data>
  <data key="d25">45592</data>
  <data key="d26">4-Iodobenzo[B]Thiophene-2-Carboxamidine</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB03136</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB03159">
  <data key="d24">1440</data>
  <data key="d25">45592</data>
  <data key="d26">CRA_8696</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB03159</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB05777">
  <data key="d24">1530</data>
  <data key="d25">45592</data>
  <data key="d26">Thrombomodulin Alfa</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB05777</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB05714">
  <data key="d24">1541</data>
  <data key="d25">45592</data>
  <data key="d26">Flovagatran</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB05714</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB01197">
  <data key="d24">2213</data>
  <data key="d25">45592</data>
  <data key="d26">Captopril</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB01197</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB13152">
  <data key="d24">2332</data>
  <data key="d25">45592</data>
  <data key="d26">Coagulation Factor IX Human</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB13152</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB13151">
  <data key="d24">2338</data>
  <data key="d25">45592</data>
  <data key="d26">Anti-inhibitor coagulant complex</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB13151</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB14487">
  <data key="d24">2394</data>
  <data key="d25">45592</data>
  <data key="d26">Zinc acetate</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB14487</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB01123">
  <data key="d24">2495</data>
  <data key="d25">45592</data>
  <data key="d26">Proflavine</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB01123</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB03808">
  <data key="d24">2669</data>
  <data key="d25">45592</data>
  <data key="d26">Hexamidine</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB03808</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB04786">
  <data key="d24">2861</data>
  <data key="d25">45592</data>
  <data key="d26">Suramin</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB04786</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB04771">
  <data key="d24">3026</data>
  <data key="d25">45592</data>
  <data key="d26">1-GUANIDINO-4-(N-NITRO-BENZOYLAMINO-L-LEUCYL-L-PROLYLAMINO)BUTANE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB04771</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB04772">
  <data key="d24">3034</data>
  <data key="d25">45592</data>
  <data key="d26">1-GUANIDINO-4-(N-PHENYLMETHANESULFONYL-L-LEUCYL-L-PROLYLAMINO)BUTANE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB04772</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB04722">
  <data key="d24">3088</data>
  <data key="d25">45592</data>
  <data key="d26">2-(3-CHLORO-6-{[2,2-DIFLUORO-2-(1-OXIDOPYRIDIN-2-YL)ETHYL]AMINO}-1-OXIDOPYRIDIN-2-YL)-N-[1-(3-CHLOROPHENYL)ETHYL]ACETAMIDE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB04722</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB02287">
  <data key="d24">3141</data>
  <data key="d25">45592</data>
  <data key="d26">2-(2-Hydroxy-Phenyl)-3h-Benzoimidazole-5-Carboxamidine</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB02287</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB04898">
  <data key="d24">3212</data>
  <data key="d25">45592</data>
  <data key="d26">Ximelagatran</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB04898</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB00188">
  <data key="d24">3558</data>
  <data key="d25">45592</data>
  <data key="d26">Bortezomib</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB00188</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB00170">
  <data key="d24">3784</data>
  <data key="d25">45592</data>
  <data key="d26">Menadione</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB00170</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB14738">
  <data key="d24">3818</data>
  <data key="d25">45592</data>
  <data key="d26">Turoctocog alfa pegol</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB14738</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB00100">
  <data key="d24">3854</data>
  <data key="d25">45592</data>
  <data key="d26">Coagulation Factor IX (Recombinant)</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB00100</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB01593">
  <data key="d24">4227</data>
  <data key="d25">45592</data>
  <data key="d26">Zinc</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB01593</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB00278">
  <data key="d24">4302</data>
  <data key="d25">45592</data>
  <data key="d26">Argatroban</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB00278</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB14533">
  <data key="d24">5035</data>
  <data key="d25">45592</data>
  <data key="d26">Zinc chloride</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB14533</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB03847">
  <data key="d24">5188</data>
  <data key="d25">45592</data>
  <data key="d26">Gamma-Carboxy-Glutamic Acid</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB03847</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB03865">
  <data key="d24">5246</data>
  <data key="d25">45592</data>
  <data key="d26">6-Chloro-2-(2-Hydroxy-Biphenyl-3-Yl)-1h-Indole-5-Carboxamidine</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB03865</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB00055">
  <data key="d24">5442</data>
  <data key="d25">45592</data>
  <data key="d26">Drotrecogin alfa</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB00055</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB00006">
  <data key="d24">5898</data>
  <data key="d25">45592</data>
  <data key="d26">Bivalirudin</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB00006</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB00001">
  <data key="d24">5907</data>
  <data key="d25">45592</data>
  <data key="d26">Lepirudin</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB00001</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB02723">
  <data key="d24">5964</data>
  <data key="d25">45592</data>
  <data key="d26">4-Oxo-2-Phenylmethanesulfonyl-Octahydro-Pyrrolo[1,2-a]Pyrazine-6-Carboxylic Acid [1-(N-Hydroxycarbamimidoyl)-Piperidin-4-Ylmethyl]-Amide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB02723</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB12598">
  <data key="d24">6051</data>
  <data key="d25">45592</data>
  <data key="d26">Nafamostat</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB12598</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB09109">
  <data key="d24">6785</data>
  <data key="d25">45592</data>
  <data key="d26">Turoctocog alfa</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB09109</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB09130">
  <data key="d24">6850</data>
  <data key="d25">45592</data>
  <data key="d26">Copper</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB09130</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB11095">
  <data key="d24">7069</data>
  <data key="d25">45592</data>
  <data key="d26">Desirudin</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB11095</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB01767">
  <data key="d24">7495</data>
  <data key="d25">45592</data>
  <data key="d26">Hemi-Babim</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB01767</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB01766">
  <data key="d24">7497</data>
  <data key="d25">45592</data>
  <data key="d26">Beta-(2-Naphthyl)-Alanine</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB01766</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB01725">
  <data key="d24">7595</data>
  <data key="d25">45592</data>
  <data key="d26">2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1H-1,3-benzodiazole-5-carboximidamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB01725</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB00498">
  <data key="d24">7660</data>
  <data key="d25">45592</data>
  <data key="d26">Phenindione</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB00498</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB11166">
  <data key="d24">7700</data>
  <data key="d25">45592</data>
  <data key="d26">Antithrombin Alfa</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB11166</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB08061">
  <data key="d24">8197</data>
  <data key="d25">45592</data>
  <data key="d26">4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB08061</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB08062">
  <data key="d24">8208</data>
  <data key="d25">45592</data>
  <data key="d26">3-(4-CHLOROPHENYL)-5-(METHYLTHIO)-4H-1,2,4-TRIAZOLE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB08062</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB08152">
  <data key="d24">8310</data>
  <data key="d25">45592</data>
  <data key="d26">{(2S)-1-[N-(tert-butoxycarbonyl)glycyl]pyrrolidin-2-yl}methyl (3-chlorophenyl)acetate</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB08152</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB08187">
  <data key="d24">8580</data>
  <data key="d25">45592</data>
  <data key="d26">METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB08187</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB08254">
  <data key="d24">8760</data>
  <data key="d25">45592</data>
  <data key="d26">2-NAPHTHALENESULFONIC ACID</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB08254</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB12831">
  <data key="d24">9115</data>
  <data key="d25">45592</data>
  <data key="d26">Gabexate</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB12831</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB09228">
  <data key="d24">9197</data>
  <data key="d25">45592</data>
  <data key="d26">Conestat alfa</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB09228</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB09332">
  <data key="d24">9605</data>
  <data key="d25">45592</data>
  <data key="d26">Kappadione</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB09332</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07277">
  <data key="d24">9921</data>
  <data key="d25">45592</data>
  <data key="d26">2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHANESULFONAMIDE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07277</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07278">
  <data key="d24">9924</data>
  <data key="d25">45592</data>
  <data key="d26">2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHENESULFONAMIDE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07278</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07279">
  <data key="d24">9925</data>
  <data key="d25">45592</data>
  <data key="d26">N-ETHYL-N-ISOPROPYL-3-METHYL-5-{[(2S)-2-(PYRIDIN-4-YLAMINO)PROPYL]OXY}BENZAMIDE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07279</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07211">
  <data key="d24">9938</data>
  <data key="d25">45592</data>
  <data key="d26">(2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07211</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB08546">
  <data key="d24">9941</data>
  <data key="d25">45592</data>
  <data key="d26">4-[(3AS,4R,7R,8AS,8BR)-2-(1,3-BENZODIOXOL-5-YLMETHYL)-7-HYDROXY-1,3-DIOXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZENECARBOXIMIDAMIDE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB08546</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07376">
  <data key="d24">10200</data>
  <data key="d25">45592</data>
  <data key="d26">5-(DIMETHYLAMINO)-1-NAPHTHALENESULFONIC ACID(DANSYL ACID)</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07376</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07353">
  <data key="d24">10311</data>
  <data key="d25">45592</data>
  <data key="d26">4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07353</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07366">
  <data key="d24">10353</data>
  <data key="d25">45592</data>
  <data key="d26">2-[N'-(4-AMINO-BUTYL)-HYDRAZINOCARBONYL]-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07366</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB08624">
  <data key="d24">10389</data>
  <data key="d25">45592</data>
  <data key="d26">BENZOTHIAZOLE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB08624</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07083">
  <data key="d24">10519</data>
  <data key="d25">45592</data>
  <data key="d26">beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07083</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07088">
  <data key="d24">10523</data>
  <data key="d25">45592</data>
  <data key="d26">(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07088</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07016">
  <data key="d24">10532</data>
  <data key="d25">45592</data>
  <data key="d26">(3R)-8-(dioxidosulfanyl)-3-methyl-1,2,3,4-tetrahydroquinoline</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07016</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07027">
  <data key="d24">10576</data>
  <data key="d25">45592</data>
  <data key="d26">D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07027</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07005">
  <data key="d24">10757</data>
  <data key="d25">45592</data>
  <data key="d26">D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07005</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07091">
  <data key="d24">10838</data>
  <data key="d25">45592</data>
  <data key="d26">(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07091</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07095">
  <data key="d24">10842</data>
  <data key="d25">45592</data>
  <data key="d26">(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07095</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07190">
  <data key="d24">10866</data>
  <data key="d25">45592</data>
  <data key="d26">3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07190</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07133">
  <data key="d24">10877</data>
  <data key="d25">45592</data>
  <data key="d26">D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07133</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07131">
  <data key="d24">10881</data>
  <data key="d25">45592</data>
  <data key="d26">(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07131</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07128">
  <data key="d24">10892</data>
  <data key="d25">45592</data>
  <data key="d26">N7-BUTYL-N2-(5-CHLORO-2-METHYLPHENYL)-5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE-2,7-DIAMINE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07128</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07143">
  <data key="d24">10917</data>
  <data key="d25">45592</data>
  <data key="d26">D-phenylalanyl-N-benzyl-L-prolinamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07143</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07165">
  <data key="d24">10978</data>
  <data key="d25">45592</data>
  <data key="d26">N-(5-CHLORO-BENZO[B]THIOPHEN-3-YLMETHYL)-2-[6-CHLORO-OXO-3-(2-PYRIDIN-2-YL-ETHYLAMINO)-2H-PYRAZIN-1-YL]-ACETAMIDE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07165</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB08422">
  <data key="d24">10987</data>
  <data key="d25">45592</data>
  <data key="d26">[PHENYLALANINYL-PROLINYL]-[2-(PYRIDIN-4-YLAMINO)-ETHYL]-AMINE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB08422</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07105">
  <data key="d24">11008</data>
  <data key="d25">45592</data>
  <data key="d26">2-[2-(4-CHLORO-PHENYLSULFANYL)-ACETYLAMINO]-3-(4-GUANIDINO-PHENYL)-PROPIONAMIDE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07105</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07120">
  <data key="d24">11065</data>
  <data key="d25">45592</data>
  <data key="d26">N4-(N,N-DIPHENYLCARBAMOYL)-AMINOGUANIDINE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07120</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07639">
  <data key="d24">11228</data>
  <data key="d25">45592</data>
  <data key="d26">3-(7-DIAMINOMETHYL-NAPHTHALEN-2-YL)-PROPIONIC ACID ETHYL ESTER</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07639</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07660">
  <data key="d24">11380</data>
  <data key="d25">45592</data>
  <data key="d26">AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07660</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07665">
  <data key="d24">11383</data>
  <data key="d25">45592</data>
  <data key="d26">N-[2-(carbamimidamidooxy)ethyl]-2-{6-cyano-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-fluorophenyl}acetamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07665</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07658">
  <data key="d24">11396</data>
  <data key="d25">45592</data>
  <data key="d26">AC-(D)PHE-PRO-BOROLYS-OH</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07658</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07659">
  <data key="d24">11398</data>
  <data key="d25">45592</data>
  <data key="d26">AC-(D)PHE-PRO-BOROHOMOLYS-OH</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07659</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07741">
  <data key="d24">11472</data>
  <data key="d25">45592</data>
  <data key="d26">4-(1R,3AS,4R,8AS,8BR)-[1-DIFLUOROMETHYL-2-(4-FLUOROBENZYL)-3-OXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZAMIDINE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07741</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06404">
  <data key="d24">11473</data>
  <data key="d25">45592</data>
  <data key="d26">Human C1-esterase inhibitor</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06404</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07718">
  <data key="d24">11541</data>
  <data key="d25">45592</data>
  <data key="d26">3-(4-HYDROXY-PHENYL)PYRUVIC ACID</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07718</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07796">
  <data key="d24">11688</data>
  <data key="d25">45592</data>
  <data key="d26">(3ASR,4RS,8ASR,8BRS)-4-(2-(4-FLUOROBENZYL)-1,3-DIOXODEACAHYDROPYRROLO[3,4-A] PYRROLIZIN-4-YL)BENZAMIDINE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07796</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07400">
  <data key="d24">11743</data>
  <data key="d25">45592</data>
  <data key="d26">1-ETHOXYCARBONYL-D-PHE-PRO-2(4-AMINOBUTYL)HYDRAZINE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07400</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07461">
  <data key="d24">11828</data>
  <data key="d25">45592</data>
  <data key="d26">3-AMINO-3-BENZYL-9-CARBOXAMIDE[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07461</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07440">
  <data key="d24">11953</data>
  <data key="d25">45592</data>
  <data key="d26">4-TERT-BUTYLBENZENESULFONIC ACID</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07440</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07508">
  <data key="d24">12004</data>
  <data key="d25">45592</data>
  <data key="d26">4-(5-BENZENESULFONYLAMINO-1-METHYL-1H-BENZOIMIDAZOL-2-YLMETHYL)-BENZAMIDINE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07508</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07522">
  <data key="d24">12011</data>
  <data key="d25">45592</data>
  <data key="d26">N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]NAPHTHALENE-2-SULFONAMIDE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07522</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07521">
  <data key="d24">12013</data>
  <data key="d25">45592</data>
  <data key="d26">6-CHLORO-1-(2-{[(5-CHLORO-1-BENZOTHIEN-3-YL)METHYL]AMINO}ETHYL)-3-[(2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07521</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07515">
  <data key="d24">12014</data>
  <data key="d25">45592</data>
  <data key="d26">1-(2-{[(6-AMINO-2-METHYLPYRIDIN-3-YL)METHYL]AMINO}ETHYL)-6-CHLORO-3-[(2,2-DIFLUORO-2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07515</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07527">
  <data key="d24">12131</data>
  <data key="d25">45592</data>
  <data key="d26">N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]-4-METHOXY-2,3,6-TRIMETHYLBENZENESULFONAMIDE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07527</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07550">
  <data key="d24">12174</data>
  <data key="d25">45592</data>
  <data key="d26">2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(1-OXIDO-2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUOROPHENYL)METHYL]ACETAMIDE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07550</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07548">
  <data key="d24">12186</data>
  <data key="d25">45592</data>
  <data key="d26">2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-6-PYRIDINYL)METHYL]ACETAMIDE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07548</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07549">
  <data key="d24">12188</data>
  <data key="d25">45592</data>
  <data key="d26">2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-3-METHYL-6-PYRIDINYL)METHYL]ACETAMIDE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07549</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB04136">
  <data key="d24">12451</data>
  <data key="d25">45592</data>
  <data key="d26">Lysophosphotidylserine</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB04136</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06878">
  <data key="d24">12526</data>
  <data key="d25">45592</data>
  <data key="d26">1-[(2R)-2-aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06878</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB04216">
  <data key="d24">12527</data>
  <data key="d25">45592</data>
  <data key="d26">Quercetin</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB04216</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06841">
  <data key="d24">12591</data>
  <data key="d25">45592</data>
  <data key="d26">D-phenylalanyl-N-[(1S)-4-{[amino(iminio)methyl]amino}-1-(chloroacetyl)butyl]-L-prolinamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06841</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06838">
  <data key="d24">12601</data>
  <data key="d25">45592</data>
  <data key="d26">methyl L-phenylalaninate</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06838</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06850">
  <data key="d24">12612</data>
  <data key="d25">45592</data>
  <data key="d26">(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06850</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06845">
  <data key="d24">12616</data>
  <data key="d25">45592</data>
  <data key="d26">(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06845</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06861">
  <data key="d24">12634</data>
  <data key="d25">45592</data>
  <data key="d26">6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06861</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06853">
  <data key="d24">12638</data>
  <data key="d25">45592</data>
  <data key="d26">N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06853</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06859">
  <data key="d24">12640</data>
  <data key="d25">45592</data>
  <data key="d26">N-ALLYL-5-AMIDINOAMINOOXY-PROPYLOXY-3-CHLORO-N-CYCLOPENTYLBENZAMIDE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06859</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06858">
  <data key="d24">12643</data>
  <data key="d25">45592</data>
  <data key="d26">N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06858</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06866">
  <data key="d24">12656</data>
  <data key="d25">45592</data>
  <data key="d26">6-CARBAMIMIDOYL-2-[2-HYDROXY-5-(3-METHOXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06866</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06865">
  <data key="d24">12663</data>
  <data key="d25">45592</data>
  <data key="d26">6-CARBAMIMIDOYL-2-[2-HYDROXY-6-(4-HYDROXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06865</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06868">
  <data key="d24">12667</data>
  <data key="d25">45592</data>
  <data key="d26">N-(3-chlorobenzyl)-1-(4-methylpentanoyl)-L-prolinamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06868</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06869">
  <data key="d24">12669</data>
  <data key="d25">45592</data>
  <data key="d26">1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06869</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07809">
  <data key="d24">12838</data>
  <data key="d25">45592</data>
  <data key="d26">4-({[4-(3-METHYLBENZOYL)PYRIDIN-2-YL]AMINO}METHYL)BENZENECARBOXIMIDAMIDE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07809</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07897">
  <data key="d24">12905</data>
  <data key="d25">45592</data>
  <data key="d26">1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07897</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07934">
  <data key="d24">13098</data>
  <data key="d25">45592</data>
  <data key="d26">[[CYCLOHEXANESULFONYL-GLYCYL]-3[PYRIDIN-4-YL-AMINOMETHYL]ALANYL]PIPERIDINE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07934</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06605">
  <data key="d24">13108</data>
  <data key="d25">45592</data>
  <data key="d26">Apixaban</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06605</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07944">
  <data key="d24">13117</data>
  <data key="d25">45592</data>
  <data key="d26">N-{3-METHYL-5-[2-(PYRIDIN-4-YLAMINO)-ETHOXY]-PHENYL}-BENZENESULFONAMIDE</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07944</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB07946">
  <data key="d24">13126</data>
  <data key="d25">45592</data>
  <data key="d26">N-[2-({[amino(imino)methyl]amino}oxy)ethyl]-2-{6-chloro-3-[(2,2-difluoro-2-phenylethyl)amino]-2-fluorophenyl}acetamide</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB07946</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.2147" target="drugbank.DB06695">
  <data key="d24">13255</data>
  <data key="d25">45592</data>
  <data key="d26">Dabigatran etexilate</data>
  <data key="d27">F2</data>
  <data key="d28">drugbank.DB06695</data>
  <data key="d29">entrez.2147</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1718" target="mondo.0004975">
  <data key="d24">47398</data>
  <data key="d25">9604</data>
  <data key="d26">DHCR24</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.1718</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.1808" target="mondo.0004975">
  <data key="d24">47885</data>
  <data key="d25">9604</data>
  <data key="d26">DPYSL2</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.1808</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.1808" target="drugbank.DB11638">
  <data key="d24">9575</data>
  <data key="d25">47885</data>
  <data key="d26">Artenimol</data>
  <data key="d27">DPYSL2</data>
  <data key="d28">drugbank.DB11638</data>
  <data key="d29">entrez.1808</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1808" target="drugbank.DB06218">
  <data key="d24">12187</data>
  <data key="d25">47885</data>
  <data key="d26">Lacosamide</data>
  <data key="d27">DPYSL2</data>
  <data key="d28">drugbank.DB06218</data>
  <data key="d29">entrez.1808</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="mondo.0004975">
  <data key="d24">48272</data>
  <data key="d25">9604</data>
  <data key="d26">CYP2D6</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.1565</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01069">
  <data key="d24">1661</data>
  <data key="d25">48272</data>
  <data key="d26">Promethazine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01069</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01075">
  <data key="d24">1668</data>
  <data key="d25">48272</data>
  <data key="d26">Diphenhydramine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01075</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01074">
  <data key="d24">1669</data>
  <data key="d25">48272</data>
  <data key="d26">Perhexiline</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01074</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01091">
  <data key="d24">1732</data>
  <data key="d25">48272</data>
  <data key="d26">Butenafine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01091</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01002">
  <data key="d24">2013</data>
  <data key="d25">48272</data>
  <data key="d26">Levobupivacaine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01002</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01146">
  <data key="d24">2258</data>
  <data key="d25">48272</data>
  <data key="d26">Diphenylpyraline</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01146</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01156">
  <data key="d24">2304</data>
  <data key="d25">48272</data>
  <data key="d26">Bupropion</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01156</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01176">
  <data key="d24">2345</data>
  <data key="d25">48272</data>
  <data key="d26">Cyclizine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01176</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01173">
  <data key="d24">2351</data>
  <data key="d25">48272</data>
  <data key="d26">Orphenadrine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01173</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01186">
  <data key="d24">2382</data>
  <data key="d25">48272</data>
  <data key="d26">Pergolide</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01186</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01184">
  <data key="d24">2384</data>
  <data key="d25">48272</data>
  <data key="d26">Domperidone</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01184</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01183">
  <data key="d24">2385</data>
  <data key="d25">48272</data>
  <data key="d26">Naloxone</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01183</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01182">
  <data key="d24">2386</data>
  <data key="d25">48272</data>
  <data key="d26">Propafenone</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01182</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01110">
  <data key="d24">2410</data>
  <data key="d25">48272</data>
  <data key="d26">Miconazole</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01110</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01114">
  <data key="d24">2444</data>
  <data key="d25">48272</data>
  <data key="d26">Chlorphenamine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01114</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01127">
  <data key="d24">2486</data>
  <data key="d25">48272</data>
  <data key="d26">Econazole</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01127</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01139">
  <data key="d24">2540</data>
  <data key="d25">48272</data>
  <data key="d26">Cefapirin</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01139</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB04819">
  <data key="d24">3443</data>
  <data key="d25">48272</data>
  <data key="d26">Methapyrilene</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB04819</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01429">
  <data key="d24">3796</data>
  <data key="d25">48272</data>
  <data key="d26">Aprindine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01429</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01426">
  <data key="d24">3799</data>
  <data key="d25">48272</data>
  <data key="d26">Ajmaline</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01426</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00208">
  <data key="d24">4092</data>
  <data key="d25">48272</data>
  <data key="d26">Ticlopidine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00208</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00297">
  <data key="d24">4187</data>
  <data key="d25">48272</data>
  <data key="d26">Bupivacaine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00297</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00276">
  <data key="d24">4304</data>
  <data key="d25">48272</data>
  <data key="d26">Amsacrine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00276</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00283">
  <data key="d24">4308</data>
  <data key="d25">48272</data>
  <data key="d26">Clemastine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00283</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00289">
  <data key="d24">4328</data>
  <data key="d25">48272</data>
  <data key="d26">Atomoxetine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00289</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB13520">
  <data key="d24">4398</data>
  <data key="d25">48272</data>
  <data key="d26">Metergoline</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB13520</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00239">
  <data key="d24">4468</data>
  <data key="d25">48272</data>
  <data key="d26">Oxiconazole</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00239</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01231">
  <data key="d24">5004</data>
  <data key="d25">48272</data>
  <data key="d26">Diphenidol</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01231</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01233">
  <data key="d24">5053</data>
  <data key="d25">48272</data>
  <data key="d26">Metoclopramide</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01233</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01242">
  <data key="d24">5057</data>
  <data key="d25">48272</data>
  <data key="d26">Clomipramine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01242</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01392">
  <data key="d24">5451</data>
  <data key="d25">48272</data>
  <data key="d26">Yohimbine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01392</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB01408">
  <data key="d24">5978</data>
  <data key="d25">48272</data>
  <data key="d26">Bambuterol</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB01408</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00589">
  <data key="d24">6124</data>
  <data key="d25">48272</data>
  <data key="d26">Lisuride</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00589</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00598">
  <data key="d24">6167</data>
  <data key="d25">48272</data>
  <data key="d26">Labetalol</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00598</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB09010">
  <data key="d24">6311</data>
  <data key="d25">48272</data>
  <data key="d26">Carmofur</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB09010</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00679">
  <data key="d24">6312</data>
  <data key="d25">48272</data>
  <data key="d26">Thioridazine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00679</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB09019">
  <data key="d24">6322</data>
  <data key="d25">48272</data>
  <data key="d26">Bromhexine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB09019</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00692">
  <data key="d24">6376</data>
  <data key="d25">48272</data>
  <data key="d26">Phentolamine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00692</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00604">
  <data key="d24">6591</data>
  <data key="d25">48272</data>
  <data key="d26">Cisapride</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00604</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB09081">
  <data key="d24">6636</data>
  <data key="d25">48272</data>
  <data key="d26">Idebenone</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB09081</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00780">
  <data key="d24">6784</data>
  <data key="d25">48272</data>
  <data key="d26">Phenelzine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00780</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00734">
  <data key="d24">6915</data>
  <data key="d25">48272</data>
  <data key="d26">Risperidone</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00734</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00704">
  <data key="d24">7013</data>
  <data key="d25">48272</data>
  <data key="d26">Naltrexone</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00704</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00715">
  <data key="d24">7023</data>
  <data key="d25">48272</data>
  <data key="d26">Paroxetine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00715</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00376">
  <data key="d24">7095</data>
  <data key="d25">48272</data>
  <data key="d26">Trihexyphenidyl</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00376</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00384">
  <data key="d24">7098</data>
  <data key="d25">48272</data>
  <data key="d26">Triamterene</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00384</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00382">
  <data key="d24">7100</data>
  <data key="d25">48272</data>
  <data key="d26">Tacrine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00382</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00353">
  <data key="d24">7334</data>
  <data key="d25">48272</data>
  <data key="d26">Methylergometrine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00353</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00420">
  <data key="d24">7467</data>
  <data key="d25">48272</data>
  <data key="d26">Promazine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00420</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00433">
  <data key="d24">7500</data>
  <data key="d25">48272</data>
  <data key="d26">Prochlorperazine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00433</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00448">
  <data key="d24">7531</data>
  <data key="d25">48272</data>
  <data key="d26">Lansoprazole</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00448</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00406">
  <data key="d24">7615</data>
  <data key="d25">48272</data>
  <data key="d26">Gentian violet cation</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00406</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00472">
  <data key="d24">7786</data>
  <data key="d25">48272</data>
  <data key="d26">Fluoxetine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00472</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00477">
  <data key="d24">7827</data>
  <data key="d25">48272</data>
  <data key="d26">Chlorpromazine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00477</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00482">
  <data key="d24">7833</data>
  <data key="d25">48272</data>
  <data key="d26">Celecoxib</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00482</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00543">
  <data key="d24">7943</data>
  <data key="d25">48272</data>
  <data key="d26">Amoxapine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00543</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00540">
  <data key="d24">7949</data>
  <data key="d25">48272</data>
  <data key="d26">Nortriptyline</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00540</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00557">
  <data key="d24">7975</data>
  <data key="d25">48272</data>
  <data key="d26">Hydroxyzine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00557</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00561">
  <data key="d24">8039</data>
  <data key="d25">48272</data>
  <data key="d26">Doxapram</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00561</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00571">
  <data key="d24">8041</data>
  <data key="d25">48272</data>
  <data key="d26">Propranolol</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00571</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00503">
  <data key="d24">8094</data>
  <data key="d25">48272</data>
  <data key="d26">Ritonavir</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00503</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00514">
  <data key="d24">8121</data>
  <data key="d25">48272</data>
  <data key="d26">Dextromethorphan</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00514</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00857">
  <data key="d24">9096</data>
  <data key="d25">48272</data>
  <data key="d26">Terbinafine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00857</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB09224">
  <data key="d24">9189</data>
  <data key="d25">48272</data>
  <data key="d26">Melperone</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB09224</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00882">
  <data key="d24">9198</data>
  <data key="d25">48272</data>
  <data key="d26">Clomifene</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00882</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00836">
  <data key="d24">9250</data>
  <data key="d25">48272</data>
  <data key="d26">Loperamide</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00836</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB11590">
  <data key="d24">9303</data>
  <data key="d25">48272</data>
  <data key="d26">Thimerosal</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB11590</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00985">
  <data key="d24">9556</data>
  <data key="d25">48272</data>
  <data key="d26">Dimenhydrinate</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00985</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00981">
  <data key="d24">9564</data>
  <data key="d25">48272</data>
  <data key="d26">Physostigmine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00981</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00935">
  <data key="d24">9710</data>
  <data key="d25">48272</data>
  <data key="d26">Oxymetazoline</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00935</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00953">
  <data key="d24">9749</data>
  <data key="d25">48272</data>
  <data key="d26">Rizatriptan</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00953</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB00908">
  <data key="d24">9814</data>
  <data key="d25">48272</data>
  <data key="d26">Quinidine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB00908</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB11994">
  <data key="d24">10596</data>
  <data key="d25">48272</data>
  <data key="d26">Diacerein</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB11994</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB08992">
  <data key="d24">11377</data>
  <data key="d25">48272</data>
  <data key="d26">Eperisone</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB08992</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB08807">
  <data key="d24">12031</data>
  <data key="d25">48272</data>
  <data key="d26">Bopindolol</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB08807</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB06718">
  <data key="d24">12352</data>
  <data key="d25">48272</data>
  <data key="d26">Stanozolol</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB06718</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB06726">
  <data key="d24">12363</data>
  <data key="d25">48272</data>
  <data key="d26">Bufuralol</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB06726</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB06742">
  <data key="d24">12366</data>
  <data key="d25">48272</data>
  <data key="d26">Ambroxol</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB06742</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB06800">
  <data key="d24">12670</data>
  <data key="d25">48272</data>
  <data key="d26">Methylnaltrexone</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB06800</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB06820">
  <data key="d24">12689</data>
  <data key="d25">48272</data>
  <data key="d26">Sulconazole</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB06820</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1565" target="drugbank.DB06691">
  <data key="d24">13244</data>
  <data key="d25">48272</data>
  <data key="d26">Mepyramine</data>
  <data key="d27">CYP2D6</data>
  <data key="d28">drugbank.DB06691</data>
  <data key="d29">entrez.1565</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="mondo.0004975">
  <data key="d24">48601</data>
  <data key="d25">9604</data>
  <data key="d26">ACE</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.1636</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.6</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB02032">
  <data key="d24">667</data>
  <data key="d25">48601</data>
  <data key="d26">1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB02032</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB01197">
  <data key="d24">2213</data>
  <data key="d25">48601</data>
  <data key="d26">Captopril</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB01197</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB13166">
  <data key="d24">2366</data>
  <data key="d25">48601</data>
  <data key="d26">Zofenopril</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB13166</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB01180">
  <data key="d24">2388</data>
  <data key="d25">48601</data>
  <data key="d26">Rescinnamine</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB01180</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB03740">
  <data key="d24">2612</data>
  <data key="d25">48601</data>
  <data key="d26">N-acetyl-alpha-D-glucosamine</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB03740</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB00178">
  <data key="d24">3532</data>
  <data key="d25">48601</data>
  <data key="d26">Ramipril</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB00178</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB00172">
  <data key="d24">3782</data>
  <data key="d25">48601</data>
  <data key="d26">Proline</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB00172</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB01348">
  <data key="d24">5566</data>
  <data key="d25">48601</data>
  <data key="d26">Spirapril</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB01348</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB01340">
  <data key="d24">5915</data>
  <data key="d25">48601</data>
  <data key="d26">Cilazapril</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB01340</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB00584">
  <data key="d24">6129</data>
  <data key="d25">48601</data>
  <data key="d26">Enalapril</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB00584</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB00678">
  <data key="d24">6313</data>
  <data key="d25">48601</data>
  <data key="d26">Losartan</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB00678</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB00691">
  <data key="d24">6377</data>
  <data key="d25">48601</data>
  <data key="d26">Moexipril</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB00691</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB00616">
  <data key="d24">6409</data>
  <data key="d25">48601</data>
  <data key="d26">Candoxatril</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB00616</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB00790">
  <data key="d24">6826</data>
  <data key="d25">48601</data>
  <data key="d26">Perindopril</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB00790</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB00722">
  <data key="d24">7035</data>
  <data key="d25">48601</data>
  <data key="d26">Lisinopril</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB00722</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB00492">
  <data key="d24">7874</data>
  <data key="d25">48601</data>
  <data key="d26">Fosinopril</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB00492</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB00542">
  <data key="d24">7945</data>
  <data key="d25">48601</data>
  <data key="d26">Benazepril</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB00542</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB00519">
  <data key="d24">8113</data>
  <data key="d25">48601</data>
  <data key="d26">Trandolapril</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB00519</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB09477">
  <data key="d24">8278</data>
  <data key="d25">48601</data>
  <data key="d26">Enalaprilat</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB09477</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB11783">
  <data key="d24">8298</data>
  <data key="d25">48601</data>
  <data key="d26">Imidapril</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB11783</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB00886">
  <data key="d24">9190</data>
  <data key="d25">48601</data>
  <data key="d26">Omapatrilat</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB00886</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB00881">
  <data key="d24">9200</data>
  <data key="d25">48601</data>
  <data key="d26">Quinapril</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB00881</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB00966">
  <data key="d24">9775</data>
  <data key="d25">48601</data>
  <data key="d26">Telmisartan</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB00966</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB08626">
  <data key="d24">10386</data>
  <data key="d25">48601</data>
  <data key="d26">Thiorphan</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB08626</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1636" target="drugbank.DB08836">
  <data key="d24">11997</data>
  <data key="d25">48601</data>
  <data key="d26">Temocapril</data>
  <data key="d27">ACE</data>
  <data key="d28">drugbank.DB08836</data>
  <data key="d29">entrez.1636</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1392" target="mondo.0004975">
  <data key="d24">48953</data>
  <data key="d25">9604</data>
  <data key="d26">CRH</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.1392</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.32</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.1392" target="drugbank.DB02952">
  <data key="d24">4590</data>
  <data key="d25">48953</data>
  <data key="d26">Alpha-Aminoisobutyric Acid</data>
  <data key="d27">CRH</data>
  <data key="d28">drugbank.DB02952</data>
  <data key="d29">entrez.1392</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1392" target="drugbank.DB01285">
  <data key="d24">4936</data>
  <data key="d25">48953</data>
  <data key="d26">Corticotropin</data>
  <data key="d27">CRH</data>
  <data key="d28">drugbank.DB01285</data>
  <data key="d29">entrez.1392</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1392" target="drugbank.DB02556">
  <data key="d24">5014</data>
  <data key="d25">48953</data>
  <data key="d26">D-Phenylalanine</data>
  <data key="d27">CRH</data>
  <data key="d28">drugbank.DB02556</data>
  <data key="d29">entrez.1392</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1378" target="mondo.0004975">
  <data key="d24">49048</data>
  <data key="d25">9604</data>
  <data key="d26">CR1</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.1378</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.46</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.1471" target="mondo.0004975">
  <data key="d24">49501</data>
  <data key="d25">9604</data>
  <data key="d26">CST3</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.1471</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.1141" target="mondo.0004975">
  <data key="d24">49931</data>
  <data key="d25">9604</data>
  <data key="d26">CHRNB2</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.1141</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.34</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB05855">
  <data key="d24">301</data>
  <data key="d25">49931</data>
  <data key="d26">Rivanicline</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB05855</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB03128">
  <data key="d24">1338</data>
  <data key="d25">49931</data>
  <data key="d26">Acetylcholine</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB03128</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB05740">
  <data key="d24">1552</data>
  <data key="d25">49931</data>
  <data key="d26">RPI-78M</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB05740</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB01199">
  <data key="d24">2231</data>
  <data key="d25">49931</data>
  <data key="d26">Tubocurarine</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB01199</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB01156">
  <data key="d24">2304</data>
  <data key="d25">49931</data>
  <data key="d26">Bupropion</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB01156</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB00184">
  <data key="d24">3537</data>
  <data key="d25">49931</data>
  <data key="d26">Nicotine</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB00184</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB01273">
  <data key="d24">4902</data>
  <data key="d25">49931</data>
  <data key="d26">Varenicline</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB01273</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB01245">
  <data key="d24">5102</data>
  <data key="d25">49931</data>
  <data key="d26">Decamethonium</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB01245</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB01339">
  <data key="d24">5895</data>
  <data key="d25">49931</data>
  <data key="d26">Vecuronium</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB01339</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB01338">
  <data key="d24">5897</data>
  <data key="d25">49931</data>
  <data key="d26">Pipecuronium</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB01338</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB01337">
  <data key="d24">5899</data>
  <data key="d25">49931</data>
  <data key="d26">Pancuronium</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB01337</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB01336">
  <data key="d24">5901</data>
  <data key="d25">49931</data>
  <data key="d26">Metocurine</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB01336</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB00572">
  <data key="d24">6091</data>
  <data key="d25">49931</data>
  <data key="d26">Atropine</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB00572</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB00657">
  <data key="d24">6209</data>
  <data key="d25">49931</data>
  <data key="d26">Mecamylamine</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB00657</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB00674">
  <data key="d24">6321</data>
  <data key="d25">49931</data>
  <data key="d26">Galantamine</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB00674</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB09028">
  <data key="d24">6373</data>
  <data key="d25">49931</data>
  <data key="d26">Cytisine</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB09028</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB00747">
  <data key="d24">6932</data>
  <data key="d25">49931</data>
  <data key="d26">Scopolamine</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB00747</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB00753">
  <data key="d24">6955</data>
  <data key="d25">49931</data>
  <data key="d26">Isoflurane</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB00753</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB00411">
  <data key="d24">7436</data>
  <data key="d25">49931</data>
  <data key="d26">Carbamoylcholine</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB00411</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB00474">
  <data key="d24">7830</data>
  <data key="d25">49931</data>
  <data key="d26">Methohexital</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB00474</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB00564">
  <data key="d24">8034</data>
  <data key="d25">49931</data>
  <data key="d26">Carbamazepine</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB00564</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB00514">
  <data key="d24">8121</data>
  <data key="d25">49931</data>
  <data key="d26">Dextromethorphan</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB00514</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB00898">
  <data key="d24">8986</data>
  <data key="d25">49931</data>
  <data key="d26">Ethanol</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB00898</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB00889">
  <data key="d24">9186</data>
  <data key="d25">49931</data>
  <data key="d26">Granisetron</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB00889</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB11699">
  <data key="d24">9497</data>
  <data key="d25">49931</data>
  <data key="d26">Tropisetron</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB11699</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB00981">
  <data key="d24">9564</data>
  <data key="d25">49931</data>
  <data key="d26">Physostigmine</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB00981</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB00904">
  <data key="d24">9808</data>
  <data key="d25">49931</data>
  <data key="d26">Ondansetron</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB00904</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB08960">
  <data key="d24">11178</data>
  <data key="d25">49931</data>
  <data key="d26">Hexamethonium</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB08960</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB07720">
  <data key="d24">11534</data>
  <data key="d25">49931</data>
  <data key="d26">Epibatidine</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB07720</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1141" target="drugbank.DB05458">
  <data key="d24">12340</data>
  <data key="d25">49931</data>
  <data key="d26">Pozanicline</data>
  <data key="d27">CHRNB2</data>
  <data key="d28">drugbank.DB05458</data>
  <data key="d29">entrez.1141</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="mondo.0004975">
  <data key="d24">49945</data>
  <data key="d25">9604</data>
  <data key="d26">CHRNA7</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.1139</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB14011">
  <data key="d24">653</data>
  <data key="d25">49945</data>
  <data key="d26">Nabiximols</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB14011</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB14009">
  <data key="d24">690</data>
  <data key="d25">49945</data>
  <data key="d26">Medical Cannabis</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB14009</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB14006">
  <data key="d24">695</data>
  <data key="d25">49945</data>
  <data key="d26">Choline salicylate</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB14006</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB03128">
  <data key="d24">1338</data>
  <data key="d25">49945</data>
  <data key="d26">Acetylcholine</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB03128</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB05708">
  <data key="d24">1538</data>
  <data key="d25">49945</data>
  <data key="d26">GTS-21</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB05708</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB05740">
  <data key="d24">1552</data>
  <data key="d25">49945</data>
  <data key="d26">RPI-78M</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB05740</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB01199">
  <data key="d24">2231</data>
  <data key="d25">49945</data>
  <data key="d26">Tubocurarine</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB01199</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB01156">
  <data key="d24">2304</data>
  <data key="d25">49945</data>
  <data key="d26">Bupropion</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB01156</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB01174">
  <data key="d24">2349</data>
  <data key="d25">49945</data>
  <data key="d26">Phenobarbital</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB01174</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB01116">
  <data key="d24">2442</data>
  <data key="d25">49945</data>
  <data key="d26">Trimethaphan</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB01116</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00184">
  <data key="d24">3537</data>
  <data key="d25">49945</data>
  <data key="d26">Nicotine</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00184</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB01483">
  <data key="d24">3685</data>
  <data key="d25">49945</data>
  <data key="d26">Barbital</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB01483</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB01496">
  <data key="d24">3778</data>
  <data key="d25">49945</data>
  <data key="d26">Barbituric acid derivative</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB01496</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00122">
  <data key="d24">3953</data>
  <data key="d25">49945</data>
  <data key="d26">Choline</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00122</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00237">
  <data key="d24">4471</data>
  <data key="d25">49945</data>
  <data key="d26">Butabarbital</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00237</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00241">
  <data key="d24">4485</data>
  <data key="d25">49945</data>
  <data key="d26">Butalbital</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00241</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00306">
  <data key="d24">4620</data>
  <data key="d25">49945</data>
  <data key="d26">Talbutal</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00306</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00312">
  <data key="d24">4678</data>
  <data key="d25">49945</data>
  <data key="d26">Pentobarbital</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00312</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB01273">
  <data key="d24">4902</data>
  <data key="d25">49945</data>
  <data key="d26">Varenicline</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB01273</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB01352">
  <data key="d24">5581</data>
  <data key="d25">49945</data>
  <data key="d26">Aprobarbital</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB01352</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB01351">
  <data key="d24">5584</data>
  <data key="d25">49945</data>
  <data key="d26">Amobarbital</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB01351</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB01355">
  <data key="d24">5628</data>
  <data key="d25">49945</data>
  <data key="d26">Hexobarbital</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB01355</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB01354">
  <data key="d24">5630</data>
  <data key="d25">49945</data>
  <data key="d26">Heptabarbital</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB01354</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB01353">
  <data key="d24">5633</data>
  <data key="d25">49945</data>
  <data key="d26">Butobarbital</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB01353</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00599">
  <data key="d24">6166</data>
  <data key="d25">49945</data>
  <data key="d26">Thiopental</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00599</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00657">
  <data key="d24">6209</data>
  <data key="d25">49945</data>
  <data key="d26">Mecamylamine</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00657</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00674">
  <data key="d24">6321</data>
  <data key="d25">49945</data>
  <data key="d26">Galantamine</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00674</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB09028">
  <data key="d24">6373</data>
  <data key="d25">49945</data>
  <data key="d26">Cytisine</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB09028</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00602">
  <data key="d24">6595</data>
  <data key="d25">49945</data>
  <data key="d26">Ivermectin</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00602</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB09061">
  <data key="d24">6749</data>
  <data key="d25">49945</data>
  <data key="d26">Cannabidiol</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB09061</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00794">
  <data key="d24">6860</data>
  <data key="d25">49945</data>
  <data key="d26">Primidone</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00794</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00704">
  <data key="d24">7013</data>
  <data key="d25">49945</data>
  <data key="d26">Naltrexone</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00704</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00418">
  <data key="d24">7423</data>
  <data key="d25">49945</data>
  <data key="d26">Secobarbital</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00418</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00411">
  <data key="d24">7436</data>
  <data key="d25">49945</data>
  <data key="d26">Carbamoylcholine</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00411</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00463">
  <data key="d24">7782</data>
  <data key="d25">49945</data>
  <data key="d26">Metharbital</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00463</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00514">
  <data key="d24">8121</data>
  <data key="d25">49945</data>
  <data key="d26">Dextromethorphan</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00514</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB11726">
  <data key="d24">8544</data>
  <data key="d25">49945</data>
  <data key="d26">Encenicline</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB11726</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00898">
  <data key="d24">8986</data>
  <data key="d25">49945</data>
  <data key="d26">Ethanol</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00898</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00849">
  <data key="d24">9266</data>
  <data key="d25">49945</data>
  <data key="d26">Methylphenobarbital</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00849</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB11699">
  <data key="d24">9497</data>
  <data key="d25">49945</data>
  <data key="d26">Tropisetron</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB11699</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB00915">
  <data key="d24">9818</data>
  <data key="d25">49945</data>
  <data key="d26">Amantadine</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB00915</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB07720">
  <data key="d24">11534</data>
  <data key="d25">49945</data>
  <data key="d26">Epibatidine</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB07720</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1139" target="drugbank.DB05137">
  <data key="d24">11713</data>
  <data key="d25">49945</data>
  <data key="d26">Lobeline</data>
  <data key="d27">CHRNA7</data>
  <data key="d28">drugbank.DB05137</data>
  <data key="d29">entrez.1139</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1191" target="mondo.0004975">
  <data key="d24">50030</data>
  <data key="d25">9604</data>
  <data key="d26">CLU</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.1191</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.5</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.1191" target="drugbank.DB14487">
  <data key="d24">2394</data>
  <data key="d25">50030</data>
  <data key="d26">Zinc acetate</data>
  <data key="d27">CLU</data>
  <data key="d28">drugbank.DB14487</data>
  <data key="d29">entrez.1191</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1191" target="drugbank.DB01593">
  <data key="d24">4227</data>
  <data key="d25">50030</data>
  <data key="d26">Zinc</data>
  <data key="d27">CLU</data>
  <data key="d28">drugbank.DB01593</data>
  <data key="d29">entrez.1191</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1191" target="drugbank.DB14533">
  <data key="d24">5035</data>
  <data key="d25">50030</data>
  <data key="d26">Zinc chloride</data>
  <data key="d27">CLU</data>
  <data key="d28">drugbank.DB14533</data>
  <data key="d29">entrez.1191</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1191" target="drugbank.DB09130">
  <data key="d24">6850</data>
  <data key="d25">50030</data>
  <data key="d26">Copper</data>
  <data key="d27">CLU</data>
  <data key="d28">drugbank.DB09130</data>
  <data key="d29">entrez.1191</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.1200" target="mondo.0004975">
  <data key="d24">50098</data>
  <data key="d25">9604</data>
  <data key="d26">TPP1</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.1200</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.3</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.1965" target="mondo.0004975">
  <data key="d24">53125</data>
  <data key="d25">9604</data>
  <data key="d26">EIF2S1</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.1965</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.33</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.26330" target="mondo.0004975">
  <data key="d24">53306</data>
  <data key="d25">9604</data>
  <data key="d26">GAPDHS</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.26330</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.3</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.26330" target="drugbank.DB03331">
  <data key="d24">534</data>
  <data key="d25">53306</data>
  <data key="d26">N-Naphthalen-1-Ylmethyl-2'-[3,5-Dimethoxybenzamido]-2'-Deoxy-Adenosine</data>
  <data key="d27">GAPDHS</data>
  <data key="d28">drugbank.DB03331</data>
  <data key="d29">entrez.26330</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.26330" target="drugbank.DB04477">
  <data key="d24">1405</data>
  <data key="d25">53306</data>
  <data key="d26">N-1,2,3,4-Tetrahydronaphth-1-Yl-2'-[3,5-Dimethoxybenzamido]-2'-Deoxy-Adenosine</data>
  <data key="d27">GAPDHS</data>
  <data key="d28">drugbank.DB04477</data>
  <data key="d29">entrez.26330</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.26330" target="drugbank.DB14487">
  <data key="d24">2394</data>
  <data key="d25">53306</data>
  <data key="d26">Zinc acetate</data>
  <data key="d27">GAPDHS</data>
  <data key="d28">drugbank.DB14487</data>
  <data key="d29">entrez.26330</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.26330" target="drugbank.DB02205">
  <data key="d24">3353</data>
  <data key="d25">53306</data>
  <data key="d26">6-(1,1-Dimethylallyl)-2-(1-Hydroxy-1-Methylethyl)-2,3-Dihydro-7h-Furo[3,2-G]Chromen-7-One</data>
  <data key="d27">GAPDHS</data>
  <data key="d28">drugbank.DB02205</data>
  <data key="d29">entrez.26330</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.26330" target="drugbank.DB00157">
  <data key="d24">3724</data>
  <data key="d25">53306</data>
  <data key="d26">NADH</data>
  <data key="d27">GAPDHS</data>
  <data key="d28">drugbank.DB00157</data>
  <data key="d29">entrez.26330</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.26330" target="drugbank.DB01593">
  <data key="d24">4227</data>
  <data key="d25">53306</data>
  <data key="d26">Zinc</data>
  <data key="d27">GAPDHS</data>
  <data key="d28">drugbank.DB01593</data>
  <data key="d29">entrez.26330</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.26330" target="drugbank.DB14533">
  <data key="d24">5035</data>
  <data key="d25">53306</data>
  <data key="d26">Zinc chloride</data>
  <data key="d27">GAPDHS</data>
  <data key="d28">drugbank.DB14533</data>
  <data key="d29">entrez.26330</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.26330" target="drugbank.DB11638">
  <data key="d24">9575</data>
  <data key="d25">53306</data>
  <data key="d26">Artenimol</data>
  <data key="d27">GAPDHS</data>
  <data key="d28">drugbank.DB11638</data>
  <data key="d29">entrez.26330</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.51338" target="mondo.0004975">
  <data key="d24">53395</data>
  <data key="d25">9604</data>
  <data key="d26">MS4A4A</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.51338</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.42</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.51225" target="mondo.0004975">
  <data key="d24">53896</data>
  <data key="d25">9604</data>
  <data key="d26">ABI3</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.51225</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.31</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.5328" target="mondo.0004975">
  <data key="d24">54345</data>
  <data key="d25">9604</data>
  <data key="d26">PLAU</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.5328</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.58</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.5328" target="mondo.0007088">
  <data key="d24">54345</data>
  <data key="d25">23400</data>
  <data key="d26">PLAU</data>
  <data key="d27">Alzheimer disease type 1</data>
  <data key="d28">entrez.5328</data>
  <data key="d29">mondo.0007088</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB03046">
  <data key="d24">998</data>
  <data key="d25">54345</data>
  <data key="d26">7-Methoxy-8-[1-(Methylsulfonyl)-1h-Pyrazol-4-Yl]Naphthalene-2-Carboximidamide</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB03046</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB03082">
  <data key="d24">1296</data>
  <data key="d25">54345</data>
  <data key="d26">6-[(Z)-Amino(Imino)Methyl]-N-[4-(Aminomethyl)Phenyl]-4-(Pyrimidin-2-Ylamino)-2-Naphthamide</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB03082</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB03127">
  <data key="d24">1336</data>
  <data key="d25">54345</data>
  <data key="d26">Benzamidine</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB03127</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB03136">
  <data key="d24">1366</data>
  <data key="d25">54345</data>
  <data key="d26">4-Iodobenzo[B]Thiophene-2-Carboxamidine</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB03136</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB03159">
  <data key="d24">1440</data>
  <data key="d25">54345</data>
  <data key="d26">CRA_8696</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB03159</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB02398">
  <data key="d24">1665</data>
  <data key="d25">54345</data>
  <data key="d26">6-[N-(4-(Aminomethyl)Phenyl)Carbamyl]-2-Naphthalenecarboxamidine</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB02398</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB03782">
  <data key="d24">2451</data>
  <data key="d25">54345</data>
  <data key="d26">N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB03782</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB02473">
  <data key="d24">2549</data>
  <data key="d25">54345</data>
  <data key="d26">6-[N-(1-Isopropyl-3,4-Dihydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB02473</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB03729">
  <data key="d24">2590</data>
  <data key="d25">54345</data>
  <data key="d26">2-Amino-5-Hydroxy-Benzimidazole</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB03729</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB03808">
  <data key="d24">2669</data>
  <data key="d25">54345</data>
  <data key="d26">Hexamidine</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB03808</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB03476">
  <data key="d24">2936</data>
  <data key="d25">54345</data>
  <data key="d26">Trans-6-(2-Phenylcyclopropyl)-Naphthalene-2-Carboxamidine</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB03476</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB02287">
  <data key="d24">3141</data>
  <data key="d25">54345</data>
  <data key="d26">2-(2-Hydroxy-Phenyl)-3h-Benzoimidazole-5-Carboxamidine</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB02287</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB02526">
  <data key="d24">5211</data>
  <data key="d25">54345</data>
  <data key="d26">CRA_10655</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB02526</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB03865">
  <data key="d24">5246</data>
  <data key="d25">54345</data>
  <data key="d26">6-Chloro-2-(2-Hydroxy-Biphenyl-3-Yl)-1h-Indole-5-Carboxamidine</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB03865</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB02551">
  <data key="d24">5279</data>
  <data key="d25">54345</data>
  <data key="d26">6-[N-(4-Ethyl-1,2,3,4-Tetrahydro-6-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB02551</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB03876">
  <data key="d24">5289</data>
  <data key="d25">54345</data>
  <data key="d26">Thieno[2,3-B]Pyridine-2-Carboxamidine</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB03876</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB00013">
  <data key="d24">5574</data>
  <data key="d25">54345</data>
  <data key="d26">Urokinase</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB00013</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB02705">
  <data key="d24">6037</data>
  <data key="d25">54345</data>
  <data key="d26">6-[N-(1-Isopropyl-1,2,3,4-Tetrahydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB02705</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB00594">
  <data key="d24">6171</data>
  <data key="d25">54345</data>
  <data key="d26">Amiloride</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB00594</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB01977">
  <data key="d24">6514</data>
  <data key="d25">54345</data>
  <data key="d26">6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB01977</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB01905">
  <data key="d24">6549</data>
  <data key="d25">54345</data>
  <data key="d26">2-(2-Hydroxy-5-Methoxy-Phenyl)-1h-Benzoimidazole-5-Carboxamidine</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB01905</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB01725">
  <data key="d24">7595</data>
  <data key="d25">54345</data>
  <data key="d26">2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1H-1,3-benzodiazole-5-carboximidamide</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB01725</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB08072">
  <data key="d24">8223</data>
  <data key="d25">54345</data>
  <data key="d26">4-(2-AMINOETHOXY)-3,5-DICHLORO-N-[3-(1-METHYLETHOXY)PHENYL]BENZAMIDE</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB08072</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB08697">
  <data key="d24">10356</data>
  <data key="d25">54345</data>
  <data key="d26">4-(2-aminoethoxy)-N-(3-chloro-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB08697</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB07076">
  <data key="d24">10512</data>
  <data key="d25">54345</data>
  <data key="d26">6-[(Z)-AMINO(IMINO)METHYL]-N-[3-(CYCLOPENTYLOXY)PHENYL]-2-NAPHTHAMIDE</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB07076</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB07129">
  <data key="d24">10893</data>
  <data key="d25">54345</data>
  <data key="d26">(2R)-1-(2,6-dimethylphenoxy)propan-2-amine</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB07129</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB07122">
  <data key="d24">11061</data>
  <data key="d25">54345</data>
  <data key="d26">1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB07122</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB07625">
  <data key="d24">11187</data>
  <data key="d25">54345</data>
  <data key="d26">4-(2-aminoethoxy)-N-(2,5-diethoxyphenyl)-3,5-dimethylbenzamide</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB07625</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB07626">
  <data key="d24">11189</data>
  <data key="d25">54345</data>
  <data key="d26">4-(2-aminoethoxy)-N-(3-chloro-2-ethoxy-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB07626</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB04172">
  <data key="d24">12501</data>
  <data key="d25">54345</data>
  <data key="d26">[2,4,6-Triisopropyl-Phenylsulfonyl-L-[3-Amidino-Phenylalanine]]-Piperazine-N'-Beta-Alanine</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB04172</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB04216">
  <data key="d24">12527</data>
  <data key="d25">54345</data>
  <data key="d26">Quercetin</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB04216</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB06855">
  <data key="d24">12635</data>
  <data key="d25">54345</data>
  <data key="d26">6-fluoro-2-(2-hydroxy-3-isobutoxy-phenyl)-1H-benzoimidazole-5-carboxamidine</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB06855</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB06856">
  <data key="d24">12636</data>
  <data key="d25">54345</data>
  <data key="d26">6-FLUORO-2-[2-HYDROXY-3-(2-METHYL-CYCLOHEXYLOXY)-PHENYL]-1H-INDOLE-5-CARBOXAMIDINE</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB06856</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB06857">
  <data key="d24">12641</data>
  <data key="d25">54345</data>
  <data key="d26">N-(4-CARBAMIMIDOYL-3-CHORO-PHENYL)-2-HYDROXY-3-IODO-5-METHYL-BENZAMIDE</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB06857</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB05254">
  <data key="d24">12946</data>
  <data key="d25">54345</data>
  <data key="d26">Fibrinolysin</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB05254</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5328" target="drugbank.DB04059">
  <data key="d24">13187</data>
  <data key="d25">54345</data>
  <data key="d26">8-(Pyrimidin-2-Ylamino)Naphthalene-2-Carboximidamide</data>
  <data key="d27">PLAU</data>
  <data key="d28">drugbank.DB04059</data>
  <data key="d29">entrez.5328</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5336" target="mondo.0004975">
  <data key="d24">54398</data>
  <data key="d25">9604</data>
  <data key="d26">PLCG2</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.5336</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.3</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.27328" target="mondo.0004975">
  <data key="d24">54535</data>
  <data key="d25">9604</data>
  <data key="d26">PCDH11X</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.27328</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.42</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.100188837" target="mondo.0012630">
  <data key="d24">55072</data>
  <data key="d25">2759</data>
  <data key="d26">entrez.100188837</data>
  <data key="d27">Alzheimer disease 13</data>
  <data key="d28">entrez.100188837</data>
  <data key="d29">mondo.0012630</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.100188830" target="mondo.0012609">
  <data key="d24">55081</data>
  <data key="d25">2801</data>
  <data key="d26">entrez.100188830</data>
  <data key="d27">Alzheimer disease 12</data>
  <data key="d28">entrez.100188830</data>
  <data key="d29">mondo.0012609</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.5697" target="mondo.0004975">
  <data key="d24">59524</data>
  <data key="d25">9604</data>
  <data key="d26">PYY</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.5697</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.3</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.22976" target="mondo.0004975">
  <data key="d24">59964</data>
  <data key="d25">9604</data>
  <data key="d26">PAXIP1</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.22976</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.32</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.100188754" target="mondo.0012631">
  <data key="d24">59968</data>
  <data key="d25">2750</data>
  <data key="d26">entrez.100188754</data>
  <data key="d27">Alzheimer disease 14</data>
  <data key="d28">entrez.100188754</data>
  <data key="d29">mondo.0012631</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.100188795" target="mondo.0012344">
  <data key="d24">60041</data>
  <data key="d25">5019</data>
  <data key="d26">entrez.100188795</data>
  <data key="d27">Alzheimer disease 11</data>
  <data key="d28">entrez.100188795</data>
  <data key="d29">mondo.0012344</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.5468" target="mondo.0004975">
  <data key="d24">60584</data>
  <data key="d25">9604</data>
  <data key="d26">PPARG</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.5468</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB05854">
  <data key="d24">303</data>
  <data key="d25">60584</data>
  <data key="d26">CLX-0921</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB05854</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB14034">
  <data key="d24">416</data>
  <data key="d25">60584</data>
  <data key="d26">Darglitazone</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB14034</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB04689">
  <data key="d24">683</data>
  <data key="d25">60584</data>
  <data key="d26">2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB04689</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB14009">
  <data key="d24">690</data>
  <data key="d25">60584</data>
  <data key="d26">Medical Cannabis</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB14009</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB03017">
  <data key="d24">941</data>
  <data key="d25">60584</data>
  <data key="d26">Lauric acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB03017</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB06926">
  <data key="d24">1121</data>
  <data key="d25">60584</data>
  <data key="d26">(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB06926</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB06908">
  <data key="d24">1161</data>
  <data key="d25">60584</data>
  <data key="d26">(2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB06908</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB03193">
  <data key="d24">1629</data>
  <data key="d25">60584</data>
  <data key="d26">Stearic acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB03193</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB01067">
  <data key="d24">1663</data>
  <data key="d25">60584</data>
  <data key="d26">Glipizide</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB01067</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB01039">
  <data key="d24">1808</data>
  <data key="d25">60584</data>
  <data key="d26">Fenofibrate</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB01039</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB01050">
  <data key="d24">1876</data>
  <data key="d25">60584</data>
  <data key="d26">Ibuprofen</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB01050</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB03600">
  <data key="d24">2091</data>
  <data key="d25">60584</data>
  <data key="d26">Capric acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB03600</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB04971">
  <data key="d24">2145</data>
  <data key="d25">60584</data>
  <data key="d26">Reglitazar</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB04971</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB01118">
  <data key="d24">2440</data>
  <data key="d25">60584</data>
  <data key="d26">Amiodarone</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB01118</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB01132">
  <data key="d24">2501</data>
  <data key="d25">60584</data>
  <data key="d26">Pioglitazone</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB01132</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB13115">
  <data key="d24">2575</data>
  <data key="d25">60584</data>
  <data key="d26">Saroglitazar</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB13115</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB03756">
  <data key="d24">2645</data>
  <data key="d25">60584</data>
  <data key="d26">Doconexent</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB03756</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB02266">
  <data key="d24">3303</data>
  <data key="d25">60584</data>
  <data key="d26">Flufenamic Acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB02266</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB00197">
  <data key="d24">3560</data>
  <data key="d25">60584</data>
  <data key="d26">Troglitazone</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB00197</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB00132">
  <data key="d24">3618</data>
  <data key="d25">60584</data>
  <data key="d26">Alpha-Linolenic Acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB00132</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB00159">
  <data key="d24">3721</data>
  <data key="d25">60584</data>
  <data key="d26">Icosapent</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB00159</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB00244">
  <data key="d24">4538</data>
  <data key="d25">60584</data>
  <data key="d26">Mesalazine</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB00244</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB00307">
  <data key="d24">4618</data>
  <data key="d25">60584</data>
  <data key="d26">Bexarotene</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB00307</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB00313">
  <data key="d24">4676</data>
  <data key="d25">60584</data>
  <data key="d26">Valproic Acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB00313</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB00328">
  <data key="d24">4717</data>
  <data key="d25">60584</data>
  <data key="d26">Indometacin</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB00328</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB01252">
  <data key="d24">5109</data>
  <data key="d25">60584</data>
  <data key="d26">Mitiglinide</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB01252</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB01393">
  <data key="d24">5449</data>
  <data key="d25">60584</data>
  <data key="d26">Bezafibrate</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB01393</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB12007">
  <data key="d24">5646</data>
  <data key="d25">60584</data>
  <data key="d26">Isoflavone</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB12007</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB14635">
  <data key="d24">5881</data>
  <data key="d25">60584</data>
  <data key="d26">Curcumin sulfate</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB14635</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB02746">
  <data key="d24">6022</data>
  <data key="d25">60584</data>
  <data key="d26">Phthalic Acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB02746</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB02709">
  <data key="d24">6040</data>
  <data key="d25">60584</data>
  <data key="d26">Resveratrol</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB02709</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB00573">
  <data key="d24">6090</data>
  <data key="d25">60584</data>
  <data key="d26">Fenoprofen</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB00573</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB00586">
  <data key="d24">6127</data>
  <data key="d25">60584</data>
  <data key="d26">Diclofenac</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB00586</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB13961">
  <data key="d24">6249</data>
  <data key="d25">60584</data>
  <data key="d26">Fish oil</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB13961</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB09006">
  <data key="d24">6278</data>
  <data key="d25">60584</data>
  <data key="d26">Clinofibrate</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB09006</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB12662">
  <data key="d24">6402</data>
  <data key="d25">60584</data>
  <data key="d26">Naveglitazar</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB12662</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB09061">
  <data key="d24">6749</data>
  <data key="d25">60584</data>
  <data key="d26">Cannabidiol</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB09061</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB00731">
  <data key="d24">6918</data>
  <data key="d25">60584</data>
  <data key="d26">Nateglinide</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB00731</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB00412">
  <data key="d24">7435</data>
  <data key="d25">60584</data>
  <data key="d26">Rosiglitazone</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB00412</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB13873">
  <data key="d24">8057</data>
  <data key="d25">60584</data>
  <data key="d26">Fenofibric acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB13873</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB08121">
  <data key="d24">8451</data>
  <data key="d25">60584</data>
  <data key="d26">(2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB08121</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB11811">
  <data key="d24">8901</data>
  <data key="d25">60584</data>
  <data key="d26">Arhalofenate</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB11811</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB09198">
  <data key="d24">8908</data>
  <data key="d25">60584</data>
  <data key="d26">Lobeglitazone</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB09198</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB09201">
  <data key="d24">9123</data>
  <data key="d25">60584</data>
  <data key="d26">Ciglitazone</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB09201</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB09213">
  <data key="d24">9152</data>
  <data key="d25">60584</data>
  <data key="d26">Dexibuprofen</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB09213</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB11672">
  <data key="d24">9439</data>
  <data key="d25">60584</data>
  <data key="d26">Curcumin</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB11672</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB00948">
  <data key="d24">9725</data>
  <data key="d25">60584</data>
  <data key="d26">Mezlocillin</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB00948</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB00966">
  <data key="d24">9775</data>
  <data key="d25">60584</data>
  <data key="d26">Telmisartan</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB00966</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB00912">
  <data key="d24">9821</data>
  <data key="d25">60584</data>
  <data key="d26">Repaglinide</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB00912</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB07208">
  <data key="d24">9953</data>
  <data key="d25">60584</data>
  <data key="d26">(8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB07208</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB07209">
  <data key="d24">9961</data>
  <data key="d25">60584</data>
  <data key="d26">(8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB07209</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB08560">
  <data key="d24">9999</data>
  <data key="d25">60584</data>
  <data key="d26">3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB08560</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB08604">
  <data key="d24">10169</data>
  <data key="d25">60584</data>
  <data key="d26">Triclosan</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB08604</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB07302">
  <data key="d24">10376</data>
  <data key="d25">60584</data>
  <data key="d26">(9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB07302</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB07053">
  <data key="d24">10461</data>
  <data key="d25">60584</data>
  <data key="d26">2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB07053</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB08302">
  <data key="d24">10667</data>
  <data key="d25">60584</data>
  <data key="d26">3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB08302</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB07172">
  <data key="d24">10849</data>
  <data key="d25">60584</data>
  <data key="d26">(5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB07172</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB08435">
  <data key="d24">11009</data>
  <data key="d25">60584</data>
  <data key="d26">(5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB08435</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB07111">
  <data key="d24">11028</data>
  <data key="d25">60584</data>
  <data key="d26">(4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB07111</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB08402">
  <data key="d24">11101</data>
  <data key="d25">60584</data>
  <data key="d26">2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB08402</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB08915">
  <data key="d24">11246</data>
  <data key="d25">60584</data>
  <data key="d26">Aleglitazar</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB08915</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB07675">
  <data key="d24">11422</data>
  <data key="d25">60584</data>
  <data key="d26">(2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB07675</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB07724">
  <data key="d24">11461</data>
  <data key="d25">60584</data>
  <data key="d26">Indeglitazar</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB07724</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB07723">
  <data key="d24">11463</data>
  <data key="d25">60584</data>
  <data key="d26">3-(5-methoxy-1H-indol-3-yl)propanoic acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB07723</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB05187">
  <data key="d24">11603</data>
  <data key="d25">60584</data>
  <data key="d26">Elafibranor</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB05187</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB08760">
  <data key="d24">11929</data>
  <data key="d25">60584</data>
  <data key="d26">(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB08760</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB07509">
  <data key="d24">12005</data>
  <data key="d25">60584</data>
  <data key="d26">difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB07509</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB05490">
  <data key="d24">12479</data>
  <data key="d25">60584</data>
  <data key="d26">AMG-131</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB05490</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB04224">
  <data key="d24">12552</data>
  <data key="d25">60584</data>
  <data key="d26">Oleic Acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB04224</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB04270">
  <data key="d24">12713</data>
  <data key="d25">60584</data>
  <data key="d26">(S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB04270</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB06521">
  <data key="d24">12745</data>
  <data key="d25">60584</data>
  <data key="d26">Ertiprotafib</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB06521</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB07863">
  <data key="d24">12764</data>
  <data key="d25">60584</data>
  <data key="d26">2-chloro-5-nitro-N-phenylbenzamide</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB07863</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB06533">
  <data key="d24">12765</data>
  <data key="d25">60584</data>
  <data key="d26">Ragaglitazar</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB06533</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB06536">
  <data key="d24">12793</data>
  <data key="d25">60584</data>
  <data key="d26">Tesaglitazar</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB06536</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB06510">
  <data key="d24">12861</data>
  <data key="d25">60584</data>
  <data key="d26">Muraglitazar</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB06510</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB07842">
  <data key="d24">12864</data>
  <data key="d25">60584</data>
  <data key="d26">(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB07842</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB14011">
  <data key="d24">653</data>
  <data key="d25">60584</data>
  <data key="d26">Nabiximols</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB14011</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB01014">
  <data key="d24">2061</data>
  <data key="d25">60584</data>
  <data key="d26">Balsalazide</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB01014</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB00795">
  <data key="d24">6859</data>
  <data key="d25">60584</data>
  <data key="d26">Sulfasalazine</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB00795</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5468" target="drugbank.DB11133">
  <data key="d24">7883</data>
  <data key="d25">60584</data>
  <data key="d26">Omega-3 fatty acids</data>
  <data key="d27">PPARG</data>
  <data key="d28">drugbank.DB11133</data>
  <data key="d29">entrez.5468</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5649" target="mondo.0004975">
  <data key="d24">61501</data>
  <data key="d25">9604</data>
  <data key="d26">RELN</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.5649</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.5664" target="mondo.0011743">
  <data key="d24">61537</data>
  <data key="d25">258</data>
  <data key="d26">PSEN2</data>
  <data key="d27">Alzheimer disease 4</data>
  <data key="d28">entrez.5664</data>
  <data key="d29">mondo.0011743</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.6</data>
  <data key="d32">[disgenet, omim]</data>
</edge>
<edge source="entrez.5664" target="mondo.0004975">
  <data key="d24">61537</data>
  <data key="d25">9604</data>
  <data key="d26">PSEN2</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.5664</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.5</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.5663" target="mondo.0004975">
  <data key="d24">61538</data>
  <data key="d25">9604</data>
  <data key="d26">PSEN1</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.5663</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.7</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.5663" target="mondo.0011913">
  <data key="d24">61538</data>
  <data key="d25">23540</data>
  <data key="d26">PSEN1</data>
  <data key="d27">Alzheimer disease 3</data>
  <data key="d28">entrez.5663</data>
  <data key="d29">mondo.0011913</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">null</data>
  <data key="d32">[omim]</data>
</edge>
<edge source="entrez.5621" target="mondo.0004975">
  <data key="d24">61606</data>
  <data key="d25">9604</data>
  <data key="d26">PRNP</data>
  <data key="d27">Alzheimer disease</data>
  <data key="d28">entrez.5621</data>
  <data key="d29">mondo.0004975</data>
  <data key="d30">GeneAssociatedWithDisorder</data>
  <data key="d31">0.4</data>
  <data key="d32">[disgenet]</data>
</edge>
<edge source="entrez.5621" target="drugbank.DB01069">
  <data key="d24">1661</data>
  <data key="d25">61606</data>
  <data key="d26">Promethazine</data>
  <data key="d27">PRNP</data>
  <data key="d28">drugbank.DB01069</data>
  <data key="d29">entrez.5621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5621" target="drugbank.DB01103">
  <data key="d24">2402</data>
  <data key="d25">61606</data>
  <data key="d26">Quinacrine</data>
  <data key="d27">PRNP</data>
  <data key="d28">drugbank.DB01103</data>
  <data key="d29">entrez.5621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5621" target="drugbank.DB01614">
  <data key="d24">4836</data>
  <data key="d25">61606</data>
  <data key="d26">Acepromazine</data>
  <data key="d27">PRNP</data>
  <data key="d28">drugbank.DB01614</data>
  <data key="d29">entrez.5621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5621" target="drugbank.DB00608">
  <data key="d24">6583</data>
  <data key="d25">61606</data>
  <data key="d26">Chloroquine</data>
  <data key="d27">PRNP</data>
  <data key="d28">drugbank.DB00608</data>
  <data key="d29">entrez.5621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5621" target="drugbank.DB09093">
  <data key="d24">6649</data>
  <data key="d25">61606</data>
  <data key="d26">Chlortetracycline</data>
  <data key="d27">PRNP</data>
  <data key="d28">drugbank.DB09093</data>
  <data key="d29">entrez.5621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5621" target="drugbank.DB09130">
  <data key="d24">6850</data>
  <data key="d25">61606</data>
  <data key="d26">Copper</data>
  <data key="d27">PRNP</data>
  <data key="d28">drugbank.DB09130</data>
  <data key="d29">entrez.5621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5621" target="drugbank.DB00759">
  <data key="d24">6949</data>
  <data key="d25">61606</data>
  <data key="d26">Tetracycline</data>
  <data key="d27">PRNP</data>
  <data key="d28">drugbank.DB00759</data>
  <data key="d29">entrez.5621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5621" target="drugbank.DB00420">
  <data key="d24">7467</data>
  <data key="d25">61606</data>
  <data key="d26">Promazine</data>
  <data key="d27">PRNP</data>
  <data key="d28">drugbank.DB00420</data>
  <data key="d29">entrez.5621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5621" target="drugbank.DB00458">
  <data key="d24">7720</data>
  <data key="d25">61606</data>
  <data key="d26">Imipramine</data>
  <data key="d27">PRNP</data>
  <data key="d28">drugbank.DB00458</data>
  <data key="d29">entrez.5621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
<edge source="entrez.5621" target="drugbank.DB00477">
  <data key="d24">7827</data>
  <data key="d25">61606</data>
  <data key="d26">Chlorpromazine</data>
  <data key="d27">PRNP</data>
  <data key="d28">drugbank.DB00477</data>
  <data key="d29">entrez.5621</data>
  <data key="d30">DrugTargetGene</data>
</edge>
</graph></graphml>